<SEC-DOCUMENT>0001193125-13-405310.txt : 20131021
<SEC-HEADER>0001193125-13-405310.hdr.sgml : 20131021
<ACCEPTANCE-DATETIME>20131021161957
ACCESSION NUMBER:		0001193125-13-405310
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20131220
FILED AS OF DATE:		20131021
DATE AS OF CHANGE:		20131021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		131161629

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>d519187dpre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<HTML><HEAD>
<TITLE>PRE 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>(RULE 14a-101) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SCHEDULE 14A INFORMATION
</B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>(Amendment No. &nbsp;&nbsp; ) </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed by the
Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed by a
Party other than the Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the
appropriate box: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary Proxy Statement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only&nbsp;(as permitted by Rule 14a-6(e)(2))</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Proxy Statement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Additional Materials</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="32" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B><BR>STEMCELLS, INC.</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Name of Registrant as Specified In Its Charter)</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD COLSPAN="5" VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</B></FONT></TD></TR>
<TR>
<TD HEIGHT="32" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box):</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">No fee required.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title of each class of securities to which transaction applies:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total fee paid:</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee paid previously with preliminary materials.</FONT></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</FONT></TD></TR>
<TR>
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amount Previously Paid:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filing Party:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date Filed:</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>STEMCELLS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7707 Gateway Blvd. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Newark, California 94560 </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>To be Held on December&nbsp;20, 2013 </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To the Stockholders of STEMCELLS, INC. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notice is hereby given that the Annual
Meeting of Stockholders of StemCells, Inc. (&#147;StemCells&#148; or the &#147;company&#148;) will be held on Friday, December&nbsp;20, 2013, at 10 a.m., local time, at 7707 Gateway Boulevard, Newark, California 94560 for the following purposes:
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.&nbsp;to elect the three Class&nbsp;I directors named in the accompanying proxy materials to serve until the 2016 Annual
Meeting of Stockholders; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.&nbsp;to consider and vote upon a proposal to ratify the selection of Grant Thornton LLP as
independent public accountants for the company for the fiscal year ending December&nbsp;31, 2013;</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.&nbsp;to consider and vote
upon a proposal to amend the company&#146;s restated certificate of incorporation to increase the company&#146;s authorized capital by one hundred fifty million shares of common stock;</FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. to consider and vote upon a proposal to adopt the 2013 Equity Incentive Plan as proposed; and </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. to transact any and all other business that may properly come before the meeting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors has fixed the close of business on Friday, October&nbsp;25, 2013, as the record date for determining those
stockholders who are entitled to notice of, and to vote at, the annual meeting of stockholders and any postponements or adjournments thereof. The stock transfer books will not be closed between the record date and the date of the meeting.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representation of at least a majority of all outstanding shares of common stock of StemCells is required to constitute a
quorum. Accordingly, it is important that your shares be represented at the meeting. This year we are again taking advantage of Securities and Exchange Commission rules that allow issuers to furnish proxy materials to their stockholders on the
Internet. We believe these rules allow us to provide our stockholders with the information they need, while lowering the costs of delivery and reducing the environmental impact of our Annual Meeting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please read the proxy materials carefully. All stockholders are invited to attend the Annual Meeting. Your vote is important, and we
appreciate your cooperation in considering and acting on the matters presented. </FONT></P> <P STYLE="font-size:32px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors,</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g519187g32t36.jpg" ALT="LOGO">
</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kenneth B. Stratton,&nbsp;J.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;4, 2013 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Newark, California </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>PROXY STATEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>STEMCELLS, INC. </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying proxy is solicited on behalf of the Board of Directors of StemCells, Inc. (the &#147;company&#148;) for use at its
annual meeting of stockholders (the &#147;Annual Meeting&#148;) to be held on Friday, December&nbsp;20, 2013, at 10&nbsp;a.m., local time, at the company&#146;s headquarters at 7707 Gateway Boulevard, Newark, California 94560. The company will bear
the cost of solicitation of proxies. Directors, officers and employees of the company may solicit proxies by telephone, facsimile or in person for no additional compensation. The company will reimburse banks, brokerage firms, proxy solicitors, and
other custodians, nominees and fiduciaries for reasonable expenses incurred by them in sending proxy materials to the beneficial owners of shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors has fixed the close of business on Friday, October&nbsp;25, 2013, as the record date for determining stockholders entitled to notice of, and to vote at, the Annual Meeting or at any
postponement or adjournment thereof. There were 54,971,174&nbsp;shares of our common stock, $.01&nbsp;par value, outstanding on October&nbsp;25, 2013, each of which is entitled to one vote for each share on the matters to be voted upon. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Our 2013 Proxy Materials are Available on the Internet.</I>&nbsp;&nbsp;&nbsp;&nbsp;This year we have again elected to provide access
to our proxy materials over the Internet in accordance with rules adopted by the Securities and Exchange Commission. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) to our stockholders of
record and beneficial owners, which will instruct them as to how they may access and review all of the proxy materials on the Internet and how they may submit their proxy on the Internet. We expect to begin delivering the Notice to our stockholders
on November&nbsp;4, 2013, our anticipated initial mailing date. Any stockholder wishing to receive a paper copy of our proxy materials can request them from us by following the instructions found in the Notice for requesting such materials, or by
calling 1&nbsp;(800)&nbsp;579-1639. Requests for a paper copy of our proxy materials should be made on or before December&nbsp;6, 2013 to facilitate timely delivery. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Stockholders are being asked to vote on four proposals at the company&#146;s 2013 Annual Meeting. The proposals to be voted on and related recommendations from the Board of Directors are as follows:
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal&nbsp;Number 1&nbsp;&#151; To elect the three director nominees named in this Proxy Statement to serve as
Class&nbsp;I directors on the Board until our 2016 annual meeting of stockholders or until that person&#146;s successor is duly elected and qualified. The Board of Directors recommends that you vote &#147;FOR&#148; each of the nominees. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal&nbsp;Number 2&nbsp;&#151; To ratify the appointment of Grant Thornton LLP as the company&#146;s independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2013. The Board of Directors recommends that you vote &#147;FOR&#148; this proposal. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Proposal&nbsp;Number 3&nbsp;&#151; To adopt the proposed amendment to the company&#146;s restated certificate of incorporation to increase the number of authorized shares of common stock by one hundred
fifty million (150,000,000)&nbsp;shares as proposed herein. The Board of Directors recommends that you vote &#147;FOR&#148; this proposal. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Proposal&nbsp;Number 4&nbsp;&#151; To adopt the proposed 2013 Equity Incentive Plan as described herein. The Board of Directors recommends that you vote &#147;FOR&#148; this proposal. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the election of directors, which is Proposal&nbsp;Number 1, you may vote &#147;FOR&#148;
all three of the nominees or your vote may be &#147;WITHHELD&#148; with respect to one or more of the nominees. For Proposal&nbsp;Numbers 2, 3 and 4, you may vote &#147;FOR,&#148; vote &#147;AGAINST&#148; or &#147;ABSTAIN.&#148; If you
&#147;ABSTAIN&#148; as to Proposal&nbsp;Numbers 2 or 4, the abstention will have no effect. If you &#147;ABSTAIN&#148; as to Proposal&nbsp;Number 3, the abstention will have the same effect as voting &#147;AGAINST&#148; the proposal. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares of our common stock represented by proxies in the form enclosed that are properly executed and returned to us and not revoked will
be voted as specified in the proxy by the stockholder. In the absence of contrary instructions, or in instances where no specifications are made, the shares will be voted: </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)&nbsp;FOR the election as directors of the nominees as described herein under &#147;Proposal&nbsp;Number 1&nbsp;&#151;
Election of Directors;&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)&nbsp;FOR ratification of the selection of accountants as described herein
under &#147;Proposal Number 2&nbsp;&#151; Ratification of Selection of Independent Public Accountants;&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)&nbsp;FOR adoption of the amendment to the company&#146;s restated certificate of incorporation to increase the
number of authorized shares of common stock by one hundred fifty million (150,000,000)&nbsp;as described herein under &#147;Proposal Number&nbsp;3&nbsp;&#151; Amendment to Restated Certificate of Incorporation to Increase Authorized Shares of Common
Stock;&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) FOR adoption of the proposed 2013 Equity Incentive Plan as described herein under
&#147;Proposal Number&nbsp;4&nbsp;&#151; Adoption of the 2013 Equity Incentive Plan;&#148; and </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) in the
discretion of the named proxies as to any other matter that may properly come before the Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any stockholder
signing and delivering a proxy may revoke it at any time before it is voted by delivering to the company&#146;s corporate secretary a written revocation or a duly executed proxy bearing a date later than the date of the proxy being revoked. Any
stockholder attending the Annual Meeting in person may revoke his, her or its proxy and vote his, her or its shares at the Annual Meeting. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>How to vote shares at our 2013 Annual Meeting. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This year company
stockholders may cast their vote in any of the following ways: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Vote by Internet.</I>&nbsp;&nbsp;&nbsp;&nbsp;Any
stockholder can vote over the Internet at www.proxyvote.com by following the instructions on the Notice or proxy card. Internet voting facilities for stockholders of record will be available 24&nbsp;hours a day and will close at 11:59&nbsp;p.m.
(EDT) on December&nbsp;19, 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Vote by Phone.</I>&nbsp;&nbsp;&nbsp;&nbsp;Any stockholder can vote by phone by following
the instructions on the proxy card and calling 1 (800)&nbsp;690-6903 up until 11:59&nbsp;p.m. (EDT) on December&nbsp;19, 2013. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Vote by Mail.</I>&nbsp;&nbsp;&nbsp;&nbsp;Any stockholder that receives proxy materials by mail can vote by mail by signing, dating and
mailing the enclosed proxy card in the postage-paid envelope provided. If the envelope is missing, such a stockholder can mail the completed proxy card or voting instruction card to Vote Processing, c/o&nbsp;Broadridge, 51&nbsp;Mercedes Way,
Edgewood, New York 11717. The completed card must be received no later than December&nbsp;19, 2013. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Voting at the Annual Meeting.</I>&nbsp;&nbsp;&nbsp;&nbsp;All company stockholders are
invited to attend the Annual Meeting in person. Any stockholder that attends the meeting in person may deliver a completed proxy card in person or vote by completing a ballot, which will be available at the meeting. However, each stockholder
intending to vote in person at the Annual Meeting should note that if his, her or its shares are held in the name of a bank, broker or other nominee, such stockholder must obtain a legal proxy, executed in his, her or its favor, from the holder of
record to be able to vote at the Annual Meeting. Stockholders should allow enough time prior to the Annual Meeting to obtain this proxy from the holder of record, if needed. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The shares voted electronically or represented by the proxy cards received, properly marked, dated, signed and not revoked, will be voted at the Annual Meeting. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUORUM, REQUIRED VOTES AND METHOD OF TABULATION </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consistent with Delaware law and the company&#146;s amended and restated by-laws, a majority of the votes entitled to be cast on a
particular matter, present in person or represented by proxy, constitutes a quorum as to such matter. The company will appoint one or more election inspectors for the meeting to count votes cast by proxy or in person at the Annual Meeting.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you hold shares beneficially in street name and do not provide your broker or nominee with voting instructions, your
shares may constitute &#147;broker non-votes.&#148; Generally, broker non-votes occur on a matter when a broker is not permitted to vote on that matter without instructions from the beneficial owner and instructions have not been given. This year if
you hold shares beneficially in street name and do not vote your shares, your broker or nominee can vote your shares at its discretion only on Proposal Number 2. In tabulating the voting result for any proposal for which the required vote is based
on the number of shares present, shares that constitute broker non-votes are not considered entitled to vote on that proposal. Thus, broker non-votes will not affect the outcome of Proposal&nbsp;Numbers 1, 2 and 4, provided a quorum is established.
However, for proposals for which the required vote is based on the number of shares of common stock issued and outstanding, broker non-votes have the same effect as a vote &#147;AGAINST&#148; the proposal. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>What vote is required to approve each item? </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Election of directors by stockholders, which is Proposal&nbsp;Number 1, will be determined by a plurality of the votes cast by the stockholders entitled to vote at the election that are either present in
person or represented by proxy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For Proposal&nbsp;Numbers 2 and 4, the affirmative &#147;FOR&#148; vote is required by the
holders of a majority of the shares present at the Annual Meeting in person or by proxy and voting. Abstentions will have no effect on the outcome of this proposal. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For Proposal Number 3, amendment of the charter to increase the company&#146;s authorized capital, the affirmative &#147;FOR&#148; vote is required by the holders of a majority of shares issued and
outstanding. Abstentions and broker non-votes have the same effect as voting &#147;AGAINST&#148; charter amendments such as Proposal Number 3. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Management does not know of any matters to be presented at this year&#146;s Annual Meeting other than those set forth in this proxy statement and in the notice accompanying this proxy statement.
Stockholders will have no appraisal rights under Delaware law with respect to any of the matters expected to be voted on at the Annual Meeting. If other matters should properly come before the meeting, the proxy holders will vote such matters in
their discretion. Any stockholder has the right to revoke his, her or its proxy at any time until it is voted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the number of shares of our common stock beneficially owned, as of October&nbsp;15,
2013, by (i)&nbsp;each of our directors, (ii)&nbsp;each of our named executive officers, (iii)&nbsp;all of our directors and executive officers as a group, and (iv)&nbsp;all those known by us to be to a beneficial owner of more than 5% of the
company&#146;s common stock. In general, &#147;beneficial ownership&#148; refers to shares that an individual or entity has the power to vote or dispose of, and any rights to acquire common stock that are currently exercisable or will become
exercisable within 60&nbsp;days of October&nbsp;15, 2013. Unless otherwise indicated, we believe that each person named below, based on information furnished by such owners, holds sole investment and voting power with respect to such shares, subject
to community property laws where applicable. We calculated percentage ownership in accordance with the rules of the SEC. The percentage of common stock beneficially owned is based on 54,971,174&nbsp;shares outstanding as of October&nbsp;15, 2013. In
addition, shares issuable pursuant to options, restricted stock units or other convertible securities that may be acquired within 60&nbsp;days of October&nbsp;15, 2013 are deemed to be issued and outstanding and have been treated as outstanding in
calculating and determining the beneficial ownership and percentage ownership of those persons possessing those securities, but not for any other persons. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:138pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Address of Beneficial Owner*</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount&nbsp;and<BR>Nature of<BR>Beneficial<BR>Ownership</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage&nbsp;of<BR>Class&nbsp;Beneficially<BR>Owned</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Directors and Named Executive Officers</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Bjerkholt(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R. Scott Greer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ricardo Levy(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">242,024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roger Perlmutter(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Schwartz(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,307</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Irving Weissman(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">166,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young(10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86,672</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All directors and executive officers as a group (twelve persons)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>876,202</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.59%</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5% Stockholders</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alpha Capital Anstalt(11)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,332,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.96%</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The address of all directors and executive officers listed in the table is c/o&nbsp;StemCells, Inc., 7707 Gateway Blvd., Newark, California 94560.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less than one percent. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 7,000 shares issuable upon exercise of stock options exercisable within 60 days. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 8,750 shares issuable upon exercise of stock options exercisable within 60 days. Includes 15,219 shares in Dr.&nbsp;Craig&#146;s 401(k) plan.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 5,405 shares issuable upon exercise of stock options exercisable within 60 days. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 25,625 shares issuable upon exercise of stock options exercisable within 60 days. Includes 17,433 shares in Mr.&nbsp;McGlynn&#146;s 401(k) plan.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 15,405 shares issuable upon exercise of 5,405 stock options and 10,000 restricted stock units exercisable within 60 days. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 6,500 shares issuable upon exercise of stock options exercisable within 60 days. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 15,000 shares issuable upon exercise of stock options exercisable within 60 days. Includes 13,152 shares in Mr.&nbsp;Stratton&#146;s 401(k) plan.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 17,500 shares issuable upon exercise of stock options exercisable within 60 days. Includes 18,668 shares included in Dr.&nbsp;Tsukamoto&#146;s 401(k) plan and
3,643 shares held in trust to which Dr.&nbsp;Tsukamoto disclaims beneficial ownership. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 5,990 shares issuable upon exercise of stock options exercisable within 60 days. Includes 10,508 shares held in trust to which Dr.&nbsp;Weissman disclaims
beneficial ownership. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 33,604 shares issuable upon exercise of stock options exercisable within 60 days. Includes 21,323 shares in Mr.&nbsp;Young&#146;s 401 (k)&nbsp;plan.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficial holdings based on a Schedule&nbsp;13G filed by Alpha Capital Anstalt on February&nbsp;28, 2012 and the Company&#146;s records of its outstanding warrants.
According to the Schedule 13G filed February&nbsp;28, 2012, Alpha Capital may be deemed to beneficially own all shares listed in the table, and has sole dispositive and voting power with respect to all shares listed in the table. The address of the
principal place of business of Alpha Capital is Pradafant 7, Furstentums 9490, Vaduz, Liechtenstein. </FONT></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board of Directors
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have seven directors serving on our Board of Directors. Since June 2010, our Board has been composed of
Drs.&nbsp;Ricardo Levy, Roger Perlmutter, John Schwartz, and Irving Weissman and Messrs.&nbsp;Eric Bjerkholt, Scott Greer and Martin McGlynn. The following table shows the names, ages, principal occupations, and public company board memberships for
the last five years of our directors, as of October&nbsp;15, 2013: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Bjerkholt</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Bjerkholt was elected to the Board of Directors in March 2004. He is Executive Vice President and Chief Financial Officer of Sunesis Pharmaceuticals, Inc., a
biopharmaceutical company. Mr. Bjerkholt is a member of the board of directors of Round Table Pizza, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">R. Scott Greer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Greer was appointed to the Board of Directors in June 2010. He is currently a principal and managing director of Numenor Ventures LLC, which he founded in 2002 to provide
funding and strategic advisory services to early stage enterprises. Mr.&nbsp;Greer currently serves as Chairman of Ablexis, a development stage biotechnology company, and he is also on the board of Nektar Therapeutics.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ricardo Levy,&nbsp;Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ricardo Levy,&nbsp;Ph.D. was elected to the Board of Directors in September 2001. He currently serves as a director on the board of Accelrys, Inc., a public company focused on
molecular modeling and simulation software for both life and materials science research.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn was elected to the Board of Directors in February 2001. He is President and Chief Executive Officer of the company, a position he has held since January
2001.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roger&nbsp;Perlmutter,&nbsp;M.D.,&nbsp;Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roger Perlmutter,&nbsp;M.D.,&nbsp;Ph.D., was elected to the Board of Directors in December 2000. He is President of Merck Research Laboratories, an international pharmaceutical
company, where he leads Merck&#146;s global research endeavors. Previously, until February 2012, he was Executive Vice President, Research and Development, of Amgen, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Schwartz,&nbsp;Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">79</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Schwartz,&nbsp;Ph.D., was elected to the Board of Directors in December 1998 and was elected Chairman of the Board at the same time. He is currently President of Quantum
Strategies Management Company, a registered investment advisor.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Irving Weissman,&nbsp;M.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Irving Weissman,&nbsp;M.D., was elected to the Board of Directors in September 1997. He is the Virginia and Daniel K. Ludwig Professor of Cancer Research, Professor of Pathology
and Professor of Developmental Biology at Stanford University.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because we have a classified board, with each of our directors serving a staggered three-year term, only
three of our directors are standing for reelection at our 2013 Annual Meeting. The following table shows the composition of the three classes of our Board: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Class&nbsp;I Directors (terms scheduled to expire in 2013, but nominated to stand for reelection at our 2013 Annual Meeting): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Bjerkholt</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">R. Scott Greer</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Schwartz,&nbsp;Ph.D.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class&nbsp;II Directors (terms scheduled to expire in 2014): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ricardo Levy,&nbsp;Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Irving Weissman,&nbsp;M.D.</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Class&nbsp;III Directors (terms scheduled to expire in 2015): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roger Perlmutter,&nbsp;M.D.,&nbsp;Ph.D.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The independent members of our Board, as determined by the Board of Directors in accordance with the
existing Nasdaq Listing rules, are Messrs.&nbsp;Bjerkholt and Greer and Drs.&nbsp;Levy, Perlmutter and Schwartz. The Board of Directors held four regular meetings and one special meeting during the fiscal year ended December&nbsp;31, 2012. Each of
our directors attended more than 75% of the meetings of the Board of Directors and of the committees on which he served. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For many years the roles of chairman and chief executive officer at the company have been
separated. We believe that this is appropriate under current circumstances, because it allows management to make the operating decisions necessary to manage the business, while helping to maintain Board independence so that it can provide an
effective oversight function. We feel that this has provided an appropriate balance of operational focus, flexibility and oversight. Our independent directors meet at regularly scheduled executive sessions without members of management. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Committees </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Presently, the Board has four standing committees&nbsp;&#151; the Audit Committee, the Compensation and Stock Option Committee (the
&#147;Compensation Committee&#148;), the Corporate Governance and Nominating Committee (the &#147;Corporate Governance Committee&#148;), and the Strategic Transactions Committee &#151; as well as a single-member committee established under the
company&#146;s 2001, 2004 and 2006 equity incentive plans and the Company&#146;s 2012 Commencement Incentive Plan. The Board created the Strategic Transactions Committee in March 2009 as an <I>ad hoc</I> committee with direction to consult with
management and advise the full Board on various corporate initiatives, such as the acquisition of substantially all of the operating assets of Stem Cell Sciences plc, which the company completed in April 2009. In June 2010, however, the Board
reconstituted the Strategic Transactions Committee, which Mr.&nbsp;Greer currently chairs, as a standing committee of the Board. All members of the Audit Committee, the Compensation Committee, and the Corporate Governance Committee are, and are
required by the charters of the respective committees to be, independent as determined under Nasdaq Listing rules. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Audit Committee</U>.</I>&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee is composed of Mr.&nbsp;Bjerkholt and Drs.&nbsp;Schwartz and
Levy. The Audit Committee held four meetings during the fiscal year ended December&nbsp;31, 2012. The primary function of the Audit Committee is to assist our Board in fulfilling its oversight responsibilities. The committee does this primarily by
reviewing our financial reports and other financial information as well as the company&#146;s systems of internal controls regarding finance, accounting, legal compliance, and ethics that management and the Board have established. The committee also
assesses our auditing, accounting and financial processes more generally. The Audit Committee meets quarterly, and at such other times as it finds necessary. It recommends to our Board the appointment of a firm of independent auditors to audit the
financial statements of the company and meets with such personnel of the company to review the scope and the results of the annual audit, the amount of audit fees, the company&#146;s internal accounting controls, the company&#146;s financial
statements contained in this proxy statement and other related matters. Each of the members of the Audit Committee is independent, and the Board has determined that Mr.&nbsp;Bjerkholt is an &#147;audit committee financial expert,&#148; as defined in
SEC rules. The Audit Committee acts pursuant to a written charter which is available through our website at www.stemcellsinc.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I><U>Compensation Committee</U>.</I>&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee is composed of Drs.&nbsp;Schwartz and Levy and Mr.&nbsp;Bjerkholt. The Compensation Committee held five meetings
during the fiscal year ended December&nbsp;31, 2012. The Compensation Committee makes recommendations to our Board and management concerning salaries in general, determines executive compensation and, except to the extent that such decisions have
been delegated to, and made by, the single-member committee, approves incentive compensation for our employees and consultants. The Compensation Committee acts pursuant to a written charter which is available through our website at
www.stemcellsinc.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Corporate Governance Committee</U>.</I>&nbsp;&nbsp;&nbsp;&nbsp;The Corporate Governance Committee
is composed of Drs.&nbsp;Levy, Perlmutter and Schwartz. The Corporate Governance Committee held one meeting in 2012 to discuss a slate of actual and potential nominees to the Board of Directors. The committee oversees nominations to the Board and
considers the experience, ability and character of potential nominees to serve as directors, as well as particular skills or knowledge that may be desirable in light of the company&#146;s position at any time. From time to time, the committee has
engaged the services of a paid search firm to help the committee identify potential nominees to the Board. The Company&#146;s Governance Committee and Board seek to nominate and appoint candidates to the Board who have significant business
experience, technical expertise or personal attributes, or a combination of these, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
sufficient to suggest, in the Board&#146;s judgment, that the candidate would have the ability to help direct the affairs of the company and enhance the Board as a whole. The Committee may
identify potential candidates through any reliable means available, including recommendations of past or current members of the Board from their knowledge of the industry and of the company. The Committee also considers past service on the Board or
on the board of directors of other publicly traded or technology focused companies. The committee has not adopted a formulaic approach to evaluating potential nominees to the Board; it does not have a formal policy concerning diversity, for example.
Rather, the committee weighs and considers the experience, expertise, intellect, and judgment of potential nominees irrespective of their race, gender, age, religion, or other personal characteristics. The committee often looks for nominees that can
bring new skill sets or diverse business perspectives. Potential candidates recommended by security holders will be considered as provided in the company&#146;s &#147;Policy Regarding Shareholder Candidates for Nomination as a Director,&#148; which
sets forth the procedures and conditions for such recommendations. This policy is available through our website at www.stemcellsinc.com. The Corporate Governance Committee operates pursuant to a written charter, a copy of which is also available
through our website at www.stemcellsinc.com. The members of the Corporate Governance Committee approved the nomination of the Class&nbsp;I directors standing for reelection at the Annual Meeting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Strategic Transactions Committee</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Strategic Transactions Committee is composed of
Messrs.&nbsp;Bjerkholt, Greer and McGlynn and Dr.&nbsp;Levy. The Strategic Transactions Committee held five meetings during the fiscal year ended December&nbsp;31, 2012. The Committee was created at the suggestion of our Chief Executive Officer in
March 2009 to provide advice and direction, on an <I>ad hoc </I>basis, on a range of strategic initiatives being considered at the time, such as the acquisition of substantially all of the operating assets of Stem Cell Sciences plc. The Committee
does not have a formal charter. However, the Board of Directors has authorized the Committee to be available to advise, consult and participate with management, as requested by the company&#146;s Chief Executive Officer, with respect to the
identification, implementation, evaluation, and negotiation of potential strategic corporate transactions, with the exception of financings. Since June 2010, the Strategic Transactions Committee has been the Board&#146;s fourth standing committee,
and as such it routinely provides recommendations both to management and to the full Board with regard to such matters as the Committee may deem advisable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows the members of our four standing Board committees: </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Director</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Independent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Audit<BR>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Compensation<BR>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate<BR>Governance<BR>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Strategic<BR>Transactions<BR>Committee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Bjerkholt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chair</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#252;</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#252;</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R. Scott Greer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chair</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ricardo Levy,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#252;</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#252;</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chair</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#252;</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">No</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#252;</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roger&nbsp;Perlmutter,&nbsp;M.D.,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#252;</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Schwartz,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#252;</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chair</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#252;</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS"></FONT>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Irving Weissman,&nbsp;M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">No</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Oversight and Qualifications </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">While management is responsible for the day-to-day management of the risks the company faces, the Board, as a whole and through its committees, has responsibility for the oversight of risk management. An
important part of risk management is not only understanding the risks facing the company and what steps management is taking to manage those risks, but also understanding what level of risk is appropriate for the company. In support of this
oversight function, the Board receives regular reports from our Chief Executive Officer and members of senior management on operational, financial, legal, and regulatory issues and risks. The Audit Committee additionally is charged under its charter
with oversight of financial risk, including the company&#146;s internal controls, and it receives regular reports from management, the company&#146;s internal auditors and the company&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
independent auditors. The Chairman of the Board and independent members of the Board work together to provide strong, independent oversight of the company&#146;s management and affairs through
its standing committees and, when necessary, special meetings of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe each of our directors brings valuable
skills, experience, judgment, and perspectives to our company. The Board took the following qualifications into consideration, among other things, when nominating or appointing our current directors: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="67%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric&nbsp;Bjerkholt</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Bjerkholt is a financial expert and currently serves as the Executive Vice President and Chief Financial Officer of Sunesis Pharmaceuticals, Inc., a biopharmaceutical
company. His business experience spans more than 20&nbsp;years, during which time he founded a nutraceutical company and worked as an investment banker. Mr.&nbsp;Bjerkholt currently serves on the board of directors of Round Table Pizza. We believe
Mr.&nbsp;Bjerkholt&#146;s qualifications to serve on our Board of Directors include his considerable financial and business experience, especially in the life sciences industry. Mr.&nbsp;Bjerkholt has served on our Board for over eight
years.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">R. Scott Greer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Greer was appointed to our Board in June 2010. He is a financial expert with over 25&nbsp;years of experience in the life sciences industry. He was founder, CEO and
Chairman of Abgenix, Inc., a biotechnology company he took public in 1998 and then sold to Amgen in 2006. Mr.&nbsp;Greer currently serves as Chairman of Ablexis, a development stage biotechnology company, and is also on the board of Nektar
Therapeutics. We believe Mr.&nbsp;Greer&#146;s qualifications to serve on our Board include his more than 25&nbsp;years of experience in the life sciences industry.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ricardo&nbsp;Levy,&nbsp;Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Levy has over 30&nbsp;years of experience leading technology companies in both North and South America. In 1974, he cofounded Catalytica, Inc., a manufacturing
technology and energy systems company, and served as CEO from 1991 until the company was sold in 2000. Dr.&nbsp;Levy currently serves as director of Accerlys Inc. (formerly Pharmacopeia, Inc.) and NovoDynamics, Inc. We believe his qualifications to
serve on our Board of Directors include his more than 30&nbsp;years of business experience. Dr.&nbsp;Levy has served on our Board for over twelve years.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;McGlynn has been our President and Chief Executive Officer since January 2001. He has held management positions of increasing responsibility in several countries for
more than 30&nbsp;years. Prior to joining our company, Mr.&nbsp;McGlynn was President and Chief Executive Officer of Pharmadigm, Inc., a privately held company in the fields of inflammation and genetic immunization. Prior to this, he was President
and General Manager of Abbott Canada Ltd. and President of Anaquest, Inc., a company focused on anesthesia and acute care pharmaceuticals. We believe Mr.&nbsp;McGlynn&#146;s qualifications to serve on our Board of Directors include his significant
managerial experience in our industry and his intimate knowledge of our operations as a result of his day to day leadership as our President and Chief Executive Officer. Mr.&nbsp;McGlynn has served on our Board for over twelve
years.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="67%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roger&nbsp;Perlmutter,&nbsp;M.D.,&nbsp;Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Perlmutter is Executive Vice President of Merck &amp; Co, an international pharmaceutical company, and President of Merck Research Laboratories, where he leads Merck&#146;s
global research endeavors. Previously, until February 2012, Dr.&nbsp;Perlmutter was the Executive Vice President of Research and Development of Amgen, Inc., a world leading biotechnology company, a position he held for approximately eleven years.
Prior to joining Amgen, he held scientific leadership positions of increasing responsibility at Merck. He also worked as a researcher and administrator at the University of Washington. We believe Dr.&nbsp;Perlmutter&#146;s pharmaceutical industry
experience brings an important industry perspective to the Board. Dr.&nbsp;Perlmutter has served on our Board for over twelve years.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Schwartz, Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Schwartz has over 40&nbsp;years of business and legal experience, including several years spent in the 1990s as President and Chief Executive Officer of Systemix, Inc.,
a cell-based therapeutics company which was acquired by Novartis in 1997. Before joining Systemix as its Senior Vice President and General Counsel in 1993, Dr.&nbsp;Schwartz served as the Vice President and General Counsel of Stanford University. He
currently runs a registered investment advisor firm called Quantum Strategies Management Company. We believe Dr.&nbsp;Schwartz&#146;s qualifications to serve on our Board of Directors include his over 40&nbsp;years of business and legal experience
in our industry as well as his significant experience working at Stanford University. Dr.&nbsp;Schwartz has served on our Board for over fourteen&nbsp;years.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Irving Weissman, M.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Weissman has been a leader in the stem cell field for over 20&nbsp;years. He is a professor at Stanford University and serves as the director of the Stanford Institute
for Stem Cell Biology and Regenerative Medicine. He co-founded Systemix in 1988 and Cellerant Therapeutics, Inc., a hematopoietic stem cell development company, in 2001. He is a member of several scientific advisory boards and national science
institutes, including the National Academy of Science, the American Academy of Arts and Science, and the Institute of Medicine of the National Academy of Sciences. We believe Dr.&nbsp;Weissman&#146;s qualifications to serve on our Board of Directors
include the fact that he has been a leader in stem cell research for over 20&nbsp;years as well as his substantial business experience in our industry. Dr.&nbsp;Weissman has served on our Board for over sixteen&nbsp;years and serves as the chairman
of our Scientific Advisory Board.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders who wish to communicate with our Board of Directors or with a particular director may send a
letter to our corporate secretary at the following address: StemCells, Inc., 7707 Gateway Blvd., Newark, California 94560 (c/o&nbsp;Legal Department). Any communication should clearly specify that it is intended to be made to the entire Board or to
one or more particular director(s). Our corporate secretary will review all such correspondence and forward to our Board a summary of all such correspondence and copies of all correspondence that, in the opinion of the secretary, deals with the
functions of the Board or committees thereof or that he otherwise determines requires their attention. The secretary maintains a log of all correspondence received by us that is addressed to members of the Board, and any director may at any time
review and request copies of any such correspondence. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concerns relating to accounting, internal controls or auditing matters will immediately be
brought to the attention of the chairman of the Audit Committee and handled in accordance with established procedures, which are set out in the Audit Committee&#146;s Policy on Receipt, Retention and Treatment of Complaints Regarding Accounting,
Internal Controls and Auditing Matters. A copy of this policy is available through our website at www.stemcellsinc.com. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive
Officers, Positions Held </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following are the name, age and other information for our named executive officers, as of
October 15, 2013. All company officers have been elected to serve until their successors are elected and qualified or until their earlier resignation or removal. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; text-indent:1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">President&nbsp;and&nbsp;Chief&nbsp;Executive&nbsp;Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn joined the company in January 2001, when he was appointed President and Chief Executive Officer of the company and of its wholly-owned subsidiaries. Mr.&nbsp;McGlynn
was elected to the Board of Directors in February 2001.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer and Vice&nbsp;President, Finance and Administration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young joined the company in September 2005 as Chief Financial Officer and Vice President, Finance. In November 2006 he became CFO and Vice President, Finance and
Administration. He is responsible for functions that include Finance, Information Technology and Investor Relations. From 2003 to 2005, Mr.&nbsp;Young was Chief Financial Officer and a director of Extropy Pharmaceuticals, Inc., a private
biopharmaceutical company focused on developing drugs for pediatric indications.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eliseo Salinas, M.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, Head of Research and Development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eliseo Salinas,&nbsp;M.D., joined the company in June 2013 as Executive Vice President and Head of Research and Development, with responsibility for the company&#146;s scientific
and clinical development programs. Prior to joining StemCells, Dr. Salinas served as Executive Vice President, Head of Development, and Chief Medical Officer of Elan Pharmaceuticals. Before joining Elan, Dr. Salinas was Senior Vice President,
Research and Development and Chief Medical Officer of Adolor Corporation; Executive Vice President, Specialty Pharma, Research and Development and Chief Scientific Officer of Shire
plc.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig,&nbsp;Ph.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, Development and Operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig,&nbsp;Ph.D., joined the company in September 2008 with responsibilities for Development, Manufacturing, Regulatory, Quality Systems, and Facilities. From 2005 to 2008,
Dr.&nbsp;Craig was Chief Technology Officer and Vice President of Progenitor Cell Therapy, a contract services provider for research, development, manufacture, and commercialization of cell-based therapies, prior to which he has held executive
positions at Xcyte Therapies, Osiris Therapeutics and SyStemix.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto,&nbsp;Ph.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Executive&nbsp;Vice&nbsp;President,&nbsp;Scientific and Strategic Alliances</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto,&nbsp;Ph.D., joined the company in November 1997 as Senior Director of Scientific Operations; was appointed Vice President, Scientific Operations in June 1998; Vice
President, Research and Development in February 2002; Chief Operating Officer in November 2006; and Executive Vice President, Research and Development, in October 2008. In June 2013, Dr. Tsukamoto was appointed Executive Vice President, Scientific
and Strategic Alliances, with responsibility for developing the Company&#146;s alliances with research institutions, corporations, government agencies, and disease foundations. Dr.&nbsp;Tsukamoto is married to one of our outside
directors.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton,&nbsp;J.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton,&nbsp;J.D., joined the company in February 2007 as General Counsel, with responsibility for corporate compliance and legal affairs. In March 2008, he assumed
responsibility for the Human Resources function. Prior to joining StemCells, Mr.&nbsp;Stratton served as Deputy General Counsel for Threshold Pharmaceuticals and as Senior Legal Counsel for Medtronic, Inc.&#146;s Vascular business
unit.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), requires our executive officers,
directors, and persons who own more than 10% of a registered class of our equity securities, to file with the SEC reports of ownership of our securities and changes in reported ownership. Executive officers, directors and greater than 10% beneficial
owners are required by SEC rules to furnish us with copies of all Section&nbsp;16(a) reports they file. Based solely on a review of the copies of such forms furnished to us, or written representations from the reporting persons that no Form&nbsp;5
was required, we believe that, during the fiscal year ended December&nbsp;31, 2012, all Section&nbsp;16(a) filing requirements applicable to our officers, directors and greater </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
than 10% beneficial owners have been met, with the following exception: the Form 4 filed by Dr.&nbsp;Levy on October&nbsp;2, 2012, reporting his annual equity grant for Board service, was filed
two days late. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Business Conduct and Ethics </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have adopted a Code of Ethics and Conduct that applies to all of our directors, officers, employees, and consultants. A copy of our code of ethics is posted on our website at www.stemcellsinc.com. We
intend to disclose any substantive amendment or waivers to this code on our website. There were no substantive amendments or waivers to this code in 2012. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>EXECUTIVE COMPENSATION </I></B><B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Discussion and Analysis
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We structure our compensation programs to attract and retain talented employees and reward them for helping us achieve
our short-term and long-term goals. We intend for our compensation programs to be equitable and competitive when measured against those offered by companies against whom we compete for high-level scientific and executive personnel. We also intend
for them to link pay to both company and individual performance. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In seeking to accomplish these objectives, we follow a
compensation strategy designed, ultimately, to reward increasing stockholder value. However, because achievement of our principle mission&nbsp;&#151; the research, development and commercialization of stem cell therapeutics and related tools and
technologies for academia and industry&nbsp;&#151; is a long, expensive and challenging process, we often set individual compensation by using surrogate endpoints to gauge employee contributions towards building sustained stockholder value, such as:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the achievement of stated corporate goals adopted from time to time by the Board; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the leadership an executive officer has shown in inspiring and marshaling excellent performances in his or her direct reports;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the anticipation, identification and successful disposition of issues and problems that, if not addressed timely and effectively, might have a
deleterious effect on the company;&nbsp;and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the speed and effectiveness with which an executive officer discovers, assesses and, where appropriate, pursues promising opportunities for the
company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Compensation elements.</I>&nbsp;&nbsp;&nbsp;&nbsp;We, like most biotechnology companies, use a
combination of base salary, bonuses and equity awards to compensate our employees, including our executive officers. As a small company&nbsp;&#151; we have approximately 50&nbsp;employees in total and only six executive officers&nbsp;&#151; we feel
that having so few people in each job classification and level makes it inefficient to establish a formulaic allocation of total compensation among its various elements; we rely, instead, on our experience and judgment. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In exercising this judgment, we periodically collect and review information (i)&nbsp;from third party market reports such as the
<I>Radford Biotechnology Survey&nbsp;&#151; Executive Report</I>; and (ii)&nbsp;from the proxy statements of other similar biotechnology companies, especially those operating in the San&nbsp;Francisco Bay Area, as well as
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
those pursuing cell-based therapeutics.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> In the case of the executive officers who report directly to the chief executive officer, we also carefully consider the recommendations of the chief executive officer when setting compensation. We
integrate all of this information with our evaluation of the individual performance of each of our executive officers. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While
we believe our officers and other employees are outstanding, we realize that the company is not yet profitable and that it is still in a relatively early stage of development. We therefore generally prefer to target our compensation practices so
that our employees&#146; base salaries, bonuses, equity compensation, and benefits all fall close to the 50th&nbsp;percentile paid by comparable companies for similar positions. Actual compensation may fall slightly above or below these targets,
however, because of any number of factors such as general economic conditions, market competition for specific jobs, personal performance, and the need for internal equities within the company. For example, we have recently paid many of our
employees, including some of our executive officers, at below the 50th&nbsp;percentile because of the recent global recession and crisis in the financial markets. At the same time, however, we have paid many of our employees, including some of our
executive officers, at above the 50th&nbsp;percentile because of highly competitive demand for workers with their unique skill sets. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Interaction of compensation elements.</I>&nbsp;&nbsp;&nbsp;&nbsp;The basic compensation elements&nbsp;&#151; base salary, bonuses and equity awards&nbsp;&#151; are, as noted, standard in our industry.
Though not set independently of one other, we use each element as a portion of total compensation because we believe we would not otherwise be competitive and because we feel that together they are the proper components of a balanced compensation
package: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">base salary is compensation for current efforts; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">bonuses, whether in cash or equity, are paid at the Board&#146;s discretion typically for achievements in meeting or exceeding corporate
goals;&nbsp;and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">equity awards are inducements to remain with the company and to build future value. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On occasion, we have considered our employee compensation programs, including our executive compensation programs, and the effect they
may have on company risk. We have concluded that our employee compensation programs are simple and straight-forward and consistent with those of similarly situated research and development companies. In determining that our compensation policies and
practices do not present risks that are likely to have a material adverse effect on our business, our directors have, from time to time, discussed with management the various pay practices used to compensate our employees at both the executive and
non-executive levels. These inquiries have included discussions about our three primary components of compensation, namely base compensation, cash bonuses and equity incentive compensation. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board of Directors has also periodically considered how bonus awards are determined and calculated by the company, noting that all
bonuses are awarded entirely at the discretion of our Board after taking into consideration the progress of our company&#146;s programs. Based on its review, our Board has concluded that our bonus program properly aligns compensation with our
overall goals, all of which are designed to have a positive impact on our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our Board has periodically
examined our equity compensation practices, noting that we typically grant customary equity awards that vest over many years after the date of grant. We believe </FONT></P>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> In 2012, for example, we collected executive compensation information
from the recent SEC filings of Aastrom Biosciences, Inc.; Affymax, Inc.; Alexza Pharmaceutics, Inc.; Anacor Pharmaceuticals, Inc.; Athersys, Inc.; Cerus Corporation; Cytokinetics, Incorporated; Cytori Therapeutics, Inc.; Dynavax Technologies
Corporation; Geron Corporation; InterMune, Inc.; MAP Pharmaceuticals, Inc.; Maxygen, Inc.; Medivation, Inc.; Neuralstem, Inc.; Osiris Therapeutics, Inc.; Rigel Pharmaceuticals, Inc.; Sangamo Biosciences, Inc.; and Sunesis Pharmaceuticals, Inc.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
discretionary equity compensation that vests over multiple years does not encourage short-term or high-risk opportunistic behavior and instead aligns our employees&#146; interests with the
long-term interests of our stockholders by encouraging activities intended to build long-term value for the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For
these reasons, we have concluded that our employee compensation programs are designed with the appropriate balance of risk and reward in relation to our company&#146;s overall business strategy and do not incentivize executives or other employees to
take unnecessary or excessive risks. As a result, we believe that risks arising from our employee compensation policies and practices are not reasonably likely to have a material adverse effect on the company. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other compensation elements and benefits.</I>&nbsp;&nbsp;&nbsp;&nbsp;We offer all employees various health and welfare benefit plans.
Our executive officers may participate in these on the same terms as other employees. We do not have a pension plan nor do we use non-qualified deferred compensation.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> We offer our U.S.&nbsp;employees (again, including executive officers on the same terms as others) a 401(k) defined
contribution plan, and match employee contributions on a 1:2 basis (<I>i.e.</I>, $1 contribution by the company for every $2 contribution made by the employee) up to a maximum of 3% of the employee&#146;s salary, subject to legal limitations. At
this time, our 401(k) match is made in the form of shares of common stock in the company. We offer our U.K. employees a tax preferred pension scheme, and match employee contributions on a 1:1 basis up to a maximum of 12% of the employee&#146;s
salary. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation of Named Executive Officers </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Base salary compensation; target bonuses.</I>&nbsp;&nbsp;&nbsp;&nbsp;We consider base salary to be a critical component of our executive officers&#146; overall compensation packages. We intend the
salaries of our executive officers to reflect their actual responsibilities and job scope. We also endeavor to set base compensation levels so that their salaries are competitive with salaries paid by comparable companies to employees with similar
experience, taking into account the cost of living in the San&nbsp;Francisco Bay Area. Accordingly, we have made occasional adjustments to the salaries of certain employees to address perceived below market anomalies, address specific retention
concerns or reward special contributions made to the company. As described below, we changed the base compensation paid to certain of our executive officers in 2009, 2010, 2012, and 2013. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to base salary, each full-time employee of the company, including each of our named executive officers, is given a personal
target bonus (calculated as a percentage of base salary), based upon factors such as seniority, job title and the existing targets of co-workers with comparable job responsibilities within the company. Bonuses at the company are discretionary and
awarded by the Board in its sole discretion. But when bonuses are awarded, we use the personal target of each employee to calculate his or her bonus amount. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">With these various principles in mind, we recently took the following actions with respect to the base compensation and bonus targets of our executive officers. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From March 2007 through 2008, we maintained the annual base salary of Mr.&nbsp;McGlynn at $385,000, plus a housing and transportation
allowance. Effective January 2009, however, we eliminated Mr.&nbsp;McGlynn&#146;s housing and transportation allowance of approximately $200,000 per year and increased Mr.&nbsp;McGlynn&#146;s annual base salary by $140,000, from $385,000 to
$525,000, and began providing him a car allowance in the amount of $10,000 per year. The net effect of these changes was a decrease in Mr.&nbsp;McGlynn&#146;s base compensation of approximately 11% for 2009. Concurrent with these changes, we
increased Mr.&nbsp;McGlynn&#146;s target bonus from 40&nbsp;percent to 55&nbsp;percent of his base salary, beginning with the 2009 fiscal year, to reflect the Board&#146;s view that Mr.&nbsp;McGlynn&#146;s leadership is a major factor in the
achievement of the company&#146;s corporate goals and to further </FONT></P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP></FONT>
<FONT STYLE="font-family:Times New Roman" SIZE="2"> Accordingly, we omit tables showing pension benefits and non-qualified deferred compensation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
align his compensation to corporate success. Effective February&nbsp;1, 2012, we increased Mr.&nbsp;McGlynn&#146;s base salary to $550,000. More recently, effective June&nbsp;17, 2013, we
increased Mr.&nbsp;McGlynn&#146;s base salary to $570,000 in recognition of contributions made on behalf of the company and market factors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">From March 2007 through 2009, we maintained the annual base salary of Mr.&nbsp;Young at $275,000. In January 2010, however, we increased Mr.&nbsp;Young&#146;s annual base salary to $325,000 in recognition
of contributions made on behalf of the company and job scope. In January 2010, we also increased Mr.&nbsp;Young&#146;s target bonus rate from 25% to 30% of his base salary, beginning with the 2010 fiscal year, to further align his compensation to
corporate success. In February 2011, we increased Mr.&nbsp;Young&#146;s target bonus rate from 30% to 40% of his base salary for the same reason. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">From March 2007 through 2011, we maintained the annual base salary of Dr.&nbsp;Tsukamoto at $300,000. In January 2010, however, we increased Dr.&nbsp;Tsukamoto&#146;s target bonus from 25% to 30% of her
base salary, beginning with the 2010 fiscal year, to further align her compensation to corporate success. In February 2011, we increased Dr.&nbsp;Tsukamoto&#146;s target bonus rate from 30% to 40% of her base salary for the same reason. Effective
February&nbsp;1, 2012, we increased Dr.&nbsp;Tsukamoto&#146;s base salary to $335,000 in recognition of contributions made on behalf of the company and market factors. More recently, effective June&nbsp;6, 2013, we increased
Dr.&nbsp;Tsukamoto&#146;s base salary to $350,000 in recognition of contributions made on behalf of the company, market factors and her new role and responsibilities as executive vice president of scientific and strategic alliances. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Craig joined the company in September 2008, with an annual base salary of $275,000 and a target bonus rate of 25% of his base
salary. In January 2010, however, we increased Dr.&nbsp;Craig&#146;s target bonus from 25% to 30% of his base salary, beginning with the 2010 fiscal year, to further align his compensation to corporate success. In February 2011, we increased
Dr.&nbsp;Craig&#146;s target bonus rate from 30% to 40% of his base salary for the same reason. Effective February&nbsp;1, 2012, we increased Dr.&nbsp;Craig&#146;s base salary to $300,000. More recently, effective June&nbsp;17, 2013, we increased
Dr.&nbsp;Craig&#146;s base salary to $320,000 in recognition of contributions made on behalf of the company and market factors. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Stratton joined the company in February 2007, with an annual base salary of $220,000 and a target bonus rate of 20% of his base
salary. In February 2008, however, we increased Mr.&nbsp;Stratton&#146;s annual base salary to $250,000 in recognition of contributions made on behalf of the company and because he had assumed additional responsibilities in early 2008. In January
2010, we increased Mr.&nbsp;Stratton&#146;s annual base salary to $275,000 in recognition of contributions made on behalf of the company and job scope. In January 2010, we also increased Mr.&nbsp;Stratton&#146;s target bonus rate from 20% to 30% of
his base salary, beginning with the 2010 fiscal year, to further align his compensation to corporate success. In February 2011, we increased Mr.&nbsp;Stratton&#146;s target bonus rate from 30% to 40% of his base salary for the same reason. Effective
February&nbsp;1, 2012, we increased Mr.&nbsp;Stratton&#146;s base salary to $300,000. Most recently, effective June17, 2013, we increased Mr.&nbsp;Stratton&#146;s base salary to $320,000 in recognition of contributions made on behalf of the company
and market factors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Salinas joined the company in June 2013, with an annual base salary of $475,000 and a target
bonus rate of 50% of his base salary. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The base compensation and target bonus information presented above can be summarized as
follows: </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;12/31/09<BR>Base Compensation/<BR>Target Bonus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;12/31/10<BR>Base Compensation/<BR>Target Bonus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;12/31/11<BR>Base Compensation/<BR>Target Bonus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;12/31/12<BR>Base&nbsp;Compensation/<BR>Target Bonus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Current Base<BR>Compensation/</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Target
Bonus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">525,000/55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">525,000/55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">525,000/55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">550,000/55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">570,000/55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CFO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000/25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,000/30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, R&amp;D(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">475,000/50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, D&amp;O</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000/25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000/30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">320,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Alliances(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000/25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000/30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">335,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">350,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">GC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,000/20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000/30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">320,000/40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The company&#146;s executive vice president and head of research and development joined the company in June&nbsp;2013. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The company&#146;s executive vice president of scientific and strategic alliances served as the company&#146;s executive vice president of research and development from
October&nbsp;2008 until June 2013. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Bonus compensation.</I>&nbsp;&nbsp;&nbsp;&nbsp;We view periodic bonuses,
whether paid in cash or equity, as an important element of compensation for several reasons. Bonuses help align individual employee efforts with overall corporate strategies and objectives. Bonuses also help us manage salary expense, while still
allowing us to reward successes. By using discretionary bonuses as part of the compensation mix, we have greater flexibility in managing the timing and amounts of compensation. Accordingly, each year we estimate for planning purposes an aggregate
&#147;bonus pool,&#148; which is calculated by using the base salaries of all our full-time employees and their respective target bonuses, and which assumes the Board will elect to award each full-time employee 100% of his or her personal target
bonus amount for the year. However, as explained below, the actual bonus award for any particular year is entirely within the Board&#146;s discretion. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In practice, over the past few years, we have awarded bonuses on an annual basis after considering, among other things, the company&#146;s accomplishments against stated corporate goals adopted by the
Board, the company&#146;s financial position, the status of its development programs, clinical progress and corporate development activities, and general economic factors. This has necessarily involved a subjective assessment by the Compensation
Committee of corporate performance and market conditions each year. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of establishing our corporate goals over the
past few years has been a lengthy one. For each fiscal year, our executive officers have presented the Compensation Committee of the Board with approximately five to ten proposed corporate goals, each often consisting of multiple sub-parts.
Management has usually presented its recommended corporate goals to the Compensation Committee concurrent with our proposed corporate budgets for the following fiscal year. Goals have been designed to be challenging, so that one would not expect
consistent achievement of all of them. Typically these goals have included some preclinical and clinical goals for our HuCNS-SC cell product candidate, financing and corporate development goals, goals related to advancement in cell manufacturing
practices, and goals related to advancement of our Liver Program. While all these goals have been considered important, and we have used a cross-functional and balanced approach to setting them, we have typically prioritized our goals by assigning
relative weightings to each of them, with all of them together adding up to 100%. However, by design, no one goal has ever accounted for a majority of the relative weightings. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">After receiving management&#146;s recommended goals, members of the Compensation Committee typically review them with our executive officers and oftentimes provide suggestions for additional goals or
changes to the recommended goals. After our executive officers and directors have completed this iterative process, which has often taken several weeks, the Compensation Committee adopts revised corporate goals consistent with the foregoing
principles and recommends the updated corporate goals to the full Board for consideration and approval. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thereafter, during each fiscal year, our executive officers have used the Board-approved
corporate goals as a management tool, for example to coordinate activities, motivate personnel and help prioritize the use of company resources. The executive officers have sometimes referred back to the corporate goals when providing business
updates to the Board, similar to management&#146;s reference back to an approved annual budget. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recently, at the end of each
fiscal year or shortly afterwards, our Chief Executive Officer has presented the Compensation Committee with his assessments of corporate performance against the Board-approved corporate goals, together with a summary of any important factors that
weighed in his assessments, which he has provided as context. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because our corporate goals have not been formulaic or
quantitative in nature (we have not had a corporate goal tied to specific stock price, revenues or expenses, for example), our CEO&#146;s assessments have been largely qualitative in nature. Along with these assessments, our CEO has provided a
percentage score for each goal reflecting the degree to which each goal was or was not, in his judgment, achieved during the year. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee has usually considered these percentage scores as well as our CEO&#146;s commentary about corporate performance and more general assessments of the state of our business when
determining whether to award employees a company-wide corporate bonus in any given year, and if so how much of the available bonus pool to award. However, the Compensation Committee members have used their own judgment to determine the size of any
bonus award, if any. In any given year, the Board may decide in its judgment to award more than 100% of the bonus pool for the year. The Board may also decide to award less than 100% of the bonus pool, even if all of the corporate goals have been
achieved, if it decides doing so would be in the best interests of the company. While the Compensation Committee and the Board as a whole use the corporate goals as a measure of success, the amount of any bonus grant, as well as how and when it will
be paid, is completely within the Board&#146;s sole discretion. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With these various principles in mind, we recently took the
following actions with respect to corporate bonuses for 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2012, as part of its annual year-end review of
performance, the Compensation Committee (with input from the Chief Executive Officer and other Board members) considered, among other things, significant company performance accomplishments in 2012, the company&#146;s successes measured against its
2012 corporate goals, the degree of difficulty in achieving these goals, as well as other events and circumstances that affected performance. The 2012 goals, as approved by our Board, consisted generally of the following: (i)&nbsp;progress in our
CNS Program, including activities aimed at testing our proprietary HuCNS-SC cells in multiple disease indications within the CNS, including the initiation of a study of HuCNS-SC cells in age related macular degeneration, the dosing of additional
patients in our spinal cord injury trial, and preparation for initiating a Phase II controlled study in Pelizaeus-Merzbacher disease; (ii)&nbsp;partnering and corporate development activities; and (iii)&nbsp;successful fundraising efforts.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Highlights of the 2012 accomplishments taken into account by the Compensation Committee in determining the overall company
performance included: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Therapeutic Product Development </U></I></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, we published preclinical data demonstrating that our proprietary HuCNS-SC cells protect host photoreceptors and preserve vision in a
well-established animal model of retinal disease. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period. In humans, degeneration of the core photoreceptors accounts for the
unique pattern of vision loss in dry AMD. The data was featured as the cover article in the peer-reviewed <I>European Journal of Neuroscience</I>. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also in January 2012, the FDA authorized the initiation of a Phase I/II clinical trial of our proprietary HuCNS-SC cells in dry AMD, the most common
form of AMD. AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30&nbsp;million people worldwide are afflicted with the disease. There are no approved treatments for dry AMD.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2012, the fourth and final patient in our Phase I PMD trial completed the twelve-month follow up and evaluations required by the trial
protocol, and the trial was completed. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2012, we presented preliminary evidence of progressive and durable donor-cell derived myelination in all four patients who were transplanted
with our proprietary HuCNS-SC cells in our Phase I clinical trial for PMD, a rare hypomyelination disorder in children. In addition, clinical assessment revealed small but measureable gains in motor and/or cognitive function in three of the four
patients; the fourth patient remained clinically stable. The study was conducted by researchers at the University of California, San Francisco (UCSF). A summary of the trial results were presented at the 2012 European Leukodystrophy Association
(ELA) <I>Families/Scientists Meeting</I> in Paris, France. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May 2012, we presented data from the first interim safety review of our Phase I/II spinal cord injury clinical trial, which indicated that the
surgery, immunosuppression and the HuCNS-SC cell transplants have been well tolerated. The trial, which was designed to evaluate the safety and preliminary efficacy of our proprietary HuCNS-SC cells, represents the first time that neural stem cells
have been transplanted as a potential therapeutic agent for spinal cord injury.&nbsp;A summary of the data was presented at the Interdependence 2012 Global SCI Conference in Vancouver, Canada. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2012, we initiated our Phase I/II clinical trial of our proprietary HuCNS-SC cells in dry AMD. The trial is being conducted at the Retina
Foundation of the Southwest&#146;s (RFSW) in Dallas, Texas, and at the Byers Institute at Stanford. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2012, we presented preclinical data demonstrating that our proprietary human neural stem cells restored memory and enhanced synaptic function
in two animal models relevant to Alzheimer&#146;s disease. Importantly, these results did not require reduction in beta amyloid or tau, substances that accumulate in the brains of patients with Alzheimer&#146;s disease and account for the
pathological hallmarks of the disease. The data was presented at the <I>Alzheimer&#146;s Association International Conference 2012</I> in Vancouver, Canada. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2012, the governing board of the California Institute for Regenerative Medicine (CIRM) approved an award to us for up to a $20 million under
the Disease Team Therapy Development Award program (RFA 10-05) to fund preclinical development of our HuCNS-SC cells in cervical spinal cord. Under RFA 10-05, funding would have been in the form of a forgivable loan. However, in March 2013, we
elected not to borrow these funds from CIRM. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also in July 2012, the Japan Patent Office granted us Patent Number 5007003 which broadly covers the prospective isolation and enrichment of neural
stem and progenitor cells using antibody selection, as well as the use of these cells to treat disorders of the central nervous system. Some of the more noteworthy claims in this patent include methods for isolating human neural stem cells, as well
as compositions of matter comprising enriched neural stem cells, such as our proprietary HuCNS-SC cells, and the use of enriched neural stem cells as a medicament for the treatment of neurodegenerative diseases, acute brain injury and dysfunction of
the central nervous system.&nbsp;The term of this patent extends into 2020. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2012, we presented interim six-month data from the first patient cohort in our Phase I/II clinical trial of our HuCNS-SC cells for chronic
spinal cord injury. The first patient cohort all have no sensory or motor function below the level of injury and are considered to have complete spinal cord </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
injuries. The interim data continues to demonstrate a favorable safety profile, and showed considerable gains in sensory function in two of the three patients compared to pre-transplant
baselines; the third patient remained stable.&nbsp;The data was presented at the <I>51st Annual Scientific Meeting</I> of the International Spinal Cord Society in London, England. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also in September 2012, the first patient with an incomplete spinal cord injury was enrolled and dosed in our Phase I/II clinical trial in chronic
spinal cord injury. Patients who retain some sensory function below the level of trauma are considered to have an incomplete injury. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also in September 2012, the governing board of CIRM approved a second disease team award to us for up to $20 million under RFA 10-05. This second award
is to fund preclinical development of our HuCNS-SC cells in Alzheimer&#146;s disease. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2012, the first patient in our Phase I/II clinical trial in dry age-related macular degeneration (AMD) was enrolled and dosed.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2012, two papers reporting clinical and preclinical data demonstrating the therapeutic potential of our proprietary HuCNS-SC cells for a
range of myelination disorders were published in <I>Science Translational Medicine</I>, the peer-reviewed journal of the American Association for the Advancement of Science. The first paper summarized the data from our Phase I trial in
Pelizeus-Merzbacher disease (PMD), which showed preliminary evidence of progressive and durable donor cell-derived myelination in all four patients transplanted with HuCNS-SC cells. Three of the four patients showed modest gains in neurological
function; the fourth patient remained stable. The second paper demonstrated that transplantation of our neural stem cells in an animal model of severe myelin deficiency results in new, functional myelin. Sophisticated analytical techniques were used
to confirm that changes measured by magnetic resonance images were in fact derived from new human myelin generated by the transplanted HuCNS-SC cells and these results supported the use of similar techniques to detect and evaluate the degree of
myelination in our Phase I PMD trial. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also in October 2012, we were issued U.S. Patent Number 8,283,164 which broadly covers purified populations of human liver cells, including our human
liver engrafting cells (hLEC).&nbsp;The hLEC cells were first isolated by our researchers in the late 1990s, and our scientists have repeatedly demonstrated the cells&#146; engraftment and robust bioactivity <I>in vivo</I> and that they are
expandable.&nbsp;While our hLEC cells are purified from donated adult livers not suitable for transplant, the newly issued &#145;164 patent claims cells independent of tissue source, and therefore, has potential relevance to those deriving liver
cells from induced pluripotent or embryonic stem cell platforms.&nbsp;The term of the &#145;164 patent extends into 2022. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I><U>Tools and Technologies Programs </U></I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2012, we entered into a license agreement under which we granted genOway a worldwide, exclusive license to our Internal Ribosome Entry Site
(IRES) technology for use in the development and commercialization of genetically engineered mice. We received an upfront license fee and could receive royalties on product sales. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2012, we launched four new SC Proven human neural stem cell kits for use in neuroscience research. Each kit will contain high purity,
multipotent neural stem cells derived from a different area of the human central nervous system, and will provide researchers with a reproducible and scalable serum-free platform with which to perform a broad range of assays. With these kits,
researchers will now have the ability to compare and contrast the biological, functional and neural differentiation properties of human neural stem cells isolated from specific regions of the central nervous system, as well as to screen for the
effects of different compounds on such cells. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also in October 2012 we partnered with a UK-based biomedical company to develop and commercialize a range of cell lines and reagents to facilitate iPS
cell-based research for regenerative medicine applications. The first product under the partnership, an &#147;ultra-primary&#148; human fibroblast cell line from which researchers can generate iPS cell lines, was launched under the SC Proven brand.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Financing and Other Business-related Activities </U></I></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012, we sold an aggregate of 9,647,471 shares of our common stock for gross proceeds of approximately $20,452,000. These sales were made under a
sales agreement entered into in June 2009 and the sales agent was paid compensation equal to 3% of gross proceeds. The shares were offered under our shelf registration statement previously filed with, and declared effective by, the SEC.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012, an aggregate of 2,700,000 Series B Warrants were exercised and we received gross proceeds of $3,375,000. The remaining 5,300,000 Series B
Warrants expired unexercised by their terms on May&nbsp;2, 2012. For the exercise of these warrants, we issued 2,700,000 shares of our common stock and 2,700,000 Series A Warrants. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012, an aggregate of 2,198,571 Series A Warrants were exercised. For the exercise of these warrants, we issued 2,198,571 shares of our common stock
and received gross proceeds of approximately $3,078,000. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following this review, the Compensation Committee
awarded a discretionary bonus equal to 70% of the available bonus pool, based upon the committee members&#146; assessments of market conditions, corporate risks, our market comparables, and the company&#146;s performance in 2012 measured against its
2012 corporate goals, including the successes highlighted above, among other things. The bonuses were calculated using each employee&#146;s annual base salary as of January&nbsp;1, 2012, and paid in January 2013. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accordingly, in January 2013, the company paid Mr.&nbsp;McGlynn a 2012 bonus in the amount of $202,125, because on January&nbsp;1, 2012
his base salary and target bonus were, respectively, $525,000 and 55%. The company paid Mr.&nbsp;Young a 2012 bonus in the amount of $91,000, because on January&nbsp;1, 2012 his base salary and target bonus were, respectively, $325,000 and 40%, and
the company paid Dr.&nbsp;Tsukamoto a 2012 bonus in the amount of $84,000, because on January&nbsp;1, 2012 her base salary and target bonus were, respectively, $300,000 and 40%. The company also paid Dr.&nbsp;Craig and Mr.&nbsp;Stratton each a 2012
bonus in the amount of $77,000, because on January&nbsp;1, 2012 their base salary and target bonus were, respectively, $275,000 and 40%. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Equity Compensation&nbsp;&#151; general practices.</I>&nbsp;&nbsp;&nbsp;&nbsp;We believe that equity compensation awards are an important component of our overall compensation policy because equity
compensation can provide strong inducement to remain with the company and to build future stockholder value. In order to achieve these objectives, we believe that equity compensation awards need to be structured to provide both meaningful value and
a meaningful opportunity to realize that value. Accordingly, from time to time, we have considered several forms of equity compensation awards, including stock options, stock appreciation rights, restricted stock, and restricted stock units, because
each of these have certain advantages and disadvantages relative to the others with respect to how they might reward effort and success and how they might help us retain high contributors. Generally speaking, over the years, we have used stock
options and restricted stock units as the most common equity compensation instruments. We feel each of these forms of equity has unique and important features for employee retention and for incentivizing the executive officers to build a profitable
and sustainable business. Unless otherwise specifically noted in the tables herein, all option awards: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to our employees, including our executive officers, are intended to be qualified incentive stock options (ISOs) to the fullest extent permitted by law;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">have an exercise price set at the closing market price of our common stock on the grant date, or on an adjacent market trading date if the market on
which we are listed (currently the Nasdaq Capital Market) is not open on the grant date;&nbsp;and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">vest over four years, with one-fourth of the shares included in any grant vesting on the first anniversary of the grant and the remainder vesting
1/48th&nbsp;per month thereafter, always provided that the grantee remains in the company&#146;s employ on the vesting dates. These awards are time-vesting and do not depend on performance factors. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have typically granted stock option awards to newly hired employees, effective as of their date of hire, and occasionally to existing
employees upon their promotion. Both on-hire awards to non-executive officers and awards upon the promotion of current employees are usually made by either Mr.&nbsp;McGlynn, acting as the Board&#146;s single-member committee, or by the Compensation
Committee. Awards to executive officers are made by either the Compensation Committee or by the full Board. We have not granted company-wide equity awards to full-time employees since June 2010. Instead, we have granted targeted equity awards to
individual employees within the company following a careful review of equity held by each of our employees and the retention value that such awards may provide. In awarding equity grants to existing employees, we consider their contributions to the
company, their roles and responsibilities, their past performance, and market conditions generally for similarly situated employees. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">With these various principles in mind, we recently took the following actions with respect to equity compensation. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2010, after a review of the market and company-specific information described above, the Compensation Committee approved a company-wide award to employees of 190,000 restricted stock units and
options to purchase up to 184,500&nbsp;shares of common stock, in the aggregate. Of particular importance, the Compensation Committee noted that a majority of the stock options previously issued to employees had strike prices significantly above the
current market price of the company&#146;s stock and were therefore of limited retention value. All of the restricted stock units awarded in June 2010 have four-year vesting, with one-fourth vesting on each of the first four anniversaries following
the grant date, except for the restricted stock units granted to Mr.&nbsp;McGlynn and Dr.&nbsp;Tsukamoto, each of which has three-year vesting, with one-third vesting on each of the first three anniversaries following the grant date. All of the
options awarded at this time will vest one-fourth on the first anniversary following the grant and then 1/48th&nbsp;each month thereafter, in keeping with the company&#146;s standard practices. In this June 2010 grant, our named executive officers
received, in the aggregate, 250,000 restricted stock units and options to purchase up to 265,000&nbsp;shares of common stock. In September 2010, Mr.&nbsp;McGlynn voluntarily surrendered his rights and interests in 20,000 restricted stock units from
this June 2010 grant in order to bring his grant into accordance with the provisions of the company&#146;s equity incentive plan under which the grant was made. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In January 2011, we awarded Mr.&nbsp;McGlynn 20,000 additional restricted stock units in recognition of his service and importance to the company&#146;s long-term goals. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, after a review of the market and company-specific information described above, the Compensation Committee approved a
targeted award of 1,231,000 restricted stock units, in aggregate, to certain employees considered to be key contributors with leadership roles within the company and therefore most likely to have a direct role in building stockholder value. Of
particular importance, the Compensation Committee noted that a majority of the stock options issued to employees had strike prices significantly below the current market price of the company&#146;s stock and were therefore of limited retention
value. All of the restricted stock units awarded at this time have four-year vesting, with one-fourth vesting on each of the first four anniversaries </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
following the grant date, except for the restricted stock units granted to Mr.&nbsp;McGlynn and Dr.&nbsp;Tsukamoto, each of which has three-year vesting, with one-third vesting on each of the
first three anniversaries following the grant date. In this January 2012 grant, our named executive officers received, in the aggregate, 796,000 restricted stock units. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In August 2012, all of our executive officers decided to voluntarily surrender certain of their stock option awards under our 2004 and 2006 equity incentive plans, so that the option shares would be
available for future grants under these plans. Collectively, the executive officers surrendered both vested and unvested options to acquire a total of 297,336 shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the restricted stock units awarded to our named executive officers in June 2010,&nbsp;January 2011, and January 2012: </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of Restricted Stock Units Granted(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:91pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name&nbsp;&amp; Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>January&nbsp;2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>January&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn&nbsp;&#151; President and CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto,&nbsp;Ph.D.&nbsp;&#151; EVP, Alliances</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young&nbsp;&#151; CFO and VP, Finance&nbsp;&amp; Administration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig,&nbsp;Ph.D.&nbsp;&#151; EVP, Development&nbsp;&amp; Operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton,&nbsp;J.D.&nbsp;&#151; General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All share numbers reported on a post-split adjusted basis. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;McGlynn was granted 120,000 restricted stock units in June 2010, however, he voluntarily surrendered 20,000 of these in September 2010 in order to bring his
grant into accordance with the provisions of the company&#146;s equity incentive plan under which the grant was made. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In December 2012, our Compensation Committee engaged The Croner Company, an executive compensation consultancy firm referred to us by our outside corporate counsel, to advise the Committee on setting a
compensation peer group for the purpose of evaluating the different components of compensation paid to our chief executive officer. During the first half of 2013, our Compensation Committee held six meetings, many of which were attended by
representatives from The Croner Company, to discuss a variety of recommendations made by The Croner Company, including a recommendation that the company establish a new equity incentive plan. The Compensation Committee also discussed with
representatives from both management and The Croner Company a possible peer group for evaluating executive compensation market practices. After considerable discussion and a review of peer information requested by the Committee, we agreed upon a
peer group consisting of fifteen (15)&nbsp;publicly traded companies as being closely comparable to the company because of such business factors as location, nature of operations, industry, and size.</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since these deliberations, and after consideration of our peer group&#146;s compensation practices, we have granted a number of equity
awards to our executive officers and to other key employees. In May and June 2013, for example, we awarded a total of 1,120,000&nbsp;million restricted stock units, each with four-year vesting, to key employees, including grants of 280,000
restricted stock units to each of Drs. Tsukamoto, Craig and Mr.&nbsp;Stratton. </FONT></P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3</SUP></FONT>
<FONT STYLE="font-family:Times New Roman" SIZE="2"> By June 2013, the company considered the following companies as being close comparables for purposes of evaluating executive compensation: Aastrom Biosciences, Inc.; Advanced Cell Technology, Inc.;
Athersys, Inc.; BioCryst Pharmaceuticals, Inc.; BioTime, Inc.; Cel-Sci Corporation; Cytokinetics, Incorporated; Cytori Therapeutics, Inc.; Geron Corporation; Medicinova, Inc.; Neostem, Inc.; Neuralstem, Inc.; Nova Bay Pharmaceuticals, Inc.; Osiris
Therapeutics, Inc.; and Sangamo Biosciences, Inc. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
In June&nbsp;2013, we granted our chief executive officer 700,000 restricted stock units with four-year vesting in recognition of his anticipated central role in achieving the company&#146;s
short- and long-term growth and future programmatic success. Also, in June 2013, we awarded Dr.&nbsp;Salinas, in connection with the start of his employment at the company, a total of 390,000 restricted stock units from the Company&#146;s 2012
Commencement Incentive Plan, with one-fourth vesting on each of the first four anniversaries of his hire date. Also in 2013, we granted an aggregate of 156,965 restricted stock units to other newly hired employees under our 2012 Commencement
Incentive Plan. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employment, Severance and Change-in-Control Agreements </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Employment agreements.</I>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;McGlynn joined the company as our president and chief executive officer on
January&nbsp;15, 2001. Under the terms of an employment agreement between Mr.&nbsp;McGlynn and the company, dated January&nbsp;2, 2001, as amended, Mr.&nbsp;McGlynn received an initial annual base salary of $275,000 per year, reviewable annually by
the Board of Directors, and a bonus, in the Board&#146;s sole discretion, of up to 25% of his base salary. Over time, however, we have increased Mr.&nbsp;McGlynn&#146;s base salary and target bonus so that they are, respectively, $570,000 and 55% of
his base salary. Pursuant to his January 2001 employment agreement, we granted Mr.&nbsp;McGlynn an option to purchase 40,000&nbsp;shares of our common stock with an exercise price equal to the fair market value of the common stock on the initial
date of his employment, one-fourth to vest on the first anniversary of his employment and the remaining three-fourths to vest in equal monthly installments during his second through fourth years of employment. These options remained unexercised and
expired in 2011. Mr.&nbsp;McGlynn&#146;s employment agreement also provided that the Board could, in its sole discretion, grant him a bonus option to purchase up to an additional 2,500&nbsp;shares, which it did. These options also remained
unexercised and expired in 2011. We also agreed to pay Mr.&nbsp;McGlynn a $50,000 relocation bonus and to reimburse him for relocation expenses, which we did. Since January 2009, we have been paying Mr.&nbsp;McGlynn an annual car allowance of
$10,000. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Tsukamoto joined the company in November 1997 and has served as our executive vice president of research
and development since September 2008. Under the terms of an employment agreement between Dr.&nbsp;Tsukamoto and the company, dated February&nbsp;2, 1998, Dr.&nbsp;Tsukamoto received an annual base salary of $130,000 per year and a discretionary
target bonus of up to 10% of her base salary. Over time, however, we have increased her base salary and target bonus so that they are, respectively, $350,000 and 40% of her base salary. Also pursuant to her employment agreement, we provide
Dr.&nbsp;Tsukamoto with $750,000 of term life insurance on an annual basis during her employment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Young joined the
company in September 2005 as our chief financial officer and vice president of finance. Under the terms of his agreement with the company, dated August&nbsp;16, 2005, Mr.&nbsp;Young received an initial annual base salary of $250,000 per year, with a
target bonus of up to 25% of his base salary. Over time, however, we have increased Mr.&nbsp;Young&#146;s base salary and target bonus so that they are, respectively, $325,000 and 40% of his base salary. Pursuant to his August 2005 employment
agreement, we granted Mr.&nbsp;Young an option to purchase 45,000&nbsp;shares of our common stock. This option vested over 48&nbsp;months; with one-fourth of the shares having vested on the first anniversary of the date on which
Mr.&nbsp;Young&#146;s employment began and with the remaining shares having vested at the rate of 1/48th&nbsp;per month on the last day of each month during the ensuing 36&nbsp;months. In addition, the employment agreement provided for an option
grant on the first anniversary of his employment to acquire an additional 2,500&nbsp;shares of our common stock. The grant of 2,500&nbsp;shares was duly made, and vested in the same manner as his earlier option grant over 48&nbsp;months. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Craig joined the company in September 2008 as our senior vice president of development and operations. Under the terms of his
agreement with the company, dated July&nbsp;24, 2008, Dr.&nbsp;Craig has received an annual base salary of $275,000 per year, with a target bonus of up to 25% of his base salary. Over time, however,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
we have increased Dr.&nbsp;Craig&#146;s base salary and target bonus so that they are, respectively, $320,000 and 40% of his base salary. Pursuant to Dr.&nbsp;Craig&#146;s July 2008 employment
agreement, we granted him an option to purchase 20,000&nbsp;shares of our common stock. This option will vest over 48&nbsp;months, with one-fourth of the shares having vested on the first anniversary of the date on which Dr.&nbsp;Craig&#146;s
employment began and with the remaining shares vesting, subject to his continued employment by the company, at the rate of 1/48th&nbsp;per month on the last day of each month during the ensuing 36&nbsp;months. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Stratton joined the company in February 2007 as our general counsel. Under the terms of his agreement with the company, dated
February&nbsp;2, 2007, Mr.&nbsp;Stratton received an initial annual base salary of $220,000 per year, with a target bonus of up to 20% of his base salary. Over time, however, we have increased Mr.&nbsp;Stratton&#146;s base salary and target bonus so
that they are, respectively, $320,000 and 40% of his base salary. Pursuant to Mr.&nbsp;Stratton&#146;s February 2007 employment agreement, we granted him an option to purchase 15,000&nbsp;shares of our common stock. This option vested over
48&nbsp;months, with one-fourth of the shares having vested on the first anniversary of the date on which Mr.&nbsp;Stratton&#146;s employment began and with the remaining shares having vested at the rate of 1/48th&nbsp;per month on the last day of
each month during the ensuing 36&nbsp;months. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Salinas joined the company as our executive vice president and head of
research and development on June&nbsp;6, 2013. Under the terms of an employment agreement between Dr.&nbsp;Salinas and the company, dated June&nbsp;5, 2013, Dr.&nbsp;Salinas receives an annual base salary of $475,000 per year, with a target bonus of
up to 50% of his base salary. In addition, we agreed to pay Dr.&nbsp;Salinas a sign-on bonus of $100,000, payable on a quarterly basis over his first year of employment, as well as a relocation allowance of $50,000, which is repayable in the event
Dr.&nbsp;Salinas voluntarily terminates his employment within 12 months of his receipt of the allowance. Furthermore, pursuant to his June 2013 employment agreement, we granted Dr.&nbsp;Salinas 390,000 restricted stock units, with one-fourth vesting
on each of the first four anniversaries of his employment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Severance arrangements.</I>&nbsp;&nbsp;&nbsp;&nbsp;Each of our
executive officers has entered into a severance agreement with the company under which he or she would receive payments upon termination of his or her employment by us without cause</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">4</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> or consequent to a change of control or, in the case of Mr.&nbsp;McGlynn, by virtue of disability. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the case of Mr.&nbsp;McGlynn, upon termination without cause, we would continue to pay his salary and provide benefits for one year,
at the base wage rate then in effect. If the termination of Mr.&nbsp;McGlynn&#146;s employment were associated with a change of control, the company would pay (in a lump sum) (i)&nbsp;two years of his salary and the reasonably projected cost of
healthcare benefits, (ii)&nbsp;a bonus with respect to the termination year at 25% of the base salary, pro-rated for the portion of the year served, and (iii)&nbsp;a tax gross up for his continued healthcare benefits. In addition, all unvested stock
options would vest and all stock options would be exercisable for two years after termination. If Mr.&nbsp;McGlynn&#146;s employment were terminated on account of disability, we would continue to pay his salary for up to six months (or until he
obtained other employment or became eligible for disability income under a company plan, if sooner). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the case of
Dr.&nbsp;Tsukamoto, upon involuntary termination without cause whether or not associated with a change of control, we would continue to pay Dr.&nbsp;Tsukamoto&#146;s salary and provide benefits for twelve months, at the rate then in effect.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the case of Mr.&nbsp;Young, upon involuntary termination without cause, we would continue to pay his salary and provide
benefits for six months, at the rate then in effect. If the termination were associated with a change of control, we would continue to pay Mr.&nbsp;Young&#146;s salary and provide benefits (including his share of COBRA, grossing up for the tax
effects, if any) for twelve months; in this event, any unvested options and any other stock awards held by him would vest upon termination. </FONT></P>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">4</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Or termination by the executive officer for good reason, as defined
in their respective agreements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the case of Dr.&nbsp;Craig, upon involuntary termination without cause, whether or not
associated with a change of control, we would continue to pay his salary and provide benefits for six months, at the rate then in effect. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the case of Mr.&nbsp;Stratton, upon involuntary termination without cause, we would continue to pay his salary and provide benefits for six months, at the rate then in effect. If the termination were
associated with a change of control, we would continue to pay Mr.&nbsp;Stratton&#146;s salary and provide benefits for twelve months; in this event, any unvested options and any other stock awards held by him would vest upon termination. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the case of Dr.&nbsp;Salinas, upon involuntary termination without cause, we would continue to pay his salary and provide benefits for
twelve months, at the rate then in effect. Likewise, in the event of involuntary termination or voluntary termination because his job responsibilities have been materially and adversely impacted as a result of a company change of control, we would
continue Dr.&nbsp;Salinas&#146; salary and benefits for twelve months. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we terminate the employment of any executive
officer for cause, or if the officer resigns without good cause, he or she would not be entitled to any severance or other benefits. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Potential Payments Upon Termination or Change-in-Control </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table displays the value of what the executive officers would have received from us had their employment been terminated on December&nbsp;31, 2012: </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:24pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Officer</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bonus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Health</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accelerated&nbsp;Vesting&nbsp;
of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options&nbsp;and&nbsp;Restricted</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Units*</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terminated without cause</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">550,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">581,663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terminated, change of control</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">137,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">736,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,090,775</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disability(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terminated without cause</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">335,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">350,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terminated, change of control</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">335,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">253,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">604,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terminated without cause</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">162,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">171,130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terminated, change of control</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">367,797</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terminated without cause</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">160,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terminated, change of control</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">392,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton,&nbsp;J.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terminated without cause</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">160,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terminated, change of control</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,384</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">552,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Value shown represents the difference between the closing market price of our stock on December&nbsp;31, 2012 of $1.63 per share and the applicable exercise price of
each grant. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes tax gross-up on two&nbsp;years of healthcare costs. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments stop before six&nbsp;months if individual obtains other full-time employment or qualifies for payments under any disability income plan provided by the
company. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All unvested options and restricted stock units issued under the applicable equity incentive plans vest upon a change of control under the terms of those plans.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation and Stock Option Committee Report </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item&nbsp;402(b) of SEC Regulation&nbsp;S-K with management. Based on this review and these
discussions, the Compensation Committee has recommended to the Board of Directors that the Compensation Discussion and Analysis be included in the company&#146;s proxy statement for 2013. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="98%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">COMPENSATION&nbsp;AND&nbsp;STOCK&nbsp;OPTION&nbsp;COMMITTEE</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Schwartz,&nbsp;Ph.D., Chairman</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Bjerkholt</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ricardo Levy,&nbsp;Ph.D.</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Notwithstanding anything to the contrary set forth in any of our filings under the Securities Act of 1933, as
amended, or the Exchange Act that incorporate future filings, in whole or in part, the foregoing Compensation and Stock Option Committee Report shall not be incorporated by reference into any such filings. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Officer Compensation Tables </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables set forth information with respect to the compensation of our executive officers for the fiscal years ended
December&nbsp;31, 2012, 2011 and 2010. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because the &#147;Stock awards&#148; and &#147;Option awards&#148; column reflects the
dollar amounts recognized as compensation expense for financial statement reporting purposes in accordance with U.S.&nbsp;GAAP, these imputed values include amounts from awards granted from 2005 through 2012. </FONT></P>
<P STYLE="margin-top:30px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary Compensation Table </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:97pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bonus</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($)(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Awards</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>($)(3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Awards</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>($)(3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Compensation</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>($)(4)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total ($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">550,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">202,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">430,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,233,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">525,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">194,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">955,507</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">525,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,050,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,139,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">335,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">137,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,457</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">583,257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Scientific</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">402,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">and Strategic Alliances</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">169,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,288,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">442,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CFO and VP,</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,842</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">436,342</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance and Administration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">204,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">683,530</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">137,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">544,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">374,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">and Operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">204,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">664,496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton,&nbsp;J.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">137,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">544,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">375,945</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,096</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">204,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">621,314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We pay salaries on a bi-weekly basis. There were 27 pay periods in 2010 and 26 pay period in both 2011 and 2012. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each employee&#146;s target bonus is based on his or her salary as of January&nbsp;1 of the year to which it applies. For 2012, the Board awarded 70% of the target
bonus for all company employees. For further description of the non-equity incentive plan see the discussion in our &#147;Compensation Discussion and Analysis&#148; and &#147;Compensation of Named Executive Officers,&#148; above.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts shown represent the full grant date value of the equity awards granted in each year as computed in accordance with FASB ASC Topic 718. Assumptions used in the
calculation of these amounts are included in Note&nbsp;9, &#147;Stock-Based Compensation&#148; in our Form&nbsp;10-K for the period ended December&nbsp;31, 2012, filed with the SEC on March&nbsp;21, 2013. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts shown in the &#147;All Other Compensation&#148; column for 2012 include the following: </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:97pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Employer<BR>Match on<BR>Defined<BR>Contribution<BR>Plans<BR>($)(a)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Transportation<BR>Allowance ($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Employee<BR>Health&nbsp;and<BR>Welfare<BR>Benefit<BR>Plans&nbsp;($)(b)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total<BR>All Other<BR>Compensation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto, Ph.D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,457</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Scientific and Strategic Alliances</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CFO and VP, Finance and Administration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Development and Operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton,&nbsp;J.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under a 401(k) plan, which is open to substantially all of our employees, we make matching contributions in the form of company common stock based on each
participant&#146;s voluntary salary deferrals, subject to plan and legal limits. We match participant contributions on a 1:2 basis up to a maximum of 3% of the employee&#146;s salary. Registered stock is valued and transferred to the employee&#146;s
401(k) account at the end of calendar each quarter. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We offer all employees various health and welfare benefit plans. Our executive officers may participate in these on the same terms as other employees.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes life insurance benefit of $1,180. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Grants of Plan-Based Awards </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows grants of plan-based equity awards made to our named executive officers during the fiscal year ended December&nbsp;31, 2012: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:91pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name &amp; Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All&nbsp;Other<BR>Stock<BR>Awards:<BR>Number&nbsp;of<BR>Shares of<BR>Stock or<BR>Units #(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Option<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Options #</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>or Base<BR>Price of<BR>Option<BR>Awards<BR>($/share)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date<BR>Fair Value<BR>of Option<BR>Awards&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/27/12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">430,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/27/12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">137,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Scientific and Strategic Alliances</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CFO and VP, Finance and Administration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/27/12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">137,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Development and Operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton,&nbsp;J.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/27/12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">137,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units granted in 2012 to our named executive officers were made pursuant to our 2006 equity incentive plan. The restricted stock units granted to
Mr.&nbsp;McGlynn and Dr.&nbsp;Tsukamoto vest over a three-year period from the date of grant: one-third of the award will vest on each grant date anniversary over the following three years. The restricted stock units granted to Dr.&nbsp;Craig and
Mr.&nbsp;Stratton vest over a four-year period from the date of grant: one-fourth of the award will vest on each grant date anniversary over the following four years. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Outstanding Equity Awards at Fiscal 2012&nbsp;Year-End </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables show equity awards held by our named executive officers as of December&nbsp;31, 2012: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Grant<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Exercisable(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Unexercisable(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price<BR>($/sh)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/25/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Scientific and Strategic Alliances</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9/6/2005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9/6/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CFO and VP, Finance and Administration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/15/2009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/15/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,249</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Development and Operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton,&nbsp;J.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">02/28/2007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">02/28/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date&nbsp;of&nbsp;Award</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Restricted<BR>Stock&nbsp;Units<BR>That&nbsp;Have&nbsp;Not<BR>Vested
(2)<BR>#</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Market&nbsp;Value&nbsp;of<BR>Securities of<BR>Restricted<BR>Stock&nbsp;Units<BR>That Have Not<BR>Vested
(3)<BR>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/15/2009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/25/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/25/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/27/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">661,780</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/15/2009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Scientific and Strategic Alliances</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,033</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/27/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">211,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/15/2009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CFO and VP, Finance and Administration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9/15/2009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Development and Operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/27/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">211,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton,&nbsp;J.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/15/2009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/27/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">211,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise noted, options are granted at the close of market price on the grant date (or on an adjacent market trading day if the Nasdaq Capital Market is closed
on the grant date). They vest over a period of four years as follows: one-fourth of the option vests on the first anniversary of the grant date and 1/48th of the original grant vests each additional month of service. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units granted under our 2006 Equity Incentive Plan. These restricted stock units vest ratably over a three to four-year period on each grant date
anniversary. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the per share closing market price of $1.63 for our common stock on December&nbsp;31, 2012. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Option Exercises and Stock Vested </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the vesting in fiscal 2012 of shares of restricted stock units held by the named executive officers. No options were exercised by our named executive officers during fiscal
2012. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired on<BR>Vesting&nbsp;(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value&nbsp;Realized<BR>on&nbsp;Vesting&nbsp;($)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin McGlynn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ann Tsukamoto, Ph.D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Scientific and Strategic Alliances</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CFO and VP, Finance and Administration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stewart Craig,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVP, Development and Operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ken Stratton,&nbsp;J.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Calculated as the aggregate market value on the date of vesting of the shares with respect to which restrictions lapsed during 2012 (calculated before payment of any
applicable withholding or other income taxes). </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;McGlynn was granted (i)&nbsp;23,467 restricted stock units on May&nbsp;15, 2009, 5,866 of which were exercised on January&nbsp;20, 2012, when the market price
was $0.80, and 5,867 of which were exercised on August&nbsp;2, 2012, when the market price was $1.70; (ii)&nbsp;100,000 restricted stock units on June&nbsp;25, 2010, 33,333 of which were exercised on January&nbsp;20, 2012, when the market price was
$0.80, and 33,334 of which were exercised on August&nbsp;2, 2012, when the market price was $1.70; and (iii)&nbsp;20,000 restricted stock units on January&nbsp;25, 2011, 6,667 of which were exercised on January&nbsp;20, 2012, when the market price
was $0.80, and 6,666 of which were exercised on August&nbsp;2, 2012, when the market price was $1.70. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Tsukamoto was granted: (i)&nbsp;9,333 restricted stock units on May&nbsp;15, 2009, 2,332 of which vested on May&nbsp;15, 2012, when the market price per share
of our common stock was $0.85; and (ii)&nbsp;70,000 restricted stock units on June&nbsp;1, 2010, 23,334 of which vested on June&nbsp;1, 2012, when the market price was $0.68. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Young was granted: (i)&nbsp;22,667 restricted stock units on May&nbsp;15, 2009, 5,667 of which vested on May&nbsp;15, 2012, when the market price per share of
our common stock was $0.85; and (ii)&nbsp;20,000 restricted stock units on June&nbsp;1, 2010, 5,000 of which vested on June&nbsp;1, 2012, when the market price per share of our common stock was $0.68. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Craig was granted: (i)&nbsp;9,333 restricted stock units on September&nbsp;15, 2009, 2,333 of which vested on September&nbsp;17, 2012, when the market price
per share of our common stock was $1.95; and (ii)&nbsp;20,000 restricted stock units on June&nbsp;1, 2010, 5,000 of which vested on June&nbsp;1, 2012, when the market price per share of our common stock was $0.68. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Stratton was granted: (i)&nbsp;9,333 restricted stock units on May&nbsp;15, 2009, 2,332 of which vested on May&nbsp;15, 2012, when the market price per share
of our common stock was $0.85; and (ii)&nbsp;20,000 restricted stock units on June&nbsp;1, 2010, 5,000 of which vested on June&nbsp;1, 2012, when the market price per share of our common stock was $0.68. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Compensation </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Cash Compensation.</I>&nbsp;&nbsp;&nbsp;&nbsp;Prior to December 2009, non-employee directors received quarterly retainers for Board service in the amount of $4,500 ($8,750 for the Chairman of the
Board). Each of the chairs of the standing committees also received quarterly stipends of either $1,000 (Audit Committee) or $500 (Compensation and Corporate Governance Committees). Non-employee directors also received $1,500 for each board meeting
attended in person or by videoconference and $1,000 for each standing committee meeting attended in person or by videoconference, plus $500 for each board or committee meeting attended by phone. The non-employee directors serving on the Strategic
Transactions Committee received $1,200 per meeting attended in person or by videoconference, plus $500 for each meeting attended by phone, but the chair of the Strategic Transactions Committee did not receive a quarterly stipend. All dollar amounts
were paid in cash. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In early 2009, however, management began a review of our director compensation practices. We wanted to
assess whether we were being responsive to market dynamics, as we had not adjusted director compensation for almost five years. We obtained and reviewed, among other things, the <I>2009 Radford Board of Directors Compensation Analysis&nbsp;&#151;
Level&nbsp;2, Life Sciences Edition</I>, which provided us with a broad survey of director compensation paid by publicly traded life science companies in the United States. We also benchmarked our compensation practices against compensation
information from other publicly traded companies in the stem cell field.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">5</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> From this information, we determined that the median (i.e., 50th&nbsp;percentile) cash compensation paid by comparable companies tended to be approximately 40% higher than that paid by the company and
that the average initial equity grants awarded by comparable companies tended to be approximately 25% higher. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Therefore, in
both June and December 2009, management presented to the Board a series of recommendations to change both the cash and equity compensation paid to our non-employee directors. The Board considered in particular the market comparables collected by
management. In recognition of the fact that the company&#146;s director compensation fell significantly below the average compensation paid by market comparables, the Board approved the recommended changes to the cash-based and equity compensation
paid to the company&#146;s non-employee directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since December 2009, non-employee directors have received quarterly
retainers for Board service in the amount of $6,250 ($12,500 for the Chairman of the Board). The chairs of the standing committees have received quarterly stipends of either $2,500 (Audit Committee) or $1,250 (Compensation Committee, Corporate
Governance Committee and, since it became a standing committee in June 2010, the Strategic Transactions Committee). Non-employee directors have also received $2,000 for each board meeting attended in person or by videoconference and $1,000 for each
board meeting attended by phone, as well as $1,000 for each standing committee meeting attended in person or by videoconference and $500 for each committee meeting attended by phone. All these dollar amounts have been paid in cash, and we expect
that this will remain largely the case for the foreseeable future. However, in March 2011, the Board approved a sub-plan under our 2006 Amended and Restated Equity Incentive Plan, called the Directors&#146; Fee Plan, which permits directors to elect
to receive all or a portion of their board fees in the form of company common stock. We issued 39,950 shares of stock under our Directors&#146; Fee Plan as consideration for Board service in 2012. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors are reimbursed for their expenses in attending meetings of the Board and meetings of committees of the Board. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Equity Compensation.</I>&nbsp;&nbsp;&nbsp;&nbsp;Prior to June 2009, non-employee directors received an initial option to purchase
2,000&nbsp;shares upon appointment to the Board, with one-third of these option shares vesting on each of the first </FONT></P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">5</SUP></FONT>
<FONT STYLE="font-family:Times New Roman" SIZE="2"> In 2009 we collected director compensation information from the recent SEC filings of Aastrom Biosciences, Inc.; Athersys, Inc.; Cytori Therapeutics, Inc.; Geron Corporation; Neuralstem, Inc.; and
Osiris&nbsp;Therapeutics, Inc. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
three anniversaries following the grant. Following appointment, each non-employee director received an option to purchase 1,000&nbsp;shares upon each anniversary of his or her appointment,
vesting one year after issuance, with each exercisable at the fair market value of the stock on the date of the respective grant. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2009, however, the Board adopted management&#146;s recommendation to award non-employee directors with annual equity grants paid in restricted stock units rather than common stock options. The
Board&#146;s decision to change the annual grants followed several months of deliberation by the company&#146;s management and Compensation Committee, which considered among other things equity compensation practices at various comparable companies,
as described above, outside reports, the company&#146;s trading history, and market trends, such as the growing use of restricted stock units as director compensation by comparable companies. Each of the annual grants from June 2009 until June 2010
was for 1,000 restricted stock units, vesting on the first anniversary of the grant. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Then, in December 2009 and June 2010,
the Board approved further changes proposed by management to the equity compensation practices for non-employee directors. Among other changes, the Board approved management&#146;s recommendation to award newly appointed directors an initial grant
of restricted stock units rather than options. Presently, newly appointed non-employee directors will receive an initial grant upon their first appointment to the Board of 15,000 restricted stock units, with one third of this grant vesting on each
of the three anniversaries following the grant. Thereafter, each non-employee director, other than the Chairman of the Board, is to receive an annual grant on each anniversary of his or her appointment to the Board in the form of 1,000 restricted
stock units, vesting on the first anniversary of the grant. In addition, the Board determined that the Chairman of the Board is to receive an annual grant of 1,500 restricted stock units, vesting on the first anniversary of the grant. Each of the
annual grants from June 2010 to December 2011 was for 1,000 restricted stock units (1,500 for the Chairman), vesting on the first anniversary of the grant. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">More recently, in March 2012, the Board approved a further change proposed by management to the equity compensation practices for non-employee directors given the Company&#146;s stock trading price and
our desire to fairly compensate our outside directors for continued Board service and incentivize them to build stockholder value. Effective January&nbsp;1, 2012, each non-employee director, other than the Chairman of the Board, is to receive an
annual grant on each anniversary of his or her appointment to the Board in the form of 10,000 restricted stock units, vesting on the first anniversary of the grant. In addition, the Board determined that the Chairman of the Board is to receive an
annual grant of 15,000 restricted stock units, vesting on the first anniversary of the grant. </FONT></P> <P STYLE="margin-top:30px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Compensation Table
</B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes cash-based and equity compensation information for our non-employee directors, including
annual Board and committee retainer fees and meeting attendance fees, for the year ended December&nbsp;31, 2012: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees&nbsp;Earned<BR>or Paid<BR>in Cash<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock<BR>Awards<BR>($)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Compensation<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Bjerkholt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,780</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R. Scott Greer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ricardo Levy,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roger Perlmutter,&nbsp;M.D.,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Schwartz,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">95,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Irving Weissman,&nbsp;M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts shown in this column represent the full grant date fair value of restricted stock unit grants in 2012 as computed in accordance with FASB ASC
Topic&nbsp;718. Assumptions used in the calculation of these amounts are included in Note&nbsp;10, &#147;Stock-Based Compensation&#148; in our Form&nbsp;10-K for the period ended December&nbsp;31, 2012, filed with the SEC on March&nbsp;21, 2013.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes an annual retainer of $25,000, a fee for Mr.&nbsp;Bjerkholt&#146;s role on the Audit Committee of $10,000, and additional fees of $17,500 for Board and
committee meetings attended. Also includes $14,250 earned in 2012 but paid in 2013. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Bjerkholt was granted 1,000 restricted stock units on March&nbsp;1, 2012, vesting on the one year anniversary of the grant, and 9,000 restricted stock units on
April&nbsp;18, 2012, vesting on March&nbsp;1, 2013. As of December&nbsp;31, 2012, he had stock options and restricted stock units outstanding for the purchase of 17,000 shares of common stock, in the aggregate. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes an annual retainer of $25,000, a fee for Mr.&nbsp;Greer&#146;s role on the Strategic Transactions Committee of $5,000, and additional fees of $11,500 for Board
and committee meetings attended. Also includes $11,000 earned in 2012 but paid in 2013. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Greer was granted 10,000 restricted stock units on June&nbsp;3, 2012, vesting on the one year anniversary of the grant. As of December&nbsp;31, 2012, he had
restricted stock units outstanding for the purchase of 15,000 shares of common stock, in the aggregate. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes an annual retainer of $25,000, a fee for Dr.&nbsp;Levy&#146;s role on the Corporate Governance Committee of $5,000, and additional fees of $22,500 for Board
and committee meetings attended. Also includes $15,500 earned in 2012 but paid in 2013. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Levy was granted 10,000 restricted stock units on September&nbsp;26, 2012, vesting on the one year anniversary of the grant. As of December&nbsp;31, 2012,
Dr.&nbsp;Levy had stock options and restricted stock units outstanding for the purchase of 17,073 shares of common stock, in the aggregate. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes an annual retainer of $25,000, and additional fees of $10,000 for Board and committee meetings attended. Also includes $10,250 earned in 2012 but paid in 2013.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Perlmutter was granted 10,000 restricted stock units on December&nbsp;14, 2012, vesting on the one year anniversary of the grant. As of December&nbsp;31, 2012,
Dr.&nbsp;Perlmutter had stock options and restricted stock units outstanding for the purchase of 18,565 shares of common stock, in the aggregate. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes an annual retainer of $50,000, a fee for Dr.&nbsp;Schwartz&#146;s role on the Compensation Committee of $5,000, and additional fees of $18,000 for Board and
committee meetings attended. Also includes $8,875 earned in 2011 but paid in 2012. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Schwartz was granted 15,000 restricted stock units on April&nbsp;18, 2012, vesting on the one year anniversary of the grant. In addition, as of
October&nbsp;2011 and until March 2012, Dr.&nbsp;Schwartz received 50% of his board service fees in the form of company common stock under our Directors&#146; Fee Plan. In March 2012 and until December 2013, Dr.&nbsp;Schwartz elected to receive 100%
of his future board service fees in the form of company common stock, until such time as he may deliver an updated election in accordance with the provisions of the Directors&#146; Fee Plan. As of December&nbsp;31, 2012, Dr.&nbsp;Schwartz had stock
options and restricted stock units outstanding for the purchase of 21,500 shares of common stock, in the aggregate. Also includes $20,750 earned in 2012 but paid in 2013 in common shares under the Directors&#146; Fee Plan. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes an annual retainer of $25,000 and additional fees of $7,000 for Board and committee meetings attended. Also includes $7,250 earned in 2012 but paid in 2013.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Weissman was granted 10,000 restricted stock units on October&nbsp;1, 2012, vesting on the one year anniversary of the grant. As of December&nbsp;31, 2012,
Dr.&nbsp;Weissman had stock options and restricted stock units outstanding for the purchase of 22,141 shares of common stock, in the aggregate. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Weissman receives $50,000 per year for his services as a consultant and as the chairman of our Scientific Advisory Board. As of May 2011, Dr.&nbsp;Weissman has
received his consultancy fees under this agreement in the form of company common stock. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Related parties can include any of our directors or executive officers, certain of our stockholders and their immediate family members.
Each year, we prepare and require our directors and executive officers to complete Director and Officer Questionnaires identifying any transactions with us in which the officer or director or their family members have an interest. This helps us
identify potential conflicts of interest. A conflict of interest occurs when an individual&#146;s private interest interferes, or appears to interfere, in any way with the interests of the company as a whole. Our code of ethics requires all
directors, officers and employees who may have a potential or apparent conflict of interest to immediately notify our general counsel, who serves as our compliance officer. In addition, the Corporate Governance Committee of the Board of Directors is
responsible for considering and reporting to the Board any questions of possible conflicts of interest of Board members. Our code of ethics further requires pre-clearance before any employee, officer or director engages in any personal or business
activity that may raise concerns about conflict, potential conflict or apparent conflict of interest. Copies of our code of ethics and the Corporate Governance Committee charter are posted on the corporate governance section of our website at
www.stemcellsinc.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In evaluating related party transactions and potential conflicts of interest, our compliance officer
and independent directors apply the same standards of good faith and fiduciary duty they apply to their general responsibilities. They will approve a related party transaction only when, in their good faith judgment, the transaction is in the best
interest of the company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Weissman, a member of the Board of Directors, was retained in September 1997 to serve as a
consultant to us. Pursuant to his consulting agreement, Dr.&nbsp;Weissman provides consulting services to us and serves on our Scientific Advisory Board. In return, we pay Dr.&nbsp;Weissman $50,000 per year for his services. We also agreed to
nominate Dr.&nbsp;Weissman for a position on the Board of Directors, and he agreed to serve if elected. Since October&nbsp;1, 2000, he has been compensated for this service in the same manner and amount as other non-employee members of the Board.
The consulting agreement with Dr.&nbsp;Weissman contains confidentiality, non-competition, and assignment of invention provisions and is for a term of fifteen years, subject to earlier termination by either party. In May 2011,
Dr.&nbsp;Weissman&#146;s consulting agreement was amended by the parties so that the company could choose to pay fees owed to Dr.&nbsp;Weissman under the agreement in the form of company common stock. </FONT></P>
<P STYLE="margin-top:30px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRINCIPAL ACCOUNTING FEES AND SERVICES </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Audit and Tax Fees </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors, upon the recommendation of the
Audit Committee, has selected the independent accounting firm of Grant Thornton LLP to audit the accounts of the company for the year ending December&nbsp;31, 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee considered the tax compliance services provided by Grant Thornton LLP, concluded that provision of such services is compatible with maintaining the independence of the independent
accountants, and approved the provision by Grant Thornton LLP of tax compliance services with respect to the year ending December&nbsp;31, 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee received the following information concerning the fees of the
independent accountants for the years ended December&nbsp;31, 2011 and 2012, has considered whether the provision of these services is compatible with independence of the independent accountants, and concluded that it is: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/12</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/11</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit fees(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">387,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">432,693</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit fees represents fees for the integrated audit of our annual consolidated financial statements and reviews of the interim consolidated financial statements, and
review of audit-related SEC filings; also includes fees related to issuing comfort letter(s) in 2011 and 2012. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit and tax fees include administrative overhead charges and reimbursement for out-of-pocket expenses. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pre-Approval Policies and Procedures </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee has adopted policies and procedures for pre-approving all services (audit and non-audit) performed by our independent auditors. In
accordance with such policies and procedures, the Audit Committee is required to pre-approve all audit and non-audit services to be performed by the independent auditors in order to assure that the provision of such services is in accordance with
the rules and regulations of the SEC and does not impair the auditors&#146; independence. Under the policy, pre-approval is generally provided up to one year and any pre-approval is detailed as to the particular service or category of services and
is subject to a specific budget. In addition, the Audit Committee may pre-approve additional services on a case-by-case basis. During 2012 and 2011, all services performed by our independent auditors were pre-approved. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REPORT OF THE AUDIT COMMITTEE </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee oversees our accounting and financial reporting processes and the audits of our financial statements on behalf of the
Board, and selects an independent public accounting firm to perform these audits. Management has the primary responsibility for establishing and maintaining adequate internal control over financial reporting, preparing the financial statements, and
establishing and maintaining adequate controls over public reporting. Our independent registered public accounting firm for fiscal 2012, Grant Thornton LLP, had responsibility for conducting an audit of our annual financial statements in accordance
with the standards of the Public Company Accounting Oversight Board (United States) and expressing an opinion on the conformity of those audited financial statements with generally accepted accounting principles. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee oversaw the independent public accounting firm&#146;s qualifications and independence, as well as its performance.
The Audit Committee assisted the Board in overseeing the preparation of the company&#146;s financial statements, the company&#146;s compliance with legal and regulatory requirements, and the performance of the company&#146;s internal audit function.
The Audit Committee met with personnel of the company and Grant Thornton LLP to review the scope and the results of the annual audit, the amount of audit fees, the company&#146;s internal accounting controls, the company&#146;s financial statements
contained in the company&#146;s Annual Report to Stockholders and other related matters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee has reviewed and
discussed with management the financial statements for fiscal year 2012 audited by Grant Thornton LLP, as well as management&#146;s report on internal control over financial reporting, using the criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO) in Internal Control&nbsp;&#151; Integrated Framework. The Audit Committee has discussed with Grant Thornton LLP various matters related to the financial statements, including those matters required to
be discussed by SAS 114 (The Auditor&#146;s Communication with Those Charged with Governance). The Audit Committee has also discussed with Grant Thornton LLP its report on internal control over financial reporting, has received the written
disclosures and the letter from Grant Thornton LLP required by Public Company Accounting Oversight Board (PCAOB) Ethics and Independence Rule&nbsp;3526, <I>Communication with Audit Committees Concerning Independence</I> (Rule&nbsp;3526), and has
discussed with Grant Thornton LLP its independence. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based upon such review and discussions, the Audit Committee recommended
to the Board of Directors, and the Board approved the recommendation, that the audited financial statements be included in the company&#146;s Annual Report on Form&nbsp;10-K for the fiscal year ending December&nbsp;31, 2012 for filing with the SEC.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:14px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AUDIT COMMITTEE</FONT></TD></TR>
<TR>
<TD HEIGHT="24"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Bjerkholt, Chairman</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ricardo Levy,&nbsp;Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Schwartz,&nbsp;Ph.D.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL&nbsp;NUMBER 1 </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Election of Directors </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The number of directors is currently fixed at seven. Both our restated certificate of incorporation, as amended to date, and our amended and restated by-laws provide for the classification of the Board of
Directors into three classes (Class&nbsp;I, Class&nbsp;II and Class&nbsp;III), as nearly equal in number as possible, with the term of office of one class expiring each year. Unless otherwise instructed, the enclosed proxy will be voted to elect the
nominees named below, who are now Class&nbsp;I directors, as Class&nbsp;I directors for a term of three years expiring at the 2016 Annual Meeting of Stockholders and until their successors are duly elected and qualified. All three Class&nbsp;I
director nominees have been recommended by the Board of Directors because of their past experience serving on the company&#146;s Board of Directors, the breadth of their business expertise, sound judgment, and demonstrated leadership, among other
things. In prior years, the Class&nbsp;II and Class&nbsp;III directors were nominated for appointment to the Board for similar reasons. Proxies cannot be voted for a greater number of persons than the number of nominees named below. It is expected
that the nominees will be able to serve, but if any are unable to serve, the proxy will be voted for a substitute nominee or nominees designated by the Board of Directors. The nominees for election as Class&nbsp;I directors are as follows:
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOMINEES FOR ELECTION AS CLASS&nbsp;I DIRECTORS&nbsp;&#151; TERMS TO EXPIRE 2016 </B></FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:73pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Principal Occupation</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age*</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Bjerkholt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive&nbsp;Vice&nbsp;President&nbsp;and CFO,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Sunesis Pharmaceuticals, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R. Scott Greer.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Managing Director, Numenor Ventures LLC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John&nbsp;Schwartz,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Quantum Strategies Management Company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">79</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director,&nbsp;Chairman&nbsp;of&nbsp;the&nbsp;Board</FONT></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ages are as of October&nbsp;15, 2013. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Eric Bjerkholt</I> was elected to the Board of Directors of StemCells, Inc. in March 2004. He is Executive Vice President and Chief Financial Officer of Sunesis Pharmaceuticals, Inc., a small molecule
biopharmaceutical company in South San Francisco, California. Before joining Sunesis, Mr.&nbsp;Bjerkholt served as the Senior Vice President and Chief Financial Officer of IntraBiotics Pharmaceuticals, Inc. Previously, Mr.&nbsp;Bjerkholt co-founded
LifeSpring Nutrition, Inc., a privately held nutraceutical company, and served as its Chief Financial Officer, and later as its President and Chief Executive Officer. From 1990 to 1997, Mr.&nbsp;Bjerkholt was an investment banker at J.P.
Morgan&nbsp;&amp; Co., Inc. Mr.&nbsp;Bjerkholt holds an MBA from Harvard Business School and a Cand.oecon degree in economics and econometrics from the University of Oslo, Norway. He is a member of the board of directors of Round Table Pizza, Inc.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>R. Scott Greer</I> was elected to the Board of Directors of StemCells, Inc. in June 2010, and was simultaneously appointed
to Chair the Company&#146;s Strategic Transactions Committee. Mr.&nbsp;Greer is currently a principal and managing director of Numenor Ventures LLC, which he founded in 2002 to provide funding and strategic advisory services to early stage
enterprises. He is also an investor and consultant to CEOs and founders of companies in various stages of development. Previously, Mr.&nbsp;Greer was founder of Abgenix, Inc., a biotechnology company that pioneered the development of antibodies as
therapeutics, and served as its Chief Executive Office from its inception in 1996 until 2002, and as its Chairman from 2000 until 2006. Abgenix was acquired by Amgen in 2006 for $2.2 billion. Prior to Abgenix&#146;s formation, Mr.&nbsp;Greer held
senior management positions at Cell Genesys, Inc. including Senior Vice President, Corporate Development and Chief Financial </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Officer, and held various positions at Genetics Institute (acquired by Wyeth). Mr.&nbsp;Greer currently serves as Chairman of Ablexis, a development stage biotechnology company, and is also on
the board of Nektar Therapeutics. In the past, Mr.&nbsp;Greer served on several other public and private company boards, including Sirna Therapeutics (acquired by Merck), where he served as Chairman of the Board, Affymax, Anaptys Biosciences,
Illumina, Chimeros, Inogen, and CV Therapeutics (acquired by Gilead Sciences). Mr.&nbsp;Greer received a B.A. in Economics from Whitman College and an M.B.A. from Harvard University, and was also a Certified Public Accountant. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>John Schwartz</I> was elected to the Board of Directors of StemCells, Inc. in December 1998 and was elected the Chairman of the Board
at the same time. He is the former President and Chief Executive Officer of SyStemix, Inc. Dr.&nbsp;Schwartz is the President of Quantum Strategies Management Company, a registered investment advisor located in Palo Alto, California. Prior to his
positions at SyStemix, he served as Assistant Professor, Vice President and General Counsel at Stanford University in California. Dr.&nbsp;Schwartz graduated from Harvard Law School in 1958 and received his PhD degree in physics from the University
of Rochester in 1965. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE <U>FOR</U> THE ELECTION OF THE NOMINEES DESCRIBED ABOVE.
</B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL&nbsp;NUMBER 2 </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Ratification of Selection of Independent Public Accountants </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The company is asking the stockholders to ratify the selection of Grant Thornton LLP as the company&#146;s independent public accountants
for the fiscal year ending December&nbsp;31, 2013. The affirmative vote of the holders of a majority of the shares represented and voting at the Annual Meeting will be required to ratify the selection of Grant Thornton LLP. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event the stockholders fail to ratify the appointment, the Audit Committee of the Board of Directors will consider it as a
recommendation to select other auditors for the subsequent year, which the Audit Committee would then take under advisement. Even if the selection is ratified, the Audit Committee of the Board at its discretion could decide to terminate the
engagement of Grant Thornton LLP and engage another firm at any time if the Audit Committee determines that such a change would be necessary or desirable in the best interests of the company and its stockholders. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A representative of Grant Thornton LLP is expected to attend the Annual Meeting and is not expected to make a statement, but will be
available to respond to appropriate questions and may make a statement if such representative desires to do so. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS
RECOMMENDS THAT STOCKHOLDERS VOTE <U>FOR</U> THE PROPOSAL&nbsp;TO RATIFY THE SELECTION OF GRANT THORNTON LLP AS THE COMPANY&#146;S INDEPENDENT PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2013. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL&nbsp;NUMBER 3 </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment to Restated Certificate of Incorporation to Increase Authorized Shares of Common Stock </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">At the recommendation of our Board of Directors, we are seeking approval to amend the company&#146;s restated
certificate of incorporation to increase the number of common stock authorized for issuance from 75,000,000 shares to 225,000,000 shares. Our Board of Directors expects that the company will need to raise significant additional funds in order to
advance its various development programs, including the continued clinical testing of its HuCNS-SC<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> proprietary
platform technology (purified human neural stem cells) in spinal cord injury, age-related macular degeneration, Pelizaeus-Merzbacher disease, and in any other disease or indication. At present, the company has fewer than 10,000 authorized shares of
common stock left available for issuance. Historically the company has self-funded most of its operations through the sale of common stock. Failure to increase the number of shares available for issuance could therefore have a material and adverse
effect on the company&#146;s ability to raise capital in the future and continue in operation. Accordingly, the Board of Directors approved, by unanimous resolution, an amendment to the company&#146;s restated certificate of incorporation to
increase the company&#146;s authorized capital by an additional one hundred fifty million (150,000,000)&nbsp;shares of common stock, subject to obtaining requisite stockholder approval. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These shares may be used to raise additional capital to fund the company&#146;s working capital and other corporate needs, for future
acquisitions of assets, programs or businesses, and for other corporate purposes. However, as of the mailing date of these proxy materials, the company has no immediate plans to issue these additional one hundred fifty million shares of common
stock, whether to raise additional capital, to acquire additional businesses or assets, or otherwise. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our stockholders
approve this proposal, our Board of Directors will proceed to amend and restate the portions of Article III of our restated certificate of incorporation to increase the number of authorized shares of common stock from 75,000,000 total shares to
225,000,000 total shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At present, the company has 75,000,000 shares designated as common stock. If the company&#146;s
stockholders approve this proposal number 3, the Board of Directors will have authority to file with the Secretary of State of Delaware an amendment to the company&#146;s restated certificate of incorporation to designate an additional 150,000,000
shares of common stock, bringing the total number of authorized shares of common stock to 225,000,000. Upon approval and following this filing with the Secretary of State of Delaware, the amendment will become effective on the date it is filed, or
on such other date as is indicated in the amendment filing. The amendment proposed by the company to Article III of its restated certificate of incorporation (assuming approval of Proposal Number&nbsp;3) is attached to this proxy statement as
Appendix 1. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the time of any future capital raising transactions or in connection with any future share issuance, the
company will evaluate the applicable requirements for such action. We intend to comply with all requirements for the issuance of these shares, including all disclosure and other requirements pursuant to the Securities Act of 1933, as amended, and
the Exchange Act. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following chart summarizes the company&#146;s outstanding shares of common stock and rights convertible
or exercisable as of October&nbsp;15, 2013 (not giving effect to this Proposal Number 3 to increase the company&#146;s authorized capital by one hundred fifty million shares): </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Authorized Shares of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:72pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common Stock</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:86pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Issued&nbsp;and&nbsp;Outstanding<BR>Shares&nbsp;of&nbsp;Common&nbsp;Stock</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:94pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Reserved&nbsp;for&nbsp;Issuance<BR>Pursuant&nbsp;to&nbsp;Currently<BR>Outstanding<BR>Convertible&nbsp;
Securities,<BR>Equity&nbsp;Incentive&nbsp;Plans, and<BR>Other Reserve</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:95pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Authorized&nbsp;and&nbsp;Unreserved</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,000,000</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,971,174</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,026,542</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,284</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon issuance, the additional shares of authorized common stock would have rights identical
to the currently outstanding shares of common stock. Adoption of the amendment to the restated certificate of incorporation would not have any immediate effect on the proportionate voting power or other rights of our existing stockholders.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent that the additional authorized shares of capital stock are issued in the future, they may decrease existing
stockholders&#146; percentage equity ownership in the company and, depending on the price at which they are issued, could be dilutive to the voting rights of existing stockholders and have a negative effect on the market price of the common stock.
Current stockholders have no preemptive or similar rights, which means that current stockholders do not have a prior right to purchase any new issue of capital stock in order to maintain their proportionate ownership of the company. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The company could also use the additional shares of capital stock for potential strategic transactions including, among other things,
acquisitions, spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations, and investments, although the company has no present plans to do so. The company cannot provide assurances that any such
transactions will be consummated on favorable terms or at all, that they will enhance stockholder value or that they will not be adversely affect the company&#146;s business or the trading price of our stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are unaware of any specific effort to obtain control of the company, and the company has no present intention of using the proposed
increase in the number of authorized shares of common stock as an anti-takeover device. However, the company&#146;s authorized, but unissued, capital stock could be used to make an attempt to effect a change in control more difficult. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither Delaware law, the company&#146;s restated certificate of incorporation, nor the Company&#146;s amended and restated by-laws
provides for appraisal or other similar rights for dissenting stockholders in connection with this proposal. Accordingly, the company&#146;s stockholders will have no right to dissent and obtain payment for their shares. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RECOMMENDATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Board of Directors of the company has unanimously approved the proposal to adopt the amendment to the restated certificate of incorporation, as described above and as set forth in Appendix&nbsp;1 to these proxy materials, and has recommended that
the proposed amendment be submitted to the company&#146;s stockholders for consideration and approval at the Annual Meeting. The proposal to authorize the Board to amend the company&#146;s restated certificate of incorporation to increase the
authorized capital stock will require the affirmative vote of a majority of the shares outstanding entitled to vote thereon. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF
DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE <U>FOR</U> THE AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION AS SET FORTH HEREIN TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK BY 150,000,000 SHARES. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL&nbsp;NUMBER 4 </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Adoption of the 2013 Equity Incentive Plan </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Board of Directors believes that equity awards are important to induce our employees to remain with the company and to align the interests of our employees, including our executive officers, with
those of our stockholders. We have considered different types of equity instruments over the years, including stock options, stock appreciation rights, restricted stock, and restricted stock units. We have primarily granted stock options and
restricted stock units, believing that each has unique and important features for employee retention and motivating our employees to build a profitable and sustainable business. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2013, our Board of Directors approved the StemCells, Inc. 2013 Equity Incentive Plan (the &#147;2013 EIP&#148;), subject to
stockholder approval, which we are now seeking, including approval of the material terms of performance goals for performance awards granted under the 2013 EIP. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Board of Directors believes that the 2013 EIP will promote the interests of our stockholders and is consistent with principles of good corporate governance, including: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Independent Committee</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2013 EIP will be administered by our Compensation Committee, which is composed entirely of
independent directors who meet the Nasdaq standards for independence and who meet the definition of &#147;outside directors&#148; for purposes of the performance-based compensation exemption under Section&nbsp;162(m)
(&#147;Section&nbsp;162(m)&#148;) of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) and &#147;non-employee directors&#148; under Rule 16b-3(b)(3) under the Exchange Act. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>No Discounted Stock Options or SARs</I>.&nbsp;&nbsp;&nbsp;&nbsp;All stock option and stock appreciation rights (&#147;SARs&#148;) awards under the
2013 EIP must have an exercise or base price that is not less than the fair market value of the underlying common stock on the date of grant. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>No Repricing</I>.&nbsp;&nbsp;&nbsp;&nbsp;Other than in connection with a corporate transaction affecting the company, the 2013 EIP prohibits any
repricing of stock options or SARs except in accordance the stockholder approval requirements of Nasdaq or any other applicable stock exchange. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Performance Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the 2013 EIP, the Compensation Committee may grant performance-based awards intended to qualify
as exempt performance-based compensation under Section&nbsp;162(m). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Existing Compensation Plan Information
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At present, we have three existing equity incentive plans, two of which were previously approved by our stockholders. The
first of these, the company&#146;s Amended and Restated 2004 Equity Incentive Plan (the &#147;2004 EIP&#148;), currently has 41,735 shares available for grant as equity awards, but will expire by its terms in 2014. The second of these, the
company&#146;s Amended and Restated 2006 Equity Incentive Plan (the &#147;2006 EIP&#148;), currently has 75,784 shares available for grant as equity awards, and contains a 4% annual evergreen provision. The 2006 EIP will expire by its terms in 2016.
The third plan, the company&#146;s 2012 Commencement Incentive Plan (the &#147;2012 Plan&#148;), was adopted without stockholder vote in accordance with NASDAQ Listing Rule 5635(c)(4) concerning inducement grants to new employees. We use the 2012
Plan solely to make awards in connection with offers of new employment by the company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table includes aggregated information regarding awards outstanding as well as
shares available for future awards under both our 2004 EIP and 2006 EIP, as of October&nbsp;15, 2013, and the proposed number of shares issuable under the 2013&nbsp;EIP: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;a&nbsp;percentage&nbsp;of<BR>stock outstanding</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">350,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding restricted stock units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,801,082</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other outstanding equity awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total shares subject to outstanding awards as of 10/15/13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,151,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total shares available for future awards as of 10/15/13 under 2004&nbsp;EIP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,735</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total shares available for future awards as of 10/15/13 under 2006&nbsp;EIP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed shares available for future awards under 2013 EIP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Plus, for each plan, a 4% annual evergreen. The percentage of stock outstanding doesn&#146;t take into account any future increases in the share pool as a result of the
evergreen feature. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table provides certain information with respect to all of our equity
compensation plans in effect as of December&nbsp;31, 2012. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity Compensation Plan Information</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:49pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Plan Category</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities to<BR>be Issued<BR>upon<BR>Exercise
of<BR>Outstanding<BR>Stock<BR>Options,<BR>Warrants<BR>and Rights<BR>(a)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted-<BR>Average<BR>Exercise<BR>Price of<BR>Outstanding<BR>Stock<BR>Options,<BR>Warrants<BR>and
Rights<BR>(b)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Remaining<BR>Available for<BR>Future<BR>Issuance<BR>Under
Equity<BR>Compensation<BR>Plans<BR>(Excluding<BR>Securities<BR>Reflected in<BR>Column(a))<BR>(c)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans approved by security holders(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,981,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">593,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans not approved by security holders(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of stock options issued to employees and directors, restricted stock units issued to employees and stock options issued as compensation to consultants for
consultation services. These stock options and restricted stock units were issued under our 2001, 2004 and 2006 Equity Incentive Plans. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012, we adopted by board action the 2012 Plan in accordance with NASDAQ Listing Rule 5635(c)(4) concerning inducement grants to new employees. As of
December&nbsp;31, 2012, no awards had been made under this plan. However, in the first nine months of 2013, we awarded an aggregate of 546,965 restricted stock units under our 2012 Plan. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Reasons for Seeking Stockholder Approval </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Board of Directors believes that equity grants are a critical part of our compensation program. Stockholder approval of the 2013 EIP would allow us to continue to attract and retain directors,
executives, and other employees with equity incentives. In fiscal years 2011, 2012 and 2013, we made equity awards under the company&#146;s existing equity incentive plans totaling approximately 131,000 shares, 1,748,000 shares, and 2,593,000
shares, respectively (adjusted to reflect the 10:1 reverse stock split effected in July 2011). We estimate, based on the advice of The Croner Company to our Compensation Committee, that the availability of 6,000,000 shares initially, plus an
increase by four percent (4%)&nbsp;per year of our then outstanding number of shares of common stock beginning in January 2015, would provide a sufficient additional number of shares to enable the company to continue to make awards at historical
average annual rates for the foreseeable future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, stockholder approval would preserve our ability to grant a range of
tax-efficient stock-based incentive awards under the 2013 EIP. Section&nbsp;162(m) generally provides that compensation provided to a publicly held corporation&#146;s CEO or any of its three most highly paid named executive officers (other than its
CEO or CFO) is not deductible by the corporation for U.S. income tax purposes for any taxable year to the extent it exceeds $1 million. This limitation does not apply to compensation that qualifies as exempt performance-based compensation by meeting
certain requirements under Section&nbsp;162(m), including the requirement that the material terms of the related performance goals be disclosed to and approved by stockholders every five years. For the 2013 EIP, these terms are described below under
&#147;Eligibility,&#148; &#147;Individual Limits,&#148; and &#147;Performance Criteria.&#148; Stockholders are being asked to approve, among other material terms, a set of business criteria on which performance goals may be based for future
performance awards under the 2013 EIP. Although stockholder approval is one of the requirements for exemption under Section&nbsp;162(m), even with stockholder approval there can be no guarantee that compensation will be treated as exempt
performance-based compensation under Section&nbsp;162(m). Furthermore, our Compensation Committee will continue to have authority to provide compensation that is not exempt from the limits on deductibility under Section&nbsp;162(m). </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our stockholders last approved the 2004 EIP at our Annual Meeting held in 2004 and the 2006 EIP at our Annual Meeting held in 2007. If
stockholders do not approve this Proposal Number 4, the company can continue to make awards under the 2004 EIP and 2006 EIP, but we will have limited shares available for future equity grants, the plans will expire in 2014 and 2016, respectively,
and our ability to make tax deductible performance awards to executive officers will be limited under Section&nbsp;162(m). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of the
2013 EIP </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2013, our Board of Directors adopted the 2013 EIP, subject to approval by our stockholders. No awards
have yet been made under the 2013 EIP. This summary is not a complete description of all provisions of the 2013 EIP and is qualified in its entirety by reference to the 2013 EIP, which is filed as Appendix&nbsp;2 to this proxy statement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Purpose</I>.&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the 2013 EIP is to advance the company&#146;s interests by providing for the grant
to participants of stock-based and other incentive awards. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Plan Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2013 EIP is
administered by our Compensation Committee, who has the authority to, among other things, interpret the 2013 EIP, determine eligibility for, grant and determine the terms of awards under the 2013 EIP, and to do all things necessary or appropriate to
carry out the purposes of the 2013 EIP. Our Compensation Committee&#146;s determinations under the 2013 EIP are conclusive and binding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Term</I>.&nbsp;&nbsp;&nbsp;&nbsp;No awards will be made after the tenth anniversary of the plan&#146;s adoption, but previously granted awards may continue beyond that date in accordance with their
terms. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Authorized Shares</I>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to adjustment, the maximum number of shares of our common
stock that may be delivered in satisfaction of awards under the 2013 EIP is six million (6,000,000), plus an annual increase each January&nbsp;1 (beginning January&nbsp;1, 2015 and with the last increase on January&nbsp;1, 2023) equal to four
percent (4%)&nbsp;of the number of shares of our common stock then outstanding. Any shares of common stock underlying awards that are settled in cash, withheld by the company from an award in payment of the exercise price of the award or any
required tax withholding, or otherwise expire, terminate or are forfeited prior to the issuance of stock, would again be available for issuance under the 2013 EIP. On October&nbsp;15, 2013, the closing price of our common stock as reflected on
Nasdaq was $1.38. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Individual Limits</I>.&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares for which
options may be granted and the maximum number of shares of stock subject to SARs which may be granted to any person in any calendar year is, in each case, 2,500,000 shares. The maximum number of shares subject to other awards which may be granted to
any person in any calendar year is 2,500,000 shares. The maximum amount that may be paid to any person in any calendar year with respect to cash awards is $2,500,000. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Eligibility</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee selects participants from among the key employees, directors, consultants, and advisors of the company and its affiliates who are in a
position to make a significant contribution to our success. Eligibility for options intended to be incentive stock options (&#147;ISOs&#148;) is limited to employees of the company or certain affiliates. As of October&nbsp;15, 2013, approximately
fifty-five employees and seven directors would be eligible to participate in the 2013 EIP. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Types of
Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2013 EIP provides for grants of options, SARs, restricted and unrestricted stock and stock units, performance awards, cash awards, and other awards convertible into or otherwise based on shares of our stock.
Dividend equivalents may also be provided in connection with an award under the 2013 EIP. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restricted and Unrestricted Stock</I>: A restricted stock award is an award of common stock subject to forfeiture restrictions, while an
unrestricted stock award is not subject to restrictions. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Options and SARs</I>: The 2013 provides for the grant of ISOs, non-qualified stock options (&#147;NSOs&#148;), and SARs. The exercise price of
an option, and the base price against which a SAR is to be measured, may not be less than the fair market value (or, in the case of an ISO granted to a ten percent stockholder, 110% of the fair market value) of a share of common stock on the date of
grant. Our Compensation Committee determines when stock options or SARs become exercisable and the terms on which such awards remain exercisable. Stock options and SARs will generally have a maximum term of ten years. SARs are payable in cash, in
shares of our common stock, or in a combination of cash and shares. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Units</I>: A stock unit award is denominated in shares of common stock and entitles the participant to receive stock or cash measured by the
value of the shares in the future. The delivery of stock or cash under a stock unit may be subject to the satisfaction of performance conditions or other vesting conditions. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Performance Awards</I>: A performance award is an award the vesting, settlement or exercisability of which is subject to specified performance
criteria. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cash Awards</I>: A cash award is an award denominated in cash. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Vesting</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee has the authority to determine the vesting schedule applicable to each
award, and to accelerate the vesting or exercisability of any award. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Termination of
Employment</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee determines the effect of termination of employment or service on an award. Unless otherwise provided by our Compensation Committee or in an award agreement, upon a termination of
employment or service all unvested options and other awards requiring exercise will terminate and all other unvested awards will be forfeited. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Performance Criteria</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2013 EIP provides that grants of performance awards may be made based upon, and subject to achieving, &#147;performance objectives&#148; over a
specified performance period. Performance objectives with respect to those awards that are intended to qualify as &#147;performance-based compensation&#148; for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
purposes of Section&nbsp;162(m) are limited to an objectively determinable measure of performance relating to any or any combination of the following (measured either absolutely or by reference
to an index or indices and determined either on a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof): sales; revenues; assets; expenses; earnings
before or after deduction for all or any portion of interest, taxes, depreciation, or amortization, whether or not on a continuing operations or an aggregate or per share basis; return on equity, investment, capital or assets; one or more operating
ratios; borrowing levels, leverage ratios or credit rating; market share; capital expenditures; cash flow; stock price; stockholder return; sales of particular products or services; customer acquisition or retention; acquisitions and divestitures
(in whole or in part); joint ventures and strategic alliances; spin-offs, split-ups and the like; reorganizations; or recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent consistent with the requirements for satisfying the performance-based compensation exception under Section&nbsp;162(m), our
Compensation Committee may provide in the case of any award intended to qualify for such exception that one or more of the performance objectives applicable to an award will be adjusted in an objectively determinable manner to reflect events (for
example, acquisitions and divestitures) occurring during the performance period of such award that affect the applicable performance objectives. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Transferability</I>.&nbsp;&nbsp;&nbsp;&nbsp;Awards under the 2013 EIP may not be transferred except by will or by the laws of descent and distribution, unless (for awards other than ISOs) otherwise
provided by our Compensation Committee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Corporate Transactions.</I>&nbsp;&nbsp;&nbsp;&nbsp;In the event of a
consolidation, merger or similar transaction, a sale or transfer of all or substantially all of the company&#146;s assets or a dissolution or liquidation of the company, our Compensation Committee may, among other things, provide for continuation or
assumption of outstanding awards, for new grants in substitution of outstanding awards, for the accelerated vesting or delivery of shares under awards or for a cash-out of outstanding awards, in each case on such terms and with such restrictions as
it deems appropriate. Except as our Compensation Committee may otherwise determine, awards not assumed will terminate upon the consummation of such corporate transaction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Adjustment</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain corporate transactions (including, but not limited to, a stock dividend, stock split or combination of shares, recapitalization or other
change in the company&#146;s capital structure that constitutes an equity restructuring within the meaning of ASC 718), our Compensation Committee will make appropriate adjustments to the maximum number of shares that may be delivered under and the
individual limits included in the 2013 EIP, and will also make appropriate adjustments to the number and kind of shares of stock or securities subject to awards, the exercise prices of such awards or any other terms of awards affected by such
change. Our Compensation Committee may also make the types of adjustments described above to take into account distributions to stockholders and other events other than those listed above if it determines that such adjustments are appropriate to
avoid distortion. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Amendment and Termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee can amend the 2013 EIP
or outstanding awards, or terminate the 2013 EIP as to future grants of awards, except that our Compensation Committee will not be able alter the terms of an award if it would affect materially and adversely a participant&#146;s rights under the
award without the participant&#146;s consent (unless expressly provided in the 2013 EIP or reserved by our Compensation Committee at the time of grant). Stockholder approval will be required for any amendment to the extent such approval is required
by law, including the Code or applicable stock exchange requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Federal Tax Effects </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following is a summary of some of the material federal income tax consequences associated with the grant and exercise of stock options under the 2013 EIP under current federal tax laws and certain
other tax considerations associated with awards under the 2013 EIP. The summary does not address tax rates or non-U.S., state or local tax consequences, nor does it address employment-tax or other federal tax consequences except as noted.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>ISOs</I>.&nbsp;&nbsp;&nbsp;&nbsp;In general, a participant realizes no taxable income upon the grant or exercise of an
ISO. However, the exercise of an ISO may result in an alternative minimum tax liability to the participant. With some exceptions, a disposition of shares purchased under an ISO within two years from the date of grant or within one year after
exercise produces ordinary income to the participant (and a deduction to the company) equal to the value of the shares at the time of exercise less the exercise price. Any additional gain recognized in the disposition is treated as a capital gain
for which the company is not entitled to a deduction. If the participant does not dispose of the shares until after the expiration of these one and two-year holding periods, any gain or loss recognized upon a subsequent sale is treated as a
long-term capital gain or loss for which the company is not entitled to a deduction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>NSOs</I>.&nbsp;&nbsp;&nbsp;&nbsp;In
general, a participant has no taxable income upon the grant of an NSO but realizes income in connection with exercise of the option in an amount equal to the excess (at time of exercise) of the fair market value of the shares acquired upon exercise
over the exercise price. A corresponding deduction is available to the company. Upon a subsequent sale or exchange of the shares, any recognized gain or loss is treated as a capital gain or loss for which the company is not entitled to a deduction.
An ISO that is exercised more than three months after termination of employment (other than termination by reason of death) is generally treated as an NSO. ISOs are also treated as NSOs to the extent they first become exercisable by an individual in
any calendar year for shares having a fair market value (determined as of the date of grant) in excess of $100,000. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Section&nbsp;162(m)</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock options, SARs and certain performance awards under the 2013 EIP are generally
intended to be exempt or eligible for exemption from the deductibility limits of Section&nbsp;162(m). However, as discussed above in &#147;Reasons for Seeking Stockholder Approval,&#148; the Compensation Committee will have discretionary authority
to provide compensation that is not exempt from the limits on deductibility under Section&nbsp;162(m). </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Section&nbsp;409A</I>.&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;409A of the Code (&#147;Section 409A&#148;) imposes an additional 20%
income tax, plus, in some cases, a further income tax in the nature of interest, on nonqualified deferred compensation that does not comply with deferral, payment-timing and other formal and operational requirements specified in Section&nbsp;409A
and related regulations and that is not exempt from those requirements. Stock options and SARs granted under the 2013 EIP are intended to be exempt from Section&nbsp;409A. The 2013 EIP gives the Compensation Committee the flexibility to prescribe
terms for other awards that are consistent with the requirements of, or an exemption from, Section&nbsp;409A. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Certain
Change of Control Payments</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under Section&nbsp;280G of the Code, the vesting or accelerated exercisability of options or the vesting and payments of other awards in connection with a change of control of a corporation may
be required to be valued and taken into account in determining whether participants have received compensatory payments, contingent on the change in control, in excess of certain limits. If these limits are exceeded, a substantial portion of amounts
payable to the participant, including income recognized by reason of the grant, vesting or exercise of awards, may be subject to an additional 20% federal tax and may be non-deductible to the company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2013 EIP Benefits </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee has full discretion to determine the number and amount of awards to be granted to employees under the 2013 EIP, subject to the limits described above under &#147;Individual
Limits&#148; and other terms of the plan. Therefore, the future benefits or amounts that would be received by the executive officers and the groups named in the table below under the 2013 EIP are not determinable at this time. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE <U>FOR</U> THE ADOPTION OF THE 2013 EQUITY INCENTIVE PLAN, AS SET FORTH HEREIN AS APPENDIX 2.
</B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OTHER MATTERS </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholder Proposals </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders who wish to present proposals for
inclusion in the company&#146;s proxy materials for the 2014 Annual Meeting of Stockholders may do so by following the procedures prescribed in Rule&nbsp;14a-8 under the Exchange Act. To be eligible, the stockholder proposals must be received by our
corporate secretary on or before July&nbsp;7, 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders who wish to make a proposal at the 2014 Annual Meeting of
Stockholders, other than one that will be included in our proxy materials, must notify us no later than September&nbsp;20, 2014 (see Rule&nbsp;14a-4 under the Exchange Act). If a stockholder who wishes to present a proposal at the 2014 Annual
Meeting of Stockholders fails to notify us by September&nbsp;20, 2014, the proxies that management solicits for the meeting will confer discretionary authority to vote on the stockholder&#146;s proposal if it is properly brought before the meeting.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholder Nominations of Directors </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Stockholders or groups of stockholders that, individually or as a group, have beneficially owned at least 5% of the company&#146;s common stock for at least one year prior to the date of such submission
(the &#147;Nominating Stockholder&#148;) may submit a candidate for nomination for election as a director at any annual meeting of stockholders in accordance with Board policy. The submission must be in writing and delivered to StemCells, Inc.,
Attn: Secretary, Board of Directors, 7707 Gateway Blvd., Newark, California 94560, no later than on or about July&nbsp;7, 2014 for nominees to be considered for nomination at the 2014 annual meeting. Submissions must include the name, address and
number of shares of common stock beneficially owned by each participant in the Nominating Stockholder group, a representation that the Nominating Stockholder meets the requirements described in the Board policy and will continue to meet them through
the date of the annual meeting, a description of all arrangements or understandings between or among the Nominating Stockholder group (or any participant in the Nominating Stockholder group) and the candidate or any other person or entity regarding
the candidate, all information regarding the candidate that the company would be required to disclose in a proxy statement under SEC rules, including whether the candidate is independent or, if not, a description of the reasons why not, the consent
of the candidate to serve as a director, and representations by the candidate regarding his or her performance of the duties of a director. Full details may be obtained from the secretary of the Board of Directors at the address above or on our
website at www.stemcellsinc.com. The Corporate Governance Committee will consider and evaluate up to two candidates recommended in accordance with this policy in connection with any annual meeting. The Corporate Governance Committee will consider
and evaluate candidates recommended by stockholders on the same basis as candidates recommended by other sources. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition, the company&#146;s by-laws provide that a stockholder entitled to vote for the election of directors at a meeting may nominate persons for election as directors by giving timely notice thereof in proper written form to the Secretary
accompanied by a petition signed by at least 100 record holders of capital stock of the company representing in the aggregate 1% or more of the outstanding shares entitled to vote in the election of directors, which petition must show the class and
number of shares held by each person. To be timely, such notice and petition must be received at the principal executive offices of the company not less than 60&nbsp;days nor more than 90&nbsp;days prior to the meeting, except if less than
70&nbsp;days notice of the date of the meeting is given to stockholders, in which case the notice and petition must be received not later than the close of business on the tenth day following the day on which notice of the date of the meeting was
mailed or public disclosure of such date was made. The requesting stockholder is required to provide information with respect to the nominee(s) for director similar to that described above, as more fully set forth in the company&#146;s by-laws.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Form&nbsp;10-K </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The company&#146;s Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2012, as amended, as filed with the SEC, is available without charge upon request by writing to StemCells,
Inc. at 7707 Gateway Blvd., Newark, California 94560, Attention: Investor Relations. A copy of this report is also available through our website at www.stemcellsinc.com or, alternatively, at www.sec.gov. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#147;Householding&#148; of Proxy Materials </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The SEC has adopted rules that permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements with respect to two or more stockholders sharing the same address
by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as &#147;householding,&#148; potentially provides extra convenience for stockholders and cost savings for companies. The company and
some brokers household proxy materials, delivering a single proxy statement to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker or
us that they or we will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to
receive a separate proxy statement, or if you are receiving multiple copies of the proxy statement and wish to receive only one, please notify your broker if your shares are held in a brokerage account or us if you hold registered shares. We
undertake to deliver promptly upon any request a separate or single copy of the proxy materials. You can notify us by sending a written request to StemCells, Inc., 7707 Gateway Blvd., Newark, California 94560, Attention: Investor Relations or by
calling us at (510)&nbsp;456-4000. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Business </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors knows of no business that will come before the meeting for action except as described in the accompanying Notice of Meeting. However, as to any such business, the persons designated
as proxies will have authority to act in their discretion. </FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g519187g32t36.jpg" ALT="LOGO">
</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kenneth B. Stratton,&nbsp;J.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;4, 2013 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTATED CERTIFICATE OF INCORPORATION OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STEMCELLS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">StemCells, Inc. (the &#147;Corporation&#148;), a corporation duly organized and existing under the General Corporation Law of the State of
Delaware (the &#147;DGCL&#148;), hereby certifies that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The name of the Corporation is StemCells, Inc. The date the Corporation filed
its original Certificate of Incorporation with Delaware Secretary of State was August 2, 1988. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This Certificate of Amendment shall
become effective immediately upon filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. This Certificate of Amendment was duly adopted in accordance with Section&nbsp;242 of the
DGCL. The Board of Directors duly adopted resolutions setting forth and declaring advisable this Certificate of Amendment and directed that the proposed amendment be considered by the stockholders of the Corporation. A meeting of stockholders was
duly called upon notice in accordance with Section&nbsp;222 of the DGCL and held on December&nbsp;20, 2013, at which meeting the necessary number of shares were voted in favor of the proposed amendment. The stockholders of the Corporation duly
adopted this Certificate of Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Upon the filing and effectiveness pursuant to the DGCL of this Certificate of Amendment of the
Restated Certificate of Incorporation, as amended, of the Corporation, (the &#147;Charter&#148;) the first paragraph of section THREE of the Charter is hereby amended to read in its entirety as set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total number of shares of stock that this Corporation shall have authority to issue is 226,000,000, consisting of 225,000,000 shares of
Common Stock, with a par value of $0.01 per share (the &#147;Common Stock&#148;), and 1,000,000 shares of Undesignated Preferred Stock with a par value of $0.01 per share (the &#147;Undesignated Preferred Stock&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The remaining provisions of the Charter, including without limitation the remaining provisions of section THREE of the Charter, are not
affected by the aforementioned amendment and remain in full force and are not affected by this Certificate of Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS
WHEREOF, StemCells, Inc. has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer, Martin M. McGlynn, and its corporate Secretary, Kenneth B. Stratton, on this [&nbsp;&nbsp;&nbsp;&nbsp; day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 201[&nbsp;&nbsp;&nbsp;&nbsp;]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STEMCELLS, INC.</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martin M. McGlynn</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth B. Stratton</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Secretary</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STEMCELLS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2013
EQUITY INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEFINED TERMS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Exhibit A</U>, which is incorporated by reference, defines the terms
used in the Plan and sets forth certain operational rules related to those terms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PURPOSE </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan has been established to advance the interests of the Company by
providing for the grant to Participants of Stock-based and other incentive Awards. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ADMINISTRATION </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator has discretionary authority, subject only to the
express provisions of the Plan, to interpret the Plan; determine eligibility for and grant Awards; determine, modify or waive the terms and conditions of any Award; prescribe forms, rules and procedures relating to the Plan; and otherwise do all
things necessary or appropriate to carry out the purposes of the Plan. Determinations of the Administrator made under the Plan will be conclusive and will bind all parties. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LIMITS ON AWARDS UNDER THE PLAN </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) <U>Number of Shares</U>.</B> The maximum number
of shares of Stock that may be delivered in satisfaction of Awards under the Plan is six million (6,000,000)&nbsp;plus an annual increase each January&nbsp;1 (beginning January&nbsp;1, 2015 and with the last increase on January&nbsp;1, 2023) equal
to four percent (4%)&nbsp;of the number of then outstanding shares of Stock. Notwithstanding the preceding sentence, no more than fifty (50)&nbsp;million shares of Stock may be delivered in satisfaction of ISOs awarded under the Plan, and no more
than one hundred (100)&nbsp;million shares of Stock may be issued in satisfaction of Awards under the Plan to Participants who are residents of the State of California on the date of grant (&#147;California Participants&#148;). Nothing in this
Section&nbsp;4(a) will be construed as requiring that any, or any fixed number of, (x)&nbsp;ISOs be awarded under the Plan or (y)&nbsp;Awards to California Participants be made under the Plan. The limits set forth in this Section&nbsp;4(a) shall be
construed to comply with the requirements of Section&nbsp;422 of the Code. For purposes of this Section&nbsp;4(a), the number of shares of Stock delivered in satisfaction of Awards will be determined (i)&nbsp;net of shares of Stock underlying the
portion of any Award that is settled in cash or the portion of any Award that expires, terminates or is forfeited prior to the issuance of Stock thereunder and (ii)&nbsp;net of shares of Stock withheld by the Company from an Award in payment of the
exercise price of any Award requiring exercise or in satisfaction of tax withholding requirements with respect to any Award. To the extent consistent with the requirements of Section&nbsp;422 and the regulations thereunder, and with other applicable
legal requirements (including applicable stock exchange requirements), Stock issued under awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition shall not reduce the number of shares of Stock
available for Awards under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) <U>Type of Shares</U>.</B> Stock delivered by the Company under the Plan may be authorized
but unissued Stock or previously issued Stock acquired by the Company. No fractional shares of Stock will be delivered under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) <U>Section&nbsp;162(m) Limits</U>.</B> The following additional limits will apply to Awards of the specified type granted, or in the
case of Cash Awards, payable to any person in any calendar year: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> Stock Options: 2,500,000 shares of Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> SARs: 2,500,000 shares of Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> Awards other than Stock Options, SARs or Cash Awards: 2,500,000 shares of Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(4)</B> Cash Awards: $2,500,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In applying the foregoing limits, (i)&nbsp;all Awards of the specified type granted to the same person in the same calendar year will be
aggregated and made subject to one limit; (ii)&nbsp;the limits applicable to Stock Options and SARs refer to the number of shares of Stock subject to those Awards; (iii)&nbsp;the share limit under clause (3)&nbsp;refers to the maximum number of
shares of Stock that may be delivered, or the value of which could be paid in cash or other property, under an Award or Awards of the type specified in clause (3)&nbsp;assuming a maximum payout; and (iv)&nbsp;the dollar limit under clause
(4)&nbsp;refers to the maximum dollar amount payable under an Award or Awards of the type specified in clause (4)&nbsp;assuming a maximum payout. The foregoing provisions will be construed in a manner consistent with Section&nbsp;162(m), including,
without limitation, where applicable, the rules under Section&nbsp;162(m) pertaining to permissible deferrals of exempt awards. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ELIGIBILITY AND PARTICIPATION </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator will select Participants from among
those Employees and directors of, and consultants and advisors to, either the Company or any of its Affiliates who, in the opinion of the Administrator, are in a position to make a significant contribution to the success of the Company and its
Affiliates. Eligibility for ISOs is limited to individuals described in the first sentence of this Section&nbsp;5 who are employees of the Company or of a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; of the Company as those
terms are defined in Section&nbsp;424 of the Code. Eligibility for Stock Options other than ISOs is limited to individuals described in the first sentence of this Section&nbsp;5 who are providing direct services on the date of grant of the Stock
Option to either the Company or to a subsidiary of the Company that would be described in the first sentence of Treas. Regs. &#167;1.409A-1(b)(5)(iii)(E). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RULES APPLICABLE TO AWARDS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) <U>All Awards</U>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(1) <U>Award Provisions</U>.</B> The Administrator will determine the terms of all Awards, subject to the limitations provided herein. By
accepting (or, under such rules as the Administrator may prescribe, being deemed to have accepted) an Award, the Participant will be deemed to have agreed to the terms of the Award and the Plan. Notwithstanding any provision of this Plan to the
contrary, awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition may contain terms and conditions that are inconsistent with the terms and conditions specified herein, as determined by the
Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(2) <U>Term of Plan</U>.</B> No Awards may be made after ten years from the Date of Adoption, but previously granted
Awards may continue beyond that date in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(3) <U>Transferability</U>.</B> Neither ISOs nor, except as the
Administrator otherwise expressly provides in accordance with the third sentence of this Section&nbsp;6(a)(3), other Awards may be transferred other than by will or by the laws of descent and distribution. During a Participant&#146;s lifetime, ISOs
(and, except as the Administrator otherwise expressly provides in accordance with the third sentence of this Section&nbsp;6(a)(3), SARs and NSOs) may be exercised only by the Participant. The Administrator may permit the gratuitous transfer
(<I>i.e.</I>, transfer not for value) of Awards other than ISOs to any transferee eligible to be covered by the provisions of Form S-8 (under the Securities Act of 1933, as amended), subject to such limitations as the Administrator may impose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(4) <U>Vesting, etc</U>.</B> The Administrator will determine the time or times at which an Award will vest or become exercisable and the
terms on which a Stock Option or SAR will remain exercisable. Without limiting the foregoing, the Administrator may at any time accelerate the vesting or exercisability of an Award, regardless of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any adverse or potentially adverse tax or other consequences resulting from such acceleration. Unless the Administrator expressly provides otherwise, however, the following rules will apply if a
Participant&#146;s Employment ceases: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(A)</B> Immediately upon the cessation of the Participant&#146;s Employment and
except as provided in (B), (C), and (D)&nbsp;below, each Stock Option and SAR that is then held by the Participant or by the Participant&#146;s permitted transferees, if any, will cease to be exercisable and will terminate and all other Awards that
are then held by the Participant or by the Participant&#146;s permitted transferees, if any, to the extent not already vested will be forfeited. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(B)</B> Subject to (C), (D), and (E)&nbsp;below, all Stock Options and SARs held by the Participant or the
Participant&#146;s permitted transferees, if any, immediately prior to the cessation of the Participant&#146;s Employment, to the extent then exercisable, will remain exercisable for the lesser of (i)&nbsp;a period of three months or (ii)&nbsp;the
period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section&nbsp;6(a)(4), and will thereupon immediately terminate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(C)</B> All Stock Options and SARs held by a Participant or the Participant&#146;s permitted transferees, if any,
immediately prior to the cessation of the Participant&#146;s Employment due to his or her death, to the extent then exercisable, will remain exercisable for the lesser of (i)&nbsp;the one year period ending with the first anniversary of the
Participant&#146;s death or (ii)&nbsp;the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section&nbsp;6(a)(4), and will thereupon immediately terminate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(D)</B> All Stock Options and SARs held by a Participant or the Participant&#146;s permitted transferees, if any,
immediately prior to the cessation of the Participant&#146;s Employment due to his or her &#147;permanent and total disability&#148; (within the meaning of Section&nbsp;22(e)(3) of the Code, to the extent then exercisable, will remain exercisable
for the lesser of (i)&nbsp;a period of six months or (ii)&nbsp;the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section&nbsp;6(a)(4), and will thereupon immediately terminate.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(E)</B> All Awards (whether or not exercisable) held by a Participant or the Participant&#146;s permitted transferees,
if any, immediately prior to the cessation of the Participant&#146;s Employment will immediately terminate upon such cessation of Employment if the termination is for Cause or occurs in circumstances that in the sole determination of the
Administrator would have constituted grounds for the Participant&#146;s Employment to be terminated for Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(5) <U>Additional
Restrictions</U>.</B> The Administrator may cancel, rescind, withhold or otherwise limit or restrict any Award at any time if the Participant is not in compliance with all applicable provisions of the Award agreement and the Plan, or if the
Participant breaches any restrictive covenant agreement with the Company or its Affiliates. Without limiting the generality of the foregoing, the Administrator may recover Awards made under the Plan and payments under or gain in respect of any Award
in accordance with any applicable Company clawback or recoupment policy, as such policy may be amended and in effect from time to time, or as otherwise required by law or applicable stock exchange listing standards, including, without limitation,
Section&nbsp;10D of the Securities Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(6) <U>Taxes</U>.</B> The delivery, vesting and retention of
Stock, cash or other property under an Award are conditioned upon full satisfaction by the Participant of all tax withholding requirements with respect to the Award. The Administrator will prescribe such rules for the withholding of taxes as it
deems necessary or appropriate. The Administrator may, but need not, hold back shares of Stock from an Award or permit a Participant to tender previously owned shares of Stock in satisfaction of tax withholding requirements (but not in excess of the
minimum withholding required by law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(7) <U>Dividend Equivalents, Etc</U>.</B> The Administrator may provide for the payment of
amounts (on terms and subject to conditions established by the Administrator) in lieu of cash dividends or other cash distributions with respect to Stock subject to an Award whether or not the holder of such Award is otherwise entitled to share
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the actual dividend or distribution in respect of such Award. Any entitlement to dividend equivalents or similar entitlements will be established and administered either consistent with an
exemption from, or in compliance with, the requirements of Section&nbsp;409A. Dividends or dividend equivalent amounts payable in respect of Awards that are subject to restrictions may be subject to such limits or restrictions as the Administrator
may impose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(8) <U>Rights Limited</U>.</B> Nothing in the Plan will be construed as giving any person the right to continued
employment or service with the Company or its Affiliates, or any rights as a stockholder except as to shares of Stock actually issued under the Plan. The loss of existing or potential profit in Awards will not constitute an element of damages in the
event of termination of Employment for any reason, even if the termination is in violation of an obligation of the Company or any Affiliate to the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(9) <U>Section&nbsp;162(m)</U>.</B> In the case of any Performance Award (other than a Stock Option or SAR) intended to qualify for the
performance-based compensation exception under Section&nbsp;162(m), the Administrator will establish the applicable Performance Criterion or Criteria in writing no later than ninety (90)&nbsp;days after the commencement of the period of service to
which the performance relates (or at such earlier time as is required to qualify the Award as performance-based under Section&nbsp;162(m)) and, prior to the event or occurrence (grant, vesting or payment, as the case may be) that is conditioned on
the attainment of such Performance Criterion or Criteria, will certify whether it or they have been attained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(10) <U>Coordination
with Other Plans</U>.</B> Awards under the Plan may be granted in tandem with, or in satisfaction of or substitution for, other Awards under the Plan or awards made under other compensatory plans or programs of the Company or its Affiliates. For
example, but without limiting the generality of the foregoing, awards under other compensatory plans or programs of the Company or its Affiliates may be settled in Stock (including, without limitation, Unrestricted Stock) if the Administrator so
determines, in which case the shares delivered will be treated as awarded under the Plan (and will reduce the number of shares thereafter available under the Plan in accordance with the rules set forth in Section&nbsp;4). In any case where an award
is made under another plan or program of the Company or its Affiliates and such award is intended to qualify for the performance-based compensation exception under Section&nbsp;162(m), and such award is settled by the delivery of Stock or another
Award under the Plan, the applicable Section&nbsp;162(m) limitations under both the other plan or program and under the Plan will be applied to the Plan as necessary (as determined by the Administrator) to preserve the availability of the
Section&nbsp;162(m) performance-based compensation exception with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(11) <U>Section&nbsp;409A</U>.</B> Each Award will
contain such terms as the Administrator determines, and will be construed and administered, such that the Award either qualifies for an exemption from the requirements of Section&nbsp;409A or satisfies such requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(12) <U>Fair Market Value</U>.</B> In determining the fair market value of any share of Stock under the Plan, the Administrator will make
the determination in good faith consistent with the rules of Section&nbsp;422 and Section&nbsp;409A, to the extent applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)
<U>Stock Options and SARs</U>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(1) <U>Time And Manner Of Exercise</U>.</B> Unless the Administrator expressly provides otherwise,
no Stock Option or SAR will be deemed to have been exercised until the Administrator receives a notice of exercise (in form acceptable to the Administrator), which may be an electronic notice, signed (including electronic signature in form
acceptable to the Administrator) by the appropriate person and accompanied by any payment required under the Award. A Stock Option or SAR exercised by any person other than the Participant will not be deemed to have been exercised until the
Administrator has received such evidence as it may require that the person exercising the Award has the right to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(2)
<U>Exercise Price</U>.</B> The exercise price (or the base value from which appreciation is to be measured) of each Award requiring exercise will be no less than 100% (or in the case of an ISO granted to a ten-percent shareholder within the meaning
of subsection (b)(6) of Section&nbsp;422, 110%) of the fair market value of the Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to the Award, determined as of the date of grant, or such higher amount as the Administrator may determine in connection with the grant. Except in connection with a corporate transaction
involving the Company (which term shall include, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, or exchange of shares) or as
otherwise contemplated by Section&nbsp;7 of the Plan, the terms of outstanding Awards may not be amended to reduce the exercise prices of outstanding Stock Options or the base values from which appreciation under outstanding SARs are to be measured
other than in accordance with the stockholder approval requirements of any applicable stock exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(3) <U>Payment Of Exercise
Price</U>.</B> Where the exercise of an Award is to be accompanied by payment, payment of the exercise price will be by cash or check acceptable to the Administrator or by such other legally permissible means, if any, as may be acceptable to the
Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(4) <U>Maximum Term</U>.</B> Stock Options and SARs will have a maximum term not to exceed ten (10)&nbsp;years from the
date of grant (or five (5)&nbsp;years from the date of grant in the case of an ISO granted to a ten-percent shareholder described in Section&nbsp;6(b)(2) above); provided, however, that, if a Participant still holding an outstanding but unexercised
NSO or SAR ten (10)&nbsp;years from the date of grant (or, in the case of an NSO or SAR with a maximum term of less than ten (10)&nbsp;years, such maximum term) is prohibited by applicable law or a written policy of the Company applicable to
similarly situated employees from engaging in any open-market sales of Stock, and if at such time the Stock is publicly traded (as determined by the Administrator), the maximum term of such Award will instead be deemed to expire on the thirtieth (30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day following the date the Participant is no longer prohibited from engaging in such open market sales. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EFFECT OF CERTAIN TRANSACTIONS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) <U>Mergers,</U></B><B><I><U>
etc</U></I></B><B><U></U></B><B><I>.</I></B><B></B> Except as otherwise provided in an Award agreement, the following provisions will apply in the event of a Covered Transaction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(1) <U>Assumption or Substitution</U>.</B> If the Covered Transaction is one in which there is an acquiring or surviving entity, the
Administrator may (but, for the avoidance of doubt, need not) provide (i)&nbsp;for the assumption or continuation of some or all outstanding Awards or any portion thereof or (ii)&nbsp;for the grant of new awards in substitution therefor by the
acquiror or survivor or an affiliate of the acquiror or survivor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(2) <U>Cash-Out of Awards</U>.</B> Subject to Section&nbsp;7(a)(5)
below the Administrator may (but, for the avoidance of doubt, need not) provide for payment (a &#147;cash-out&#148;), with respect to some or all Awards or any portion thereof, equal in the case of each affected Award or portion thereof to the
excess, if any, of (A)&nbsp;the fair market value of one share of Stock (as determined by the Administrator in its reasonable discretion) times the number of shares of Stock subject to the Award or such portion, over (B)&nbsp;the aggregate exercise
or purchase price, if any, under the Award or such portion (in the case of an SAR, the aggregate base value above which appreciation is measured), in each case on such payment terms (which need not be the same as the terms of payment to holders of
Stock) and other terms, and subject to such conditions, as the Administrator determines, it being understood that if the exercise or purchase price (or base value) of an Award is equal to or greater than the fair market value of one share of Stock
(as determined in accordance with this Section&nbsp;7(a)(2)), the Award may be cancelled with no payment due hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(3)
<U>Acceleration of Certain Awards</U>.</B> Subject to Section&nbsp;7(a)(5) below, the Administrator may (but, for the avoidance of doubt, need not) provide that any Award requiring exercise will become exercisable, in full or in part and/or that the
delivery of any shares of Stock remaining deliverable under any outstanding Award of Stock Units (including Restricted Stock Units and Performance Awards to the extent consisting of Stock Units) will be accelerated in full or in part, in each case
on a basis that gives the holder of the Award a reasonable opportunity, as determined by the Administrator, following exercise of the Award or the delivery of the shares, as the case may be, to participate as a stockholder in the Covered
Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(4) <U>Termination of Awards Upon Consummation of Covered Transaction</U>.</B> Except as the
Administrator may otherwise determine in any case, each Award will automatically terminate (and in the case of outstanding shares of Restricted Stock, will automatically be forfeited) upon consummation of the Covered Transaction, other than Awards
assumed pursuant to Section&nbsp;7(a)(1) above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(5) <U>Additional Limitations</U>.</B> Any share of Stock and any cash or other
property delivered pursuant to Section&nbsp;7(a)(2) or Section&nbsp;7(a)(3) above with respect to an Award may, in the discretion of the Administrator, contain such restrictions, if any, as the Administrator deems appropriate to reflect any
performance or other vesting conditions to which the Award was subject and that did not lapse (and were not satisfied) in connection with the Covered Transaction. For purposes of the immediately preceding sentence, a cash-out under
Section&nbsp;7(a)(2) above or acceleration under Section&nbsp;7(a)(3) above will not, in and of itself, be treated as the lapsing (or satisfaction) of a performance or other vesting condition. In the case of Restricted Stock that does not vest and
is not forfeited in connection with the Covered Transaction, the Administrator may require that any amounts delivered, exchanged or otherwise paid in respect of such Stock in connection with the Covered Transaction be placed in escrow or otherwise
made subject to such restrictions as the Administrator deems appropriate to carry out the intent of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) <U>Changes in and
Distributions With Respect to Stock</U>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(1) <U>Basic Adjustment Provisions</U>.</B> In the event of a stock dividend, stock split
or combination of shares (including a reverse stock split), recapitalization, reclassification or other distribution of the Company&#146;s equity securities without the receipt of consideration by the Company, or other change in the Company&#146;s
capital structure that constitutes an equity restructuring within the meaning of FASB ASC 718, the Administrator will make appropriate adjustments to the maximum number of shares specified in Section&nbsp;4(a) that may be delivered under the Plan
and to the maximum share limits described in Section&nbsp;4(c), and will also make appropriate adjustments to the number and kind of shares of stock or securities subject to Awards then outstanding or subsequently granted, any exercise or purchase
prices (or base values) relating to Awards and any other provision of Awards affected by such change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(2) <U>Certain Other
Adjustments</U>.</B> The Administrator may also make adjustments of the type described in Section&nbsp;7(b)(1) above to take into account distributions to stockholders other than those provided for in Section&nbsp;7(a) and 7(b)(1), or any other
event, if the Administrator determines that adjustments are appropriate to avoid distortion in the operation of the Plan, having due regard for the qualification of ISOs under Section&nbsp;422, the requirements of Section&nbsp;409A, and for the
performance-based compensation rules of Section&nbsp;162(m), where applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(3) <U>Continuing Application of Plan Terms</U>.</B>
References in the Plan to shares of Stock will be construed to include any stock or securities resulting from an adjustment pursuant to this Section 7. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LEGAL CONDITIONS ON DELIVERY OF STOCK </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will not be obligated to deliver any
shares of Stock pursuant to the Plan or to remove any restriction from shares of Stock previously delivered under the Plan until: (i)&nbsp;the Company is satisfied that all legal matters in connection with the issuance and delivery of such shares
have been addressed and resolved; (ii)&nbsp;if the outstanding Stock is at the time of delivery listed on any stock exchange or national market system, the shares to be delivered have been listed or authorized to be listed on such exchange or system
upon official notice of issuance; and (iii)&nbsp;all conditions of the Award have been satisfied or waived. The Company may require, as a condition to exercise of the Award, such representations or agreements as counsel for the Company may consider
appropriate to avoid violation of the Securities Act of 1933, as amended, or any applicable state or non-U.S. securities law. Any Stock required to be issued to Participants under the Plan will be evidenced in such manner as the Administrator may
deem appropriate, including book-entry registration or delivery of stock certificates. In the event that the Administrator determines that Stock certificates will be issued to Participants under the Plan,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Administrator may require that certificates evidencing Stock issued under the Plan bear an appropriate legend reflecting any restriction on transfer applicable to such Stock, and the Company
may hold the certificates pending lapse of the applicable restrictions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>AMENDMENT AND TERMINATION </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time or times amend the Plan or
any outstanding Award for any purpose which may at the time be permitted by law, and may at any time terminate the Plan as to any future grants of Awards; provided, that except as otherwise expressly provided in the Plan the Administrator may not,
without the Participant&#146;s consent, alter the terms of an Award so as to affect materially and adversely the Participant&#146;s rights under the Award, unless the Administrator expressly reserved the right to do so at the time the Award was
granted. Any amendments to the Plan will be conditioned upon stockholder approval only to the extent, if any, such approval is required by law (including the Code and applicable stock exchange requirements), as determined by the Administrator. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>OTHER COMPENSATION ARRANGEMENTS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of the Plan or the grant of any Award
will not in any way affect the Company&#146;s right to Award a person bonuses or other compensation in addition to Awards under the Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MISCELLANEOUS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) <U>Waiver of Jury Trial</U>.</B> By accepting an Award under the
Plan, each Participant waives any right to a trial by jury in any action, proceeding or counterclaim concerning any rights under the Plan and any Award, or under any amendment, waiver, consent, instrument, document or other agreement delivered or
which in the future may be delivered in connection therewith, and agrees that any such action, proceedings or counterclaim will be tried before a court and not before a jury. By accepting an Award under the Plan, each Participant certifies that no
officer, representative, or attorney of the Company has represented, expressly or otherwise, that the Company would not, in the event of any action, proceeding or counterclaim, seek to enforce the foregoing waivers. Notwithstanding anything to the
contrary in the Plan, nothing herein is to be construed as limiting the ability of the Company and a Participant to agree to submit disputes arising under the terms of the Plan or any Award made hereunder to binding arbitration or as limiting the
ability of the Company to require any eligible individual to agree to submit such disputes to binding arbitration as a condition of receiving an Award hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) <U>Limitation of Liability</U>.</B> Notwithstanding anything to the contrary in the Plan, neither the Company, nor any Affiliate, nor
the Administrator, nor any person acting on behalf of the Company, any Affiliate, or the Administrator, will be liable to any Participant or to the estate or beneficiary of any Participant or to any other holder of an Award by reason of any
acceleration of income, or any additional tax (including any interest and penalties), asserted by reason of the failure of an Award to satisfy the requirements of Section&nbsp;422 or Section&nbsp;409A or by reason of Section&nbsp;4999 of the Code,
or otherwise asserted with respect to the Award. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ESTABLISHMENT OF SUB-PLANS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may from time to time establish one or
more sub-plans under the Plan for purposes of satisfying applicable blue sky, securities or tax laws of various jurisdictions. The Administrator will establish such sub-plans by adopting supplements to the Plan setting forth (i)&nbsp;such
limitations on the Administrator&#146;s discretion under the Plan as it deems necessary or desirable and (ii)&nbsp;such additional terms and conditions not otherwise inconsistent with the Plan as it deems necessary or desirable. All supplements so
established will be deemed to be part of the Plan, but each supplement will apply only to Participants within the affected jurisdiction (as determined by the Administrator). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>GOVERNING LAW </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) <U>Certain Requirements of Corporate Law</U>.</B> Awards will be
granted and administered consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) <U>Other Matters</U>.</B> Except as otherwise provided by the express terms of an Award agreement, under a sub-plan described in
Section 12 or as provided in Section&nbsp;13(a) above, the provisions of the Plan and of Awards under the Plan and all claims or disputes arising out of our based upon the Plan or any Award under the Plan or relating to the subject matter hereof or
thereof will be governed by and construed in accordance with the domestic substantive laws of the State of California without giving effect to any choice or conflict of laws provision or rule that would cause the application of the domestic
substantive laws of any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) <U>Jurisdiction</U>.</B> By accepting an Award, each Participant will be deemed to (a)
have submitted irrevocably and unconditionally to the jurisdiction of the federal and state courts located within the geographic boundaries of the United States District Court for the Northern District of California for the purpose of any suit,
action or other proceeding arising out of or based upon the Plan or any Award; (b) agree not to commence any suit, action or other proceeding arising out of or based upon the Plan or an Award, except in the federal and state courts located within
the geographic boundaries of the United States District Court for the Northern District of California; and (c) waive, and agree not to assert, by way of motion as a defense or otherwise, in any such suit, action or proceeding, any claim that it is
not subject personally to the jurisdiction of the above-named courts that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or
proceeding is improper or that the Plan or an Award or the subject matter thereof may not be enforced in or by such court. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Definition of Terms </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms, when used in the Plan, will have the meanings and be subject to the provisions set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Administrator&#148;:</B> The Compensation Committee, except that the Compensation Committee may delegate (i)&nbsp;to one or more of
its members (or one or more other members of the Board (including the full Board)) such of its duties, powers and responsibilities as it may determine; (ii)&nbsp;to one or more officers of the Company the power to grant Awards to the extent
permitted by Section&nbsp;157(c) of the Delaware General Corporation Law; and (iii)&nbsp;to such Employees or other persons as it determines such ministerial tasks as it deems appropriate. In the event of any delegation described in the preceding
sentence, the term &#147;Administrator&#148; will include the person or persons so delegated to the extent of such delegation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Affiliate&#148;:</B> Any corporation or other entity that stands in a relationship to the Company that would result in the Company
and such corporation or other entity being treated as one employer under Section&nbsp;414(b) and Section&nbsp;414(c) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Award&#148;:</B> Any or a combination of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Stock Options; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) SARs; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Restricted Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Unrestricted Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Stock Units, including Restricted Stock Units; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Performance Awards; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Cash Awards; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) Awards (other than Awards described in (i)&nbsp;through (vii)&nbsp;above) that are convertible into or otherwise based
on Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Board&#148;:</B> The Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Cash Award&#148;:</B> An Award denominated in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Cause&#148;:</B> In the case of any Participant who is party to an employment or severance-benefit agreement that contains a
definition of &#147;Cause,&#148; the definition set forth in such agreement will apply with respect to such Participant under the Plan for so long as such agreement is in effect. In the case of any other Participant, &#147;Cause&#148; will mean, as
determined by the Administrator in its reasonable judgment, (i)&nbsp;a substantial failure of the Participant to perform the Participant&#146;s duties and responsibilities to the Company or subsidiaries or substantial negligence in the performance
of such duties and responsibilities; (ii)&nbsp;the commission by the Participant of a felony or a crime involving moral turpitude; (iii)&nbsp;the commission by the Participant of theft, fraud, embezzlement, material breach of trust or any material
act of dishonesty involving the Company or any of its subsidiaries; (iv)&nbsp;a significant violation by the Participant of the code of conduct of the Company or its subsidiaries of any material policy of the Company or its subsidiaries, or of any
statutory or common law duty of loyalty to the Company or its subsidiaries; (v)&nbsp;material breach of any of the terms of the Plan or any Award made under the Plan, or of the terms of any other agreement between the Company or subsidiaries and the
Participant; or (vi)&nbsp;other conduct by the Participant that could be expected to be harmful to the business, interests or reputation of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Code&#148;:</B> The U.S. Internal Revenue Code of 1986 as from time to time amended and
in effect, or any successor statute as from time to time in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Compensation Committee&#148;:</B> The Compensation and Stock
Option Committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Company&#148;:</B> StemCells, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Covered Transaction&#148;:</B> Any of (i)&nbsp;a consolidation, merger, or similar transaction or series of related transactions,
including a sale or other disposition of stock, in which the Company is not the surviving corporation or which results in the acquisition of all or substantially all of the Company&#146;s then outstanding common stock by a single person or entity or
by a group of persons and/or entities acting in concert, (ii)&nbsp;a sale or transfer of all or substantially all the Company&#146;s assets, or (iii)&nbsp;a dissolution or liquidation of the Company. Where a Covered Transaction involves a tender
offer that is reasonably expected to be followed by a merger described in clause (i)&nbsp;(as determined by the Administrator), the Covered Transaction will be deemed to have occurred upon consummation of the tender offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Date of Adoption&#148;:</B> The earlier of the date the Plan was approved by the Company&#146;s stockholders or adopted by the Board,
as determined by the Compensation Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Employee&#148;:</B> Any person who is employed by the Company or an Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Employment&#148;:</B> A Participant&#146;s employment or other service relationship with the Company and its Affiliates. Employment
will be deemed to continue, unless the Administrator expressly provides otherwise, so long as the Participant is employed by, or otherwise is providing services in a capacity described in Section&nbsp;5 to the Company or any of its Affiliates. If a
Participant&#146;s employment or other service relationship is with an Affiliate and that entity ceases to be an Affiliate, the Participant&#146;s Employment will be deemed to have terminated when the entity ceases to be an Affiliate unless the
Participant transfers Employment to the Company or its remaining Affiliates. Notwithstanding the foregoing and the definition of &#147;Affiliate&#148; above, in construing the provisions of any Award relating to the payment of &#147;nonqualified
deferred compensation&#148; (subject to Section&nbsp;409A) upon a termination or cessation of Employment, references to termination or cessation of employment, separation from service, retirement or similar or correlative terms will be construed to
require a &#147;separation from service&#148; (as that term is defined in Section&nbsp;1.409A-1(h) of the Treasury Regulations, after giving effect to the presumptions contained therein) from the Company and from all other corporations and trades or
businesses, if any, that would be treated as a single &#147;service recipient&#148; with the Company under Section&nbsp;1.409A-1(h)(3) of the Treasury Regulations. The Company may, but need not, elect in writing, subject to the applicable
limitations under Section&nbsp;409A, any of the special elective rules prescribed in Section&nbsp;1.409A-1(h) of the Treasury Regulations for purposes of determining whether a &#147;separation from service&#148; has occurred. Any such written
election will be deemed a part of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;ISO&#148;:</B> A Stock Option intended to be an &#147;incentive stock option&#148;
within the meaning of Section&nbsp;422. Each Stock Option granted pursuant to the Plan will be treated as providing by its terms that it is to be an NSO unless, as of the date of grant, it is expressly designated as an ISO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;NSO&#148;:</B> A Stock Option that is not intended to be an &#147;incentive stock option&#148; within the meaning of
Section&nbsp;422. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Participant&#148;:</B> A person who is granted an Award under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Performance Award&#148;:</B> An Award subject to Performance Criteria. The Administrator in its discretion may grant Performance
Awards that are intended to qualify for the performance-based compensation exception under Section&nbsp;162(m) and Performance Awards that are not intended so to qualify. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Performance Criteria&#148;:</B> Specified criteria, other than the mere continuation of
Employment or the mere passage of time, the satisfaction of which is a condition for the grant, exercisability, vesting or full enjoyment of an Award. For purposes of Awards that are intended to qualify for the performance-based compensation
exception under Section&nbsp;162(m), a Performance Criterion will mean an objectively determinable measure of performance relating to any or any combination of the following (measured either absolutely or by reference to an index or indices and
determined either on a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof): sales; revenues; assets; expenses; earnings before or after deduction for
all or any portion of interest, taxes, depreciation, or amortization, whether or not on a continuing operations or an aggregate or per share basis; return on equity, investment, capital or assets; one or more operating ratios; borrowing levels,
leverage ratios or credit rating; market share; capital expenditures; cash flow; stock price; stockholder return; sales of particular products or services; customer acquisition or retention; acquisitions and divestitures (in whole or in part); joint
ventures and strategic alliances; spin-offs, split-ups and the like; reorganizations; or recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings. A Performance Criterion and any targets with respect thereto
determined by the Administrator need not be based upon an increase, a positive or improved result or avoidance of loss. To the extent consistent with the requirements for satisfying the performance-based compensation exception under
Section&nbsp;162(m), the Administrator may provide in the case of any Award intended to qualify for such exception that one or more of the Performance Criteria applicable to such Award will be adjusted in an objectively determinable manner to
reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the performance period that affect the applicable Performance Criterion or Criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Plan&#148;:</B> The StemCells, Inc. 2013 Equity Incentive Plan as from time to time amended and in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Restricted Stock&#148;:</B> Stock subject to restrictions requiring that it be redelivered or offered for sale to the Company if
specified conditions are not satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Restricted Stock Unit&#148;:</B> A Stock Unit that is, or as to which the delivery of
Stock or cash in lieu of Stock is, subject to the satisfaction of specified performance or other vesting conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;SAR&#148;:</B> A right entitling the holder upon exercise to receive an amount (payable in cash, in shares of Stock of equivalent
value, or in a combination of cash and shares of Stock of equivalent value) equal to the excess of the fair market value of the shares of Stock subject to the right over the base value from which appreciation under the SAR is to be measured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Section 409A&#148;:</B> Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Section 422&#148;:</B> Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Section 162(m)&#148;:</B> Section&nbsp;162(m) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock&#148;:</B> Common stock of the Company, par value $0.01 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock Option&#148;:</B> An option entitling the holder to acquire shares of Stock upon payment of the exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock Unit&#148;:</B> An unfunded and unsecured promise, denominated in shares of Stock, to deliver Stock or cash measured by the
value of Stock in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Unrestricted Stock&#148;:</B> Stock not subject to any restrictions under the terms of the Award.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g519187img1.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">STEMCELLS, INC. C/O EQUISERVE TRUST COMPANY N.A. P.O. BOX8694 EDISON, NJ 08818-8694 VOTE BY INTERNET - www.proxyvote.com Use the
Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the meeting date. Have your proxy card in hand when you access the web site and follow the instructions to
obtain your records and to create an electronic voting instruction form. ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future
proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or
access proxy materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the meeting date. Have your proxy card in hand
when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO
VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. For Withhold For All To withhold authority to vote for any All All
Except individual nominee(s), mark &#147;For All Except&#148; and write the number(s) of the The Board of Directors recommends you vote nominee(s) on the line below. FOR the following: 0 0 0 1. Election of Directors Nominees 01 Eric Bjerkholt 02 R.
Scott Greer 03 John Schwartz, Ph.D. The Board of Directors recommends you vote FOR proposals 2, 3 and 4. For Against Abstain 2 To ratify the selection of Grant Thornton LLP as independent public accountants for the company for the fiscal year ending
0 0 0 December 31, 2013. 3 To amend the company&#146;s restated certificate of incorporation to increase the company&#146;s authorized capital by one hundred 0 0 0 fifty million shares of common stock. 4 To adopt the 2013 Equity Incentive Plan as
proposed. 0 0 0 NOTE: Such other business as may properly come before the meeting or any adjournment thereof. For address change/comments, mark here. 0 R1.0.0.51160 (see reverse for instructions) 1 Please sign exactly as your name(s) appear(s)
hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or 0000186643_1 partnership, please sign in full
corporate or partnership name, by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g519187img2.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice &amp; Proxy Statement, Form 10-K
is/are available at www.proxyvote.com . STEMCELLS, INC. ANNUAL MEETING OF STOCKHOLDERS, DECEMBER 20, 2013 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned stockholder, by completing this card, hereby appoints Martin
McGlynn and Kenneth Stratton, or either of them with power of substitution to each, proxies of the undersigned to vote at the Annual Meeting of Stockholders of StemCells, Inc. to be held on December 20, 2013 at 7707 Gateway Boulevard, Newark,
California at 10:00 a.m., local time, or at any postponements or adjournments thereof, all of the shares of Common Stock, par value $.01 per share, of StemCells, Inc. that the undersigned would be entitled to vote if personally present. The
undersigned instructs such proxies or their substitutes to act on the following matter as specified by the undersigned, and to vote in such manner as they may determine on any other matter that may properly come before the meeting. WHEN PROPERLY
EXECUTED, THIS PROXY WILL BE VOTED AS DESIGNATED BY THE UNDERSIGNED. IF NO CHOICE IS SPECIFIED, THE PROXY WILL BE VOTED FOR EACH OF THE NOMINEES FOR DIRECTOR LISTED BELOW AND IN FAVOR OF PROPOSAL 2, 3 and 4. IN THIER DISCRETION, THE PROXIES ARE ALSO
AUTHORIZED TO VOTE UPON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE MEETING AND ADJOURNMENT THEREOF. Address change/comments: (If you noted any Address Changes and/or Comments above, please mark corresponding box on the reverse side.)
Continued and to be signed on reverse side 0000186643_2 R1.0.0.51160 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g519187g32t36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g519187g32t36.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0I(4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````*````&@````&`&<`,P`R
M`'0`,P`V`````0`````````````````````````!``````````````!H````
M*``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!ZP````!````:````"@`
M``$X```PP```!Y``&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``H`&@#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#?^IF;F=8^M?UAZL^PNPJ;!@8K-Q+(J<[W,;]'W1ZO_7URWUD^O>9B
M?7NQ^9]IKP>D/<S&P:SZ8M>!L]6_?'Z*_=ZC'[+/T'I^FNE_Q0L%?U?S6.'Z
M=G4+FWSR7!E"P/K?E?\`/?ZU5_5[I+:QB81_7NHAH)AO\\[U?]!C_0K9N_37
MI*>O_P`7_P!:NI?6C`RLS-QF8[*KO3H=7,.$;W-]_P"=5N;[UU2X/-^O?U1^
MJ'3ZNC=&'[0NQF[*Z*""W=^]?E`;/4LL/Z3TO5?O_,7'T_7;Z]?6;ZQ8^)@6
M.Q3ZH(Q:):QK&N_2?:GN#GO:QO\`.^I_VTDI]L26=UOKW2N@X3LWJ=XIK&C&
M\O>[]RFOZ5CUY'U3ZZ_6CZZ=:IZ7T7?AX[K!Z%-;MKCM.[U\NYO[FWU-O\U7
M_P`(DI]M20:R:,5IRK6EU3!ZUQ]K9:/TEFOT&_G+C>K?XR&W99Z5]4L5W6<\
MR#:)%#/Y>_3U&M=^?NJH_P"'24]PDN._Q?=;^L75W=3?U>VG(HQK64T74-`9
MZ@#G95=;F@>HRK=3[_\`MM=BDI22!FYV'@8[LG-OKQJ&?2LM<&M^]RX7J?\`
MC8IMO.%]5L"WJV4=&V;'!G'TF4L'VBW;_*]!)3Z"DO/^EX7^-CJ.;3F=1S*.
MEXH>TV8H#'.-<@O#:ZV7_2;_`*7)224__]#K.A_5W/Z=F?6'"W&O!ZI8[*Q,
MNL@.8^\/9=7Z9^C9CNV^F[Z"XK#_`,3?UB9<^F[JE%.%:8N-)M<][1.W=0YE
M-;OI?G7+UY))3Y+]8J.@?4>EG2?J_7]J^L>9#?M=VU]E+7P&N9HVJFVV?T&Q
MG_"6?X-#Z?U[H?U#Z<_&PMG6/K1E?TFVOW55O/&/Z[?=:VMWYE/\];]/TOT:
MZ;ZW_P"*[#^L?4W=4JS7X63:&B\%@M8X,:*VN8W?2YC]C6_GJ[]7O\7W0OJU
M4[*QJ3G]18PEM]Y&[=$AE+/YJC<X?3_G?^$24^6?67&ZK8*\[ZRW67=<ZB`<
M+IS=#56XEK;+Z]OZ+=]'&Q*O>_\`G+O]&_M?J_1T+_%OT;[;UMX=US-9+L9D
M/M#9]F/4/S&_Z>U[_3]3^HQ<-B9OULZA]:\C.HPW9/6WN=M#JR[[.[^;;8UC
MOT5?V=GZ*K[1^CK_`.-7I/U6_P`7+<;(_;/UFM_:?6+';X>2^NL_V_YZUO\`
MVU7_`(.O_")*<RK`^MO^,*UM_52[H_U;D.9BUF++@./I#<_=_I;?T/\`HJ$_
MU@MQNG65?4+ZE4LHSL[VY^0W4UUD>_U;O<_U75>^U_\`@J?YK]);[.E^O?UN
MI^K/22:B'=2R0685/.O#KGM_T=/_`)\_1KG_`*K5=-^I72+.O_6?(V]8ZK-C
MF/\`=?M^EZ-=?T_4>YWJ9'YG\W_HTE/;="Z-A]"Z51TW$&VJAON<>7..MEK_
M`.4]RY;ZS_XT.G].L/3^AU_M7J;B6`,DU,=Q#BSWWO\`^"I_[=6%9U#ZY_XQ
MK'4=-:>D_5^2VRYTC>!V?8WWWN_X"G]#_I5V_P!5_J5T3ZLT_J=?JY;A%N9;
M!L=Y,_T-?\BO_KGJ)*>0POJ!]9/K3D-ZG]=,U]=1]U6!40'-!,[(_FL9O_;M
MW^D]Z]`Z5T3I/1\<8_3,6O%K[[![C_7L=NLL_MN5Y))2DDDDE/\`_]'U5)?*
MJ22GZJ27RJDDI^JE%Y+6.<T;B`2&^)\%\KI)*>GSNH?6GJOUK?GV8-M_4V/(
MQ\5]3K!2&EWHL91&W;CN]WZ3]'ZOZ2U=Q]7?\6>;U')/6/KM<_*R7P6XAL+C
MX_K%K#]#]S'H?L_\]KR!))3]34448U+*,>MM5-8#:ZV`-:T#\UK6HB^54DE/
MU4DOE5))3]5)+Y5224__V3A"24T$(0``````50````$!````#P!!`&0`;P!B
M`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`
M=`!O`',`:`!O`'``(``V`"X`,`````$`.$))300&```````'``@``0`!`0#_
M[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!
M`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P/_P``1"``H`&@#`1$``A$!`Q$!_]T`!``-_\0`:```
M`@$$`P````````````````H)!`8("P(%!P$!`````````````````````!``
M``8#``$$`P`"`P```````@,$!08'`0@)`!$2$PH4%18A(E%Q(Q$!````````
M`````````````/_:``P#`0`"$0,1`#\`EUXU71;^[?5KLCN&]35P>-?*XL!@
MTCH-@(D#FXP\#'3\E?S#7R+-9IIS2B)?4+<GD"@PGV"-5R@X?M_WSZ!`=T@[
MN6[3O=R6/5T!V>B>N_/^62*+TSJU!5Q5=(+FFK>R"8<3ZUAR03<G6U]:H'A0
M\-KH)M>3C8N8WEMY9859JWP&@/K_`'5'9'K+0E\7A?%(0NIV"%W:9!*M>H(I
M?LLLJ:<QY"_/+$<GD*A<K6ND#_9(BE#J2:!,X#7^P*=.8F-"()]/`/`/`/`/
M`/`/`/`/`/`__]"4;ZAC05'^?>T+`Z$G@L1@Z(WRQV<<O">6Z*I6V5U2))AR
MTA642L39`GR$O(!AQG"@!WK_`+9'CP(B>N]FB[W=4H9S5TY8Z]04IKH\FG[5
M[H)8K&UBTE#$E)9-EOI]@*A(%+A5U/D#/:V5N_.3)9#*AFB`8-'A$K"$KES]
MUN27%2@8/HYH^B'M7.:?CYT-B%3T>[M[G%RI2(X2E:[6S>:-M519?+9I+'!2
MJ=Q1](_NF70Q1@Y$FR(L/@+@Q'MCW/ZL=%*;I[729/E'K2K5;5::@J=2N<0A
M$-A\:DJ53+55]2%T0.<CDS)&&DL1#^<[EB0&#P(LAM+,-+3"#8C[M;Z:L\\Z
M9=KRVIM%GKZ*)`FIV!E]Y;C.K!?0@P(B*UU#4YN'B6R!3D8<B`0#X$A/N4*S
M4Z4LT\`:ZW:/M1U"[H[GUUJ=HF.;Z\5F]V0V&U76=>294Q2]83$7-.^%6OL)
M8[(>0$:.+?J/W1Z!*8%B:`D@*P%P5$@6GALUF)6KKZKF-9;<W8CW&&05I,LF
MQ7(:.*QM4XL+"G_K9BL$O5`0QYG5+$QZP6#CL%I21>@A^@<Y\!:+:W[(:&:V
MJIU%XV4$]]#MFE('%&ML%J3.2/7&O#"2E*7+^KD10FTV;,S&YX*$M<#%L?BN
M$X\"+?#1>XH(>J?7TW5Z)[I..\KQN?/::MBMJ@M"`U35-BTG'6EF@JBSVQ@>
MG:]89$'AL;VXZ:QJ$_M8\1AU-PI3*5)HS4*Q8F-P8$&2/`\LN6\:;UV@#U:E
M\6C`Z?KF/$B-=YI8LH:(G'TN<%&&EI0N#RK2$JG%4$H04Z4G)BE29Z`*+&/.
M`Y!4G9S[8,-ETV4T-R.U.MO?:Y%OS)6B7"A4Z;(`(PQ$9DIXCM<Q]F5W+.$#
M8X"`%66N1Q0K!99@P*LE^PP05&L%-?;!V6N2LKJV5V6H[2:G$$[BSG-*+1L=
M<2&2NE=IWIN7R-N9X;$X99Z(]8[,A9Z<DM^F:%P3F#Q@W)><9SX'_]%@[2'G
M;>^L5N]C:.$Z.,0UOW@LR6[)Z\;"5Z_1]++ZYFNQL<E<=LZ(HHDM+4K629T^
M\D(%;0N,(4-:M&6B,]WS"/2IP6"ISZ;G1%BELAA,TWOHJNM?)XL2)[(6U"\W
M=(YC-6%I"YB:R7VK'6'UK#'I2`;H>$LE=(U"='E288'YO3XS`N[H;!=!.`<2
MCNFW.&%F7CUAV&PUQW.P-LG1JP;4UXBLRPU-K4YQ@L30RP:MIU.5C@/^6*0-
MQ*Q&2,UP<51@"F["@+5U\WNT<^N]KM(*LHT<5Z"=C+R$,R[9S"C3994E6S!Y
M-3_KZ;76>U*1NDV:H>]YR-2VQPQ4ODC]E4<N6-@!H"$X0_\`2JM-I9.EB6P/
M4^S+&L?HMMTW-"W673%@#^(]TK53^_N;,U32U(<D8C6^OFU]4)/PH9`&,)+H
MY+AC7O"@DU(J;UP,\Z`0717ZO.G&;VWPDJ!SZ+;&1).XO5,PL;#-;?;8W^S-
M6L%.U\@3'D(HZRIOE)5RE]<%Z1H6NJ41)*E3A$A+-#H(O0O6G[)TG:)YMXOD
M_//DT:K0OL6HF$JOP;.O5K2'J#FU:<-Y;PO,B&[(UO\`Z2!]2I(XF"40-J8U
M9OSJ<!7;^RBN-:Y#!?KL\(:QAE;[';+$DL.UUO-&%;F\5E5[I'1'R8J>V8JR
M\R95.'F#?D.C\X*!'F,,>,_';",.+DEPB!K_`$:TXI_GUJK5>KM.MZ=LAE7Q
MS`'9\4`(3N,PEBW&7&:3^3*L8!@]WDSV8<J-$//L3DY+(+]I!)0`A`STX^T!
M0.M,C5:VZ!PX6]6X;HXJXJWML.3/CS3T)E)8U:+]>YN,7*%(K8DR1>2#.6*,
MY"2:5DS!KLD-+P4,(]Z8X#=(.MT_8]JNZNR\QAT/4G8D4&U/KM<W))5&FET7
M"7?S![>G1**_I)G"W_&0(A(4^R120+VKU*1<6(P0.#ZK:4:I:1P,BMM5:*@-
M+Q0L'M5%Q9K$-]>A?,8?\\GF#N>Y2^5*L'&BR$UR7*C`^OH'.,>F/`RC\#__
MTG^/`/`5CZ[?5XI_I]LT[;:Q79Z9ZZVS.D<0:K22K:];[>@\D20J*MD)971@
M8O["MWF,/X(VR(DY^1.BQ$?A-@6$Y1@S3!AE%SY^OUHMROC;Q;%65FZ[1;61
MZ(OZUBM*YE;4I?5;ZG;L."".UM&PIL02K<.SHWEIR'(I(I>R"U!A9KD<0(0,
MAKY*JN7J[LIU;MW8*!ZVRFX.B3^^RL+4D?ZSD#\'560X4(XHURUDC3T<1!H@
M73L6#A@8E<P*<&5H+-`J$48Y@2+"@=LY:_7+;*NL([>#JQ-P[K;W2I[_`*\*
M68/CE.ZMJUV'@@U$J,_H2@9LR<M8@B`4I5D@8&@O!1+:@P-*2O&&<G=;KC#>
M5&IKBLBB]I==LKC;W&(:R5Q^.2Y&EN^,)D3M9L@9BU!1Q<+KQ*M"<'U`,#@[
M"1H,!]AQQA(1`\NXKK=P=U*F71CK#;6&S?#>?"RP':+R8TJ4[`F1`Y7E^15Q
M"X>>(J3.4QD3N\`=I<KR),UHU2EO1+#B,(`G'!B`_P"P?9G[.TA?8'JVV.&A
M'+\MV71R66(\&.2118R1(<6-6WRB6M`T4AM=\++"$)T8C1S='4WY&"752<()
M2GP&CN8'%/27E;$"RZ5A6)M=;JWITTXV.LA(VO%HR$W!9V%:&/*`)0-]=1,T
MQ2,.&MF+3X4%!*_/.7'DA/\``ET\`\`\#__3?X\`\`\`\#C@(<9$+`0X$+.,
MBSC&,9%G&/3&19Q_G.<8QZ?]>!0NZM4@:G-<A;S79:B;UJM&U$F@(.<U29,:
M<G;RCC,"+)-6'`P6$0L9"'(O7/\`CP-/?>FP/4G;GJY(-B)/J[9UE[=L,S<$
M=24++J+F5AHZ(1Q5\?$E;,+!59S4!L.:Z>>"S5Q(G9(H9U3ZG4N#J2L&:M^4
M&F>>'UFKGV8LA5NMWHL*=7?:T@$B6L6O;M:*V1+"DQ1RI:F37#.8XY'`1L#<
M8LSENB,5<$;:B#_H>=DK)B#`.NP:"PNL8?&Z^KF)QR"02'M"-@BD.B+,WQZ,
CQQD;RL$HFIE96HA*WMJ!,5CT`446$./^/`NKP#P#P#P/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g519187img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g519187img1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@#9@*X`P$1``(1`0,1`?_$`)D``0`"`P$!`0$!````
M```````'"`4&"00#`@H!`0$`````````````````````$``!!`,!```%`@$#
M$04#`A<%`P0&!P`!`@@1$A,4"146%R&65[$BXB.TU#65U78W=Y?7&%@:,228
M&0I!T9)343)",R4VUD.V)[<Y-'1UM29X>7&1H:*S$0$`````````````````
M````_]H`#`,!``(1`Q$`/P#^_C`8#`8#`8#`8#`8#`8#`8#`8#`8#`_SKKGG
MG?76]<\\ZWUUUUO6N>>=:^.][WO^36M:P.`GH+_U"GFN'W2;\T>-Z/\`0?Y)
MK]B[U<;+XQY*B>I/!8:0:J+H.F<DM%33@#PHT=-NTEE6*+]JBKSM/M7E3GKC
M01@7_/;Z*IANG+/7WX4_?U"5$BKSV>M&*H1RZQT3&=?UW9>2B0`^.K#&+1/^
MN6Z[7UOC7_LWO^3`WJT?_4N_C@#@:V;^:"%L^Y;AMT+P:A-!>7ZW/RJRFJ?:
MO#?II/&)5L)3@I!LZZZX69N?JD.-<[5^WVCOE7H-->?G#]OQ-@K,;)_`?^0*
M.5FV2^]?R&,EHK.Y:.$IZ^HX?NJ]8`1I7CI%'^OVETOQO6M;U\W_`+<"2JH_
M/9$O4Q/D=XN\+>T?0C<=RBWF1]_7J%71J$GM_P`C^,&BYY<JG^NAE?BFZ2US
MSSRISO7/7?.OFP.M=)7?-K+XX;V!0T^I,RHAM9,?*G#$JT4WSS\RB294<FBW
M[4Y_^;7/\N!8[`8#`8#`8#`8#`8#`8#`8#`8#`8#`X+>IO`'K6RO9%C/*2E`
MJ#>;;8CW/JMS-WLIZ;%()^02J*!L#S?2R;&*,UE2R\-?+'X1/G;I%LH@D:KK
MG7>OJN^>50HDK^)&W[!\W>I("&\217SVQ.>+:RA,3I&16]7L[3M_\@\/=3/@
MQZZ$R,!*S0&.G$(Q(UA/$N-NADJD_)'I4HT0TS1^<+?U9^.Z64S^5V8W5&_+
MK1EYQ9EZA84-*XC%_)Y&+5G#8MYB`5L>8MR4SG@OT95[4;/$B&^1\5"N6S[2
MGU>OCPY7WH()COXM_0$L_)3=-BVG1J3GSM=EX>N4;3G#R4U&''3GS!>OG_N!
M1V/M)'!)TX]%R"4,IRU:*,HV=#LXT"_MA5LY3)-F?6!:"#>#/3XC\:$\K^;N
M#]B^YKIO&H;!N69S*?Q1U(9:'IOTK6`^"Z<2P0X'Q%HQC/E>J!7/#-IM+3A[
MRZ[4X[(/7.U`I)&?Q,>U"J]KU_>,3BEQT%(O(_Y)2=0Q2:S:*E3%3>L_2/I*
M(V+7,":;_4],GD&7YKL?,XT8WUON+EC!5DZ52UPU^(2-%/Q>V75/L+RQ/`OD
MY@1J.K_+?C&&<J0D)Y'DX>O;P@5@W/,KX-.G%QV%';%@RJAJ=CRBYV"M"+\N
MMI13GZKANAST%8:8_"I[>@%>QNN55$JY.SV-?CR/G[8HL_7,`>5!/J.O$I/+
ME,6''?W28XO*\8(\=LC`:<(]J(R4(FZ$+M&R^N%'@;I5GXVO=RM[^>[B]7>;
M0EE&PJEJG+&U6^_*%I0V.V/-/R%WYZ`=&HZT]%6/&I'!8D<KJ<"G[%]&$G<B
M'MEM,E$N'3/A+0=BO#?@Y/R*1_(!):PIJH*@G5P>A)R7\^'.1[<I'E:DYJ6K
MD*V'R8=$B[(X/A`VW&DA=N`:;EB\Y^NX53^ETYX4V&K>X8S^7S0SSW(/'<JJ
MHU.&4),N?2,8;]`8A69F=UFO&;9B`RO6=D.#\I%@_0)J*DJU(J."CA0&'DR9
M+I3A5EMQH*T-J2_.NTMZ`0%QZ"&E//;W=.@[1MSA]3[6TF36QHW"YGZ-E\3%
M[B/"#9[2T[IPE%HBVVR6T]$VQTY[Y7V#^JD$K>+@OYGHQ;KZ1^V'`*=U2,C'
M&PD+K*1U`U*&IN7FT$HA/9EPXT$^$5B]7UD1N1W\CI%RL3L)R%;IKKBT&7(5
MO\5"?S%WQ%/.LSGEI797M7RI>LYK:9:S5_.HNR2L@$T_Z?=RU(%&0=>IGH?Y
MXF=G<5(S5!$&",Y;])F5.>FJ*G;GL/JC!?SS]UL%^UD-@)3A*>U.2GS:0V+Y
M#X+G(XTK61\^RA=9DPL1(1,%&K&G"XA*B^";9(I&GZ#MS(U6@WI)MV&QBCGY
M<;+2]>2GSK92DL5\T^B'E(^9X_9(R/PF(>E(=))!8)>RYE/RTH@@-XL1\V@+
MKC4?&OA:O`TV;J%]SPH\V56[Z#6_2/FW\R4^;^@*I$6A;$HK_0;AE&Y<`L?S
MO`.;-AD'D7FTM52%3=M0X>?P'T')$XU/>YZZDRS2)$.R'+=KWMHLS39!9FD&
M/YBX]KV2C9>T)/(9HWL0!Y6?G75&;K^M9@Y<W^3J.R5E0$F_=!"LQ46;5X'D
M`AX&[)]FU5G+=LX1_47701:I#OS*=\T/Q#"%X!!;!_K1E&X+/\8RJ4#YGU:U
M2N)(<]+.X##QXN5>?'E2<S-"/"(,J\ES9\HCT\7Y[48;&!M_G>HOS`QBYJ7E
M5PW'-Y77J<PJ%W;\*D4C\Y/8SJ.2BO?5S2^F[="(PL1*ET(7,!-0;`)M"'2O
M*CLDMST[X[>_2#O%@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@<8_SV^_KA_&U^.:PO15"A1)"TW<T@M8Q@](!FS0"`+SMZ\;KSLL(ZYZ
M;$M"&[#I%HBX^+;LBZ;Z5Y4X^9+L*[_C5\L?D;<RWS[ZRFWYL>O:=`S6+NY+
M:53AZFKWJOI0XDD/<+AQ]?3<(]?+A&T:E#YNHM\C4>YZ1;])=II===)Z"+OR
MR1G\T?F*MO97MZF?RA0&)T-5`.1VE`O.BODFMCIX1%!^F*;6%=V4;Y?NGKOG
MM3O?WSAJMUO>_P"7GX?]@>[\4D1_-#Z0KWQG[9NO\H4!F="6W%8G;<[\Z(>2
M:WCQXK%I`,<KJ0GBR@O+)TS=HKJ)[V^;MD=[VGOX<ZUO^4*V'?27YFOR.?DY
M_(-YE\0>O*>\6TOX-DL4K_EO)*CC]DF9X4.<D&_9Q^],QF0/_NGCX"]5WI-9
MJU:M]H)<I**;55V'<K\<E$_D@I$7:S?\AGLF!>O"4B(Q1>KGL'JT16?$&8#V
MII.4M"*0D$#X+[..73+M+KOE3:/VW7PZUKOX8'`SR!^<+T'._P#U$/H[Q;:,
M[1*^-Y;85J>=O/PGN)@1PB)W!3(UD^03'3!@);%RI.6?H95%RW>/'/S+$6GR
M<)ZYXUL/K^?O\W/HWQ'^0/QSYP\R3;B.0B$N:^M3V1]&)`9(W+0ZQ;$%QF/P
M>0%38DGU%V*L59/7/SME&CA18HTZTI\>.-;"^?\`ZA3T-<W-3^4OQ^>7Y6YA
MMS_E`O0;0/,^%.U&Q*'4JEP*<6L='.&W2;MMT]&R!FV652[3[_3%'G/'7/?7
M/6@H%(9A=E'7S'_P$?\`I_XA6U)'J1KX#,_:GM:>1\=(G4(=&AHY14D345&E
M4))9IE(TU7<.731\M]T]3'L$6B#199`+21KQ%_ZBGR9.:\G%9?DIJ_\`()$R
M\KCXFXZ4]/U^VK,.WBQ%[RG(9'%I:(W)CC-(0UZZ[^DS<-G'/.M;3:O?Y6^P
M^OY`K;B'XR;Q@?FC\2_C&C^_RB?E`E)62O#*,>280^&1T*CIM);3F72?VNFT
M::OVKQZD/1VQ#Z59D2+E%1;GI)R$P>=OQ_\`YS87=53VS?7YEP5D1#B7#C%Y
M44%\TP=C#BD4YWT[+0^`'7`YNNR4<J<\LTWVQX]9)%3I?G6E..4^@]/Y;_9G
MHSRM[O\`PVTQ0T\;P&MO5WJ&1PV_(XUB<1)\3V/ZD%7H=-%WY@(_)"%UN),]
MVHX8*MG"BBWS=*;WSK`_H6P/Y\?$_MKTQ;/YUORE^/9_8_Z[YW\[5G4A^GX!
M^VHNPU$RLE$UXZ-.OW".#MI(7Z>+G76]\O7;CCC2FM<<\_+K`[NV)*U8)7\Z
MG"`=Y(5X;#I/*T0`[X[('%8Z$?%TP['7/"N]O"?;/2*7PYZW\_>OY-_]F!_%
MK^.6<_EE_-E6D^]?P'\S<?\`)TX967)@D>\<UC3L#EX&J@`)\CH&E88PP292
M9XS.LU>>V[IXV(_=H_U_2W2FU$$0_MF!-"0\&&8&"G1LNR%#FA4UVV09]ER3
M9HBB^*=-&O"35KT_=<=*[33YY3XWW\O.M:UK6!E<!@,!@,!@,!@,!@,!@,!@
M,#E/<%VWU&;HM*J8WU9R\J,^E_,THIH6QK>5%X@_\YLH15S^\>=34/#BD=:1
MOD_&9<F826>?K"2KCA)LG]9Z-36"$*V]^^XI5):/`%O.PC3"72T6$FLK4K.U
MHW')$H^FT$"R4/73A4Q(R8E"OH;)")=4L;9);>+L.VKIB+TQ)KI!(%IW-[>B
MGJ2ZDH&_YDM:5BC+90&@!6BIL_#R&&\U[XP>A8R%F8`T,3,RL]+9)/M#2B7;
MW]/59$4E1SKA)/AL&3A/J'V%;=%^[G<CJ9Q5LZK6FK'(4RC$XO,=S4/928BX
MF8>$_;'6)<)/96`U%8^0;O!>_E?."VM?IZ;91DHZ#4)[Z8]]C-`B`^$LN1*=
MG/7;,''J0L!>1'8?"+XLJGAM:RN0%9"7&HDKR%B8X51D#4>+0"\$.E_H.&"F
METPP\*]I?D*G$/0-,Z4KT.\9!Y`5<NWU.7B0:2(GT=\WQ@;%V@C<K`.8VYAY
M:WI0J2[T[,=D&L2ZYXY9+<D-,PQ-F^ROR'M#-D56!IH**+!:]OX3&+0&5)9;
MQ>9R:"-O28N/6U`8LH5DHMDQ:%JOBJJ,<).'J9+N1<Z3([X="^703C<WHOTK
M7EHU2O'3S9>I9OYWKDG)983\Y6;-(Y#943EK[]ZVZ0$0TN,E2O*`Q8()XBJK
MMJLP4/I$%U=MV;SG8>BQ[_\`9VTO&DBAT6'0*0W=3_2-D5I+*>GDYCL/MB8V
MIY1CB1*3$01N-2&*H5I`)W-#?`E^Z']NFXIRFZ6X[;]=H!$H7VU[HFTSG\*B
ME/`Q#829)_H,VF/GFXVK(>RC<0]9%"D<+1IK9O/+\X4D%'1!NW5V89+()S'C
M?;+KIP.X4#U,_:_N:4'9C%P%+QX`6;O6I(.^+4=<QZ.Q*.IU1<,^5C\F>K3&
M#%C<_,&X(%&((\,1HY/HQ]9JZ)<+->,#],O1GN8U9-5L)/'^X,'XL3SZE8$@
MC=*6.O$34$M)C5LGD$0T'.FCO4=+QLQ92L:>R+3I3:'8=1PNW9\_=((!)UI>
MQ_1<9M^VZI!0B*"X[4$S@K.;W,K75C62#C-=W<BW,U;+D8/"Y&P/28I%6D7D
M0B4MD7#=-F]=!R/6VX]5;CL(U$^[O9LL81^(L/.Z4&N`X\C7!AG*:;NXS$X'
M')@EY<8A9F;<-WT;:OT-$+7F+I07^J-'R2,94;.=ME6!%706)]+^BO65/3=]
M#:UI<?9PW=2=VLQGS:#SPA'![6&-C<?M&/%VD;./';R:<2L_$"L?!,U.B1D$
MJ:2;\K.!^EL"FY[V%[E3DIR2@8>YF849!SSJLX\+H2W8K%K0?PA#V+PA;*O/
M9(E*14=FRT4@;->,/'2B_7;YJ]'K=)NVZBH2R^]M^F81=,6J2R`]<".E+YKB
MHVA3FF[<:HWG'["NHY`RLMA;Q"<F0].]0&&,F3SCHXY,LI&[=*_9J)\(=):#
M=I-Z$]B1ZWK>$Q*M&1*N(/9<.0:_N:N[6D1B=`IU/:]KI=.$2$"5;C@8>$"#
M;Z0N^FPDYTKPS[XY23X[45X"OL!]?^^;"DU1KI1P+&E)FB\@!D63\TVHO6NI
M"O<'G\<=LP.:U/6<C<BH'74\.)MT";L%]T['N=NFS=1DZ32"0FWO7TH=W$FJ
M56Z@C3B/P=I9TT/><?14M'1>YG`BV'4IIP7#Q"X.0FG1:0Q`.,:EF:SU@+4>
M=)J=O7+U@G@1?$_8/N&(`W^I5%B,JD2`R8]]2`]YZN'MC+[,B<OLII$?.D=A
MD3?M>(=*K$;LVC%*6JJNPZ"8_E91NY4>-M;#;YU[9]Z0F)$9.]I&,+=NW0N0
M#0PRDKF+FP8)>;>E(LI7:;5&:(!9O8;QE4D6>(N%R469N-27M%MPJLN)Y<A,
M?KGV3Z1IRVHG#J9I8G/1#VO!LI,LR526$8Z=$I"'M-1ND/ET5D.V[16*&X<'
M2*,=BE_H<EDTU7:*KQE@1-8GJ#W$S-`:S*Q\;&W_`#;=,BM3^!T!<#Q&V!)Z
MR_-I2:Q.)<=R67#*N1A==V%(>2YDRL49D6HQ;M'ECTU(;:AL5LWCZ]IKT)Z*
M*"4B<O@120,AE,Q\O3EIRV.OGL#I"EI1'J1A/<#.I,A<N]`V!:$F3ZFQ%%4<
M+6C';59!Q]/A%L&]V#Z=]B0?RC#;A[K")O++G%T&0!P,C7-A<AZ1J;CN>\Q\
MS,(QQ+G<IEYA=]$Q8U<@W7%LNW4B273;<H(:TN%<A7M'\@L9G3<(Z\VOI(E+
M#NI.TC<C!3INX*.BXZ/:/U'7,K;`!*<985BCPL0X(GQ2^G^G^DW'3'ANX62#
M:0GJ7V[*[)J9*+DHN4`6)'0$<?:?>0K[BL*`2HE8]6\6*==ZD\T'R+HC4\5D
MY$9QPL4:C7KA':RGRJ-7J"(?1E[4]V2$&Y<1BHHLN1&5Q(+)DZI3S_>X]&*S
MN,U?-)P?\G:&$I>(>R6P04JCHL*I+F:FQC_]<Y^U%].D/H*!.WG;TAZ!EUQC
MJZL6*.8-'ERDYZ&!Y!4UNFY1,X_S*;?61FR-L:=M8%!`,5ZC0<1P-*L>UGGW
M?"J:Z?+X6FH%.9-[I]Z`)!,Y.%JE$ZU5%5J$*Q<G2-RBX;0$JX=^NBQJ&FW/
MWJA>W)C(7<*A`)V?`.$A?')=HLW'_,Z8\O`E>*>F_<<<+259[2THEFY18/[!
M$CI!$YT];P:26K<_IB/5>:VY8,(XT6IJK-1:.-I21^V2>;CA!D_450USKI0/
MI77KW\AULRIW"QE(UM6+]Q.3XC9R>5Q;I4-!4@42ODXWA$M4:2>-AW9$L_KJ
M+)_N)`IPU33D:G7(WOGL;TZ"8Q7LJYIUY:@'HT+!Q]=!;8MM`*R)2"N;"LUU
M3],)BS3!6PIY7T)+"I++GAN>Q7MFQZ'N6#)!A(!SQ?>TF[CI4)%\'R3T380Z
M[[.]&MI+%CLRG\!5A]5&H^:C@NK8IKS]4!Y]'8\U,/%5"26YS)S&GKWI!!UV
M_250<ZTHV^B@%^<!@,!@,!@,!@,!@,!@,!@,!@,!@5"]PV+XN@5`G1?OF15,
M`\Y6F5&5/(T;L^UU7TB*RSETJ*`%5GR*C-DJO^EJN$G2G2'+/MM]?2R72?/>
M@_BYA47\X_CW_.!X+@7X3O63ZWJ;]83,@,]2>3JWM)2YJJ@4"UVPY)R-^?9D
MI`,3:)@W+\PTT_65*ANPWSZ<Z;..4]A_4K^>3_\`([?D-_\`X;Y=_P#]QV!E
MOP:__D@OQV?_`,+-9?\`[)P/XRS/FCP#>GYJ/S*`O?WN":>&EP5YAC]8*";<
M$4JA8K$_^HNBZCHA)6"S$YH:/5&.6B7'?*FT'^U>-=\;WOD/[(OQ<2'PI2OC
MHM3WCOV",]>5MYI1ELEFL]6MB/VQ+PO,L(2>P.F\N/`^M(->-I)O.6/'::>N
M6S;Y>=?#C>!_&)5=$34]^#20_ELK\:ZW>=,?ESF_Y#11EIUTD=>UN-F,;@$[
M8Z=?R=JC^'S'9!SSO^LV@/4WO7P^.!O\NJTK^2'\7/Y]/R[R"-$F#KT;:\!(
M>>6Q_K3D]&:(\AS.*D5T6JR7?2;1/L9\&;GZ._I[<`U=?'>OC@=-/:UU"%S'
M_I<?R9RQ]WQ2X^2Q*&6C+7.^U!L3-W]3T%%CCAUYK6T&;-L5#E5%UE/EUQIG
MU\V];P,G4UYP+\1O_J#??#?V>5;5?27Y.A,"LWSMZ,D:7;:M^CT:^ILC!Y++
ME>/LH[PB3-OF2BJZG+9FJV9=+[31>HJZ#^A>]ORN_CE\WMH,XMCV)1@ONR)*
M#BT/81N<"I^7*/I`\09,B/0>!+20HQC2"CCGIR5<))#FR>_BHMS\=:V'\LO_
M`*FKS#%NOR+^#/87H6?7O4GB29UJX\W6MZ$\]+;XEM'RWD],9#$RY);3(ITV
MC$G3F:>W&N4.E7+-B]Y1THOPFDH'6+\0OCC\?OA2Q"5A47^5$SZW)>GHB#@,
M&BEI^CJLG/)55L0[EC96`@`;QJ7>21RW:]\*(Z2[6X1Y[YWQSU\=8%8/_4<S
M6*U#[Q_`M=5FFVD*J6O/7<J)SJPC?*Z,7B8]N9ILBX>&R*:2J;)!$<Q7<=;Z
MU\=((*=_#Y4^MZ#O/6OY3OQOW)/8O5E4>X/,EB6/-BG`2(PB'V]#CTEDA=1)
M9?@<&$CR:[M^[[10[ZUPGSUO?/.]X'\W_G?U1YS\:?\`J7?S`FO5US0#SR$L
MFGJ02@ARVI`SA8.4K-(M5)%5$08,]-AKA;IDGVHGQ]772O*2GR:ZVGW\`_I[
MIOW[XF]$"[&,T1ZEI"X1=11O<OLYY7%@`)>E!HQIL2=_K<DT$=O.QH_IL'==
M\]]ZU\VD._A\?EW@?Q4?F>@OX98U4QK\G?XM_<%;>??<K&71^60R.>4K:XX>
M79)C\K'?K@]Y44?*<%H$:20>.2;UPDQ'LE.F_:1!LKM;`_N!\;3:T[)\E>9[
M!O$(M'+CFU$57*;/".&NF#@=.CD*#$9,BY':X3_37.RSA7I1M\O.V_?6T]ZU
M\OPP+)X#`8#`8#`8#`8#`8#`8#`8'-BQO?+^N+WGU/HU6ZFC&$3&,CY#(^96
M%BO$9C$B2\H`D'+$<X;F'DP*;E/IULOM+K],XY9,7//S[5Y;<N@K'7OY6YZ&
MIP)*K=IT!)YV2T@+<"X!8P(+TXL>:5SJ^83%`\6.LEC3>JF%8F6`QS-GBWR=
M'TU$NF7TOBXT$T]?DN.A960$SGSRC%HK'CCX9*YDG=<9)(AA@;TH=\F'3Z8M
MW%PNW+%C;X;ZO&EW#3YH[M1\KT@X2TP5"(A7Y<2$I,CE6=2LHY#1"BZ$\<:D
MC^23-9TK,O$.XUJO8N5CD#?21F;@'K7?;KE=NU72=M>%F?WC;2?;P-_8_E7Y
M(:YY:T'V0[$0EA;<X<A;EB!L-':E+I4(\&DA1I@&[:2:Q.!]],^WD=Y^T2:=
ML>O_`*X*-W;%RX"9O2'Y$H+YQ-6;'#$-<GSU<](;X$I3*,`'LC:K><[E]#]D
MF2)E1/IB*:CJ:="UG2_P;HKN?K]]\I(*ZT&TA?<4;[A4>E4PBP^++/?1$M\X
MR99O8,?-08')(G"YI-U9((L-5J&%R:,/6,33::[VW9.$";KMJJERLV4YV%6N
M_P`I\DD@J($X/0XE@.GLGJT3%)#.+7%MQKUB?GWDD#8_11F(`K+`^PL<]5L]
MAG.UW";X@-6^NB@AMOMT$E03V3<5E^*_2WH6$!JZ5G57QU>05\SF:1P/%^QZ
M/FJI;L5<SAK'7Y\@Z?M'<X?[^T8.&Z;GE)!M]RAKKMYH)B;>A+<2O@/"'P2K
ME*\/^8(_;\?[4D98#+'TO<3^#163;D)<FS4C,>CK-E+]?IC-NF0<O7*6_JN4
M?JII<ASNFGY*/2D1BLY)O!]8='HZZD5B<)1D!&+*CK6I/VYZ'/U:$$DX1Z)?
M=2B03`E26Q\F>K="W$3:\JOE1^VSCZX\+)W;ZF]>;NB%5SYZK5`P4*><*ENQ
M["2<#82!EQ)+`G\JCI:+V/8A2WZU[K&,C14;WRF29!SSOA;ARK]FOM%)FX"%
MO5'O:?>8[&]DQRHX)1J[E[3<>G?GX[H&\1ZG_I<;$9'(K4W;[^.&66IF,`4Q
M&6YU#I'MD0X$0PLAVY[TFAI`+I>O_2<YJJIJ4D]5OHYT=M"[X)5AAZX'Q>1Z
M#M3L:F)DZD,8RVT*FB*9]D0C7#??),^T30YVKK?*J^DTN@@25?DX2J0\%K>1
MP-:U):G`"9,R<CDEA<575L=E3,VO5I!2(P<:G561]P1A\.VCK[><DWFG#I!1
M%FX:J\K[",R/YAG(1X7>N:*3DP5R*C?<5#0V7G5Y0U.B1GH@G<8^;IG8`'?1
MG]M*T.JP$IOA8]18@HOP2V.2;N56P2"\]O1>2VC#)L<\=Q]]R*EDACT3MT_+
M8"\LF*04;Z?C7DA_(Q0Q:*/#`0H]LN9K+_HK<OQK]';N%%'7+E5)FL$F>B;_
M`+WIZ^)T/93V$=U+$O+<X]&[B?54*OYITM#3\>AVHXG,%[.%C5FCY^8[?;6[
M&)]<?)RA\?A\5,"*S?Y9/VBSD<IF'FZ1LJ]CH)>4]FH[9$>E4K?@"+/U#^RE
M&4(;`V/7960E?)Y])VUV_P!<C6I`>O\`5<==/4&02$>]_39]YP#W1$*C$1J2
M;]'@:%ED;LB5O6`42S(OD4"$MCIC0`.6,[TV(M=,VA$:'75>=*(=\<ZXX45"
M'H_^6TF,;UE%K&\XR7=FGPD+D,Y;P63MST5%1>40_P`ZR7B0@B_Z)IHJ>6[]
M%C^?T(@NP00^Q<<:*K[[9=/`F+TK^1%6A[@4A7$.BFX1!I44C=CR*4V('!R8
MN4_X5K%]!Q\5"X3]NN7YC[YZ)",.Y%U]WQM[V\8(CU5N.5^0RE'?D?#7/,JS
MKKFH9#&YI:$BL`&!8+R!-T/594K.[:@5[2)-R0``"Z0RK2E>!_N4'P\>055F
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M"HF2#3X^SZ)K"/P(]*V0EM)2'H<O40R"%?W60`M5A(\=Q<+-0M]04IM/;-;;
M'9!!1JX<!`S_`/,$@%CL8)&O,LPT=F$>:S\&!`3L7)FO==(@K")'29$^.C&F
M0>5MB=9$FS$:ZX28NT.D73@DQ1T[^T#&2C\N10FS.NZ[HU^$$`)U*@KV1V<9
M4`JO85%`/I1`L7$`G`P=SJ>\3.@M<LA'3IR.?,GNT^R+=ZFLW;A*S3\FSQ5T
M.$*T<V8/I@6DXNL3,FN.)Q.(2%K7T^MF`3@W8,D?A7`^J$-O:B=JAD>]E]E%
MB#-IUVV7[4UP&4NS\BCZ(UK0$K@,"")%;TJNFKM<.+`FP02(AD%LZS*3@CD:
M)2153U9LS'\VYKKIHP=-$4N&_*WUE.UVK5R%>I)^8$639DGFJ)$2&L!K:3:G
MC127N#I.:0R2TTK/ZL5@HI]"P[20)3-;OM`SI1!T*;AN5'S%V3;_`!ZT'3WR
ME<T;NFGH^;`07BJ=`UC\,W6'Q8H\11G7\KD%=-N0H]LP"+M(>Z7B"VA6EQHQ
M?ANE]%5HV715;IA9/`8#`8#`8#`8#`8#`8#`8#`8#`8#`B&\//\`1_I>!/:N
M]!U+7MT5V0<H/G,-LJ*!I>`V0:\+)M22(\TT=HM";5-PIRDY2UPNGRIUKGO6
MNM_$(:\U?CY\0^.2)<UY>\LTG2!X\WVR,2.!04,*DQ!AOO2G0U>2;06.[&=*
M<ZZVVTXTAOKGG>^/CSKX!8&UZHKB\ZYF%16]#@E@UG/PR\>F<+DC;[T%)`CK
MI/MP,)M?FX^NU5Z2YWOGXZ_[,#ZU;5U>TG7<.J6IXB&@5;5^"91F%0R.MOLP
M<;`#N/IL1(MK\W?T&;7C^3CGX[^&L"KGHG\:?@+UK-4+(])^0Z'N6P&XQN%Y
MFLW@`8E*%A3/XZ9#WIOE%$@1;,>-_*ARNHII'C^MX^7G^3`S]$_C_P#%GF*(
MV=`?/GFFJ*AAMSCN1%JQV#1I`*,G8S@86"\,I$BW[^+U#@4=>(:UO>O@FY4U
M_P#38&_0SRAYLKOS^Y\J0BDZ[C7G!['I1%'E,"XZS1@#N.35<DYE@AR!WSVV
M79R!P8==NN>_CM7M?K>]_'>!_L6\H^;83Y[<>4(E2E>Q[S:\C$DACNEA<>:-
MH`ZBTP5(KRD(Y!<\_;KLCZY=UVZUU\=J]+][ZW\=X$(>A/QN^3_0WA^1?C[,
MUJ'AWG5_$DHS#HS"VB`W57/!;SLO%)+`^5N'"0HO$S^^7;7XZZ2[WKI%3GI%
M13CH/YO9G%O?OD^GT_#7Y3OQKDOS7^'X%]-I2OIFA1#687N`B0E)!E'FLYKQ
MZ[XFC.7`0_.FO!5D]&NTTN?I;)$-?VS`KYY[?>%:5FJ$X_&A_P"FB]W3ST\Q
M4Z<P:1^I*XE4&KJNY)WSTFQ)]S:Y9I/0\74&N%OG^Z:-6[I/GC?RND=_#K`N
MT3G/_J"*":S63>_/%%&_E#\K^DD>BUE^7:"<1HI-/,22J/3+FO8[%I&"<LK5
MBZ(Y@V672UR?^J1VHMR10ZWTHL%+JODOXKZ^MF/VOYM_],Y^2A3T_&9`-D\.
MCQBA+"B41ALX#O4B`HHW*2*RS\!C&AI5'A1)VB+53;[XUVDGK7/\@=33/L#T
M+?\`#'M-_EV_!;/3-<2,NUE<91KX7%/4<$$,5-[<1U"5,^55%X[84?:K](NW
M;5PCUM3I37"*/'77.PMWX^\"?C.2L"'772/XPHGY^F4$?IR2'6))JC9P*4QT
MVB@JD@Z"I=.G3I)]RFOUS\WQU\NNMX%V/2/X[/"_L&1AYCZ>\I4?=\N`#=AA
M,JGT##&)(T#_`%>E^1.CO2"9188BOWUVFW45[22[[ZZXYYWUUO8?3SQ^/+P]
MY-YGR?F_RW35.HVH$:1NR&T+AP\>UF\>8Z(\M@DF:*<KMBPM/@NZY^@MSTGU
MRX[UUK>NMZP(SA'XC/QA5M9;.X(+X/\`,$8L<:4T;%2894L636#&>5ON$RP0
M?VQ4$!B:+C^V)KM6Z2J??]=SUK?\N!T5P&`P&`P&`P&`P&`P&`P&`P&!S<L?
MW#2,%O&<4X>K-1_88F]_/=-_=)Q<T0;29K=HJISJ,S>2IE`R,;'=0W@ZWWH4
M]):?/^P27T?DZ[:<X'BB7N/P;,W;Z0,PX]@?#M$JYZ=%:G;\&^AB,BJ%-C!Q
MY-B/(<.6O#R[XP2Z#)N-J,$GBBSINW49/.6X2%6'L[QY<]=2JW82\&%87$Y9
M`H])32T+3UMES:LICQF$2YW\C5Q].)FB\N;'7#U7KGH9O[AR0X:N&[C28:($
M];>$0?0CN/0=H$C(F4H@8M-!-#K"X0C999F$/L8E&3C2.MVZ,V-P70Z2-](<
M\<.@/*+CE;KI+Z7`2?#KX\L+G[;K^&P+[%C3L9L:;VF1%T]T)@H-$-8\S@\P
M9N2J0=L.+2:22^E"KG31ORNN00#)NU/ZW;7KL("L/USX3N`>_#6/5\Z/')W7
MYZ*2,64H>6-K+&5W(A<`2"A#)%H+1E$>'6MU?D='Q]HBZX7($)%IM]-)=)_R
MV#='/LGQ!H&SI\K#'+,*/C4CG;ZI25$$-A8=$:OL(E#K/EAR,<Q]>,APM,VP
M,T-D#GCYN!I5VS5XVHF]:KK!*LEO?S,VBL-<)0-S/QECRVPX;#HK"J@7FY22
M)5<;6'6%)QL9&B'*I"$`UX$W<Z?I)]ID4D!VV7+E59BFH$8]_D.\;@EYE"N&
MTA9\@9+U%Y>`&541<M$0_,0LHN5FDA%B63CD7"`L(HV1*/U"B35ZV8A^>.VO
MP<,>'`;$R]<U5*(+8L^EE2&H=':YNROZ`>,+6A[P+)W+*7Q>F+#8%U(MW&BY
M$8/04LMHHS8J:Z0748)+]N&WS_V@-7<>EO,!BCI%<$1\_OI4(1OZC1DFKXE3
M#:-3TG85XR&ID878Z,0,1_IT?E#R*W$(.,G7?/+Y9-3Z"JS1?A?2`9`M^2CR
M+'WP4P5=R]B2E-9N9>/>]5F=ZD;P8"8GI"]@FQ"+-28.9*'X$%-],TVBK+A^
MW6:\K[>=:1[#$Z]I^;2\GK>`0^GI#(#4TM`75<P'D*LW'!].GY.<MJNG;"R7
MCP*Y'"SSIY!I0R39<=]\/FW??]OY1(-MNPPE\^[O$\6BUQ00_%!=F2:LQ$ZG
M1:D']:]NTY#)X9*+4#ET?MR,:*!.3?1NJBY%=UM%==$2LV*[Y[;O6W:P8_OV
M;^.F+GH[$S<(CD"ES@<>@Y*)2&D!<>DM>AV<AD$)0BDK"[$:>C@DM.K/VK!L
MRY>-'"3I19723951782U#[I\:V)5"TY_A<*"0",2^G*L?B9[1[6-*Q;J;N(7
M(*8</XX9!\:"PC:-SBRS-WUQPU#IE5E5]-54WG*0>,5[H\@2!^&2:,370N2R
M`%%HY+7M1FFL5/SN8FX=+V,-&&70?CE>4NN)N)E2J>^>>.FJW;W2G:[5UR@&
M\6_Z[\V5I4W5[V`B]?05V>L.L7Q7F$]$'Z?-='Y@)L%B11))-NOT$<2KPDIR
MAOOKLITW3Y9(.EUD$NPU7?L7S-VHC^WZ[L&6<DY.4AT!<P^A9"<;6D^A.[&_
M>JE8N68;Z4G95SL%)OU'GC:2_'SJ_:I./U%M]V$1Z_(=^/`7&#\`"M13R%0R
M;#XUS#H]5+/405-<RJ7H?JPL+MDS`#4Q,XKPKQS][PQ?KE6R&F:#A=Z.^["2
MS7J?R^>@'IBQ8_5RUD._$C>53:1Q[^&PAK(=2JL`4C:<?L?B0MD%14E;MX`N
MQ9K..6#M-DDV<)\['KM%U@B\W[V\>.597)KUJ1_#9D,D%@4X`ZL.KA9`G9@6
M.VE+ZE-`(3+S+%L*+#].F"RAP8L\19CM/%DNU%^>%5>@D(G?OA.HSU'W2L0;
M1)"T:IB@:BS8^/R@5`^*[NFRZ^9.W4=C#5FUC$1=F9-(XT\E;Y1BU>M1#)HN
M15X9L=_2"&COY`O")Y221R"U6RN"2V)+JI&S>"C*G&:D%AK2F=U]&W3PH#)`
MUG<LD58E;5&.G30NDWWRJLOM!Q_W9ZJV"R4E]-^16@[S1+RT>9E>+QEFE:6>
M]U=RL4!R\?R#BY!TZX*#&KV(3"/*+-!KAHG\#G'#1;E)NH@P==M@K]'/R2>+
M^3<6.SJ%HUQ*QZD<AM<25Y"1[Q5>!R.KZ.L`M)H&;V+%R9E6()6_P8ITCRT:
M/5%5=K:'_0Y7Z0"?+F]<>2/-]DFX98HG]`EQ("^LTN2#5GT55D3V)1J0V$EO
MC8=@O(93*FL>@;YZU60:NDDW#/AO]QP]4;H*!H8GVIYL"NH-6]64W).7<KNR
M&PN;1-C5/4&#T_.)=;,A@30W:/TPVPP:4*S"O"CIC\OU5'Z@U)7ERGIPR56#
M"K^Q/.CN=6S6EM4-J/1ZH[@;P<06*5UQ,`NQD+4A[!K=$I0:Q-4)74"963:O
MZ2#>_=/G._F=O^N&B'#S;<-/@'O+R9+XD?FT_H;4.=''\+F5BIBZV9V4@QZ-
MQ^%.*[F%EG0460YY*G9G-E(X"[<)N7BKYDNKSM)MRJHD&]RF[/#_`*P@=JP<
M"@;L!I5L<GD[D86N&4H@AAPTKAA$YJ09C3PE2-<OVLL=V4A^GI]K],2I'E]W
MQ\S@>NH@$80O\@/C'B"1QA9E*F:DCM.L(2+I,58=?-#+!+?,1H!&.1:OY&3;
M*!PDZ!*WG&A*S?;U/AO_`"K=O?I-W?34+_4RT\W6_5\5LNJH%7CROYXW=RD.
MLA7P(/RX=$FQV.FG#T8J(;]HF.D"Q0<]Z[YWVIPY<I;Z[36[^<)FCL-B$0;-
MF43BL;B[-F+9A&;2.@Q@1LU##W+]X/$-D!K5LD@+8NRKI5%OSK222CE7KGG7
M2G>]ALF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&!26P"'B-U-9Q7%L%:P#3&Q[=@#L]%YK-QHD
MC8UG1")5/S!B`\)W)N';M02)+Q<?PCM!NFLY5:IJ(J;=(=.`KQ'E?Q*U43K\
M4+E-*(;CIV675"Y`?LPO,PD=D-6UQ`?.Q0PO,99*CPY@LQK"TX^#&CW3KZ#Y
MBY:*LT%>D4%N`W>5POPO%?+]J5!$[GKJHJLNV%MHJ;DCRSFDR2;PF4LB]7,Q
MT8ZLB3R%F*!)1R&%PPAJVUR,$?ICGM%OQ]FOK0:`T0_%5-!LD*OBU=L(C&_I
M5"\,2"TSL.AB<CAFIAYZ3<QP0K.1`]A9$=C5$/!C:9,6+8OS'A::C4ITS1[V
MD$JL'/X]JTAM^5Y#[>J6!=%PABNKE)<VXVD<I$OY3)+66<J2=]+Y+(B*\GXG
M<WE;IPH\VJXZ(*._NM[^CUI,-,W7'XW*'32HJ;E8LQ-N*!&R@M)[#G\O='9)
M5CF453`PLF5LTU)%GG17J8UE%$`&V1#A\+6$L]"=-DTD]8&P3_S]X0C<8`N6
M$HK&L9A=<5DL'J6X34W0FDDE+"U!\G;R)>/E)[)S3:RQLW>6Z\)$DWJA`<;.
MEVI%[RY(;9K:#1HY9WXQ9]2_F"MDYW%>8'$QSFNJ@8N)R>A\D@K2`4I(W\GC
M,_D,9/!"<98.*EB1)(ZT-.TQQ?A%1%RFOWKY>0]4<C?XI:SX7D;(C28"+O(\
MU%LY#*;9Z(P1R%.M_0T)=5^$&2N=D1HT>%$E)^V=A$V+9BP:N7WP3Y^W7^V"
MPW=0>+*VA,IK`VYB`R*E99`;:F`^?VU)#A)[)B31A%:VEQN33J:E)*H@]85$
MDP%;4>_9]H`>TDN=\-U=:#Z0YYX?*Q%1Q"I;4)"'$Y-4<[5<#)^V=,%I/4QR
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M-;IVKG0MH]3XZZ8<!W#[GYEQ[CO@/`7B?XW);:=G0?IM&3LR@%6$+!L9O$9W
M,NP5:@J_;0F$+2ANSB,N2%P"U@PB$AV*1H6W9R;AJ%TAIWK[;M/09N'5S^./
MT[7%:TY$'$&GD:"PHQ:D+@@NT)>TGHZ'7_'7)68&#GV4Q9V*X:V#'[5Z4.-R
MJZVU>#:.W?&MKM][#5W,5_%60=O&_P#$:GVKUW(YKMJF*]'R(&XCY0"+DABT
M6<)_2;)8=P4(1%3LHZE+<+]@-,<%E5"/+C:^NMACIO#?Q4Q^#2=>126N&<*F
M44F=C/8W'[JF[=B1A<?96::G@Z)0R,SM'@5&R?#B6[)QT2T;-"SI,@FLT76;
M*<HA-52U]X-F*EN`*M4@4D(7-4X\7:T;;S\Z9-K4W*1Q<NRC>@Y*3.R,!A7+
M6SW;C0X7P-;#U#.NOIH]K)?$(_+L_P`7\@`Q1`E8],=M$I9)8_"9&A?109*D
M)S))D!LJ4.(W.V,]9S!&4FI3+QY-P2;O].EVYI/>U]M'_P`JP;1Z?B/X_>(>
MSKWT0#KN3MJ3HVSNXY5[\TY(S@;3YRKS,.L%C'XZ@=;R,QL_6P9\AS\W2CQ9
M-DJX0[TJV[72#`S*#_C1<.['E<GF56`U&T[`-9L\'7U(8:PB%G,)&'D0HD$8
M1VP`PVO9TI)ZI0=.2(=)@^<.8\YZ<J][://D##+3#\75EUW!(@2L&HN:^IKN
M3L8G"R%GEXDS0'5Q;*=<EU3D:U*!+FP8TYMR`HIMU#*)-H;*-.'"?W*O6^^@
M_P!4@'XRN)*Q81LG6IF9@D:P=-HU`;T+:,?MPJQHNOH;IV+$V4P9EH,4`L:_
M4?L%_K,#+=N(=.6[Q;MIVJ&_F:J_'KZ(DIJYWSVK['*')D&K\[)1%L%U8X4L
M-Y#B%7QP,]$@)DVB3J;%H+-%!`]7IMT_>#B"7"':B:B.]AHDU)_C#CDJ_BV9
MFE6J2V*3:#60_6B%I'R*[J7SFV6B<#F4HA<.EBHZ8_I]FW)PY8+DF#Y`%^X=
MKI:;-W>NE`R!+O\`&K8YQ[+Y/):A;RX<S=79-1!*W$Q1'@82=5I+G9"S8\"G
M.PDEC?!(/%"G(PIP_%).=L7*2&NG/"BH?OFM/QP1,#5EI#D:U8UVX>]D8O80
MRUGC2KWG-1<#3;!>:O%)\UC4X$5^<K)HJR;E$BJ(8TQVOPDW<;<+;#'1>2_B
MW\NP6=RN!2"BHE%C5&,OWAQ$9-S)2$BI2OBED+,67(EJ5,%B;(,7ETGX^DBG
MMWUWMUPI\W+/>D`S\<JS\;<OCZ\*BQ6J9$PKDZQCJJ@RXS1220J8EI'5\*#Z
MXEW,W7E@2<ZF=01<8R><O>"C8N'2015X=:6YZ#>J_P#6?BV'*0:C*HMJ$'4V
M\>26C8N-31O+6C..MYI&8.Y)EIF8.O$WCGF035BNKV[(.";]!U]YQRXY4TIV
M$KCO7/ELMU#^!GH>F7RE@&EH["4FUC155:4G$'P<8H+"(\D]JOW>R,C&H<\\
M:W\ZI-GSS\=NV^E`L1@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<_S_E;SI;%[WL2YL"1/K0(\
M0$A:,7!F`2FX4F0=4#)(BEVEU'W2X9<^CY8#..4%UU%E&R[E77//"S7M(-9A
M/XRJL@Y.-D&%G6N[:QJ<M9FTCJRD"9Q/:8R;4/88H$QBXF#CP<6'\2_SI'7S
MO85`;MZXZ>==ZYTXYTD'H:?C=A8F5]3N/WA=(28A2A%>M#2'-6ON:N!'2M]$
MI#'`(TK6SX<?1+)>D)*WV\.)DWR*?+#KA77;7OIP'D*_C*K1^3-'V=O7*(DA
M3F>"6I]NO73YZ(A5IG+H/6)#VS<Q7Q$8\0/O+Y.])/W:"Y)ETFS^DO\`(BMP
MX#T3'\8M'RB%AX2/E$_C0^.-)XPCSAGW$##H0VL&UR=MDE6:\BBA5TT,!S9;
MM`84;JH%&:222GW/:VE%%0E.QO%T;G<BJR9,K4M2*3"G(9'8K#)$U=1"2O>R
M42(MW8"92/B:1*0I2&1\,ERC-YM;6F[U(NLKVGITBT70#`2/\?U5&8-4]=BI
MA8\9C=95&6H,AP/?QE^_L6G9(5@QV5Q.6/#46(_ISZ1F:['JJDP?`E\VX[<)
MMNT.5$OH!'+C\8D`<@&HCN]+W;E`\=;P&,2P6_KL)(XW5P^%W3#Q$`8.`U?,
M&:J`[^/9Y[HLJCV<57VAQV\VBETFH'[AGXM:,A_!'KF9686>%TK(T_<O'4.:
MI:<6F']#!Y.LQ9#8>T;L^44_2T@Z9\_#OI+2+/E7I;Z:^W`;+<_@B)WG8]9J
MR]ZHWJ:O?.%D4F08"C#IM,IN3G`)&#QPD?2_1M@.$JLB;\ZZ!N]=JKHF)`X4
MY033XW]8,:5_'!#Y%("<ND=X7*5E$VD$>D=PETT*L&ZM=W"IE6<U@S4H/8UN
MD/B0^-/JF$-OD`)C%'S/2W+OM957:O(2W./$E06)5U?5!)W4L7AM=T)8'G,<
MBS(C&1`C`+)K$74TA5(/$@^])G.8P*XV@LVX;H\+]][Z2[3W]/`@\7^+ZIQ<
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M57?:J#/6N.44E$50EJG_``Q7U-R$X3"3JQ3(!Y7$ZJV-0PVM$="85%[-GCJS
MISL25$Q,9*2A,O-G[ARDL3?O>6:'?*"/'///QV'AHOP9`J,ED1E#*Q;*FB<%
M"'VD9`RKN%("V4FFD1@T)G<U<+QB'QXR_*R<)7S'_NBKKH8R77==MV_&NV_#
M4--7_&I5)F".:WF=D6M,XBSH\QYRA`THO`V&J^J-R9J@]'0054%!1G9DE%B%
M-A^N'QC9)4CSPIR_TYXZUSH-&4_$Q2CMS&^WMFVWL>!_62"X$9W7@,"\E$B=
MVVZD$E8"!D"18QMZ;_C.5Y=[8II+.OM!_2RJG:"W3H)AH_\`'Y5M%V'+[.`R
MR9F)5,HQ,@3XF3:09F39E+,<Q$I94H8'@D/&R!`A*9#"F1!-KIU^FCUM]\(-
M](\M4VP1I`OQ64M"`\Z'.;&MV6/K$@TH@$B.R`E#^RRPJ5Q2H861)<N6<.;*
M.3ZH2DP_:KMUTXZ</%7:JFM\JII(!O-T?C@HZ\+CEETR4K+!T@F\82!2%D*2
MASE#LJ/KR85:#E(<I((H;D$=)B8A.'B?TF+M!JNNFCVHGO7W7#H-(B7XL*:K
MDXYEE9V#9$"F+.1$2\(E8=A5STU"!!U"VVDAC*+@]79;]VL2+2[CW"2YW1)R
MSZ^T52[TLDX4=AOP_P#'S`PO!A\"M&TA\M[FL:GD.F*VX(2*08Q$K,OFTQ"#
M-B_A:P22#MFO2,I:K\%VSU11BY1^3M-RAPYP-=$?B]\\!8B`@[4Q9*L>`2?F
M5Z2=G@G;TJ04#4:%)\%'[>--5>D2Z-"#%%OM]-^DU'KO2&TD]MDVX2@U\5Q?
MKSE+_-)RU;9.Q4Z!C$9B$L^^AL?GE3"Z[&`!]5.Z[,1B&!V#245R\BP\HR*O
MVC]VJ7;Z76WVG\J'`1R[_&O47!'ZD;G-D0Z.ABK&55W#`/4'V`K>=M>:J0<R
ML&J1ACXR8T^94X)1Z'%73X:GRN]WPCSTJWVT#6))^-2$!:R8`*FE$C1G4)EX
MJRZW+3(P,2',+"C\4I2(`"Y1R+A1+XZ#LJ+$.VWU1Q!KHAM3;IF]9[^RP-MC
M?@QA(J#J:L+UGAJ43"!S*U+(.26)_HPUF;EMP3J8SN1MUDG$7;-'@X<ZF2K9
M)5$>-TX^CI7[9OKO[=,,9,/QE5++I;,9;JQK6CCJ;#;G:F$(RYA`M19W=4BM
MN3E^WY1.%]%9,#CABY23H6(,K$1K9XT9K\I?/PY^Z#,&_P`<]9GOT5HYLBTF
MX+ZW:M@Q]BM!D&5I)\>AI#Z<9-)"\W"E"\?;-;-EA+?>P3@6LX'N=(*J==)\
M*Z##E/QI5S*0@.-SZW[EG`$/"6E:*C":]=ATB-?`RM;D(G'%%8K7X)PQZ`)5
MFV2Z>-NT7CWI\[[64ZWMMIL&8%?CFJ](O(Y9*+$L^;3J7MH<QD\O+*046Z)L
MJ]E-%R.'-TA$9A(4`-T-;^>0#);;9JGMVGVZ44^*RB7:`="L!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,#E'>7XZC]A6]:]K0J4UX#>6_(W+\AR<CDCY(P<FYJBD:ZC]W15_&S8
MS9"]:D=521<1APZTFW11D3CCZS?>E=N0U1C^)Z,;=P]V?-1*1*B'T"(2Y0F$
MD#I29N1\O]*R2U7!3ZT@Z3<KVNSN2/-"/UN>^'",7217Y4;\-4FX=*:)A4SK
M:J8-7<WD`V6$H%#X1"VTH9:+_>R-O%H/&@3\[(.C3M\Z[-F)&P?N>MZ54U]N
MJC\_72OU.MA+V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P."=]^:?3]K^E/<ID;"R*[:>^4+3BE/@Y)Z7^
MT3>3Q(+7L:H<Q4HF"6##BD+K(N<!D2\O'3&.[V$EK?3D&8=\$7J?`5[DGX\[
M\3MNZJPK=Q8HR#%:7K&D?-]B<7^!=J`X.1CT3AWHJ^1!)_>ZUT`;70+VQ.R>
MN]1M\W=N10S?+Q)?ILGR&#$^0_=U0F+O82]U95^VA*4;AF'C:T;$]T#J]/5M
M.W!*_64?3,PP-)0@N<SBVD4ZX;KB4Q7[.:@NU62CH?TQ[:/@GSR-5GIWS7)*
MQ)QVI+!GL-'>9;+A?1:27U0S9->_#ECQX87EUKA&_HR?##B@\!4L69(%0CHJ
MY26/ON%T&KE5PGV&KR.K?7%C^<?!U3N8!,8S,:#E$!B%PG9[[!K=6)3"R&B%
M>@YR:M+=47"WLDCLPU-2DM#2,?D7<L!R48W37`K,WGU4@[NP^Y8G)F,@=%7#
M*$.X[-)-#W8>52&+MR_RA)88BP0ZX9,C+Q04PG/(C[X4@\^@^4:+I_5035WT
MGR'#'T]0/LN5ROUM<M/Z?T?81WU17<^J$Q+?2<69PJ:5EX\H+HS7<6>AA]A%
M!$0C=\^OXTP%RP<HU8+ZC)/C9)+?7"Z?`3!X9HZ^/.KB2V1?41FEE2F$PPR*
MCGH5Q[$;%89;\+,N8*'K&NHK6)J:(0=J*C<:"[>$#,HV*<MY0JZ5&]$>"SEW
MH.S[&=0@I\WZ9,8J1^08Y-=_8R$0[^0.S<*-'9;K[=XI\HQJZ2Z347W_`&KA
M3G?/76MZWK`];J5Q=DX0:/9(`:.G.C&VS9T8'-W#C4>2TN?V@BJXX45T#0WK
MMY\NM_;<;^*GRZP/H"DT;E""[J-2`)(FK9?39RY!%F!9!NXVEPMINNLP<.$T
ME]HJ\]_)UO77R]:W\/AO6!\.9?$^TTUN)1'>TEC_`%%$E>38WI-64\*]H=QI
M/O3G?/9_E9+KC;/6]N-=<[U\GQUO`.I?$V.D.GLHCK/ERLW;MMNC0UOIPX=N
MG+%J@AM9SQI59R^9K(I\\_'KM5+OC6M]<]:T&34*BTE^VJI)@FY369MU&ZCQ
MOPOPX(?/]@AVCTII3E9]]/KZ/.]?,K\N_EUOX;P/@U/@GWVWV)H2\^\<+M&G
MVI%FX^Z=-4-N7+9M]%;OZ[ALVYVHIQS\>N.-?-O6M?RX'IV2':<_9;?LM//K
M)M_M-ND-.?N%FRSU%#Z'U/J_659ME%N>?A\W22?76M?+SO>@^JCMJDX;LU7+
M=-V[X74:M5%D^'#E-KI/;GMNAUUI5;AOI;CZF^=;UQ\^OC\/CK`]&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P.&H"IB#+V5ZTBXBT/#Y7U--
M2-DSVKYX[EQ(G[;K..6Q$ZEA<=#KQ94,BI#*]I"H!CMTU%MG9IE)7BHIZHF&
M^JZ5<A\(IY1@%=_DMKMDZM+S(#4AA,':-$PK<W=N/7RU5P3QTY\PQKSZPB!-
MDAL-2`60$YK83]ZR*.^I$8<[Z6'<=,G;W`S?M?\`'U=_HCTO;]XLI/5D6C#O
MQ\[HZG9V:F?0^0TS+6X*[C!&>$XL_HB6N-[<S2P1*Z1J/S:+%`[<-RZ^#M1!
M%OL.:OG?SQ&"]@5G-S?I/\:,9KZ]KQ"AVM2^?+JUW`!?5675YQM"-U+YLC/Z
M(V1ECZ^0GG*ID9<N2Z"OVQ)\Z<\M2/9=CPH$EFO-\..UU3JARW/QE1:4O_7E
MJ>G;5F(^WFTFA2TM]3W:3F\5'(PV756G!+U:R[SL@5BW#(X.CI\4X&,C`DXU
M31<\=A#,R_'_`!PCYZE%<6_ZM\/0.4UI>,[GWIH^^NR`2\;-+ILZ/V6)"0"R
M#9WSA!)96D:FKVUK$TKHBXD<JC+A)$@%))OAJND`LW:7XMI;/9K,*[C5J^?[
M`>1_T>C?M54$_LIQ%S=8^-YR;FUH/.G3LW3U^\=32V?6R`MT_)D8P3#DX_`F
M3-)QVZT[ZY#L[Z2\U+6YX>M+RG"PU;C7LTHDC4<79S$,P?5[%R#Z-\`!9Q02
M(BB##K40=?*18?:B&W'#QHCVD@W^'.DPY#V]^$F3FK;M^Q:KZHL!#I!#=UO4
MM0<I.H#'X/`@$.HV!M0O4AA58KR)+FW80E;0F3LUEB8)@ZEXXRU'.B+=UOH)
MEKK\8MS"?150W#8[7S7,&X!>W9O;Y)VF;EW<[DEWR#T#:DJK817]@5H:%QAC
M%[DN_C8:?`S4>,O(BQ6#F`S])9#[4+F^>?%#CSC^/[_A8JQ]`ZMN0O1<CCTB
MM2MXN@!"[]"3*%/V1JV4&HI@`*$T1LZ);=LNUN47FF#9!'7TODYXX#F/)OQ"
M7G*(_"`PB!>'JE9IULYK<R'@N["*<UO(11OS^X"^D(P9)UT,U9WI0[#J<(`?
MW*Y810E'6Y9!1%T3VB]T_#3XA_Z>QFZF+)G9EDLU*F,5^/;6<UCQE><SF6V.
MO5TRCTP[C2EU5_-HW6\*/6)Z(M`RQZ"HM"H!R_8OABC,@JX51#V3#\.'MF5E
M;AF??I&E1UA6G)ZG]$@9$&86F-7K7TAYJB=_!O,,1V_*NY6ZGM1U8I.X4.5+
M=IAR!05$^E5Q&WSA95R'3/QO^.V,>6K>L>R55Q1AEU%*B@='AFKLHNPKL1%Z
M'J>M+?F#8&\:M1`*PKMDE8C^CCYG]=5^-!CMJ+<*J.T^PC`3X`N\)^0FP_<W
M[[@A\9)M3^4C:?>&)2+'.K*AU2`:$\M%7ACF,ED(^S$59*K!;R9=LU=JINCK
M7MLB\^FIOD-SEOCSTO+_`,CE;>WBME5:XK^FXU8%65S2WV4T;FAU=3:IR.I"
M=6F_+A8!Q*K#O3D0J89?M]3EO'8X+41)*.$5F2X=.PJAA4.)5D+0:P/JC&"A
MQB'?N2HAF8[:I=$V@HF]'"'A$:W>[[X075:-55DM<]](I];WQR&3P&`P&`P&
M`P&`P&`P&`P&`P&`P&!_.%Z$DGMEK^07V.S!&O3[6N&=9L>/+X:*Q7UR\KXE
M*W7D`DHHI#"=9P(OYD7<HW>MQTYW-2K9PD33WRCKYM(<["//0GH+U?:T(_'2
MK7W_`!PP8;':ALF->P'Q#S[[^K<F0NH?7OG=6,+RIM1U-N+</J+FW$IVQ),F
M:L:7=<N^57&U.4N<"S%&L+RM#U%:T)O>8?DRBDPEME>@PHWF!M34"\<1CR6@
M+8./-4H&6`6`#F`*Q"P%,;W]S&R/=B;F2I=L>03%HJ<(AS>F$&_+H/\`/GF0
MO`9?[J)S9#PA++DOY\?GUG=6/$[]?V_3H)\0C-?ZC:@:X;1KVNU3)H/41AP(
M'R)HV>-D>MN5D^>PG*TIE^1'J8W(_KTI[\(>C5K+]L(G8XE7TL%^1&_BEA0=
MW//*DNI+I6*:@#:["TA;5VL*2$OEY\K-G!=D7:_8I*IH!&R,Q_.P+=2^)\L+
MJ.6O6L1%P>#3-"+;2J&[S8?\;_K^01>WUVIT0C%@9R9W6X@7)\2]7T.8V<R2
M9=[Y;J))]!?58Y<Z'XW_`'\\\PGOR>R&PQ=>DU:2->JX><87PI9'57`UY`EY
M^$R2+![P*-V4FZ4Y5X*#NV*4DT[0CWSCDTN.0H?:\H]])2F(-*XE?Y`N?(&_
M0ETHU[+K4@7LUO<Q&O/^'&@7[-&UF5!U:\]2HPMEZ&?2]&&.9`);JN44W/"Z
MBC%)@IT%R5O0/JQ>LO4=/C0OL_N[?^/.GY!3,@[H>\FHG?C]Y?GE)&3,HU;A
M6O4(7P&ZJUY*]OF3DCHT@TV_Z72X434WP%2;7??EG;P2Q@Q@YZU&#_+=Z4;Y
M3!S&,A;/>$_3U:O?1<VGUB>L7[6B(N=MZ0@N?,O=?1\@0CC-P];F>I)RCS]3
MX_*&RE>OR3/+OJ:=020>LN/.L(;_`(\!<UDK=?TY^L#6,HNV[VWI$Z.\Z73`
M@4WOL,6"A0869.)/VTDT)CY5J?9-'"3;7S!T6\IP;WI'/^/9S.;7L:Q3])NI
MWYS\*AK5$J@(]8\:$Q!"Y*^O*QBCO[5G:4[+RBSF$!?R5/39CVQ@BBG*:;M\
M2ZZ#E2Q7_)A,H;"XC1,F_(6YW+PGAT;Z:-^HA]K5B7B/J:1>@@+#T`'K66,(
M:PE\6IA"K>SO<U>0=%Y"0C%(4J%7X[5<;[#ICZWJ#W022_''25+S2>M'6E;4
M0]-2P1=E[!X8X[`4_M^#W.;ZC`-W;*K-:<==\@E2*;=0FYYX2<_R_'G`A^$O
M/:%G^HQ'F>9%?9T2@T1]&?D./6[/V`Z=P*)N_-<C9-N_&/$(]")!VT7DSU-R
M6:<BF88BZ,L.V;[E^@E]!7XA5!R>_)53?E:LF?)+W[,+>]$_C#F`@0]=QZP[
M4E<+_(M*9U6WZ,A,EVD>?;HMP/C#AZJQ='>14='-47^NE^%..M=!K-O_`/F^
M121>P):&-^MFP&5QS\I`BB.H2K9UFN3$LA-@*C_,T8_ABI#$QE!M$H.T5.U[
M*HXJ5U,DFO0Y?I!RY;)N0O63=^MCOXP9F.IHWZ#/>AR7IVAHXS(/>_9E=3_]
ME'O0-"#[%092KTW63*^(G`TJN(&-ECPP(_'B&'3]RTTHLW7XY"H-ZU-^8BIY
M/#`;:YO0%@A*MJ:"S2:6!3\NM&;;AK&=^Z;*<$6<-B^Z[#M/<=DT/YF<!V)D
M1*$P)*1`V/WJ+91ZMPW6#:^9E[A;RV8NI83_`"8J6$NK^01M[#CT!@DL<U9$
MZH8M++;^)G_@QR\BG->DK?)R#4"3BFHP[(.B+)<TK,>.?HK;0#)0P)^6V24)
M2"\\M7TI7GL"<>L)/Y6]T,6T):R.I(73EWIA2B'H?R=Q'VG4)C(FDX#%1',6
MEK;MVQ8GCQY$RFN[XY30#=_RLE_RD17T^'`>(.?01:HYEXY%T(3>PX87/1ZO
MK7MNP;):_P#$;P9Z:.M+613<8@0_:ZW:O;GA$ZW[ZUKZNM]!A*%LK\GDU]0T
M\\N"MO7`3QQ.J*KKQ)89?G[2)'8[;;[SS'9_*?7?4=9=-;KB\LX]$*EH.XEV
MVB4=0&?;O.>^5.?GT$"GP?Y`:^K_`,5JG;']\.F\S,>^7WH-Y)EO:<]*"GT0
MO"$0_P`QCCC?RY`I;:<5;%:E'OGP9-5HW"%-*.7B_?:RB770?&TE?RYAIUZG
MFT6,>O&$,FG_`)E8>@.8UU9D_?$RT6--D?+<0)5.:AK4300SN+:6.0B8B52&
MY*L.[$D-M5WB'*X2!>=\?EM_?/N^?1RH?6D>HR[(?8T4\B(Q6,LY$>JZ2^89
MA$`\.E4;KJ-MR5LP9;T_#A<\,NECXU)(FKN/-V'S?<<:V$[>UK\]/6!Z)\MV
MKY7'>\'%8\;@PQU2@JB;_H8?,9&GZ!",9\5*2*15P6!"B@VM^5-E15P1@7#7
ML4Z4=QXVW+<N%FX?T5X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`X<N4_(
M7GCTGZ_NR96K-I?ZBB$_E]F/)Q(*B],6!1?FLA:M2U#!(7"A<3A:Z]6$;4.4
MT.AXA30MXVE\C2?-VB.DM.]-^@TYQ(?-2_JTEZ=Y]7#_`-ER9C;OY!(A'CWF
M:V&Z4)D'G?S4Z\.3N173;Z_8Q@#K'S\R:'=*PA^RC<F:RZ1N4%U]J;;(*A9F
M_P#VUYEMCSQ.*.<^@B51SZ^:3G=?)SN3>?;N!-ZM+3@!.Z_%S&>P^3``CVMF
MTBD$:,;BC.1$QG4F5'=I"W+W?/U.@Y[>2/QO5[900M87FKV-!;(A<I1\_2&:
M+.J*L<V%:;A+ZKO8_FF&UG+;)N,I9(VMB@9Y`%98Q-F9(;=`A;,6U>`?I(MA
MP9"YO!7GORTI24-O3VD%C4=)WMZ:]7-FLIIERG.;3/\``JI?1WIDS^H5F9"Q
M8J439U9+F:8HT&*Q_P#9,TT$1#OG(<5WT&S"_P`4`"3AYSY0'>O'FYN!-@K7
MLE</!;1&2:,5??,-](5.0D00L^N-T-!7??PV63CJ4N>E78%?OOE7B-,OE16<
MA*_F=#QEX:])^ZK,(>PIS:DHENZ;B4LC<OJY0F:AR,*FLP@L8KV"S*O:N&.K
MK6C$YL?42;B`GZBI$FS)B)>)\KH==Z#H*E^13Q;VXD::U^18:QB=3(7?(9$;
M'R8%#QE;+1NN9C^L+3,R"8Q;9-"+W!%'RHGEWLNDA(A^^FNMN.-;#<HK[0\U
M3:QZ\J6,63P4G]IP"/V9"@7,6FC;E_%)7$"-@1KLB6>1UN%CI\W"`[PJ@'(N
M&A?IBT55VVUSQ@9BRO6GGJGK-BM/V59(V)SV8AE9$*&D!D@4%L@?#&7D4"TH
ME302YBD*8$F=?'>V2IAZQX>_H[S2&U.FZFN0CB/?D*\CRG=:\A;.)+=6V>81
MZ$<NZSM<5T[7-RV/0*+%SG):#LNH=$IQ-Y:*$`#1C[`2>(D$6[!PX5ZWSR$Z
MU+?-17MNR-U#.0\^;U)9T@IJP"`#[MP*!V=$QP0E*(CP64;)#BY".I2%JD][
M9*N4&SS:C7M33E!=),)=P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!S6WZ
M4O8U[W2\Z!OV$RJ2/S:3ZDY-9!Y^^'0`%YKIZP1\?9(J(/AKC9"=VMVX</-*
M,UD6;-)'CGKXJ=*A'9_\J0T2G).4J:2:.Z[U:`VS>)?:P>(,@T^H8>D9N>I(
M<0<Q9^G/;,&AC\?<QQCQRQ;R1(LKWMPR38J]]A,%?_D!!6@!N%_":Z<FI#3U
M)%[B,0IO,A2DC4="[,O.NN*^*,D!B[B,RU[_``0<.N$G:?S<J/N6_7&ND>U.
M@K2,_,A$)>%+GH)3NU0PI>4/.9'8EI!JWB1&,CX7.[JK\@RD#N,FDNCES^<(
M^!F<=&[3UOIM*FR+E9#AJZ<\A[[,_+(""L(D4AT*VLJT(VI(;%AKHP+)3X9#
M*NDUIPQ*/$HV@LS=0:631U"6Q1)4A\Z(YGM?COA?7&U\#*&_?%KC_/%G7&X9
MU9P3A'JR94[]K`9'Q9<4[A$3KY23J_H,U^G&FLA/+/6W?RNUF++A#OK;==IS
MVEWO81QQ^7TE%HU,>))2!22S",75:-=#D5#?$`:2>+P\CZ"D0Z=CDEPTJY1@
MG<1IO4=9'E%>6AF:-2R"B8UF.4==A9JX_=<LK"ZZZ@S.#5XI$;5IBOYC%W-C
MV=S6),)/)Q+I`T7;SXYH#,`("!@8L`^FJ]:)D7*TB>LAZ:76GJ2W(>.T/R/?
ML2IZ<N$#1AR5QNSO-DB]*FQSJ8(`I!#HX+*TS%Q(5L/:1>2)2AP3E-W#ON7W
M*K-BP"LW9#ZBWRHMEPKG*_RYR%-O'"(.G`$<0`2$TC9@246:.5ETF9QR$^FI
M,Z:4Y'>(^S>R6-$%O/WRJ2!W]BZ%J/.V[@1]5H]TW";Y/^4N$"9):;./0Z-2
MR)4ZWD!.12-E<D72)S\>&8C>DA5!@$`Y!G;T\_6'2S1\&2),.F6]-=<KKKOD
MFW(9(=[]FDX\S*7E$ZOB4,.C/25'4D=%3VP57D.YC]H3:GA9>4B)4.C@LETZ
M8QVU>$4$2`P?KDLV[_D7:?06=!``?\NDOBT*JMK9_G-0I94GKB!V/(NX/83?
M]HNHC):MJR>K$A)$M$FK45811S8VTFD6>KICN.62W6S_`$GK2FPM?Z(]_,*#
ML*P(8O`X\79UU'X,[(N)#;0.`RB0G[*82E[&NH?$"X!]^MUV!U&>NI/(OO4]
M`VVG;GEFZ2&O-\!5RQ_RX&P8JPA$8J*!M9G&*_N]R$DARWG,BK`[9]/M;H<K
M"`9*)0)0B3@CYC3#Q\B5*_MI5\BHJDT;JJL7VD`L+&_R":F\(]F$$H8-B4D\
MN1"1R=D@+FC6P-2D.,?68#&RAH0;1H1"U194K6;KMMRS*%/EY[V@]TS>(+MN
M`T9/\GQ/9%H&?4G$XP\E#QX[@9N;7Z*BT`6B(DMZ:%D2UD3=Y7JC&N#CWKS$
M1V,8<HEF[OLNTX5>-OI/-MP][+\H8N5FXG$:WJH/+9C(B)=L5#N[B""V\091
M^5^F`Y9W(7@J*RAT@[4CGF4D28MN6OS/5""#?7?''"CK`C1/\O;QDLW:27S*
M3#NUH!!Y6OVUM8>\$#BEGU4.N.%:('24&`C_`.'C")GF+>22-MMST#)<OM<,
M'K$>L_Z"0G'NZU!]'U-;*PVA5RDO]B^DZ-D+$G;K:,59U"*?9^K%@^@5T.@3
M]HJ46[I(;]-_V%U^H*]JI=M&?2O738)2K'\A0"R@ESG$*BG(C5`TH[NNS`:[
MIDYE`L:>C7\1J=BS$-]LVY(2FTJI35,;1TMQR(<<\LE>E>^]*Z"+F7Y4XBT?
MDX_+8+%F$B&.(LP0<Q"Z8_-()+2TPE_FJ/#0U=37<9C^IL4%#?2K!<HBW8IJ
M,WHU9KK2J:S=WV$FD?=<@#T?YMM8]5$)BAGTF,)RT*&F%[C8W`(A"F-<E+6:
M*2FVR,"2%(S<W$&27+80F/VV^^[7YZ?_`&K19Y@5^+_EP[18O'$:H(?)7BL7
MF=CB!W-V"F:HVO8%$/1DP/-;,Z:P,NI7=NJ,O.+Y-M%]ID$^E"*?U2*/VC[Z
M`;9W^4;H/,>XA,Z<C4:=1TG&VD\33O,41-(,IG8$2A0!_6L;7@8HG9>Q`Z<,
M"\BYWH3P':)NN>%'G2;?;H--@OY=.YZB47"T&P<M8EPYD<X))6^NW8,*YY;>
M6R+&11=,Q58DS))`^&>HF2J8YVS#M%-"5NN"':3ELIT%C1ON;J953;$^#0(G
M%U*<M:J*/FG+PJ-,=,;C.6A%H);=?M>.V;%%ZVK;J4,D]E-;TF1V[ZV@DGTC
M\.PP4/\`R#')#1MFVV5HI(,=A<#\_61&8.RM8>:;2R-^DV;%:OD"DM4A@A")
MGF;IPHD40Y9$FS?CCCM%RY^?KE,(0F7Y:B5=QN5/YM0D;$28-W+OV['VUW/R
MS*7)UI-/34#L9-N594UT^%N1Q?RZ7=C]JC^VK@0_;N7RPWM)TW2#7M?E*ER4
MM<O!\)0E$5(JCV\.B2CX-&C)$J<GGHB)#V1V7:[-L!PG2=>A=\+H,UU>-\.>
MN]*Z4YYX"?H5^1MS)KF@U,F*B`1HP<M-_2TK[7N0>X+M)P,)^@11`Q648=0@
M42M2M!SOS\\3<&/F#N45G_*?3'731Y],,:3_`"3%^;.<U9&J4C$H/D;NFM+Q
M)-E>POIVW<UQ;S.J95(+8$CH`7(56F4Y??JL<8ZY+NCK9NX3_P"[=I\[4#1$
MORXA-,:]<N*@$+JVA(:7$1[8*Z0)L9%Q_H`&7.PDM:Q3B)M$X%N`(1YSQ8B/
M/!#40Z>B.TU"291/I(+S^7_3;?TT/GI(=!2L-;UK)D*SEJ9<JW>N6%R`&7S6
MW7G""+)KM;BKSBZ`U0CK?T2+KI7Z::>D=_.%IL!@,!@,!@,!@,!@,!@,!@,!
M@,#E%+/Q40^1V#?]EL;RFL:EU^7!7EU/Y0/JGSF3G$5D586%4=AQ*-,+!D51
MEYC):V'O:3!->8Z<=DA6F[;X_1VKKGOD-EC7XR(G!W4M4A7H"Z@;4]Y[XH,+
MP^95-+"$?Z(VH^NNP;)?D9=6QK4VF%T66;)OIDU,(N@9M`DHU^Q103;\HA"B
M?X1J&3CKN%<W3>S>!FX^&1E$&'.*U%1DO.(P[N!S#9<+8L*]0ZA,=@O-Y&^0
M<."=L(@+VW&=(#^=L-?5"Z?F#QK'O(""L-I27%AM0F;$ONUY9!CC`06>$99;
MTJ`F8@$!GN6+1U&H#3,:&J@08Y'77>Q*;)%953[3GKH->]?_`(]J;]KR*!G[
M?.SI#^&W`+]HL(N2%#$!:S&VZTM&4+I+N0[]Y\UAC*R;Q8SQ]3Z:\;(/6_'/
M"BVEN0D[S;Y@9>?'5D24M:=CWA9EL$8DK-;1M/J(\2DD#KN+MH;7T:Y;0>+Q
M"/HL(Z#05656TS^Z(%2#UZNIUVY^7@*63W\/-,V(&L,-(K=MHBVG4YE,@;-#
M+"JY*"C<)G$]O*U)56:46DE=E([*13RSO0QV1MBAQN2,LC@R/O$W/U`37Y@W
MD3^*^FPQGTP<;6'9ZI'TG3,PHA^6=J0QS*(=`IP*CHHBDVF*D2W)YR6C+>)L
M$8NXDSHON,,D-MF'*?"KC:P;TP_''2K7T9-O1#D[.'!"75@4J1C%!I$?$>(?
M"C]>US69>.QFQ(6-CUOL(NU`5BR=AQ7!_EB!.D2I5EPD^?[61"/KG_%#1%XS
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M:Y(EZZCC1Z^DZCB,Q!ZO'II%"]`"H.S7'\OG<$:C%X[=HI[P<=G6;4#IGIFZ
MVW=Z^@F%\))8M*0"'`+M-A1@:-V2;KA!Y-.8NP060=66X#QB'G9T2TDFN.&_
M<FF+%P^=*=<,N%N-*=<I<]=<A6Z!>Y?)9E*%Q"-P^41N*3B01V+UUV]J/J.0
MN3S"12.N8@^C8)KI%/E`S%GULB=E?KM6R2:'3O:*CC;%YPB$@F_1GGTU&ZN=
M-JVDEF)7"ZF+F+Q&.50E*CR8&K)<@VG<V,QYPEQMK'H7+2C193I/Z[]9X00Z
M9MG"ZOPT$&2K\D'CL[U-1Y^$36>.X7N1AY2)2JX+-UVT%"@C]A2>4/N$2A)J
MSAK(36#U\Z8/>VYC3@6DGV-^[[9I*A8JW_5M'U4</1R8@)<=&Q.KFTWL*1QF
MO7<OBE?U_,4);J,-)>JQ36((HV$O7)%JS:-6COCM=JER[TWY7:]*A#0_VIY8
M9RT+$E*>L".2>"]"H0?:JT<WZ7HEU,CQ.+1.%2)0!LGV*5GA8<CP-:`?U-%Z
MB0:+?R(K?4Y#1XG^2#P2NK3+8.'YC[R0=/'<)8I0&*</*Z:'#R5>,BJR$=)$
M=@TY>=^(SK@3]V[::;KZ*),D6KCI()%I+V%1MSS&OJ+KBBIJ*BT[B<WGKM*3
M5Y'X;&8J/!`J4LV+$#436<J?40LL)=XXDP521Z7;/$5$GJ2#K7?*8>>F?:U!
MWVM6(<S3DMAIB42QB'%)32"`R<;A5I#!<U.P&)/Y0P6?#Q\[*5Q$'!L7VUX[
M09L'C9!1R@Z=(MU0Q<P_(OXU"V,C'+!$GA$D[D=AU:A)Y778_E!2.Q2S^Z7F
M1YD]=.EC[ZKGMK,'0?M5LV5TXZ'N7JC?0Q#M[H,<Z][^+8^^J43)*]D4'(V5
M'6PFN&$IIMB$<[IV5O86(#2<<U_MKCNJY40L$:WVS'<.7B'6W/WP]MRQ?;;A
M^!OY!_+8:##)(.C"(=S+&@T[9X0=!237D4%ZBM>&]G3";.-\$##4_%K%&*1E
M1\T;_K;32G/.T/MG'"0;.I[F\R2+;**F:GLM1XM(H:%F<1/TRV7<UKQ*)C`A
M]9R2QQRKETS&`)-)+6%/1B[?IZLWTNY<KI-OLWO2`?>[_:7G^@;3D=7H5]P2
MN%YT"/JI-Q$=!L)21,.8HP)J.SZ'W\B[+#8;,.GFGKH;^GN^&ZS%-[MSSVCR
M&'>^O89P6\5FB]`MDQ?JJG=E3TUX:"SO\+XH?+TS"XS6G*C<*F3D+*2V7?(-
MFKQOAF-;LN'#E3CKKY$L#YLO;WF,D3L:L#-1FQE958!-R,.4?5\#>0B3;@`&
MVI1/VD<BJ&EEACV&-ZC)\I[7;(Z>KJIZ;[W\^M[##07WGXPB%IOX\$'61'YS
MZ$MX@B4.R<(8=KRXV*G##SF*E;90](B1U.M]3Z/=QD0B.:\LV7(QT\Y9MAO*
MK_L-]L3UEY;J"4&X`8IZ7*KU5-D(;%E8M2C`E'R]QRL)7\NU7M4KMOHZ<S\P
M!M0<^5Z22:-%N?N]=.^E6KCC@,1+/R&>1AL3<D+$C,V%P>/$@"H1:2U&X*`R
MBFIV2JN-&H>/8\&>W2*5X#&4-8JIH)K:D1D3]'G;,@U>]A*<?].><28ZYRXF
M(F$7E71B<V9=P=I6/3N3!7D4.3ZNC0Z2"0;8B\,S\[NOC7#!HE]TY*"4N5DN
MNVKA'I4*KN/=_D%I,#?HEY2LI[_;E+UR8%7,D.@!';D5+)QZ(!+0T$ZU.-QI
M@7"=TX;=*OFS[>C#=TDT;+N5=-VZH9J)_D@\<B#R,%(0)_6GZ[/BT1B2?$(C
MZ8Z30U<K`AH"TOTP3VB2:0^;RJ8LVJ#?[1<DW49KN7K9NU:K.$@QE=_D*\35
MK79/AE"[EK^!+/7L\7,65!S:^YC/;,'P>Z@S1W(I5(SA@M/K+$6Z(,C]DUTT
MFR;C3=RNQ[:_;)!LD@_)]YF'P*5RB'5U9<X0!5T?D?Z>*@`\<#(2>#P.U[`%
M5$XDCM[L&E*W`FDY#IFLC]X%1TSX4X=[3=L=N@LM4%Y4/Z8D=H0(-!E_URFY
M$P834%8$*`LG`^1Z-27Y>^1+AP1(M73"1#2"J2SMNTVZTMR_9;<,W:#M8(Q-
M^WO.T=DKZ(JU=9SHXG8I6KH2V&U"BHE9\QB5HCZFF3>N'*SILW(CH)/).U3)
M/7G0]JD@]VZ2451X<*)!"1?TYX.-6G5%[2>!6LTLDF6KX-1+LO%9PW'S,A>+
M&P$J*E$.A38\I#=O;J9_N](`5(L6;[YF3_DCVR43;?,$\5[?_D:.06U+.K2)
M/TA[24Q&6V!T'@;UQ+I!=-YS<DD$@*W+WYR#ZW>[!EG#-<4LNFF#<FVZ6^VS
M=3^L#3I5[S\GU8:)0^55C.8?)B4*EL_+PY6I!*$I(D70QO();$WL18/U9"2E
M\@8CDU>W.VBH0PHWXX2).%=)\[".A/O[SGYQY(0X=3UT1&LAZ=CRPO-I(P<O
M'I^U-W@G!;-8/)!+I,_X*D1=I%S+8Z;-G6C9(BR3;M.W:+P=TJ'5\.4:'!(L
MV/Z[[8&!S(HQ[53Z14[:$&R3MMTHEWK7:7?2*W.]\[_EYW_)O`R.`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P*/VT4\%BYK/1ER':?$S7H/+)+8"4L/<#'>ALU@->UA+UBJZSUNU
MX>&:X$1EBY:\]:=:&Z9J_3YX5X5["O36-?BKYDU55Y&P=<3,[Z".,QD(C$?D
M)Z4IK,$(GZ,Z;LG8EU)54(O`600M8@[8322+%/MZ1;_8_#A?Z(2.8X_&K"!]
M@0B6'ZF^F"=1J/6,/G,T-RPV3(-K%,R>.B3A*5FC1^;$6UG<O$_I[7?K)DD^
MF*NM=<<M^0UJ)5]^+-V2?5Q"CM3NY(]:0[I?D#<<J<S)9M*^*/C4*3&S5I-^
MY/\`4+#]U\/:IM"&E/TYV(0^&FKM#A8,?>)#PFW\WVSYPZM(>VK&9Q==[)ZT
M@A('+GZE6Q=D%B,JK&MP1U(B"C`S]EP)=GP.':0?BVR;HDSY163VZX#>;:C/
MXVH]8MBM+6>U5'K+6%QN1344XF9T&>C?)PM%BL>E@$,$.M.H!*3A*JA9#]6"
M(CR[SB-\.U5NTA_:J(?$L\_&;W$A%7/972W$7\V\]\"8X,GCU#N)-9._#C2<
M:TX"G4RDM%2XE)A;<J"45(MBRI%AP];+;<--=A%/)?\`$/6$D'P9D6IOE_8<
M,)QA3EC*3\JCPBL2='3J<:$E3G9LK'X'7[RE#)7H6T^NS9\CR::;)+GA9+`L
M9;@KP1-XW&+VN1>KBL/D(52N@TGDYU^TC$I%#FLS;?MLY']D&HF3KP5L0D2R
M?)5DX<1?YB3GC;+?+I7D-!A7?XXFZ+^,IZK>//S4CF"19I8LJ<JR.4O*`MZT
M'#J92612F2EB1UDC.8=(RHLH5?=K$A[%97C?;9IVF@$81H]^)0=,1(0(>KQK
M(&+>)2=`^^F4\Z2F1"?RX]$XD!ETG,'U%;0DK&15"MMB$/JDG`1(:BY;H-TN
M>%-!,\4L'\;,6D==V!#K$H\)(FSY>N*_.B)SMHLOTUAM85QV`X23+\MR0+B%
M<0Y!-1VFJ/VV4%/..][5;..@UZ`NOQKPR5`YY'G=90R>QL(M8@\2YFS@B_!_
MN9X;9MC.HT/E4ABSZ:_;6DY8B_MTW1AB'/),F/TF#E!#H/,+FWX\+/N.%0QB
M*C[^1MWIR50&7MGS\;7\X)V%**WO1Z(3,#9$W%V%J53^X6!IJ'*MW;/];X==
M(H)N$=?.&P)U+^.6$AHQ,V+.NF+$-&HY:41*-[%/<*&8(5/P>/P/EL]>S!)*
M4U>K*0$;8@0KM5Q&FCM$>FU;([^C@9F!5_\`CXM1Z=A<0BU1EI&^JNGV\NB;
M1ZU6-_PTJ:/O!-7CRJXTJY:E1M9B+$58=*-G3KAAT23275^*B'Q"+K!I;PS?
M"C/TD+N6+1ZN:2EP.=6L<AT@BK**%7M?/*EF\7?3V6OVBQ4='V3:IHPX2WR[
MY&/A"*;AOSKM5)]R&6,G/Q:6+*)K>!:6TU*)(Q)A#TU-\S(VYX;R)P*_8K(V
MZB+0MH;S*TPU4]"2#I(?^H((1OML]ZYT/[X1#?V;OQ+;+`W5C@!&MPKSQ3R:
M:$A4.M!L)A-2*S!#I![&K"CLLZV`1%'O/0XNF]TZ:/QG(ID[Y51[^&]!'(*H
M/Q:VMU%:VC#.K)0[E,//=`(<`G,O2-&(;"5K$`S+]3%#I(V+KCT^[-D(X[^H
M\_,2X)]M7WW''T4^0UZJ[K_%S<!(#)(F7A4;(5:%4M*-N9"3/UM]U%I,H*]*
MOSSL:[,"4Y<!%R>3='^F!I%SP.,(NG3=MQ]+I?8;A(8WX/CDA5]33!ZSGC7T
MC<B;ME810\[(02OY/6U3BC),CTR[*C(_7S:(A/)/U2Y-9MHRW>L^V3Q73;6V
MZ0:2Z(_B6D$CD`U_Q44E_>D?DMHF5B*Y^00E9HG8)NOC(P:U?.WD<"F7EE6\
M^<(1P<W;KKF2GZLBTV[^@[T&VQ>;_COJASZ&%'O0U3'B/I*2!)-:RQJ9QWE0
ME'SM.Q,!7<:_50'3558(#H@&-=IOG#E<CV/54,O76].>G.!K<@@/XKDY-$H$
MN/A9R8F+62I)@WC<RL$S*%;+FVKQ//$I8?"R=4V0>2!T3GH\F;(N7'UUWQ04
M[<];5<-<#<+:JSRK1EC4P%0\D6++S-G35O&X46K`D%0C'[M!0?<K0C,L826Y
MX1PZ$C(?0O!KAHZ8/`VGHOAUSK91?>U0VQC$_P`<LP@EAO1O=)E8'4Z3/FP2
MS&4?2'P1*+5^&JP&<6,MRZ+@/^CP>MV8P27:K<[X4":Z9N/NVO7?`:21*_C*
M%QE^%E3ZIQT+,MA?*QN93/IRG+.Y'"+7ACUV4)EY.^F*I5E$I=*6)A^9Y;KH
MJ$E]KK;7WOO@-YK(#X):2>PK$J6;Q%"14F[_`'+;DC"6O(BBD8$1%*V!KMA-
M79>2$^&U?BSY66.WS'77`ON2-'CESST0;+=<!K\8@GX_*NN0D/)3>!%[TL2[
MY5/![:93OLE(Q5B22R&DY[#Q0&H1X$0Q!*:2,2VX1:-FFRSW]-3=]/'NVV^@
MC8<Q_%XPLBS*@-0N$1,W5-E1&M?O+!+NFHK^(!>%1>6`@=2JFI:^-QT=5(":
MB6[!TQ:B`\4='_M1"R"CUUQV%C//5.^7YC1UH1:#2$#>D"MJY[2GML2]DN-2
M;RZWS\TY/2@HB^A;<&P%&HF;8,D&+H7M%RP6%MU>5]O4NE]AL37P3Y&:$>2R
M5+A5'VE>WBJCLY,'Z3TPN`0BS^3DVCZ1.&969F8\U2:$#;E-4N112XTZ<J_)
MS\`R$@\0^7).<E\D+U8AV<G/9/N0DA\LG81??ZZ=<R>2<!/T24#TXFA+9$_<
MO3*8GEDF8=.W"CW2_3A?:@66CX`)%`(2+QH4P!1R-B!H``$%MDF0P,$#LT1P
MH4.9H<\(M&`]BW3112XUKE-/C7.M:UK`R^`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P.<5X^)?.)
MNW"_I6W;2L0.\_<$2*<CGTIBJ,5CQ1^I7<#!#A2A"'D)0,CQPW$16DAG!#3#
M]7>.U^$]+.^]\ANX3PW4,;MD7;82?62Q6:7(?N<S#_W!$',/E=N'%[D00+G=
MNH>M*$5`S*\S#)NP8$V2"J;9ATY377;=JK!I-?>(_-Q*V$_5$=MF<V`4.3(E
M/@!16:PL[%NEG=BFY;^G,S#&*\G3L?$2DTX'CTW1-U]@.208(=<<(<ZV'QW^
M/GSI!HU"XV(G-HQ=_$Y,`6@<B9FHV4/@IOM7SZG$"^VKR#E`CQPR)>8HXJDF
M08K#E>OO>'":B*^DT@U%?\5GG-7[$T<M6[C@T*PD223@[,H*\32=2>+S"&RH
MCP7_`(?)NQ215":/W:K!@JS%:+*=.OM?J]=:V&ZW[YH\HWW&%;BF-BD!H2RY
M;2-EQF<#'<+-AM&RD"DM%U@]CH*90R71TFWGT4N!Z.;IOV#[ZSQ^DLV^BX33
MZY#18#^.&N&R+&8.[FGO#>+3\[9_F5>,<0@")HEA)B%?D6SL",-P5]Q("I49
M`AS,DC(>28SE)=RFT9LMK[^0)-0_'/0X^O$JL#2ZRQ0=M*C<Y*K;-0D\2-$9
M7Y]_X<)1^XV4L@L@CQ$5)8DCT0=(JC_I=&.E.N/D9==,L#_)M^.2B)K2%44A
M*))/'0JHI/-#\+E15Y"3I]!W9S29!)6#Y$R^%R"`)Q]P'G[Q@)'HA4T0C=)H
MD/Y0Y;<<["(A_P",7Q#;*RLWCY<Y)(W*!DW`EVHXG"B`\\DG+[H0[VP,O(6Y
MED4ZKZ0VV?9,_P!"?B^==-6G#O[G;;K:H6%1\40`[-P-ASRW[>MB2\A%FQ!:
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M0[ZXX"PUX4MY+E$O\]QR?2MA"#]0L7H2J8*#E@X`F2CDXC+V%@01B.+(/5#<
M7$E8HT+@]*<\(-9'&F3GGOKIKTGV'DIO\?M+4S81V<")79<M)%:LE%1*@YK(
M8^5:,J]G+Z%.R(S3\;%Q$N7206KAJW%_<$5&XUGI5LT233USK@(RJ[\:/C@#
M4+N*A$2A\(?CPW<?FY)"%Q^91:%-8D$B`AJ(=@(/%4?H)1:/(HKO3#)\2<][
M6[<+];Z^'`9B<>#O-EOD)0$0M.?L#`"5SO\`>XJ+S2&N],R5X3BQ[_-Q>71P
MS%#@I=N_>7RZ("6K]JITV;\BW:>NUVR;CL-B%^'/,=.53<T9,RF5LJ^GM($*
MYL8O,)H&8\AZZC"$N,%9$B80#AT0KT(WE3QRX?=_,@APBGUWQKGCKY@DCS]Y
MZK"O)K,[DCM@S:R;#LM(F)G<VF3R-IK2U^`/?;NBB8:+Q&'@&7Z1RR:C$=C&
MC<?]BT0ZUPHKVHY6"&7?XS_-YVK/X/2&4V3)XR]-?K358E)HKT5Z=@:=2HJ/
M));8Q!J-((PR$,&GT>5VJ^UGS/A1]]SQVNBJ&8F?CCS,"\_Q.B9W,C(*$A[&
MDY-(R@]@T.+&;"]'BK/J==%^SC4-$Q1GU)'%XDD!R#48U3^]TVWUM3Z:NE06
MK^.FA[;DAF0'I7/V9DU)>Y_VT0)0<N+0EO1:O'@.1<@)7"9"P>I!5*\3:MVS
ME-=FNB2><KIK*?:=M`]X/\=_GB/Q%6O!!":,Q*\<GP+;5F8C#%=-A85`P7S1
M)GC1D.BK0:R5XA$`9+(:0:IMFY959327T.^&R8:+4?X]_,48-+SREK#E#!VA
M:9B4QTK$2%5$-QL]$9M:R<[AZ)C^'S\M*!R,TLD^S))'719X/620115;*-OC
MV%W976,9E3^G#\H.&')*CIFM/HV44?"F7ZM)%JUG=2/',I30&H,G3=P#LA^K
MVDU39<\D/H]<_*GQM'H*MUUX]H=C#;CK$!:,LFPX[`XYY5()$S5=2-]5%?5T
MPD\EB--B6'[)["/5HH-M-XZZYD[(Z3>LG:/)!1TAQQS@5VLW\77V492%4%<\
MCA1F10Z5U)9LWGI=`X6ZI^;*.2$GC<9&-8YJ.L0O*JW'209%N,2:M6#%N.?"
MFS=5)T%JP'DN@$!=NP0<<ESEK/ZDD%"S=!8XV150B5H2JU+0=?HC_@&S2Y/.
MWUV%-MW*72_*;?EMQOC:B7?:@0:Z\%P>&3Z0W'8/I*?$*P'#QT\N3]Z$:T%:
MF4R@=EQBX&YZPI`*@8`1%X-$WM?"54F0-(%WPDBX3<KK-E^D\"3Y7Y.H"_C4
M^M$1:4U00GYRQ(E:J\.D\6[!RB..V-1U-9U2$MFHN87`1]T1\RB$'3@:JQ.(
M.T7W+<@DDYWQR%E:W#5I10*N//8.1_0<#(5(7\,"R`BV6D96(P8A'VDG,]=H
M-6+=RU`/IL,2<J\I)\I[?(ZWK^NP)#83&)E2QX"-DH)^;BSH0QD@EH59."`)
M[(!R!@$T+-$ENEF#DP*<IN6W"FN>ET%.>^-;YZUO89S3MKM32.G+?:O2G2/*
M6ED_J;6Y1^XZ2UQ\WS;4Y0_K]\_#XZX_E_[/Y<#$*2N,)'Q454D(;B3'!AXR
M&`=$FFBY43%GH@;)23`?]7[IVR`D)`Q0>*<<[X;JNTN.]\]=\ZV&?P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&!REMG\;):S/2MA7OS<KD:SG)>'2)NR<#3[L_'.HN.J8+W!!R[:
M5CX^Z@'?\,.S3=!TR7^V/D^W/*6E$=+J!%-;_B@/UIR$^O:]>V)T.,_9*B+;
MK^53B*2!/J.,@/\`&@C&'MDM&'/IANF/4<(FFWTN/@Z<IJ]*[Z26;A[A'XEV
MD;BBC(29HPK)&1\>B-;2FD%GT!,5^+@-H0`=&I;&F,R9.W;@>_LG4O3TV<H,
M]2MARXTCSWVFX;!F>?Q2HI1QB.`WP5#R=WQ8#6=6R+CG:-FV`I(YY%I+&#LE
MD[:1I."<I@(^/.FC-=STMP@N_6[0Y;\]*)J!,Y'P\<)^?XM5.T_-PM]%K=0M
M'<"!4F8'><).W;PDI`]1R85GJ?*DC6NNBFI-ISI^EKB3,V:VT>M-]J*!5N"?
MA\/0QW\ROH3LMRWCE5"6I16.29(BOU7Y#SP\[`NAG,^Z!?LP/Q0FN8^V52=.
M!7)3G7"O/3594@&R3+\3AR11_8?B^MD!X)Q63R$0HU%RJ<&8]#(8Z%WB,D*#
M*6J/S(>Z++Z8S3:?];^EF1#7GG2W&NNL#W?^6F1ATAIYA$S*Y]0[<"1+TG;*
MR+5B4FOG*,UG73+^"LW<'9@:GLO4F=B4[&>V;C2[_3!AHGPNIQTZ44>!+7J[
MRQ=7I[OSDC)-4T)=1R#7@'MN4/@IB3A(`>L6,1(`(F=0!W\B!%FE@Q=5J\>`
MBSA5;0MRA\W7R]*\*\!7Q[^):6-)+*3PGT6UZ(R6)SL&$(RN)$SCH8\EL7G<
M96B&@?<N;1HY79!E+US!$>]:O$U3FEGFF_2G2*C4,!U^(&7H"]C^?2`:&\OH
MC>44(2>-08HG(08.W2]Z&V45BBQR;/!<=$1I2ZNDOOPJ0`BX:C54.][;O$DA
MH698_CE;/O,T/H4[.Q;=U';S/7D/D`,"3)M(65-LYBU8(U@A*Y"67BA2-*2O
M[U@^;=-T4'_"BJ+5#2N^>0AOK\3DA*,B&E[MC==N"H]P,2#4Q6Q"(Q"$[YBU
M<Q-,W7XEW.7[H*>/=5_LR66VO\7)4AWUKKYT^G"X>&7?B@FTIYY*1WT'&:'E
M"Y8Q,6D7HZLR4=JJ(RZ/BX0&ITG!88[G_:XX3`G+:6&"+51;M(N;F[I;KZ.D
M./JA9NV_QX5]:%P4S,W3&NG5=5?!:SKXA`Y=7K:7$3D7J*2FI!$8YP=?DN6R
MD:<[D"GWC)ZT=I=.&3976M[^IK8:3Y)_'(=\S7<VMDM=3ZQN6E;MH9\7[64,
M3S];J!U#"%!+Y128O@;F$Q_^%&G@AJX:.G#7LC\G"B7:"R[X(P0_$DBSA2HK
M5EQPM,W8U00=EI"%G1Y"7`6M;^=8<%B9TR#G+.1\QX9(:$V800Z=.62+LG\_
M;-QKAQP\#X"?Q(<_I4B:2BPJV,FB5626.!)8SI,6%+!;//414M'!;"[9"#P\
M.KNOQ54<J"/M46+U)$P]237;]=_4Z#,R3\9$YGVK9=6-8M)S,M>P*T1TK>R.
MDS,BU4SB>O+7>\)T'R8L=;N--3*5GI,9'V]Z<=&&H-MU\B>^N4VP8@[^*B7'
M_P!?X5N6&#>I>SEG;@L-K8RG(JQZ.NKS<\P2ERO[[3_:E42).Z=-3XWM/I1^
MS%[3Y[YVZ2[8!(PO\9^HC?59VK7\WA</BU>V:XG`^'CJYWM,)'7@:%-3L*B@
MUQ(',-"I3$M''[MV3:#&)=JY**K\.5OG515#4+5_&+.+(O*Q[C=6I5Q1I+)0
MQD32#RZGU2<:DC$+<OG:WXW%K.8B96&1E8X`G1"@7ARXT[<K(F.G/]JX1VQ7
M#P`_Q6&0J+<4\NR,:[X'EB0.>,Z\(LK2!3%2ITH1":XCA]:=K(H^;:AF(=C,
MXU$^N%%6A42TX[<=?14<KA)-(?C?,U%Z1A=^$KG<SAR##-W\E[(#)"-/'9X1
MK0Q"Y_MAMG+^@C"!3Z<R4E-EQ3I!^DV/.^_DXZ[Y;NFP8^#_`(URL(N0/80V
M>UXQ`C;I)VNUX"5B[#SN,#OXV77<>HA!I(VEOZ9'V-EZNCL--^_L>^#+`5S\
M$];<\:8AFK,_'63EME3JQ1T_A<F"O[$0GE>TA<->D9K38%&5@95JZX[+PS*8
MB7,O86)9TC:S9MUO3?0L\#8ZY34XYWUR$'#?Q"E@TT@,@:WLF_80Z8Q62O'+
MB,R$+)SY$,&\W\&;")EXU.1JKVV#1>@%&_ZFKWO6Q)CE%?Z_VJ_!$)_]%>#)
M]>4[L@BA:L0&UQ/3SB?*1$O#YFX/?O-7SXR\_P#(1W)XW9<9X2@^AHE$M\&S
M5-[M^NIPITJAQ]-4(K!?BF=<CTOWK;4>EIH57#N+PQYW6+`>UKR8?=TDO'IO
M#V(TPP&"#4.8U&HS9O&+5@[ZT0Z7YZ14VMRJ&/H[PI:!"N_;U66A$('7P"]Z
M-!4#%3[@!')$<GI(2]]"KD[LN!@!G4D'V%*3VK8%K/"CE0"3+K,E?JL&.N$-
M[#_9M^)GB0!OGCD^AD2.%)+)YK/P@*!O0D%M4X?NRUK5%"K`:#)#P4.QV##+
M4['AN7/;A5HJ*:*<?*CK;?D+'V)X)96*(\K1P[.FYN/>=:\BE=R(;*8\_DZ=
MJBX[:_E>R'VSW9Z4$W?;60M/-RK!V@17+=.-&M]N%'&D5.'(5`.?AR>.U62(
M>WXR+&(*">%T&4&/`'*^FL('UVP,KOHS.11%Q(*LC4<9<0M;APV4$</2*":J
M/*B"J(2RM^*N((?J1!E/0\;FY9\.?#+-"0MN.L,%*7?I"T;NF<QC\E[-]OV\
MXF,0GK>-+OM=[7[;"4]*[5:?*S3#8?(7XZ77E^P:\G#J;PB7E(?';7C+Q#]I
MG^2#838,;\_1]J6AA$Y,3BD4(/7U"Z>&44$.6C_LVOK>NG*2CQX'53`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8'(V_:?_(-./2TL)UC-#<&I$GH;'6SH';'Z;I:&N`M7."!$,#=
MN'C:+S=G)1<D3^H@"3=\-UTE>3#M-UM@/#4'=`^UH_<%8S*4*3VY8'1UG3:P
MH0QU=P]7YZUC,;]7`XC"95%S#-H[L:Y)@TF\,3:'WBBO:"7'7#IZCVT<<D@G
M#V!6_OR7SZ&2CR=8@N&1;J%C2$LB<ID2`]%*=@S!*+M`FD.`IM)4-(81<A<\
M2614YW^MUP";\?%-XMWH*MD_'OORMH:_C%-7#.58X6FLNE,R$*VAT0EAI,K>
M'I23"MUV_(2&`MX$_*QZ<PLH<Y;&AC=]^FND5=.5_JIO0M_YTI_UW`YUU,+J
MMB23M`S#;B'3(>YF"):,<'D7=([I<I#H.Q#"14<<<LALV[?;8I-]J*OT^5]*
M<::<-0IK4U(?DAG-10^1OK(N*N#"E%NY`+C=A7<@_F;[T,3IZOQ^STV=-8T[
MV,@Q^5K%UF$:=(=-HX51Z=.!R?"G(],)-$^9?<LI/LGLDMRY817Z,[@Z,;@[
M7T4NXF4=IE[,;B6L\'/IB":.E9K/U(Z1CNQY/1!ZZ'M?I-VS[;IDH\5"$8_1
MWY$[-Y,,)V8MA92"V943J6KF[G3CL9LYQ5\I\AS-'^$X`:RCVP#(,7ATZ=/B
M/6VC*1]//MNE7*;A-,4'P.>5_P`G4MHN<U[9U@S*QWLOB\XBCX*%N(%7.G5I
M2.MQ0!K:.SW3Z7.G_GI23?JO;B'*+,M]\O$%40#/A+;7D.BOJF)>E+NJB([H
MM(E4=A"+$M%%XN1/@!4B&1U"O;MK*-2J/F?T\^U9.3YDL%,,=\<\.$&3K6E^
M?CPLAT%(;A\D^[)6]U&$)7*IY$@$X/EJA(G;Q;:&1"-"IM?A(/JW`YX4\)6Q
M(S48E$*;B'+O1!89H0KPX61VFMT4#UV'2'Y+UZ_E<:A9J7_O\F?DO#RP&?HM
MN&B:[3;2V%JD>U=6PQ.*.8(#B"!**CI"EV98IN5F7;GH/(/I*=/@]4$\T_D*
MB%T18LSL&1!JU?7>_L:;LTK':2=D0<2NQ8W,K*)F61:1#DM0V15YVO&A01$0
M5X$$V;I=DV&Z=MRJ8;G/O'WI=_Z3NNX*]E4TBW:QZ:3*JC+>["+<28*RJ/\`
MA$</C12*+\D$V$):*T-,$R09PC^E/-+-._I+=*<]-PQE(^??=75_UO9%\DI$
M1AD-N-*8(1IO=SPLR`I2:EO0\&GSY)DM('_$MAB<E/Q';!@IR+2^GM1TV!"U
M.'""@8PW!??$_>W$YA\XL\M`8/==D5I6(@;.WM*3*<1)*.V!*XK9[N23"-,W
M#D96]SV.PB+GA/7;201Z`)/T?U-!UVS?A9.E8S[Q$'I8SM=X,.)QJI[J$@)1
MJ?"D8U:-LR^V'\TK,Z-CS&-D"T#CL2@CI$'\[YJJJR^GVDDT<HI)K+ASJ<A/
MR3U@^@`6PSEZ2)U+K+BBE>@(#.),;<1=9:0>6T9X0M"5,N+.#R&$I,FD^^B$
M,R+2'`]PN];IM..N>083"6\S_E0%/(PW@/HX^B][HE)-P?F,T:S$$&O`I!;5
MU8&I6V)O4=%A).Q3<<6CFV,<?)"&8_GA%<<D@N@3"8U///L61^58=%Y%+Y4_
MN6(^IH9:L1[D5A)L3L?@<=E3!8:-EY\3*IBG-A,?=*N3#@00/&^B(_CEEVX4
M[Y2;IAME=TS['?T%8L&FLXL**GY197GS4?<.;I:2:U8_!A!FHN/3A$5;8P5K
M0AM/FHJ4N(^T1XTX'HN^=(Z';618CPKZ)H/\F8TM-.YG9T^G\.[G[]9U%87<
M`FLY%+@>]W>G"2U;3U^5DI&#AX[T<A"AMDNB$Y()"5^=CB"G#GHT'OCGF?\`
M)3()?*TK%O9^Q8NIO,2HJ5#3H!V,CRC^+^B!]<2FMV*^B1,<C$$99$!Q9JF+
MB:933=??3%QOE9XZ#?:QJ'\DW'H6F;"M2T>48(3&BY=:L`BDF9%H!!3<A_BP
M8L:ID>"CX6^EP$([D,8%QPIP!=N^D`VW'W@O_O"1$/8:H?W/*[E=IN;)G\6J
M]]<Y@U81L)=J;%M-*I[MMI)*J!5!'!8O@S4?[%J%JK'Y:GQTQ<2)\X^KPJ[Z
MUI\F'Y],U9^1"6>AI2>HJ5O(G56XX[##.4+/X',3D?<52YT^9L`;YP\'0^QG
M=F_.V'DM1]=8=SVV([,]H_6$MPTN74M^0Y^.FB,!/69$WY,&'YJ]Y)/2@B6(
MP"NFQ%VI-ZQFPO@.P7G]ZRUKTM^C2C1)/87AXS3ZD_Q%JJE0UE>A_P`G//+!
M)&SK!>HO*8D4=?N5K5C8@G&GRIF?D8VV!-VIPB.*6BW&O@(UXX+=E5'3=OVN
MA-F#GCKMR&]VU$O=JU/^1:]"]63Q;[@'=S"PRU>VRN%$@I0UA1=.E9?:<^-\
MR14X$CQYP->DPZA`KT]<\+M^5CR2/7+X/0I0GOP)(@17NRIY-G)><GI.5<#[
MO3C\3B7/7I8X<D+!_#WP]!,O#)IY21%1V+"&?U>(T>X7<JZ0=..S*08*IH3^
M06)V!YVK:V;/E<F,2Z63,S?LK'&WY^*"*:KA[`;$JIU&2[*#QN,QV6OU6B=5
MREHKVW(2W[PG)T$=)]]<-`D6>>=O:Y.V9;8,5N>>LQRTZF4CBD2YN%R-@K<4
M(L[RZZJD*O$4@JX],&I6XNSTB[13A?AZL30TZTXZY'[9!5)?RY^4*0)KRM],
MS86P`K^5/*[4<W@Z-#X43G5(&(O/77+5S(23:2AG<I&I-0'UE&*8YX31*M1(
M72;IN@$K#?-OY$M!&\H*V4=E,QC#85NNHA,K/'#`XYMR\].OG2<FX9M;'9=3
MIFWD4`8)'UG\C(MVK-3GE\Y[X>+O0B=7RO\`DRY"R:4-9;(^;`UIR!ACO^+J
M*4N<0;10W)@,/F!M>=$Y!S'V,L-;7<[;S=R^:)II]<JE6:&PCL.^X/17D*'Y
M.\M>#FA8_1GABY5>LN2NFB.B/+-XNT'K.VO+OY])J]H(=*<?#K:?&]_+H,I@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@<??05K>_GWH&RJS@5>%F%/C#]:IPLW$HW.4SIR(-W-,R4
MW-&ME,XVK!VA`C*B<CC9(*J8T\Y`L5'/Z?QSK;MP&EUMZ4_)`=2#_P`5JV(5
MTP>R/2QDM#?-UFV2<!S+8(>^3H[<8)HP!L]KMP;7=-=3]L\=!$=-.4E3>ON.
M'G`8B$6K^2",URT6F!*P'C40880LS(7_`)*/S2RT2"<-M*8$Y:G$8V88O9H)
M)V:%C\+06'#N!K<4^Z([<;X63?-`VTC</Y..@0F3O:@0*R0\_E1AK4@F&GXX
M-K\S7M@1D/&(P6L05._C+X_9((Z^<.'+SE%AVV&<+)<[1VKOL-2L7T?[[5:Q
M.*UU#[@FS(P*492";D?)DYILH80F*Y@`9="V2A&1E(D>J17Y'+9P2XBW+CX-
MUD4S**G:F@DSS3<'KX5<U7>?;$0>D4)]Q:EO2`Y.6/;R;U]659SJ8QDN%.I.
M3:#]-&RR\U@?,.=]M=(:8-)!KGZO3-/7`;Y7%A^Y>KX3''XFY94@UO>50UT,
M)UW('9,M`)'+O5I!G8O%A%I8\<L!<;80B")LT4FGV'#8YM/7'*3AEPS"+1,X
M]NUC-;CB'8VW)XK<M_D'=82XG5<GE`6O(@[]*/:[.-$B;<HXA,'A$.\YL11P
M-M]R,;$72R[OGA\OT[U@:K77H#\B)&&5'5?,,GZ4^=,:Q%3>X["\SS!%$/'9
M$!\A##,Y.MG1&,QDC-0YZ=66L]&)+<=H=1S?;IN@BEQMX$[>?KC]X385ZK;7
M#%H35QJ%Q*1.*E-2F'S"/Q,!.AYRS18EN;.G1<>C$Y@/4:CL?,O"`<H122Y(
M+[V]3X51;-`@$/[/_(5-WE6VC$?/ZG%.VC7"5P1.)(5Q+Y5+7D6DSBSUVL..
MF0FMPX5/XM"8M%S#+DE(8RS-OI1MDDHXUSKIH'YC/H'\G,DATM*N(HK$]0D9
M,'HPC(/-UD+%;(T_-T8UC'*8MN!:2@.O'1$YEJG_`'"'D5EE`22O3)XDU<ID
M`ZI>;;"FMCU!!S5F1&6PJRMQ6-K3H)+(8\ABZ,A("&SYUTS9*N2`_M-32NNU
M4F[I7MFKWMNY3;.4U6R03S@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@>#@6,3)N#28Y@F8>,F@UV6X9M^2;H<P7>.6(]P_Y
M3TZ79,G)%PHBEUWM-/M=3KG6M]];V'OP&`P/*_8,2C%X,)LVA$:1:.&!`>_;
MHNV+]B[1[;NV;QHXX40=-'2"G7"B??/7'?'6];UO6]ZP/JBBBV12;MTDF[=N
MDFB@@BGPDBBBEQKA)))+C7/":2?'.M<\ZUK6M:^&L#ZX#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`XV^DORON/-5[VIY_D]+IEYI
M`"X2S03,9+EN2$V\9#O-EIWS;'H`4-6C_/RF8!)J*DT)Y$_6Z:N3[D+I1ZAR
M0^5,(-L'\LOJ^L:LM&22GS5YS5L*%>.X'^04"#COHB=GX25\XS0G)HX]A1>6
M-:0X?#[ICTD&,.6RJ+%>,GV3IRNV>(],5$NPLI4GN_TK-?<,V\@2^B8&)8T^
M_KH!:5D09+TU/XML].J'"72KH%.AWG5"HXJT']R!`>@C+I&`(/?AI1)#YEVR
M:H0BE^62^C_K.T/,4(\QPLHHQMOTSY]I642B=6I"`$ZN6A*7ZN*-1X[81FD/
MX-<.+/3:KCM!P4D,R8,BFJ3<#E&35SOD-_X_*Q,3/X[[W_(L&\ZKQ>N8@<"!
MZ2A=FR<F(FTX9-)A#JGLB0V&)BT6E;V$LHO<!*0"Q[0<B:?EQ\?X?)I\_J#=
M#@*Z2;\YM@5A7\ID5L>.9P(D8GS=ZOO&)-XL!O<T!G?7GJSHS`H7)734Q1$=
ML&IJ-MH?(>GO,IF0,)P+Z;=<])+H*(.50WNR_P`PUJ5U&9K>*OGBN27G3^+W
MK+S15Z_-S%$+L)7AY5JR\YV_+V#!.*\<QZ,57-Y%Y\.#.%&A5\:$#EV)9RT[
M1<+(-@BEG^>&=6"YC,=J?RUUW.R-F5;3LUA,E6NJ93*K[//>;+HO*VX)(ZZH
MJC[/LDT9K*0T\H'26%B7+,@-?HF>E&[+>M]!W,&>@(")<^?X19\NBL'NCT'%
MG!6#5L]6.!C,K-QJ(CI78(V*`I@&CDO4XB+1]]1PB1',"+9#X?<MD%M=I<A3
MUC^2B*Q21>P!GHR,QOS@Q\\7=%:3K#=AVC$47-U&9I20VY8<LH39K.8I"G\U
M&N%U&#)9^Y6:CDN5G^VR_P!=J@'/FO\`\[T\DT9KHO(_+(6/%E"Z4BNL"O8L
MR#GH73A>;>(H+'C41B<NJ2.RHS/B#[W4!?M1Y=J$&&0@)<D.?KM"PM3H)@K7
M\Y%;=4+>]T^A(5&*@?02JX[>M*00;9/4A+WE`[&I2:7G7,%'NBL2C?Z3=749
M@KQN9&HH/AS-;M)9%VNCUU\@1TA^<F:QEQ37=I>96(03(9LRKNXUXZ=N-8U$
MYM*)YW$04)B`&8T'#^NIQ#`),%)),-DR\=TH"D3!<*L3VKOGD-N!?G5@@'RC
M;=TWC7\1@EWPX#%I15E`1FSG<I7NT99GFZB?4$#8160/(,#,:+Q^%>A@K&5\
M(AWG(]VT<KM-/$.V_/81]+?SRR*J5XJ_M'S&W_:NXK9S&;$HA)K2X)]7#5\<
M]:'95#(D.G-&Q!HS:P(EY24"2QK(G08\%*RAIT@Q?L6BCMR$_0C\IUVE5Z=Z
MF?G*M@XE][`'>,O0YR/7-*#(ZO9]-WL41K66PMV]J(4-(0,NVG`U!=W)7,;[
M=2)=,".X>/W#;:@=N\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,"BT^L3R>+N&86Q-ZQ'O;9J*4U]XO,VD3A\=<EQL?]()59/D8VVD9`APMJ
MJU%)R)=F]K?3X04;N=Z14YYWM4(0JJ'?B)BL'+UA54-\V1Z">M.6T0/Q$;%D
MQ@RT0S=TR"1R+FFA`>BHR@FWTR;,XXR<;:!%%S*2(OCKM[QRJ&]6.&_&C!O3
M\@O"R1]/1?U'&FP242*Q2B)09*MJ`@45A@/MX5;:3$GY"(C,K"LTF.MN2*#!
M^SWM'22B76P]M45W^-4U>;?TG4T0H9_Z!L"7OUFMBB12'<\(3^;0.1DS3UNB
M]2T\#30U7\,,)$''*#9_]F-?-''?.TG".@P$6NK\:)^D4J01<U1&J5Z(V21W
M4DMCBT6CK5>L+:L.02@N_CI5DW;"_NK'JR0'AOW'TEROZ6Y>->%=(J[X#:_2
MEF^`&RME%+VXK"<2K5+V_3DX`.QC.02LY4S1F,F-D5"237^BR;!I2\;,..&1
M%RS:$R?:#=-3I;?RZ"*3D2_%23BED>X%J:IZ8-IXIS35I3\15ZIV5DWMV=Q*
MDCL?D4:2%[+,CLS`S$8,,O/M$G[^/N>-K++,>^-]A@[4$_AJGR,GD]I!_,QK
MLM8T<)R0\[%=-RIJ>5U5LC@D9F7ZB);MBIAG&J;$&!Z$A0[5&<Q]@]U]UMLU
M<;2"ZL/OOS!$(9.(G7$UBZT;\OP!ZO)(I$%'9EQ$8-70\F+=IAF:7+AS(64>
MZBKL8ITQ[=Z2(LU&:G6G7':6@AP/ZF\,=N)!)HR^AY.2>BG=,+V<,;@F:$BE
M#>Q0U=5O%"=ECY!^GMGC.%P^91]G(4%>EW``8X;IO$./J)<*!!T.B?X9Q#>C
MQ,.BGEQGS&;4=S>E6K:.(:?Q^R?N*J8ZE2'3MCLB):_4)P/3!X2VF*^GN-]-
M.OIIB>N`V7S_`'/^+&+4[*RE4LZ3JBOK[/."MJP0A$!\>7/')W$EGYQ.Q8GM
MD]:*QI"((N4GSG?UHNP8H.$_K\(<*_`,3%P7X>JS=QXI$HYYH`D?+LE/"8NN
M+CW+PG"Y3*3\Q82%8.GPQ>/I<1:R*#G^5WJ7)+89<,_Z^JV^S<;3"0M]?C:\
MWQ`MY.:06HX-4-V5C(KB-0@-!4R52V5"Y@<AE5K\]J"QY,-+R<P5DP@4)$MO
MNG#D:D@@S1TV;H<<AH9J._B8H5]0<J?UI1((3):3M#JGK#;09*10C^$+7A-2
M>;?21)F5$+*2S=[O&_"S_P"L1+J24BWX[4Z?NTUPQHT#^'&L>Z\?#H?YPBK[
MS.=[?5IK]E.DCD-D,T,R67]OHXS6#J&920_=4$*O_K<)D.A1D*OW\S=XSZ^F
M%S"GMOR@'1D+E[><'VUB[V/C2KMB[>%6:A.4-N78,6%=BF3UO)B;U#OGXMAO
M3M='KOGA7GCOKGG8:DM^0;RFHI#N@%G#YH/G,RC,`!E(6GU(D>Y1,I-7$9C"
M*X]GULYP#,;M4*_1,\M.PW8MXDYY=;X7;?6"6Y=Z@\_010FA+;7B05Z'.%HP
M^%N'JBIGF2A-0K9&.M@K5!P6('>/XD1_2;1NBJX<=&F6D>.]N$M=!AR/L'R^
M)AJMAO[RKM&$H\][[DO!Y!P+WTG#HY8':*2[;2VUW7,.EXQ_]+C72OT7J6OE
M^?KY<#9)%Z1HB'M5GDNM.(1-NV"0^2.^Y.2YC_3(%/F4L)1`H]2+\,UF30VQ
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MP*VFJ4E!FYX[R!;I<J=G$R"2C+ZW*B.U`D,QZ^\R@`HZ0EKHA#4478!B@M;1
M!1PN_&'W<W9C2+4>U;KD5F/U*TD/;A7E+:;-N$>KN-I(ME5.0CJ/?D)\GGPY
M"1J6D+CL>8G"<>3*RCCL-T_(`Y9:,1-N&H=7:D@2CXIQ4!E\L7<-$17(I'[S
M[GZ/"_2(;2[]Q>2F7<H27O>"]+0X_P`Q<Z@U=O'SC@[^J2X*X8BV[)DX6D7Z
M<4@!U!ZJ.Y=(L>P[W[CM+39;?`2U)[MJ2%KNFTKL*+`%V0B(GW7!(H@A]`+/
M9`]BD,**=[WOC3*2R,<NS:*?'Y55TNN=?]F!@8+Z4H>RX;Q8,%M&*R*&J2N*
M0?DZS>*)-=2N=O8RPA`7M)VBV=)NIBM-!'8K?2>DR#<HU70Z40724Z")9U^0
M+R)7XR9$"US1XHX@D6-R\Z$BR!.2G?TN/L5RA)J/'BF2^R!U,6T6=\#T^MO.
MV;=9SI/[=!93@-XA/JBL9^PMTG'$)819TMO6I3T(CR\K>%.MIF5.6\/$0M:2
M&Y,3WT#61VQ0;??\N_@WVCI?7:?(:O&_:E1216DN>!=D!VUZ>>C'IF/%3D%)
MM`<;KL&#BT@?#9@=;]O!#6>IC96EWL&P6(O4N6R_:O/"?T.UPCA;\CE*N);.
MH+&8U.9G+(7:S6E6H(`7IM(K+K`7<'6[EB&$';;#&HZ%':BA;KLK)FP`:XZ&
MJHM5G#CMNBL%QJNLB)W'6T!MF!O^BD)LN'1R=1,BHCTW5>1Z5"6AH2NLW[WO
MMNOVR>\?.GO>]\=_'G?_`&8&]X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`YA6/&?'<E]6%8])[L
MLP!/I#9]4D)G3XYP;%4Y*;[BU="R5./I!*UH"NQ'6<W@Z(1\.#LI4/X)]#1J
MBS!TKQSI0(#C/EC\9L!DP:6)W*X<R.H/3L$\XF.SKN!+(]^@#$JK&6UM1G<;
M1J]F'A3]>4N@Y!!.'-(\H_7+/'#UTXVZ=J8$V>A?-_C^.^BP5SW#-[F[M*PR
MSR7PR'QH;)K!ZZ_ARC3VI`H`#P:M9?/1T-$+PR.KN&*KW09J^?K*H)(N'ZW2
M@2A7/EFLX#Z2>^B&TO&\"8I5\GCP2/EB+Q(R,-WA<$SNZ636P/U=ZU9,2#4A
M-'HR+ZVP:/&(HL3;+++<K\\IA'O_``'^2+*<6&#1M:>R8$:L2;@[&@0^RX[T
M&<6CM>S)<@((_81]&2,I15;>ZR"XQHB^2[2038*$4WO3)#OD-I;>":1)]SEI
MS>-V&#=PBIF)ND@VLF'(G;E"%UU^'(R7\@H8P28"HB_+N.6J(%$,EQP^5:/-
M.6BNVVPTQ2(>$;3GUP5HP*S3FZMSF*D)9+_X>SP;.:VD2?55BHRPCTZE-9=1
MP*!.N*D"NDVZJCH>4237<?!5IWWOD-R%>"?,;=!VLXL"=R-(-4IVHP;HO8@!
M?5>T2K#[+K1E`@:XX(PY1BL+&6`>X8OR6WI3EWK7W;YSIJFFF'@!>:?$WCM6
MPR;V8,8*/OV,3J.\BY`7B0]3<:DTA)S"P48<2"QH7.#_``Y/SG;QPX)OS*H]
M)1!-#MNU3X3T&%COXOO'[4EIWV3DLM5E8X<142)'()]]*_T]Y7C^3R-:01J&
MA)>;2FKJ##>RR?Z@H+1VZ7^P;L?N/Y`CH1^/;R_6UG1F!C+M.QT",JN</;`K
M#AY74<)V)#V<M\Q\L^)\3C<(CPUC!8VWK<(P<;10'GB>S':BI)7E9S]4)_/_
M`(^?/A0>.X;S&T(XH+IMC0#PK'YL)X(FZ5$QDS'Y%7Y7M_'2J&Q\I$&-*$W3
M1)L417:-EV3EDIQUUV&@O?!/BB\8)6<G`R4B[C/#95Y44J%GX>>9,D[!.VI/
M/I@P\^B<JBY!Z697D;:H($!KIPV8JH;2Y2=M4G/(;RA2GE[T>TK&65G:TN$I
M4"+.5+7!^O30L2V&.Z7G<59/C0E"81`J(E?4!DT"V)V_00=@7*+MZW6Y=<]I
M_1#<E_&U!'XG2<(&2:6)!*!$<=`D@TT&O'DC$GI%$IVJ_GSMX.)K%>)%,J\8
M&-NT/LNUG+=72?>FZBJ/00;2OE7Q9+;9EM^5?<TCLN6KE",L*$DK$CIM@R:6
M"`GTT:*Z*,HZT-R$`E&?2;Q0<\?D"7;-@Y9-.7&D6B2'`;O$/QZ^9H')@MG#
M99.-_:-($VCJKJ91ME'U&\3BZ<1BJSEV'C@AU-GB@A77#1V9=E73--7IN.5:
M-%5&_8>P%X$\TA2D++1J63<>:"-ZJ#Q!^RG89VX<:\^\42V!-V[=X&>LRRZ;
M+S6%;E^=I*?.GV_W\$5%>>T0U.>><:.-^C+*M6P+991J?W`I47\%&M;%=\32
M*$/.\IC3"0V**&F>)D"-30K,Y9'`4I4T%[$ZCP4(V((]?155T'H$_CK\OA_T
M?[.Q;,[C(V1I/VL7<66!<1QY:V@<-#'YH]7[`?KC^?R<97;+L@WZ?;8\JZ<+
M-F3;M=;KH)3],>=/+MOV)7Y>[R3IC-9'#K'HB%"V$J=@^Y,G8T:*/'+G]+9<
M]]/I9"(^(.+1XHIK7Z)HF3VGOYG?6MA"1WQ5Y%F1P^%EEY364S.70Z2S^PW#
M^SH0@:G@.7/3,)0LV0MPT7&"A[4#P_<@A:PEN,%))I\HJ(+*I<]<A\K]\>`@
M-J@[Q'7-U4T`D-R4E*[T2)Z*E"%A2*+7;6!RI(6ETDKT-T$+SP.S%-DOH-W#
M-4RY5[<.TE--$PEA[YP\M658EQ2;F7F5Y@>L45';#9-)AR+T,GT/5H*W4(^-
M;+L4%T'K<?5<7?*\(=J[^R<+[UUS]7?28:W"/QV^=:X*PQZ,G5D].`<\0EPP
M6]ET08!#IWF3T?9`T5^UP<0"`&;;B0^;X^4[X#M1[LFOP_=/E7:SQPKT'T;?
MCTI*-&%I@*MV[HO)0"KAO#Y8RL"*-"54Q?G^-18O"8>NZABK-F!<C[ZD.UW)
M-,@:11^S63?I*L6RR8?!Y^.OSX\Y,E&=D6Z*>R!I-!2TC&V&`4(IU[:!&TI1
M-*];$248(\+1.3]6P46V[7TN<1X0:+MB*2S;2VP2W\=?EF80X/`>3LJ!@GP@
MT(C+</*(J1Z4"')]8%N.$`#:61J4#W"H\S/B"H]^DAV0&(-FJ[5PBZ:INM!M
M%U>/:ANM4:ZXM.9@C`NMXE#$&`^=#RH*7CZFEK\Y6A.PT2S4E*9(G#+$*KJ.
M%6A0>H27<=H/E5^OI:3#TUWXM@$6I-]5!"U;$E,M-2"ESTEN#L]%^9_JQ?/C
M"MTZX>A4N(RI$QZ414J@8HD.="GG#GA-;9#3Q1PY45#54_`?F5A7A6M59Q/N
MF#^2%^21U]8PGN4[GDOI>34BX<+/E1.F6I0ZB$[<NT&_;;>MD5$EM(])?VCH
M)AK2N*$\J=RL@/G+EN]MRQ0(DRZELF8$WQBQI9+5&`H4P:#F++34F9E5C)\=
M()(\\);>);WI)+6MX'[C=&TZ*8U+%(M+)4!*>=(!*O/=<D.3#=K(!S4_"(8.
M?.4_UX(HQD\F%@8R.=M7?#9PTX7X5WVFIK2B?(0W*?*'GJZ)3:W!^Z[!E4GB
M;LE&3`\[(*[DB=-M9`<@][2R.C(_-J[-A'\>DA+N/E5.9"U/-AB:#1,9VPY;
MIIIA<RLXY7E8P.OJKK]P+8Q*%P6/QZ#B$BZ+];4,C`<<*$N$5U'"KHFV1&\-
M_G=[WW]3?>N^NM[[^.PS$-G\,L)J8?0B2"Y.R`2(I$R[P0O]TU9R(+M'107T
MXYYTDJNSVXX^;I/?:>_FU\.MX&WX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%,>/&-=<7?;OHD^Z4
MDTXF4[B5F01I)"<V4K^M)/!*8B-4@3;NNVTZ9P*6&AR\85)I%EAS4HUT[^BB
MX3VW27T%<WWXSF,CL_=LJW5M1`W=$0]'&(R,@K;]MFK7A]S1FQXM-&[GN6.G
M2;@;6NI##4.M]K?,Q-H.^NN^QR:*P31Z6\D3;T!(*%G&IW7+*84_&;*`F&TB
M@EG.8?)W=FI5WLD8$,J^OBM)9&^Q;J`?]W;N3)5#I![WRIKI1)-;055GWXI9
M+8<UM.=G[LA;TE8GZFIP,U49T.+2=/;1A5F!W17]MVR&4)N(5J*J"ARJ_*ZK
MM!?:Y/I]M1=!4/C_`.47UU,(A*%KP8*[CLQ:RA_^F5H[A#HF^VXHN0EY<W0K
MNQ(D#'6.5D],;1^_Y9]L4@K]!KMFI]AO;P)EIW\<56>>9;4-A"9%"PQ.J=U,
MV3*LJ\`Q%X:95WYPM.DI&+V80-;78-K%/V,K+"/'Q6UV_9_!;3A3O[I,)&NG
MQ'S<;J^7R=H.([J\I#24AY^WC.B/[;YI^/O`G+9);F0L-E>)'IW]7:G_`'?[
M;Y?AK2OQ^;059F7XAJ[V.**Q*PHY6/UY$S-<IQ^N6<6"EFC/?DOH+7\N5CDK
M`$"D#>R7S2N[=,DG#?IP[E2ZG&^5TN^W@2C8/XX8S.:9\UT82G\37_@G%9O#
MG;J30-Q+UI)&9L.&I2=E%64EGK\[&&R*@]JVX27(%D>0_?31776OI=\!X(5^
M+\/`_2\4OD)9_P!,!%YM(IB)KQO&S@5C#V;V>7[,0<+KO<>GPJ.1V)<M+X49
MDVKD2_0>:%:[321TZ^FT#3+-_&MN46D?,MKJJ2/$9V>LB0#!)6EASZQ[$"3*
M\HS>TK"V%,%K":EYLRKMZ/;B8\[&L1SL$&Y:H[6^&M[4#?O'WBTE1%KR/@Q,
M.3L9KR@:HIBO4U'0?3R06&RK6`0R_+[3C;0N>*1#=A@*Q@0_D>]>+.FSX43<
MZ[VB4Y46"`&GX9^D@E>C%KJC#']C@8W!U`4(JV1UU7Q`%&X?`X@E9J43B=O,
MW[3T401@VEEY+T35;]<.M(:9_!OPIV&T2G\2$;/I2*'B+<AT<#R<9-G+_8VH
M1B5@!>I-Q>HY0#%S@Z:C$0U6GDKS4ZDHG[%3HRZ8J[^X0T1[TU"QE(>!XEYX
M])6/?HZ:BTH=+&DT&`8)L.2`-HR/LA]6R?,-461F7,#<PF(:KYLQCH]&/-5&
MC9URWY5U]'>W05T;_AVC"-3[@3>S8]&Y5]FV`*6#`ZE:P\J0A`2@X?2`2"$N
MA\RZ,]Q`HXA#8X=')$$FI%R[=II<-NU.'*830=_&W&YIYEKWSS)9J$(L89(?
M04OV]5AI"21O4BO2N[XA350"`F,XD3T6UK<K=FR0WYR"^_JBN.4=,_J<;;!%
M4C_$W&N;$%SP7<^X1$A)9H7U'`D>*Q!I`6P@A%)4[,5:YB\_CH6'RN0GXPX<
M&B#MF0;/4U^.U6W72"WW882L_P`0R$!80/[6Y(Z0?10B/VH>_AL>>DGH$01\
MT%63P&^/6P?[C,JDBGFMKR:<L]Z8/D#2_'VOSM^%E@C>X_Q53**Q6,1&@A5<
M3A`[6L8J"0(2^%1D3"H&0%PRF(6:OYA'5I2Q<M+7.)U9MUJ1,/U0N/265:;9
M$-K\NFP6Y]._CO*^@+>,VF%M2(PYX9&H_0(R2F1MDS:*E!]*W%2[,/$)&7EP
ML4/K<JUMY8L4!N1COAV0:J[TKSI[WT@%=^_PZ.-AT$-7/%.RB9PM(U^/X6'&
MHQY]U:1:SA<$?NV-IMY,\KAD^E9+M=C]\GMP6;#2/&D=MUFK@+XR3R!Q,O)@
M7R3*)ND0B4=1H`(//)!Y&F5?Q&DCU525X)..'L^)'7A67D8`^2_4$B:*[%H1
M1U_WA=IVX=!4J4_B7$/IR-)PZTA<;KAC>#*Z$H"7@)*5D!Z[66T!*24?83@C
M8"4G=-)2A2"@Y]IXLNRTW,;4Y9]=M>.5`\3G\1;#LK5YC^/)\P^@,J+K.G)\
M&>165@8V9U(_I\-'NXE8475$S.I*MHX!$433GM]P3X^Y)+M>%EE&Z@25<?AJ
M5W?Z/MV=K%F,2KM0!3,C@P"4#V,YA$WOR-R>*$9_-I;!V!T._>0V1U15L:@)
M4<Z=,U7XWLATC\G/?*JP1J9_%+(#L7*U\[OB--Z^E:Q:22N/-*<<\\(RDS6U
M\UBI&(0C_$WD1%:6"@;QVF,CZC1\Z:-0S=I]_P!(J=?3"7[_`/#!JY?0M?R&
M/*5S7%10:G(##1Y-A"&[^P8B3@%UB;-&!:9=,30!E5K5X,C38:^=<-7J:XQ?
MINFBGM+GK81/S^)82)$"HE$9[7$<C#&``8PJ]XHE@M,4RH_S<6\WG&(TNVG`
M\>VJ^1<'W4X5CZK193]][_4%'JWU%.=A(?G#PG)*0OR`D5Y"\.5'2U)CH^))
MD]C$"]OW@F1G$3CEUS!DQ?OW[NU(Q14H(!)6>>_0_=Y@WT23;H=)=)<!$-A_
MB7D4WB!""-+MKH`'<KS]O^X6WGIFI9$BU,U)D]&3VQK";V*QDDRM6*.YHXX3
M>HK#&+[GYU5VWSJ[YX"2VWXOPH>;P>8`I;77*XNV8];<T(G:39EI<^D,9]:2
MCU/R4KZ3H3,:O!Y7-=R7B*R0LY3+JDPPD=\$TM->4=A($K_'?'9?=<LNPI-F
M+D^7L6#V%$OO8*T?DJ^=Q.TJ)L4DVC9U<]ITS7D[&E/TIPY;\-N]-RG6^N5.
M$MHK!B+K_'(-LZ;VC9L<GD<B$]LZ9&Y$7.O:J"R5V1BY:L:'KK^&LA?NC+5Z
M8BW.Z1T]XWO?/VK@GI9LDDZ:).%`A(3^'B/-8(^C1&X6RDL=*F&K6PA59)LS
MP>)EHAZ.C7<`'.",W,%M0KM>_N.W0_I]]!ZU#Z04YUMSI9L'0;RAY[7\W5]*
M(B[*0L@[EUJV':CMK7,!ZK."1]S8!C1=:.1:(=R25J,!8OO6]:4[>==N5>NU
M=\)[[^306=P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P.4%[^9O<\\]`RE_!+X;A_,TH<-&#R"O)E(
MFQGF,3**"2-H,V[9(*Z0:/!,\I..#X_KAUI)$%8LN^/TNN$$UPA07XF]\0#N
MF8M7?H*3C:N@J==,U(YS<DK*%0IT;`/-PN3R1V9E;$GW(*^:GH%-TT8LLD]&
M;Y/\;0'I)K[_`$\+$Q:CO1]4T/Z!XFMPVN<D9SS]""L=-@9O9=QSD'Z&C.K3
M(S0U"`G3$C(OT,THK$4$`0A+31^DR71TS3Z56[<!!!#SM^2V5@6$@0M1_%K+
MF]>IS(L^ZO28C(=5,LF5<V81L"@!==,0Y0459C;?F@A&/2_?UGP@(%1VG]+I
MBFU(!9.05C["E=+.]'7#Y"7%?3,GLD_5T4O^20\X_H,HG(4(S48.\XZ$%E8>
M0`DWHDHYY'\H-541K@=PY[0<[4["FED^(O?EME[!'3&81EW##021LQD>-77/
M9K&^CZ/'8N!'Q;>3!U_LGK6(E'C4HZ:BX[I=XNK\6+CG2;OH+->HZ']PS*PJ
MN<>?YTV@\3A]<Q(.]?,K7F4817D""<X&3ML9B3/[B+ED70PF$[%.E1;YSM9L
MMWMP.Z:MONPB.PO%/L$NN%B2-B26PZP;3>I3H<9,/2=D?>Q4C&3GEJ;6!,)H
MN5'&GMNBC1RO)NB-CY)99D.6*I=->&R3S?8P-RN_PY=DY].7/=$&D96*;-Q2
M2'JPE`.\K"BC]G9RE&06N(6/>QP/SMD'C@B7P7]0)H)=+##"+AOMXU=;1[2P
M-3CGD+\@18M.&ME^D)L[!&)O+S*B\6NV8PKDU]:$^GTH25BW,3;-)'`@`Z43
MNO\`AR$;$&;#K4>^.V:O+/2Y,)2N[R=Z!F5@4K=0LHJ=G,"\^PRJ[-:`KBE]
M7'I]SW/HI*[5CL4E,>;M6L.6E_87EPH9;)L7KU)ER.[6;-W'U40@&+^'/:D4
MD#:P)-*QD^D#_EEJUFT(NJ6U7/+4$.*_I6.N8ZTMP-&PT@`/1\LKI%^^(I[8
MK'VX?Z:VT-$ED^`E>G?,?Y'HU<=7$;3]/MY;48!>*,[$9,)C(>C,D8L8L'M"
M1E&;):-#VZQ!YZ(&J1CCE15NFM7#A1/KA)3O[3085YX1]$-+_NBX(#-GL#+F
M+,=2RMI*UNBP7;!ZPF=R4?,Y?Q*X'OC8=U'F-?Q:0"N(XZTZ$*+K?,@FCTXX
M<-PWFC_-_ML!YLL:`VU;CN86F:GU(%XZ7DT]<RIH@A!S=;/[9-BR[H(X*!`U
MA.8\5=LA7:BJ2/2^OD0&_7[;HA'2WDSWU'F54-XW=\MD:X8C2!Z:IRKT79SX
M<3F;*#1L1=Y`^X^`Z6/H07D8ATZ8C1Q-$:W6<]]Z".4W2R:`>*N/(7M2E*X%
MHP*4&2$BB7V<#C=>$O4%C=0C<#_@;<4$?'TNBX@T*:F7%XS`#,^EEV*Y1)B,
MY;HK:4;(M50QTV\9^SYK'1[&4'R<NGL1FKZ4MY^^]3V2SC$J6,U[:$(ABP*J
M$P'[:ANZE93IDD6UUO?$I[8K+K).EG'U.`WR.^4/;926B1<\N&7#X&G+B#BU
M"<3]%V2*<VL$6D$[+PM:`AP3,&[HT9"(D1$`20L,Z8\'54M+*[4VR3=.PDWR
MM47MZK;4.2&Z99U:,6-UY6<>)Z.7%(3GVTT;,*Y%2F1PL#^DBXF,"#TA\A?.
MVZH5J5=/ED>>23U)RITS#IY@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,#@[ZG]E>[*E]CV+Y9J:*=6(2(17KVC2RS2N4B#`KYFJF@K$
M:6IYZ(FF:7**EA2_US#(D&8._ALLD$L77:&_G9)J:"DCK\@/M.0^=?3LRI'V
MDRO/JF?$=8^LRMU1/S;6;-E67HTVZF0N6>,I!&5XVZ"]C'8]!N9_27B>[!BV
MAGT2C]7E^EK86\J_UKZ0#_E5G/CBTO4(LW7]:&JCB\<$R%_Y=K.86WW+O,T?
ML@V66KQ6N4;.G#EY/3"W&EX<]%CV/*.D>TMZ;N-=A`L<][>X;+_)!<7D2,7K
M'8N'-7KZXH.`CTJ_J:>&*>9P;S]W/Z/M@Q6P\4.M9K%F,\:=<$Y+)'[N+&4^
M^!*"*#YXV=H!,KOV;^065?B*OGVVR(P"!>D9],8U%_/%9@(<G+8=3>Q=WP?S
M&4X*N9$%;F9^O/IN//2;I9^A](6,+M&B7&]LE'#@*,#?S$_D/MFMO0:]60HT
M)N&Y[%\\Q_Q#7S/SR2L.45C#&,1N(AZ2E\S@PU!F;G@I<YYX*I)*.5N="_W,
M-[XZWQ\G&PM-6WYD97)?1U/RVSIW$:-\@V-(*T1DK>RX^-B^ZZ>2_P`$RNW9
M%6\HG9Q!@L-E,6]'A.Q#CZW7"FG3)1CKX\]?#8?TCB2HTZ+&G`SYJ4#F1[,J
M))L5N'+(B-(MTW;%\S<);Z37:NVJW"B??.]\]<=:WK^3>!D,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#D'Z3_)A+Z$FGK:
M`MJDC<ADE./J1;42W=2TD/YMYM+HU"I?>JY[Z(1VI'=T;%)<D77TUT[^[8K-
M_C]+M3?P#<I'^4BK4-V-'(!5MD3">Q1P=2$"VO=;\Q8XW'0R]YEU-7\L:6$N
M+'Q!JV\[R'3[GYE#B>]-N.&"CAQI'@+7^?/3$.]$>>`WI.+@C_[1+`SAD=QL
M3\39Q&+:>,C2X*/]J_N)MI<T*>-6;(FW'E^MI<Z<-&_?>N-!5B*_D^K69D`R
M,6K&S#1R3B%]AZQ9,X`E9^SPAG.Y1(QIQ5]9+.'1AT"@$`?$EQA5^Q+)]\<H
M;1VNLBCT$X4/[@K?T#*4(Y&8/9L:&E(E+YA&9=-!D1'1V3-*\W5_[[9,$A,R
M-GA[R-=W$"YZ[(,6;9UVHXTV55TV4ZP(,!_E;H^2<%E058707[CB)@Y)E!3*
MKR+0!700'74G(6,N8:6@J'+@$PMF#^^6@MP0*JKI+I)M>]\)[5#?HK[WATB5
MOJ5EZ[ET8IBF:$C%_"IB6;@79RS8J;EUYQQR9B<9"GBRK86^2ISZHY(MT,*J
M]/N?N6K;C?/6PC=M^3V/!)`1AMCTM/8E-N[D-5(&B*!JMBA46[T1`1B$JS+D
M?/'O#7B93`UIJF]%?J@EJVWPLLYXW]1/@)`\P?D8KCTI*XO6S2OK(B5BE:Z!
M2N0-7HED7A<=F+FM:\LV25UU,Q)!P@J3`A;*8<HO5F[8>152<IH*[51VGT'F
M1_)I2!%!9Y'X7;<A9`8B4G5BNV(**M>*OC<-9P9S;>Y:F6F8]=U(*7<V6$:2
M,0)Y)%$73OOAJ@[VW6^0-W#>\ZSE$UIROXC!;2DTDNMI%R\?18C8>R9@8U)%
M[KTO)Y4\-346FR%@&%"'7+KAKIX[6Y[:)M$7*R^TTPUZ5_D/KN*S$M!^ZENP
MN:_B44J*!_I0VN>6MJSZ/676-52@;$5REDC?TD9'9+;P;M=^?T&;*L].U4.E
M=M>N.@UIU^4&E!HZ(E3%>W(*9624IP=5W3@+"5U)^AZ-*SF.>?"PY)A/'G0,
M=;4JKHH-:?J_Z>X%JZ06*I,&J_+C02L/]UT\2@EMS]N'G_3"DD08R?B-`QFS
M@ZRCDOD$%XIE%#1W[#=EC9&&;)O$%G*`]N@:'..GFD%^E$@BFP/R=5'54@>1
M.P*PN$'*!47F)DU'&7%624R*D4+A4WL)Y!7#2-6B5Y3.F(K7[YP-=*=I"GFU
M6W.G7.U>OI!(M9^S>K+N1.O=5!-X)$&U;WY*"4VG#Z$<)N)CYZLVM*KL2'!&
M\5F,H353B,LEY)B0>N^FK5=P-Y58*.V:NG.!$$?_`"M4C)VCMV%K*ZGZ81P:
M>2Y1DPK)\RB,)!#J0-/;!(%65GN!1N/_`*/Z!`*\(!5BA)7OAXFFV[VAQM8-
M\BWOL"<"^AK&*U588"IJ4H*M?0D:*.$8R\F-M06?NKMVU.1".#I2[9M6)8;4
MR2@ML5=C"72KWKAXW:?+SO81\1_*-!UY$^@\3I*X"\Z!V=":RD88LC#Q(H68
M>W165,6JQXEK*5&HRY-U6>LM+G[?;E-`\LR<_IKAPW14<\ALTB_)S3(5DU?B
M:XNN9M^J<9WT7_;(*#?5CM9NZXA%E\E2:9^P@6UR>AMBB&/+!G]TY5(NOEXY
MZ0X[<<AE;?\`>X^O?.Q6]0U72UV<C\XNBN"M225Q&1LGW.Z4@EORL]&.I&&D
MQR%LD7[JJ5-(%4GS]IMHOSUKC:O7T^`V.Y?;@>DIV&@YVL[!E<@/UF#GC&&P
MEK$'$D9*N(Y=LVD:),U)YW&(=RUC\4HTMUUI-WUVJ\Y221Z6^X3UR&HW7[O-
M5[.J;C%=T7*+7!6_#ZIFX@^+D,3`OE6EIV;'H$,CC0%*#8';<]P-/\D]N'KE
MJ.232[356XZUO`S?G_\`(W1'I.SAU7UT#M'E^4CC8RC(3D.X:1EF9W7\(LPE
M"S!!B5)*")$)BU@,-]*+)Z&N'B3INV=+*(\_5#3T?R>U0X:LOIU#>WZX:A3J
MVHS%.Q-;)G9'20MA8!$U;;13JSOT-@"&)5B53_3'KUM('"W33E)AWRZYZX#$
M+_E*JYZ<:LHM6T_)`Q\X-AIH9D1&OX.]"5^)IV][7:VF.C$GF;"0N(M(.*+=
M(CE2*`I!XS?(NTENM:[2Y#WQ[\IE)2$:0--Z\N-('#I`&CENF_TJ"N1=0.91
M8)BMXB1DRK:?*.9(%DIN/O5T5XTD<Z09-_J.$T>NTT^@]\6_*5YPE57&[);!
M[4'OQW;78.M"L09L;`GC4F'AA\0[A'*QWF&%TGHR>C^5?J&4-,G?UV[C::B/
M7Q#`3O\`*A3D.VN"=0NPQ<S286D+)C23:#%4X/8U9,[DV]A\Q'QRPWQE=!V1
MI`QP@2')N1+KA1KM%YO2RO3<-WB'Y!8?)I+<1)_"I1%Z0I_S]+[Y<6D:0'*+
MS,!7<^L6#3@A$XN#,&S7(86M6C]1'@DB/)N.>D>N6V^%N>L#7H]^4&IY-L*B
M*I[T"J\>OQS*0-5HM#&?[.3/32L*_BSTBX(3YFWD362R>XP**&P'1?:/*CO;
MCZ/;%QQR'PY_*YYK<G(&#$`K=/=3M45I!Z$A+8FV"-7:=5-3KDN@S.KD.UX'
M)KB%ACS1HBY>CB3,FGM+O]/5WL,-!?RDP,]!Z_.G*DM!Q()TK"H0);PEO#BL
M=DUZ20?6#TQ4D0?R":QTMMU'N;68J=E2S08&71:/?I.^U&_*:P276'Y'J2M6
MY@-%`HM:S&;$29*)2/LE%&2H2O[)#"YJ7+UW,"@4X810*C&E?D.52333L!TX
M[:HIOU%'2>L#1)3^6KRW#C$\C9L?:B<EK?EXE*@#:(C'1!L4$&['C4D!M=)R
M3[=V4B<@@@]J3UKO2+/J9QSOM3Z9+?:`7:H:[(UZ#K499D5$2@`.?%I.`<A9
MB'Z"G1IF'R0I%3;=9#E9TS>LMDQ"O;1ZT77:/6G::Z*G7'>L"8\!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,#GM,;8\+&+EN2"6K"HEQ:%:OSK:2/I95#L^XEB<EH^ES4K5B4A'1TT
ME)2Q6L3<=%/`J"VS[MF)YYTQ49HHJ]!JH"<_BVCL?-6*%0H@"'(=O19TJO!E
MQ3_C96+7,L]C;P42CS<T.3U'TIVPV*VW2Y;..RHW2*;I19MT$A(65X4@43;^
M@AKJ+#(?<3N35/TO'H9+R"$O/"&LI+3V*FJO!1QZ4_=8D?6A?H_P_$</FB`9
MSR]^GI)76!6&Q!WXKK)A3JFPTIB4"$N9=Q'W\@JZ!)+<O70==D`71(3.15C-
MH>_A(HG88\;V96[[&#'[UBS3>MU_MT<"?HC=7@>HFT#C<*?0-N+&U,@[C1$.
M#>GI`K$[*4I,0)`-!C02_FLODEKIE(JLX8M6SPBZVU:]O4N>NF^^@B&F[J_%
M4I"&Y.*QJH:\0FU4:/$HL1K_`(3,NH-((_$W+>".MBQ1=B:DCZ%HQ_MM#V;E
MT:T'_3>4F&F^FW.@E2%6?X$BU52V\FT(AU<POT+,K9K*7:(U:^V>M3=536WP
M,V0D<%%@"TD<1%KV#E)MXV?L$4!8]Z]=$46G:KS6@Q@EG^,2-Q<Y:`""U'S%
MJ6M()"GLO!U6>,MN+>?6`+3C;"/NQL6?KVA,.;/,M^6+D7HPL@:=]\I*<.%5
M==!@(GZ)_&+3LJCQNLD*_"F$OOZHW*H#7!O3*$Q2*5O.Y>H7*D6H))-A6RD5
M\_$!2,@9\N![Q:/I,-..^!_7+4/.\(?C3JA755V$0C5@S2*VU.;3,/)76QB>
MS%2X;:N#A"1E#2L%KOD-S()W;#YH-9#$FJ*99ZR:(-FRZC1/Z8;B]L+P1Y[3
MK&\X=7$-X2OPH.ED+GE7UXF5E!Q_.)Q%:X:&VPH8/U+$F7ZUZ-5^^^FWXX%I
M%'_U4TUG'22H:PC)_P`=]#W?Z&:RP(U!6PUM&/6+9,UG%='3W;B22H4)NYH>
MBDF8QLCPE"ZY91P:2,$T_I#XWVR9=DG2>TFW>@SL_'>(ZKDMG0<GY=B#\]H3
M6,N8"Q<"@CWBVUO2\[/4@('P/M^_0;_=MI>^68$TU=L6PIL>TXXWRB_6[[#3
MXQZ&_'?74>F%<.)>I/(KZ.EUTVM;<HF,")D(S*G!**M949E<[=<PJ.@',*E4
M&8,1$/)-6*P^2MQJ#=@X?.N%%.P\-D%_QWUM6=4W)$*`IZPH_:-BEZ6BK_AO
M6-;L&4M'P2X.YA^^C5U&(&)C<F:A(-(8^5Z*]\2!P]<:&K\][4ZXY#*UGZO_
M`!M%U#-^M0<9@5B6=#VO%D*EJH+$)GV#G$;;V`:!R8I#@,JC1P8^B49;R,XL
M-?OABH5%J9>+=,56[OL,TVL/\6=1#)6/8,Z9C89%1_"3:XRMC9`;*6_#-JVD
M(N/%V,5(-K'!1<92R"!E4.L28@&L531?=M4AW'"(94;;OXRX*TN!C']U,S&6
M))VL"M9.+UL?-B+./N$)Z8U&$%0$3)#K'9!6S22N72`GI^R#\<OU%]-];6WL
M/(4MG\:[V<SON<M*B$3\T2/$9^0.191RUVYJ683$^V-'IJR$NH@#/.BOFY\=
M:(JOFY9^K%M*;35<#M:1"5J1KWPC*(#-I33E85,P@_+F;0RQE'%:]0;H<JW9
MQ[B<Q6:!)B`CYH*U8"HZ*2<LGS=%%LR8-4M<<(H)<\!HQWT/X4E$=%#'X"-R
MZMYP3L&8D.G=7FEVCB52Q&+1)\\Y@!*,)S>6R:Z6-_I("^Q@E]W(1Q-TNCVJ
MVVIWL(_].>LO%U`@J,LLU6\/LZ/3^GIX=KJ;#R]0!.$*CJB)M!I8%'R]LS&&
MK2`T]B5U/V8N.L55B+[AZ1;_`$N.NU.>PD]U?/X^2LVA'ZNX@J<YJDNI5D0=
M%ZVD[=:M'H"1P<:^!<'5HIH+%P$0G#@".=/U'28@2=Z;-.W"3SKE+8:$_P#2
M?XWJ%;S>XXB)B3":U=#BL=7$0:J)(,L%2.1.")&TFX`"M%Q7:,3(0^'LFJ4H
M[TA'5&K-F@N4Y011UP$0!RWXH:PKF45OS"H7,8C7Y$P3,KF*\)R^6S2P8:]M
M*.RL<P9<QC4BG#@!S&)8W+/![9:.MVW)CATMPER2^`;XG9'XI9.')D)+#*B9
M.9@/"6'((\?J@@3=%3!W;"/.0`78N-%P,WE@PYZ`[%%@L:<$U4"LD>I.$?K.
MG6^@_P`N2B_"0"KH/[?$`.S55U`R!W3#0%0M(-W'[,.D9(+/1:0N7ID+R?>G
M3TN=,5'2VSHQ%\JGSHKM9/A7G`ST95\BW#!85Y)CU)$(G7/K.!3>T">Z^:Q%
MY6/;2JY1#@9:(G+%BY4W%RTL738LV/Z./[?]C!##IFZTPTFV1Z"'']R_C>9%
M&+(UY7$L3$=]>F_!&FQ>OZ_XT)*!$9MV4N(LLZD6V?\`!G0Z4G/JR)UUV5^8
MV];J(Z5=ND^@GF)>AOQ@1XG+9K#"=2#C=QAI6E/'@FLI#HQ*XX#X`20\UF(C
MB'=/VL>/.;A&.V*+YN@UD;^6-NF/+QT63^X#T@K<_&/`TN8V*7J&*=C0'[I6
M&$("<%%&7Z.7'62WCY3DU&4BB%E#RD$9%FD5=;U*.-"6RJ##Z;='Y0U8/Z$_
M&')FT;=2$354"5B-@7I,(T/F]?:B*T>D0*X++?V)-C2'05%K#'UCV;4AV0H,
MC^V!4V4$=N?L^R#/K2(?*U8I^.D_5T+L(A4<>2K&TY(!@+N>1NO]01P#'4FR
M7MT8*EC*1BH[)`L9+N/.0Z/+?39:=D.>1K3?6F^D%D`QM3^E?Q^L&,*N7NH$
M*&<PBIX*JB9DM9MT351=G]VX',5K+$8'S+/VK+ZF'04[J2D7.]#Q#`K_`%Q+
M:+Y;706OB48\5V[)9ES$H-3DPE<B"6"1GJ[:!B^RQ(18TQ2K:R^Y.]<A$5NE
M9I-/.R0THFX[TN^<Q!+ZG/>F2?7`61A,&A];QD=#H''145C`K;SMB&#MN&K1
M)<B^<DR;Q36OBHY?E";Q9TZ<*]=KN7*W:JO?:G?76PVO`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
MYQ6G5?D2]K.LNH#RUO/K#5LAK)Y^ZA,6N!:+Q*P)-1-9QP>W/ST?""E2"$']
M1Q4"LJ)+/E!SM-SM-ZW6X>J-U0TB*^+_`,=LW#+P\(783%(+';*\X_,M8JB^
MG#V>S\1Z8/-PS7E1I'3<PC$JG:1`2\'M5^`[(NN/1URU7<-=A*A?R'44@K6E
M:LKZY9)!XO3EOS6=O3D"E,='S:3')A#K<K*6Q[HZ#;,@D97?R.Z5/N$&8SE)
MMTFFR:MVO>VZB`?-YXL\AIBA,;''2$4C->BY(_.Q@!:?8T01JZ8S@38Q6'SY
M)=XX=J5>M+(BW71^*K53A!!=MRZ^V</$EPP17R/XJ#R6%1P?)"43L2Q[*LVU
M*I=1>Q7RDNXGME%(_=YR50I/KHPS9@PXWS^BD&36;]@&05@J,22Z17^AV$)D
M?)/XVJ9GLGKXM-R\3L>$4/$[F/B7DO(K3H3$Q!8-6$5]+\R3]#<RXK+@DAK$
M>TVY3?NF#8@T2<.!_*[OZSD)DC]3>1;>AU<TE#K>LDQ(AA+T;9H24A)E(V-O
M[5D]CS2#^EE)J;7!(]@$CMA6$8"/&)%H/70?)=\#$T'`OE1H&6BQ[P*'J&"0
M&(VC%4:M3]?"(C6[47+R#IN3],1Z\6DZ&UO$7?&EW4A1#66APDHV:[<,4&2*
MG*JNFZ2JG(53YIC\6D4$VO%'LUF=:AXG,8F"EX21,+"J10!W>8:ZJ?A-91]0
MY`(H7EPJ<L+8E"+#Z*I@OTGVW<<O>6[1EVD%E:CI?R+JW)_50.2W)*KN"FH'
M<MC+V0A:(XP:?5W=Q^<1.:?N$]#XS"CP5[:"KY)#87OL:^:-NT6O&VK?KY`G
M,WXII,W#:PA.^)D*'TX*6%5X2#RU^U.`N5;`KJSDWVWZO#CD@0:R^K`ZZ?;E
M-7CZ:2B77/2:O?.PQUL>&Z:N&;3&?2(K9@8[8`+F)S#40G3Z/L3</?1CJ&3"
M*+-DFZ^VP:PHL@P:&/H=I..MB&2[15HZ1VOV$IS7SA4T_G]*V3(@"ZLCH'<E
MU7:;,D\8!4&TI`H@'K`Z$;*\#I&P'I-&[H>D[X4Y8$&R+I#Y%D^>L"LI'\8?
MF,V`1C<@W9DC&L@;"&"N3U@$":@BM8[&RT=@=7,?N&W274(KI0MT2$)K\+/=
M%4N'#MRZW]3GL)SCGD6EH["*C@&P;@X!I>Q3MKQ5(YL8KP]G<E!6-'S)@\+'
M"QL==H.&5IE^DF2#)LQ:*]H[;HI<MTN>0Q5F^,Z@M%U(B9!W/8J:E$I?2@H=
M@DQ?1HIS^MU!'*)E$>8JHI.&["-2FLXFQ9.VZ2?*G"[?AXV5;O$TETPB62?C
M)\SR8(TB[G^(K.*1R0EY'6L0;3'[R(5`\E*4M1FZ=;Q8Z+,@!G,T3G133M=Z
MW?O6>G/.AR['2#?20>>6_B_\Q3)>P5B?-A(<6/P"9&VK*6(:9HA`"1A!D#1;
M/`SU,JDV2-K<L7Q;]2,@N4V^@[T=IHUTB&=E?XZ?/AR$SR)C!QEHM-'IF0<N
M9!()/)QK.6$!EU,AY9^P_<`<N69C75\'''2/)-JY6[^WZTZ35036Y#8?/'D<
MI5$4G`"S[=D]T;M5:Q7MEB3::R,5D+ZQ7S1-ZOIN3(G))]09%!Z09+KHE]/I
MKOOY4DN?HIHA\A_@VIF`-0;W-KO*G6?\-]0^>G+/(F9K6R=2/"3B!MZ^>/V:
MP<`S&MRBC9XAMBL@:1^/9+AXNHNLJ'[F7@JE)="ZJ@;4S:<)!5)`K!K`+W")
M^^%%I#!+70CJ5D@9F8?M2Q`]N9JQ=JN\>?.B0^Y^HJFNGVIUO8?@G^/[SR_'
MQX*U:S@#'@2LK:/8\`G!AB)ED0F4^$6::KJ6\=].'9*$=3($U<)()+-W22/*
MK;3C[9T[17"+A_XJ/,8@9*F`<M<@=Y-@#R&2F1";(<#9(<K\L%)Q^0P4J59B
MT>B8J4BR"?ZJ_<<JGB+IDW>+D.WO';A0)+DGX^Z!D&F3EJK8L3D`EI*V`*71
M"=DA,F`,IW)[8DTS;"7RJ3QLAQ(^[MD3);?:*G23)VGI#:*S5LND%?6WXIX`
M4F!).;SPJ9I>/#2*-)U2+:DN$*PD1F:5K/7\YTM,9#.(R6E6S]:)=K[V'38$
M]E'_`&[:]_7WQ@73C7FJ/12L3E/A9U9HJ#N1L.$PU('*U0$@K-K"@4>',%8=
M)1#=J33>$3D?_6'WW>W+=X\=+I*H]M%>V_0>V!>9ZQKMS7!$(E(79FL^K>=B
MCAH\Z(E#AZ^9,WFELRB5*?*BV+GYA+D>R"JFDDD6ZZZG+=)%+?*?(0](OQU^
M69;*C<PD4.-%"LE=DGAY%Q+3VA110S=<COLOIR*3=\,_F)364NFZRO//*_0;
M2;#2FFZ?/.@P\/\`QL>9X3%R,8#,9GQI\!<@$3G$FX%G!*/!ZJ)-&B8A2/#`
MHQH?@YZDHV[%OMM>W'W+'M9WTZ5<N>U0\Y/\:?FX[*"\VD/=C2&82,>S[DDL
M,S3M[*CDY%B4`@.U7,JZ'<R1E.8X-8M$QJ3)VU`,?L6NT1G&VR'R!\&/XR_-
M+.4-INKNQ24T4XE"LFF!*8Z6E4U,2>269+OW$>DB(IN:'%P$BMPXX'Z"KB6B
M6ED$E4%D63--`-^;>#?/G'G%UY:?BI&6JLA-F5A$6ZY_L457DS*P1ME:48JQ
MAJ!$QH.Z/B^$EA8AF/&=L%%FWV^DW"VE`TFSOQG^7;78ST;(1<V9,K.M"QK;
MG#8/,GR34U*;6@0FNII\C,D@49"6KD$'368JL4VS\.07=.F#ELJ\=]+!(M-^
M4F]33BS[&:31TVDEM^@C5TS1K%QRHF/F0/5?OJ^B]:O6!LI)G"81BY==RTBH
MS59</YJ]?OTT6R3M1M@6]P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!S7L?\?:T^N3T/9*=APT6(
M]'AU0DD^M5\F>VI"F3R@Q="$.:_L1E<@:),>E1(O[]+9&)$NDG#A9/>U.-\;
M3"J4M_&1:8^R@+N*KTZ;"V):5>SBT)1'ZRC]7!JB%5[:%13I="BH3^O2HO7,
MMD(BN%N%#3!Z55*DEFNG:#+AFD\P/>P_"I'1U?AXD,]#2>-R`"Z;J,YI&HL5
MZ?D>(9`H@RIHH?9S"R)AIW)ZXO"K(=8?:[19@/(%(ZDQTR;M5.NM!)"OXF8Z
MS*,58Y9X<>$BID3+H@-*U,/-$C<C'N*1=N(U=9[F7CE[9II=W2:"B<:^D*41
MV1WO[[KIDSZX#-P'\;$BIV7QRQJZM6O",QAI^>6;'^Y;1S1)9O9TRIVP:F;Q
M0'*`DV3,0;S-'M3G3\=!V2#GMAVU^1,CUI3>^0E;U;^/J.>HY+,9PXLHY7<W
M-P6H8/%95'`(]^4AHZO)?:YF;CM]/GR24BB=T1"VG@`Z(<<IH\HM6SQ)33UN
MU6;!8VJ?/$0J6UO1]L`>&&C7I";PZ:2--J#:#%1JD0K:,0%`;T_;K**%D'K\
M(\,=]=<(_!\7==;YZ44454#1>O)@?]#D`1.5J(\FO5L1]0MG*<<8\]AUXI85
M>SW4$8IZ>ZUR-([@";+MYSOCOA)SOKZ/7R:XZ#X'?(PF0U?>D!(31\N=OBX"
MMN2&=.0;5T3'N>I!'.HD!:L5'^N%F<+KJ&B8PU5^LGUVS9:5WQQUWTG@27$Z
M;?PV<W!8@R6-7DHN.QX7)33XS&NGG8BNX5#(Q#AE6!NFY]ETDQ;="BI-J]ZW
MUPW)R!XMTU5WWUKL)VP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P.>
M7I3VA8?G"T9(`*TW#9'5<7\W7'Z<?31E;AEC.W$/I'NO14HC;*NU:D<`^Y8:
MDMCLT!>E)(FQ[:I*K.%V_7RH[#=XIZAL@G6GJDC(J/8H7?Y57+,3E20JQUI>
M"GY/5+0^\8F.A5@/X)%GO2\G`S5J,Z^[!(=-2Z*W.N5F_P!)PJ%:9M^4QLV)
MV`\J.F>+1KJK::*>BI3/7=D(1)(W3T0@U/3V?.(`+3ATD3D$["";I8)M!;MT
M-9.W8U^@N_9*IH\K!_EF_D9M>H%+7W.Z)J(6,KCTA4OFMK($O0,\?B2,AMVO
M81:PB6FFX[S.\.A(R,AL[:I+IM&91[T5X[1Y2^W_`.]X'3NNI,YFD"ADP>)!
M47,IC`20*I1PD7,`.-F!S=_SH.5/QR'FR`[?"^MHJNQ0YQWQ\-J-TNOCQH.;
MMB_E&CM6^JIKYQF%(S@9%J^EKUG*K^6*-^*S&0(+Y$,>HI%+%'6Q'T_W2(?B
M^(]^VMN-/5D%]%^5?MN.T<"$O_.:8JH><T$*,"\3&[0TET6JY2ZT2U@-;(AM
MUB:9D]+U0WA]:RB.6Q8C#I^L<1X<D(XP<B4-*;<))]]+)!=?PY[>"^Z(I(+"
M@$,X"0&*+,8<;/.)8W+.MW&U2[?SV`#0Z08>\6#P$:^&<J&W'VJ11Z]4X9MU
M&S;3Q<*P4%^6AA=<O!1!6G&`=U)K.K:",%@UE$#?8<?8THOB*I.Y*SD%8PA;
M]Q`75'=N'+8/LP'Z0+H<Z+<K\;1[#=+I_)@YIV533A2C5)-7`>Z3OEN%2EG8
MS<;*9AZ5&UL"L$1%R$.=P]4?%ZUD;PPL&XD>R[UTT>L%%E1>VJJ*O0;(Y]^3
M")^D(!XXLFC@03TE9D<%3&&1^+W`E)(/(84C,)\/GDV92TI`8J1:B(9!($J6
MX8NAJ!HD1=I#D6FD>%B:82UX[]9F_3S6>_N>O@-6R&%:BK@C`=3DJ8LJ'=2I
MN96ZB-P5W+8!6TPKF=1Q<+V@XWPT)QPIUOKL07()HN.D@Y]0O\U+6:PR#GTZ
MAKV/DYY)*F&-7!VY;!W"HR.MJE;ON5@VE1(;YL>V!U+H^C2BHIVB)BY:/*N2
MS91N;5TD[2;A>TA[4<,ZRNR8-:S1)RNJ_0-3^:([&&TTZ;@Y_8US#//2<.?Z
ME3Z*-GL6AW[I]",VSITL*<O$!X]5WIKVKWRSY"`(/^5Z&&3ME59.8",A/H.`
MWL)H$)5#>QN3B=J2/FPH?7,QD]>R!:&A7+J(QDE+>7B?;L>V>NV26_F0;K<K
M)(!<&[O0TLJ2X*8KT?7L>DL5LZ-W'(S\M?SXA'C433J")MI8Z;CHHA`S[.3;
M.-WB:/':A4=]OU\W76N]:UKH(J\2^^8_[2AL@E0:N3-?/8A6%1S.810Z>9DS
MT5FEB!9<0DM8F4VPYDB@3@K^)=)\O=;Z1+,WC9ZCPDBKQKH(1\C?E/9>HC-1
M1_NHQT:?VQ(((-2=1^QR<G&QH?87F.W/28S@FG)ZQK8^]D8!K4Z@4DFU8*@^
MER"2[$N]VDZ;(![+F_*.QJ8&4*?P?3?*,K']"5RDX-6`Y#`T'%#^GJ'\U*2`
MP\#0"6&FP<^ZO#@VIPS'/W;)L+4;\).E5N.^`M%(/49"/^7XQ?*43B\OE$WD
MM<02'1&(321<PPW-K>MZ/TW`VW4\F-;1&2#(W^X)4S7*/G$8Y<,FW#C:+1UT
MFEI<*3P_\M;B1^D@'F)[2,?:V1S8`.KIC%0UMF3\Y7D:EQ6]4\^EU31E*GV@
MVP*HJ<=4_<K/%BA2,O6L:>=K;8Z<M>FRP6!O'W^UI7UQ"O,3NOQ)=K*65`JN
M).O."P:1Z<^@;`M:OQ*D?C6Z[(PM\,A+JKNGA?LM*P3E=L^Y3&H/GB?#5</#
M9_Y(895'E3RQZADD'VFS]+(U,=5A:\Z!"GL"@LP@W5IVE,531=DS;2A"FJU'
MD2:S1N@W<&%6B;9#Z2KGC?(:G:?Y*G=*UY,O1]C4X)%>1XQ=I2EN+>9VBH3F
M#9>*>B&?G.53"0U<SK]59N"?25`L\`("BAAX1;#$^77#!1\EI,+<F;OG@?R?
M(_13JKPK*7A:FD=N(54^LAJX8]#!(9_*AP$G8T:C4D$I&7D9;)[<+#V90>@_
M[Z20<.V_/+M0**SS\LC.KY,Z@4VHQRVFO-+4;;87@78J3F)RU]:0*:GYQ!HY
M(R,*%.EC53#P(ERXZ<,4.B;`W]RDDEPR<:P+G^2?6`#UM377H>,!6D>I@RJY
MZK^5O9(@]<RX-'F?#.:R=^)V,'K1`,(FK,F,9ION]/W;8;]\LW:<.$D<"C(W
M\NC:6TS$[@AE+"&XHG/[)BDQ*3VW/T*LX`,C(.(6%5/<KMN)5W/(M#9)Z"J"
MQ`A\)Q)>0,>%*K.V!4RV<->/N0MIZX]D]^:"M"`A\:@Y=U>Q>:#F1ZPK!D<)
MB$<3AL._=W6W)""5;<9HL\,\=Z0;\(#^6^OATIVOKG7.N@@IE^2XNB5A_4AH
MQDUB-K38S"*DD0*T%"[X^[K[V+3GC6U",J!$*^!=1-BPE=OHGH[I)P24,AF7
M?#SD2[4TAR%G+$]>`*S(>P4Y!#RJXCR'1$.O4X_&$FJ[Z:#94`MH\I'A`Q=L
MU2&$6"=5]I<*K.>TEU'W&]_2Y2ZWT%2W7Y60%:3^[J@]+UW&*;L^G88P-CF0
MRV>IG$+0FAZ!:LR/5O!I*]KZ'D>S3F+.FZ;E=T-130(?43XX62VV6<A+_GGW
M<=MPO;8F?T@0K`W6`7]?=5<.D,@F_H-@U3EA:)[;2JD5ZYB$FY2+Z')$A)B-
MJ2B.$V3KY$R'*R/RJAT5P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!#=B4!4EL%R)JPXBA*')
M>H+'H8L@^?E4AY&J[:>Q4A/HNZ8,WS9MWR=<PL=O[K7.GC?2.](JIZ[[^8/K
M3='P:C`I\1#>Y43=RZ1]RZ92R>S.3V'.9A(_T,)%FI233"8$RYTLL,BD8&BV
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MQ9?(!4_U&I')XNP'EXJ:KV31R40\3'S`T9"):'E%5`"B),4DT=_J([EQUWTJ
MHMTH$A4]Y;I2A"W1JJ(NZB;Q>NX;5Y)-O(9`[8&XO7KHTYA2IT:_).6!:21U
M&0O&B!=9/HGL>IPT[7[;(-TD@K\V_&/Y38M4TA["W&!$88&%X=)&E^W*E)ZS
M3$R(]*V8*K3>YKT\KV,]'Y,\<.!XO;9N[WVGRORIPW;\I!L3S\=?EPP\-NY/
M')Q,M2,4];FFDNMFS#S!Y*R<-"UZ5MOAJ\E/2;&ZR,-CC%CW+6WT3B>D-K).
M$W"JZRH95'P+YKVFLN5C\RD\C<NX.5<SR66A8DDL)60US/CEDQ&3\30K)'!Y
MF?&222/D]K-UD>51#E05WST,ZZ:;"1J1\N5+Y^(2(O`$)F[*R(#%8;V3GECS
MNRB06OH(XD+J#5S&W\[D!]X#A$1=2TFHR9(]ZUSV^4VITIOY/E"``_XQ_+<>
M'Q5`#S=8<Y`N8DP@$[8^BKMXL.!Q6"12?PF(5]#9FI.%34<KH%&;2/MD@K51
M-@I^I=]JIJ*<)=IAMK_P#0I-_/'KXI=J[>S'T=D$S"[O^WN(\6GD1!P()%[2
MY"IR[ABPM(!W6`$@U/-^$B"1<:D^TI]S\RG0>81^.+QX(DH&<:JC16?1Z35K
M-VT^/RR8G)H_G-56%9MJQF:&I"1/+OBTF=SZX9$_*N5NNME_ON4'>E6S5HB@
M$TV5YOK>V;&KNT)BK-U)'6`F:!(PR"V%,H[%51M@BOT26MY#$0AAC'I/^J"^
M>4OF?-U^DM<<[3WSOG6\#PT[Y3H>A"-@%JI@R46(6F#K"/S]PF7.D-R5C3E>
M,*IK]5]P4)/$^20B`"FHY1TGKAP\3;)]..U5.==X$`!OQD>78Z)B+$!N[0YF
MO^H>U@<]9>B[MYLB%1JOX985?0N`Q:<*S=4\$KN.1.UI$V0"-U>!^^RJZRB?
M:^^5.0SI'\<WF$JYES]Z*LI0E+^VKY0GQ=%J(/XO(]3:MK+.S:!.$)8GN#3F
M;6+4$;.GBPW3=X6*"^5U^^NEG/U@G(KYTK^14OU1,L(6%,8C]R/)(GI79<W-
MV4T.@I<TGD6DS*SG9OJ;M)+#I<-9OA#WA[RNP59-]);URESS@1G'O!OF:+]L
MWHJ&&=2%G,:]L;]Y/)U-G\T>6+6\ML>:B9Z0E#P\L7>2H^;M^4<GG7:F]GQY
MUVP?:78J?;Z#9;&\?TA:]KLKAG`R7$Y&@PK,>4`M;%G8>NY<G3$VD%D5,O.:
MY#R!C#IFYKV=R=X5&]$6;C23OOCKK7>DD]<A',,_'7Y@B(T6!?`)O9<7CE;G
M*CAL0NFT;`N&)P*O9&.!!B\?@T?L&0'AL6Y<@HRQ8<N&G";M%DA]!-7A-17G
ML/;&OQ[^8HL[#K,(Y-G@^,R.-3&*1DY;-G'8=%)='9A'+!<R>/Q(I*W0!@<F
M$WBC(H><?;]=EWFE^W'S?>/-.`E1KY@J09YY)^6@;"3QZER,:D,*0CP&<2X6
M3`0N2.WZ[J(1:5-S&I-&XT-9$5!PUFT=I(C!/*;)KI)LDDEP$3R7\=WE";!X
MV(FT`+S'J)Z@?00W))[.RDG;NJWKB?U)%R*TC6D/ZN[))5Y:!P:Z655[[?)/
M?F<?4421[3"40OE.DXY$[E@L?CA0+$;\$\BK.`C99*6C$OWW7S"KB)H9PD7U
MU&)*?A0EFV)$1FVCM^NU3=K]]N_F7Z"+YG^/+RQ,2)TFWALCKU651QI"Y<RI
MVQI]3X66PE$)U&B$0DL?KN11T&8!2&/)M61#A5OM5PB.9?VSGMHAUP%CWM/U
MX^DU5RY2/IHFJ48R$;6O;)X^8,8V/E$?;18PR3%M'*(YZV5!LTD$^'"2ND-<
M:Z3^7K^7`KB>_'SYID+F:NW@:?-59B97D;+0BV[+$)5L?)7)&/0LC,4VDPE"
M"=3OY?=T,%R4MV$TS^_(LD_J?%'GZ6!_CGP#1!$N5,G#%Y2165U^TJVQV,C]
M!6^9#6[`V.IPBSC]LAWDN4'SYNW86*6:<J/^%%M-''*/S_(BEK@->+_C&\;2
MED]2GU;&+--%`DM`&9M9-B6#-9\;8S)W4#D@J5F1N2N3KLD,;T+$V@MUM;3@
M6Q$Z0;=I\.7FG`23%/%E)0HQ,#\>4M)H6ED>-Q!D]5NJUG;FNHA)94VG$BBE
M1.74M5=5<`-2IDV=+-PW;3G7+1LW3^1JU;H)!;/`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`JA[>O67>:_-$[NB"1E::2F)'*L:CH>R&
M<F2TJ2EUNP2$E(Y'1BAB/MW<K-")&NV$\K/6[?1-1#:W?TM=ZV'.ZN_='I:T
M+-BJ`5[&W<'>^>8OZ`EC2"5<&-B:[*2NU?1D3*5!:TKG-U0:;1LQ5S>G&L>,
M+C(J2)J2-L6[6'C^>&[/D(=#^[OR"R"I_+I>+18B=MGT54%C6N$B2WFJ'/4C
MAJ+5W14EB`0<VC'K%^RCE-262VHY:O908*LB;%+A#YV*>OG6V'3'U]8/HJ!0
M:@Y!6LW@=9R*;W31=0S\/(:\5M0;PXNB?1"$D'8$CS-(&JW5AW11XHVZ[36X
M?]?3^IPGSK>MA26:?D&]*H#+UCXJ,B(*6J*EOR<V""MV8P8&3KRQSWB3T!7E
M?05O%`0FY>Y-MD\BYE\SDZ9-N(ZT4=(+#U.TD=IJ!8?GTM><5];0.M)U-(`Y
MILR7KRIVI^,P</(DI?9\II!Y8KP5-B,=MTA-O/\`9ALXVT0!#"<9?Q=]%-I[
MY*]OGB>VP5Z]4>\/8M073ZJ2J6OP4[JSS*W`NI,@?KATQA("(F/-S*T"4WE5
MUI6B->ZDD<GAIC\8XQCCGMX"[Z_M[?KOI\T"'+8_(S[(J?T&8\\,2M:6$ZKJ
M9!84XM-M3O0JM9P?G<B\Y-8>VMD^M=S%K04=:N+O<1IP89_K_/9Q!GO[;E9?
ME@N%E"OH+V!'ZF]82M]>E1N3M+>NZR\YPX@M02C`;H#(Y+1HH^;/#MW'O]3-
MKL[G[VWY3<LT4>QB?6^.]+*<\A#_`*!_(;[$KTO(7M2C:7GS^0>A[/\`-]:4
MP<CIL?(&!VEK<IN"<R22S!E,>=K<7&WEI!LBGT.:M@R\CCJO*B_";C1`+'NO
M><XF_P".*:^QZG1$.9`^M^50RM4%8@N15XB_'L5Q04=;$X64F$:Y>V$.B.^4
M7;)P7'-NI"CWPIVW2^;GD("M#W7ZZJ5A918H_AR#BBV=#-S]>V94+2(6'9CW
MTE(K,`L"Z3:&7/-0D3'5FUBC1^VX9.2VC*0\MPY[:_#CIH%E?Q^^F/2GJVG;
MU?S!Q%XO.HFO'XM`2\IK/]CR>/SF14_&IN[W9E,#+3G"G[.'&96P(`'J1QBK
M*(V\2<)<))](O705F)?D#]BG(E(YTJ(IBBDHK3WL2V$(?*`SVPW4GD'X^3U>
MU1<]?J2(=/@#%B#M:\I5($`Y!OPJ2'16/,'O;;IT5609!H]A_E(]+MH[3+B+
MQT1P7L-Y:7$L`P.HR-L6>`3A'J*TZG9AXQ7#FRH=R>E:,)KSOAPQ6=I+N"#9
MXHW3Z[3Y98%I+7]I^@8OX)\G>@A(^.E+2O:45..DR5,07F\_OXS-HQ*Y8[)U
M1`6]D@FLEDA$&";N$QJ<B?<->U5T$%B/:272X59A7Y*?8!J!6_;)D7`G@*K*
MBJZ2MWD/@T8+T>X-6M1-?3X'*)C9?'H%Q.QX\:0L5N<(#`P(F.:C&BC+1SO>
ME"'`3S;7L#TS2LPG,0XN"@+8Z\[QVE)O..Q5=O`YZXDKS]`[I_FK-CQEG&&U
M;SZO`S+MSM9KP1V0?'`NU63=+I1%V%4:@_)E[0M-K`Q[B94=5ZAV)#9M(YC=
M5+.8GH,73\NSOT81#(P@3Z&(.2'GJ1"Q8-8#8/9!@N006+-N&?3D:MTB%YO&
M/M>Z;TMN()V[Q%(1$+SKV4S.H8""C0^2L>>H@PKXD8`M[DCEC&2#2RX"E*7;
M.;Q>712-/F9/7'(WI5!HOTY#KG@<XID*_+JI+I3W7T[_`!Q-8'W(C/4*:S*I
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M_'?R_&F_5N]_+\=_+\=ZO76M[^'_`&X%EJ&9^WFP"P>?3TC\JF92JV9ZJI>A
MH5;D:`,G>F)?1#JP6M@SZ6$2C;LETPVCH:LSZY0Y<:ZWOKI/K@*T:$?FD^&O
MC8?XO?C_`.WX4WZN^'Q_]OP__#M@67I5G[?;PBQ4_14C\JEK(5;*ZJ5W2L*M
MR/0AB\_2'O*'5BCIS/I.>*MM']M^N]#'3/K;/2G.MZ4WSWR%:-"/S2?#7QL/
M\7OQ_P#;\*;]7?#X_P#M^'_X=L"S52L_;2%76*C>TC\L$[J53,?PE(U+"[:!
MU<Q6ZCW/,?W8H:8SV0RPJFE*_CV\T,?L]J#_`(<)[X6_MF!67](_-)_2'^+[
M_8WZN_W[8%F*W9^W$J8L%"WY'Y6?^AE=G_X5%:WA5MB:89:Z!,^8O_$&/R>?
M&IP4VC)]..W_`.FDV?U6&T^$?IJZZ4Z"L_Z1^:/^D/\`%]_L;]7?[]L"R\+9
M^WTZ'F;:Q)'Y5=^G%')C=>&87"[<'T.U9]-1F@',SC1R?$[!(.4GNGFWFV)9
MMRHETCI/7'7/>^@K1^D?FC_I#_%]_L;]7?[]L"RT=9^W^//TE;2V1^5%_5/;
MI]N'FX["K=:>?D&>WP_8WF2Q<E/GMC.W7`W3K2^VIA#CI?I+?.N>>>^>@K3^
MD?FC_I#_`!??[&_5W^_;`LRP9^V]>="#4G(_*_?K7:ZWZ4=80NVTO.G#;]RH
M=M]$(HXGJUEJKZAVE4^]IF>.=D]\J:UI#6TMA6;](_-'_2'^+[_8WZN_W[8%
ME5F?N'?G)NU;R3RGKUQIWSMV=6A5N]><NF/[J5[ZY;Q/B?\`%F<N_P!D?(GK
MKHUOC]5^93X?;_!+05J_2/S1_P!(?XOO]C?J[_?M@67,L_;W7G@&UC\C\JI>
ML.7+;<D.&87;CCSPLST;>].^0<693YM9+=SU'-MN$]KF%>=/=*=]:VEOGCD*
MT?I'YH_Z0_Q??[&_5W^_;`LS+6?MON@XHV@DC\KMO47"PG]\FI;"[;?4&Y;\
M_?\`Z[J*1D//1]ALEE/BU^TV\+N.>/E5^IKOYN/E"LWZ1^:/^D/\7W^QOU=_
MOVP++6`S]P*TC`6]5R/RHR]'IJ@_XH%[`A5NE*1>H<AR/,EU`8[')^'G8Q58
M_MITQV1*.])L^5N5==J=<=\A6G](_-)_2'^+[_8WZN_W[8%EK19^X%JEKE"E
M9)Y3'7LEP%_BX3M&%6Z9J5^IS'UN9%NN0<3GX&8B>%95]/ME^ID7NTQ^NN%?
MG6WI305IV(_-)\-_"P_Q>_'_`-GQIOU=\/C_`.SX_P#X=L"S-R,_;:]>UVEY
M\D?E<5:R2+'^++ZY(7;9^O7SC0-'DENNQ4)GL:D8I'N2?4[0T2>/.N6.^>.M
M]*ZWWL*S;$?FD^&_A8?XO?C_`.SXTWZN^'Q_]GQ__#M@6:O1G[;<1:O^/-$C
M\L!YLDBI_%1S>D+MN219ZX_31^D=U^R@$]BI86CHOIUUUHBX>=;;=)<ZW\_/
M?705E_2/S2?TA_B^_P!C?J[_`'[8%EO03/V^Y9077E61^5`A%-J3U9G?H*%6
M[*&3Q[M$1^C]05.N9]#UQK5-?E_MSHAT[[[XZ;ZXWSOE3?85L3$?F@^HG]6P
MOQ@[2^?CZNDZ<]6:4VG\VOJ:3WU>O7.N]\?'X;WK>OC_`-N!9#T4R]R.G,0W
MY+DGE$$SX8E-3[GT5";>E;ET2VH/_1>XAU6E@0U)@Q32T[^ZY>Z<J=]=)?3Z
MYUSW\P5X'"/S*:(,-EK`_&4H*T]:;)\#J?\`4Z1#L=I=/[[A@JYO%9LF]Z:_
M/I+I3CM/E3X;ZYWKXZP+`^C&7NMT9C77DB2^2P4>X&/=3!+T9![AEAEP9VZX
MV/4C2]9V%"V+09PQ^;2W#I-=7I7X;YZYY^.L"!P0G\Q')P-U)I]^--:-\EAO
M4A1!5%ZB;'%06GB.RZ09R0NYVP;EE!_U--NUTE4>%M\[[XZYUO6PFST2Q]]N
MI2$[\F2CQ^#A7(#GF1M_1,$NB5RE:4_J+W?2P1Y6MC0T2W`;$[;<Z2705<?<
M:4Z^I\F^>>0AR*BOR^<2B-]S>>?C<<PO@^'ZE[>*U+Z=92AQ%^2+;<@1C;PO
M=9`4T/JB=+<LU72"[=-QOCI1/OC77.PEGT(P_(.ZF8Y3RE*O&H2O=1UKR6:>
MA(!=LIF?<LT_);>KCB%;V5#@:4=Z%[9\I)*MNW/+CE;KI3?'7'/(1I`Q?Y:D
MYM$E+.G7XZGM<\2,/U.VD#JGTL,FSF)<OD-GT(D1D%S%@3&1JC/J<LU7C5PV
M37WSM1/OC6^=A(5_,/R*.9TDIY:EGBP+6?Z"/Y79W]7MY2>=;E&G+_959(E7
M=FQ&/\@>VFVNFZ6VFW'*FE=]J=<[XUR&C5P+_*^E/(FI;DX_'F_K'@XRZG3.
MN*L](B9XYC>E/_KBC$R<FN(U'V)SM+_Z@H\:.$.>O_HN.M?R8&WWN/\`R0.;
M`<*^9)=XB#59L4,TU97O75[R6P.3FN%/UE1P4K^T8G'>A2BOR?:\<L]+<<_'
MY^NM_#>!K-7#/RIHV#%5;JFWX_"-5\$];F[*KJN]&!K!<A_MU];3BI266^>C
MC(G]U]+?SNV;A+Z>NM?+\=ZWH,W=P[\E[BQC"OF^8>%Q%2=-1.@#&[JWOZ16
M,D\Y&-M'>C!6"6K%XRNU4,:6Z::19)]\-M\<J;[[UUUL/!4`W\H:%C1I6_)G
MX(*5'PN^_>+"H*R]#`;&<-]BG_(S4:+3.VY'&6:_!S;7I?;IDOSTTTKSQKE3
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MEVZY59]J=H_'2?7/7PZT&MV6,_*RM/I6K3LW_'N/J[LPXZ@[*RZM]'F)\V`;
MUQ]JE*R<6N$''7ICG?S?449M&Z.]?#X<:_EP-NH8?^1UM/DE?3TM\2F:M_2"
M7*S*AJ[O:,S[9[>D/T=5(G8-H2R.Z$)[^K]RGMIM;OX\_)WS\-_$-(L(7^61
M6<RU2J9Q^.YC6G<@)]01G855>E"LY;17;I389&6DHY<@<`^D";+Y-.E6;5NV
M[5^.TT^>?AK02'Y]8?D.;3=VIZIE?C$W6^XZ^Y8-//M?WA%YOS+-OAFQB[LC
M8UF3`"I'>!NGFETN&O+GI?I'?"G///?/017+!7Y>NY3)>X-//QNMH3V?,]0]
MM+*E].OI2WBW1%SN/H25Z'NH>)>'TA.T>7BK5N@W4<:[Z33XXWSSH)D\[,??
M+63G._6DG\@'89T!^6--_.T$N>*2=&3_`*@TW]8X\LJQID*<@?TK2_/TFZ"3
MC[C:?7U/DUUSL(-+B?S'=%BG0&?_`(SD@6R3[85(O4'J5<LF(VZ5V-3*+L[P
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M;2*9&"5DV<-;&R3-H]9J'MHLW''';M/E?`J5%H![;<6M'74*DGX)U[OA$(9"
M8HM%J)MY2THG7(MBK'Q@\#T)O#J5A(8+&.U&+=-O])DW;K=H)ZYX4ZYZ"X(Z
M2VX&JFZ(!:=G_CD:>V)./+2$@+'!9,&JDK`QT:#MTC%T5U(K*=6S(AXV"#WZ
M;MWV129<#>&^M?(W24UT'/P,]]"`XN/AX"Y/_3R"H8>%&(<,C(JLYRSC1L(7
M.(%Y!%V0AK?Z8TF,*27I-T\9<)J)+OM\JJ\=*[UU@7*L=H3(^13@2_)/^*PC
M>DUEP>>MWUC0IRKY%E)$F:^VCDP.PN9V$O,)'+7\&BC]NR)Z,=**OAWS)=;;
MM5$M!#0VJ/R$$9N5E@A_^$E_8\F5'AS4C'>>[P=S,^XKM>+R(8-)%&UUJ&B;
MF$.!01\BDIWWV.Z:L%N=)[1;=<A8%[+I=U0'=&`+5_&/QZ^83!\9GT">BB:U
M`('5+.>RX\2[IEE9:%GL9@H4=MWZ[EZ_[6W)^U':GQ[[YUH*VRJ.>\9?:<54
MFT[_``<2>ZMBY9%(3N4TQ<QJSN@[9,Z+F\=C'):]7,I['M45"C8HU:ZVFEQV
M[37YUKI?G86]"/;F-^<ALY\QSK\>;OT-RM'H[=-H!(S*SGG%V'KL8::K1\;J
MOK%9S=@M"Q[YHF/;E3CE(4U[<<;3YY4X^4*,&&WKJP(M"RIZTOP'32$MK4<]
M5Z2*U/:$ABR-VR$BO)7O[.>.K[=B>;1.EBRK];3+K]5=.'/2_7S]J;ZV%A;%
M*,8I`FLMIJP_Q)PCU.UG\5(>KY]9$>XY@#BUQ@.6,>WC#F+V3'+$`SQM)]D]
M"^Y&6>$6[/9!/>^ENEN\")8^7]YN&<:A\3NO\&R[*.CW-OPV+1^MKE5:`A:#
M@J0=6A&@@V_^DA8Y%V0?+*&VJ7"?*BZ_>UM;[4WL)<L"IATAB=3V)Y-"_B5W
M<#^)]IVE9%@5`E+HC(14J;K5Z5W5!6M9G'Y,UB<EFY,P&WP1(D$W23KIAWUV
MOTMKL(1>4A[=KLQ348?I_@J@TA!FC?7GV/O?.%P1HT,D3QPV*R+=1"U[G9/V
MYEV^[0=OOT=/2ZB_TUE?CW\G6!93TG2YJT&E"M_.D6_%Q(C8N)@66^/25+.[
M/:?I`\*3*56A0K6"RZ/NP<4&CVLK<L$OF=)<,M+=L]\<IO.NPAZ)UK^1$19+
MBT(P9_"T.LRRW1H`9G\4H.]&-B3_`'&'?#>7!E96/NS1R3/@*T<TD_146<;:
MJC^.5^=?;ZUP':C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`\SW3S;-WH=T
MUY(;:KZ8=/>%5&?+SZ7?VO3OA#M-?MKI?Y?J:XZY[WQ\?AO6_P"7`_GE,_DT
M]T4Y7OM*U;OB_E"1Q3QUZWH7R48$T]"_0"\LEIBUIAY&<2&=!A+N42DB0:!Z
MX]'ODAX-DT=E'Q\6CKC:B2ND>PVA#\IGI6SJQHRTJ2@E+B`EN_E4M/P&HQN.
M(W5'9&QKL'8L]C5>V$YB#Q[$I9$Y^I':]<*'0IEDV[;OW::?TFWT5$^@L!#?
M=WH1?\D9SR=;,*JRF:J*RZ;1>DV<[BMYB;'OJ-Q2J!4^96A3%VMPA;S393UZ
M;X,-2T`TY#RF/"Q2Q!15W])1MH.M)E\H,#EB27'"JH\:^?)IJ;WKA11HU57X
MX[WS\.M<=])ZUOX?R_#`_DU@/Y^_5,C\TN+T+UIYT4!E0/BTSNWHY7_J)>H*
M4DGIN[FM73RH+("/&G[KMRPZNB;S]R<;@;UYP[;-E$>V_'2S3M<)R=_F<]B%
M:3W;D2H6@FJ-+>*9G[_OC<M*VD.&7;Y\&7Q:%;58_P#,K==(5((*I>-54\3F
MPQW,&C_L8D3&,'+)3I59VF%K!'Y!O8]G^JO5/C:F:J\Y/;7\VU-,[T%FY=-3
M2`*RXA9L:C4@\7PE"+CY$E,8;-CSLF286.\?)J#X]I@P>,TUT3S+A(+<_CW]
MCS3W9`YOZ`XJYQ5="D)&.AU(#I<V)L;9D)B%">`E^E)N,65V)%!XK=R)>(B$
MV_'U7>XR[(=]]-WK3G@,Y[K])6G08/SU#Z+C\`,W/ZE]*1#SC7Q.U^I$I6D)
M<EH38EGR>;S`9$W8N1R-J&A-6DDV8MF^'JOB3AMQMRBE]3O04=N3\I=R^8K=
M\$4)Z!KVA&ECW7*"3'UP^@%FDBD4JN"R&[HWYBI&PZO[DJ4>-E4;,N*=BG#T
M6];O'4?&-2B*W:VV73[`IDZ_.KZ60)?D!Y$5/1$T:^0H1[BD:PH2'N^-DZE)
M>9_03RE:/2NV1R;A*$V&+],-0AATSW"GGW`AT#>(NN.=I]Z2#M%XN],V[;TR
M]1T/Z%C%<!KP\G61!8A*I'3;R3KU78$9M>IHC<<!E,<'3;C]V18JB$E78XL*
M>+/?MWK':R+I5!PGK@/5^2ST9;OD;Q3>/I6DP];R*:TW'FLQW'K41E"L6-@V
MQ-FS,#=*1`B-+M"RR#S6VJWS](\=\_VSCKG?\@53],>[/5'F[TQY[J>:Q.CH
M13<OC%`M)YZ!GT)]"*U#8=Q618[V!655<&MJ`,)E$?-1^*LD6!"+\62@NTE[
MHXU&\/6?:2SO`[,8'$>/_E7EZ%S$:-L2#02,2:BK4][%?8)9NZ/=CZR\E>38
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M"+9XN*`+2F0L_OW*:2JB#+2O?'/77.M;#CM/?S+>@O+]YCJ#]3UG295Q7OH"
M05;Z-N"FN;`'U_%:SD/F*I+PJRYA$?F!HJ<CH2,S*WV82;(OWC_EF,;=E6ZO
M"7>TD@O!^./WG;?N$%</4EA->0*00:H_&\TC78;N2%!"TG].>1X%?YQJ>;O2
M2;MP#BTOF"C%KRV6176&H\[[4^MUOO`S?X_O:]]^PI;9P>?4@&I\7YJ',J,]
M"J+KFW;E[[F!&7JEK0NH7KE7ED=HF&P;D*88G'"?;DOS+6:7&T^V#S2@6#]T
M^D3WDJ@?XYAQ,9+#`%Q^<8I/.I8\>L!0*LK6]`5K4UA2_EXR60^W?0R+3=R5
M1[6WMMSVT^*VMI_-K`XGV[_ZA!O&I//I74L'C5I^:UJ[])&Z/L6,PJYYK*)A
M-*4\?^:_0@=K,8W!0Y9]$8;U/+W<!)"3=M&;0"T':[>.&O?U.M!,50?E:]'V
MIZ(M^OU8M5,=@E/Q*%GW(QK0/K29D).O(?#-<^K2?3CT5%V[KS76>F<FG2@Q
MNPD+QN0<,6B?R<]N'C7:@3;^+3\J4C_(7(>XO(:V`5I)8;Y/HFU+@B:#HJK(
MH3>5CSBW`D@B7T'KE='JOS,!AT<E<8<[VHY=AY*CVHJI_)O07]]JVW<]%>8[
M3M3SY4SB[[<BC$"K%:Y:#C)UP12)RP"&DAY.+QE5"533]C10B^.[`B>^"QSD
M;M@RZY<N$NM!R^7_`"2>H#WGKR!9M7$O'L^D]V>[F/B^T7R<7])1</&E9%)3
MHP(36JVP$X1;%/6A&Q8#K<CA\EY?J,7;A/2#Y=OOA=4,%8OY:;IBMG7^0:-/
M*49IBN;(]I4'5<#L@Y:X[T+;%F^-J`<67*)A'2(,<1K0H!(6$EH9N*+<B2O[
M=Y4,(%%NT^F&!61?\^EV2V#05]!JBK>'3PE+O%%36O'95!;UM\Y3MQWO"O:)
MN\(HZJRDOOK-G?,+->81"L:3$-U')(#(N2"O/26^.N`L-:/Y6/5M12(R??U]
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MDI%)<&'G>&K'1P.RE`%WPQ>[00Z=L])+=))[[WQR'/O\@?Y'?1?DN^+&`5G6
ME,SFFO.7BL)[<O5I-"LS"6A*H)S<TLKJ91:IS0=1S$1$G#16+J%&'ZNQ<H/W
MFM-.NT.5/KI!Z:Z_)E9/H/VY['\64L*I`&2K"+N.O,-ESLH<D8R?SFFB=9@?
M6`>RX7%9&*DHQA7TEMX0-#Z:=M%'JK9ZMOM7A#OE,*;#ORZ>YD_.'A6X97$O
M,`LW[DL:VP@/F"TEZ\O!&MXA4L"GTA=:?5C4!*5VU/9&?D,(^E]P*:IL1C!Q
MM=UQ\B/:N!/A#\HOJ&(>@S0&25Q1LD\]U=9OXY:,MLF*'7!75TN9G^0.*P9H
M(L.%Q.>?<HAXO!;-GC))U%CS-K(>`_2OUG*;UMTBJ'?7`8#`_GG]7?CP]+7;
M(/3K>'UI6H/1^Z;)NR`6\E/@3&P;("3OSS651-J3Y:NH653B@G<HC2QL@X-J
M/A?W8$3UPR=;[Z[9A;U'SQ>Y%]Y<M3JLA3RQ*"!^IE7(^WY?5!B6F9',X9VV
MJ))[*JFKJ+0S[!W)T^$E568ULH,:?!3OE=;7?7854JC\>7IWS5)H[TK"Z/\`
M8<!%Q2R72L/E+AG60ES<GI>#UO'[NFIL'*FME"R(YY,*95+G7_&]D"NK,/*-
MF77?"K-X%K_-/BVW*A]+QVY)/*G#^*<-_P`@*"\`3D`!Y!ZYUZ&]+5!:-:I5
M<(8P<#(F[.012&/537)$D]^T=HH)I<\<][UR%2;`_&9Z<LNR9#-9/(H.FP]+
M7U&;@NS<>=J@YK2QCSY=7[Q\F3.+2[IP_3LZ65G7*J([C7+,*FBN'8I[^X1U
MUWR'Y\C?C]]90>94\M=4&ID"?B%SUCZ)G-ZP>8)D'^BT9H$K5T]JBNHWJ+LY
M*V%3^6%U?N57KY`=Q'%5>-\+._D3P,[[3_&YZ!O"V_3-FQ!Q')/&[37,,HE5
M9N01R,#4CQ'PR5H"(W=N6(PEU-&LHK^PB;E@YCCDHO'3,>)=O.VWWK)!-R%I
M*_\`-%K2$+Y!<V+`EVQFA_3Y^?RQ2VI12TZEBU=NO,UVUP/<!C-05E`HF[Y2
MG%BCTD670]!WP@@HY56[WPGS@4(Y_&'[#F*5.,$SL+H8U056Q*@HU88DI#+.
MW(T*OJ;V_'A%HZB,NK\^'3@L]D7HL"P<A'+=&0,V/ZDJDX:K(M5U@F;Q!^.J
MZ_-WHRL[13C<,KNH'C:]3UA5"TL(C8#Z`S\K!*2JZIB</E#X6U6E#<S64&4"
MR%=?39=7<9$.]\]*N'7/`65]0>,)W;LU]1R"%#XJ!4N.H?&D*B<L8.0PB8C9
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M.N>-)(!A8W^+&_8_6WI:)25>&6N8M_S!ZJK&K7\H+QD:G4,RM._YI/\`F/;3
M#0$:M,HO<88R`-]F#C@P=B1<,^9I+JM"'/TPM5Z^\GW-=%KW"WKJJH(PA$I\
M:-Z@CTW)RX$'0-R\7;8^RW%;&HPQ!.SHR$30*Q5"/'VMN&Z:3Q3?;15/YN>@
MJ#(OQD>EY?=TG]+QR.5Y4L@F-N4W(.JH5EK0B)&4GUZ=@<^O*MR[F-BM1[J5
M.AU6!;#'.F7*S7]V<JL/J]\N'3Q4+L>U?)-P7=<90Q!HK#3H&SJL\_UHC81V
M1-!9OSL9I+TH4O`].PXET+=DS"DS"EFB;/0=9)UR:CK'3OY&_7#IL%+?._X]
M_7GD>74K)X[!(+;<,I-3SFX@]=#+/8QB0Q82R\P>U(3=$$9'Y.%T'=1^$WWZ
M9[>QSKYT_JQLAMMSRGMAQPJ'2^A?*2L(]877Z/-19".B;"@<!(UY"MRI*0#J
MJM&PNBQ7UNO&0C-FW"@7UI&HK"W!HBU[5T<?BE'6M)=+.=N`Z`X#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`J8>\/^:Y,&N(`9@CQR*OKT%77J*T6_$NE[
M;J0795#FHGD%E:"[8XDN%0$.*+C/70]ETW'.?L.M+(*:<./JA'4T_&EY/G32
M,,2<=L@.UA_J"?>RP:4+O*Y(-I+T=94J(3.3V*\W$IP(V3<_KY=ZHQ9N/JL!
MB3UPBU11264XZ#9`7X^O+D<]$J^GQ<.E'%D_OJ56P/$.K0LPA5$?N*=Q%>`3
M>XXS2[Z6.*LCMIRV%.UQK\VS$HO%V[IQO?6E7+A10+EO&B#]HZ8NN-J-GK9=
MHX3UUUQOM!PETBMQKOC?/?&^D^]Z^.MZWK_V8%8&'B[SL-HNA?-S.%/$J@\S
MR2CY934:W+):JYBQWSG)04NJ%VL?5-=GSW$8/1MFKTD0<N4GO*7TW/*R?77.
MPK:;_#WX'.(QP>K5,E&1Z.+SMGJ(1RW+8C<,D4!L>TU+ND])36*A)DQ"S.@>
MK675,L8221<QP6JX709M$&;A=NH$[0KP7Y?KRSX_=<1@1`5;D?L2\K/ZL;4U
MFKF5R63>CN!:5M-IP3='UNYO%3B4<"\,PI/3H4&XCPCD<W:\C6>D@FFC:-K3
MSC6@BHJA`K1J`@C$V/#`RY<P=5;E+#G,DL>6.-DSSXD46Y)2^6OW//':W7"'
M*VDDM<)<<<<AK_HOS14?J>#"X#;X@X]'1R9QNQX:?B$QEM=3R`V)$%7"L9G,
M"G\$,Q^7Q&4".7CA+ATR>)=*-G*[=7YT%E4^PJ-U^'?\<J\8.18EYJC!]`W7
M<:K),_)S,ID\[C(*+2B=3QH8@MAR`V1G$%GQ>P;*-R$O)!)!H>-G'NWK]VX7
M32[X#8IA^*OQ%.01F/R&K3*C.2!/448DSD?9=E""\FB_LFP^K;]`1F0F1<K:
M$S(&56?OD^R:KJ]I`2G&EQ>F??S?,%D/._E^F_+<=D\>J(&=:JSN6N)[8,MF
MTYF]HV-8<T<"!$>_<L[LBR9!*IQ*R;6.Q]@.:[>/U4V8]D@V0Y313XXT'Z]/
M^8ZE]@TS*:`O)C*2]73;;#B5@XG/IM6[TZS'NTWR0I_(*_/1P^J&<.$>-N&G
MW.F[G7.N5>.N=?#`@^?_`(VO*%I3.'SR>QFP9&;C$:J"*'VSR[KDYCMR"*`D
M/[QI;?H:+(3A&/7X3KB9]=EV#V5MBCOI^KVHNHMKK?.!?#`I)8_XZO(-KS7T
MM8DVJGE]-/7U30ZC?0L@82N8@WU@59!^E^1,17Z#'F/`9D^8K<LR2C#35<HQ
M01;NNU4D4^>0C:4?B4\)'3W<FC52EJ3,ZG,5LQDX\UV39'FU$)8$/KR>5,-E
M\<84C*8,PCIU_7%DEA!-=DDAT6:+)\O/K;01Z3"46O@>A$+:\^7D[)7H>L[S
M%"I'7]3R24>DKXDW3:,S%\J_E[>8#CE@/AEC/I6M]KP1>'D2#IXB+'IJ*=<,
M&G*0>;RU^.[RAXV.$9/14$D(J1/8PX@C`S,[.LVT7<0KYW*'4V>5Y7G-D2Z4
M-JZ@KZ8O%"CD6$38-';[2:J_"G2*'TPLE<=/UMZ`JR?4I<,483BL+/BY6&SB
M)DU':#0W'S+;IL]:_=CW#,D/<\\]:[0=-5D735?CA9%1-7CCOD*=@OQ9>+1(
M)X$,5W*+$5.(W4C-I+;%KVE9TTLO7H*KX[2EH=V9+YG+BY^<]EJEB`J/,_U!
M=;0D:/038Z;[X^;8?.N?Q<>3Z>F\7GE3)WM69*+@J-C7(2"^H/0\9@\G!^<H
M-&JTJ8=8$"%64WB%@H`X+$F(QS^LLWNR;9/OEYM?ZJF^@MO5-&UI2CJUGM<`
M5@;B[+;D=Y6/VJ7,%M'++E@>-@3IY+DN^>\"478N),$],VFD&:6T=]<)<]=]
M[Z#R^A//]2^IZ9GOGZ]8KQ.*ELT4W"3:**$RX=,V,:E&!E%KV2`OAA=ISR0&
M(][Z073ZW\GPWOX;WK85F4_%_P"(=OIH_9TNW#]V"IZD7E34!+)H#&/E_9T0
M@4&]&*MQ8N0-1XSJ>QRLPZ?/VJ:/(Q5MTLQTV566[[#_`"/_`(S_`"Y$IW)I
M]$N+NBB\W8QT?.89&_2U_!:HG",5IZ-4($4F-2L+%0KJ2NV]5P\8,[6=C555
MOLDEE.NE^=*8$IT7XE\S^;)V=LRF*W0ALVE%-4=0DE.('9&26/UKYQ`D(K3X
MXN@7+/FKXQ%8T1VPV5[XV2>-$4$W*ZO*"7R!)E\416/I2L#U06\#>'H5('4?
M**IBI!(8C(`\@B,A%RZ'RJ+2Z)%`DIBDKB4K!LR0TB/=MW31XV34X[U\/AL*
ME$/Q8>0"4&K>`KA+=1&UC?!'U"*.L/15\#9S*/1!9VB^>W)9<\8V$WEEFSK[
MA'6D79QV]TT1WM%ORDC\$]!ZYU^+;Q99%H3BV)?7$F(&[$(362RB+M[:M@75
MCBQK%J8A1,TN!A4HR9M*Y$7#(*A*N`2\E:C4BOVJW:FE=.>MK[##RO\`$UX?
ME1T]+.:ZF,.F<DE%`3<G.*SN>X:RFG[S\PU=,Z6IB5,)3!IN"-"3\9K&?$Q"
M[IJLBJ3;J\;>[7412[X#(D_Q:>/I'8,.LZ;1ZV+&ED/CM91A56Q_15]S@1/Q
MM+S^4VE4BERQR16*_`W4^KJ?S%\3$KRIN6[:N.DOA\>4$>>`Z(X'-^5_B1_'
MW-&YOH[YZ`]2.4RZ^)K+[&&FI,&MB9E?2X2RHW<S"86H),LY])XO*P5LF&O`
M=Z06%CDMM=,T&_V#+Z`>B?\`XIO%%B2N6SM_7\UB<UG%M1J\I'+JKNNY*CDK
MJT(M3)SS\TE+(Y6LZBY,,Z*U+)2`HIPR5;I%?O%7#OE5TITML+N5?6%?TK7,
M)J.J8F'@M;5Q&1$.A$/`-]MA$=C8)FDP%C&2??:BO?#=LCKYE%>U%EN]]**=
M]J===;"L=]_CS\I^F[>`7;=4&D4MF`.'1VO78Q&SK-C<`FL'B4Z=V9&XC9]:
MQ>7!H):,:$SUWT3Y8'V!!HJOSSI5-1/G7&!Y:S_&_P"+Z=L&`6Y6U'QV*6U7
M4JN":#K3&NBW%C2@]?+F4/K25LZ:=/\`J0VJQD1*7NW2;21."34>YX;*,TT-
MM&WT@P9?\9GDTC67GJJ!0*SX%&_*Q28F*'*U;?5U5A.X"]L`>?$S+;&Q8+.P
M4W?(2`5*'[9PDZ?+I=-W/2?RZY^&M!^1WXQO(3.Z@/H$G$[$F-F@'%3E^"$_
MO6ZYS'SLTHR))0BIK.FT*DT])0Z?6M!@">],)(:8ORZ+OO;S2_W?RKZ"Y\3@
MXB&NYF]%/I.\5G<P=3<QQ(Y?)Y4V8EW@4&"58Q5I(RI-M#8QPSCZ"B8@7RT&
M).E'#CA#2[E=10-QP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P*CM&$NN^:3
M_P"K/9##8I"9`K%Q8F+./L7+URS^?3@@_<:ZU]3:G7/S:UUKO^3OY>?EUSO?
M0;)_P[N_Z9+6_P`?_P!A@/\`AW=_TR6M_C_^PP'_``[N_P"F2UO\?_V&`_X=
MW?\`3):W^/\`^PP'_#N[_IDM;_'_`/88#_AW=_TR6M_C_P#L,!_P[N_Z9+6_
MQ_\`V&`_X=W?],EK?X__`+#`?\.[O^F2UO\`'_\`88#_`(=W?],EK?X__L,!
M_P`.[O\`IDM;_'_]A@/^'=W_`$R6M_C_`/L,!_P[N_Z9+6_Q_P#V&`_X=W?]
M,EK?X_\`[#`?\.[O^F2UO\?_`-A@/^'=W_3):W^/_P"PP'_#N[_IDM;_`!__
M`&&`_P"'=W_3):W^/_[#`?\`#N[_`*9+6_Q__88#_AW=_P!,EK?X_P#[#`?\
M.[O^F2UO\?\`]A@/^'=W_3):W^/_`.PP'_#N[_IDM;_'_P#88#_AW=_TR6M_
MC_\`L,!_P[N_Z9+6_P`?_P!A@/\`AW=_TR6M_C_^PP'_``[N_P"F2UO\?_V&
M`_X=W?\`3):W^/\`^PP'_#N[_IDM;_'_`/88#_AW=_TR6M_C_P#L,!_P[N_Z
M9+6_Q_\`V&!%TA"U/$K)AE.2CUN6CUM6*R?DH#6AFS`8Z=S(>+X<]DG\9BKI
MVD:-,F/+-7:JK=%3A/Z?7QWKY=X$H_\`#N[_`*9+6_Q__88#_AW=_P!,EK?X
M_P#[#`A)V]H(>X<,W_MENQ=M`MC21VU>7)$FSAK'Z?E:4#M<VX06)\*HBJUF
MR_`@ZOUK20HEUILYVFMOY,#U,DJ>(HP%9GZOEBW\4I`QBL`;ZE^N'TFD)0/-
MI`,%,1RB/#_AP1"5N>=(?533Y61$.NN-[^EU\`W"'5U$[!ZEG,*]%6#)>H+,
MS->2_0N3?7_;TWCJ;)8W&27]JY^B5&)$4-JI_P`ORZ5Y_EP-0D*-011C:A.1
M^K9<'84@:CD=MMT]EOTT8`;EP6*R.,C)'U]'?V3HT"G`ATAK^7YD2"/7\GS?
MR!*I*B40PY^8+WE98L2*9.B1,F0DZ+-@.'L4%'3U\]=N/IH-6C1LETHHIWUS
MQQQSOK>]:UO`TBK8G6]X0UA8E->J)#:D!*KO&PN:5_8@B6Q<BN.<=M'R3$X#
M</1KKMHY3Z34UPIU\O>MZW_+@9685Q#J\1CSB>^F)7"D);+H[7\56E<_%1Y*
M23N7//TZ*PP"H6<-.2\JDK_^T,![?:CIVK_6I<==?R8&H01I4EG3"8U_7_JN
M7RR:5]V^3FL:#RW[DI&NQDSEU=O^2B'T>?H;:S>!&1G?\N_@['+<?_2_'82]
M_P`.[O\`IDM;_'_]A@1_9\-@5*PPI8EL>EYO7\%"?1_699*):F,!"N'"FDDE
M2!!;G2#-#?>_ZY13?/'&OCOK>M:WO`SD0J8)/HP$F<-OZR)%%I(P1*`C@V1[
M68%!Z_Q^B[:*[3YVHBI\-_#?PU\<#9/^'=W_`$R6M_C_`/L,#5R-6QH.J?1,
M>BIR(ZBHP49DJA69-!K<$).+$6X@B5=/>D&S%F07$.>$NU.^>>ND>M?^S`\Y
M"N(@*;RIV3])35@V@ST>-F2[N:,T$HN0*L!)08R.J*=\\C'3\:>9+I<*_+TH
MD[2ZUK>N^=[#:'=`]L6KEZ[NBU$6K-NLZ<K='M[Y2;MT^E5E>M<I]=;Y33XW
MO?PUO?\`)@:(&B->R*"@K-">GI<1KZ3.@S`!,&\V:;`%7\BD;6(`V#0AUOE%
M1^4E;Y$:BC\=*]/E.4/E^IOY<"0_^'=W_3):W^/_`.PP&_.[K7\N[DM;6M?R
M[WL__P!G_P#I@:L*J^+GG@I@#]'34R[.1E.9A4!,W8$>B\167;-49.,VS56X
M?@5G#Q+CAVEOM#OI7GX=;^;6!M/_``[N_P"F2UO\?_V&!K*E51U%8F@X]$3M
MHJ&D06(D^7DP:L],Y3(T0KB/QY3MUTEQLR<3D;#[1OSO:KCMXEPGSUUWSSL-
MF_X=W?\`3):W^/\`^PP,<^H]F+7%-B=\6*.<G2.PX-N^EC9HN9+:'ORVQ8I)
MQTFH1(Z%"G3K:".NU?MVRJGR_(GWUH,C_P`.[O\`IDM;_'_]A@/^'=W_`$R6
MM_C_`/L,#'/J/9BUA38G?%BCG!TC^CA&[Z6-FBY@MH>_+;%BDG'2:A`CH6*=
M.?H(Z[5^W;*J?+\B?>]!D?\`AW=_TR6M_C_^PP-,EE=Q&"O(B.E_HV>Q\C/9
M*UA\+'D95PB_E$G>(.':(8*SUQTY?O--&JJRFD^=\I(I]=][YXUO>!N?_#N[
M_IDM;_'_`/88#_AW=_TR6M_C_P#L,!_P[N_Z9+6_Q_\`V&`_X=W?],EK?X__
M`+#`?\.[O^F2UO\`'_\`88#_`(=W?],EK?X__L,!_P`.[O\`IDM;_'_]A@/^
M'=W_`$R6M_C_`/L,!_P[N_Z9+6_Q_P#V&`_X=W?],EK?X_\`[#`?\.[O^F2U
MO\?_`-A@/^'=W_3):W^/_P"PP'_#N[_IDM;_`!__`&&`_P"'=W_3):W^/_[#
M`?\`#N[_`*9+6_Q__88#_AW=_P!,EK?X_P#[#`?\.[O^F2UO\?\`]A@/^'=W
M_3):W^/_`.PP'_#N[_IDM;_'_P#88#_AW=_TR6M_C_\`L,!_P[N_Z9+6_P`?
M_P!A@/\`AW=_TR6M_C_^PP-,F0"840D%FX>QY5*A/Z\,%'XY*WGWZ#UF04Z3
MVHU[WOY6[A/7.]<]:YUWSO>NOF^&M\]!<?`K7Y]_PQ=O^M0S_5[P+*8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8')#W+XRE]O7#,+J`>ED_
M.A*5>/#WD>J2S:QY/`>G]VV5.33F+-I8T#.@Z$M`E-FT6@UJV>=&FY3OZX]+
M[KA'O019^._R^K7GHV1RJ7WQ54Y*U]75AQ2%^=ZMO2S++"^8]R+TI<*TCB`Q
MG+]ANY&`C+1!&-IF"XQL09DQY$<V;,V;=-+8=PL#^=VTOPT6Y-_7$YO$79]7
M(5C)/5%=345#RC>5?N!IY4G#HI9_MRH'OVP=85U);K]`],"P_?"NV&V+7?W?
M?*WR\Z"*9=^&Z:-GS(]<UH47M"9-Z,8SVRI/;5O1R52FW89!/8]1PN/,B+IL
M/5?<'Y5Z+A#@6LD39OUG`1PPY9K:51VX#P@/QP6,=F<^$0+U-1EB7,5.%I)Z
MAJA&];>%M[\91.PO(/6H!;.XRU(F(0(W_"J:,"Q=F(6><O)0DBZ;O4'Q!+0?
M[+?PJ>Q)!&@@0[>M56FY=K5ZM)7,[G]Y`T1$JA]9^+X@WN!I^C"##NS)S$6G
MF^2Q@0TDG?:3L!)^'CMWRZZ>M%@_HQO0!J5TE<47V8!QW4DJNP@&Y!)W.F4;
M!Z,1(N.V8D+SKGKEH#&:<?7=J[UO2;?COKX?R8'``)^->Z["B%$%/,GLZ'6-
M`H/YKA=0![I3]'VQ8#^OYM!(3>40M>+56K$OU>%3&M[NDE@`AY14FX:D8H,B
M2'+5JY<(,$F(6+]>_BNN?T%0'E3SU5E[1BG([Y@K23R<>>/BI!;QV1^L&,<C
MX:I9\H_FRS@LS&1(R^DQE20]O'$A0)/FRC=#YN5.N0GWQ'XQM?S]Z(]#W/9T
MLK$J\NP20(KQF`OI(]7CQF5^F/2=XNMJ]2`((44!<L[>18M5MZ^HJX'N/CSK
MGGGKH.I>!!'J,;&3OFV^HW,I@VK^,2NH+#AYB:.VGZBG&VLNBI2-:*)"N73)
M4R\05*<_;L4U>%GR^^$$]_44YP*Z-Z;B['V6C<#N\X&@=Z%]S?<">\Z87(K%
MD:=85@YACTB\G&M\4$S>M/WGT-Z`\](RY7IWVYUKXZV&D>H@]2>]H/`(/4?J
M96OI"E<TN`Q:<UIPZD;@_):]@D@-'P;#L:9#-2<9C)_@,7>D4EEQW;@:@PZ5
MUT]UK`\%J>8*.<4O;T",6I#U8]?-/^8*7'=D`+":ID)O$2$J`U[8I0"V.*.9
MV1L!\_9<J[3VBY59@.^N7G7*&U&P1[97DVB+&N>9PLY=-6`;RL>#KNK*AD5C
M7">N*O8U10M%K00FT_>'3H!!NYPX$%0@LBKPJZ5*)<-^%NVW;G`VF,>2H-#K
MVJXY'O0T#WS&#$HFT)K<4P;=6**@XBV/0DZ1KNEN6$][T(K-T'MCF-21F@'>
M)/6<1:))Z;_*DFP#!Q'QN`O6%>:IY`[=8R&&5Q-G,AX[L"I9,U-,2</]?L+U
M-N(4`*2R.OJTL90["7$/+O'[8AM4?K?7*6N>.D7`7V]"M05G0*>>>Q=L0F!6
M;8\%,M0C0WV!/F4A2J*OZB6W`7Y5@_-A?LFRZ:ZFN?I)I[[[WO?R;YV'.VJ?
M-$0K[J@5W'M:GY15:4G66_0'2XSIC9CF-S[T\^&UW7Y/NUW$?W&AR'J9(&18
MZ8$NNM1M@EPFAROI!L'[BOD6C8M!ZC5,7A442;>,$H704<L01&&%=!8\3K^W
M*BMXTL,+FYHJ(%3^=0J)]`)(LR<*-^GQ0AQM/Y$W+#L-@K#Q#5,+*1X%:5W5
M1/6-0FAML2VNNAK0,#(A`U*&ZN'6O8L=-V%)%&\VEQ`FA*I!)'>MLGQ=@V62
M2371T\Z"5K7\^U39@(S%PDWK0N[]`^D*_P#5M.L"<+0L*O/U^E053G)"X=#P
MIQNU*QB6.:\76*&6[L?K[F3:X^95PMSIR'JI$8%C_HRV+H+V@'+5O;,Y:UAY
MY``9>UF$383LW%!TMO<JW(`7Q82`6LZ3UZRVS&$''W+%Z'<Z3WQT5X0Z"P_H
M*@FMU$Z)DJ/,*U)*%N<=;<<ZG,._>`IUO]F32`F!J2:!8*0#$/TJ;]OV+U!;
MK2!0<TZ5252UUS@0;2-*1?R%/I_+[+OV#H<6\Z[%1YD?59P$C,2",]GL\5E<
MW(26:$^+#M;E&QD0G;]D@QYT)%M./HZXVDBV#8;MB=5619L*L[OTI&:_#T*9
M4%WK'F$PCJ3&0LTB#275O&YT46DC1*`%(5;45'FVJCA#M5Z@@]'J)[0=J[Y"
MI=-^-(,FXA@</=%/V+/:1O:LK.C[`A6KY6'EW,7\Z-8H9E[,:^GY$B:LVRH!
M<8F7G96'(K,E9!^F]+H*;X6Z6"?Z1H4#X3=^@[FM"[24EB]D2=H2=E33*3=N
MV?1BQ)N>'OY1QP=D#(S)ON+(1"Z>M![/K8T6UY[W]'E%!H'WL0C0-Z>F*O*?
MJ9U&5^7A<YD)2;]4Y*EX5%6MK4LV-CU'%\DPK>!00P*BQQB=33[>J*=;Z1YZ
MX3[^'P"!Z=\;TG%W%')6#Z`I:S`2DSXEL&A#%`6-B%MDF50(U**F`@,5LB5<
MRJRI$9&ZDYLJWZ>\/#R7"J22;E#[Q0.G=T-DWE.VPT6EC:!(NJUG3=:<O!6C
MK.&)+1<HFI*W03:[71AM'N.MN^VOU4_N.4=I_-S\WQT'''S_`.8*<Y2\O.VM
M]+SUU9SCF[_-AL=4DU"Q)I%DK7K7T/.HI&G#\LF.@1*55_&2`!V/>I#'WZ:6
M?<=L^>>73%0+M?C>C/8>@"1@C(92?D)NS[&"$6DUY(\R:OPE42=_34!J$ST1
M:L^WIJKH#`!PHJ_23V@8.)/B2:BVGGUE`O\`X#`8#`8#`8#`8#`8#`8#`8#`
M8#`KAZF_T8)?YVQK^ZE,"Q^!6OS[_AB[?]:AG^KW@64P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P.2/Y5O#WHKW>!J:`T[9U;U-':M4L2YF
M\BG$9-35^X]&Q^.LP?FMR'"B#,8_04(28D)D]N0=/'B@DHQ']IBW_P`>])!Z
M/"WC>^*/]&7E>]P?PX9IW*`F+CH'!Y*9D*@:3S7U%>=ZO6'W!2,@.7`E@'M!
MJW37_P#JG:Z2FMIZYUKOH.LV`P.4?Y5?$-\^^(/5U0599E>5/#HH4G]IR*4S
M2,&YL3[MD#!GL9\^<`(V'.1337]J2Z8/93R:4(]=!34>%KICR&]])IAA/$GC
M7T147JBVO2-V[K!FI;L.F718)`9*</\`Z7-YS/(?-RK9KV5BX#E8"V<BGO"2
MV]Z5WSM+XIZ^;KY0Z[X$)^EJZ-V_YQO^I8RH,1D=HTG:M=1]4VJL@&2-S:"'
MHT*4++MF[MPB,X?DT]N.TTE>^4M=;YXZW\-;#AUU^/\`_)1W$:""UO;S>B>:
MO\UVM2\O#]>F)K+.999\SB5NA:<NOIU`J>JN*<]>;9-(6!$<TYCZ3LTU,]IO
M5UG$;%*N@BR\O$WY$HJWL"RH<3LX9#W]?^;:_KWS95GKRZ9J[CP[5M^=XU8]
M6';"<Q3FQ28Q;H'*)<XL1FHW,CAIY^BY3602[2Z#H#^//Q)?'FB[9M:=S.1L
MH=VCYHJR!OS_`#?5K6@:@IZMKL]!R6/U,LA8(]%.?`(C3MHQ<(SEZW;4DY<Q
MEVHJTY[)+N%P[!X%7_9\TKR#^9;6=6JWD+J"2X.-J0RE%7,+8GN5+MD`BGQ3
MA@3L<_%X$(VT,S=NKV\+D&K!HGQTJKUOGCY>@J!/Z\\5VD[E$DLBT]0.42BK
M4)U.8L\E=8_O.-5D0\PSNC-OWY:+_O!BM&DX5=3AVB_'DB09R>^CPU<..>NV
MZH96LU?(%8)U_LWZ="G)2PM*U?7R)@XSAD%^]?GZXMF#3),I'PD5`#(>#%1Q
MK(G'+%1-H55<1YXJKVOMH]^`8JO`/B;YTZ6@=HR64/?5EN&;HAKAH,[*IQ??
MGR?U_.=U,&?<1)%E`8/"##I']+$$^$W2+0PZ[15^"R2F!G(AY%B5QR6R+A'E
M[TJ5Z>.R=>-1J>P"LA1:+S*363Y_]`%INQ<N0I\[,@&[!I4(FU8EGRS-LAP0
M9)I<I?;]H!'FJ&\G4'>=4'YYZODC*6^98L[GJ<5F;N+BQ#OKEG;S212<IV,B
MXH/IT1:^E73EV.8ZY>I<Z'*I:1:]*IN0LM3]]^7*E94A0T`M!:?D[CFDW<01
M%GPD2*<N9P:NJVBKF4]-V@E"-L&+^%R,>B@Y23(:6&=H](=]H.5$PQ?I^BO+
M3J8.;,ONS$:Y<V#R#A_#TB=C46X)(LZSO2DV\>%'B(OHDBJ_%>GB:ND^7&]Z
M?\-NT^=<?<<+!2&>>=?"$XC$RDDI]#G+'/TH-/6W/#<'!5L.X8\2&`TV&$+#
MAPR#CZ^AS[B`Q")K)<-EF'S<D."CU3A!UPOP%M[!%^1Y#.;S@T\G1`&5@$HC
M'L2TT)`#8(1*.:LFASGG*._;G"4;=1TIKH""4?<(-UW1#]841^13O77T.0CV
M(_C?\PVI'9?.(;:,SED0N"L&$#;&F+X.NX8O8Z"IN`D#+8@H)2>M7R*OG((B
M2"+)(()OT7S=TC\OTF[0,%%9]Y4H]&J"8ZUB36'4?8WJ3R)91F400L.:]S:W
M&CWT%895-+03AFFV'2FF^^DWG#9^TVS<+?<JJ:^9ST&^4;1E%AA<>\P5+Z!8
M3U2I[XA5_3$&X>C%R08/7XZ.]QJ*5ZQ`LVH`;'6$H"Q[91%DHJT&:>N6W*3/
MAVS9H!=0_<,"J6?(Q&UKDCC$U;<G9JU##BS1F(?C1'+."0A4*@Z9I]J%6K^Q
MRR>^"#_:6M$)"U'<][ZZ:I]A0_W&E^/OT4WJES?/I2)P]$8-.,X&X8'8GWHD
MG;<=KV6LBS=0T"/;045CC<0_8N4MH<?1?I]]==?42^`1!!HMX/4*75<4L],R
M)]V;O2`.9E'K-U&D'D>D=`>I+DN>,`^`G,?>]E8]J<AI.W4?-.>VG`$&JKOI
MLZ8D'>PM`*1\?U]Z&]"^HH;:KA6Q8C"]_P`>@,96;G(YS`8O75?BHO!&[#H4
MH+&$H_\`H`XN-;BG;8FX6/;Y<_79NV/"(6T*>BZM&O+#CW)GLM/*J@J]@3RM
MPB:169@A+4"-DJXU5JW7V)6D?(@RR6Y8\/-K=)O6RFM?2<(J=A#)OQSY\N35
MX6FV3;D)#ZLC436[M4:)BSJ3!HBS@L&"QQA#C9"/NUEX@01AS$HN,(Z>L'RZ
MRO*Z7:"FTM!64+)?&?G+A:\6UCE+TF=<GI%3Q(?%8_$S!@K9GJSTHWERSN/B
M&8L`$CK`K;P=RR8/&SYJ`;IC722CA9ZU54P.B=XU]'+CI:<U_-B<DC4+F4:V
MSFZL==],I!W#>NVSZ71U-\-X?.VJ<BCR#D8[48[V[Y;.E-M5>%OI*\ASNHN8
M^*8V^\=-H5:\^81P\VMJ]_-3:>I$$!;L'?\`(OVT1@I@U*QW4M34'2VR^4`_
M!5?E?M=X@V^\<[V@GV%W/+IJDBT0FNZ-LIC9@%Y;=G3<\2:/VCWH;)K:EY2U
MW[!+[9FQ_P#K%WS,^5A"_P`BG#P4H@NFNXX[TMV%E\!@,!@,!@,!@,!@,#Q$
MB+(0/?EB3CAH.&,G1%^Z4^;:;9DR0[<NG"FN.>N_D102ZZW\-;W\-?R:P.,?
M_45?A6_Y_:J_FY:G_P!H&`_ZBK\*W_/[57\W+4_^T#`?]15^%;_G]JK^;EJ?
M_:!@/^HJ_"M_S^U5_-RU/_M`P+Q>0OR">-_>PZ<EO(5[Q:\1U:/0(Z=.8R/D
MX_F./9.@4<@4'G$E!`U5.B:`5UTGM+E3G7T.OFWK?P^(7'P*X>IO]&"7^=L:
M_NI3`L?@5K\^_P"&+M_UJ&?ZO>!93`YU>_//'5YFO'SYI&9_(=Q'U1"N9MW!
MIU8D.1'5$6!2=Q-5Y8C!99&42<9V:"AMK;><N-)*<\:XUSRHIKH.3H27_F3H
MVC(C#H0'LJ:.5#$`.\')K5`Z43"#?NQEZ@7<U4]Y9@)>>FD';3:&P1(X6?)\
MF1HZ0*;Z+BVZR3T:'0;\Q$'N:PO--6!:H&V0\+IWR!?3G5316WI^6%QG=07(
MP2*.X?2%D5%94B"C;`(!.T^6IUDDV?Z:.W.E4$%$NPI8'O'\NP*'2D(8KN_`
MYP;7=?1]ZR2JN`V$M4A)Q)O/4?@TR@ML\16:N_24IE<(,S@I9_PCQ]2/$QW&
MF@UIQRG]Z$Y@;!_*>;J&;6Q+",]A,A`U+XL;ZJ2+>=8$:D79RRX+2)3V38D-
M$F."9^7V32I`E,%`,9Y44'=DFGV*S0EO;?C@)UH9?V#7WXIW1(3'IV?]@"()
M>!Z-!;:"-^[%)21_9]A&8H[,P]X;X&=R92+/6KM@`Z?HL-K?;C^54F_PWP$0
MT="_:%S^B/$5L7C*KL8US68/W*_<"I-7$8K'J:IL;#K6(^;IO?4"#L!O,)M2
M>51)C"Z(WE!LFUX$JJI,1JSQZVY#U>^(%Z&DGMKSJ<IR+7^]>#XE5R$$G5?&
MYL)IN`R=AZSK$[=KJZ?TF2B($[!&_,;*1,5&9]F1Z*(K_:L$MO>D=\AL-:1_
MWRT-5'62,]GL+CY/U1[H(W%;I2IX'(3DDK.+V2_.T"]=H&F:T4APNU!O>D>5
MA0YNFNQ5[TS29*_151"LT8]!_EW<15V^M"#6K$>>O0<C#%E:C\XQ.S+$C6F\
M)D3^+UQ&(K,&4!BDN\\&)XW'L5)O]XX5;ME/E6DR2:RA,>&YV1,?R+56Z]@L
M(E)/3TI4>>R^#D2D(CSI$+5=P;SG)?.#XO6XWSX&>"6T4L`$_P#0`81%I4W[
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M'\#=V3Y3K:+$)Q\K#T=^L3ZY&HPBHE6=RQ!\`KWJ)Q%%(.G*$BBG3P*DHY>-
M0`0)7-__`/J`%;#J9C*(-*2L:9RR&-9PD:\XP",B9H).R\+HTG(#[%9)>%#@
M@1XNW6>,-I](MDNG'7]LY^;03K5ES?F=DD1K`]+(_)0YD.76/S6./J+CC%U-
MU]7!XIBINL94X*Q.+.(Y%0T>L6V7(PN"9H.70:.H.N2)+3+M^4")8M9OY<8T
MI++2;Q;T?(9E,K8\^,Y[##M%QX#P0T$I\GJT*UJ!#N/SB&Q*KP%J+KCF<L?#
MA[>1LT4%'DH8<_1+/0[`_D?O&[?/=/0.=T*\C[N<'KEAM/LH(<XCZCN?F;T9
M'*BKM&.HFE$7+Q_`+=F$>EI%LR[VNXC0`IQOCKC?6^0HP[O[\HT%LZ=?K$'M
MNQ*]@]KLPLX;`_.,5Z11@J-FRF'5Z3\]O0CG1FZ!UH53T)E<U<;TLI#S'739
M+IDW^X9-PO[))UZT%?C_`(!;@B(%3WK*,4S1]KV34C6/`F\DL*3QT?"IC?E+
MA03C>Q`.:SX2T/`1.D54^&!ETWVFIKE/^4.>,EEGY;9._FU6.'=B@I'(?,$Q
M50/0JG:]"U['#QKRWU,0<XAMSNW:KA'T&&]=/^X`A%%M;:<1%KP<Z0Y<?`CT
M$HT';'Y"GWH_R+"BX.RWOFA_YS@RUH2^V:=7B,LD4Y:Q"X&]F%+'4Y@P]S7%
MD`9_'8>W%L%2(UJ3%DW*Z;`GMQ]Z+#M=@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M5F]=-JO?4D08VXXG;>,.IW3^A'=8L2A.?*6*VMJ%/ZI0B[`0-+N'1)>R6@KC
MY56ZC/Z>^ONOE;_5ZT'.R5S'\>!WDG;,ME%[2LB>HN(5R[MG](M%1\;C*4:B
M-OPFIAK@)'AXQ*UHSLRPG;06S9($V)-VX<_'7_>FW`:Z:C'B>[V?%LLC=PN^
MY;Y+],ES%^3\;+WDI2!5'U-8%(S!>.FXBA(R$P@2EWG734.Q<`TDF:C%-!BX
M038\L0DB)6YX8@4PI'3VT[K`W#_$2PWCHU8G,M%6(5.R)_!ZVE@^]1QD(@W;
M1J3O(]%F#3C[-#E)`<S524001=K8%N:Z]U4;=$?AD@IDD0GB4XN"/4^)0^P=
MQ_KDB;A+ZUU#ZW95MS\0J-1B'AY'?'/7:^DN6G>D76U.$@J;(A7BVZ[$FOI]
MNVLN7%@%W0OS_82[PP;BK&%GY/((-3K$P)"&6#<O^A:DHH&FZ&\KMV[?XNB:
M;1-=RY4>A927>:_-M%%M^ECA&?1UE6LB.VH78#I'(2P.134X3MGMH9*Q!@V?
MDY7(TGE]GV`EFA\?J]/FJ7T5E&C+:(17=T^\2>V4:^H"W1ECF."\P[[:C.XI
M8\.XA%C$6=Y5&RBL]D8]DR;1:5N7L.EK5DS<./AM\.0=I[^'3!=4)=N(%2OF
MNFY/$U:[L:30CTE8T'IR3QVO].S1=LYMF+POSNS((]*OVK@$!%1".CTN^VW>
MU>5N/F3YZ65^.!4RX+>\3S`EZ*1OIK;$*X5'-?.4GCCQJ<_9UP,ZBNIP`KN5
M5\X5%;"FYA"+$E7/7"J#A+AELC\A#APBCOI$.D?G`-60*AZV3I)VH7K,M&$Y
MC"BCQ/;%<ZPG:[J;=&GC;D4*Y&+G7Y]5TJAPQ:\-NEMI\-TN>-)<A2"+-*IF
MXR%%Y7!9R&<^E/47H&,E(>WL,U(H%7UIQ6$^B_/UEG8U)&<3&NDD+)C(8RY;
M-':;!NJX<<N$]-G#?22H1=55X_C8\S2`[=,4+3F$OK`Z0`MV4IA$L'+NXW(@
MC&?FK&CHPK&V$E+0R5-(?R5=$%EGO.W#7I-DBEVOI!8+M^O0-3Q^OY!Z%L&(
M2B<=UE'HLJD"B9(B@5+C@=RUA:0ID,&L.5NRA']\0`0OPAPGVL\32[:<ZWIQ
MUK8<Z@]?_C4F,LC=!M#UK2.TYB(*!H_#)Y*K""%8LX!`R%5@ZGE+WH9VM"N@
M@_S>\$M.%6SGM/\`1E7"JKA=ZBJ]#%[B?@B5U;")?<02X@A>>#=VIMOP^DMO
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MML6EY5^A$Q=*VL^NNM81%]==<=L(5&[%+.WG+17I=59)Q]LJMVV1;HHA;'`J
M6)\64H-C$3B#I.8R$)!P,/B$71D4M($%AD+KZT(A;,'A_P!RGILJ]!QB1048
MV0^XVLY4&M]MUUE==]]=!MOG'R]4OE:*$X740IZ,!DWPYUVB_<-7*S9F$!#8
MQ'@[=5HQ8:4'@@(E!NDHORL]7WKI5RNNNIVKT%A\!@,!@,!@,!@,!@,#XN&[
M=VW7:ND$7+5RBJW<MG"7"S=PW6XZ360714YZ35153ZWSUSUK?/7.]ZWKX8%.
M?_+D_'I_R'^,_P#POTC_`/:/@/\`RY/QZ?\`(?XS_P#"_2/_`-H^`_\`+D_'
MI_R'^,__``OTC_\`:/@/_+D_'I_R'^,__"_2/_VCX'#3_P!/S$XK!/>7_J#(
M9!XS'X9#XQ[PC06-12*!AT=C4>#,'5U(,1(,$(;,Q8D8R0XUPD@W2323XUK7
M/.M:^&!_4O@5P]3?Z,$O\[8U_=2F!8_`K7Y]_P`,7;_K4,_U>\"RF!S!]Q53
M?EO^D_%\<JU[(F-:C!U_22X%$[)]%U=!E.A3VC.8:A(3_G::P0F^EJC9T:V!
M8&W:PASK3[:C=7?']:'!*>1S\F\CA`C=;Z]YI%APH9(_2"\FDWIB.20-ZE`5
MMZL>W[*J`'B3T<2G4:B;)2#DH+$1[I.II?(6(T2WX[[<NN=A_1K[_)WRU\E*
MRGS=.YQ#9V%GWGJ1EI%$*D?V?.7-7IW%7W\5^VU8M$FAX@HUKMR0(D6#1KV_
M78LW#--'E1;X\!S-F]X?DXI\QZ4-UM'K$L:O)S;EEGH'J44=/Y">I:`B;>\K
M1=.7Q+CI,Z<EH<]6EFRTN-C'`'O;#4>56;MG/#0@DH'4B>'O2TR_'5*)6PY=
M5IZS/^22,GY:PN*&BI&,76YJWLRX$1*&R/@7).2O,J^=JP9/>.'[5QVGRIQT
MLGOGH**4@>]IQZUJ$\B3X;9,II!]2,%A]AR@E7=Q"#TAB<D\]3F4V->Q7UHE
M/7[^O[<B-ZL@\)3B/9+<BZ;D>BZ*G]>DX9!X(6U]C02L/`UH1V-7W.[LC7XY
M?18^QX+8$JM1W'IE=\0JVMI#2\9NV/FI`D%XL61V%T09IER2:4A<_5<I=/.N
M>-ZX#28-['_*>XF5:PYE04IMJKK/G<2B+3TF=\Y2R@34%AS:U(6!G5HV/1DN
M,+GP/W#6PUQ;$<MMKUL1$G<AUKMNK\O8;L1L[\E%;1L`PAXT],"@*[/9TBGY
M&1TA,)(XM:*07V11L,I^-A^5Y<LG6`2QZ6L23EF"XW[EIIB%^X&M4FC93CD-
MA\">WKY]+/[D86%,OIKU_-_*#5?B+^=3G?$=D5L%9:M;E0M%Q,AD2$KKJ.KB
M&XH?8_"FAJ8W>RZG:R']MZ#MS@,!@,!@,!@,#'OA`HHJ-7)C!Y%8._Y*B%GS
M)L[5%%.&SEEP2&J.$E.V+_EF]62TLEOE322O?/Q^7KK6PR&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&!@)'%8]+FC!A)1+0PS&2".2I@W><]=)M9#$3;&21
MHLEKGKC>G8<Z,0<H[_EUI5+G>];U_)@5]UXM\M\JI=ZIF+:10`"HT@.^H8_1
M$!P5B'$C7*`#]3_1$3Z`2/,1VRW+?1108T29]N.FO'*.@W(;YMHH/'$XB,K*
M,LHTC'+)B*0=%NXTSXC5PNQ[^S0_/.W&^_LYF\%-U'NOC\>^D>?EWS@>`AY:
MH`G*ATV>5F%W)QI\G)N";=R89?J!@P[#D'ZDA9,B3<?*679./LG:;,DD[9H/
M&W#A)+A;6^]AX`7E2EH<$B0&!QMS"64'LH%:<:Z#F2KUP-D0$"K#$F3=>1.S
M:C>-KU\[<1[0U+:;1H'<=(-.&_RI]<!\T/)M(#>"R4>BO4=3E%D02T)IM@1?
MO7$Q-UG(M3"#B3#PZN7>-XE')6DD^:BF7;5BW[XZ323X16734":YG#(M8<4/
MP>;`V$DB<I%N@Q\&32VJS(CGG&^%D%-<]<*I=Z_DZ353ZX514YY[3ZY[YYZT
M$81SS-1,3Y#_`*%6X5JN"+`Y`P(.%BA0OU(8X;GLE$R(D:*D'I8W(4I#:$A>
MJOWJSAVY=%W"JZBG??QT&^6+6T*MB+N(;/PG)V/N"(0QRVY?E!#UD9C9AD?C
MYH0:!O1AP(9"FAR#EJ[9N4'""J>NN.]8$=2CRU0,S3><R&M`SI=Z[,$.R31V
M:#G&I0_,Q%AERXD^%)CS80R\FH%H1V\9N$'7#A'6^%.>>NN>@F:/1\-%`(6+
MQU@B*`1T4/!A!C;Y]H#Q0IHDQ'LD=J]J*])MFJ''&M]===;UKX[WO?\`+@:H
MRJ>N1S..CV,0$-F42G4CLR-MTTU=)AY[+GLN(R64,];5WODH8>STPHMUOX\[
MZ(*_#6OCKX!%Q?Q]YK.-!3-_4P'E$(WCC$7V->'0KMJ,B@4K&PP7[\,68/E@
M',?-NF3D>HIVR?M5MI.DEN-<ZT$QS^OX=:4+D5=S\"TDL+E@U01(`+SMRBV(
MCU.N.]H=+,EVKMOUPHESWPHDHFHGWSKKGK76M;P(MC'E:@8;*8M-HS73$3*8
M>R<,@YE$Q)57+C;IY*R2I.2\N32Z$TD7ZE.S;GDJ9X?DDW!=XKRORHY6Z[#_
M`%3RKYZ4=P%[NK(]RI62"36&H(]DT![!FVD7,O',B0I!^F,DS$++N-%AZ)1%
MZD.*:T[:\I.-?4P/?6_FBB*?"L8Y5E91ROP0Z3`I@W%1/AX$9]R2,P`-5H(F
M\28NTM$NQU?QUB,X3<?51V@T2WUQM3C7>!.>`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P/YB/P2?_`)1;_P!11_\`S`PO_P"T+LP/Z=\"N'J;_1@E_G;&O[J4
MP+'X%:_/O^&+M_UJ&?ZO>!93`8#`8#`8#`8#`8&G0ZNZ_KM$TVK^"PZ"MY&=
M?2F0MX=&0D81/28GI/1*1&D@C%CP4.D=(\?7=KZ4<+?)KY^]_#6!N.`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P.7WY(0FK'F/X^Z!D!R:#ZJOSV.4A]Q1Z#SJ85
MN^GL.B7D[TY;`B)%Y5`#4<ER,<W/Z_#$'35J^;\/=L.$E_G0Z43[".*-I6$^
M2OR<"J.HEU8,9I^S_"-D6O,*ZDEN6K:$9=V37GH&GXA&)H*;VK,IJZCAQ",6
M"38NNARS9-\AVC]QPITV0ZX#L1@,#F)^308I-TO#=*$STR$US?GNF$5K;XB#
MS:65V4F]>LJ']$65U#'\L@IB/RUB`(3"O1#AZDR?-NGB+3[=7KI!55/L(QJ6
MB8#Y"_)E5]14$XL2*57<GB/T=8-AU](;AMJSXJ9GE2W?Y<`0*8LAUJS6:[CT
MA#@;5.LE%QW;7[UL\YX<<J_00VF'8G`8',/\HB3V1Q'R#4:TAEX.#7U[OHNH
M[;8PB82:`F9A61*/65*C,+6ET+*`I<("GBL08Z?Z'OFBSIHGVW[4^BLKQV$6
M02@:\\;_`))/-]:^>%K%AU<WOY7]<G[4@1ZY+>L^)2:2T_/?*O%<2A(/:LXF
MR(&21EG9)UMP[';:*.&A'M)?ZO'"6DP['X#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'\Q'X)/_RBW_J*/_Y@87_]H79@
M?T[X%</4W^C!+_.V-?W4I@6/P*U^??\`#%V_ZU#/]7O`LI@44]MF[UC9'R.6
MJ">D8I&77L&DHM<T:!PA&2%[!KN7R1$(^".9(NLO^QXF.^OV]*N$62KAUPDD
MEIRT1^O]8+CQV7QV6*2)*/DN2*D3DCZ(2#GEL\;_`*=(AK5B\>C>MNV[?3CI
M!L20Z^HC]1'KY_ASWO>NM:"C'Y)IM+(+2]?$(Q.'M=LBEZ0<'-)0VL>05`T:
M0]V$F#IX@9L^+5[:1V%BG9ABQXZ<H!76UEMI-NMI\+]*<A&%J7Q;-&(7[/*Z
M6.V0!7C/BQ_%'4W*.957<':V::E\.L*PV#XJ3KI%U&QD;$CRA%-4N):[=;T[
M<JLTUUMX&GN?8?IZ?5?=/`;]@5/;PGRH:LF$U\C4UISZ9M9.A1=?V2ULT854
M)BXJ7@Q692PI&Q0EZS:N^R8KGX.'RZ3T<D$Z6+?5MQ-1E8T**1JY8O\`\$]G
MV>"6AL5F3*'2*QXO*ZG1YDZK,=*98L2C903)5G;$4V^<TV9,GJ:+MYTY_M`:
M/5'KOT7.;$@;!>/UP<JMU,`$),36/0"QA7=FL)7,/3T<#VQ7;XC+R8J(PQL/
MI(*Z[:O$SO+S]85Z2?\`#?MBX7";_0'HRR*OO>H*UC(6-J@)LK"]*-S4:EQB
M16.YE%K1Z`RL%7QH&18@8L0J&$EUI>84(MR.G(U+GG2;1!-T]1#/^)VMN=5-
M)I#=L\=3Z=2JZKN?=/.P1^*C`D?"6=)H;&0$?BYZ4RO80`V"QI)9HFV510[;
MK\=[X56Z5=N0Y_>9[>OLW`QY4':MFVA%N;/\/HSTM9,<..S`JQ[)MLK%O3%3
M025#Q,'<I1F"C7$7*/4W2)U@*X=D1>^^>.][8!,MV^M/5M4U-.+7;16J'[!7
MTG8-.PEBYALO8)0*#UW(+F$-9W:!@[:,<'R;BRG=?A!P_;#81%F\/I](_JG?
M;=JJ&MV!ZY]'FX+>ZT>/UU3TWKCJ#&5X>_IVT)S**HAS2R*V8RJ6S\XY-1^(
MR:-SF`'2I8=]%`(\9B6JBO'#OIN^68AGIQ[5OP=.[7B,``UI*E8X`25AC1:$
MV0NJBU61H+J,V_)2PF2+#3=;6<[M4TB*'C=(NV^P>_@^=](DN&83-&_0MW#/
M8T:\RV`T@1P"\I]&3/I=!(3*!CI_,6S5\]+&7K,W8!9S`X4M]KPU8ZTUD0]5
MXI]JL<0?_38JA?S`8#`8#`8#`8#`8#`8#`8#`8%:_3GEN">IXQ#`DLDME5])
M*SGK*SZMM*G9BM!;-K><M(](X>L<BY_3,H/ZY+PR8EQ#YH_9/F#P>16350ZW
MOCK@(\\\^&X30=GG[L*7%Z)]#6\9@:=6C[`]&V0RG!>'5QT?0E9.&PL='8Q"
MXR#&R*3,6CXDM]@J^>*L&O*B^TFZ2?(77P&!7+TWYA@7JF%1N)34[8,**P2?
M`;3K2R:GESB$656MBQUB9#CY9$)`FV(,DWBD>DA,8Y;O6;UB\'D7"*R'?/?\
M@1?Y_P#"T+HNUG]XFKJ])>BK94@!"K8]-/1]F,)PZ@=?'9`#E<IC4($1R*PF
M-AD9?(8L)<DW/;)=\YV*:)_7Y22TGL+NX#`KOZ:\RU_ZJK\7`YX4G$6<Q:<1
M:SJ^L"L94YA=CUK9$+<+K1R:PJ1H(/$&9=D@]=-5$W;5XR=LG:[=P@JDKUSL
M(CHCPA#:6MI.\Y'>7IKT?:(J"R&MH7)O2%GCIOQ7,.F9F,GYP,@P*,Q*$1P4
MYFI2$A>R3U9HY?*IBFZ7"R:.NT^PO)@,#YK*?1156^117Z2?:GTT>-J+*?)S
MOKY$D]?R]J=_#X<Z_P#;O^3`Y7]_E8!<=]\?\`7Y5.OD[ZX^;CPM8W7'7R];
MY^;CK[W^NXZ^'QUO_P!NL#\_^:T"_P"0'\JW_@4L?^_L!_YK0+_D!_*M_P"!
M2Q_[^P'_`)K0+_D!_*M_X%+'_O[`?^:T"_Y`?RK?^!2Q_P"_L!_YK0+_`)`?
MRK?^!2Q_[^P'_FM`O^0'\JW_`(%+'_O[`?\`FM`O^0'\JW_@4L?^_L!_YK0+
M_D!_*M_X%+'_`+^P'_FM`O\`D!_*M_X%+'_O[`?^:T"_Y`?RK?\`@4L?^_L!
M_P":T"_Y`?RK?^!2Q_[^P'_FM`O^0'\JW_@4L?\`O[`?^:T"_P"0'\JW_@4L
M?^_L!_YK0+_D!_*M_P"!2Q_[^P'_`)K0+_D!_*M_X%+'_O[`?^:T"_Y`?RK?
M^!2Q_P"_L!_YK0+_`)`?RK?^!2Q_[^P'_FM`O^0'\JW_`(%+'_O[`?\`FM`O
M^0'\JW_@4L?^_L!_YK0+_D!_*M_X%+'_`+^P)'J/\B8BW;(BE;M_&OY#ZZ6E
MC]9@G-;<\BSB`5O']HL';_;N5S$F[48`6"NFGT>%5-;YZ743X_[>]8'0_`8#
M`8#`8#`8#`8#`8#`8#`8'\PWX(N^.OR+_P#J*=<]\];Y_(&&^;7/6M[U_P#7
M*[N/Y=:W_)_7\=:__KK>O_9@?T\X%</4W^C!+_.V-?W4I@6/P*U^??\`#%V_
MZU#/]7O`LI@,!@<O?RMWWZ/\XTQ4%C>9&CH[*F%\;>3Z#,`3(Z3L>FH=05^6
MA94+!\/&+[IA*W8>`Z=A%4OI**FF;1MOK:;A1-0.617\V7J6`5D%X'4Q6%K3
M5E$JZ8DFYPS/P4[C;UI%JQ=D['O@#'84H(BH?TLC,GQRO$Q*>T^V(Q?2NE?@
MOIB%J@WY%?49(0VLW^',&Y7FWD[R18$%KI0I+4H8&LB\/4@OSS.U9<1YAZTJ
M69@GY=0DR4:*Z[_1T$TW#/E?7;GL-#Z_,M?PPT3!$?+00Z7B?EVV+9.`XS(R
M;8Q,9U53*]M$SE:C372,B+5#N2TLB(<?`6Z?LW)WCI5QSTVX0>A+%#_E3M2S
M+G\@5Q+*SK07&O18N;-GTEA4GW."!<U')C>L8#2F(AHW)#KD+6YP;4;(ER3^
M61"6WZLLT?E!_;=DL6#N3@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,#1XK6-:P0S,I%"*]@\-D%BE^9!8)V*Q,!'C,Z/\;<[X-S(H('
MLWLG+\;>K;TY>]KK:^KW_7?UW7Q#>,"N'J;_`$8)?YVQK^ZE,"Q^!6OS[_AB
M[?\`6H9_J]X%E,!@,!@?GY./C\?EY^.]<\[W\NOCO7/S?+KX_#_LY^;?P_\`
MF^.\#_?EU_\`-K_YO^S7_L_EU_\`YP/\^3GXZZ^7GYN==<ZZ^&OCK7>^>N]:
MW\/CK777.M[_`/GWK6!^>4DN?DWRFGSM)/:26^>.=?32W\GQ3X^&OZQ/?T^?
MCK7\G];K_P";6!],!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@5P]3?Z,$O\`.V-?W4I@6/P*U^??\,7;_K4,_P!7O`LI@4/]HWQ/
MZ:>5\G"91'XMPI'+#L-XU-AAY=>SB=>'ZI#AZ0#[(OF>V)&Q6UBO5$UF/U"O
M*HSC;?G?&E^>@E[SQ/++F9?T:)LYY#G;ZM_1!Z"1/B$C28\>Q@75;5;-XNP*
MJEWKQZ6D[=O->]D7>N6Z"KKKK2"*:'*>MA%7ORW[(IVKJ[(U?('<8.S*[8?`
MR)87_"#@TE'R8&8&2*01W?1^,U0Q(K*@$=:4*O$N=I?430UVY[1XV&LRSTU=
M*56^O91%(3"50OFJ$FFP:Q"EGI:DLVEL<I^O[:/'E(>(JL[#03%*,S=;L?OD
MB1;/"P[27:*3!UPZ3"9H?Z+<RGT+-:5_2(0P$PU=4!R1?V8S;VD<DK"`UM8K
MXD/J'J/)JN*\Z"V8V;\F$2RJB;]JIRHUY1606Z"J$J]374%_(PG0(HP(=UX5
M&C8X"B)CBNV@AS*R5#V5:K)5X1&&"-]"RCP]#$.%"G,=?Q%J'Y<I=J:*=MD^
MP\,?_(M(A2_GB'GJL?2LQ8_GN#6W.)=S)689L),3F/6P2&#A"",09A#K5D1I
MY\F24UV-=(M7S==JQ<[3<()AD$_<UM#[/\X1R=UG'88(]&5'N9(=AY<M+X16
M;HV18/84YFEEO8;$U/W=+&+W@"'`I#-,BTE4Y03(\\=)J=AH\`_);8#6NZ]5
ML^J8+J>:AL2F%@N!EL],A1Z-EZ\\R3!16M&SNO&G<BMDMWZ59[1B7P:M-]"W
M'")572S7?82NMZ-ON))A1R!:M9Q]?WY)?/$@DEEOMUWR-J[N)FY6(0'J0^,D
MQ+B5CW:"+!JHX00Y>:Y3X4^*ZVU>0Z:X#`8#`8#`8'(ZV?8$[A-I^@!LANR%
M5+7<*9SH<NL4A`R2G:D$UXAYE?,)^@QV11)2R46[W>!`4!'NT'#)<NJ$3;-7
M'7+Q!^'0KSM(YW+Z.JZ3V;V'4GAV("B4D4!+B7#!1ZY3VHGVHI'R)B/<E.FF
MT]OTQSMT/2??6X:JJ(<I]["C]E>D[QCGY&JRHD,3Z'TU(F4`8%>S8&#<U^[+
M2*%^@Y49C:TNV3U:3*Y#*-=#WD89(L]QYZ/&%.5U?N>>.,#H?)9:U2KB23:+
MGXHJV:PXY(P4F)OE'L)U]D'=OV)<J0!].5EXVCVCRJY4:;[4VVYZVG\>OA@<
ML/.OO2=.&</@<_.0BQYPO)7/5@3&4SFJJ]"#0BZ=!H-P5122I7%B5GZ`.$G]
MZ-2(!)FO'7C@1ML.(I(&>]=.0W&)>^['LPG2*<3@M-@!DXN*LP4T>G;A(F1X
M^L[<H>RK@BS!D9%0%LT%W<([A?+4L`<\=M4'739%%XNF1X<M@MIYEMNQK54O
M1&Q6%<#5ZYORR*WC+6!R4N;([B46-+,@+J;#BX(.H"D+X?RFMOA+MPBXX4^I
MQOGCY=;"D$<]OVPRL*Q@::H>T)>?LXA!8-3QCF+UO"JP29>LI1YC$]E[3CG4
M[L+HEL6R&'S;`S%U%7GWNE0KC:'S-$@S4\_)P8@L[MZ`._/A)V3K)W&8>W?M
M9@07'D;&,2B@X>2;O$N8%P6Y@+,M?[11L6'-2;Q=F*6478-.WK%)0+'^:?5$
MZ]'2'KIK3X.%P(;7M;2>0FR=H\FI>TE-E0YI+V,>%Q(1".@I($)2Z415**&V
MRKC7:"B;/7Q631"[&`P&`P&`P(ZN"7E:^J6T9\!%\'#D'KJ;2\,%4X643,%8
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ML?+T2M&IY(!KX_8;VI'`UU)S-=B#28.<NA1(F`A1*U'XZI%;.>A'"C<.C('3
M<2\>_!'ZO*JB.\"KK3\@-B32LT757-*M-R;AMYZ#`3DSF*5>S*P9?.2WF5W+
M"KNB^1$U>PJKS0"^-MTS#,W(>QCM'YN$7:*S)=<-77_,`Q$S=&N9)1>@TCYK
MZ03<@7[LI9U"V?<<BAZ0N&O!5E73HZZ8$74'D2#19,9T[6X&<?!I]=?3?@+'
M45[2L_T*]"L812L+8<)5_-95.2DDMLXQY"G8O<5Y46Q"1P"VJ9V8.M",SI;M
MVY5?_HSEB.?;XVW4>(;;J!CJN]FV9)H[X5'&(S1,AL?U!"6$RL41$KB-,^8)
M%6H<0^DL^CC`E7*_!X8-(&V(OL8Y=L'>I`308(*.DDW+U$.C0\F.+-^G@H@R
M)M.73]CTZ'NT'K?E\*?N191GTNV442TZ&DV:S9PG\?G172[3[UKOGK6@X45I
M[6]MQ6!5_;%D1@?-:_F49E-I_0L5*O*HE1N$0JHB$^L96!=54ZM`<[B@Q\DP
MYA^S;<,;*[=N>2OVB***Z@7P]R7C(*QAD'7KV]X!2;QQ:$FCLRGLP%Q>6@`6
MHKYTMVYF,2D@HX5&),>I$2B0?[A--RT*=#G7_=5$NUTU=!:>H9^I8U>PF2%F
MK,%,2\%@LDFD*3=:5)0@[+HJ+D:T>+LE=\D1[AIM_P!<\<N4TU>T^==?#^7`
MDW`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%</4W
M^C!+_.V-?W4I@6/P*U^??\,7;_K4,_U>\"RF!A3$;CTAZ$=R`"%.=@##20@>
MS`MB3Z"2!APLFQ.".GJ"^QIADFY4Y2<H_(NGI3K7/6OFW\0R+=FS:]NU&K5L
MV4?N?O'RC=!)'MZ\^W0:?=.^D^>>G#G[5JDE\_?QZ^FGSS\?ASK6@P<LAD/G
MH=2.SF*1J9Q]99!RL#E@(7(@ZKAKW]1LNH,,-7C)19OW_7<=[XWUQO\`EUO6
M![&\<CS,8Y"M`09J'>-M,W@EN+8H#'33D<W#\M7+!)#EJNVY$M$FNN.N-\Z;
M)<)_#Y.=<Z#YI1>,H2)Q+T8Z"1EKL0@`=RA(0/3D3D$U<]O6H5P;X;Z)+"&S
MQ7I5-MTKM'A7K?6N==;WO`UZ0UE"Y"\-G.PC(--#D7>0]6QXXT9!;)'@GG'?
M/V@B<-&VI`.Y:J]_60UPM\B2W.N]<_-K`QL2I:KH4!KZ/A84"4;59$N8/!")
MEBC()%'XUT,;AWHYI)C7#X]\##!MQP_[Z<;[?;^.U]][WO`W1U&(T]220>1X
M&[10;,F2"+H2P7219C'K8D.:))JM^^$VP\BR1703UK7*2R/'?.M=<\[T&/=0
M*#/NPZCV%Q-XI'BS`\`[=1P.X[!G!0Y,0+-!^E6??0PL-$H\-6[E'Y%D6_.D
M^.M<:US@>@O#8A(!KP*>BD;-AR!)L9("2X,62&OC#-VU?M"KQ@\:K-7))J^9
M(K)K]\=*\*H\=\]:ZXYWH-DP&`P&`P&`P-*-UK74F4/+2.`PJ0+2H>*$R=4W
M%01521B@3SLB#&'NW[!?HP/#$%.EVB+C:B;=;K?:>N>M_'`V$(#"1D0/`1L.
M+CX$0U38B@@0>T%"!C)'7RHM!XU@BW9LFJ7/\G*:?'/'.O\`LU@?AU'P+USR
M]>A!#MYRY'/>7;H:S<.>7@?IQV(=\KJH]JZ<B^W:NVRGQ^=#:G>^-\_-OXA[
M&`]@*9-AHMBS&CF2/#9FP8-D6;)HW3U\J:#9JWX30013Y_DYYXYUSK7_`&:P
M-,'535P=J"9":V@(MG%CCR31EH.AT=9-8Y)"/W'ZA(`2#8<DD(./ONE?K.V^
MDUU?J=_-WOYM_$/M_#*MM"G8+5>P?]#?R34R?!OVF!_2GLOT_0*ZE;L=]A]F
MYDFBC9-S]]WQTZ^X3Y4^?Y^=;T&>'QJ."2ITZ*`!!AN4+,7$F,#Q3%D5D3@8
MSY'C5SI!L@F[+K#F'&D$.G':G2*.M<<;USKX8'@;0:%,S!J0M(?%FI^2/!!&
M1'&T?$H&#Q"/I_1`OC1-)IR]*/`B.OD9JK]J=MN?Y$]\ZP/,2KFO3+J2/C$$
MAA5[,@R$=E[PE%PCYU*H^UTIRU!21PZ8JK'`S;E7K2;5UM5#C76_ASKX[P,^
M,"!@B6D`P@6(0Y;,6?*(Q@T8)<M!;5-B-:Z3:I)<:;#F*7**''P^5%+G7'&M
M<ZUK`R>`P&`P&`P&!I+*M*X&IQ=$=`(2P2@[LD_A23**@FJ<0?&=.-&'L7X0
M8)\Q]V5T\6^Y4::1[7^KW\^^OFZ^(;M@:)_"ZLOL.Q7\.H)^EJ2S<^4&_M&/
M_8*3KIUI]U-.V?Z?]OU+-OM?6V1WS]Y]7^O^I\W\N!G^HQ&NU=K]QX'VMOMP
MIM;H2PZ5WV\5*K.^]J;;[[^=TL=>]J;^/Q[Z>+[Z^.U5/F#YG(G%I-'740DD
M:C\@B;YHBP>Q@X&'%HZ\8M^DNT&3H*_;.!KAHAVAQOA/M+?'.^.=ZUKX:P/&
ME`H,@4Z-HPR)HF>Q0@#V72CH=,IT#C[S@B!#=/\`AGIWT*"$$^5VC???T6RW
M.NT^>>M:W@?IU!(0]2<H/8;%7:#UBZ%O$74>$.$G8Q\W?M'PYRFJS[X78O&I
M5TDJCUK::B;E7GK6]*=ZV'L!16+Q=LW91F-@8ZS:,^![5H"#CQ#9L/3<.7B;
M%N@/;MTD6:;MXLKRESK7&E%>^M:^;KK>PU=.GJD1>`R*-6URD0C)%Z7C;Y.$
M1GAY'RQ(FJ;(DP;KD9I<21?F5^W:RR'2:BKKOI7KK?>]]8&V@H\$C#!07'QC
M00/5*'#2C1BEI%%0M)C9"22`CWSK_P"B=ESQ9R[7[W_*HNOWUO\`EW@?XI&X
MZJS:CU0`55@Q9.!S)BH+8]LV@]VWTT=,&K;I#:+=DY::^DHEQSKCM/\`K=ZW
MK^3`QYB"PB1)_2D$.BIU+4@8RS21B/"":?[I&-4&0V2_(]9K\_N`>R;)HH//
MA]RDDGSQSWKGG6M!GD!X]JZ?/FS%FW>D^T%"3Q!LBDZ(=M4.6K7M\X3XY5=]
MMFW&DT]J;ZWQQK7.OAK7PP/9@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,"N'J;_1@E_G;&O[J4P+'X%:_/O^&+M_UJ&?ZO>!93`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8%</4W^C!+_.V-?W4I@6/P*U^??\,7;_K4,_U>\"RF!1?VC<GHJGRWF9M1
M7\$^F-QW]&Z0F/\`%P!/#+L;^\!9@R)/QCN&2R-H\]#FT5>IN&[OE32ZCE#K
ME1+22FE`H["_S=UH*J2/RJ]J6M:*V,3*#4TXE"AD1/,);#2H^Z9$E9<`Z7L'
MHB0CS6-T.?WL4\TUD[M\BW0:C5MO$-X%N_R->L+9\JTQ6\VHJ##['F]BVX-K
MT<`?0*R;*=+CEZNM*R55`\"JQ9I.399YNO$VG/T/FX8HNE7:R?:;?OC805&/
MS(4T<@:4QZJRQGZ1"#I'H49C1RJ75?W)+XZ=IV%VY"Z@ELCL.+NRW=83J[PP
M_;HR/!ZD'&G"@5,AM'Z?02"'_*C6<L#/93!J%]%R^(MX9YF/LY.S#U4)8%9C
M[$#U45\[U.S92"V!9SB:3->WAC)VX6:)`PKOE3[Q^DC]-7L)&J+W"R,>#5?;
M5TP\C"F045:9N40.+MTSDA9<P.S9C`AD7'MNBZPY]+RG<?;-N^=$/T_]27Z^
M#KEKK2V@B^+_`)!)[;'I+R]359T%+(]&;#_XK./0Y>Q^X"M(*AD?EN2P^NY1
M7K1"+V^LQ?%49K.QKA8R.YD0QP,>--,TU^UWJHH/5[`]N6WYS]%UO!8K":[D
M]3:BM52NW>SKF3M+(78W#ZDK;RZ#2K)P-45C?ZI'#%D(EUF9)LI^JHMNFB*S
M97OE709"$_D0<F$Z^`E//UN2&S[4]!^GJ9`UW!FM7I/X6R\SS]Y&YB4L`Y(K
ME0A_?Z/'4/O.W`DF^Y**I])M6_"BB2&PTV!_E^HRUVZ&JKJ.^K!-%)H?#QB/
M`PU>,7DLKR+Q<K-#URA2TFL@!%N8FPCH=3KH4Z?MY7RZ6;M^Q7':_.]!EW'Y
M-.X\K?+>6^7KG[)5GZLEGF>LX[##%1GSUS\P2B7'H29341LG9<>"QEI'JTCY
M8NJU*NV:J[;[)LU^X)+KLVP?0Y^5BL6,%M>UX]0WHF95#5)6`1QS:84%7:$3
MD<CL:/5;-0[48U)60TEX0`-@EP!RY(X;%"PX]OR[36<<KMNDN@M;97J^NZS\
ML;]=/!,JEE;]P:#6`P$03F*R:6&@]A+QUO'FP+;:5IPXR]64D[;^O;F%&2O/
MS=(N%>-\==A4B9?EKI.LIW*JSM"IKTA$X@-6<V!/H\L)KR2NHG*7<9>3,'43
M]S#;&D`Q:92:,MD5V!%)?J*]K/FK54LDZ5Z13#R6?^7"IJ7_`%I*T*%]%Q5[
M"8W]Y9S/8RI#6Z[G18?<).`5<4<@;=)-3TDLQG19SL4^#]D`2'*P[]1?,>GG
MRHA`42_]0/Y-E4HKV,*TWZ>C7<Y,B`Y(N?B59?I->_KD@9`AI*9]!K9+O^QJ
MZ+]-[\1*!1;EKOX;3TM_:L"58C^:;SO-0]?R`+4OH'H)-"*/9<LN`KW@=7\(
M(3#S?#0ECR1US9/:9J-E'OJV(=]-X]^ME6?71%!RT2<#G"6!IP/\S\/X+2&0
M3JBK.B=1EI1Y^&59)7W5?#GJD)O.KW%H!;3M(Z0LO5?0&*GP2C3L,U>E&AA9
M511HNT3=I[3P.C_J/U77'D6&@;!M=E)/V::-'8ZJ;`,QSU$.9%US.+"#L":;
MTH-5Y7FRT&[`!]):5VZD1,>SZ^3[G2G(5>#_`)3J??SX37Y>I[QBCV5S8Q`X
M"8/!8-L1.RT(G$DJNVUPW(J?$C`UI4EK19R!*Z*M!ZSM;M)R-3?,NNG'`65)
M^MZV#^8*V];E!\E85+8D>HR8*NG3<0B3@\-O4E"V`R639+LQH>/`P9M.$'\B
M6;N7.F(]JZ73TORE\.@I;)?R\5XWATND\,H"]9%^F53+YI$'IAM7L8C<KL6/
M^<%O6XJFG#U[/E3H&3&_.7;:6_J"PW85)@O]KIYV5Y_3]A+=<_DCKF7W31/G
M&25M9L.N2XJB@-EF12S2*'(_612Q8;8,XC,/EQ:.RPLZVY)`ZK-J:(LFSL0V
M4^Q;N72+I\DCH(V]@>\+>\]>F7-8Q.%A#E9P/RL_]0V$]W4]R6!(3#$(<LY`
MG$&\V@+U&OZ4X>AJWZY8FI6BNQ6>NM\<\=Z1ZXV%)AWY?_5`OT=1GFB75311
M:;S.P:VC<O=0AE;:D8E0JW@GDJ?AF,'F)!TZC=9GZ_K/T:8>O'$K6492AY%4
MF@SE!X8;,T0ZY>L_:\'\AN82A,*^LZ=)2R,VC/RSRNF,2>-H'6E*MHB3M&?2
MK4HE\6<K"HN$F"#O346F1)O.4E$V[917Y.>@@26?E/@$2`GY0Y\Y^E"(!C9=
MU5O$WXX;3?S63KS.K<'7HJ91%H]N1FZ:Q2K1U(F'/Q+\BWYS2[),6U=JN.N$
M0UYO^7JGS!5./Q"BO1,SD,P/2X)0@8,(J]HX]&-ZYFUD0FRC]<N#UIAQ\>#0
MA:K";YQ^[5HXZ=,MH;:(N%E?H\A[&'Y>O/AS5C]1N#VB2XAE:55:42Y,]UG`
M']OQFX-U>E$WU<A+&L:)G28KMU;X=OV05;),%'?+EHBJJ]X0;.0QP[\FG2[T
MG:B,"+R[S=(O"59^TZS#0Z%FE?0R;.:R]K$7\3EH!22OXP\5;=D$W:BC3[9,
M8@BOM91=-/ZNPNK#O0J-R^5./1],-(LHM)JOD4T@XZQ)Q'AT-;GA;`KPW&SR
M?P-]/0`>/CCPSI$J_8*D/LD$U>OEVHGTGH,;XMN>Q/0/GB(6M9D?CP8Y)"TW
M3#%8@.DX2'V+`P\V/A:\MZ'QZ:]JR^/Q&VH4P8R`6U)*K.>6)!+OZJB??'?0
M:5ZI]&6M0ME^9V<8BE>R*I[,M^$53;A,T6DZ4VB/=J2P3!H-)!B`D6O'([%T
MI&1TU4(F%NDB9QV,"-DTG)'ATB&;]:^TZY\=_P`)U+"C<OD3:U9P.AR"L.5A
MR[J,M'L@BL8<RPJ#/RP!(C(`07FH[3S]&9DW#9%7I11/G6N-*!0NT/S40<'4
MUK2*M_.]X&K2C%;6-9->0V5-*T&B)5!H-7USR]Q;I0HRM7M,?68PE1Y=J]9]
M+)2M;G[?;08K]SQOD+5_D5]X!_!GC>3>BWC"*&YZ^$\!JEA<LE#:&Q>7V:_B
MAJ6,Q!:3$.T4QH,4`C9(H[^'6G;EH.[;M==O5FZ787KB$B83")1>6BGH\D+E
M,="2(:1$NDGHM^P-C6Q-F]&O4%%D'8]TW=<J(J\=]\*)]:ZUO>M_'`V+`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`XG-?RU$X9-/2
MS2UJ=E!^/UKZ+MRCZAB]-P:2=2Z7@Z!AMB69;U@%;!M<U`*6D:,9KBNWA!P+
M`%5R;1UI-CTBJZ=(<8'0[ROZP@_KR-SJ<UE%9\+@$1L62UN#FDS&!`XNRGL1
M>*#3TC@C%E("QWN*-R:73=-<HT%N%5>.]<H?#G?6!:/`XV>@OS"U'YM]U3'R
MY8?,6XKZN/+TTN";R07*6KRW&]JQ6"R2]$:X!U8HHV7+`G_G^%$2O)3ZR?&R
M[ABQ_DVX^;0>B6_F.I^/CT0Q:KK:KBQWTCNNLR<:G#.IY`2JZSZEC1$HW2GD
M5@MU$"IV'28RP[9#R85TN/=N$]H]NVG6^NTPPG/YKJ2"`"3R45!?2W[>&!OO
M)RTBM>QZM9*\926HX7:$H:%#%O/^JSK6L3EU`5RYJ7KBAC-FZ4^5XYZ;J==!
M?GR)Z5+>HH79<P*U+(JA_8/H6]*,8BY%(HG)5I0TI:PC$`[FK%[$"I9@U9G'
MP9;73;M3?3=PBKPFHX0TBZ6"MWN?\DL0\7W_`.,*3,)05UOTI8R8:=/)3.&$
M6,0JNB$O@51!I1$Q#OKE27&U[:MT!]9EQ_*E'F)E[O\`K6777(5UIG\SX(J(
MA<7NJB+/!6Y+K4:P(:YC3&`!JA+1N8W3Z(J"M["YG<PMK@5"@1V2^>B(!-M)
MG8DN5DR[-L/9+<D&N!X5?S90]2DJ^E,CJ*84W:ELT',;GCH,ZM7UO`H6XCS>
MQC@4!-`L'M6,3-7N7PRK2I86JHF*:O$D]):<\+<J\)A?SRS[IKKUA.+7@D1@
M-IPA_5Z/!1`C8@R(L1=@Q7=N7=1G<OA?<7F<K>\!^;+\]R9GI(LB+?\`;=!N
MYTWVBYXZT$E^IO\`1@E_G;&O[J4P+'X%:_/O^&+M_P!:AG^KW@64P-3E,%AT
MW4BZLNC8F1*0F6#9U$NRK1-UU'IB';/V8N2"]J:W]J68-2KE-)7G^NYY6[UK
M_MP(#+^(/(IT.Q`%O/-7O0XWN)],&"D;:\HM>(,M-E8NW2^E\G?+(9S9,@1V
MW^/T'#4T];K<*(.54^@D2\//=*>E(>S@%[UO&;/AP\^QE+`!*&G;IBSD(YD2
M&LR[7Z*J"R#Q$<8=M_FYZU\R#E5/KX\=]<[")WG@3Q:]<RMXIYEI]NZFS6"L
MI$X&Q`<(5<-JT<QYY!N!_8KAEL#U'W,1%=I]C_M>U-C&GU=]_;H_(&Z(^2O-
M#:NY14K:DJ];5M-(W!XC)X:V`-FX0M'*RCX:*UP,5;H_)M%*!Q^.CVP?M+I-
M4;RQ0VWZ3[23ZY#:P5!4I&:;Z\\@JMA`VC5(V;AZM4(1]AN"K1:2]D%#X!>.
MJI*#UA9CLJYVX1[XWPKM?O?6M_-O`\==^<Z+J5K`FE;59#H:C5X.<1R`]!12
M3=Q&0]F&P4FL5LQ>=;4=]JSJ1QE@_++J]J+D'K7A9?OM3X];#XSGS50=FVA7
M=TV%4D&F=J5+PIS6TXD8-J5-P[?;]$MPJ%5=<J(MW#,LV3=ME=\=*-':?*R/
M2:O.N]!F1-&4^!/B)2&KF*#9&`D]DS0*9:"D$B`R67"\[?VE(&;CG7SHE)X]
M4Z5)JZ_KG/>][ZP(8)^`_%IH`_BI;S-41*-D[*4M]Z#>Q)BY%K6$LR>"USFF
M2NND$6[D22=,U6">N1JK)VNW[;](KJ\=AF9[XF\G6@M9"]A4)74N[MX_$979
M/!H-ITA+)1!0JT:C,D(-=J\MDC[*,.%!:KQ#A)P]&*=-'/:S;K:6PVZ1>8_/
M\KA\M@)RIH:YB$ZEHJ?2@*W&:&($9N"&QH,$EJ:XI1D\&R$.)APMLU=M%$%V
MZ#%)/CKGGGX8&VDJ=JLO632ER-?1-Q4P\+'HX/KG05DC#V`")*#58P%8@FZ2
M3!H,`=AVOVB"?'*:&FZ>N=:USK6!I<S\K^<K%FLBL6=TO7TMFLNKLI4\I/'X
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MF(I$H'89`QQ"8[;%76R:C(UM&%V$Z?T_,Q5CPR,R=211T\[;QE*?1P42<_I:
M@X@O^G\M_NN6ZSA)4-(DGA+QS+WUG%)+YPJ@N2N8_')39S]U%67WDND44+*'
MP9E^X2TFJ@_;G5E7JO;?:.W;M=99Q]5197KL)G(4W5):H'7G\G7T3(4D]KKN
MHW=6.PS-Q"'-8J1S]H]P58`HGTQ[C.XQ_P!Q^UWS]/[;^L^'PP-#WY*\R=3]
MS:?=$U>I8#RN-U$ZDZL1$JOG-;=">(]W$ETU&_314:I&T^1?>]I[5[%<\LM]
M[:ZTEH/-"/(/F>MY%7DNA--0T!*:GB*T#KN0MV;AP8BT154.]IA&)!\Z=.5&
MS'B4E$F?2W2JC%N3>(M^DDG2_"@2VZKB!/I49G#Z(1][+9%"FE<'CSP8V=/S
M,"8DC)=K$"?:_"G#V/HDI$^6TV4YZ2WV[5^.M_/O`K[&/!GC6%QD=#XIYMJ<
M#&Q*J:XT8.B[1#EDX;SB"V2Q<H.=?%YPY%3BKXV09*?4^=BJ!'\M]IIM$..`
MRM\>.Z(],3^F)_=<31G:M%=S5S#(H;X9/(:Y)3?N'*/"DA#N62RA=P+ZA3;3
M5+:W#7KA9?APDOQWKGD,[._)OFJSX*VK*PJ2KN7P!I/I%:36*'8\S>AT+!EY
MZ22672I-LIS_`%I.6&)D7[*;^/R$4BCM!QRH@Y63["$0/XS?%0P);@4[1D.G
MW\<K'D]G625G`D>5-&CDBM"9VPR8-G[1H.Z#`XE()V^;BT&7*'7#'K2;CMQW
MTJHH$C&_#7D*1$)25+>>:Q7?S%G&&!QPC'D6&_MX:0AY:-[#)C^VJ48<C"=>
M@'&EQG+-958&/Z4[[VS;[3#9/^$CS/\`M-""<TC7J40:52,HYB`0`MV[`=4@
M,JF=!0$9PC]/L;'P)M!-XP30Z3Z9.DDU4>N.T^.N0VCGS_2O%*$O./-:13FC
M#,0/0(Q6'([G45+Q&5(/T)2%*LM=?,10D_)5UT2[6[[6?JNEE%^U%%>^N@UZ
M`>7*0JG=6H5K#4X2(IMC/Q\`CH(D32`B$+,7%N)7]1BX=N>GOW*PI/:/*O?2
M3??76^.=;^3Y`V"=^?*0L^?UK:EA59"9C8M/.WC^LID?!,R!Z&.GR[!XNH&>
MK)]=IZY)"FCQ+GOY^$'[1!TEKAPBDKP'EM[SA1-^/(<0N6K8C8SVOGKLA#'4
MF&Z>KQ]R_=@R+W3)37:?6VSHI&!CSM#OYT.GHQFXWQ]9JAVF$93'P1XQL$"E
M%YKYJJ62Q]%(0V3$E(JR79Z9@DY^B,8=)_#G:@Y%O:DC2[;=;V@ND:=IJ\=\
M*]<X%B)G7L&L2%FZZG<3`2^"R0$0C!V*2$:U*!"H`J,<!B(IXQ=IJ(JM'@MT
MHAWKX?':?>]?'^7`^@*"0^,&#)^/1X:'+R`;&@QAXP1VAT]%0YJ]8Q=ATESU
M]NDU"-"*Z:'"?'&N>%-Z_E_D^`;;@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@5JL#QSY:M6(%(#8M#UM,(<:LDW<)6/FHZU<L'UG2
M?E^C)YHOSK7"NS<G9EGC4FIKK7)!D\<-G&E&ZZJ783%!J[@M9BB`.OHH#AP8
MK)9+,2`N/,$!K!U*)D9=R&4&U&K?GA'3\X;?K.7'6M:^=53>_A@;G@5HL?R!
MYTM`%.A$EJ6`NWE@2XC9)L\_AL9D))2T7M=_PI1L9=O*!1H07D;"O^$Q''+]
MLZ9JC$],UD%&O7:/05CH3\27BRDH)'8F5JR.V^=`'9U)=3NQ(S%4S*Q2PC+X
MR:09A(B$C,1#`QO9%9`4R;,.$QR"R_T^MK.WBS@)^/>#_'<F`K1<WYWK-['W
M+8XQ>"-`]-63\9*"$2)R@.129+-]$`<H=P0/LFQ7^HT()CTDW":B>M\;"<*^
MJ.M*H5G"M;PL%"]V3.2UESA(`U^Q;2*>GF@YD;E3QHGU]JF6,(B4-NE$N$]+
MK<[5[UTKWWWT&NS[SM15IOI>3L>IX+-R,]@(RK)@_DL?8EG9VO`IDW(A40=N
M'::BO(5@?D3UZDDGOCY72^U?C\_/&^0AL+^/+Q''7CU^"\S54*<D[(CMNE.F
M0#2"1:Q(B:,R:,R,LVY7TV*]@Y7(GYALV<<*,TS+Q9_I'[Q3I?8>)+\<'A-$
MAV4X\L4_]YVRD([??<8141Y92M:9*GFZ3113MHBF^XL,VAKY$^=HLR:[9+Y&
M_7TM!8*`493]5EB1VN:XB<,,&!&@)0E'Q*`]V^"ZG4_LW0QRJEK72C/5@6I(
MR_R;_D^_-.U?_HE>L#1O4W^C!+_.V-?W4I@6/P*U^??\,7;_`*U#/]7O`LI@
M4S]E>G9WY=`UI*(I3XRU@TMLF+0.2).;*90F1H.9A)8]%8U&ZRBW[<DYFTK1
ME1$_VJ-#I)CQ^F@QXN^),4D^.^PN9@5S]46Q8])5"1L>LX1";`,!ST78$8_.
MIV<KT;T(DAQE&OO61P#`;%<JD698NTZ^W49)I=M_J]?6Y[XXX4#_`&M/2$1G
MT^)5(LT*#["CPLUT6<H"#BE<GY!!',7"VR(KF;%10;J7(5K*Y@/'OEE&;'OI
M5SS]-/KI-SR@&.E/J^NHG+;;B+R/6:^4I*.-#\_DHR!E%82/=$PT?D(>+MI<
MZ[9A74D*!9(W<ZXTKRT:HZ4[=N&_/&]X&D5A[=@]R2MN&KFN[4D\9(>?Q=_!
MYZ.!"U(^49D9#,XSW`6W/9I-QU.$2\)=-TT^?G9.5_Y$G'26M*]AJ7_&^^7>
M><%!]02@E%+D\XSKT_-9J+;'"(B#P>"`(D3>QH,/YC[>12.<O'TU9)<LW#,?
M\GSII_UZSCA/@+:5G;T%N$$8E%=DU9''1!QW'^339HND-,OF(P82=J1YTXY2
M2,,$.BFFO2Z6]I:>H+H[W\Z/?P"G4=_(A%B@ZE)#(*6N:%QNX5+8;N'1F-I/
M2<`YK2T*OJYO(I>/"."*#*#G"]F([4):<?.R41UQM!7GKM5(+`^?/5]+>GE)
M\G4,A7._PZ--!1OM9IINDY:%.RB8*0BU4UW":X0]V#>Z;?5VB\Y^UZVLW2UT
MGOL(?E7Y'/,L-#6><.FY(U:53;"M*FT^P:2#DK/V:$R>E1())X1:ZZ5$BJ\-
MOE$GO3%TLP8\N&Z*Z+T=V\#[G?=$!@'-M2"R4Q(VO8?U1;NMI/&33@H0LP=?
MXY^M"FO8B1"(BRC1]5\+6^*:KY9ERSZX75<H[Y5X3#\GOR`51Q6-GVK74,MR
MW(O6U3ZM3]7AD!*)QJ3\*1*)SE.'"92:T.%-)>WBDZ%D'+5WM#:;99?27UW#
M%ZW0"09;ZLBT#DK@9-(O+XL%'T&ZO0@\+`2:IQ1).21B-)0D*##-"Z!F8-B4
MF0:O&/#OETF^=-$FZ;GE=11`,/#_`&_3$UL&(UB-860RE,I<=AWO!F!%QPN$
M3+E[;([B`3HOWM1@&F+A]1\F3302[<M^]#^%/K?2>,>W(238/HRO:VL2*UF?
M0EKH])^(XHN_!18F8CD1XG,JW`Z[ZFIUMQ]H`U8<\YZ#"/F^I]9]QU]7Z*/'
M2V@UWRY?I[T)5QJUI'6QFJ!>I]8<?C,>DG2W<F<1.$2!['&Q^0---4VK`J4=
M"G':C5JJ\0;[Y^ERNKUSUUL*^55^0D/+0<??3"!==2.P#,%Y@%?T<;)7A.F4
M?LRJW%UQ;FV0+.+15:LY.SK)FL3?)*=/!2J:?R,'[U?>D=AN$E_(IY\BY2QP
M#EM99615?+.(I(HY'((]/'>__P!V[9EKF0M1HYTLX;1YC'J-E+I7M_IDZVD,
MY[30[Y>C^G03A3=_#[FEEUQH7!9S&V5.3D+"TI7)1[%K';!3.5Y#+$9GX<NV
M?N72H[H7-&_]:X214VCTBM\-?6^FF%?[,]97!4]GVN$/TI$Y+6E=:\WJ"2<`
ML24R"W);KTI=/5-QAFTK-U50L"@5"O!1%XY2YD2R:G/+5/A36E5U6P9OK\A7
MGA,(YE"F[)YBK.`.)RZDO-9RIP*2(,:Z2MPI6/.VK-=XYMH56:OZRL#1146^
MVXZ33[[<<[1P,TY]N5NSDC&%.X#=S":OX6O+>8P4K0@->LR'<:M67`H&3>.G
M?(EG.I8`I60N!S3[CM!1-HEM1=+[MI]<,9'/=]6$8E44HE$2M*"]VE6\+LLF
MQ,0QX_;U:)L9P4%5XVL<V&4>C`[BPY&#>#P6T^EOO5T=;4TWY4XWL)RHB^89
MZ&B#N9PH?,`[,>5:B'XB=1<A$)&R6)Q2,3L&NY#$=?73:G83-!1-MU\?FTW?
M<<*\I+\*HIA']?\`IG]\L/+CW]F]#/\`B2CDID'T]G.7?[/_`&U$^)/]KUUH
M6W_6_O/F^C\^M-?D_P#HOAU_]#@1UXT]E%/5IFV1[BOPD>%5V0;MQ\GB,O/3
M,&Z<+S&Q8D]A$H>&J^@C4':483@2)`J,&K&V;9H:9[^\^;KX=!]Y]^1#SE6Q
M6W0<H?2QJ8I@Q"@LG'\`$-*O5Y[(S<2`NA:KHHU:LQZL@CCMOI8JH,TY^5'M
MK]PF\9=N`L9;]L-:JI2>7,F",25C"X*4G&@H]B^Y)O&3`9T2WMPRY:+E6C9J
MWU]9[\C99TW;)J]<-U5>-(]!#,C]N4_$IC((&<'V'V?CK`6GMT&@9\I')--C
M("NY&(K"$'/MFR<DGQ@9:@/MJTY323[^\^7M5/M-7C@(=COY0_/"K5DSGZ,N
MK^;KPRQ9X1@3H`_,2@&)@;RU7"`(F#8(<R#]\R")T^8)(C4&2_"2B.FG2^UU
MV7+L-S>?D>\R"9!&(E(C$KB\ND#>4=DHG(8NX'R6$OHN0E0A0/,0GW*I!J3-
MEH230'Z9)OD7&T.%>E.$'#958/$[_(=5;EE"]QB$6N2.RF>UY$C8`[!3$7<U
MF"L"P:SAP^<V6J[;N>8P`?"K08DQGS<J=ON/BDI]MM-UVV#R1C\G/EF:"Q!N
M(DYU)Q!20.13@E'X02-,8\!;IUTZU84G=BU7;<)!5AEK@76EU>OO4^'G2:K5
M-PW<H(A92A;R1O8/.3"%?3RO^(/:MDU9VC.6`]EU(7-<3`Q$'DCCZ@\B_P"'
M0,BZ#]]<;[^FHGW\R?6M[X^;81L-]OT@0DTABBW,]#$@<FE\8:+'8&=&#Y8K
M`E[58RXS#G:J6^3D="F*8/,NW?.N.>UT6_2>NT7K198(D6_($P+PKT"9AM:E
M_P!T4W&;$L*),9VH>B4)N&NZM8PXY,2\1FS6*'>D30L+.!J2[)1CWIN2?(H;
M5[XX=*M@GJ:>H8S7\]L*(R:.R5%E`J\K>9MW8\.5*EYP5M*;OZ_BD6@HIDP5
M9G")&6)-1?&MO$5N23SCA1+A#_O&PE7FT@?%5.;>)!IF"`L(F0EY0"?B)D3.
M13,2R</"0U_$'3?@JD::_:*)_1YYZX5ZUKI/OM+KE3H*ZPWWQ0<Z&##T?W/'
MD;ZB\LETTE#2%$3,7J@/#S%D1X@O9<ACG9H0&1>G*BD;9FY:K/F+CH;\^E])
M.67;D,CQ[;J=NO$6D@B]QPUY)]LU"+6859(P:L"8'I0UA,',3_M=/M`(&L67
M/41X1REVZ3<N=J:4VCRV==(!CGGOF@6SJ)-F_=@%N);N-N/OA,`/O!\9!2F/
MT;)&$IE[OZ*?`..MV7HR)<.%NOG527(*<:3Z^U<[2##N_?U81FJ3-P6;!K4K
M"+!;LLBEEMRB.C?K+N*UEDJC):9MU&AI1JI&%>(FX6XXTILDJXYZ:-6SIQSS
MSV'QD/Y`:U8MS^XG7%T3XA'+=KNJ'@L+!^AJY+B?W'+J-XG<<5/OAB!R&")_
M7YICVOQOE5==HEM/C;=VW<]A/-;^CJUM6T;AJ&(K&UY91Q,8'G.WHGMD-1)$
MV^W'#5FLHMT\^9+CX;YZ<H-N'B76EV>W+;^W8$02KV'N'7M;%9FZLFJ$&J2!
M5.7<3EL.=$R5B6-=TT<0VO*\K2/CT5D"ZI(BWTVVY=NV?P>]J:[X2;-5770;
MW67K*M;>FXZ#04'9A-XZA@F:ECSFO3PR)Q!`YW(6PV.R\\02;MPTO[)1`LS6
M'?!15H\8=I.-I=*MOKAK=Z^MVU*3*9PGNJ9_*%XEY@M7TOW+!S=FC!5&58I.
M.E(2]*\*O"[,Z:60YXX[38..4MKHZ^7O:GPY#7AGY"?.[N6U=7Y=Y,(=/[2D
M1&)-(5,(NL#DT2D328;@#`;,A2SKMTP[D4Q^5DP[::>I][[TLKTBWUVKR$_V
M#=\3KJ90.!$!,VD4GG^WKMD/A$1+2SJ/QH88C<>+3:6[%I*=!(B).3`8W<NM
MZ4[2TZVOM/[9N[7;A4N4_E$\PPYD"?&VUP))2=PBX`)MJDE;MP3A9)B.)1NT
M444&_7:=;2UD3X['$5/DZ4VFMRHDEVBISR&R2/\`(UYVB<2L";'D[)&`*Y);
M;EW1*!$0^BD?X-6%'EYY'53:XUH3A29FJ9`W3<[527>*L..&J"_;X=R\#;&_
MNNA.I'(@)%U-8ZRCLG2BRLQDD(-AH.3<:F)>NR!<3(W26FR\:"S\7P&=OU>4
M6_#Y\TYYZ[X6UWH-ZM?T4-KSRU+?44?A4OGP<'42MN!(2,']"I8=&+1U.1#6
M+MB4TFL!4TU<<=O]K)]K,$>5>]HJ=I_2Z",G7N*NX0.(H6X#FL5DD/KY:5V'
MT$@\MD$4"RX/63"XI1504ND*2(GK&"5H0X-[%I-/K+,OFY3WVXX[0Y"Q"-HI
MKU(2MKJ#6&/3&Q:12=2`'([R&L?O]N(DE5@G[=>/>44S1'H;OEIQMQ]%?2J?
M?*GR=ZZP*F1?\A,')%JJ1FE9V;6T<M6D*XN-*4R('T\&0%2Q7MA-1D9LIP(^
M[9QKIXG`M]#7G*SCA_MSKYDV_*>^N@L1YS]*U5ZF@KRPJC*O"8$<?5C9'D@T
M3:/6)304))FB:W#=R]:=\$8S)AS]/Z:W?2:3OE)?23E-=!(((@'LR0RX6PD)
M^E)5`@DI]82'S3#]231'E_IG%94;A+^:2O3`.];!OUJ1QIXW'-T>G+7[K:;=
MP[1ZUVKH,\-][4>>8R!S%QMH3!\!MJ1TUS'(C7A>1RLU*H:Q/E9>N&C@OMP5
M[8QD3%2#EVBX3;%-<(I<<,^U7H]-V&'L7W1#0F[V`5Z%ZD]A^>$8@>G,4E[I
M]"VY"&'Y:XBI,Q'2+,1)WWW[%T-=\M6Q%B/T^4324X[TR73>;"V-C63%*I`,
MY3-7BXR/NY5#8@J6X:JN&0LG/)0*AL>=&5D]?(+"]R`VU1</%=\MVO*OU%>N
M4^>NM!4YI^1OS"1//HR.D$C>FV55-K<T.2CBZ3YP">PZ-V*S#\L';AL08R!Q
M7\Q%&O@\2;,>&#W77;KGM%UP@&_5-[)J>[Y#"(_6HJQI'S-:_'61U)&L'(J0
MR)`3!FQ(R*;S"7(J+`1Y4C)ZH/CT4FRSOCM=AKK2GT'#59</I<?M"@Z(LV/U
M)8DF>#IE(8HZFB3-D-4(<#P7+>6K!UGZ:"OZ@HK)UX(8;L.6J#G6W#'KA?:'
MU6^U0C1S^06LGC:"HQ2"6P6DDQL6OH.5C)F#&(R^K@;/++K*`,9A9/;I!US&
M0KYI:+`@+^.E>W_/7T^_M_INE&P9IO[HKD>-C3R81:P0CN56-:\)1'#8>>-K
M1`54UK1^I9!+;(6Y8,VT3%,C\Q#_`'/7';M+7+[73=1RDFHKR$Q4OZ-@-[D)
MB/A8^;,MP]*/$M/9;#RT8&RN*R]60I1*;PEZ13Y1D<1DO[6>]-7*?R][X2UM
M1-/Y^/F">\!@,!@<T+<O7V7-_7$_\P>2O^&.%LJ7HZG+=L.<^BXQ:E@.I.0O
M.7W''(S&H5%ZSG-;I!64994L\<$'[\BZ4=*D4$D6R?**BO82OX;]"VA?<,N4
M3=@&!A[=\[^B[&\Y3XE5JD@XKB9E84,BDG&S2'"98X?R>-CC,:G#'E<:^>/U
M6;]%QQRZ<)?34Z"[&`P.;%W7M[!DWKHMY4\F<^;(CW7OGBOK\L*?^BHW:$]X
M-?Q6L6T8!%(A"XG6DUKGH;L+JHB#PD1?$W'U?O6R*#77RK+8$F^([_MN[`E^
MQ*^`E=#K>\T>B9)Y^FINH_W*WK:<K,*]K*U`4QBH.8NR<HBZ3R+VLR:.QKQ\
M1Z0(,G'2;I9'M/>@NU@,#FU?M^>MS'KICY(\F(^=(J2CWG(7Z,L"Q/1,?LN=
ML'S"6V9)*SBL+AL/K695VY:/6KJ%D7Q$D^*JI_34;(HM>NNE54PD7Q7?MR6X
MMZ1K+T&(K)K</EV]4*;E4EII.4L:SGK,]3]579&91'8]-WYF4Q5RG';7;CB`
M]T0)<\/V"JJ+I1%;CE,+P8%</4W^C!+_`#MC7]U*8%C\"M?GW_#%V_ZU#/\`
M5[P+*8%>+N\MU!Z$DU03.R6<VZE-$24S+ZM-PFUK1K![&Y!(1&H\:?J=UO+X
MKR;_`%"/=+#^TW^G27V+MTAKG23IQRH%A\"IWL.7N8_746B[&G$[V(6A8HB'
M,*^6L)*L$WSH!'95;FGG,K68/TDGK9.L>N6;93[=%V]4126<((=**\A5RK/3
MWX_TK!DUPP0O,-VA+HD(D?<328VE*GJKRXG-4$I+'*RKMDJ?B:=A2&12"'ZE
MS:--]K]DNFRC[OK:3A7@/?</I'\>JS:[8?8\@D"+F>!JYLVSQXV,W,RE;PH%
M&5*Y@7`I@&%(2@-9$3$&8>1[#L4&Y-DDNBX<M];X=;X#0*5]&>"(/+&!N&:L
MBLX75M+N/VK91Y:]$H#+(09YM2U9#%9WS)6Z[=]/XB]ATK*,1TC^O(.=:>*L
M^=:6YY5"?JEN3R?)7]-0V@_W,I+Q%.SFMZL<H5G;TI"57".),WB!\99SA1FD
M%`),K#HUJ/4X.D6CUPY&Z31<<INMK*!]XR[!>`8-Y+\U1V$K2"NCDA"5"I86
MSP>-]\6).#2SQ-03"]\%'95[)#Q`L;>M]N6+(6+;*\HN7;K[9DN'T\Z5G15T
M5H5.ZJ&>0D<-M#T/"FT%L:;'2AF+:2O(2YES4<T8RTR.BD>E,SIT2=:!FKC:
M(GGK:''"&U'2&P]\X:0SP57LFG51U$:D\?+FOU><-"%MO&(N)1\:V(JAX_!F
M<X)R+I-\7/E.`L1AX%FW;/S99)MKMFGW]7D*134[YI((>A)D<\UVZ8)OIY!Y
M(*D$4NZ7:FQN+IW9=-"O9D-.*RV/D:1A\-DQB9.7P8<\534C\D^FW246=;&-
M`MGQ'Z>MJ^KC\S32FB41)#8/4EA!9>&M0LC*"<8K$^4C-:RQG^V"3`O61(6;
M[?:#J,B+EZ_8IK]$^6OSI-UPG9KXW\]L]RQ-"(&=#)M7CNL)''E;"L5Q&GL:
M)1*/0,N\3`.)6J+:3$U#H@*'NY`DGP<71'I;Z=_4VIVH&WGO.=42P*D%F`8Q
M+N.*P)T^L6DDOEI22O828?@2Y%)])536C;F0+&(PQ><&-K_JR#MORJDXX[^/
M6PPT.\I49!7@4H!B3[HV$-C)0E(3,MF$@/DY4*<6D\2E$B+FSK][(Y`\?75)
MEW3I[VNHZ5)[VK\WT6VD0V.;>?ZNL*?Q*S)2%)NI7#>@FQZK&52D*&+<Q:1\
M3&'I3"-!S+&/39"%S)/1</P6:O.1A+XN&^DU.NM[#?(7"8Q7D<;1.(#-"8^S
M>FR#=AIT\>Z3=R(X2DAE7[@@X=.N_O#)=PM\O7>^>/J?+SKGC7/.@A>M/)%$
M5(5%FX5%S#<D`*IDHTX-3J=2GF*M&<7DD+#1:+H2:1EF\?@D9C$P)M!0%KRD
M)&</5-MFZ?>]=:#60GA?S)'R4J*L("0Z=S%T=<&.7TZGY!FDG)!MPB2S`*.>
M2=9A'QB[._IA\&[)-!/A4VHIK7U$FW2(37"J@A%>227RB(MC(MY.4HOJ1C>Y
M1)"$;<O8A&14,#F6<9)%'8,4=[B<?'#W3QJ@BN];CV^E^E.D]=8'[.U!7DE.
M%I(:CW+TR<7J5R4>;(ED-NEJ,G3^R:N[VBV?(MTOVQ-":[W6N..=.M]_3<_6
M1UI/00MQX=\T\*K_`"P0EH<YBSV)JQW]]S_<5^V(Q?<%?'DXSN3;"I3AU!?@
M$[/\HZ,_I.M-?N?I?UN!+Q>D:P/3;FQ"\72>R_EX!??JBI$MKCMS&HM8L*#=
M*#N'_(Q5-K&;8/M=\=([X5Y?[Z4UUVDCTF$2(>)O/B36#,%@$N(L*]C[*)`6
M!:T;+)LG<7!$RYB%`94T>2M5":CJU)'7*T8Y+\O>H^HI\S+I'KG76@G:!5I"
MJQ9%!\("Z",S3P(_)(Z?$7WW+J.0:(5N'5^<D[>*)_9PR""F?PXWSSWIK]3O
M72JBBG85T8>$Z&%"8P%$N[P%,X/)G,H@_8WTQZ%9OX4L^%.@CX!$R:%E\$`$
M'?#'G22P%LKP'4UPGOIMOI-/?(6<A,)C-=1@7#8>-_2(X&T\T-'?=/7OVVG[
M]T3=:TY(.';Q32CUZIW_`%ZG7R_-\NOASK6M!60GX,\T%'%GNU8K*VCJWW;Q
MU-5A5J6@*TOP3E<BG!D>'082]!K'1!Z5S$P\(-&*:#=]T4<)K\=H[X3X"QSZ
MN(40K=Y4;@$WU73Z$.*X7C+==VT:ZA3D#W&502#EJX1?MF^@?>V_/::O*W'/
MPWSWKK6MX$8RSRQ1TU4*N#T0<*/BY#9E8H/D\K#E61WB(0J#LCX4B)-LW8,Z
M(`5T$TQ=M.T5V3L<D[1ZX=?,KT$.2[\>GGLY#9+&HZRET0*GZKF=6<R5"P['
M-N-(3,9.ACB72`<5F/;2:S@6G91SIH6*;7)(;(=_3<<;3;[1#<4_#WG+AT'?
M]Q>4.2`P=(1I(@\L^S';Z<<2=_)RQ)Y9CQ>6]N+))H%YH5=,W)KIZJ/7?*=-
MNDM:XUP&6)>-O/120A).O#2C<H#/QV1ZY&3J>B1IQ_$>Z^<19M,!`V3-1<S"
M1\C5@%XT'%$7;%)XQVMI+YW#K:P>&-^)?-T5`J1D9"2JP7I@8#-V9B?6">T-
MCQC<`Y[C`=8Q*'JX>-#&M6@6[!BVZ2;L4!^N$>>/JN-JA-D$JZ)5N]F[R))F
MF:4_EQ2='!3V2R`R#:28\NJ^D+^-A3!)\.BJ4@+N%G[UN.3;-W#]PJOUQ]13
MKK85@'?C^HCL/.&,N_?<L+SRPYY/7\FYLRRHT:`HSBPK1G*T1@[J/S)FM`HJ
MFWMTR->LPW;%L60>+=ND^NE-:3"00WC7ST!ZL'D?#BNV5F0V0P&2AG\\GY4$
MVBLP%``LR&Q4*3D[L=".IB/B8K158.FR6?*#&RJO?2J6N\"0IY1%7V2N?>2R
M/N79*212.PU^6'GY"#+-@\/E:LZB2P4B%*,'0`[&)DIHFP),ND"#9XFFIPMK
M:?'RA_KVBJT)TR3H(J'(EZR-1@I$C(LO)I,4-%A9O[GLNN2E[\NXEKTT1=/%
M7"I!1[T][<][5VI\_P#+@1.'\/>;P>QO+.(2!9LS92IB5'$K(L@L*G'$R-SV
M2&EK+%D96Y86.YX/6G)';+HTF]_3E33G[72.MIZ3#[L/%/GYB\BA!4',S+Z)
MOF[_`(=R:V+3DZ\I[&FQ<ECC2Q>STP(?Q(%PV0`V3T&T.??-P[AHGTTX2_K_
M`)@^40\/>:H0(=!`L(,+LWB739=606'8TH(],.-4^BQ%IE)%*R9!`4&'T%$&
MC%LFIRBT:!$DD^>>57'U@_,Y\/\`G6R&!03,(U*R8@K.9S82HI&T++&,6)VS
MQY0?934)P*EC)0#&Y]T<>N2HIGT@/=/':J^T=*=[W@;.3\G482$'`^HN4%<'
M^P3AT4`3.9@I`R(1>V)7>,=+A#PL\V*@RP>TYN3*HN&JJ2FNW.T>M]-N.$>0
MVB)4!6$)M&8W*#$ENK#G(M(&9-F)5*)`FV#</N"K@5'QAPN0&1D:1,)Z>ND&
M"+=)=WK:O7/S[ZWL/K-J$K"P=S9:1@WVR-@-*];2`V'DDECQU->ISY"55L6`
MF`98>_C!Z&24FJ^9/A_;9SRY^3KKOK7'&M![*QI*LZ<1<(UW'>@6G@*,QQZJ
MJ8.&'+\;$>C2@;I\[-DB+EZ2^ZD;YPZ>J]]/'[ETHLY555Z^?`Q]C4%65K'$
M)#-!19X0Y@4]JXAP-E4GCX^0U]90Y,=+(I)QH(N.8R$:YY137;;=)J*CW?&E
MVO:*OQZV&KN/)U&+V"%L].+%&$Q"R4E+-/A,TFHEF:,$C:4FWN5!QT@;"94.
M'29'1%BR((N&C%WUWV@GQ]1378;?8U%5M:LBA4JF(LNN=@+A=0&]"RR5Q7[L
M>Z+QV0NXY)D(P:$-Y=$GLAB`I\N*)\.F"SD<CUVEUK77/00:I^/CR>Z:\LR5
M<DC*"'*K0?LW8=D%E@P+30</&1$&Y?2Q=P'A,:'"D4!(=OTF.%I?4TV12^JK
MOL-1&_C:\WKPDK$)\PF-A.3DJE<D)2,A8UD!2R3.5$[77<0Z/JAID@M$H,D&
MNJ1L.Q(Q1JP6Y*.%=I<J]\])AMER>%Z:M>NI#6S88WC(B;[Y#3ATJF8DCHS`
MS5LC+?L",CDR,B;M0A67R,?UT@6UPNJ)45^H@EUKCA/06IF4*C$_ADEKV5BT
MR</E\=*120!N5W3!)]'S+!861'<N!R[1XT378K])ZZ0434XUOX\]<[UK>!#D
MO\GT9/)C*YQ*XJ3+%YL%)AI&Q[F<T;1=ZH:B+6OB\C1A[.0-XP/FY&`,4`:I
MQLT2+;$I<M=.-)?'G86%>-&Q!HZ8/4$W3-ZV7:.VRW.NT7#9RETBN@KQO^3I
M-5+O?/6O_;K>!7$/Y$H40!`QOJ)$3HN-`X?%Q'$LF,RE;E*,5\>E<AA$<=O3
MYX@Z)A8RZFI!!L@Y[6YVQ4X:J?.@DDGP$@T]2\"HF)]PJNFAUH"4)=%.^9%+
MY9-B6U]#AH5FAHU,C)TMP/%@@K-DT;<K:0;MFW'//.M_-UT'T_@Q6VA`H%J.
M<_I02SR-R#&OZF7_`.[6.6F9JP7\B^K]_P#75Z7ETB>._MN^NFG/UOI\I:2Y
MXXY"%7OAGS@04E3IS&9=HK,94WEIB1-K7M-C*>'#<7*P/Z")E+&8MI`%AJL?
MGIP?V&:N4AWV15='26N-):2#(B?%7G$*1M`DQ@S_`.K<#5XPG#5S-IT[%.1Q
M&8D;#(#P@AS)%1D6:OIR9>E%M#4FO2CIVI\V]I_)QR&]^D:58^C:.L:BC!5`
M-'K3`=PV5O50J9U?<0+NFR$L9BFZK\=P//D8]]RW'$OG[Z$OE$GO*2W2&DNP
MT67>+?.\V,RPX:AY=)Q-(Z+CIQ@%G,YCT>WH$RB@L'(1\8"2)A'A<S#B8*%9
MMC#=LF01:"VZ/*ND^=\]!)%34)5E(->FE;1YR$X4CPJ+KK/I%)9(^=!@TLL&
M<L$'A"3%S#YVYXE5IGGG;A13IPMV_P!\J=]<)H\IAA+&\RTY:\U9V!-H\5?2
M1M%G$+=]CIA,(\+/QI5O)6[(9*@4?.C`TH2!?O,LH-Z?(+]CUR"RJ&^%.M=:
M#7B/CSS^3DH&6J1$NS-`)0!EZ2@B>3X,R,&(L\K\I&>)6+%29H-EXB/FJM`O
MV@\DDZ8HO6'UN4OG7<[6#:"7FJE2_+GDA#>5].WU@DG'_P!>Y$E]1[:4[BEF
M3I;XI%N-\[.3:$#'OPU\.6^VWTD=)H]J)]A'/F#RDW\WF[;/[G9"9N[.*@.6
M+'MF<%@X7#HBK)EHO$P`<U,IDW%H,%9<]WVD*V("<:ZXY9BV7'/7/86[P&`P
M&!S!M2N_8-/>S;-].><J6J/T7%+TH&C*ED\3FU]DZ"E5>22AYG>,A9&6#W^$
M-K!)C'9D+NK:?7'Q'NQ[H7O^19-?6TPE/P51UOT]$+ZE5ZCX5&[+])^H+,](
M&H#7\H)SJ-UJSF06%1,#"$YV5C4-<3,HQ!0-NZ?ON!(]OMZ[5213Z22X54"]
M>`P.8]TUQZZK#VE(/5?G"G*F]"QVS_,]94)+8/.;U*4))80:J.SK>GXB4B"_
M-26L%E@*4L+@7:.&W?(]TP<#4^^=KIN.M(A)GA.E[HK`7Z3L*_0T%A]D>H/3
MDF]`OJXKR7D[#C]:AW585+4T?B2L_*Q:$*R\WV)J9,D^=(B6+5-R0Z;H\J<(
M:65"]F`P.95\5AZQKWVDAZZ\W5+5/H`3+?+X+SC,:ZG=VDZ&/Q5_#+7EMF`9
MH#D2=56L&DXDTA.';%XR51'N6BK1!5-1?A97E()#\/4W=\#(^J;A]!Q^!P2Q
M?57H1I</=75U-B=E@ZVCL;I"GJ/CX)[892(P/J5R$JUJ?HL\5;B6C1MT0Y;)
M_5^CTMV%\L"N'J;_`$8)?YVQK^ZE,"Q^!6OS[_AB[?\`6H9_J]X%E,!@,"&;
MOHJ'7]'`<9F9.<A6T>DZ<K%%:[G$BKR2MB'[>D42?()26*O1QILQ+1B6$6+G
MA%9/OI%SUOGOCO7'?(07K\??F]D3DQ:-!)/"')_]LN17$)EA.-MH&<BCF)NQ
M<F@:#'>N`IW;B#"MJ=J_<H=<-U$])<I/'W#D/P3_`![^;#)8Z7)")J]6DT>B
MX(^D[L*5O-F7<3;P,>/EA@D[(KGC,R=B:S"M';]X[7Z<)-.N]\Z7<.5E@\?/
MXY_,.T7XQT"F9&+%(L:B[^#$K#EKR%N>C@R=@UY1L"J2V@E,F8"S#C%L1XZY
M510??'7Q40:J(!.%/^<:VI%1!W#4Y`N4XC'<3=%Y`>>%GI$:K,Y1/EU7:77T
M!R;I633%\KK[=N@DBCWP@DFF@DFGR&0L6A8/:,P@\RE+N8_<04B)*-X^)F<@
M$0V2NHW)@\WBG4TB;)ZF&DG43FL?9%1ZBJ6ED7*'R[[[;J*HJ!D!M0`HZF,;
M1(Q)8NR;VS+;?-LQAEUTE*CLX=2TM)0YW;GM7:\:?R"6J/M,]?!))9JAKC7.
MD^?@&L7UYPA?H?BNOW?(['CCBK)PE8D1>5W-R<.70E;<.4!,B))-ERJS,;&L
M3+G;33E)3[1PIIPCOA?A-3D-?9^/Z39)VJWT,D3IG;[QJO(F+V6&W+0*R;38
MW970&%I=.M?M./N["DY,PLU:[YY4=OU.?C]#A!%$,^CYM@C>:3N?('K.3D,Y
M#G02*O\`$R7*-H`/EQ$(:FJ=7-E22FH'N8G8R.?/_LM\\[<LDMHZ1YUUQT%@
M<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"N'J;_`$8)?YVQ
MK^ZE,"Q^!6OS[_AB[?\`6H9_J]X%E,"KGIOU5&/+2=5OIA`[$E(*S[-B-7]R
M&%-(LX&0PO.93'(3%W$A3D4JCA,LN;E,L9-F@L$W+G'B>G*R#)1)HOUP%H\"
M`_25W$O/=9.;+859+K<18'``@E'(4;@8(RR:R$BD%:&-N+#E4/"+LT3+UJW4
M33==.-?<Z[Y3ZXX4ZY#*0&^ZVL"6%:W''V36U8L&9E)M7:CE)Z5BKOIL%4.A
M5#(W;N+2$C#WL@9-"_Z2^?)CW#MOROTG]PA]0-;L?UMYSJ(Q*@-E6H"AQ.$Q
M]*3R5(PT-IMF`A5]%1WQ1(I"E1Q,F@YG(;ZS!HJN_02*M%5$>$ETN^@U]K[B
M\F/!K,TWO.%["OH":LYN845)-Q.H5'FTE?ER;@FX'I,F3QJ-AAAWH>LHF169
M"G;A-#M!LLIP'FZ]N^=G4BIZ)QR:=2N0W;*^XG$Q08262>#G3=2>M'[B7-RS
M(8K$ML2E9'&>VA#3<BJY&.N$6ZGVSCZ02-/?0=<UQ:%;4[)%Y#J<VR$G)Z%-
M!D6.E!+MI7R(9<\D4D#)DL%`K]<'4?H?>+(IJ;UU\>N?ZWY@BF`>]O+-@U_7
MEB,;0&AA=D/08<2.D#(J.,"CQR/Q"2)C9&TVQ4X"L6@V?!>E2ZW?(/?ZLRZ3
M>=\/&O2H3M:-T5?2P\*4L^8#HBRD)?0,,H]2?NE7K_EDZ).^N6HQH^=)#A0M
MDL[?O5..&8]HEVNY522YWWH(7F'N_P`B0!M)7DPO:'`FT1EJ$&.JN]&.](R9
MPK*6O#!ARW%K]&V_)"#F6:CMCIRS2?"G;7M7EPW52Y#,)>S_`#$Y_>6F-MA2
MJD!0%N)(W"C)*;=\\%W(AFT3!,Q(1ZZESM-W(&";E`1P^69=OF^G'*6UD_F#
MV"_8/F8U)%8F)N2($#:3&$D?I-EWJC!9K8J];(0W;0WIE^AOG!G=Q17O2*+E
M19!"0L%5N$TG27?0;(MZ!KM`21FBI#KBI!$`D5A%+GWTVU7+$=%C;@(8&J%-
MN-/5"B6V3APGI-OVBLW0ZZ3[ZWOCGH-R#6?!#U>[M4=($?V!P$*R)Q('[0B'
M38"`6GFS;@H/+LV)82L&Z'+\ND'+=)PW41[X4XY[YWK01*#]B^:)'Q7ZHBV@
M*R-I.7K:"+N61X:W.:9/FXQ-[M<F(9HBPYDD\0;BGSWINR,KN$4V"KGM5/70
M8MC[5\[&"%)L([,"DFX]!3"00>M28"%S)\(?FXY&$Y@\4+/OT)+@"&>@739P
MQ?NM)M'[=XBY044:]=+\AYWWM_S:U(Q`6TFQ$Z[F=OM:.&IQZ%S0MTRG9"(E
MYN+_`%=%N`^X8Q<S'P_:S$U\G8I[QWRH@NHCRJJF'GL#W7Y=KJ*V?*2UI"7_
M`#4RQ5A)@H9H4?G7)<0PF+YP-C[!-CK<@3YW7IU%5\TVJ,:+!2&G+E'[!YM`
M)GEMT5W7]<C;3GAWF*1,HVCRC55XT>D2;A[*.6WZ.%'A0+<L6-&W2CK7/+5B
MBY5Z^7KKG6^.>NM!'97V1Y@"=R;DI<\/:\0^+AIF?<[7?*L&L</]1#D8^:D4
M&2K`NLI_$(!M5LS4<.FW)P?TLFGIZVVJ'E&^Q*+,268148:D[DA"*2B_H(PY
M[KR?-AG5;RU64I#'31XXC:?2QU'<2<?<"]\<D$M]<\:1Z53<)H!@$?9U=N[&
MI6LV`*5OS-P4:5]$+$F`Q4E'X96HX,-)MW9`Z(3(BI(7+.B>F[9F'6>J=?2Z
M4WO7*C;[@-JBOK>C9*-J!RXF8T"4O"-I2N!@GZNWCIR#<[6Y8OBI`1P0"Q]`
MFJAVBTZ?N6NG;OCMLC\[E-1+D,0,]L>=3TLJN&QZ8%I`7N&23*)1+H5"9HJT
M:R""@P<E-L)6LN!;J1#:H*3#GC-0CPW2>LWJ+E'KMLIRML)<JVZZKNMD<(U9
M-1,R9QLOH*96&?=I_:/%6;<BQ7X3?-FBKP.9&.DW0X@ARHP)->^5FJRR6_GP
M*^V?[V\_P"$2661\Z]M$C';*A-1;BD#%%2!1[.K`EKN%QM%-VJ/X&IQ9P;$D
MDNCNE.Q':HEXW176>([;;"P-N6W&J6KLG8\QX<I"1G0EMVW0TGM3LB;(-!8Y
MFJ]4ZX&#DE'[SCCMV[609(:W\ZRR?&M]:#0R_KKS@!/V%%2MJ@FTBJS2/,W#
M\,SCI\->.",6$)!QZ+,4ON2R+9:<@VNQ@O[TAPX-#T^D==O6VE0\+OV=Y<8:
M)J/;JAS1L&KU&U"A!PL_2$LH,N'$2+]66+]L=#-.VT</L23@?I;9)J.>(NEF
M_#=3A38?CCVCY?\`OVXMU;\?$D%X(O97;60,I!&U&$.;CI284(&OU\.-Y`ON
MA$'-.TQ[W;<DJU$/5N$.DVJW7`>T7Z_\W&BL)!#;4#N#5A,9"3C(G8V1($>F
M$3*$P4H=GV;D,BXAJ$>/!W`][LSRP^V?\<ME/E7433Z##A?:GGB33*K(+&I<
M7/G+@(ST/$MCH1--M&I>MVL??247+%70%LK#'FF,H8N&NB:;;EVU<IKI]=(*
MI*=AZA?L.A70*-R$U-6<58S.Q)Q6T2X.I.TW9<O`9HI!#C]XR;-G#N+!FD@V
MW0<N"_#!(>L];(N^D%ETN.PD2J[ZJ&[E)4E54Z$S-2%%.1$EX')D$=CG:BY%
MHBIQ^H,V?Z@-</@SUND];?69JN6+E'A7I5NMQP$7<>V/.:;2UWY>9D8VQIFU
M%:9F+J0PV8CN5YXB(_7%A\51V#5=S!H@*2<N5G`U-PF@T9.'2N^&B?U]A+=F
MW#"ZLJ*476:(<D(-&(FI,.R03K@DV)B>VR;@>Y8O6NU6/(\CIPEO3Y51-@W0
M[^X<+)-N%%>`TH_ZP\\Q6636"22T`(>85U'^9)-`+A(HLY#,NF,/)<LN'#0>
MX8EY$HQL$$JF*8JN2:O!AEOAOUIRC\X>'GV)YG[?-AW\7(]PZ<5QU;BOU6IM
M%N)KKEG('VI-)'JPKAE%6ZR,2+<I(DE&CI986\1X2Z5:K\)A]6?KWS<]ZB?*
M5K@D.9JSD;T&N09G131/41XE?<C8R)Z4$LVD--BOV(;Y4'&.V#_:@=[QRCUV
MU7YX#Z!_6_G0[JM_TZT!'7=MOG0Z`HO!TA%.3#MJ89Q[E-XU*AV3F.<$)"2:
ML&*A/AFF1?.V[=KTLJNCQV&TV1?%>53-Z9KV8.CJ$DOF7E817R0J+GSK!<X&
MCC^3O-'28@>\91QC]@PWQRN[[3XVHIK?\B7"RB00G"OR`^5YC73*RE;+9142
ML;:QHF-E#`HP-`#CD:3,]I%F:#)UQH(Q#A'SMR:1[6!MVK%RLH\Y3;+=)A8>
MT;?K>EHPE,;.E3.+1YP1;B6CU9L1)+OB+AJ\(<M!XP,S(E2"B`H:Z>K_`$$%
M--F#1PZ6WPW054X"'9?[@\G0'4PZE]XPX(E!'P@;)7+CHHJS;/32VFS9$<\:
MCG#20_9N^M(O^AW;O@6OUI-YM#O>N=A]Q'M;RW(%#2(&X0!M<!%A$Q(-Q#"1
M$G*@0Z/AI07H2W9AEESYMPPL4`IT*8<N2B7ZVQTHWXZ=H:[#_&WMCRJ[>(L6
M]UQ+M9>$#;%Y4Z_54V*40+C61I@2=DU1O`YBY5"/^'W3)95-^DR36<*(\HMU
M^TPDIQ=$*1Y<E^'?2\!#"+=)3"T.56B,#@[JE)"RC,V#R@NZ<M^V1!H2_4M:
MWPFHASH&^^HIQM+G78;#`[*A-F0QE8,+.<E(B_X(=H%7+`H#Z2_27;EB2X?#
M3[(66%JLG3-3E3AR@CWS\OQWKY=ZWL(UC?JWSS+&&B0.TH^LWV\<,.DWR14*
M_2=-S->`-\N!9H</)MDW1*VXQILHHCRF[0/,ET.E$'":FPB-#\AGFA3F$/7,
MADH6/SNQK@JH?)))"93'1HZ94K($8Y*$"Z!86V)L@;IVKM9N5VAL8DW3[Z=K
MMNN.^.0WXQ[3\N@6<E?$[@CZ243F;6OBZ3=C("#]28/E)8@Q#@Q8X.Z)2K;Y
MW`SJ"*XM)XV6<A7Z/"FU6;CA,/>6]7TU'$[H)28\Y"1FAW$:;6!)>Q!@FV&;
MDH+4C2>J"@H\C($0C$3WPLL2[:<COI;[4Y7ZX16Z3#XK^Q_,S94P@M;8'ER#
MCL=E+YGID?[?*"Y7J(_H*`IEP(Z=GC[SNP`/'8ECPY*MU#@_A9NGV];<J!M$
M)]#5G,J`C_I?LQ^V*JD$%:V*F:DOT6G3"+O&OWC9V]3:JO-?6<-^N=IHI;45
M5[4Y3XYZ4ZUQ@:L\]D>9AK40^*6T"$L3<.DD\9OB["0"6*$<AXV7F)/V8>$0
M[9M'C0497QY=<40Z;%>4PK_>FV_M%_IAZ`OJ^F92:KH1$9%W(^+)8V.1%/&H
M\FPVQ0JM-3F8M2(LPR'&>#PM^G]NJ)Y;]%4]_P!LZ;:1UTIH,+!?:WG2?P6G
MK"&S1^&`WLZ:,*Y3ED1ET;)D"#XP'CC1J59$0J>X\F[DDA'C4'3[I!BZ(/F[
M=!955=+GL)2IJUDK?C)H]^UC<,?QR?3ZNC<>/.@;]ZT-U]*247(.$GT=)EQ3
ML>14'Z<M^N%OJ:15YY4X34UWQR$.5W[I\SV)&7LE1L4=%OT@A-!IP/,.%P94
M0O`6$],R1=;E=+IF]&-0-82![P]:*N&:R09]RFKTJS<II!.-C7%6U20Y"?6'
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MTT&ZO35?289\#[.\P29G`2(6WX^Z'V@46$0)\HS/L6<C6X=`6#=^U=$!#5!"
M.EB$J%-AQ5?I(63<E&:31PNHZ0Y4#8J.])U;Z)<V/_"DJYD(BM).&BI*1?9+
MLQ!E\<A<<G;-W'NGG"#P@'5!REIVB\^CPW=\*<K-NUF_::O83Y@,!@,!@<]+
MC];>@6?I&3^9?+/F.'7C+*UJ6M[>M63VCZ#YH2)QX5;TFLJ,U_'HSH=4MPGY
M@>>J5,9=/^MLA[)@ARWYTNLJOM-()7\>^FBWIN$V*]F%9*T_:%*W3.:"MR`)
M2]E8($1/H,W!%UG4/GK$1'-2Z*'(S*ACYJZ6&#'7&W/:"[5)5'O6PMI@,#GW
M>7K2^@?I!?R]Y?\`-$3O.=QBEHG>MDG[-OWBA89%XK8,VG4#@@8$Z'U7<$@E
MTG+E:T-KN^-#V+(>U;H[Z<**N>4N`DSR#Z8D7I"-VRVG]5ZIFVJ$NF04/;<#
M93=E9<993`-$H18#`I"[`9@XMW*8L>A%CB'B2SD2+>-W"JS99MQVAOKL+<8#
M`Y_7[ZVN^+>CA?EGS)YNC%ZV6WI-M?T[*V1>J=#P6)P8W.B]>1-@,*L:PMT_
M*I6>/QHIVHWX&-6C)HSY[4=;[722V$B>1O34I]"M;KC5F5*E2ES>=;=_@Y:\
M&%3YG:<2X-OJYK^V8V>A-AM([#U9)'3T$LP6MO[L0+>LWOW#95#^T\JJA;W`
MKAZF_P!&"7^=L:_NI3`L?@5K\^_X8NW_`%J&?ZO>!93`K#Z8\KQ/U,-AL?G$
M]M6,1.,R!J8D$0K^3#`L;LX:T,QZ1(QFP&!6/GNEQZ!R*LEVQ`7V+/COE6X9
M$6W#ISI4+/8%3_;,^IVN/.TL/WH_D+.!+&X&+^WB78U*3FI.[G4>4AP`*L:5
M;!6[DO)6[9+M5ZLW:)(;4[561XYZ4Y"N+F>>8/.<N]%^DI#/+#VWI>&N)I*X
M`\(04R%KDOZD?@9O)P$/&!.$)0O*K*D=:B7&]&B;@*W<N=Z&ND6ZKW2`11):
MK\0^CO0MD2J97#8,=M9[6=-'IE!2QZ##F,#!W<_J%K!`HR7?M<UVK^M2*N(Z
MFF+:2$@'0)EG"K5/ZQ3M3`VYQX'\21N+2&YGEED&%=!H%8,6F,[(G:Q<"FS5
MOW9D1D$E=6(^@Z\A`OXFA-S(SM%D3:B^^VR&W+59=#KM0,O"XGY)F%W5U.:7
MNJ5V`4G1:R_0;6.UQ.:O-0:R2]>3ZS7G3TPL49)R!9K%)A?)L<Q0#OFS7Y_M
M?U53>FS=7L)9?6)`;TEGCNP6K"[(,[L12XXW%W"#2M="DN?VJ1*6!55ML7A6
M5NV:AEI6*R[)_'N5_I.1'R\D44W&N'(5B4H'P!-Q%)RPE;"H)MW8/=65@]EI
M^HC;BQ%:I9U-0Y.,"$9#&98V9,SKWSW'/KOF/(N0-'Z^T?KCU7_V>@NN6;4C
M[$Z'2"IK]?)R"G)#(8\YFM%3"+.387B7`M")=$2+DB&E#)FUD(GZ?23QNBB_
M:.VB:[%VBLAWO`H5;=7?CT!N7[BQO1TJ5#"[G6K9+IK.87R"HHP2U?=JO(*^
M>MXRB]:Q1[)^I/QVZ)J%GZ+X>@/^Y32'K\)A_BOGOR:#!W#$;:]F;2%UY(&[
MX8(3F%:(A:?KR<3FN"`F-$!\AA!$9-UK+/0V-M2[4WP=9+%.VZ+%NT5<I)J!
MFYY2?D`31MA5?6/H:+-),T\YO1`PI/+'8=M8O`[,J[SI40BRG'[7!MS#B0`X
MM5$1,`^66D''9U\U[U]'@DSZ3#H"O&:1_P"$?4.2FXL5Y[2HI"-IV"D5C:HA
MK5[>&)C.9,J6D3`Q$W;7]OI_76[(-73%?6^M.$54^N^.@KC6E@>6HK%J7\'U
MQ.9%9S"]:HN4M&CX(I$5D15=<E#;27DUG:74>"Q]F.D<A=!PP$(*6T$Y8[::
M8-6C#>N`S%P4!Y+YN_S,4L6R&,1M.)1X!"JQ`&2->=%K`"5R:822--^EI7%"
MY\.]"2E--;A\`=!'+QPYVU446UVBCR$*56R\"5`$I$5!O9T?&+<>@Y!/JT>?
MOVFF*4RE).+AJOE]<C(B,AHJ%-(Q)8W(V:CK@,*&O'!$M^M(NM.'_;E8-<I^
M'?C[@XA:0U?[>:O2+OT)7YY&P$[(IPX1XL^/0J4PH;&2J_$)_2I"XE%=R,F@
M9?F47I5YTKV15?\`#GCA?@-O@7BGQI8I2\Q%&7D:0E3><RA":O*H+4\I*:O6
MFG=VQZ<PI1_S6Q)V4:G'5GR\?MU(MFB0]VSY1:ND'(O?R!,_H>U/)S"M%P4D
M]!*0%QYLL.I1W$N@!$(>G%66"4*;K:&J/AA..2\"^^_Z,/19)-Z+=M4D^W?*
MG*2Z&]I!#B]#^#(M:%RRTM?[=":M(M`Y7:S4U+JX5E8?0LK0IA"9GY0XA^[+
M(E)D]JV(:>,G9-TV^N6UM!F@L5:[V%F8=-J/M>_Y4?@UO$UI!(ZIB\`?Q,82
MASN(6C#!P-2UHE8,,5V.)2ETA#QM\KI+$6#QH/[6*IHNDENTVW6@F6"T1#:^
M(UJ3"/)"LO5E*MZ(CB9$@V<-UX:V7B#CAX5328-]NI#ON%--;<<;23WSTIKZ
M7]=S\H18,\;PV/*PW]I65<4.8QB`#:R.,8U*0X[JPHC'R\JD$492POJ-=R!D
MXC)V:DW"*P1V(4<Z==(N]N4-<I<AJ5/>!JYHYK#>(/8-F)$8E9Q6S7)9YS6_
M/<J6D=;1*JY3%9`+%5V*`_H$CC,)'JN7+1JU-[)<*N]/]*KK?.$D>6_)-8>1
MXU((I6"A-44=>A>]<E1L*'K#1$8!M8W&0*2L,B,3V81#B&G/.WY7]0,/%>^U
M'+Q;KK7P#789XIK:&;>\(RRQS374BJ4I&61@M'MHPJ-4E:$AN"OZ[`]BXN,<
M.XD-F<K(;54)]OR[ABJFW4?;Y;H[X"P]H5T"MJ`2FMY,N3;`9>,[$E%PSE)F
M33:]JI+=;9N5VSM%%7?2.M?'I+O7R[WKX8$`R_QE6\K+D)*E)I]')6M,)-80
M21!24?5<Q::R27TG./UP0P-1HL'=:$G:%#?0:OV[QHHV7>HN$UN5^?I!JY+P
M97)UV45D=E7/)&!D6KT2&&Y)&7FGL]?UQ&:D.VT[+:AJ1]S.SU>Q-LP63[=[
M!I;6<+-QR*ZOU.0\EF^(0]UV_9\ULJ?RU6O)G%X<-`UM&'0@2S$S"/0BSX(K
M8SPHXCKT]N3C0UF./TQ-%_R,Y6116<LUU4$NM!(\'\FPR%?NQ_\`O6RCTKGD
M.G,3F4V?G`PB1EW%ARLO,9!*FBD0CT;'1R2MR1?:0_L:W:-F#5LAPDCKM/:G
M0:)37@^O:)_8Z\!L"R6I.&V#*9\Y(.4JV33E>IQ#X;#)=%3@4178F/M8^98P
M$6YZ6'M61?A\BHMI[O:Z^E`V*8>+ZZE_+=/<NL<"W5DEQ%9,W"%8YKB9QF^9
M]'+)LVN#G96+%%FD0.R6(#=<*C>F!EJT;;11?\:66WV$HU'04+I=T1>11[(G
M:Q.)1&&.-'2#1ZGP(A<AL22B>F_#8<Q^D[4(V<1TMU_+QVGPCKGGG?'7781K
M+?(8&3/YJ1'VM:\-=RFT$KA"N(RO`>G%>S=]61BGYF[B"LB@1_[@=.X$<<-W
MC4QHJFS<=_<#_LU=<[Y"8BE,PPE1I'STGP3%UX_JAW3*:8]_O]9'0QU$%(1S
MPQ)ODGN_U-H#4^"2ZW"W]MYUWWSU_+K81%/O&]:6`>-2MV?G8.3$Y9^_1Q@$
M5#)JQF:M8S1D<`R,(U)Q\FQ[<QM3SS'G[5%XD[:*.].M.4EVZ_T.0]1/R)7D
MF@ML06=22P+`1NZJ`%1V/()8:$NY";#QY6>.6ISE5H`9"FAY5Y8CU3KCAI^F
M)\(MD$6:;9'Z/00F*_&A2PN05?).)G9'3RJ^9`Y#,6C:J@81P=D[ZT7Y@^V#
M1ZKQ+&(.7_=NE.'2$?Y$-"'#0;]ZDYVP3WT'YAOXR*#A1:G3S$Q+WQ:FCKLT
M&6(B*HZ9$$.YZ,LT6!:!6E9-0U<@0$S$)NFB$,0C7]:LYX4VII?K>@N-8E6L
MK!-U;)-R6218Y4T]YG8!['=@U."6W,;D$./QH\RD(0ZS=`9%%Y0\;+=(<-W[
M?OOA9LY05XUUL*A3G\9WGZ?`(N!+DIM].(B(I'@[QW^PI.JE'XS&IO$%AO3"
M:P.3`N53H"?/.%WG#3AZV<(MUF:S;M/OZH6IN&F!]NB(HS3F4UK<_!9&K)X=
M-Z\<1]M)XZ1>Q"40`M]CJ4QV5`%$R<-FA)GO:S%7MOVOPX0Z2<HHJ\!6N6?C
MNJ*;NW_4FG=P$@_ZS*SL6CJDECVV$%(6(=ZEEG*@"'<2[D)+NPY?\A,AV8>E
M%47''RM.FR':B78:#&_QI1-DTL`$>MNS7$3?DFJ55@1CV(_:P,%Q%J(#F5B:
M9.#.^9@6F#VD4$2[(ML@!="7KIMRR3^\<;V&WZ_'W74)I]W`*V<E3Q,/"CD>
MB0^RSJ",2*/7]$GZ":-YIJ&Q5@ZX!JQ$^KMSR-;(=Z7^'2//'&M)8%D*RH./
MUOYOBGF]`R8)!0%5-ZS)RQ;M#J3R)PO'^Q$EFQ%<@D4;N)7*"CIR4=K..'/*
MS]RIVIRI\W6MA\J0\[1*AJ:YI*)G)4[C>NY:KR1<NQ(4F.[F1$B3((19E#`\
M8C,'%"W!/OD8P"CV#(;QSQI!+G>M[V%68=^,6G8.-!#0=EW*AH=,D)?('"3R
MLF*LXY;NO/Q/4>DB0NL&+1(8[->98L\>.F";(R_7T_VX>J_?K8$SD_&D".,I
M`*-32QB(DL1O]V(8=$(NU_:;'TH71DMDA!#QE$V[X@.U*-N7H[HFH^<L]NND
M=JJ-TT4TP^<*\65Q"9D-FC>66,:>1N7"9)"AAHK'>A4,#`]72L)@0C@7%QCY
M]$V+^_)"MSV07>E>N?LT>WG:+1/C89FW_)T4MUI9B"T[L2%K6T8JLG,EXJYB
M#E`FRJ5;:X>*N1$OB$I"D(=)/CI,Z.=-UT2K;YFZGP;JK)*!%#O\==1N+%F=
MMH3">#;)F+Z.RA28#1E3H&PUD`"=8&E+$'D>ZP5>O7Y@K40A9P'(*O8UQ]1Y
MP@.13<_(F$])>;(2GYU&>:NSDS<Q(/&`D>'RQR6'=6`B^C;]D:!3#HLD&2"J
MRH=(AR!'GOH=MEVZ2UKMMTCOI+859NW\<(&W.'LL>W5;1NVV-53R$1:534A#
M"8]"4S*%7-#M2UVDP@+8E'6J+>["'2@F/+"0W>F`WXLNM,$><"S,$\Q1"$$(
M5(5Y3-Y=,(C,K(L%[+)(\CZ9&93&U!/8.3%I*/CL<``$DFXKZ3=@V&M![=HB
MW2Y^3O>NM]A"I7\>E;'VE%##MF6X7$>=I&Q-UP*>NZ]79M&`"PX+9,.`O-+5
MZJKK]IEJ\8,4"[3II(70=5TT=D''#E3K`M_7U=`:V9R9B`6)+(RN>S6Q26R;
ME%RHF>GAYW(C2+3I%LVTD-2?O.]-T^M=]II_#77?>_Y=A0V:_CCBAN/A(>RF
M,EE()W<-12J2O[&,-.C47J6IIS8UF)U37W,)B\82)"Y<5LP]'".S:KA=:+25
M\@LY<:;M$-A=&Y*@9W`%CC'<QF->R"&2M&:0Z<0-:/)R6-G^8_(HB\<-$)9'
MI7&GJ).*2XFP62>#W/&DG?7:>N%N$E>`K`>_'!Y^-P9C`.5YBS"!/N5HUPN[
MC,C1!O\`J3T3+ASW8J71:0`SVA)?SP!^1`HU>MET57G#A-;:_'206';^>8(T
MHN*>?&RQIO!X<-@`T6X9]AAIGM.N3H"1A5UOTH(Q!-U79..H].>&C!LWWQWW
MRBFCSOG7`5[DGX[JCDQ5^[=SNW&84NVE_1N),#<1X"%SLO'7J%5D[MTYA+J1
MIE`P3T3(6S1%%^DPWK3-5=NLLW^HH&SOO#59NIUU-V<TL\-^HR\O.);&1A>,
M?M^;2!Y+;7F@)0_M_$7QQLRAYFZC^V*`YZPY635;<O=NOM4MZ#Y3OP31UA%:
M$+'OUU9?S]$(_7X#EPUA1G<EAL9*1$Z+$2%S)(>:?"W/)J$LEE'X%4*043[<
M([6^DKKG@)3\^>=(_P"=Q,D%`YG/IO\`N-W&-[?S]]'7KT0%A$)CU=PZ-"MQ
MJ,Q=MH6#B<7:);5<IN7[QS]5PY<*JJ];P+"X#`8#`8'*"R7UY^:?>ES^@P'D
MV\/3=77[YJ\WUN*(>>RM)KR&#S:B9WZ,,R(9-XU<%N5$LF,D`:XQJXQ^.7()
M]J-G2*_"/7*6U`E+\=5=6O$HIZ;L6W:U,TZ8]+>PK9]"1BKY69B9N=0V"2:-
MUW#(PSGJ\$/2J&L9840@*A%9D/*D4F2+U)%1?I?A7GD.AN`P.4]Q.+P\\^^Y
MCZ6C7E:Z?3576YY)INDT^_/Y6F%99!Y[4%NWM-B*<OC5OVO4FNX])8_;[3H>
M_&NGWR.6#E%PDE\R':@27^/>#6N';>N+;MFK)#2;WT]Z[E%Y0RKIL9AQFP8M
M`M4U1]2!?W]U7\BF$-%R0X_JEX2^Q8EB/+1D[;\*K?7^JFF'0W`8'*B]>+PH
M7\@'_%1$_+UP^F:NGWCV+>?GC6@RU.]3>#SR"W3.[&X<R:-7!:52-7,5DL?G
MFN&KT<^>J(.QZJ3A!/2J"G02)X%AMLIR/VC>]K5)*:)_XHO3@NT(%5M@&(07
ML@!!HGYTH>DVQ"=\US*)K#0Q>1R"KB#Y!@T+O^VX]9OM93E;OM),.B>!7#U-
M_HP2_P`[8U_=2F!8_`K7Y]_PQ=O^M0S_`%>\"RF`P&!']G5V-M*)ZB)8B3%-
M-2FOY9R]$*()/N7U=S^,V$+;\]N4'"6FSTI%D4''];\^VZG>N.N>_EZT$>V%
MYWC5BJ70J3D,E']W;7,$K0[L:LPX_10\!)SPJ.>`MN&*^TG[Y>P7>G'UOK);
MY23^7CG?S[Z",_0OF:16,,]#D(/*>-F[SHAG4G<-DSE`1$A<K!.9'N#VDQEH
MV,R*7Q\U"_W<Z=<H-D7"+ERU;=\<H+<;6V$B./-L3=>9QOF'LN90BC&OXY`5
M9`S^RXD+Q(`@-Y5.K]NFSMFH9,O1^W+I3M/OZBZZG>_CUU\<#3Z4\=02C>JW
MW'9/+BNJS4L]43R94#;Y?]6FC$T"_P"I<L!3/77Z8G$4=-/I?3WS]53Y_GUO
MGY0W**>;XI$1U'#61R1.4J'ETWF,;4==C=J&'\[CUA1PDU.?1'I<=M&C2QG?
M:&D-(]Z401^;KK6N]=A&,S\3126]#-(6'.`"'[INDC+&[%"+/.9A"[[MN.7/
M/J^<JDP+I<(Q4E</&HLR+#I`DU8)JIZ5VJKRND$JTAYWB]%=OU(Z;/E^B$'K
M:"*Z-=#=\IC:RXE?(ATCR/8,M<NW^Y<XZ<_]J>]\<?)SQ_7?,$%CO`D&92^S
M)7W8,XZXL>>R*?\`<?8-XN$CP0O*8)><%-/&H<4#;#'$@(,K\)=.B^T$R!'D
M8-T^4<JHN%W08F+?CN@<;LU_9:]G6-('*O5;\"!!G]LN&P9A6EI5-;P<6D__
M`$3]16':DU1,FZ*'/:2#,<NHFEQIQ_WK8?J>_CIJN<VA=EI+2`@T*W6$=MBH
MQ_$*]E0\3(2(^K1!,R@M*HR6).Q3\73@9+H9M=-+COITLFIPMMDHQ">NO-@%
MQYE9>924SG)<.P@HB&HSXL4;%IY]V!Z:.@TG6?EVA!B0*#2H]!PFF[0<MU.4
MN4EN%4]]:Z#YU+YM#U:9C<H[F<HELH$B+J;FRA=$(P:R8_?=GQNV9Y(UQ`88
MQ9"5>)+&DT6#9KKA!LQ[VFI]937UMA_EH^;1UFV$UG.Y[+HHU)PMO7%DQ<`W
MC:H^R8,+-DI*$`OB1D(3,QC[(T9>?6<B5VCETT=J(]=\]<HJHA5%W^+6M3BX
MLM+K=M*2R<=T)06D"C:!">R`J+Q:,P:(#5A8B(M!;?86)Q%HDJLBEPH\==K+
M=_+SVFBB'Z"?BWK6+#R8^+VU:(?4DCQ*`2YQ]O!""Q^KY2)>!)Y">=/XFNB)
M4E3!='Y2C;CA^P5:\=(=ZY[5X["WU.^=(E2QX\?CA<Z_7D$?1CCAL5Z']-F[
M-"U[GMSE9O\`:,6JVW&SEVD6^]]]]ZVU:M_CKZOU5%`AAYX9CW<E]!RH1:4Y
MCI.]34,E:*`8=$&06&3."3UI9H&6\QUN"1`RX_Q*Q[=)=X2;=O7H=#EF[7<=
M:^XP,=(O!8*1S$W.'-O3YJ94/:L*$HM!$(_38';[N0U'+CM@,T'$=7=2)L:D
MU)AG&PY)=PP;IKODDM<\K-MLPVJ!>+(M7EO$K^#V).G-SRF(,(+8<\?MH=MU
M8<:$PH7'@;"1B&D9:`4^8W+!.I&,^S;-N63YX];\ZVR>+-]A<`2T=L!0QB0*
M.#;]F/9M'IIXW9-79=VW;)HN2CIJ,;,QK9P_6XZ5[3;HI(<==[TGQSSK7.@R
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P*X>IO]&"7^=L:_NI3`L?@5K\^_X8NW
M_6H9_J]X%E,"&;O]`U)YSCL4E-PRYK$1,YM*LZ6A_2K5\_>2.S+>EPV$P.*B
M1PUL[>NWI4V4YZ4ZY3^DT9I+NE^DVZ"RO`3-@0M?5[1+SK`]V--P=@G(ZF:$
M@G*=;P&26*:9.3:_3,<Z=@HLR($T1BI#:;;IQM/Z7"[A+CK>M]ZP-PBED0R9
M.EQ`8\.W*AP6/'I'!';UFUGL-9R@>F3#)36'=N-GHJ]=-E-_!)ZBEU\_'6M?
M'Y=X'Y*6E600M(`!JQ8((.Q.-=S.5!2DNC[`M&H>GUSQW*Y`.=D$G@:-<==Z
MUM\YX3:ZWO7]?_+@:?#?1M&3T(,D$<M2#+L#$9D$V&\O9*(&/GD'BYPE'3<Y
M0'$'C=ZI"F902OQ^K:XV/ZXYUWRKOCKG>P]0OT)1AR;0ZN`=N5X;F]A0PO8<
M%CH:6!BKZ7P@"22$%I-'?L';A`N*9D5.D]J(=]_-M!??.M\MU]IADI9=%4P6
M;PVM9=/HR`L&Q!LF+02&$BC=O(I>QAR3!:1J1\9WWIP24&IDT-[23UM53Y]_
M)SU\O?RAA85Z+HJPH;!Y]%+:KXC%['?B0L,(;EH%MT;DQD:W+,H:U;.7Z3C<
MV^Q<\]*A]\_J2/7QY[1YZUO6@^MSWQ7M"!!TAL1:2(BR+I^GTM&H;*9EV+&!
M!+R0263GD8L)*J@XG%@`]=X0(.M)-T$D_E^;I7M-/L(P(^X/-85I/2!V=N@8
MZO9=&(21?E8G+&K60G9C."]8Q[F!*=!>MSP<]L>.%`G3L5ITW0>#'/2O?""?
MUMA*<5O.`3&S9C4@E61H3&%-.W[U,U#Y0`#&V#5ZW%EWT-D)D4R#3!C'S#Q%
MD_6'K.$FSM7E/?6^OC\`P*'I2MN[$M"O7G$L!I4VS3<V)94DB9>.TS'W7<;B
M$O[#+6N919PU0TVC4Y'.UF_+G>TDE._FWK:2FN0D7FSJV[#;D2=A0=0!H=V8
M_7.)8`Z#_I*81S)5"?ZGHA]C^G\1QFL0VO\`4^EIDEVOOKZ7/7>@T(7Z9H@F
M:B47[L^)!Y=-JEYO,!$9"89`Y(O57T4%UYDX&$5D%&@EDDMOI;OO>OI\(K=[
M_K$5.N0FEF2'$>WR8]^R?=C'O8TEPS=(.>QY%-%!RHP?<HJ=[:/4V[I)3I)3
MY5-<*<];U\.M;V$%5QZ>J"R(\"D2)YU`^93/)=6D6!6X.7JR6RB:0>3.8;(P
ML;BTU_231U=I)V2K/C[5%7ZRJ>_I_-K?.]AO6KDJ';=5WJU:WVU0F_-9K.=3
MF,;;HV1WW]+BOU5M%/IIS?M7^MT)WO3_`'U_)]+XX&KROTQYY@[)R1E=VU<%
M9,9_':J(N'4WCW28FQY8][81^%F/H/U=AY"1<)*;TV=:2[X2145[URFFIWR&
MW![4@1V32F)#9(,6,PX^*BAI+;QIRAQ*C`560MXRU<?7VFZD2`9';A=ES_WE
M!+>N^^-<[UO`R@:P('(S"\=CTVB)V0-0@F3.00:2!BAAO&SZ>E@4@7&,7J[U
M$(:2WKIH[ZXT@YYW\4^^M8$%2OU[4T.L>4U64'6<YE,7:$-=+AZKG!:,2&2B
MZVYN![7D3E[,.I&3]D)UC\QK@*DZ^]59)*=)\]=)J<\A)H:\JB-#H@01L2(C
MNYW7S:U8N(/'Q<?D9&O7`A,[W+-1PPZ9FD0S`6I]5VOVARFTUSUI7?&^>O@&
MZQB712:@6<JALGCTMBY'ESV/DD8-#3P%_P`LW*[-WTS,"G+L>ZY:O&RB2F^%
M.M<*)]<]?#KG>M!J@RZ:<-)QI8-;-9ED9F:)1N'JC)Y%GZ<KD0;>]%P$:[:E
M5>3IH5O6_N6K7:JZ'_T_/.!L4EG<(A:P%M,9E%8FXE)=N`C#>2R$0"6D9YVH
MDBT"`4BCQJH7+NEEN.4VS?2BW?7?.M<[WO6!K+B[Z6:?KOW=O5>U_:YX7%9+
M]Q/XHC^W90<561"QL[]0MS^DGBZS=3AJS<?3<..D^M)\=;YW\`^CZZJ;&(3!
MT2MJLQ[:O2#`3/G#Z>19HA!RI5UVR%C)@LX*IIQD@2>)](H(O=H*+*\[YXUO
MK6]8'L?VQ5@IQ+&A2RZ_&NH&)8GYRV?S*.,W$,!$TM.!IJ6(N"2:D=$D$-_.
M@Y>:115X_EXZWK^7`PZEYU)S84-JIO/8T2L"?`"$LC$8$%61<F]BH\?P3[DR
MS<<LY491YXT4UMJ]6UPV=][^1+OOK^3`EC`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%%KM]PZK&ZGOGRLO,?H_U+:$
M<KN*6G8`RC&5/,`U<0^?GIA&X$M*I-==OU"$6+S$G7QO;-@-5(.N&XU59QPC
MQTCM4)8\O>G(EZG@LDEL=B4_KF00"QI94-HU?:0H.)GU:V;"ML%#L4D/,9/R
MR)$>OTTPQ?M'P@J2'/6#Y!9)?KYNN>0LC@,"CM[^VTJDN5MY]KKS9Z(]0VVA
M6@BWY;'*,8U(R80"O9+)Y)#HB9EDGNFVZBCFGLND4.+HL&`]R_?=)C'"RR2*
M6D^U`DSR]Z>C'J.)30X(@]CU9+:NLHY3]L53;0H"*GU<V,`#1R3.0)GJ(R69
MPTNV(168"2K%^(+D6#M@11ZY5TI]1),++8#`I#?_`+9:4W<(/S_`?.WH'T]<
M9*MNKA-PVC&-5-$H/6:TG=0L/)Y;)[GM6HXJCU)92.>-![%D\>D%OL'*O:*:
M*6E.@D'R_P"HXYZ>!V(LSKZS:?GE/6*XJJVZBN`5&QD^@$UXBD4G@]F06A<J
MG$*-BY!!YP(+#R`DP_9N&C[C6^^%^%D4PL[@5P]3?Z,$O\[8U_=2F!8_`K7Y
M]_PQ=O\`K4,_U>\"RF!0_P!N>#(A[9YIYZ=M6V*ID=)3R/3F'EJX-LV[!=<;
M8E:S@PD;CY-D['ORCUC7'(X<2YVF[#\D'/:6U$U5VZX7PP(MNBL4;BK@Y7C@
MRL`1-O(R[Z*MV:9!5ON-RH)*.$^6BJ[;A33OL+I'>]]Z^3E3?6OCO7PV$+5G
MY6_AW?\`+[HW-F9489[MAS'HRA"F@>0#GUVR2N)7.=S">)''BTZ8C2E9LTH^
MCL>/Z%,5U6ZJCS7#?M$(6M;P`4L_T'*[X6NK[+M^/:]PR'$H`X.A(X='$*%/
M#M2)GJ?"H[,XGJ14$R6>-="QQ@BS)N6:Q;:*`_[0(6G?XQ9/_"R7QV*V7#I$
M:?P"9]L@[VH@<::EK7-UI;M9B?HE.9.491RE4P]N.57,/Z9O.%W;;7?ZAPDX
M=HK!;FJ/)92KI[`+&1GD5*GA*%](6(@C5W(85(>;SL$59KGFN6S:;.7-8MHS
M)`Z:22+A:0</&;ASM7X.EMNL"5K2I1Y/K)J2RA$D$@"5;-+"CQ%J6B.I-LY$
MK*'`VIMJ&?I'P#N*29B]C+)9F0^+YOPG]=)1FKM7A1$*+%?Q30]VA7#0?9?;
M%C!OV<-?"]1$J/"F8_':T\X5\3^V$0VPX8S;2HHMYL&O6SPCHP-9:(+I*#7?
M23=9,+B^IJ(G]_QZ#1:(VL#KN/`YV,EM@1N2UP^L:-VT#"-W*PJ!2E@+L6M2
M2,5U(MM2+UMP]4;E/LN&;Q)9BJZ;+A$S7PUQH?<HDA:+AT.L)JD`A&FT/19O
M*_AZEUS*]R0DHY[D;M.:EGDLG#EGP]TF+X2%-&J>V_;CEPY<A,4/\_EP/H^<
M>@ST\'2%U(H4K7@$0P@`N*G&<04DC.6#@T\EXPNOQ9"$%*IO4HNIV-'.!+,R
M1374?*N=K\A!$N\(K2&Y+YMH=,:N&N;HD%5S5!T2H;HY8063T_U1CV)@9'87
M-IBV\XJ%8U1K9R\CFPXYPI]^KI(DBHDFK@:=YG\)SJM'U/2><S^)(IPEBH_E
MM9QRMQR(DS-T:[L.H$20:1I23;*/P=S#)GPYX`<"G';9VGM/[Y1'?T^0E=/Q
M^UBHBLTF3H-806MO(\A\KRZ!G(@/;/K>AW<;"M!C4))MR88RKL@3(`=H.>72
M15@HS?J)?!OUQIQ@27XWI61T#YSKBO)T;4E-F)C%I%:LL<N$7SZ2V1*72QN5
MD'I1%LRY+]-'SS[)%S]%+ZC1HE\...=<\<A`[#P4])@(LSLBUPTNDL2.7,8%
M20%5"$43:\W%ZDJCU$[3'CB$YE[L6^!'*SZ%)ND'W/2[9[PMUSPJUUI8(VEG
MXP4IE"X1##%NA?LJ\>K@H_L55#F))$ZO=0A"`N!D\W!K-BI6P+24"MN%-R,D
M\5$;6Z5YV`^@NLCV$I_\`HP2,/\`[1G(4=(R$GK6;"B!ZLQYT&E*:W]+W1Z.
M;O9("822//9&D><70[#N]ID&+K23;3KE?ZBW:>@W*Z?&+"W15_),K'+5[*+J
M>U*>"3:+QT9L_6$NJ9KPS'RJ/*.G>^2),JTVJW5VOOCKAJNHC\W?/6!X*@\-
M1.FO2\POV-2/XACL>?`HU`NA\CUW#42L7IN'O!@XHXG3V*:B[,+20OADT:1Q
M@]XWWO3EZZ30;<)!(33R-5B5S7+?SX2,*VI:K1`2*ES\5MP5KX!S6,9K9X)C
MG;@@NS3V22CW;I=TB@T=+<.^VJBG:'/.L"J]D?C.W8SVO$']YOD(K`?/S2C$
MH\K!.G6R'2-!W)0CR2J;;3@;'7"141<"I!1J2$E'C==ARW:/V[5TZ24"[D"I
M!C7D)LZ%`#NV3:Q)I:,R9NV``.U2B2]EOGA#;,8'73?!GR8%R\WWQ]=':+KO
M6]JI;UUUSL*'5Q^,-_`2M6R#N^NR<D@-P[M(K(F\&DS0L<'*AJ"%$H2P<&;B
MD_*`21]4&T[?HFN9".1V_P!*#&0UT.&N6P6!]:>8Y;Z-F]0(BS$2CT(#12ZH
MI9!D[#V,QDB`*QV<!8\MJ\3>DQ7[4F+MN!=?;'N=N]"N^.>NF;GY]<\AKEB^
M!P,LKEK#8K*XW%#NK)]"3HM)BE5A)8R/,O1[JY^9<P*QSHV#T]D4>%W2^Y$%
MUGBO23I#:B[=P@Z=-5`AV(_CJF2"AB0D;%@0*31ZSK2*U,S?4Z,G`'4+E-IW
M,>;/;O:*S,)W<\O-1>S=.&SO:H3L&_U\WRNU-N.W`?9_^+<?M*;#PET%!(0_
M&:.'!AG[?DR7:LIHPK2Y0!+YX]C]HQM4N_)<TJT:.^XOJ%OGC1]W]Z[>.&8Y
MRU"1*9_'^K2$UA$GB=H@^AL"AQ(>%'.JI2<GDYP7IROZ<=F.9D^G;XOQ7C89
M6[%^VC/7*BW#M172I19/2'*(=$AJ3YN.8(%'B)$DBR:I$2#=G^G(/WR:"?#M
MXB/^X>?8HNG'/7?*/UE?I:ZUS\_7P^;8>W`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`Y`3ZW6/DG\CGH"VK:K7T$2K"]
MO*GE*(UW.Z<\[W/Z``N9?3=B>I7D_BLCU24*GI6'&APVT@CMMR4:M4'[=UWM
MNJIT@MQP$H?C+&R=W&?7EL&H+/Z_C7H;W)<MT56,M"&'ZYG!BL2D0JV%@Y29
MK^7,A<QAZ4A*0=\NR:EF;)^HPV@X[03Y7XU@=+\!@<A[<M5MY4_)-8%W6C6U
M^EZEM[Q70U8P^=TWY]N*_P`0G8-4W;Z.D\PB<G:4G#9V=AY)./6D'>,E"+-N
MT()=KZ06[4;+<<A)7XVTY!(-^W;H?02Q8##?0_MJ5VK4K2UH+)*PFTAKIE0O
MGJK4980KV:,!$TBK`S+*V+?8)%F3)XY8I).OH\I+I;Z#I=@,#D->5D<>7OR6
M.?0=E5O>YNF[&\-0NFP$YIJA;<OYDRLR"7W9,W-164B:5B$ZDD3<.HM.63L>
MY?LD6+[E-SPFOM5OVGL)%_':J;F<V]\W]U!+*@M>^AO6@2:U%Q;5?2JJ)K*(
M9#_+/G*HR4K7KJ>#`DWC89].:^+MV'ZJQ9.7C9KISPCI!9'OL.FF!7#U-_HP
M2_SMC7]U*8%C\"M?GW_#%V_ZU#/]7O`LI@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"N'J;_`$8)?YVQK^ZE,"Q^
M!6OS[_AB[?\`6H9_J]X%E,"*[#O&GZE?BQ=FV5#H*3.1R9R\*/DQQD)>%HQ7
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M3U(Q#=QPH^"Z.M57H?9%#G?SMOU)HCVHC\W_`-'QSO>L#.X&I"9["CQ`6*!R
MH"8('(FWG89N+)M7^RT,=N$&C24#E&JBJ3T$Z<.D^4W*?722F^^?EWO6]8&V
MX&#(2:/BC,?CQ(PP9')6H32C8IPXX3>FU`K'9,MP.0ZW\[GH>/YVLK\O_P!`
MG_+O`SF!AVL@#/39>.-7Z2QL"T$OBX_G2FEF+0[^H:$+J]=<:2ZX?;%./D^7
MKK>OI;^/P_D^(9C`8#`8#`8#`8#`TEG8\'?S\S5C61L%;"C\<%R\M%-_73*-
M8R9>.1XTWSRJCPBY'N'S-1'?:/:FDU.?E[^7>^=;#=L!@,#!O)-'QY\)%GI=
M@UD4D9FB`$*LXXX(%F,=_3?UUTQ;;W\ZZ`G]8:_7ZU_(G]QQ\?\`Z+6!B)_8
M4,JV*OYM/S[.-1@:N,:.BCSARMK;TT49A`P]HT9(.GY`D7,$$&K5LW257<.%
MN$T^.NNM:P-P24X63363W\R:O'"G'6]=<_'COG77._EZUKKGX\[_`.S>M;U@
M?O`U([/H3&-%?W!*@(CH&E&5C*3TFT17%(3,TXCD27(-]J?7:(20\T6:,N^^
M>>7+A'OCC?77'6M!MN`P&!J?4[AWV`<JG)!#H9()!S%0Q%@[3(L2,BZ?O!6Q
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MOA+Q)PGKK^7I)3GK7\F\#.8#`TF#6/"++9&R4#D3*3#8[*3L+*D1W#GI@E)H
MRZTQ/#6SU9!)L2_2WWS(*K-NEF^E^.T]=[[3[YY#=L!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"N'J;_`$8)?YVQK^ZE,"Q^!6OS[_AB
M[?\`6H9_J]X%E,#D_P#DX_'1*/>3FGC,.L8/6<II2.6FE$C[]N57<:D%E2ZB
M$S@]UP-3[Y6B$LJ"#RV-ED^OBKSL\V71YZZ;[WR$84M^-6\8-'F(286-52^X
M%(/Q[P2OUHDSF*7$BHGP9ZAFOH%C);`3*H\Z:7'8XZPGK!=DS^Y$,'3--7EX
MKRZ5TB$P>?\`QS=E3#?4\3E[6K;#BENWI/K;@;60WAZ&D4?[9SSTI.+KX&EZ
MI/BEX#3CZ.")CQSWU#?G2.&&2:S[X\_#OD+B^I*JD=Q5,ZB,2'0TK(6\GA\F
M&,YI)[$@#7[B,2%B7Y=`+.J9VWL6KIB/^V^X%'A:;Q5D\2XTHU70453V%"?^
M!GU*^:=A95:]<S$7^T63TP\*E)TQ=V-,^X%Y;A<DKZ8B101`4/JV5LO/Q5H1
M)MNG!%XUE2RG0[A7AQR]"7JD\1EH+=$"O!XVJV,R*.[B`A^*K[]Y=L0U;@:?
MNV&N*GC)&0J]OGL0:3>Q0A)#ASRW;K_H?*VFK3:3)HV#=+?\K2VS/3T*MS]1
MACB##!<)&&-G5Y`K,XZ%C&K93FT(AX9NS5BQ2)WNPL-BQDGWKEMOEJ(X^=%_
MU]G]@$`P?\<Q:/Q[S>TTWJ.$2'S;75?US#"E?IR'Z8GN*WI`)S,IY&N5`L?T
M#/VK`(H^;$V>TU^.'I15KVZ=-%%EE0\?FO\`&R=KQ*KV=WR"-6@,KN<2F;KC
M'IHR?9F)2ZK6JX<"L%%EQ$H(&92M[*X&]D+OA9F\7:DGVG/1$@0^L05"Q?M_
MRU+/33*KDHG_``\^\@Y*P%=/)\[E+):)OIQ7IF$A[+@R\79O%NK`K4D4X*BT
ME_MDU5T=:X=LEOI.T0JO:'@#T98D:MB-.K!KQXB2D;!]5SE_*)COMRBE<OIN
MUMR&QA9B!RZ(*O1R=[C&/Z+^DF63O@#THB\&NNQKL2%D)WXJ5GTGESL\[A1&
M)6),?+LLL2,=CC+,7-G-*=R;F>=G!";ETU>_OAH^&(<(N%G/"S8?RB\Z53XY
M^(5.;_C-NS[NP%C]L#9?J5T%"JO26=3N1@UGI".0_P`^1YS&2&]5K(7FXBT-
MU`6+,GAAU*6/;B0J\.8XHFN5Y*!/]%>-+BK&_*<MJ1S*`E64,\WQFG)W^E<O
MMN#!&.@UQS1C#8ZYB3-*'!VQ+:+E5VP,,11%-'Y5(TBZVD_0#)^D_(-O73Z9
MA%LQZ80H%!(O7YR)N&RKZ1!)LJI(JZO>$G!7ZG'`?[AV%*$+-"O^%1LD!?:]
MAU.E&CQU^GNV`29YW\XV%4_D0OY^D<CC/[H<B+4$1XE&]ZT+CC":.3ZL:;.B
MP:(5TW-$0W);CMT091X%IPKKKKEII372JH<^(G^+&](`'K6-1.R:O1!0Z]!M
MPKZ[7EG!`2Y%2VGC":D=>F8U+'::Q"+UV_$.$&*P!UUP]0W^I=,TW8YX%^O"
M52SBMX)/B]A=R9-_*[)DPZN`LP^LE)8=YVK\F^AU!0\VSZ*%4DBS.$LOOW*O
MU-.5UB773CGA;YDDPJ=4O@*8R[LH1NB-0,-#3WH`E.)76:I:6G5;3C\>L;U0
M1'3"S&SKY!*TMDH:W(\@F/Y5?#]"P:/*JVT^&;%@&/MWPW<VY0<+!8?4=H@Y
MI>8HF6C1^33T<.M"'DK3DUB"R7H;?`I^FR843$W#:)QY`<C(.'3#7'U4D&VN
M620?L3^,VV]2:P%IC<S>>A)I7M6P=\4-R*1MB9\9$GWF50_'#P4;&VQ;]%1:
MTF=Z'.'4H+]?/)UN>6S/I8DX(!9_T!YJ^QBEBEJX"NV4<`>3#=2UE7E9#UN)
M:&FX>6-)M7KV%L.7X82D@"."6.V[?IVV2YZ0YY[ZX0UU\`E",4=8?/C9W2)N
M<J#+FF=1R\?-;'8KOUDVET6D--&I]+1/39XV)-PZ=BRA\Y9(MW"*K9GI-)!1
M/?''7(4VD?@6VY`WC:8-I0-4\LXV6#!F5?G+5Z:T!ON:6!*2;:E^G8YBB61N
MT/+FP28*]MXXW;L6>MM&2_/*:'(1-7/XI;;KDW4"@NW`2<5KVVG$]5C08_)A
M#0)PM):6.=26/=E8I*B;V4KA*P?`E6K=['^>QI3:?3_IIV\8.PO1[*\L2OT9
M(*;,Q?FNM+5ZE8H_96<.Y8R-P(C/$(>W%6O62D8:N4W%B5YW&U7`Y!YVT056
M6Y_[TW^&^]A7.&?C8D.M68RMR10^TQ\J]*TU=@Q27]]R=,FC6MW3:QS<D+`=
MP>.,`%@R2#3'F.]=[7.K]MV*2:I/IEPU9LPSR_X^Y9)YM/G$]*5X7@4QMD%,
MY*/X?3-X4NB.M+]DMNZYMT:X;LQ'):'P@RC"A;-%8@/>AN%$W'2++:`UN$KT
M=Y`F=2^N+<O-U-&Y2`3&/D@42!)&7.B(X,[9U0SC41)1WB(,$>`E9-J^>H!W
M#@^8^5`LKILT&]*O=O0\=Y>)DK6M:[I@VC52]"K[JFA8#,9&9;DT)WOFFK?>
M34Q&WR8X$NC(8?/H>]09K==DVBK1P);\;0<I*?.V"/*I\%637'I>JK9[L08[
MKZM@)H`(BXXV38=1>-;>7F@#KR/`E8<Y</H6L*LL*NNCW(6(]J[`):_37G2`
MYRR#+>I_!\[OWTS"K[BMDC((I#H5&XH*()KRCF4QYX.D4L(E#P!$<X0"].^Q
MLGWRCI;?.U%4_E4ZUQKG>@@&LOQEW=##'G0F1M01^FU-86Y89BHV:O5!(/Z4
MEILT0D$)70IF/:<EIVPK8FT+CVC>*\]\2!QIT0*<KD]%`M)5OB52NZ^JB"BH
M_4<-ZI?U9);FC!:#-B379J"R"0RDB\^Z9<@`^XW-34?DB8I^T26(,%&[+C?W
M7?'>DD@H[Z&\%6Q`*??!Z^B8VXRTW:+C"D+%_NY0&2N,[$?0H="\94_T6:E!
MDE!/K`CW(TSOGI-HJ-Y^Z78)-V3UH'43UG1$JO6LXE$XZW@LA7CDM2D!F%V@
M0D8V`SMGN!S6(-V4C?14<6*I]QB0REE)6'P9K\=E`;;7_=U-INVP?CS7Y<9T
M@>L2<28@/G5HS=W%V#FT''!+N6%HG':JJB%JBS3@DZ=[;\$IC`7QOIJW[Z;<
M.2:BWQZ<+N5%`J_<OA&U;>]232V"4MKY*JI6'C$9>QK2AEH>D<.'2CSK)"L3
MEK8=&$'1)IM2I3W">U9`Z&JHGDTTQK)3D@X(AD*`\N676WIB)(/B9?5-U+32
M+Q=NWT0:PR0W0Y/V)"JS6B*C\JL\>L:^\ZR5T#*L^F:#-NJF'[1[4[1ZTD&?
M]7^/;HOKT!7]DP>R8Q7L9B4&+1K@TWZ(-;%"D3T0N>*&UA2K...G;X>^[L,,
M[33:GP*7"@=73M`AWVP6&A&M:^4)A6,KIF+-Z]B\$/K7-Z%M-S):)9R!]65*
M0*P?.9^M.P`Z83!M'"3HR:LG@$5T,X8I\.'*>G&DM<,MK:#"0[P5Z.A8,$,`
MRRGX^W<NQP*41H-);1_;08"V>^6"4DL6+*.`WWY>R+"*>>B3PDQ=\LVO#N3=
MJJ$'BR3Q8F&^R+\<+,I78>-#W$+:2KF1^B9_*)&KU*>NI#9EC![%84[.G;CE
M?I^\/5.ZES)1HNMO?8WE@EIA]/[9II,*QF?Q,W-TPM;](MF***V;/6\WD('9
MZ3BA<T<<L[&00U+"9V&V0U:.(\?G_,@9=MPSA3]48\[149+])/VP3M+?QJEI
M#'K5:/B-=38O9#(L_D"=@:E!0;8DHC]VUQ:-3J6(Y>-SJZC>/Q^'$`^W?#=X
MN-_6%E&R*W/:J:H7J]!T<G??ERR:&)AH4R<SZK'T10#$FZQZ`B#_`$(3_1D>
M^.QC!X]CP4\V0Z25Y9HKZ11Y4Y1X4UI/04HL[\>TQGC^PIK$B]?4Q84_@",`
MX>P1W(%=1*&H></X6(5@'/=1X/\`=P)K/FZ#SCYA*'/V2?*_VFG22:6@]4"_
M':<$PTXWD$I"C[$0\YSZI*AF0DL9D1*AYA/9KZ".]R*`O^0$`$LF<>C5O#1;
M50:%";TV%?;(-6C/ANWX#5*J_'I;,&)4XN2/UTX8PR5,#BVE91*C!*FA(VW'
M5A2>/4CR(@->10@,O2)K_MF4-U!$;:-1_?7TD7O.^DNPO#YGH%;S)4$$J6%!
MJ['"QTWG1J9<@&+P`.V%E!B:2%DYCC!FP^FYD+=V]#,UN77T4?LTG'7/>^DT
M>.PM+@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@5P]3?Z
M,$O\[8U_=2F!8_`K7Y]_PQ=O^M0S_5[P+*8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`KAZF_P!&"7^=L:_NI3`L
M?@5K\^_X8NW_`%J&?ZO>!93`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8%</4W^C!+_.V-?W4I@6/P*U^??\`#%V_
MZU#/]7O`LI@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,"N'J;_1@E_G;&O[J4P+'X%:_/O^&+M_UJ&?ZO>!93`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8%</4W^C!+_.V-?W4I@6/P*U^??\,7;_`*U#/]7O`LI@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"N'J;_1@E_G;
M&O[J4P+'X%:_/O\`AB[?]:AG^KW@64P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!7#U-_HP2_P`[8U_=2F!8_`K7
MY]_PQ=O^M0S_`%>\"RF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P*X>IO]&"7^=L:_NI3`L?@5K\^_X8NW_6H9_J
M]X%E,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@5P]3?Z,$O\[8U_=2F!8_`K7Y]_PQ=O^M0S_5[P+*8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`KAZF
M_P!&"7^=L:_NI3`L?@5K\^_X8NW_`%J&?ZO>!93`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%</4W^C!+_.V-?W4
MI@4!INUK4=7)2@0U<1TS(9@Y!R:;356QALH\]65#9C%3,@C8>O(4*K-FG7LA
MG8]EP2C@D@^!EFK)MTIVZ,<[WHB%^?/O^&+M_P!:AG^KW@64P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!7#U-_H
MP2_SMC7]U*8%7:2\UR,9:8RQ#GF",5<(_<[HGW'$O:EQ6!&XJ_C/<D#Q:71F
MA.JQ8TXD_P!L7N^QB2+QKR*9.T_I:16;)HIA9WS[_AB[?]:AG^KW@64P*(^L
M9??+2WO,5;4J<FX5A/GUE%+#5K_BCN3W$>AVH`D@0=.+TCLE#]QX7U*%E'C4
M2CP:<_'CZ'>M<=_$(CA7O6T+0?@(Q757U"6ELXG,2$QW3ZY3W$>A\;ET(]&3
M;0.UG8:L#16.71%VWG-R@7CC=HX3:=GF7>W7RI*Z["R_LSTJOY6I9:S&@>.'
M#:YE$('"20V5!BW[Y,!()4^;<$Q8`UM-?D+%W?7';GEFTXYYVHJOQKCZ:@4>
M>?DCG9&Q1G8$/3`6$FHD[&BHQ,[6_3#\9EA6>^=H\'G][.6T.>+UK7.QMFON
M@2[7;[B0<N6O76D>ETMI!L$)][78AYZ-7')*T@<Q"UU2/FPO(I$&GCY`[,;9
MOVO:<EB+]I'6,#1C`2JXXO9ZBI$GHGM?[%ITX1:\\?'CD/\`!?Y-),Z>C6S^
MGHB.V4\VSFWA;=>X`?6CL^@["S2JT21.,AQ".1"+%1E8KNVQB2.!#91D[^IQ
MWVNS=-=!<*K?3O[[\EDO3#N+=.'D=B%I'SD*C"AA=RY,U._E@LU&Q/<@!A2'
M1-X_BBB'/.VZJ'#A3Y45W:.N'*P53'^WK>4LBN7'3?S]+:T?`P3"T.ZMM<G-
M`@@O.+RK&K(N=@TOXKEIW(2@%"S$5#@IWID@WX9JZ16675XY3#3*\_*+,+(&
M<%X]4,#?#0LK)*3`BA99_E+NN4&WE(D/(PQBXKQ,F3ESX?ZH:_(T+)!4>OT;
MM13I'[Q-)`,1)ORP2:-@WA-*GZ]E3S<A!*-AL3NENZU'8Z5KB;V:Z@]GD#,5
M!CZ^O=@PAG0Q4(NHLT0>K*+*..46W?/86IM#U3+Z\<V$9'JUHH`W>(6CH6_M
M:8?PRK2)/8Y1A*X+"D<\L)E'I,[:(ORPYS&F?&FZW')I)!/^37:GS!7*VORA
M2^!=R3F+5-64S<\2*0`XP#_C,19'PZ$%-CPLA*6PP9UR57A+*>)D/U&$])IN
M_P!:%I=.%?M];^'(1V,_+Y/7;V1Z>>=8VD)9P>'D@+T7:9,H_P"YA+7$!$=\
MR,<XKX4T$P./%I0^7=D4WBKG]-9IJ?0X[54X1"7&7Y"[DF4:?$8K3<``K$JL
MD2\:>%[((R5PC<#.@IW>(KAR)C$1=#"U8J,8&JWY=-B?11ST];[^T2^5;GD)
M5KKVW)BUM>7JAE@6KR?\=*:!S0C8=?SUY)0;B<%0%B'M@8J''@79%N)39ULY
M[X>F?TQ@\VLX2;.NG([MLY"\$GL(0)J^46C'G(R7A@<)D,S&+ARS5R*D#8&&
M>EDTV1IE]\TZ;OOL_DTNG]7GGX_'X=?#X8'(:!_EKE1YO6S>7TY`8W(YC=\?
MK8H"#VC(#VTHB>G%05MJ6`B)&MXVP<OQ\EMCA55FZ[;]J(MDD4-+*.5%&82'
M*/>EWQECYZL615A$0L#N"=61'UV4?F3R1AH?``+\''&]NW7+BT'`.X)&8<1[
M<O2&@[8MQI)VV2<*HH<.7K<+5^S;MM*C(W5TGJH5$I"]?3F;]2R/3(L\`"#D
M)A/G&]K:*,6YX;'I01%E^W]=M.FG:+3>NU>=<*]\H=*_$*OC/R0SZ92NS8A!
M*+`;(@9_`Z]@2LVLO4?3=$)?=86D%RD^'B(W(Y#'QVWIK1\9TT8O$R(E':6U
M45U$M]!,U;>VRLF]-VG0$[KT'!`]2Q$\6E-AKSYA^F,"\'BM12B7DEQQYA'2
M7-=.4;9^4<8Z23URB([7>)H:>(<)AT"34X5XX52[X434XY4343ZUWPIQWK77
M'?'?.]\]<=<[^.MZ_DWK`_>`P&`P&`P&`P&`P&`P&`P&`P.;OY+)/8+.&^7*
MO@5F3BHV_HWVE2U#V#-ZQ)M8]8[*MY$%G\LD8Z%2QPQ(KP\N<7A39FH2:IZ>
MH,EE^6ZB*O?*W`157,`F7D[\@M"TG'/1_IFX:M]!>:/44UFD4](VT0NG0:8T
M;./-+.#R."G)*QYD<4<*B[<--2;9)WVP()]-^^T.5FW"FPZ[X#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%</4W^C!
M+_.V-?W4I@<_?-,\HLQ,ZVEU6UG<<BCKJ0Q<3)+$E_I.U9G(*\M:WPTHEC>O
M3U;&Y,5$R(;`6:Z`LJY<*ZZ#J.$.=-W&FSARD%_?/O\`AB[?]:AG^KW@64P(
M0N2:EHD5I,2`;CN2UE7,#K[LP0:\NM!@"<7E]C2O;;77R_([.1ZN5QB'7S:Y
M3<O$E/AUM/GG8<W#7Y.`<(CTR+L?,7?4N&WE+`2D0`'G*KXF)#P*P)D[M<S(
M1-7N`&RDRB];OT1CMBY+@'/7S<.Y`U2:O^F@6GH+U<$]461<-6%J6)!8W6Y4
MET".3!/1)G+.H59\OK<DY>Q\U&Q;8428R^!JNV'8]R<9]M>T^NW;9ZDJT3".
M+>]2_P`/./0I=;RW$95%(3:-;>;F)1O(NR<@L^=S!K4C@(PDT-C]12DF&KH(
M.M!+C2_*ALAMP-[11%[Y6;J=!I9'\DT/:Q0\W4\\F-E^:0K>X"L`7(LG>UJ[
MN5G4\)JY4OP`BT@3=")'94],QA739L_Z09PLLZ31<:X2:=ALL1]?D90#DDX`
M^4(NS#U7Y>U/Y9LG8T;CDJ'-WA2[``BH(:-*P%BR<1<C(J(5Y[=%7\>1;LR;
M-51AIPDZ9MP\=3?D.#R2=4)4,=H9R''3L4Q92=S&W<B'`:H,/YM==?"XPV$2
M.K(+M54*>HLFF98D^(V5':<)<MF+[I)SRB$Q>@)A8%8VWY<@%5QJO@-7R`O8
M\HM!=N@U0E?<4J^/=SMS$8/%N(*<$*=GB2_W:JW#I@\VZ0XY151[5Z<<A#]/
M>QGUBOJZA=>>9:R;G)T:6>$6@RW@7$-C\%)5A5MX<G$SP6K7/Z]-7$=L5HD\
M")LD44B[7CK9#MFL@_V$O3VKX'YE`!C%90(82XM+T_Y^8V06G,K-S$XV0E]I
M1J#B2$?W/&LUZ=J`7DC309,4W0K@:V=.7;5;3KCE)P%>;!_(0G'HI;"IOS''
M3("+S9?MB-[GJ9IE(XF(N#T37Q^Q9='Q%52`\,(B3OFA\8Z8B1DH<I,GR#QP
MJW39$56@22[]+3%F<]*E4:4I29<!+L\Q555>A%C]"I#8/%WQ^G&L;/VD3?5H
M03""HVXN#;A!TTT7[VQY6:-D.U$^5'0?&:^SXK$3DAK(Q2<*[L1N0=5Z3BZ\
MZCZ<9Z./V/D\5I&0FW$-T^8UFN;]8LV;XNL*4TD.%J./LE>W2+3D-UK"][)F
MEL&84"K/S^RC`GS%!+1B/4?N+];=JV05D5LP!:,,3<<K5Z!?5TQ4KWECR89<
M=.F#7^O[8=]K[8M0KVA[JCE90NI)`XHV)EW#'R[7]G$RPV01*(2MF>MNF[4N
M-K&8'$&<0VW<Q`HXIE^F<*-W;!LQ7=)K<LW*35YMN$APOVTF`F%,T46H..U\
MQDT[FE.R=0+82\C@\!D$?.#@47!A%159-E#/$X[.(?;JFF\6'=NMJLF[IZ]Y
MX16"V5$/&%CP;@Q+HS$WDH@UGW#!5"C6,CVC=4M6EF2ZM>I0';JI+="G4@&1
MI)=?Z/>OD[5[2UO?'.L">50XA=OIHL*&K-=(.VNFRK%LHWTV?\;3?-M(]I;3
MT@]3ZWRMQ\/E4YW\.M;U@>APR9NN.$W31LY32^I]--P@DMPG]5NLS5^3E3CK
MGCZC1PHEU\/^U/OKG?\`6];UL,>C'(\V>/R+<"%;D"JHM<H_1%L4GA)8(EI$
M,L_=<(<KO%1"/.N&O2G76V_.O@G\NL#_`'N/1]1\2)J`PZA(R.2$%R'8QET^
M*B4/N/H"R3OI#:[X<C]VK\B"O727/U>_AS_7;^(9?6M<ZUSSK7//.M:YYUK6
MM:UK7PUK6M?R:UK6!_N`P&`P&`P&`P&`P&`P&`P&`P*N>LO,3/U)`X?'D+&E
M]03JKK5A=W5):4)91DR8@]F0/9)$,57C<T#'XE*@KT2<?L'PX@T427:O.]\=
M)+<I+)A$M)>+[%B%\A?1OH?UG8GJ2Q(-6LXJJJVYVMZ@J6)5_&[0/P616.^3
M!57%`CB32.2NZR!H\.B+I9)BU:*<((\]N%5-A?W`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`KAZF_T8)?YVQK^ZE,
M"MT#O'T1-IW5PN7Q`BR?E)OW_$"I1U&^@:^W4`IH,/*=E27I1_*M4W;`T&X3
M;I*-T6&Q\FZ7Y[8)\])\;Y"QGGW_``Q=O^M0S_5[P+*8&IRZ$QV<-P;>0M.W
M&XU*H[-`3A!PJT=C)%&"";\:];.4.N%.-=ZTHW<)_'Y'+-PL@IKI-7OG8:^O
M2U..F!06ZJ:LW(PW+.)\:'+P.++,"\Z24Y63FA1HH*Z;OY8FKQKKDBKSV\UU
MK6]*?'6!LP>%0Z/&9)(X_$HR#D,R<LWDO/!P(H89E3L>ATU8.I(49-4'QQRQ
M;=[31[==J]))[WSSO6M_#`_PU"89)0T@CLCB,8/Q^6*;5E((T`%%0TE5VBS;
M[4D`Q\T79&5-H#F_'Q<\*;^1!/7_`&<<ZT'S<0.#/&#X4[AD3="R<8:PDD-<
M1T.NP(0QCP]391%\S59]-W<89IDG/*3!3GIJGIPIKE/6N^OB'^CX+"!(?N.B
MH=%1D?4C[.)*`A\>$,PZD5'(/6H^,]C&S--EU'V+8BX319;X^V2X74YYXUKO
MK6PQ`RI:J".8@\#5G7PAW7K!^*@+H9#(XP<P<65YZX*#8@NU&I*QI@2X[WIP
MBRV@FMK>]=ZW@;JN.'N7;$@Y8,G#\9]S^FO5VJ"KL?\`>):0>?8N5..EFGW:
M&M<*?3ZY^IQKX=?'6!K4<KROX<FBC$8-#HLBW?F"K=*.1D*#30)R'M)0^11X
M&,FO*3\XHCQT\6YUI1SOCG:F^OAK`V9Z/8$DDT"+)H_11=L2"*+ULBZ22?C'
M:)`:]337X4X3=CW[9-=!36M=I+)\]\[UUSK>@T\Y5M928<Z#R2NH)(!#Y9LY
M>BCD1CY8<\<,S+^1M%W3%^/<-G"S60E73]/OOG?7#URJOSO2JG?6PR/<$@ZA
MY[*NX;%.Y.2;`F1&1]QX1T>?LXN0V7C31Z8VSV0=-HZ6W]TQ344ZX:./[8EK
MCO\`KL#&$JKK`R5D9TQ7$"*FYB`ZBDN,DH?'GQ64Q?I+A#J-R,@Z'*NS@#I!
M/GC;-SVJWWQSK7R?#6![6=>P`<_C94?!X>Q*0T"O%8@29QD*U?Q2,.N&B;F.
M1MX@RX<`P+A-@ASVS:])-^^44];XWKCGX!YG58UJ]?"B;VO8,[)`HX^AP0@Z
MB8!P^#1$FV^R)184[5']KCHX09[^DNQ1ZX;*I?UO7&^?Y,#[N*ZKYV="RAW!
M(:YDL;>EB<=D3B,!%CH$B>;I-#I`*648]/Q;TTU0X2=JH*)J.4^.>5-]:UK6
M!]X3"P%>QIC%(RV6;"6+@L^U]TZ</GKPF?,/Y">*D'SKM1P])&CI5R\<K=];
MZ477[ZW_`-N!M>`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P*X>IO]&"
M7^=L:_NI3`J_$^_5&YY4&K?3EGZKNQT_W_\`OKGRUKS7K_ZT2;:&_/\`V`5W
MZ*_=/*NTOV[^H:V0Z;_7_5-:U]3`LWY]_P`,7;_K4,_U>\"RF`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P*X>IO]
M&"7^=L:_NI3`K#05MD)=/HL*Y]67Q=[]T1='7,>:^6XW`Z[<UY(NI4Y@$U,R
MA:FQ3L/`38T5M(0:1D//$D?,5NF'UDN5TD@LSY]_PQ=O^M0S_5[P+*8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
MKAZF_P!&"7^=L:_NI3`^<'\>^8JTE3";U_2D'A\J%]<;'&(^/5&KM.$42#9N
M@BDW<<-N6C-`JYX01^3Z2'*ZFD^>?FW\0_SS[_AB[?\`6H9_J]X%E,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@5
MP]3?Z,$O\[8U_=2F!LL;]*>=)E(&,3B%^TK*I23<N&8V-1NU(*<D!!XT3<*N
MFK$,+.NB+MRV2:J]*<)I]=<<I][WK6N=_`-5\^_X8NW_`%J&?ZO>!93`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M%</4W^C!+_.V-?W4I@1^8N*C$HR6@?F2>T:[MM9[(_V7!X*>KAR9=R-D?4*S
MS@='DGFD5B2>G!%V\Y^3Y^MZ76_E^13K0;_0>N-'KRTE_P#4]6P<TG_V[_K/
MG4^3^7?\N_ZW_P"?`LA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
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MS]VK[J!*%W/+:;Z3>JNYGHP[BT9:3M64LOV<*)O6L;3@;O\`5B3ARW10!MF[
MCMZJDDCM789:1>U_-$4>3$<>L1TR)08U'`!D:G`K(?DGY*6D).)C_,-'#H@[
M>V(R?DH671^ZCZ9-JEV,<Z44X^EWO02%$_0U-SFRY)3\5F[,O8D2'*E30!(:
M<;I\,VG,=Z+?IAMZ+;1\^ZCG4O%<%F[!VY<"%235-[P@HNEST&"DWJ"GXV>M
MF'Z.E#,SI:'.9I/8Z#ALZ-[$,$08:1I#NBP2+E!+H^L%D@YYL:U5<$DV3Y)S
MTW^CU\^!J!3VWYRBZ(E.;3]&,DG]9HVF_1Y`3`^""Q[^'9NU7;9],P,:?1/D
MZC`8R1+(C.G?!1X.:=.$&O:?7&^@F6)W)6TTKI[;`22\)0$4G+>S9R1##4-4
MCFX&1+"9HC*`TO&@CT8=Q8B">)/D2#5LJWZ;][[YUK7QV$5QGVCYEE[F"L`5
MHM%2MEGBT6@X,A&YF"D1Z2@%0>C@!*.G8X-.,S`<;)6)1TV<MT54`3GDMWSH
M9KIWH/@+]K>:C/([0Z?D5W)*8KP9,;NN[.1-,33=C#2:ST\#7AB9B,P_@;8H
M!?<A(H-0.DC3+K[SX.4OF##LO8<7DD5"S:$P2?%HZMZ93\RRE25QXW612.G.
M[27I[J6C14Z#BEIE&^)E]OK>Q_77?+9;OY_D<MEVW`3C![HK&R3!4!")8UD!
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MC?&]8'JWZSI\@'E9^)%WLN#U_:,:JF?$F04Z)&QXS(+"U5[LBS*R`4+$RP-&
M)CRLV).!*[Q%MMFYYWWM1#I/82U9MGPRH(B_G,]?D1T<'*MD'"P>-2>8%.UG
M:GTD4F<=AH8_(R/?_;WW]NT5^DEQTIW\J?'76@@=?W5Y716.(\6CM]T!8Q1^
MMV'@]C'&YG4W4K)*,CX8Y#1!\WGYXCW<\3^(T%T1(-]2!CM9%/2_&]AD&_M;
MS$\?MQ;&TFS\@\@FK%:-!\7F[]9T`_0]R?8YMII&5M+SSF.<[?=17CXR?EIS
MTKL?KCG?6@S$*]:T%8LFB$/A4S(R"13>,*3$.Q90*Q=),(^D9FT;[=3$DO$D
M15>.=22MSPW30^N,=]$13AKI+:_'T]A\(;ZOJ*6OJD`=E"(:87?%%9_7D36!
M'RKY[`'+E[J-RT^2`BB0"'#92.;<+,]E7;/2RROVJ>U'''7&!*M86&/M"$CY
MD/'OA/UWTD!E`I+:&WX22PV2F(=+`;I1NHHV65#R<`[;?53ZVFKI+7?/];UK
M`J]"/R(^69=6L*LHE.GL*:S%0$RZ`RN(3<><CQ$W$H]->ES;;J,ZVVA8P!*6
M+A>6?_8IR@Y35_4?IJ<];#<3?N'S#'!$I/G+&>C`D.G)BN#)9S7EG\#U9A&E
MIFA+1L?=_LS:$O:PGJNCW1U\(Z?,`:0ATH_6;\)==:#\F?<GET#J1[?66LO^
MV3;:/.>`T#LJ2*FRCE_(Q.^8(C'8>45LIDQ,1`HS>NX]R4:,'C!9!RHDKQOC
M`L\"-B),$#R0`0;%@,@%#S80JR4TLS)B"S1%^-(-%=?R*MGK-QPHGU_]-QUK
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MPA#H3!G`:THZ\2DCO2$>5:&&JW#W:2FNL#(%_:M%1(=*C$^/DX>,CEN2NGD>
MW,0GQ4H0/PB"-K%E)!Q'140<GP@()$]/"3@@Y;\C4Q#/9'[K;-1-782=7GH2
MH+6F4W@,!ENS\IKS2:DG9ZC\H&,>&RDBD\1^_!'C`0?'Y>+1E<++#%70AT^;
M(OQRZ"G?*J?7.!IDR]B>=J_.S:,R^>N@QVOT`BY\:I!["=+O/W#)HY"Q3:';
M8Q1TE8A!673`4,5;1_HFX;/R"""W":BG/.PF`Q9,/!5__%`@_?ZAFP@R0I/F
M,=DA8JZ&F>&G0K3**BA#V5OB1#I^CPDQ18]O>U5-)Z2^I_6X%<6WNNABCF4\
MQU2Q)4+BWGE'TPM(X[5%BD8^5KY5W+V78X21YC?'"LY;N84\24!K:0(\N-;;
M_2VX2<)(!L@;V70!1"N]O)0<C1&S8*)L,$%E,!GX,@-`G1DD*A49=T]C/#&&
MF3S:&&-"F)-9JZ-=#''Z?PZTGO>!XPGN#S)(5Z\0'6$2XZM5%N\@RI6M[4`,
MRHE^6%`@TA>OSL)&LH[%I*9.L6H@J349C3"[U#ADNOTLGKH/I&?;WEF8#-EX
M_;8MXRW][M/ZX*7#7CGEF\K-DFHS&DX\S)/4C'5R1987TBEWR79G&KECMPW[
MVKR%K,"IY/W+Y2"\SI0Q<8,6VK61-HK,B#\1*6HL8:?$9<!'I-BJP'D<;8DI
M7!"P)J\8*N6;F1,]B$E>R7:37L/<4]G^:Q!F9QQW8W?<B@3@:Q.QX?#)^7.N
MRI,T)C?`*("!,5>O["D0Z1GF8\B.`)DWPE\YX;O4FZN_DP/%//:WGV"5[+K&
M[E!>6#X=$I#,GH*$1"5R65D!,8CU<RDQR+`,P_WB[AF#MN..%==Z3Y02)\]*
M]<<HN=HAF)![!\[1-^8&2F?K1MW'8"\LJ0\GH7/Q"`"-#82O9))J<>$(JW9B
M)J-KUJJ<<QEPHG)&XE+MTHPY0XZ[T$U0:;Q^QHL+F47Z-=`S&G>V7[ABLIA)
MG7V3YR.<<OHQ-0T?DXKOETT[USRZ9H]*<?*IQKI/OCKH-+L&_*FJN4PZ'6!*
M_P!M&IVXVUCJCL%)5P&W&^E$VZ1R6L0SJ)Q+HBNCVDS_`%9ZR^]6XZ3;_4[U
MOG05G$?DN\D/3?(0O/2\35+V$UKR#K26OK*%_O1V[AE73%(Z@U<PY)Y&(TLA
M:X])!\9X'M727';Q%3ME\%\#?EO;E"A&*I&;R1]#6Z]G3ZL0Z;Z*3M^_=OJV
M4'IRPV<%,(BH4A4?"\DDUWC\NBT'-&?7#I1SILIPKL,R5]>TS%D9N]FI@I%V
M$/N[N@6^EXE.21V13Y"OA%D.F8F)#8HO*'#9*-OG+[ATBU<,%Q#+HDDX[9=\
MJX'G<>RZ0%]W5N1.YY&F=$VG#Z<E1`K5%F]M3\YGHF&$(B+KOD9$R#JPUCKZ
M=,6#=(0F[<*NE$]\I[0=,EG(8JQ/<WGVMPL^)DRLW+$JZKQO:!F*`JJLQU)R
M$1<.(8U5=1T<ZBC/@^\#.+$"<%VK511R#V13_4.&O]=\H;/(_87G6(/Y$,E=
M@JQMW$8.[L*3Z-PN?C&X*/CHBRL`FS)OGD518M9F(@A!$R\C?2FI$S%*:=+,
M>$/CW@3?"ID#L","I?&_UG]%,\.5&6I#%Y/"S7'VCQR/<)D8O,PX"3AUTW33
MOGZ;QF@IO6M=:YWSUSUL-%F5_5)7\\CE9RZ6Z$S.4M6CP4-T"DI!FD@4=%&`
M']<D`L,]CL66E),(\:!DBCMFJ9>M5F['EPNGVGH,E4=S5U>D):6-6)@B<A1'
M?'0PZ3BDOAZ!9FN.8&&9@0WFH&.OBT=)BBC=RS)-DE1[Q!77:"RG/QWH(29>
MY?/9PG68R)F9I,N[3LUO58)S&JKLU\V'&2%?'+,!R$]ON)(+CJ_D\5!].14A
M^3H,2;*;=MW*C)N\<MPU>._D4\O$H$^G<GF1.`HAY&]C!L+)8=-_U=B\9O+`
M1[*LD&$9=:DD/X'U:??+GQ?W@-HT#O>UW:>FCC:86)K^]JNM.43F'P*0/9`8
MK@JN"ERZ44F#&.LC3-QTU?"1TQ*`&,0DA(:MKG[I$8^>*->54NE=<<JI;["!
MI;[7B<2G/IF+.H)/>P7EFKA,]G<U6B,[2#DS9UJJ381:-_9P@D@7'M@NDW3X
MP@X5;,4NE5.T]MVKIPB&S2KV92\.MT!31<H1U(R`XB^D95`(=6BD,<M6,`>C
MPA65<"=QXA(B_-G!-\CF3IP_;-R3=RX12;+)J[#:V_JFBGTGYAHJ8$#LBV+D
M17;&.P:P9&FGQ%W,U:$Q:S\'%2`Y"3N%JY.?IX?M7DJ6X&+=L6[CC6NMA@`'
ML"E2`6E7YZ0.8R1O>$B9O"F*T?EQ,4HS,1TK*&8Y_+6,:W&Q!EX*`O\`IHR(
M+LGS[MDLF@AVIQOC0>N*^Q/.DS&1@P#L%;3&:M0A"&]&X78$5<RP9)9C"X#'
MBT;82F*AGYP.;E5B@F[5XV25;+IE6SCCO;932V!9G`8#`8#`8#`8#`8#`8#`
M8#`8#`KAZF_T8)?YVQK^ZE,#D+0SVOW'IFEMC)XO)XP*4IJ/Q-N7CE8M/2%6
M%F=<3QM%Z/EAQ"SRT]?1``&TY:378Z-M..C#5?[SM3K]9<I!UU\^_P"&+M_U
MJ&?ZO>!93`K!=LI\W5_:-)3B[)8`C4W;H3R)5(G(-_5:K=RPA7G<K*\(_ISW
M@9T(<A`Z?9951JW')O.N55N>7&!3&V(AXSM*(S]_Z"W):<U&_6\]3?/)80A!
MUZM8KFJA(.3OH[K@98X%I!CM/]ID'#OMN@^CK=%9_P!N!B[/;A$-*G5$?CG3
M5]0-Y/=DH8NIW(XP)MMJJJ).N&[@C/K/DX,$`%EZOD'-CL$I20DS=-VY1DS@
M+P)VBB[9;`M=CPM90=7>2(1Z8M4G3\QX(7"]C/.IA$]O1I'ADR(-:\[D1EO(
MU8\E*)<3?="H\X+<O#IGD0Y?I=:18]$^M.0U2Q$?&\<])W78DJLLHM=[/SW-
MA4X@[!TGTH-K-O'H*[EVAZPR+\&2;\:%4!/=B719^T![,<D46#/LJLZ=!`,F
MI2C9-/XI(#=_!X#Y^94T`:RZJ^Y<Z0DA8JY\DV3&P1^5$TGY*)J/!7GM0B23
M/,5-(=H@=\?17VGIUP'02#AJ!GE!6*WC!)69TQ:KJ\2DY^IV:4=N5+$D,M=6
MT`<C_LF,F#/&)<J29=C>FZ1!CWQ]#?&E>/A@<_?+5?\`B>P8%05H1\]942[A
M\P/S>B?WD;CL`E;ONR)Q&*3YG740KZ.Q0$-ZM,>LSA'**K%%?]*+.$M\IOGC
MAYV'AI6C*'K$+2;^%!?45?/K#](613,F,,+!JP5(@LCAB(Z`R&%6&\A.V;4S
M`9ZY\I"MK$8YRM('3EO]V\>IJD":BP7#M`50M`,X9&+*EMGK`;N]<@IA785$
M>\DK&-7(]F92^N!8]Q%8IV7$P<O.8^](.>2J[SE-1WV@FLBU^FFB$25E8U"^
M7#WL.UIB573*65[<BU?2U>&Q&7FFPF62^/US%:^B;&.H+2&2,&*:)K9XV\[:
ML1SL^;*O6*2B#MOTN$;3RA/(KJRO99ZV'UIUZ](;@8F;R`^[KB7@96'M^41^
M:QUK"8W^TIZ9F:1B80#D>B`E0\NLT2Y^U'LTF6VO*06ZO*'U[(/!\IKF(3L(
M/JV240&KV)V0<=22?(-X3(`(F*1V7"GT=?=2R8R_]&>HN@:S1QT^?F]M>^.]
MJ=ZWL(`!4GX<N`X&KB%6Y*R[>24A&RX&NXK*G:,638\4^K2,0M]OTI'%-B[9
M'5!K8]LT<O\`CG35OIVJ)[51^XY"<(6T\R^4IR5C92VS2ME$*UD4QESZPC:A
M<H[B'%A7G>\AFTF=B0`V-@W)&22V8O4>/D9<+,!BZ3)O]`<II,/!<9KR/*+#
M9+32Q55+"(Z$Q$7'XW(2#-XZ)TG/F5DCQ.U&#?E$$5_>CYLT27<NF>GKEPDS
M;*[<]<ZP*N>5/%W@^[:KBMCTY)[)E<?V5"21?HD;%@#`J1OZZK3IJ*E`(%$H
MX,3(]P@4"<JJ\-NN2NG/ZCMP[Z>].U@FV0>5J7\C5`;FT"W(1XVN;1KV[$&F
MA\:=JLQD%==Q[]BAV001$N'S->#R0J-0?$U7ICI9[RX>/7?27.L"+CX/R+'&
M?H9W`[5=R(Q:/H^APUZ,U7#!RJB21O=[^G1P:X;AXF,<HFY4D9C_`'*"[PHX
MWRQ4%[)+*"6;!N$G^N[I\5VM6=@U_:5K&UQ-66970R>#JT$/Y,?#2LG8^JT%
M,2$=<P^6@I>%83-RJQ+)]#R:`MVEKO>D""+3OD(TEOB"M:IKR438QZ'L&#1<
M+,:/)56<5=<N=U%#(F>\LC]"H<(7CQ,H<MFR^*!&#$U'3<FFX?D-)H#-J.WB
M+P(Z+5;^+%#D\=4]#BAG1JHF8>0/VDTB;LZ49/8NU'ZLXJ5=PXG+2DD-1Q+2
M;YBX<*QHA]173L.JHHIKH+,T`<\,^?AP<17]Q,NF\HJ-^Z;?N@GM%!2!0Z<^
M@K8,.2+-O'0`:)E6!Z53COL8J@/<IL@;I!%GPF)<Z1#0ZTC'D2;&/$?;B\5Y
MI-ZC`$0]`I`6KH*QE$=@ZA:*1PR6Y)15S(XQMR#'Z:JK-"80?,%$.TE-%&::
M*"86]AARO/.@ROJ<GU@BE+'M246/*F#9-B_24E$KG=AO9E,G;!FV2?\`Z+'6
M\SLAN.:+OE4D?JO&37:O3E=+CL.<86.?C(N:MZ0GN[,*`V";FL8?%T9*Y'KR
M@;H/4%:`DH7)6LDA\C0`B'L&81U0O)67VB2*^T7+(TVY<:[5"<O0]?>4+`J.
M%PU9*16)'`-_B99M]!2D`*R.OR7JZX[5JDA-'K6R![X,[B+J?3*1!]\-&;HP
M/X0Z7':X=,4W"8?NLZO\A2OT=/:P@LLL:53"J&[Z;]B=2'2L`JCB4SFTQ$N@
MT*<_IC1TZ1*6&;-N"B2BQ73-^Q38\NF_(_3!$+$QRVO.%).Y)6R%Q.NE:<K^
MO(F1@K]T2D*D:$1!L(C0KD`.%`E7\AF!+J:!&Y=LPZ?O=.'POE1NAVZ0TN%(
M+E!_C.U:<I]7FI80D=JE0D"MXN7@LD+/5W<'D@RAX;''#)MRAH(J)8@(Q'CG
M09-3HHFW?NB'#;K[_6U`EU?R!XCF,:,^F^)4_P":]+U;9'<FF_1@&Q&=14VE
M:RTIDI:1%HMJ;QI_#V-DGVO;/A\Q:-MHI:?LEG3!'M()RA=I^>`2`J#1"3E.
M@M_=>@;C4D!%^^B_(E!,\3,VF1</Y%Q'"\?5!R`LX1^SX3T0$_2WVMPDFEM7
M05OHEW^/6&QRG:VKZZD9#]S<<]D\#'F^_P!.6,V/,(:K44C'&HJ!AD-C<;#O
MA5SL6J3;0X.U?EC;)Q\[@@1^J[#4XMYJI7SD);1#UO?7+V67"2)0>M&C8W(V
MC!A`F$?\YP9*-C7!-`L2;B`[BHXXJH](*Z0&=%MH.7CI9;I\Y"4+&->!3K*Q
MR,MN3Z"!NV[!`RC0PX:V^7L:V**D5('Q4;',0CLB89.:V@YGM@N/2=LN7@5^
MXX6[VR=<I!IU"%:0\YVAZ>M.4>D8P_@[.2,ZJCL*%HS%X&KGYK.N^PR@<.B^
M:DG!4LK)#YQN43#J$VC!2-/^E%FJ#3M@+#!2ZJ_QZ2VP_4,I>7>:)3&4@^&%
ML,A*@*<(C!<FFM3GU!0`2^K.7)6>V>R8''&^@S_F5M6#0LBQ1:-VCULAL);F
MTFI^1^>I[YUCT7LZ7U167EFF;;@TKB,QK\J\M:IF.W3V,.(T>FQQ\-,OV_58
M_`FVEC+@2=:J[16X=M7*Z6PR5)U-Y4C*%?PR"V-*F6R%.CZ)<U:8D@?I[+XI
M/8S.;UC`F6C4`6B#60!8P?D9%@Y#.1R'#;IPFIM?ENCPB$@K^*:I8)1,O)[`
MM4PQK^#1^,F%)!*H\T&S`16K2=ZKD]/^`\3#(.RU8-+`)]#W#3[!);K2"I'A
M\HU0[3"OU<2+SIZ!">3C8FNKG;16V(HE4T1[E1.-A7T35\MRI:U`T0M",_N!
MP=3+GG=5N%.G#5)T@NTYTFOVW^Y2ZV&'\]>+*ED,5\Z%H%'C4#@M%^EK(L20
M0N<\Q-:>)6%2@Z1><8I"F12I^QD!=P@(:B21APX<\E7Q=R&&NW2RK_I9SP$\
MU![?\RDZ]?V(3OM38N46020Y'6`V[&G($]-,7)M*&J,F#-;E.(Q80%>N.S/U
M%Q+=LV<JJO=)H*;3"H$ZIKPM`X![")V^,LJL84&OU?F:QG@U$V"TQE\9C13U
M5"B=?.ZO8[E9YB@7M+4Z';./EBP8H!;*.^VPL1RCP&V+PC\?@PU;]H=W:?KF
M<N"-?65*3+!W%QLMK>P9G+HD3;'(X\8UZ1[F$REMB&QS`H,=*RADT)F-"D6;
M/1#EHL$J0NC/(=J3^S([%[EL^=2*5TF5CDKBKV;F2*`L#;5;T>"DDY3,&([R
M7<6C(8="86^?J/R;UV/5=(N>VC;913;D->LL'X;[N*:U3;OIR2NK1<UT2[L2
MNS\U&BN'IDS0KFJ2EVEF`.'"!C"SWE#%NF>^F:C84FS6X<IC.''TUM!;<YZ"
MI9M:`MONZ]<D8U"+>4,5N#9/S;,KJ,R)ZP.&S/(L2_<-Y%"B%*RI@-9:43<D
M.FY;E!)QMHI],(>*4MYD]W,*/]>/B4V>Q1"&AI+%&17CF*"'D<Y?JR9+]QA9
M7'>Y%&NOG<+H$^ACL7R59_*F[4=MT&?2(5G#T+X:FW\%"`^TKAN-S:UE/HM!
M9>7F6T'#PC%ZI`JMFKQR\C,49*!1=;UD)_34TT-NRS571!+[WE=P[V$A2B5?
MCFEJ4H_5[U:_2F,VM^)ENVDD,-^5)#>@")[FW;3O03KE*-*QR/L'[(OKY@[=
MCWMWIUTW[TI@6INCQO4MZQ2Q(=,74L:B+2L@5:,OT((!E%'<A$UM&JI;H-$)
M#'Y`.8,N8K%&?:"J:&B`XHGR18.6CY)NX1"I=JV33-4%_8\TL2(^@6$4IRTO
M,%AD&#8K"9)&;!N$.#KS=;$*S8Q]Z9L,6J::1*,C#VY,JP%][1TKQRGUV\<*
M!)$Q\K>;>/XP^H;(+6)%G%\522B<Z34*M"#R,#+7;U4U<BHMT"BI&9DY$B?K
MX'P&9=N2Z#-_]5$:T33>+(*A[Y)07F:904WZ$F-S3:253+ZO7DYV4/IF&90@
MRXD%/"ZE)WKIL$C`G36QI#4K%$3UIIR@,YTIWMN+2>*]=["4E?4OG5S-XD?U
MZ'#C6"M3SV1[AKOIP."OPR+GH\\ETG[)#6[F.R:%"JBDZ2(UYVT??;-S/7;;
MK;!?:`0M+)MXDNJV*MFKV_'K(W+P8$@*B;,X0C,+LL/4\PG9FMSLX9G(VFHS
M9PJ?+''@!QMZ);EGFM\[_44>$$^0EJM?2/D:/P"E*VAMMA"H`ZR8T[5XIW^M
M$)%(>82*AD>Z:/Q_8A,LCPV%2T$NY?O&[9IVU,LG7U/MWC=10*J1!/Q+`R%.
MQZ%7C<9>4$O2$+@%<28=P6E!J.2&MJ+F0Z#U844<UXY$LJ>5I&1%&+(@]9K=
ME6YKHAP46<?$D@&'LVHOQ\R>''/XES$U"X_5UK<T@PD1U^$*/$)3"8[:<PD3
M4:&DL4EWZ<S:QGT')_U`D\&MUQXQIP7;.&B#5H4V%\J`F?GI4Y:]:4O/&$E/
MQN>RN56""2?NWJP.1R25'!I]%BX<M&S5V+&RJ/OA_?+-1RFQ=M5&ZO?*O.^<
M"*;&G7C1J[];@)S;@T.]FD.#0R_V_9QZAT&$$!`ZIV#*.+)CE4>C_"MD#&#A
M$?T]=-"9=@FNDFLZ;IJ!ZR/D6D;N>N[>$SBU$@UF1A`V(91^2IAXXQ/F8U70
M@?:X8&8C*A-C/D`581[A/A_M8>CVPZWV/TJY>_<!N]6>0H-4$H"2F)SVXNEF
M#1Q^Y!!.<\+@[*D"SZ</T9C8K-H'8K'CS)6PB6DTDE6HKK>FBBK-18>P4;!I
MI#\?U%$I/2<H6>3WE>A(7'8+!1^CHIPQT)BS&7#1+E\X?1YV<;D.V,X?IOMC
MG@]`K\&NWR3GIBQVW#8I+Y.`'K%\@&^5V/$(\A#9*I%1[[15]+#9IS!!]=Q1
MB3(\/FH5U&10_C9EUPX:+N%9`*$N4=H_;=[Z"S$4!$(\/?LR<E*RI=Y)I:=1
M(&.6W+A@/D<F+'AD;;::II\?I,3'$4AK+?7S*;:M4]]];Z^.\#9L!@,!@,!@
M,!@,!@,!@,!@,!@5P]3?Z,$O\[8U_=2F!S!\_!I,MZ9@4B=>M?,EF2QX6:CR
MY.&>D(S)[`/M@H^5\V:P7@`R$!7<Q0MUVH.<C@#A\X:5HD&5X&N5^>NN5`Z<
M^??\,7;_`*U#/]7O`LI@4!]CPJM9;8U"HVKZ(&4I$3HBV*O)PWH_%`)Z\F=C
MD*GX<U^R6E`8PIS'G/[<Y1*+C.F)1';UOR@[0VIUOH(8OZMOQ]VS&I:XL/T1
M$`C,=Z/D)TX;>2NIRR0>T9S63BN)-7S438$4E,=4Y-P*.ONVVOL5R+5PP<NV
MSGG[1?7`0Y(Z1_'O(N?7Y62>IS(1)Q:X.K+@,39[4W#2$S,(;F=J@H<"(3BL
M7:I]\+5GQ5(._=*E"`=H,;)BW#78I-306>KN&^)/.-UW/=C&_(@PDR46&K6(
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M`98T3&\=*!%!/;WMW]BIWWMPBGH,O%#7FXC"ZM*2B42*IE?^+ZY9?$HI:4AA
M(26/KV1MFVH]-(BLF'?'P98`C,I<128\L7JWS(*,-=.MJJ:Y4#;;;M'S+:@B
M,+=>FXO""-:WQ'4`,LB\MA"KH7:HT:::[B;UI*1LA`OVQR)EB:#CE9KUQRU4
M4<HK)*-^5T@]KZOJ3NDC?T4@MR/$Y\[MJJ[%G3J#2&(&I#5UE5)Q!6<([0"E
M@AX0BR2(T^@F\9DVCY!P[0?M^OD4X[30""?3\6\<S@)Z/?V#;:#J20U2E)58
M[$29J\P5@\HJ=Z4YK9347GPA[`=O9`4DRK!VV/)*C.U7/'"GVG6N5.`D6SG7
MDD-3!;QU(O0\8K)M5M<5XU+M49G`@TTBT/A!6OT8ZZD`-\*[C*X<R^>`F)08
ML)_3B+0ZBS[:\HD6Z:@:W1ODWS93_-4^E:^MB0&8%5E"K1J,23DC7NXN=K3E
MD6+?KTBDD+A($O)`31@36=("MN_V\R=\<NVK!!SSM388J?0GR/ZDMVH9=)[B
M6`6/:OG,HSAM3#9760J72JK+>KRQ6.W/;X2-.S$D+=1F3FW?#%F<<QQ\0")/
MTT'"@KI;`TF6UW27G6XJ9KJ07WZ`*VWZ0-3SF3;;$*=%]VA&!I%2=G2=DK]Q
M&'"XQ`X.7?[X2;Q7ED2>-GZK-5!^UZ6TD$\5YW3-)EZJAM7RZ>RP+:UEQ"/.
M9%&C%=RB+MCT0\;QD;`XQ8CCO[0^."32GJ]%R)FJ(:*K+E>$%E5VS!WP@L&R
M%X]'/:,=26_=%X5.&KZRIQ75C5XV>P@<VL#B)2<4C(8E-V7V]AB'<=*/8TU7
M8E`[U@;;,G"R2+QI]T[1V%?TH9XAA;.ZD9!ZF8+"VDQ@<&.-3]DUTT2IK45M
M^77;'JL#]L00YQRPZL!0]MRJ7Z)DN6`UPU[=\<BUND0^U@!?$#7=O($_5(F$
M2*-E'Z4O*MK(KY0E5TUL+T2EZ'`=[&EPI0:C(6]L,D-,1C]N[Y<,=)MW#=?Z
MVNU`G:X+'\T3V"R&`RKT_#(N8K-G5ULE9\,G%<M)#!GL?D<*EU?V0\2+LB4)
M^S?GW85;M%R/6&.D##9+I'23]MI0*#&/-GXR8,7(7:2OXR]/1JA>[1*/6EB1
MTN0,5L$C@I^7LG4>&1CI0D7.MQ^R:_#9'CG;A^JH@V12[3Y3"9F_E[P_8MN1
M:8"K@^ZGMSUQ8QR/1[]4K-Q))I&K24ODKW*@#H[!WD]#?I`^\I9RP1&O6:#Q
M!CQVZ1=_ISKOL)VM2K/.6_0GETK-[D_9UJUJ)<MZGA'1^#"#\V'!V3E!QRJ0
M<Q_JP=B7:6E.2+`:28C3GT.4G3=S]OQSP&9-P'S][7-T[=\'M]*7C:*G:Y*/
M'ZE.0@P)?'63^*R1P*ZF7`$Y(Q#1[H.QX>\@B@[@R$>K-'>W+1USKD*K<5EX
M+-16-%(IZYX'1@DRC?F5Z<CMG5H193^*,Z[K6#$ZA*OWD9)MF[2;1F%1]X^?
MCOL2"7:G*[)XU1=?+V&1YZ\.5%Q/VYCU,3DS*1W_`$/5RPA.30LZA5,]@OH&
MPKOKBI6G,/AZ#P8T1LTI(&Y14XJ^)::M%&BSI-9IO?(2Y6[_`,D4E9-\V0T]
M2"R746?$(I,X;(IU7ZT7I!U.;<GDX-1UJB&`C)*D1/6V:.<=<EWY)PV[;;8)
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M\O0EW/43CC.,<!H,*9H$D`[$$D)9"V+%1NTUKEM\.`KGY\!^<F244)7][0KJ
M>79<%E!G<*T%MB%.=25:O[0H$Q$(D%45@M?NY4_;R>DP#97I`&-Z5:$5$>>%
M5.^""@7'L"O(1[,ET"EM?WTV=U?7HRVJTM@36!>+F%9WQ,B=1FU(";*/`LCY
M$QYXT@^E7:S!1@46:NVZC-WPBMUWT$0(4AY!\(3.MS\GG12#HV%>;XG`B<@Y
MK>,Q4-(1=5^@-M(A)9()BD9*F`+>-VI*%4'AIV2*[5Y;Z6>?005WV&PBO(]"
MRV>VC)ZV]"3(;8\_F[VTU7M>F:C[=PXB,=W144N?LHXG7S\`:?OE;`E<7?&9
M`Q+&^-,4&OWFEQ*728:Z8\S^-R^RM%!;V?QB10MRW!/(H.G,)(E`FK#L"D38
MZ)EH_*(\:'2(<:.U1'Q78TBW>IN42'2#KA15TWZY#"CIMX2IJ+S:O6-S&C(^
MI_('G*C)>Z0)AB&QE"3@X3A-7S_1AH$%QY\_==V#IR1?M-[:)-%$%>&O/QTG
MV&PQ%OYE%>HXY=^O0%0)B(=XC!QNLVG-CC%RY2MQCTQ)3]VS!)[PQC+%*+1,
M0LW&$D/J=Z&.S7;C:3?CY.0G4K:U#7!7(VAVUS.IR+NBB[/;+V;%Y'"OUTA!
M8D/2@-A3GM^S19,N#/9`DJGVX%AU6K1_KO?2+;C27.PB*D0'@2'%*V<T?;L'
M$`GUYV+,*H@<;FL<1B*5CK5@TI>QX?&`_373U!HCV[Z>O&&UM+I2@DI_7ZVO
MPTP+$^6K"HZ;`K0$T+,MSV-0VYY[N1R9N1&&0SJ;VJZ;7_(&L>,"MZ:D`C#=
MN))M]_+KI-/6N/F6USI=4.<ERQ_PC#JW'$!'H&?GM<F8;XS^TJ*955(I1(_W
M$(E4$,5*_<RL2E%`J4JC4J>.2)+MR-<M-"TW`UT@NEM-<)`LB2>4;5<^FP`F
MQK5A!&N?2D&B,NGT.+50QVUN.S*'COEXA7%?)6%P7:;;]UBY^Q>J&!B?R%U5
MEA;E9RW3Y2#-A:&\'5-9=RR35Y@A,@ALBK*:6%'G<@JUJ3KXR+M>NK.8?K!E
ME$6U@%$IW8T*#<N&)0B0Y1[=?:L4V?3A#GD)]KF-^9G?L:P+1@EYB)7=TOJ\
M3W(*TCLIKYRT1A1(;7;\1*2K2*!6DKD[=4*S#.@BQTB3X&LS#A0=])J1^7`^
M5L?C^INX+(F]J2&1V0,E,Y8/&;W]"-@6XP6NXK)*K6Q,2Q(1@EOEZ-$-TGB.
MG';A#I^GK:J:B&^D-AZ(KX1KV-6-6MI.K!LR2RZN]6BX5)%^J]8/9F4MZ66C
M-9DO)R\5K^.'N0+P_;Q1;0!@Z91_ZC4:KTSZ78<*]A8NJ*L1JNIXQ4:4MD\N
M#Q".)0\&>DO,>0DB47'-?TN/#7+B,@8\+<K@0:2#3AUMIIPXTAI5?I1;KOOH
M(2IWQ96U,Q"%PX'))J5'02Y75W`_O^H@'9(25Q!RE?\`Z0UC4.B,9AX&+=!B
MJKM9D*'L.7)A59\IO:SA?Z@5VIO\>!1@&GPR\K#*&FQ.,/JCKL1"CS9RTA=+
M;KL%70\`D5)U_''JKAJ,#_4:).T23IG\V].R9=7KI?`Z9BA;H:X.+.#I8SP7
M,=%&C8IH7I"/->AHQAH$%_3AH];8GE=@H[UMWV[=?<.UO[=]+Z2205Q)>58^
M=-W^4/V/9)<=Z"-5B<+QM12"L1,'<U8F&1#(P9V*@[&0<MBR8!KI_HN]+=]_
M)OZ/2'S=?$),O&H1-ZUJ;K,V?D<9'&GL=?K%8PJ*T0TI&I&)DS9B[9'Q1P`;
M`%70CAL2'/V;EF08*K-U>-\*;^`:,*\MP`-YDCWE5B7EW$$BD-C<.CLB^]#)
M389J'.AY**2)%XT`MHY^O@BXAJ[2U^E_I_2R'//;7I'?26PBH]X/ALO)+%)K
M;MTRQP:CY!C-^"92!HHSB5N8K:$)%3\GR/@#-0,9C,9MXLT8#Q/;``FD@.UV
MP[TQX^</59'C1A;%J<FI?/)-_!K^#U<5P7J<4L):H3LO7<KG\C"EYF87CS@^
M@U"*RMLX9\AR`SI9XAW]WI9#Y$L#>:B\IQ:IY.TG/<\L6?3E(?,Q9&4S)W%$
MGAQI,`-'Q/7ZDPB$2BH9)>/Q3SU&V33MJW;?4VFY<.=.'+CI7D(LJ?\`'Y`:
M7006A-J6XG(T+?C%Q_NTMW6I$T^-1NM3E-KC#G/\.4&$B;RFMI&\:%R#Y%P<
M>$%MD/ON'6N>^0WRT?&L#L_B5+=S6R(<8F,^DLX+GHF1C'ZERA.*<"41-X@R
M3D<3D(YM&Y'7H-+GYOH=$61#6G35TEUQQSH-]J[S?`*AD?4EB3F1?7_0Y='6
MX\D1:NQC(7,K8EEPD$6R?`]!UKIG))@X;MNNUN]\L$DN%/J*\]+=A'#OQ37A
M">'9L^F5CN&I"6=SB/P[]0C"4;A$F+6Q55TS9]'5D8IQ)'2,ZG=-!5WB),@0
M39I;=IL-,^7/7RA<;`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`KAZF_P!&"7^=
ML:_NI3`H=Y_O6PG%T0NI61.$M)SS+Y)_&>C`4*IB/5O6XWK@P8F)"NIS%[!?
M323FQTA<\*\]=($WQ/MRLH1'"-JJ]L0O9Y]_PQ=O^M0S_5[P+*8%/_2/FF0W
M_.ZM=I3WJ&UZ"A]N0NTA@\4&)'YU%[(?5<LK$![@V$*)1]@3:PASP[)-%6Q%
MK\R6F_S;[ZZ3#3*=\&16IK'>6>O9\^G4C7LP99"2TH2`**_<!(1?4!%#W[]$
M;^I$.^0=_D=KN-JI[Z59-N4$V[?7:'0;V8\F"3THF9@C8$G4`R>V4[H%QE,=
M'^-1>9O*7D%)23ED;Z8*$7X8V!,I/$T%_F49/6W]K5V@IM+D(;A'XU:H@TT)
MS!A+I.ZV[>5H58,W0J*=NQQ:!SNCK#*+[.]AU"J[&72#S^#Z5:<=((M>5''R
M:[WRRVR"0YEXDB<TO*9W8\GDK%+38?`VY>)@V,>%AWQ"`2^JY:()GUFPWA66
MN&:E2LF[%8GPY(#4'[Y)%UIOVV;M0Q%D>+$"]/2^$0*:$FDL>T?Z,J2)DI+H
M:J'://0DZ"V*0D)=%`$^^LO'Y"`;IM^?MUD5&V^M+HK[W\<";ZDIB05*F'8M
M;'(28>])VM,K.5,1\`S?S^QK*E`F2MY(AH0S9M(J.CG7)%N@P9<Z250=I[7V
MLLE];H(YMWS$?MOT-`;(>SOL!6,6A\>8R:&BAPEP9G,EA-R0^XX4B[+$PCQX
M`CPJ10QJJXZ'ND7#SC:B'?.M=<+)!J%H?C^K6T7$`<E91($>X/95T3I1-R+C
M)QH;#WS;P:Z)W$%V!<4X8-4N9/&1R+!]I-1PU9H=\[THJII5,(H_\K>(=LY%
MIS>5H/3TCLV(V*K,W3**J304M#PTPC@_8&5Z&<R$+*E@TP6^H8;NN.NEN/I[
M;['**#MA9/SWX\@GG6Q;@L.+&211W:Y<H0^Q)C`22L=:';`G5HF1B9UFP2.&
MT%YG8A%1'[I;:;=KRBGRGM;2[EP&N.?$$4=R_P!22?NP)BS9>I8,;A$EC@5I
M'@8@-J2#.1A:3_:#AB+"23!!OQI%F3?-^WW#+?3=TJ\Y^GTD$9O_`!=.Y/ZO
ME-D'94Q$T7T9:6-'8T+*L"T@?VCU+_,$Q<$W#-]7;%_'QO3SS=PW=(]2`L@J
M@_Y[;)-5/Y&P7AJ>M!=1UX"KD(1(DAH#1?38B3VVT16V8-$SB_:VV:#9O\R;
MDIWSSOGC7];SKX_'?QWL(&B?C2#1$O5)AG*)4Z<U+'*&C0?3O07Y2C2@(1<T
M%C2Q7M$8FIM<PPNP@N]TEM/C2[9#Z.D^=J\J!-<XJ0'/9C#9>6(EFZL.CMCQ
ME$8Q5;I,2C"S!8847[?]=MU'/*[%N&XZ;;3[XUSWWUOK77\GP"`:;\8!ZH#P
M]@0L^9SPC#+=CML,#)D7$0RBZD.\YLO,47BR[".A![+0<?7PMLX65YYT[<E.
M>UMJ<I=Z0X"QE;5F*K)":H"B!$AS.+(F5F/^B/VOS,RLU(<D7X]G]J@AK].:
M*\_*C]3YU?E_^BZZW_+@5!,>"$7X-T`&WU8X0>,E$L+UN@C&ZT()5W'[#'6P
M(G\91T2B+E>5J'1ET&$4'Y51PX8Z;,.N-=]I/>B`9:9^.2S*OHO!Z.L1>OWH
MGT?&[N[EAH4#DQ(`/%">@[L6%&E@9$4<=_IS9NW2Z(\?4WQUVIMQRKRGO`UH
M#^."MX[TD*86'/E(,''@T(A#7C>).$XX2:&Z+-R<LL=_;_!<]W+%_/@773=U
MWMNQ^Z??;\<\]M.&0;99GA2)VM><CNB4698.T9!`)K`$X4U["[$@6-@5:YJ>
M2+1Y^]'/'8E-0.M^H(HI<\_$NHLLX[<)=HH-P"/#<>3OJL_1DLL$Q,+%@D5B
MX,RY=Q6),6,N-0@!9$8BTG3;I,''40=-@EJ%.'2(OI'3GOA#?/:*?W23L)*M
M'S&,LZU`%D.)W)P#%NA6J,RA8QA&G`N<=4K.C]FU(JL8(B'4AC?47G,F>.G6
MA[E+15#KANM\../CT$QUC`!E65C7M6A'+E\&KF!Q.`"'C_ENF\>#(A'V$=8.
M7O+%%LUX<N&H[CI32*::>N][^3GG7PUH.9@S\7*LBI^OH3:OH"<$)8'`5X$F
MKR*B(B.BY0/7D*C<7B\5&A>8Z.9.V\06!J],"SYJJ]6X?N>U$>%>FNV074D7
MFIB0K)G`(U.3\2)AKN-7W'I>@,!%G0Z9'KEDEROV;P*^9<B2P)0I*WC':2G/
M"^VO7*GUON.?J["#[4_';75GL76EYO*A)GF2R68!"7Z?'BC$3()5<=LV^3<.
M`CE@BU,-/N;F+C>$5N]:TVT@KO>W">U.PWXAXIK]2CK'HH0:?,([8)FN3GW)
M"/1`RD&<U=`Z?@$8;-PG81D(Z9\C*7&*]=-^&;QHNJIV.<,5$FG;</Q"_%4/
MAO8)QJP+$D1$(/>L^S$E?C"9DRX?^>Z[\ZN2QHHH.T\(%E8W7+8ATOWWM3L@
MX5WUO:7R)\AJ\`\7OXE>D>GKZQ7SRLZUAE)"*^@J(\'R0*S*IJMLFI>)I-#N
M@"!7C7[7L=SRD/8N^6:SC7"W7"7R=IN`EZU?+T6MB8OYL1E4MCQA\+JX7RM&
MU1#98?\`PH+6V9`$!KIZ+?+-R*CVWWG?7?7S\I]LV_7'.MZ4^<*?Q?\`$[5H
M5X"*F[6LF2EA4K'R]\Z6;QA@F7(LOTKE9%?KD2Z)\)/TQ7.EENW:KWOM53OI
M?KO>MZ"P/F[QJQ\IQ=M$JHGKSD:ZG<7+25P9BL4V0-UY#(`E`(Y!%W8\8U<+
MOFP\4.56+J=[==K(J:3TBW[Y;<!('ICS8T](!8L(7G\EK[J.O9<FZ?1H5%BR
MQN-6!7THK":QQRE*@QENR_4XI+W?V[QORFY:/.$E/BHGI1!4-?\`-/FW^"DZ
M]*S]XFQ9NKLM5,S&H^,/D9$,AU;1H*W8`Q#1P2#!%1[V7S8A))F49I\+HM3$
MJ=)<N76D_K]A%$F_'V-/V_8-VM[QL<=-920%EHBLY&Q,^TKUZ)LJK;39H,4#
M0MUHN$9GZM;M6[!3Z+9$<\6Y^7IW\'F!N4>\2@XV.CL<:6?-'<3#UAYGKTB(
M(C8JL].D_*T]'3FOIJL70$->AQ0OTV7:%VC='ABXX<:403;*)ZWT&DO/QT0A
MZB?"*VC/M0B2BIXL5B6A\-[Y6G\YK*R*94GO)Q6/=E^>A5:6@_9)BOGV.5=(
M-W2G&^]+\KA;&<U`C,)'#Y>PEAV)2:!PZRHK%R@AL%>:8.;'#@Q7<B49&!S]
MD[)1Q2/H.&::G'37M3YN5DU$]_+@4G:_C%@CW=-JSBS))-GE4B5(V2?O8M$6
M3RP`*<W8V:U<R%5-DY^VG3NQ6RY8K(T/@4*NG[A?OM-W]!T@%K/-GGGCSO'I
M2%[L&1V0\E)Z/E%C4D$18(Y8C(A6L$J>*@VS.)!PS!5,?$:\8[7<*\=KN7BB
MRGQX2Z201"+Z\\01N")B$W%F3B3:BDAI7N&;?L8B,V`KOSVYE[JK:X<:"`6&
MCJ`[N=DM/BSG6R1#2B?S]\?2U\0E4[YPC1^+W#%74BD:32Y;2!6J;=)=#MNA
M!4`C6J+82'^HR[2T)6XK)K\^EN55?^\K?#O7]9\H0=8W@P-8PZ=@"%N35M$S
MME_QD@D2V!A;H17EED+`;6;*#O3S01M(IDP/RE%7Y6)!]]%BT=K)H[UWRV6;
M!-E.>;H_1$&EL+KF2F!.Y&)AXX<<Z$Q/[F+N8+2T!I2.$Q0=H!9QI11H(KQF
M^VV59],ONNU$^4>6WR(\A8ENFHD@@DLOTY631335<]\)I]N%...>>U^TT>>$
M4^E>M;ZWSQSKG6]_#6M:P/M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,"N'J;_1@E_G;&O[J4P.7U!/G*UA^=(0X(+/*UBUA=+0+
MR\D?$N+L\^$A0&1IC#5P)(^?8Q*7`N$)NED2?#V3)\<JND_J$I#O?&G8=///
MO^&+M_UJ&?ZO>!93`U"<S457\=5DAAJ7?-N2<?"MV`$:L6+ORLG/#8T%8L6"
M&^>EE718LCQO>^N>$^=[[[ZYYYWO0:!_&O?]$5W?S$X_RO@/XU[_`*(KN_F)
MQ_E?`?QKW_1%=W\Q./\`*^`_C7O^B*[OYB<?Y7P'\:]_T17=_,3C_*^`_C7O
M^B*[OYB<?Y7P'\:]_P!$5W?S$X_RO@/XU[_HBN[^8G'^5\!_&O?]$5W?S$X_
MRO@/XU[_`*(KN_F)Q_E?`?QKW_1%=W\Q./\`*^`_C7O^B*[OYB<?Y7P'\:]_
MT17=_,3C_*^`_C7O^B*[OYB<?Y7P'\:]_P!$5W?S$X_RO@/XU[_HBN[^8G'^
M5\!_&O?]$5W?S$X_RO@/XU[_`*(KN_F)Q_E?`?QKW_1%=W\Q./\`*^`_C7O^
MB*[OYB<?Y7P'\:]_T17=_,3C_*^!BR'H8:*=`V3^K+M0=2,HH%"I?P^45V])
MHAB\@5;<](DU.$=\!P3M;?:F^$_@CO7S?-OGG893^->_Z(KN_F)Q_E?`?QKW
M_1%=W\Q./\KX#^->_P"B*[OYB<?Y7P'\:]_T17=_,3C_`"O@?%Q>:;5!=RO4
MMW<(MD55UN]0+Y]\I(\=**=:XX+==];YXYWOX:UO>_\`V:P)=CYP=)P(22B%
M%%A,A$#3@M95%5LJJ.+,D7[)15NOSPLW4[;..=]<=\ZZXWOX;UK>L#+X#`8#
M`8#`8#`8#`8#`8$0R*XQ(&5DX<TB-B2PN%&ABA?N(Q54L/'(G^B6A:"[]1TS
M0[=K\"E>^DT]][3X^7?7P^;6L#'_`,:]_P!$5W?S$X_RO@/XU[_HBN[^8G'^
M5\!_&O?]$5W?S$X_RO@/XU[_`*(KN_F)Q_E?`?QKW_1%=W\Q./\`*^`_C7O^
MB*[OYB<?Y7P'\:]_T17=_,3C_*^`_C7O^B*[OYB<?Y7P'\:]_P!$5W?S$X_R
MO@/XU[_HBN[^8G'^5\!_&O?]$5W?S$X_RO@/XU[_`*(KN_F)Q_E?`?QKW_1%
M=W\Q./\`*^`_C7O^B*[OYB<?Y7P'\:]_T17=_,3C_*^`_C7O^B*[OYB<?Y7P
M'\:]_P!$5W?S$X_RO@/XU[_HBN[^8G'^5\!_&O?]$5W?S$X_RO@/XU[_`*(K
MN_F)Q_E?`?QKW_1%=W\Q./\`*^!B1GH@88<&VHZK;M<N(Z7_`$(RGJOU$MLB
MOZ8,,_:];6)I\K?$89;*Z[3WVGO2NM?-\VNM:#+?QKW_`$17=_,3C_*^`_C7
MO^B*[OYB<?Y7P'\:]_T17=_,3C_*^`_C7O\`HBN[^8G'^5\#W@+E$FY4(A[R
M'V+%"I]F8>!E9;%%10TAH$FT7(MDGZ3IXBF\3;O.5.>%/D^IQSU\N][YWK`E
M_`8#`8#`8#`8#`8#`8#`KAZF_P!&"7^=L:_NI3`KS67CJR(384%D).>0MUJ%
M2!4V>M<4SLGB];H9[8/VG0*T'Y>>D8BY:&EW_*Y/6VSUAOMOS^FL1F_M^F86
M!\^_X8NW_6H9_J]X%E,"'+Q_^Q.-?ZXZ%_\`QU0/`F/`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`A^SO\`[+*"_P!<#_\`_$I<>!,&`P&`P,')_P#[&I#_`/J,
MM_<#C`TVD_\`0S4?^K&!?_>J)P).P&`P&`P&`P&`P&`P&`P(2AW^G&[/\WJA
M_N2;8$VX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$+U+_]D=]?ZZ%?_P`5=68$
MT8#`8#`A&<?Z::*__1[3_P#O<$X$W8#`8#`8#`8#`8#`8#`8%</4W^C!+_.V
M-?W4I@6/P*U^??\`#%V_ZU#/]7O`LI@0Y>/_`-B<:_UQT+_^.J!X$QX#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8$/V=_\`9907^N!__P#B4N/`F#`8#`8&#D__
M`-C4A_\`U&6_N!Q@:;2?^AFH_P#5C`O_`+U1.!)V`P&`P&`P&`P&`P&`P&!"
M4._TXW9_F]4/]R3;`FW`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`A>I?\`[([Z
M_P!="O\`^*NK,":,!@,!@0C./]--%?\`Z/:?_P![@G`F[`8#`8#`8#`8#`8#
M`8#`KAZF_P!&"7^=L:_NI3`L?@5K\^_X8NW_`%J&?ZO>!93`J[['M*!TA1!6
MX;2/\16MZSGE,3*<R90<7+(@(R%N2!N"A9<<!'E3#I!DAK??>F[=;O7&M]?+
M\-;WH*&_]05^'K_G3B_^S&]O]UN`_P"H*_#U_P`Z<7_V8WM_NMP'_4%?AZ_Y
MTXO_`+,;V_W6X#_J"OP]?\Z<7_V8WM_NMP'_`%!7X>O^=.+_`.S&]O\`=;@/
M^H*_#U_SIQ?_`&8WM_NMP'_4%?AZ_P"=.+_[,;V_W6X#_J"OP]?\Z<7_`-F-
M[?[K<!_U!7X>O^=.+_[,;V_W6X#_`*@K\/7_`#IQ?_9C>W^ZW`?]05^'K_G3
MB_\`LQO;_=;@/^H*_#U_SIQ?_9C>W^ZW`?\`4%?AZ_YTXO\`[,;V_P!UN`_Z
M@K\/7_.G%_\`9C>W^ZW`?]05^'K_`)TXO_LQO;_=;@/^H*_#U_SIQ?\`V8WM
M_NMP'_4%?AZ_YTXO_LQO;_=;@/\`J"OP]?\`.G%_]F-[?[K<!_U!7X>O^=.+
M_P"S&]O]UN`_Z@K\/7_.G%_]F-[?[K<!_P!05^'K_G3B_P#LQO;_`'6X$:SS
M\]WXCB\CIYZ/]DQIPUC=E/3AI;FLKT^5B+4JNS0*;I36ZN^;?'9@XT0U\NM[
M^9;6]_R:WO025_U!7X>O^=.+_P"S&]O]UN`_Z@K\/7_.G%_]F-[?[K<!_P!0
M5^'K_G3B_P#LQO;_`'6X#_J"OP]?\Z<7_P!F-[?[K<#%'?\`U`7X?W8,RT0]
MHQCM9T*(MT>=5C>V]]*K,UDT^=:U5N][WOOK6L#JE0SQL1HVF"#)72[-]5%=
M/&B^N%$]+-G,0#KH*ZX5X35XTHEWK?PZYYZU\?Y=:W@2O@,!@,!@,!@,!@,!
M@,!@<LO0?Y(O%'A;TG.HGZNO,;4$@L*O*MED-'E(=8\@_78ZP>3\"\)MGD-A
MTC'I\(%V:J'2:JJ:VNN/C\GR[YZV$<?]05^'K_G3B_\`LQO;_=;@/^H*_#U_
MSIQ?_9C>W^ZW`?\`4%?AZ_YTXO\`[,;V_P!UN`_Z@K\/7_.G%_\`9C>W^ZW`
M?]05^'K_`)TXO_LQO;_=;@/^H*_#U_SIQ?\`V8WM_NMP'_4%?AZ_YTXO_LQO
M;_=;@/\`J"OP]?\`.G%_]F-[?[K<!_U!7X>O^=.+_P"S&]O]UN`_Z@K\/7_.
MG%_]F-[?[K<!_P!05^'K_G3B_P#LQO;_`'6X#_J"OP]?\Z<7_P!F-[?[K<!_
MU!7X>O\`G3B_^S&]O]UN`_Z@K\/7_.G%_P#9C>W^ZW`?]05^'K_G3B_^S&]O
M]UN`_P"H*_#U_P`Z<7_V8WM_NMP'_4%?AZ_YTXO_`+,;V_W6X#_J"OP]?\Z<
M7_V8WM_NMP'_`%!7X>O^=.+_`.S&]O\`=;@/^H*_#U_SIQ?_`&8WM_NMP'_4
M%?AZ_P"=.+_[,;V_W6X$85W^>O\`$@$-V\Z)>R(TV;R2S^CX57JLKT^5\*ZK
MVOA'W:>M5=\VN.28ARCOXZUOYDM[U_)\-["3_P#J"OP]?\Z<7_V8WM_NMP'_
M`%!7X>O^=.+_`.S&]O\`=;@/^H*_#U_SIQ?_`&8WM_NMP'_4%?AZ_P"=.+_[
M,;V_W6X&Z4;^3GPK[<]-U37WEST`'MB8QB*VK+#@0=#K*CZK"/<C(\+Z)=O)
MA"XZ,4XY?OD4_I\+]+;WW\=<;YYZWR'6#`8#`8#`8#`8#`8#`8#`KAZF_P!&
M"7^=L:_NI3`L?@5K\^_X8NW_`%J&?ZO>!93`BN])07A%*6],X\=A<7D$3K&>
M2,#);(4?)5W'C86+E"(DY/5AB:I%&%B2#9-<IVASTMPQ35ZXU\VM8',7S[ZY
MN"0<5A&9%+-3E^IZP"TO:QHUS3J<@!HR_P`])W!%`4;D-'M)?2UOQ(NKVH\T
M9&N(F:'L%FC1VPZ=).5'(8L!^4R>3B2QN%P.A*H,2>PP(&90QD_]&+M5(M&C
MD,]5SCL-=@X33AXO7UE!1OEETW>!FR)7A-^8^A]SK].<]]AI4P_+M()`!L9M
M3%6P+9_GRM;]WUJ8ELWDKED/FE24C6=SR6(3D6QKAH,?N0XRR]-U$`18GOAT
M/3X=*M=/_BS"T\B_(.,@\B%0*31JNRTS((>94V2T-M=H4C4K=^@RER#'[R".
MWL6'E9*$@NJ@65573:ZZ<\N%-;Y0^VZZ4"(IM^3:S:YK:@IY+?,<<Z?W_4D@
M]$@([&KC?&6H:HHW'*A-O`)>5DZIC@%&X'+JVTFZ+/OI..?3'JN%3"2??.N0
MO1Z,F\TBTC\H@H4?U%D+5]-!(--7.@84N]?PEE3ESV81CS;DTU>MA:ATK7C)
MJN[2X^Z0:*+?0[35ZY4X#DQ3GM'VA\:BM>V#P<+YWM7T8PJHE,;*CM+1,4FY
M_B[<<<[$U.[ADL>'/X?JP2'M/NR<R;#S'!9-#EI];APZX1#?)I[RLN.6W[A?
MBYPXE,1J,T-@/G*%1#7G21QB>3NP:`\_%ZKCZ$;8&G7IR<2>17%<6]HK#&FP
MCAKTFAPIO:?>MA&+'\A][?:5P:EUJQN.O:VC<4J^_80&@D`0FR_H=M<4[I4_
M(;3H:PBT7N^+U?<:XP"5AJ\(6(/HYT]=+&AST>EQ\`NYX1]!6G:_C`C=ME3]
MJ6L!6K`L\[*SYY0+V&QPD_J<9+5B7;7S&5..1=?:.+KJ]-3'7$D2:H*<[3UO
MY-["HL%]FW27@<!$R?U&$$60GZO\J02=&>8YYFD<0D$%OF/-'),-6MEP0Q(:
M]G<2.KL'Q0"[X8`Y>*'JHIE&:O/;=VY".2WY'O3@V0UK^U)6RL">V/:)642G
MSSJKH)V+A51U)=-IQ&W*:A,R`RI&QF=V<5_$$&Z325!U-D9-KA<>[3:?=CD0
MM@]_(#-8GXR_']ZW79.;88>A2$=82B(5]$F'$JMUW9]&VC*JI$5X->KM40!B
M0V`"!\<<J=I\<(.%.5M\<ZZWH,5YD],VYZCG??`STZ.CL;LSQV)]&UI'8Q!*
MF6.@Q5@7A8Z%?3)L/E(0G(WS9:EX\"WVW()*-NEB:B_>N>^T.4PA".>YO8$6
MKSSX_?/^;G7M_P`^_CVN>;V,M':@B`ZKB/J/TX!K><M5XLR>1PE(8R0BSU8:
M'Y&M2+]DYU]PX[ZWOCK`U*Z/R'^F*-K(G9D?MJ%W9$(A-OR@<6L:YA,'?%H/
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MRF]Y=[4#HQ]-/_Y/C_X>?_=@/II__)\?_#S_`.[`J9[KM*64?Y%OBUH`9&1>
M8PN$+$P$D*C1I4>`>*D1[#9ET/+_`/UI=)C$'G:WRNOBW^/&MJ:WQK>L#FG`
M/RCS<#:)'S^2U5_H=T&](QKS^!O06;)0%K.6MLDN@-6RI^)B\"EE<<<A9XW)
MQDRX'%T.BKR/$EQPSCILHVP-B@GY5)ZTA/E%">T]!IS/KBJ.N;1LLI55A.$H
MB!9SF=PRM=A(SW(8F@U[L((:E73PL")O1Z0[2;9AP^<.GZ&^0[>_33_^3X_^
M'G_W8#Z:?_R?'_P\_P#NP'TT_P#Y/C_X>?\`W8'[P&`P&`P&`P&`P&`P&`P&
M!SK_`")W'9-00^KG%;6O&JK<2"82=&2+.S501RP),!!5Q+#J8JJBGH0<ZI$A
M(1)IJT*D`YIV'7*@F+WAD19K<;4P(SX]Q3T$'E<N>BHK)`I>NO!9^KB1]R\K
M*)#!_K:3SV*=6+<[5]%"\BJE$6\"<.RH_P#4#[9LBDU:(+(N%'2W00Z!_+?)
M'0%6Q9#3=2C:F`N7T:E4R$7D:D3?<KYJR]K/8&8RL,I]=$Q6'32C^D>RG/.R
M"J!E-PW8*_:](N0V.J?R)6Y<%MT3&VT<HV`0XK?=U4)<"TFF!_EX9DD&K:KK
M+B3>MW3J.LN64C+@;&[Y3"DN4WSIXP4Y_M:>N_IAM,3_`"526W25-0RDZMJR
M1V!;49HA^0:2&YEVL?K.47!6'K.S#48F;F+P&4&4RD%;>6^V:K+;1N_<+&N.
ME$FO+?KZH2OYW]T';N]-6'0)6GV4380QY<X1*1(34>3+I'*(F\2@$D6,15Z/
M#F=1J;DY1T^`/FZ76M"T6ZKOA+L@AQP$FMO3D9C5U>A!UO3Z'UG6=9S&EJ9A
M_4K=B@(XI/IY6R5K/3I*3$N$$VO,C:RQD%'(+.$FOW09;GCYW#GGC`I+Y<_(
MQ;%EBZ)A\EB%<GIW8S6'0)RZ(2U6+6$6L:;>8GWIL#:^ZC#P]YPS\XKBDD0J
MQIL[[<?>[<+)-^N&VTU0V>*_D#M9J$H9-[641ER$DK:AIQ;LO,6'^BF!Z]\>
MF.?,XYC"0(&KFP>0_M^0/.2JB[K]%X6'MMH:3Y<*Z[X"?/-'HVYK"\K6_:=@
M"JFD]QUK(?2`IO!JD*'":/9"J)K8("+Q*1"2@Y@?!R$CW%4F^D.N-K.4.DW'
MPX46Z2X#EX$_+S/?/RR6[/(CO7-<2>JJ,M9&WH>E#XCW!)$;@?-B^G:T['P&
M-+@2H^G:M:\S$6T<?_7_`(:/>6!!RMUT@\V%B%_RL6X"CD:(33S-#0)VS"9:
M/P(6)M@G(&T5,0_T*?\`/$U6MUZ[KN-MP@],^&X<#/TY1[T[<N4AZO2"RG"N
MPEN'_D(MZ?5];EN`?/U9#(+3-+0VQI"SE'H,2,D)N5SZFV-GA8T",\0Q6LVL
M98DGB3-0X_/-F[IDZX=\<)=)]MN@D*F_8DAMP[Y-/-VH1H"NV3>DZ<G\+%MR
MZVHS8-.,3\A829L1DL6C,A03'(UN3%D6OR.!_P!T:;_0=.N$$W3@.DGTT_\`
MY/C_`.'G_P!V`^FG_P#)\?\`P\_^[`?33_\`D^/_`(>?_=@/II__`"?'_P`/
M/_NP'TT__D^/_AY_]V`^FG_\GQ_\//\`[L!]-/\`^3X_^'G_`-V`^FG_`/)\
M?_#S_P"[`XS>\?8-I^>O0A$;#[<C,>&02CJ)L^/T$7CT+)O/1)^=>BI=7,]B
M+!PY&N;.3?MH`&X68N8^MI(,ZX^^?MW33E5'H-4K+\GEHW78U0A8O'?/\*A3
M_P!"QRN;(D$GGLK49FH79?EN97Y7*L.>DH3'EQ!YTK'%4$N2C9JH771:\(HM
M^'BWVP6R\*^Y27L=Y.."-2<5PQ"1F&SF/J;EHH\5X"S8]/@+:*S<!PBS+Q>=
M1_N!]*/N-I=LNE77;5)3:S%QOH.B7TT__D^/_AY_]V`^FG_\GQ_\//\`[L#_
M`'7''._CKGG6_P#L^.N=:W__`'UK`_6`P&`P&`P&`P&`P&`P&!7#U-_HP2_S
MMC7]U*8%C\"G`!S.(W.K.<U",$V/'2DI<+'QKM[W&WT:E6OJ??L^71GD>W?H
M;4WU\.V^W"?7&N/Y>=ZWOL-]_?'HG^A$/_/X!_?N!\EYQZ"^@M]S2(+[;Z2G
MW'UY]'OH?0^3?U?K?4>_3^E]/X_-\W\GP_[<")JXG#[]IA?X14C1/[&_<CW]
MN_PXGU6_M/\`=_P>?J/Z+^V7OZ/^Y/A]Q];Z'_>OA]3YO_IL"JGEV7T^WLRW
M=T=4#1];#A0&YL35G3V8:F#$>H0MOF/L`?\`&5,>1V#0><3'?.V&W'?T>W/U
MU>F_T-<A9\'..?W:4_;=(^??WW^C#_UO]#GU3_NW]O\`[;0_2OU3[![^L_HW
M[0^E]O\`6_M'Z;\OR?VGX8&(!SB/_<5]^VJ1\S?=_H#_`/A7^ASZFON/VO\`
MJJGZI_#[[![]3]`_6_F^X_3O^[_=?'Y_[9\<#;)=.#7Z3`OWY2-)?H7Z]'_X
M7_NZ?5G^D_N?[;?[5_87ZR]^S_7OL_C^G_IW_>/I_P#U'^MP-(]"S&0+O*!Y
MMZG33(NGZ!BZU)=P6>RK9I:Y$H;/^V+5W_#/3][^V7->ZD7)C]6Y3`?I6W'W
MRG''R[P-OFLX?_P[W_$:D:)_A-]]Q\W[UGU7?P[_`%+]17^G\?UU[^VOOOU?
MZOR__=/N?F^']?\`'`C8%.*O_><4_;-(^0?XA_:1_P#8_P"A3ZA_WG]A]BV_
M:W[4_3WOZY]I^F?1_3_L_P"L^A\GT?ZSY<#?C4X__?Z.?N&D?/\`_%']4D'[
M1_6I]5'[^_6OT=C^ZOVY]\]_</ZI^@?;?J'VW]M^S^E];^U_)@?[34XZ^P/?
M\/=(T!^F?J#?]S_P:GU4_8?JGT>_M?U[]D/?M_U#[?YOI_<?VSY/C\/Y/C@:
M0VG%<_M<5]G2/DG]E_Q$>?HGVT^HO]K_`,6?IH_?_I7TGOZ3_$3Z7T_K?1_^
MN7R_+\W\GPP)"#3@A^]99^WJ1HO^(O[A"?OK]&GU7?O7]U_II#]N?NS[%[^N
M_N']'^Z^Q^\_[S]M]7Z7]9\^!MK.<67^BQ7]/I&N/V[]R/\`V1]G/H/^B_=_
M;./TK]J_1>_8_<_9_5^W^T_KOI?/\G];\<#20$X5_?B/[6I&@OXG_LQG]#]`
MGU5?OS^'OV[#]/\`H_ISW]P_LS[7[;Z/R_\`<?I_2^7^3Y,#9TYQ-_LV/TJ1
MJG]/_1HG^F?3GU?_`&?[?_6$_P!C?8_*]^A^C?K_`,GZ3]/^T?>?#[?^V?#`
MT>(3@=^AG/V%2/G']M_4E_[D_:$^J']#^K^EBOW[^N?HSW[#ZGZ+]C^K_<?R
M_:_0^X_M?T\#.6/."?S0K^+E(T;\_P"LI?PZ_B//JP^;]P?!M]#]E?N9[\?U
MGX?1^3['^W_#Y/A_]+@?D7."'[UDOZ)2-%_Q&_=`/]X?I<^J_P#>O[T_;YC]
MM_N7[1[^N_NC]J_J'V/W7_>_T_[CZ7]I^I@1F`F*.O3[%Q'*<3ZO#NC)DB!8
MC9Z:_AHE57%K`>[*<Q?[;Y:=_=JMH]B^9!]JX[D'U>&WW2?*7PZZ"U'[X]$_
MT(A_Y_`/[]P'[X]$_P!"(?\`G\`_OW`UN83BVOVL?_?](P/]D_I3S]T_O"?0
MW]K?HGTNOO\`]?\`UI[^D_I7T/C];[C^T_)\?F_DP(M9S@=^L5]^GTCYQ_<'
M[?'_`,*OLY]4/ZQ^U?U5+]*_A]]%[][^W_USY/M_TW_NWW?R_)_;/A@>9M.`
M7ZG'?LZ1\T?K'\2I)^T_MI]3GZG_`!@^=M^[_P!N_2>_=?Q*^I]']2^V_P#K
MI\WR?6_E^7`G_P#?'HG^A$/_`#^`?W[@/WQZ)_H1#_S^`?W[@/WQZ)_H1#_S
M^`?W[@/WQZ)_H1#_`,_@']^X#]\>B?Z$0_\`/X!_?N`_?'HG^A$/_/X!_?N`
M_?'HG^A$/_/X!_?N`_?'HG^A$/\`S^`?W[@/WQZ)_H1#_P`_@']^X#]\>B?Z
M$0_\_@']^X#]\>B?Z$0_\_@']^X#]\>B?Z$0_P#/X!_?N`_?'HG^A$/_`#^`
M?W[@/WQZ)_H1#_S^`?W[@/WQZ)_H1#_S^`?W[@/WQZ)_H1#_`,_@']^X#]\>
MB?Z$0_\`/X!_?N!I4_G%A_MU3^*=(UE^T_OA_P!7]_SZ"?MW]2^YX_2_J?N)
M[^F_??>?+]O\?[9]3X?)_78$9^C)J>4JZ6IW32W:$+4[B'$B7A$]/_O)%3N3
M-N8@JV_A.NXGVVZ<@W\VOHI]M?HZ7^XYVU^YU@8KSY-Q>J.@NJ)I*N=TSH0K
MJ+;<3X;]7;;Y3OZEL_\`O9WS+?W%OO\`5/U+]8UHG];[O[K7S_6P-_:3@O\`
MMN._84C2'[0_<@+]I_:3ZL?VW^[_`)$?VS^W?HO?TS]R?)]/[#[;_O7P^7Z7
M_LP,Q')Q-OO"/[1I&J/U#]S$OU;]N3ZOOO/WE_\`7;]8_4?TQ[]?]S?_`)_]
MS]7_`+U_]7^?_P"Z8'O&3BROWA)_T:D:W_?_`-H&_>?Z9/H/^\/L/M^OV]^Y
M_M7OZU]I]K\?LONOZSZ?Q^E_)@1>;F^OWY;&Y125:_NC]@5GJY=2B?`/VK^R
M_P!=FO\`#'<T_6W?[&^__5OU;[3Z^_U+Z'T_GU]#[3`DWB<6-^\F7TZ1K3^(
M7[4W^G?)/H+^\OV-]_S\?LOE>_K?[4_5/E^/T_\`N?W'P_\`I\#V<SBU?II?
M+2,`^E]L.^C\L^A?T_M/U;7Z3]+X/?E^V_7?A]O\/ZW[O_Z#^V8'YC\XM/\`
M4I3^U:1K[]8_6>/WM^WY]"OU+]P?9-_D_=/Z<]^Z_6?T[Z7P^[_M_P!#Y/\`
MZ7X8&O!9Q)_TIU^W:1IW]$_5Y-]]^BSZN/TK]?\`IJ_O+[K[%[]I^K_2^?\`
M4_G_`+=\OS?7_D^.!ZY'.)M^AEOW=2-4?MK[$E^N?N.?5]^A_IGZUS^L?JWZ
MF]^P^Q_<7P^Y^M_:_O?A\_\`;<#,I3BU_P!+)_0I&`_HOZ6A^L_2GT,_2_T7
M])X^V_4_D>_:?I?Z%\OR?5_M7VGP^']K^&!%@J;N/X@53L!25>?N[^'-@ZIO
M4?GP3]M:@.C$'_B'N$_I+O\`9'W&W^POW/V^_P!0^VU_:]?;_<8$\_OCT3_0
MB'_G\`_OW`?OCT3_`$(A_P"?P#^_<!^^/1/]"(?^?P#^_<!^^/1/]"(?^?P#
M^_<!^^/1/]"(?^?P#^_<!^^/1/\`0B'_`)_`/[]P'[X]$_T(A_Y_`/[]P'[X
M]$_T(A_Y_`/[]P-2?3BS_P!W@_U.D:Z_?OV#_P#;?WT^A'[O_3/IJ_J?Z']P
M]_6?L/I?/]?[?^U_+\WS_P`GQP-)93A?]K__`%NI&A/V7^LBO_S*?57^U_W#
M^KJ?HG_U![^D_K/Z]\_VO_W?[OX_3_MGQP-SBTXLK[N5?LFD:W^__<;O][_M
M:?0?[O\`=OR)_??NK])>_6_<?T_D^K]W_P!Y^7X?-_)\,#</WQZ)_H1#_P`_
M@']^X#]\>B?Z$0_\_@']^X#]\>B?Z$0_\_@']^X#]\>B?Z$0_P#/X!_?N`_?
M'HG^A$/_`#^`?W[@/WQZ)_H1#_S^`?W[@/WQZ)_H1#_S^`?W[@/WQZ)_H1#_
M`,_@']^X#]\>B?Z$0_\`/X!_?N`_?'HG^A$/_/X!_?N`_?'HG^A$/_/X!_?N
M`_?'HG^A$/\`S^`?W[@/WQZ)_H1#_P`_@']^X#]\>B?Z$0_\_@']^X#]\>B?
MZ$0_\_@']^X#]\>B?Z$0_P#/X!_?N!&MF/[(E+`$TM8`'J^OF\D$NC)1`IJ4
AD"#A-7O;(<T;@-$G"'3CKYM:[[2X3YZ^'77?PUKCH/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g519187img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g519187img2.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@#9@*\`P$1``(1`0,1`?_$`,(``0`"`@,!`0$`````
M```````'"`4&!`D*`@,!`0$``04!`0$``````````````P$"!`4&!P@)$```
M!@,``0`$!PD/`P$&`@L"`P0%!@<``0@)$1(3%!465]<86`HAU)755I87ESDQ
MP=$B0H*2M'>W>)C8&5I!(S@D43(S-+4G825U)K9Q1&:A4U2$-A$!``(!`P,!
M!`<(`@,```````$"`Q$$!2$&!Q(Q(A,405$RDE,5%V%QTB24518(0B.A)47_
MV@`,`P$``A$#$0`_`/?Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@:U-
M'TZ+PZ629.G*5J([&7U](2G#$62I.:&M4X%)S3`:$,!1PT^@BWK6]ZUOTZP.
MCNHO/GS0IH2CK$Z#B]JP^>3FB>7+JMQ)4U,VC;%94\AZT7N<<J33[,XXQN1A
M"2539LVS(B=EFN"A>>46629KV@RPG-7YKN/"6.#*D,7Z?D,WGDSZ3KA#2D7Y
MLLF17:Q6#R23$E][0^6UXU-REQCKO#V.:H''8CA^ZGHS-[+.V9K1>PRTB\U/
M`S".#N".=S^80*5UO2UNRJWX+4-ARFHJ+KGHIQ&T4G)NAITWL0FVGB)^YDF%
M$$.NBU:())ARXI*G!LW`AN\?.A1]=2QOAM6T#U#>"M#W1%^$)]+(Y2TY;:WC
M=HJ)V]0^<-44G![&K9K.F4:)81J$C(TC$8XZ6)?2>3H8O5"<)OYC>.ZSFE[0
M:QB+T@3I0=76]<KTLF5%SR,-D]KJAI(S1*UY'51CVWH5TR0QA[?TH2S-$)RG
M5,9[TW"5I=;.T$*6?YSJ'BX8&WUW272$]F;]V/0G)\ZKMZI^=5_85>I>@(>X
MV3`[0'#7V/FO4@9IM`6HU7'$(`)E;H/0PF>[;(,#@2/VYY3$/$/;_&?.M@5^
M2JHSI.-3E;9MX@7+"A4.O23NLZMK>1RI)HC;2GKB0V7:30R.CDJ.(+;#70A0
M,>BP#",(?ISSI44HYNIFU^B(I.F"RY_`KJN:R(%0-963>+51E`T]?D^I%QOB
MU'..,2M7#JO+50S9AZ]4#9@CBUGNY)I20X8`R@/,M'Y3=]B5-#ZW61J/5YW9
MQSR(UVI8+/.UD(N1FZGBK!+$DEK9UA\;7-Z-_6MTA)5,`%IXVI6Q'(WA4J(2
MKR2P!,+;YI>('&#VC:9B^[VJI*Z8%$ECUMO'/=LH:SO=K*M!!2B37.\RW&AL
M]K.CY:[NB9&Q`D,+7.9RLM0F*-1>NJ`$KE^0VLK$XCZFZ[H=O>)`Y\QP?H8V
M7579#"\P"91.XJ"@3K,7BI[(CZTD3G''8>R$(C!D[/+,0.!*E.8:6:6+8=47
M&?GQ<K0>G=_Z,^B6MH*-<>//65N71R18=NV4BY6.9A1`:6G>BVJ7UNS(T-DS
M,$H/3,C:S+UKFM<6A226B,!L)V@[%&[S&<A.T79E[<W7\NLU\NK5`)>:4-#S
MQ?TT38X:S!=9Z953Z!$I>P1])3)H92:[`&-N"U"]&C=JM;3:#7G+S;\0-E5T
M?>AV[[,I2]2]JF:V"^?;*+@,';C+G<*"1+;.D*MH3)(FH<+*;#4P&W7O+R2D
MT%8H1DI1:-V&7??,KR&R/-IL!3%T=(72K^C%G(1147YYL1[(M'I]ME$@CCM1
M]++T[<%!9DX9$486/:\"`W:5`PE^]J#RM;]3`K!2OG#BDJC3E;%S1MHK*I8U
M77D2MN2MJ:,VBJMHFM^)NGX?135(RHLX,*9$UN+JR2HM2^LCB:F>$CH8`D@@
M199^RPM`#S+\=BCDP<1MW0J6<12Y:KH=#1:_GNR&^^YW8%Y0U?9%0)H%5RYI
M3OCXU3^N&9P?DBHSW8M.UMRDU7[MLOU-AS;1\K]-Q_QP7_Y':A@EEVS!J.)M
M!L,@"^)2&NIFYS*K)RKK62M#ZTR%F.?H8RLDM1&[=%RMO$-M;TYZ@PC>RA%X
M$'UMYJ:^7]16I0ESU);%6QMJLOBNKZRFI]3V,>6T2OLJEH1.X7&NCU`VD;-2
M\G<[&EWQ<;4:@XP8A@`:JT0`7M,"W?-7D[Y+ZQM][I:GY/+UDF3-,_D<(>Y)
M`9+%H-=45J>>@J^SY52LO=D9+5/V&"3XXIN7&DB+&+9Y:@@!R06E&!6R[/+'
MJI/)K5_$Y-7I'FCE[G4=37MT5MZ.(#4'3/3D;M26\R5&<R:*V0MW8#15P`J5
M&Q^A*=)&K0M@V<`)P6!0^4SDQQ=V*,H72R7"9O,\ZXKI7`F>J9I(9Y&9#Q"U
MJ'?H#XR1".-KN^HT;*F&V@:Q$D*#7U1(&DE"6>:O)#L(+0^8*G+,<ZL9J@1/
M<=E#QUY%^6+7K;H"O+#KZRHJ[S7G6S.@H>4U,;:VNR)&\2B.0@I2F.=%!"`A
M*%42J$0M`61L-;I3S54TZ<^<06GT7!K*K>0]?5S2$L7/T)K">RRA*VD=^3`5
M?U_&G^VSFXEI`K>YAH*;W8@2U<WE&%J5Y25*:4<,-"K?SBP!_A-ZMEHP605#
M<D%D?D0CE4.,BKFU#^>+0=.%G6U%CC'6BU4#"L*D$VU6]>:D+RTM83E`4X5A
M*+VZI,8G`'"A_F1D[_:Q$$=(76Z)@47-X[*R87UI3VN^.]BI^U.+9GU0^I8;
M&T<9&XM4K;7&*>XQ\IX`D2*$HMA7&$*Q%E"#=.9_/%R_<?.FKXN"%6MS<J(Y
MQN;K!5$IM#7]<D=::IFV`U5(5=?2S34UH+&DI+T\,J<:!"26<)<ZEE%!&'7M
M,"_W1G<M.<Q1VG'">,-O22<=`."AJIZC:LJJ567>\Y<FJ(GSN6)FNM(NE6.Q
M(('$DIJQ\/4")2MH0:`8;[4PH!@49JKRV%=/>03G;FCE^'%S'FVT.2G?JN4]
M`/L'LTLU<VCDDB@[3$8QHI$V,T)61N91\UL?U,C#ZZ=^).8_=R7`OT["HLK\
MZ%N1;N&=\X$PKDB1QZ&>0."<0)*20W-.47<\T8)T37^Q=!0BI2X<\11[KJ([
MG1ASB:<L1$Z*95X=GE;+`,07Z2>:;C]W:%KI&8ST[,%*NXI!0=:1Z)\UV:^2
M2_;5A*VQ4UEQRA&I*U[%9B:ITM7.BN3N2006IE3>P]X4A-/`5@<Q;YJ.%$Y=
M'C02>SI`9TW%VE]YS2,-/SI8NNN0JK83TM)JH@Z,UK3*#+GJ^>*=%RV,+@HG
M./(@&K%8`)2330!.%;^1_F6UK$JZI(@Z35395JVAU+43=#%<)=DKS$9?QLM+
M;+X_2*#?M$\-9HZY.#80D6*3/8N1KVW!3['[T#`ZFNC///->>^HO)7SFZ4)%
M'4SE&M(FX\N.I<H=R5_0UT21!S:F'5#VA$GT6W.!,BZBCHP:0;&=ML"<=Z/2
M`6P!;&F_-%3+A1?#UB=#PBRZZDW8%;4%*E;]"ZOGLLH.O);T1(?B97T1=[;,
M;BFD2U[F&O==)TXEJMO*&6H<`)4QI9PPU6OO//S>XU6XV/;U2]"U4\FWWU74
ML3K%)4DTG,^D4&Y&?5:&VKG^"FAE2B3PZ`,X$QDH]71FV-Y4B9P"6K"=^N&T
M=">:WG.&1>]P46?(;$D=(5O1EK2"S7*I[:=>8F6&]"-U8R^IU\AM>#QYU#[W
M9D$L@H]A1)"SEJA608$THLDHPS0;GTEY?J-I1WZ2J9IBMHDW[4%!]56S6#9:
M%4SZOZHNZ2<J52OLV=Q:$S]S:B!OC:V)"B=G.:=/IO6IO;&-RE7LK>!M7/WE
M?H.Z[1K;G<MFLA3?#_7U,/UF$0JMI;*:OJN=7#1;#?;1#)/-4:0Y0T(SH:^%
M'$NZE*%D`(TI,>N*6#]WT$.]/>6LKF7R$+N:)_#RX+S14'(3CUAT+T#*819C
MX?MO<9"\0V%1:LMQ-&<R"$X2M(D;@*E05HWA]5?`B$C3AZFQA(+OYI./X_%`
M.S]&^G&>Q`WG%><%O.*_FJT"NFVRW+"K&3W#6<>6TH%H'*Q([+@$25K61Q(`
M<WJ]A]F(XL99^B0VCK;R3`YFZ!Y>Y[1T/9,O=^G:AZ-M5OF0F=V1QRO@T3`6
MJ5DLDM3I6M::`Q:XOJ<I\.$H3@CB399Q^C-JB=:"OO.7G9Y<L3FECN"]&NRJ
M4L-!R[SQTA,($XU'8Y::9(.@'AIKJ.%<ZFKF?;E<3*YW>X[BC8H2`UM:L$4<
M'TI!^\X'9-SAV#1_4E1R2YJX?'5KC4"E<Z@5HM%@L2Z#2^II[61OLY]#+(CK
MT$H^-OD7*$6H/T(9B<Q&<4I)-,(-+,$'59Q_YRH?;E-]AWET]53ISS#.=XG&
M.GJ[*;_A"6R&U.#;=,?R:0O=/'RR@.(GY^.B#D6ZMZ8(@(A[3:^YL[6MA8\_
MS/<<HF=S5.+5T8URQLZ)K/E_=2N7.EFI+E76E=E9/]O4J2WUH8SZDI[!:T$C
MAZMH6"*!KTB`%4%-O>_5#:(?Y>.,YO#4\W:'RQTS<+F'IOK-R:WNL)0R26.U
MIQ[8`:MZ!:)#'W%.0XMEAP>>Z,;MLP@"/5&%"&0(9?J#$'/4>5KEXBVJ0IT]
M#<[2Z]'(J[*I^?2*F9PPU!*)A;57GV]7E?IK#<6\AK6RI[AI'KG>Y!5H&];O
MW)6J(6:$1H*CV#Y:[DC_`(2:Q\H4.HJ%R>YK-9**/9Z-,D;Z3$5$AN>[HK42
M9F2/X$X7HSV'QE":1L0`[&?H(!;T'>]X$*5G]H8@$RZD%$)1#HM">08QX]F[
ML:R^@#W=\>'R,SXN!4Q9DNJ5NCS6B4`>%43CU\QU$:G)+&YFO"L*4!6S1!+P
M+T*?-)Q>D@Z.1FE7IN?JK5>J:,YQ*I&9&]*-\VCE9);L?@.-4`(VXIH^U4ZN
M3R0QU]N)O&WJ"RRS1K!:2X%>+`\YU<&R>]66G(([.U?U?37!=VP?I&7Q6RE-
M)61&>V;?C\!:$OK1*)JI)'E(6>1D%,8CBQC<GY,Z)E)2,EE6FB"U+%YA.+GJ
M[7NCE+Q:D7<6"SNF*7<+*F%/3F.TE^E;D5DDTMO2"I+76MNHLM>HM!X>XO8-
ME&B3J&Y,+8#?;_\`8P,;5_F(Y9N'3^G@L#ZO<GUHH.)]0LT//Y<MA'-+#H*?
M3]NKN"V=6$6.9-/$[CLM<W(*Q()"48:%L*.4'@)]B:`(3QY!+KZ"YMYJL_H2
MB&FF9"&D:XL:TYW'+>'.4_QA8H-%%<C3LL27PH6]M[PY&MYA(CEA9I`-#!OU
M?N"P*Z2'R)37FJS15GU]!VYV3M7/3/T),[,YC@UF2^$P"(NMJ2B"K9!-TC_[
M=VC\/BS,T)%BY5ZRA:;LQ280D&0D/$6%D(=Y!>;IS?FN>6)\D>Y0NG5BU5%Y
M:MC:E)7,XMFHFQR>+0K&(R<9VS7&60EO8'42GVJ8A"I&RN)2-2I-1*``"JMK
M^4%]J"_NXZ4EE4-C<U4/4CS+.:+&.?%PH[=MN0CEE-TW8%%S$!:3VL/F:2).
M1+JRA($?I[8D+N:5ZIS4<`83>C\E5+A6-\?7QJT%[T,]E@CC)(S`7APJD71#
MQ5J*U4G.C582D29N464Z,ZXE*CT8$#6)U4$M9BT#H9I'@1M2OE,A=BUW7\ZE
M%?3ENEUM5US%)8#SU!X7(IC<2Z8=`578%MGQI&=O3=%)`T-<*K=V>BW31[<E
M2L;>8I<-IC#B2-A*"/R@<JK)Y$8$)QL1K525UJ2*/3[(ZVDL58ZQL:]R4!E2
MU7:I4F3M,CAEAR\]Z;D_N)K>86W*'5`!>:EVM3>U"._()Y`9GR3;_+5.UU$H
M#-9;T*\NR)O8)2\.I#M(G1OFU7Q9FKUH&RF@25RKFK5-7IP23*2?_JNB41K;
M::$U:Y)`Z"3^_NP'GE>JJ4G4&>Z,;D]R7[7]0[LB]I6O8*9A<<FL2G,IU.GV
M0,*M,(Y#O42(3I=Z4DIS1K@;V;K7H](5WHGRR11^-U$+A9FN6RASN:?UI7MI
M\GMTOM/GJV8364$IR>V3=C',7E`V`BM=5(7<9;3*%RI6M;4KHR+P)%JP8=$!
M"<&ORF<N*V17)WTNVH!&"8W7]E(I%8E62.(-+O0UERY'"(_T@@/<P@,(HYK?
M'-&)_=E@$JB,-ZU.O=TJ%"<!1L-LC_D;YMDD<=).A46$F1$,E'2F,H76O)`U
M/MDQ+I2W9!2%&2NN&)<42Z29CL:>QPTM$9HHHP")0E5G@*(4DC$$1][]P6=R
MW8M<PV/E4A5T$ED%E$K6]$=1%VDEHH^:LSRU-;+22J:5NTJ&6K9$^(%AKD:_
M2=82A)1%?^C1.1@%($P<N&>2DIQEEKQ.;<\6JWN%803E!^)U59:.[VV;S#IF
M#O<T4QJ'2J)Z211=%H,6S&EBE2Q6@CZM.F/4C4)@;(`<&KH/+[0:^5'K/BK8
M:2CTO-9=YFVVJC2_V_QV-Z2=N604,"&$$G.YUD&V\SC8TY1(CR5KJ8$LD8B/
M54C#<7KRS\M,D=+=AM-V.\@1'W01,ZZC-4.\GGE9ZY[C]=S.VU5@(&)4O9&=
MMC4"M9@?251+@J3.S:Y$;;QJCS2R!AD4WE4Y@6-"A40W7("3JY9`HM!ZU<ZM
M>([85HI[2@DHM&O9A`V62J&9$=")+74&?'?3@YJVS2!.T*2EP$JG19!@?(/*
M[R6LU%5["HM64Q.01:HYH_V!'*IE3A!JMCMV6C,J3A2NUGW:<C4/6EVS7[NQ
MNB`19S@T*4)QJL@I*2<H+"Q')'1ZGJ.MI;8*JM)951D8O;H*E]1V8`3Z<5X*
M-N&857J1D#3&#+V4]BBNS#R?_P"!<-*4FAGA3Z4'!0UB\BL]E?<UO<NDV#Q]
M7[95/0<?J1+`IZMM91?4^BAM0U9;#]+F#X*]V@;<H5)9VO2-Y:C8R0";-F'B
M]`MAT$PG^6+E='$UDT7MEZM[$OCL#FM5"5TA-RW'H:`V7;$$I.&SFA&<*(;K
M/F%UL.THTF]G[%*XE)']O7&)0HE9"@8?`?*M0YTH*A"&I^K'28*Y?(JO;8ZV
M<_R96M=+HB%?(K8EE+H3P*=-HI_&JT4G/*S8SRV<HA`J)]_VK)VGV%A)OU$6
M=R`9UESU`7B_T$BJ5LMBL(DC=&FO#I4RR&/D2)F72%VG1S47#&5`V*@JG<9Q
M)[BC3$G!)1*E82TI@4;G'DCN=!7#+9\"J.MWEDK'@>E?(#TZAD$KDS>XC@EM
M)Y8O'7-*[0LZHD<M;&&K96X%KGOT)#1IF]((H.UAZI&$]=O^1RI.'45)3NQ7
M1F/J2=3&Q8W8#XV&+GZ6L/Q2H2S[:C;/#XFPE+%LCFTOD4$3-*9M'HL6PJC#
M-[#HH0@AO9'1MHQ?B^7]275':UK5[2PQ\M1GBL??G>V([$8`K*`Z0=!+I1"P
MF%3F4ACQY)KP=&M&M.UAHRFX]8F++6J0UE=Y&J86L733I#&.PGXKFN-WDL=)
M,JAR])74IF=!/"J'SFO&F7IS%A;7+TL])`UI6]W);%CSZ1JFHM>C*,4`#"N_
MDJJ"JW(4+OYALF!S&/P*RGR328FL9235LFF="T\Z7)>L8JIT<]ZDDJ2Q6+Q=
MZ4(%^T(6EW`V'%(EZH\/J"#'"\L7*J$<9^,B6WH2G=VB"R65JIO6;G%PU#$K
M9F;E!J?E=N)'162YQ)GM)T:S%+;H*=4K2-6PKW,EO2"]KH.S'`8#`8&%DC&F
MD\=?HVM-/(1R%E=&-6<EV`*DE,[(3T!YJ<1H#2PGEE*-[!L01!T+6O3K>ON8
M'3I&?!SS1%JF>*?0V=>)\?>JI\?=1J7%2[0?;N6Q>.>V'*WZA<2#"8,2C"[R
M^0.8T\B$(D1)R/6@HRT9GI,V$46]X;YNLZKIRU>=^CK-I.+CN'R0]"W'9T>>
M8&?;D3L?MR*4BP)(W5\=E542Z!OE?D_HV6`.*=R!.#>(1"DE28H`6,D-Z<O`
MKRJ4P-=:P*TNA:PH9_I_GNC>B:+BDF@RB']30'F!0<JJHJU7I_KYWG#$^&Z5
M'I7];%'./C?&X\:4T(`>C>@G&5>)ZHWJK7JNHW;=Q0)T4>0IU\E44G[`;7ZZ
M0P.^W6PUEA?!+(U2&#.\2<:^;U+DI1)V]Q0+#?=C-;,.,&'0MA5U?]GOYF=U
M]S+':\^@7$-R5]UI5KB:H3TB&2ML/[#E;/-[#TYV&13Y5CV5(XW(F4D$?<I:
M[/AS8UEEMX`[3%Z#L+'V_P"(NH+3L>PKA07)=E=V?-KWXYZ):95%5%>+M02Q
M.*Z[>:NKHZ/,TK@<@:'!JDD2D2X+RF="EP35)P3"/8Z!H&PL5T'P/173]L`L
M^XR'N3HE/+%[<AR&N3CFS4'D]7]!2.MI-,53J2-K,?"I.V+ZP0?!BM,M("C$
M,9N@"/"284'7TT>`GG^'5#6M/UETGU75[7&.:YKQK:<DBDBJPZ3="\MSVT)M
M;+W5]D'R&JGQK9G!)([#>26^0QM*ROB-"Y*2M*!^TT(`3<;X=*")M-RG3#8]
MMQB$*.A>,.FV:D6<^";KR+69Q%`HQ5M<Z95KA"5LWW&I/7D):6QY0*'4\(PH
M_:IA)S3!#P(S)\%M''49/.7)!TOUK*.9ET<)C5'4.[3:!?HYYJ(;KF9[[CCM
M!V-+6Y!%B2&'6!'TA+0LGFI2-)'PFM.]&)%"@)@6VJCQUUG5_&]Y<;_'>62"
M.=$L=T-%E3XB*T]7<D$==\35PJ0*XK%:EK6"5?%B(]'CRD[.E(8Q$I@)BM&Z
M/UK?I"!)]X4N4;`9R(XMD5L,$<?^)6?A"ZV2*OL<9D'0-70ED9&^HYW9J8,5
M/2GW73+LQ@<(](T1:4XGVQJ%06I;1:1A"K5P^'^PZ?K>EGKC^1.5A=#5;TLY
MW2?:ATOHSCRQ6&-R>FW.E)1%ZMU4G(\JH0EL?(@>6E<T#["E)BO:I6O*7DK/
M9@$$<55]G-A,DYDY^KGI>];#263!*.#5]A(*O.KF:0T"XKI69]1LSA7TNN:H
MI)/H>_MLRF6VY^>V(;`JF;>B++<"M%;V5L.QF5^)JHWJ!N\=B]PW77,]+[YL
M3R.5W<D760%7-:KZ!LUUDBN2)(ZUR6"OD(?:\4,LQ=6D30]-;D$Y`L%[4P9H
M"S0A#0O!/S@HK.5UFZW1T5(")K2/:]'2.6OK]7JN8.K5W9>$.ORVY<N7)ZZ1
M-A\S;)E#"0-9VD@$@4R@[2A.>9L`P!@>X?%5(Y6X3;H+EESD3MTS)>@>1;M;
ME+S<;53JVN%/+=13"BTCQ3$M'2=O1H$LDU>S18F<FZ8,+Y'W(M6?H0$PPI]A
M#?>6/&$\H/%C:W`_5TN<%3STFZ=2/UL/L$F@YA((QOI:U)S884K?8TDAD?+F
MTPBB.4IPK'A2P)$KDZ$G&Z1Z(&$&PWDCQ)58O%-7:<W?=]@S:R;UX2Z)GTV>
MQUHVN,DL?@5GKIGKI08TQNO6>.MS5/`5JC-D:=,D+]H8<=[D)&'8-`#G\5^)
M&@>%[@DUI5-*YBXM2MLG['`*]?XK2J5LK9GLZ?"L>5I"I_%JKCMRV&<0]"]R
M:3Y5)'DUK9=:1`V,`0#"$3V=X&>&[B^D/,;#13A_Z.Z!NMUO<'6ACDPDW]3T
MO+>8XZ5XW4[(BH\%DC47J%'$F]O84:EO6^HA+,`H&>(\T0@E63^(+F657)VE
M?)\CMICLCN.@#Z!LAWB4K;HT7!T+[&(_%K!L&I4[>Q!!#[#L]'!XT:_*]^\I
MUQ\>2;$1ZOM@&!$]+>#GGJF9%&I8BMBV'Q\C_0M.=+C+(CM%U[&5=@4KSK9G
M,L>;TL*JBHH-%&**.D`LT]2O3HDA*I2[HRU8U(C#E?MPCQ7]GQYF4(J19RKP
MOT#'1M2\R51'D#BDH^3+5"?DRS!VG6,@;)'*Z>>Y+7"Q\?SMAE26(JV!%)BB
MB/?"A;)_C!OZCP=4BZN\H#*.B^G977;F\]N3B%U"\/E8%P:JK7[W:;-C%S65
M##6JKVZ4*W%JB5LO*-@;WAP=&IM/6'+/=S%)Y@]AO<8\-7.\5GL)L%#8ER'N
MT$N#B2Z&M(J=8<)O52/A/FJ2\O5@VKP%0TI0-EE$)E!ZU]`686<<Z``-*8E)
MT(@04PL'P?KEKQXZ><XN\*9KR1QYT).[[D-F6K8#81:1=6/\C'/=<2,]=P*K
MHXTV!5,NM"/QIX<GF0/`E82&G90P*!!3Z"';;U[Q,P=5O='V,U6]:O/-\<VR
M&9O]*WC3PH,KE$5*LN)F0:R(XXQNS8;/X#*(S,XP(!2A.N:S#"5*5,H(-*,)
M_C!'G*7C!Y]XWL6N[$J!ZL@:JM^4U?)[>TRQ_;'Y(_1]YO*0=$2RR90N^`T;
MNY6A,[.E3@M<519Y#>/WL>BD96O5]4)FYWXTJGFV?],69$ANC_+NH>@9%T1+
MW:5)8XK<(S))+!X+`UT8ASHW,3:ZHH:6VP).<6F4GJC=*5*@6S=A'H(0J8/Q
M$U.RU'1D#JZ\KXJ*R^9[VZ&Z`HOH6)JJV<[*A4GZAEEE2.X(TJ9IA7<CK63P
M61M]IN#7M`O9#3`I2$H_;>\%"-,",E?@LYT^"^?D;'>O4D8=.3FHYRYMDK/8
M4>"]5K=DHN<R\;DZ16:40TYJGMMWS(SC6R3Z?$JY@''E2E`B;48#Q#P-HXN\
M?<SK+R)=Z=_6Q%(/!7&^U<?@5)5]"Y^\6`F9HFVMT91VS<;V)=%(BRQ&:](.
ME<Q1>YM#:G4>Y[8@:4+59AGKZ#*VWX7.5+LZ.'TY.WNRE\[^EA%.NT[<6X14
M$>33:(4+":'01(!!D4.<38*J15PQOIZ<Q2)6)[;BQZ4!3^E/@04I^S[<TFZI
M%*1>5^@:*,JSE"LHVWN22D).K.!QQ/\`5AU8_-DCE=0/<GKDZ0.XA:EB&)+&
M!OD_J$#6%"$2'TAFK'\#%!6)HPXZ]KJ;'-HO7JNY*V7K(KSK/2:N9^TGU)+[
M\J^.,-GTC-8TZQYRG20#XQ.SJC7R6..0`"1.`"M#*,"=Y3X@N=I-6W7E5ZF=
MJ,\6[&9^4F*<`:EL+3J(@W\APZOX37A<&+U"_@Y#M\:JZ1C=]*DZHLTXT[:<
M"8&P``$'R7P+\Y2RX;<N%YNJ^%+I;!G9VE+:(FF=JF5'W35DBJRWFTR?;J;=
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M!&D!J98WC1+T9I`MEG:]??H"FLS\%_*T]K2'5A(IW<:MIK_B'G7A^(N(UT`5
M+FR,<N6TTW55%HGH7.`N$?=[$2S9D3_")"Q$?'7)![1*<V[*-'K86&C'C6@,
M6X9N?AQMMVRVQAOY)9*:Q[9B,?IFMI\+5LA+;IH7$8_6]712JH<A'%2_@5`0
MDC^M(6[0`A$(T`3=!6:??9_^`'=MEK-3$7D7+#/9'-%G<IVJU42='VU!9U:6
M*LA+NA5RTB7L$M"IEE>O\%3K6->3[$19BI4!0%04;H`0L'*?%;1TLZ+7=++Y
MU:I$S<.HN7.KS69(Y18,:#.^4.?)GSE!6(!!L5.<_BH_Q";J5CL5M3M6:Y%E
MB(/()T(D00#*_!K1SU%FZ+Q7HCI6LM&07N*HIN^0MRJ<U[L.F>^[<<[NN2M'
MLZ5U7)43.WMD[7%B9W%I(0NZ9&3[(U2<(>S=!^S?X-N?&WH"L>@"KDNQ0[U+
M.N;[)B<=<4-+N9!,IYIIYOHV,(!3A?4ZBUD-=O\`"6_VZZ*(7Y''P/:@]Q(2
MEGB+]D%CFWQBTJU\&4CX^"9I9AM342^T,_QB5'KHN9/G53S[=$3N^*$/ZOXL
M!CRA,[R2()TKCHAO($8A,,"5LHW830A41G^SR<*-$4G<#*<;;%#;&C_9$<D;
M,5((NC%I%V1,Z>F;TH;7!)#RU:)94"BBHZFB&][,)3)TF]+BU^Q;P.0\^!/G
M9^K6'1MRMF<&VE!+<EMMQJY2:9Y`1Z0J9Q6J*HY'#C*/1<YI^=W"(J(<W$GD
M>]Q90YHW\O3H0L+/_BX&_33PHT1*SGYN173>\6@TQH3D*B9U!&0=3%M,P!Q'
M<K==-)6*O6#J[X0:)J4]%+TCJ6U#0,Z],[*1>Y%G!(,)#<)#XAZ%<B=J=R";
MRD]%T[W'ULGB<R=6@$*E$_[LK>UJXLZ`2\;#&DDA+JU"T6TO`@"WGD/"?0"Q
M#5GB#O0PH7X_?%'VI6MA3B:7W>$SI@;/Q+47$-.2"NK[BU_V9#XQ6%O'V,2N
M@,CDG,-612*UTW1I"B86]&^,<BDJ\M2M5.2\2C9`@!W]=#4K&^D*(N'G^8.3
MTSQ2Z:VF-8R-UC9R)/(&UEFK$MC[DM93W%$Y("71,D7"&0(Y.<5HS6MB`+7I
MUL(8N[B>N+V.N0^32:;M([LY;)Y.D?P`K92=-D%)?I=(0/['[^R+]DRSWN9*
M`>U/]ND]F67KV'IT+8@CNJO'%5%.]#N%\PZ5OZ1"IL*U;90UM\2J9(0(K!N@
MU_63M>LLU)6:>[W^-F/,L=G%N95TE.0-ZUP%Z@1)TR!.D#D="^-NA.F83US!
MK)<)QM)UX^0>6OSXPNS:T2BJ9M7%81:K8=,J@?"F@:J./[6U1,E0(Q3[Z6I&
MH5)C@&(5)J408]#XWZZ0SEN=0VK;!E3HK?C_`$6HH`1L&!`7+H"-0QKAK=82
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ME($NK..H.[5GR76+[+9@\MW($VK&=0AW/(AR!QECG5,`DU<Q]),T#+%6N-;;
M5+))S1J"FM`V!]N27LKV0-"`(-UL[FBNK;L:O;#F&G-3JOJTO2IR8DF-2)XO
M(8CT"B@3;-TKZ0!)\);-)0U^F*2;3*4VBPJ#O7T/>P;`%-"_%-7+Q'=0ZS+Y
MOFUXF15<(YL1LDH6UXT@%R7$),TRA\YT>EL-@,;72.-W$;&VIMG+PK&-^D+$
MVEH=JDX#E@U(89!X[E:'IGBYVVO=WRC>)H'98HQ+9G.RWR>6&OE#UHBE:5E<
M80Q1M)>H/S&WHRG5@D#HY*77:],AT(!ZGWY<:%L;UY=D]ISQ#9E;],W;SO+1
MP;=8RPB`DUK-8/-X/IY6OR(IYK>YX%8\*03!B<'5;I`_-Z-(X:3KCDRL2M-[
M$DH*C/WAXHPYHCT8AEE69$(7$XMS-'F.`.;75ME0-6KY6B,]KZOG::1>R*_D
M;?8"==#;$6!6M;KI0U!>$;>[)$Z9>A)-T''+\-E!D01!7(+0MT^-)H)*X6L(
M<$=0+M.:UQZQ6=HP*8'M0ZL+BB9XJN\'$\]O;R&TJ.N#4(+>Y-JM*#0-A*,9
M\9-6LT;<F9VL.</+F^UUT_6[V[-,9J"NFT31U/'*IB<L,8H56M;Q2&1SXI,=
M/M8&8"=%O7MC51ZX2T\_9F@PUD^*BDK$=FR5CF,O03>,-]%(H8^O,:J>Q69@
M%1=7VC3J`Q;`[)KV50J3D32"VXZ%.Q3@B.]DL*2+&\2)2F+,P-K2^-2GT]:S
MFM#)S9:M#8=;\]5Q)7L8X*W.QY'.UMV!<[#(4B&/PAFB[6\2J760O"YDI&XA
MM+1`))1)4FB_3L)=IGFN747-UFXE=$F=J9?9YU';#_6$F8H.>:7.^C[38+<(
M3,TD9XDT2($;@4L<)>:ATJ6J%1A$CTG4#4%HT@DX2+6G/T-K)SZ'<4"QY?2N
ME;;7W!.FQ_-1*&]$\N=55I42UD8RD:)$83'SXY5Z(W9:@:@_:E0?OVOJ;``L
M*61WQ75LW)ZZ;I3=]XV&S46S5'".=VJ3JJ\(*IFKJ>O6F;[:((V*H_`F9;+Q
MR!]H"*,[H\/IC@\',+0426>4I,4JU`3\S\25LRV1'K.326;&/4<Z1N7IQ(B.
M5LFVP^:7;3SW2\E95)8&0"D48;8X^FJ4)830J@+0`$8<:7K9>PD>L^<H?5O+
M\1Y29'B1KH+#J914BWOKH>W&2M3&D,3^)Y3FL4I6U*U">QM__<$,"0!'MONZ
M*T'^+@5;F_C-K>6QF#0MLMRX(5$VOFBNN/K<9XXJA(_I`<]5B8>=&X9.UKQ#
M7-;'G(7PL\)CW6.#9UPT$A<2`B#L:4U($YK>).<@VE6UMQ*LX56TF@%GS6W7
M4-=0:#Q-+:4VG=4V14;N[VF8V1PI?+5Y;!:;JH*5&G!5^]F[V,T99AQ9@:BP
M\&UG&^4+0XO:IC89=%SO<\:8<R*'!C5N-*5[.5FW(FJ*T<5#",1=>P18I4$Q
MM(Z`<36EK,*;P&B1I4Q100^Y>+"JG^^7R^Y-:%BO[X\2#X2,;#V&I&@]WC*N
MXZ^NIQKFR)I&JY8Y]<L&0/5:M[2P)I4Y.IL<CYAZ1(;ZYFCPAI$R\.='SFQ[
M'L-[M.TM*+#D?2TF/3I62FP2%*LZKJ&TZ<L1M=+0.JY1:LPC44CELK_B<UNC
MRH01LI,D2EE')$I!)82A97C#IJP[>:+@)ELGBKP;%:<AM@HT,0IJ3*)\S42M
M6*H*-+*Y_6<MF=9NBU"XG-;VIBR]I&ZM.P%;T4>22J+#LIP&`P&!J-@2;4+@
M4WF(BUQP8G$9+)A%-C`X2MR-TPLRUTV6WQ=H/2NLD7#TE]!*!*:6H6&;T26(
M(QZWH/-?2GDYZ>5H+/LQVL_]*M/TA4_(O5]FB!$*8E4O-IJ;3ZU87U/&VIOY
M[3N##$'&OJ^2-TT2Q4QXE,Q8SV3;>X.BG3D$&!S;B\CW8-<KJR`\3[44LX4?
MY=MR7TLZPBH8K&E$3ZDZ2?BAUZ`F5!?+PNI=5U(+43"Z*X0BCR2+.;2H<WIW
M6>\#2I0U@?4%AT]-K3G"61N56.$I8JYIYLD,9B5?M,68"E/D_P#*&R*'-6Z7
M&\L]%U2MD40A:8"Z82(IS2:6JB?0VN"Q<A3B"(6CN2_W)]6=#/W4;56MR,'$
MW1S57<>45]%I4T=:6+0?>5\P&G*S2MHXZS,;U([.C4?:4RPB$(&5]D8G@MP9
M?=$)/LMA(,N[+ZLH<^QX]"I6P4BPOUN^26WPS*T'Z#)&=^N:'="H&Z)T1IPL
MB*R[XSQYD:'DU6IC40)33.2)3@?`2@G20_0P[1^[^LK0I^O>4D2&<J:/GUY@
M?%DH<V5OJUMC;<ZQJK@29RBH[8Z61G0J#A#)'0K:)O.B;]+)*0D-3-Z!,,I6
MH3A#_BYO.V;]NBR+!M^W'DR87'P%XZKG2U$8WMK)%8J^S&%6FDLR6UU$W1M!
M(6]M(GZ49;@6::<$A<LTE6:]8E*65?CM6F2M[UB](M$S69F(M$3UB9C28U]F
ML3$_4I/LZ>U'<![B[CL2R(C1Q@2XI(;!?4')Z2?IZM3*B8GTMR\^-TI[0MM2
MD<T(F`^#S6I'93\4DY^]MNW1HV$C8_:""+]*.X_`'^O_`&QVOO?(%9G><9QN
MWOW#;9VW]JSN.#Y[%?;]L<=6V._QHW>UY''3\QO3_O\`E]S$Y(KZ8F./P\KR
MN;/7:_9O>?A>KT>S+BF)S7Z]/3:DSZ/HUCH5/V[W;=T[BE1)RDU:OMWDIJZ@
MTR5U2!0FK&T./V):B[ZD$A(=DJAK7L4GM=T;6")@5!T2(HDXY-[3>]B"[R\!
M?Z\]@]O;SO3)-^5X_@+6WN[VU>0FMM_L.Y,M;]H8<,X[5R4RX./QY]YR,XY]
M46M2F7TZ1$MORG+;K+7;1[E\ONUMZ/LVPQ_,3.O32;S%::_MF&S\W=Z=;77<
MU9QV4,VH)7UPJ&V9-+@OK8Y%J"P;D^,OT([M99,[.!7LRU;_`-,)V=GCQYH0
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MG.5C`TJTA*0PH'>[WPSX;W?>G-<+V-V;EYFW#]U\=PF79X^5WELF+C\]-QDW
M?/9LM,D32TY:TVV//:/RO85QUMO<.;)FK>V-7D>0KM\>3<[B,?Q,%\D6FE=)
MO&D5Q1$QUZ=9C[=M?=F(AO#)UIW#9UOOM2L3XTUD8]TRZRB`R![JDI4UH>UE
M?/<:FKCP0]/[LE$QGHZ?<5BJ5.#WL`'-R3&F,6E`5K(YB,Y_?^&?`':?96W[
MSY#;YN6KM^=Q[?>8<7(37)?M>O,Y]K3N[%AQV^+%N2I7'Q^':ZS@P7K7D)QS
M@W^TBDM.1Y7/N9V])C'KBF:S-.GQ_AQ:=O,ST]R=;S;VS'N:ZULY*KR!]+N]
M8-?8<&BCD[4;<DUE]`4S2ZJ`B-ES3:KE`(Y$*>E<E<D:0$B):GOL6-R.&.7O
M.P("&MU;EOH`$HPP46+_`%M\5;+NS-X1[@WF+#Y`X/8;;F.3Y.N\TVV3CZ;S
M/N>2V^"EK?!G)B[:S[+D\'HURWW&WW6#6TWK6*SS&^M@CDL59G:Y;3CI3T]8
MO-8BDS/MTG-%J3KTTFLCMTGU+\?W2J%]Z^^VWN\9'S6Y\_L571)LF`:A044X
MNGTR64S30KE:):XOR8N7I''9AL("F5`CH48G'6CMMGXL\1?XYA[QV_;WP^R_
M\?P<YCYC-O\`<9-M^97Y:F/_`!G+'Q*[>]:8;3QN3#$5Y6;X[<G.>-K,XX6W
MV_\`C3MYRZ[CXLXIQQ6(GT?#F?C1TUZS[\3]C2?1IZNJM]#=K]7-[/R[!6"S
MXT\M#93'`J")$6*\PL#QTL;::)E9KS6JTI$$?[6G,B@[Q\)QDLV)F)!QMZCY
MBR3^\%''B#ZCY$\#>'=SO>[NX>1XG=8-[EYWN^^YG98MU\/@XX^V7+Q-:VG=
MX>/VF'=X_@;ZU>1KDC?;7>5P<3\*],<3@[3E.0K7!BIDK-8Q;?3U377+Z](R
M?\9O::SK7W-/3:NN37678;T3UDZH[J;62,=,QRAZD05*=+H1+2:O0VV5T)=;
M'=T@J^P:3;6]06:\R1;7>HPC2JH[$S$<L6K)*`TE2$M$(`_F?QEX:V>?L/+O
M^6[4W7<7>>3F8VVZV\[^_'3PW%Y>*P[_`&?*7O68Q8*;WX^3)CWO(UR\?BQ[
M&U,F*;9XM7<[WD+1NHICSUQ;>,>M9]/K^)>+S6U(CVSZ=(B:TTO,VZ3T4ZDO
M=O6:2(2F012TF)[MQWK_`*P=K#H(^JV)49Q;(*GF25BJ)4_$H$B68KD[L><0
MTJT\G5'[EIR_3FR"2(B!E[]PXK_7GPUFYO:<;S'$;C;]EX>2[>Q[+F(Y#+6.
MY\/([:V7D:X9O:VVI;'$7W&.^QQT_+JX9VF_C-GR5M&MORW(1CM?'DB=Q-,L
MVQ^B/^F:6TIK]/7V3ZI]_7U5TB%F89;?6\3Z!;(U+;M765`F?O'7)RMC=:=@
MD;.DU>R+C471H9Z]2&*L[:H3R>,6`X%-2`]N"A:1-";1*U,J7&B5A\HYWLSP
MQS/C;+RO"\!CXKN+/X[_`,AKEQ\EN\\8-YA[F_)/E,6'<9;UG!GV=+;C-3/.
M7<1N;S?!EP[>D89SL6XY''O(IDRS?#&[^%I-*QK6</Q/5,Q$=8MTC32-(TF)
MGJ[7V";Q&5.TQ8HY(FIZ>*]?TT5F[:WJBU"N+R-9'626I65Y*!OUD;@?&9*@
M7!+%]W:964/]P6L^(G2-IP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&!^19!)(?5))**#ZQHO5++``/K'F;./%Z`ZUKUCCA;$+?\`*%OT[^[@?T1)
M(S`FC**&:`LTH!@BPB,`4=LO9Q81[UL02S=E!];6ON"]77I_<U@?PT@@\L9)
MY)1Q)H=@,*-+`868'>_3L(P#UL(P[W]WT;UZ,#^C)),V`1A18Q%F!-+V,`1;
M`:$(@!-!L6M["8$`MZT+7W=:WO6!_#""#O4T:24;HLT!Y?M"P#]F>7OT@.!Z
MVM^J:#?W="U]W6!_3"2CM!T<46;H!A9P-&`"/0#2A:&4:'0M;T$PH>M;"+7W
M0[UZ=8'P:F3G!,`:048$THT@T(RP"T82=_\`&*'Z=?QBS?3_`!M?N;_ZY=2]
ML=XR4F8O68F)CVQ,=8F/W'MZ3[$.?1OH#]S]#%9?F6P_]/\`_1SNOU1\D?WW
MEOZK-_&Q?DMG^%C^[!]'"@/N_P#V8K+[O_\`)C#_`/O_`/\`!_Z[_=_]N\?J
MCY(_OO+?U6;^,^2V?X6/[L&^;Z`W^[3%9;]/_P#)C#_U_=__`('_`*_]?_;C
M]4?)$?\`W>6_JLW\9\EL_P`+']V&J,W'7+C!)9;+FNBZX(?YP>T*)&L,CJ-4
M6I,8V5-'F[W)"K`>@9BP-*0LHP",I.!1L/KFZ&/^-FXWWF_RYR/%;+A=WW#R
MEN-X^N2N"L9K5FL9<MLU_7>NE\LSDM:U9RVO--?32:UZ(Z\;L*7MDKBIZ[Z:
M]/JC2/W=/J;5OFWGX6@:%2M8"T6<6H+"*$Q\02U!.][)/+UM!O19Y.Q;V`8?
M0(/I^YO6:B/*7DF-9CGN6B9K,3_-9NL3[8GW^L3],3TGZ4GR6S_"Q_=AA)-R
M?SI*HV^Q=?44,0()`U.30K6QIJ*BD@1$NB90E/7,,FCGP8_QU[(TI$8G7H5!
M"Q,?Z#2C`&:T+,_BO,?D_A^4V_+[;FM]DW.VS4R5KGR3N,-YQVBT4S8,_P`3
M#FQ3Z8B^'+2^.]=:7K-9F%M^/V62DXYQUB)B8Z1I/7ZIC28GZIB=8<>'<A<P
M0&*QZ%12BJT;(W%FA"QLJ$<8;W$XA`WD@((]Z<G0M:Z.BXS0/:'JU1QRI2>(
M1IQ@S1B'N3G/-?EKN/F-SSW,=P\KEY3=YKY<MXSWI$WO,S/IICFN/'2-=*8\
M=:X\=(BE*UI$5BF/CMAAQUQ8\5(I6-(Z:_\`F>L_OGK/TMDUS=S_`*'[75+U
MCHWV.D_M=0M@]K[OHWV^D_M?<?7]AH[^/ZGI]7U_N^CT_=S5_JEY(]/H_/>6
M]'J]6GS6;373373UZ:Z=-?;IT]B_Y+9_A8_NP^-<U\^!$6(-*5<$1/M]DB#"
M(]H1.U6O0JV2+2#6RO>M:]!GJ^CVFO\`WO3E9\I^2IB8GGN7TMIK_-9NOI^S
MK[_7T_\`'7V?1H?([/\`"Q_=A_?HV\^_]OTTK6&]DF^W)WN$Q_>R3]!&#VY.
M]H/^T=ZA@M>N'T"]`MZ]/W=X_5/R3U_]]RWO1I/\UFZQTG2??ZQK$3I/3I'U
M'R6S_"Q_=A_?HV\_>L:/]"M8>N?[+VX_B3'_`%S_`'<&RD_MA>X>L=[`O>P@
M];T^H'?HUZ-8_5+R3I%?S[EO3772/FLVD:SK.GO]-9ZSI[9ZR?);/\+']V#Z
M-W/_`,B]8_\`M_\`^+8/W?\`V^GW']W_`/']WT93]4O)']]Y;^JS?QGR6S_"
MQ_=A+;4U-C&W(6=F0)&MJ;$B="WMR!.4E1HD20H!"9*F3DA`420G)+"``0ZU
MH(=:UK[F<7N]WNM_NLF^WV2^7>9KS>][S-K7O:=;6M:>LS,SK,SUF636M:UB
MM8TK$=(9#,=4P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!@)6*4`B\D
M'!R6!1-0L#P*($2M0XHXN?*`MRG<?)DBMH2KG9*P&.VB0K#$I)R@"?8Q%@&/
M00[#K-T[>;GT:],!\5WI]'W?1;O6_H]/_7T?_9']S`L]6BSNHVE+%/N./<F(
M>C"]O_Z)6NM)C<+K2BW06!$*+?I%?I3!6>=-FSI1M0!P^#&Y7[-!HL9/KG;$
M#05A^%O-Q^0/BN_6[UM\R.!9R*+.[!\]RY1.(]R4GZL`K<M0-GBDRN)9SVH0
M:,:_@@4NDCO!$-CHE8RMK?>=(VH\`1!(]38M",]4*Q_"WFX_('Q7?K=ZV^9'
M`LXB6=V;YM<5+C'N2@=?:6#TTLB*97$9S:-O^-"4!8G&4'P0JSRUFX7LXS82
MF<8-.F@%ZW[#8C-!6/X6\W'Y`^*[];O6WS(X%H'57W/KF]H4LD>Y.,Z\VH3_
M``\RNLQN`GF\M+\8U856VB4)(,=9QRC41T0,O1S06';CLP&]Z)T$S85?^%O-
MQ^0/BN_6[UM\R.!9V:+.ZP4!"E%>1[DM5U,-6T:L5HFDRN)#0"5#M.Z_#PH5
M(V.".-BKU9:K2'232YJ3`&6(_9FP;"7H05B^%O-S^0/BN_6[UO\`,C@6;M!9
MW<53E:G4M'N25_01H63],#;:$RN)IIQ"(4?4BD?Z-7N)P1ZFSH$J5:)`B^%&
M]'[1OV,9OJ':"#85DV[>;GT;]$!\5WI]'W/3;O6_H]/_`$]/_P!D?W,"T%X*
M^Z"(+7!G-L>Y.=;,-3D_I=27A,;@8(*B5?`R,2C5<.$#@LD?W1/J0[4!!MS3
M(Q;1Z+%O6C=B!H*O_"WFY_('Q7?K=ZW^9'`M!T0K[H3-T!WR='N3GEV,3N>[
M0!T1,;@C+<D5Z3L_P,&`FUM!98I<4YBH3AI5MQ`E$`L*?8-"V(S0`K,E=?-?
MM2GTM@7BU"CV>3[V)+;?68U(4OM`^\;3A-I0!0C]%>GU-"WH.Q>CT[UK`L?T
MFL[T2N\6UQ_'>1'MA&V+]S4SI.9W+%G<AXTI(TU@BQ-7P.8(U;8-'[7:@2LP
M@T)N@Z`$0=[WH*_,+IYG1/C*&3P7QAE1H3LVZD1K#:_5:A\*8MK2-/!C*G<*
M82H#W8#=[3:8!YI9(CM!T,00[WO03ET@M\A":5L8.0XUQJ]084>"*2J.D)Q=
ML7E94K^$E^ADL:.L:]E[.HCWP/I*+1J@\I3[SLT/L_4T`0@B&#N?F#,F<3!9
M,(\:Z6O!R-E#.E,'M+J%?,T\1$X)]2(Z)H7ZGVUC62,IJV:)$4L4$)3%&@!-
M,`#>Q:"3>AEWD?33Q.7RA%^)'FL=QYO$K5]#3R]XU/`RS:MRTZDIV^MJXED?
M%'@(-(]IS1*M*1'".T,L(0@V(-"K-R\MQL_B)=QPOQSH:L&^(PSQ96=F],.L
M_31O8M_"!L1;I34C-'5KX$'H]B6M5)TXM_\`O#U@;5?"_P`FR>QG$KF*)\(N
MU1Z;VG;2MOBP>@8]8PW7:0.WP#BV5]64GC);>6O].D@BU8S!D^C9@0B^Y@82
MH7'RM'61%2K[AWCV;JA&L4ZFRVH;)Z/>K(3M^FY;M&**M<SJE@C"M8)VTG":
M%6L(!I-LP0=['H(=AR[J</*819<C*YUB'`+G3P=M?Q17758W1+%99VMM"#;U
M\8VN#59(HNEV!^VJ"E]V6'>NCT4(SU3-C"$.51CAY/S[)92NEHEP6U4^)*[[
MD*ZC+#Z$D%DE+`M:K;"%E:Y]6$:BYZ4QZT0%9L]86,"78Q%Z&9H(=AA;8<?+
M"38LK+HR&^/%PJ4#B'4&6VQ9723/8JAH]T3;&.5MD0J=]C2-Q]^V=K04:L\K
MV6@;];UMBUH-IH!?Y*U%A%%]317AIHJGX&<Q'+*`G]^2.PM2#7N_P,44VV+6
ML6CFV8STF^]#VKT>#T`]0`O3OT!HEAN?EX+G<P+JB%>-]960)&[A@"NP[/Z<
M;9VIB.EINF$Z8-\;J%VCZ*1F-WL]JRD2I0E`=ZVBS!!]&]A)?.J[R+*9NXE]
M:QCBIFKC4;6":57.L[O.33<<OTX-FD!+B@LNNHDPEQL35M;LXTM2-4%0$G02
M]@$,00B*5NGF0!*9*"#P?QFJ(4&0/(8>HE=J=3(Y2?%@N*G4>.DJ1HIQ<TI9
M`:T:)$L+2GG)@*=C"4,8-!%L)PYM6]^J9#(P]?QOCUDB@69.*(G<VS6Z91(3
MI#[\#2HJ1IK/@$0;4K-IM];98TQIQ^S_`$:V#0?NX%?W5U\TFG5STQP3Q>F,
MFG%;IF,=;9ZN)=1M.E)NFT;F2CI8](4XB1^IL\)0QEA-];01;#Z-["QG-RSN
MU2HF7TO8]R2R)0(FG=>[YNF5Q2A0I<=C<OAP,R#9\$B!:%$67I'[H)#M08,0
MCO::#H(/6"LYKMYM/:&>Q@7BQV3[0?LMFVYUKHS97K;]GLS0:2V'1GJ>CUO1
MO>O3^Y@6:H-9W6HC=C"ZBCW);1+RDJ3=1D4',KAD4;6KMM[OM<&QE5AP6+NC
M8E"Z!0:*VV$JQ[3B4;%K0PEA&%8=.WFY]&O3`?%;Z?1]WT6[UOZ/3_U]'_V1
M_<P+/4XL[K.K2S#>@8]R6VW&4E<]TXAIR8W"]UHN6ZCYPF<-F.LV@L?E+4E'
M*O9@4[:D:P8&_8A@T([6@;"L6G;S<_\`6`^*[T_]?1;O6_S(X%GZ[5]TF4;8
M!]LQ[DU%TJ6-_P#T5M5=S&X'.C5A865O%%]V`_R6"M,^;1G2':H*_3<V*M%H
MM%")]<W8P!"L'PMYN/R!\5WZW>MOF1P+.1M9W:+G>3J9='N2B.L0K%NH8S1N
M97$JYW/0:7MNFX4GDKG!4=E)5@FS:S9X4C2<`)X2=!WL`AB"%8_A;S<?D#XK
MOUN];?,C@6;)6=W?1L/4J(]R3KL#WT6DK(3,KC%S9MN^-18`"/E`X(&SPK?B
M1ZQFPA9]E_"OH+]/N_I,P*R?"WFX_('Q7?K=ZV^9'`L^]J^Z0\Y,*F-Q[DTW
MK@2E)J3LKW,;@3\Y%)-O:T*X3#)T$%4V8H4ACFDPBM*&@H.UNS`BWHK01["L
M'PMYN/R!\5WZW>MOF1P+03E7W.70<(45K'N3E?40SV/5CM$YF-P-]!I4HD3G
MN2;A$B8(,YV&O/*<=(](=+VM,$P@1VS=@$$&A!5_X6\W/Y`^*[];O6_S(X%G
M+76=V$U)69U&Q[DIPO<TEE_3&W6O,KB9ZD0J!1T8I%JLWF(01]F+J25+?5`B
MVZH$8AMWI&;H!W_;P*Q;=O-SZ-^B`^*WT^C[GIMWK?T>G_IZ?_LC^Y@6AO97
MW0GA]<CYECW)SM/C$XMVVFO:8W!'X>B5?!;?L.JY6U_!I,].:?X;VK#O;FG2
M"]U"4+T>T$,(0J_\+>;C\@?%=^MWK;YDL"SW1BSNI,1!?HD1[DQZ4F)7;=EZ
MZ,F-PQ@A*MT!H^`PP459P67&."4PS:_WO;AI,,`0I_9Z%L1GJA6M"Z^:O:U'
MIR@?BX`V[5IM.`T-M=8F+0H=G`]\$C+44J40-6%/ZVR]#$$&Q^C0MZUZ=X%B
M>DUG?*5]C0>/XYR"]QH32LW,3>DYI<\6?2'W2P.D!<:3U?`9@@5-(D'IV<-4
M:2<$[T:"'8?NX$"QQT\RXI"PAET&\8Y$4$]-090='+6ZI52$F.[7D:>S6%,Y
MTTC;5#T6V>UVE+4'%$#/T'1@P@WL6@FOHY;Y#$TO9P<BQGC)Z@(HX2*0*>CI
MS=\8EY<M^$G'2@EG15E7DN93XYIHTD$`T]06IVI$<'9>@!`(011`7/R^F3B(
M%VC"?&VCK8<D9@SY5`;0Z><9PFAXG`C4A/B#?(JA:F%;)"FOVNT12U2G2C4:
M#HTP`-[%H-_O]?Y*T]@F%\LQ7AIWJKX&;!$K+_G]^1RP=R'?O'PR48VUU6LI
MCFF8'_:]U'I5L\?I'ZX`^C7I#5JH<?+"=8L4+O*&^/%OJ4;D+4Y6U19?23Q8
MJ=H]T4[`.*-DOJ=CC2QR]^T3K85BL@KV6Q[];UM!UL,I=KAY1R+*D!7.$1X%
M=*>"!J^*JZ[;%Z'8;*.,VT(=OFI`UP2KI)%TP"W[:D*3W98;L:310C/5,V(.
M@^Z.</*$?9;$5TG$N"&JGA$._P`9EU'6)T,_V64H"T+1,&F)KGM7QJ+J"#'[
M28*S:A84("/9@B]#,T$`@P5H.7EI*L*6ETM#/'6OJD#P>&"++0LSI9IL)0P>
MH7[L9+6V*5*]1M&\;,]?UP(U9Y.M>CT#WOTX&Y<_+_).HL#V?5,5X=9ZL^`W
M(7OG/T^OJ26!\9=&(_@<KX-L:M8K'?@,96U'O)GO7O`!:+]0`M;%Z`C::N?F
M'!,96"NH1XU%5?@D;T&#J9K:742"8J(B%Q4ZCATK1,=/.+*CD9K1HD2TI&H/
M2EJ=C"48,&@BV$Q\WK?(*IE+\#KV-<;LD)"P>M&#^;YO=DHE)LI^$4>O8OR2
MSJ^B#2G8/@G:@7M$YQJCWC18?4]38A:"!G9U\T>G9TTQ03Q?&,>G%=IE,=K8
MZN)=C&C2HW3:-T)1TN>C)<1HO4V>$HP903?6T`0@^C>PL/SFL[S4F3?Z6\=Y
M%92BVYLW7&^<YG<LF,5.^Q.?PR";ZLR!1(*!N`'2/W82#:DT6Q'>N$/J@]8*
MT[=O-OZ=^B`^*_T>G[GIMWK;T^C_`*>G_P"R7[N!9:E%G>9\&M`SHN.\BM=E
ME-QFZ724I,[E?8,O=O@9T$4"T'"=0*.O[2W;D&D01":4RTW2,1XM!]H$L`@K
M1IV\W/HUZ8#XKO3Z/N^BW>M_1Z?^OH_^R/[F!96N%G>QM*V2?;L<Y#1=%E#=
MOT/M=<32YG.E5I>F1")B_22^R:!-$Z:QF2/:D*OX+;EF@(M%"+]8W8P:"M7P
MMYN/R!\5WZW>MOF1P+,L*SO`7.DD4R>.\CE=:A7*-1!E89G<:CG0]LT[->DH
MY))G"!I;+2KML6UHC`I6@XO2L)`="V6(P00K-\+>;C\@?%=^MWK;YD<"S*M9
MWCKFY"I0QWD<77NUX=.;(KF=R`YN`U_&90$8T,H)@8[.,7_$[1(]!,:`E_">
MQ@];V&@F;"LWPMYN/R!\5WZW>MOF1P++S59WH"A((HKF.\B*NH3%S;JS6B:S
M.Y4%")&W:5XV\#@DB8H$XV&X+@+0M^DP7!K2EB*$HV,01!+T,*T?"WFY_('Q
M7?K=ZW^9'`LM;:SO0FKJO-HB.\B.-U&I&[=TH+;F=RLU7(%^V$D3L&KW:'0)
M^ECLD!)_:`3B=D2(8D&@C'H)N]@T%:=NWFY]&_1`?%=Z?1]STV[UOZ/3_P!/
M3_\`9']S`LUT"L[P3M->;Y6CO)#P^&(7#=L%]`S*XXVTHW/29FVU@KPZN8)*
MECDA&L$X:4"<BTA@2@I]@"(0C=`"MJ1U\UVU272Z!>+8*':DC2T22V^LAJ@I
M/:@]Y$E`=2@"1J=$^MZFAB"'8O1Z=ZU]W`[2<!@,!@,!@,!@,!@,!@,!@,!@
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MPR]]B+0@7*4<UBFW%S./8#A`$H*7+=IO9&JEIR@TPLD+<_[#_?W_`"'_`"-?
MTW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-
MR^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]
M-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7
M]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?
MTW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-
MR^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]
M-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7
M]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?
MTW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-
MR^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]
M-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7
M]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?
MTW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-
MR^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]
M-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7
M]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?
MTW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-
MR^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]
M-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7
M]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?
MTW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-
MR^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]
M-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7
M]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?
MTW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_(?\C7]-
MR^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7]-R^=W`?[#_?W_(?\C7]
M-R^=W`?[#_?W_(?\C7]-R^=W`?[#_?W_`"'_`"-?TW+YW<!_L/\`?W_(?\C7
M]-R^=W`?[#_?W_(?\C7]-R^=W`IWUM%_)OX%3Z"[)6^3^YO('S9(;]KZD^B:
M"Z69MGNYD8L`YP]C(ZX?UTHEQS4]H"6D\)0TQK>82MVF$<%:D$I("'LT]/W/
M3_T_=P&!43R!_P#@7VY_A$Z3_N:FF!0/[.+^Q.X&_LXF_P#?-96!W;X#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`Z`?+/VOV/S+<
M;9^@J;1V*T15_-SI?-VN\-JZM^C[%@:M%.ER`J:=%4B^7!6MPL7(/Q.CCB$R
M3P%*Y/8'5,M`+0=)BRS0T:V>G>[XCU?U6UQ#L6#2"C:F\:[QY'*]B>^9H<2%
MT3RYROMD@]6*)J?(=2,Z+1@%<-KB%W-2A<G$)HRCR2_N[$%0Y9Y"?++`?'`G
MZ?1OT\=KMM1YXG;*A:[SY4Y]K6MGUPOE<>MEB*K5-37A:$DG32\)#4R1.<_H
M6!6E(4I32R]GG'`3APH%YQ.K>AK*Z`,I]^KF'43=U[>/VFN);*F%=@=TE.5_
MTU:%WTE9%Y6"C$[Q\4^6G3>A7A-'&U<L1(1NZI$2:/9(AE#"QG1W8'D/J>P^
M7^7:[ZLA'2MC3"\>QJ_LN>\E\V4U.[C3M%(U74-D0^$6%4-G7?"*HA=MQ;<]
M4"D@$CX@+,:#T)Y*$!XQE[#L<XTZ7OR;];7ES;=3UMP14_QUPA:9`I/`XG7=
ME"L^^!=`EVA\>6*%RF7Q)I<P'5RVDB:FIQ<&]M4EG`(5*`#T9L*\0SNKJZQ/
M#&LZRBLCH]-UN_2JRX5#E,Y6Q"NJ_6NC7V;+Z&C+.SIIQ+H[##+&<X(U$HXV
M@=G=$WO<O,1IU!I92H>M!9;Q9=167T'6MRQN^)J_OMU4C>[W5\JC5DT8T<\7
M1"4IT(A<^CL8MB$Q"=6+5;_+-,<L"M*?(:ZFL+DT*4@PE$J`J0[#JOO+R]]@
MTEUU)H\CCT=LJA*A[XZFKJYX:Q1!-^D!'QW1/'G'UTRJ7P]2F/VX/\XJ1;=\
M@E1J4L`E+XW-VT`-:%HKTA^=!>1SMGLB.Q=!"^L>;N8"(+P]->X);>-BT^UR
MB&W`VJ^J^CJBA2):WO$RC"&`T/7]?4BB5RY[;QB>?;/A`P&)/4]!X>FNO9(&
M6PB(R`3[$I(K>8K&7A<]01:-PASFI>F)`[;<XLI./4JCHTZ@6:4MPS1C,,1&
ME#V(7K>G8;E@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,#S(?:R?V8$*_QI\V?UJ7X'IM_D?S?WL#ZP*B>0/_`,"^W/\`")TG_<U-
M,"@?V<7]B=P-_9Q-_P"^:RL#NWP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&!UMI_+EX^U7.DUZR(Z!:#.?:XOTGFF<V1J.2[33&+542UAAQ"-T3[8M.1,9
M.72=`K`]Z)VTB:U0%NC]IM[,T$@R3R.\>P^V6&E)3;!3!/I/TFBY&8DCI&Y0
ME9W&_P!VI^'7DQ04B2#:/@'VDB@$_9QMZS:C2%8X+RD)1HE>_8X'&C'DDY#F
M*B6)&"Q716?":8OGH"1@,@LW2>Y5;S3=$PY_N%^!M4PE:5*8W:<$<T!2(KUU
MBXLC2A,6:G,+,$&5UY#^1/TB<>U0=;*1)/\`O&O'"T^8HZL8I&E4SN%-T+;I
M_MR7G'-0$L.4.,;<@C0IG@Q"H7J"CDR<!AY)A80G6F+[JWH%KGCQ5$B,DC?6
MENV91<R/,9WEFVU6=4$E51"?Q\)3T@;S5Q;*_HS"`JR`F(U.@^N2:8#>A;"C
M]D>9+QZU*S=1OD\NU4S).-KC@M"7\G#7UA+G.+6=9*M<BAC&UMB"-*5TM3/!
MS2MWI8U@5I"RT2@9A@0E"WH-Y9?)QS%)++LVL8ZAZ"?3Z:FMDUY:%AM'+O0+
MC2$)F-1LBR03]D?KQ2UX;5B%2Q-Z+^-Z[KH)IQQ)1>Q&'%!$&E1[RX<KRFF7
MOH-GAO81U.,L-C=B!GJCAOK)$Q2"`RI/\(-<TAJE749.IE&"V;>G%2N;?>4Z
M1M%I4<(!&]#P,(=YI.!FZL"KADLYM&$0)52TCZ*;G*><]7E#%SQ2$7FM/P!?
M9;&QR&!('IZBJV1WM&@MZE*0:%R3K##TOM24R@983//_`"7\95NEL%5(+9&O
M%7IU!H34,.ATVGSO.WSJ)A<Y-049J!FA<??72WY+9C(SJ%*!%'27$X)!0C3M
M%%`&8$),IGLWGR\J<GUZQ>6NL6@-2.<U9+A%;L+F-,2:H'JN6HE]G#79T/M!
MCBLDAJB-L*DI<>-8F`3M$:`\L8RA:'L*I-WF?X$60>R+"7SZSHDP5M5C9>AQ
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M1"?1M4L8GB0(6\"C24:M!HX@L9@0D^87/X1ZE3"YY'6%/O=:V335`0^?ZK+F
M>3VASY$J+LZ4R"7\PMUVSZ!0"1U;6D*F,PL5Q>8IM[6HPEJ'83F7LDLX"H0<
M)V8/!S+&FH.6#N<:0ER.*7QU!5]4THT\[NCLIB5D4X[&,O54^TRH8MLY@AK&
M[QXE,_S9<,II7J?="=+3SCDY8P^C$?@P=V[E.\GVF:#:6Q]Y+>.F.;[-EE,.
ML?)B'+G,089,E$CT^.D?2F0=LKC=J-BU$VKQ$+?77"]W(&()FM!&E?3;P%B9
M;[FJ7FBNZO4R**09NNB+VWQI9E4S:R*HZLN6*02$3(NN+'K-D?K`JNS;H<VL
MH3R@0JD:-T"6<K,2C"$>!/UN+?%KXV;/YCB'Z'Y!5TK@S5T1?%30OFGFZT[*
M3MS6[,43K6]K?GR.E*]F3WLA`PR=M0JW%U-]799Y/K^UVG3;(#GE=8^+TCH%
ML65I3\EN>XY0QQ3IC])G._'US7HW%,O8D":8(QVO)+)K&M9/'V(NXJSJU&WJ
M5;@K($H:6()9_H+3;T$(82SGP7W=(ZFY7D7-%?'1FEK>N2@:"4V7QA8,:YT:
M+:K!\FCU<-1U9<<GK%%32Y22\5Z]KE;,G=Q(G0QJ,,"4>,H/H"\W%G6_$/1,
MWLTWEUF?H_+K'889?4A>9'0MHTN7?%?*6=MJR`7E"7NPH3%&^UH&>P0I$SH'
M9L-5%E(T:4L6BRQ$>N&=Z<\EG*'(5FIJENU_LM!+/T4'WJ_C@M$W1;;'!:;1
MR-?$W&S+#?:L@LO;X1#FI[;#BU2UP$04G`#VAFPE[T+`XB3R8\POEXN//\%*
MO.UYBRNE2M<ADM.\V7M:U1QD5X0V*V)6KE);F@<"?JP8&)^@LT;G?:]4Z%)$
MS>?[<XP!8!B"&IE>73A0Z63N+%V9+O<X(PWJ_?I#'3-P$T[/-<QLSV_W^RU)
M<!T(+KBUI)5C;&G`3DA87)<>(2%0$C1VR3=`#77?S(\3Q.E5G15B*NA*EI1.
M[U2S(+$M_D_I"KX])S[H4K$\"60I7-JS9?CFT+BT6U"I8V:5)T"0PH]0,LLX
MH0@SD^\O/#%=SJ\ZR<K"FTCL+G:W:3H>RH97E,VS8TC!;G0K7(G:J8-$6F&0
MYZ63U[D)$47E#+9@+?=%)&R3]EF["'8<97Y?>*BV:MW!F=[RF<@M*<W'6<?J
MZ"<N=%S"[&NP>?4L>77)#YI2['6:NS8.^P%#*F]0M*=&M+Z$ZHLT&QE"T/8?
MC/?,'Q35K^ZQZQ'&^XB9$8%5=F6H[NO*726XY1,-N=.L50!TZ`?D57JVZDQN
M13<I]X(D@VXY![L=[R$K11FPA/O3_>_+W'2B()K[G3S'-S)E?I<G41VNK&L-
M!&J\BCA&VF66G8+C7T5DR"NZNB[G,6HA>_O1B%M(,7E^DW>M#V`/VJCO+EN[
M;^L/F6M[&/?;<K0,PV]-9T/FK/&WL=;R!CB-HIX!/'F/((18RJJY;)VUJDI3
M&X+S&5P7$D*M%C%Z-!Q^E^^>7.1)3#(??$[>8L\31L'(BC&FN[%FS-$885*H
MY!C;`LV10J*O[%5]?E3.7-C7MY?E#>@][6!#HS80&B+#46/R=<./<OOF&BO=
MDCBKFUFF<CM*13ECE<"@*>.UK-Q5A9;]$+#F#$RPJQ&>N;0#J-/BAA7.);<_
M#+0F[T>:4`88@?E.XG*9>;9*;9DC#%^K(I`IS5$J+J6VE463Q&TY:Q5_6D@L
MN2HX4H8Z?;9[8$G;V-K')U#5[TZ*P$!^[H>PAV&X#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`\R'VLG]F!"O\`&GS9_6I?@>FW^1_-_>P/K`J)Y`__``+[
M<_PB=)_W-33`H']G%_8G<#?V<3?^^:RL#NWP&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P(!ZIA%OV9S?=U<4%,8_7=QV!6LKA-?V!*"W8YG@S]*FL]B+F!A+
M(`QS/7QE,O,6H@%Z]`UI!01[T#8MZ#H0;/L_DFKUM=:4B70C5<?*4_=_'G(+
M+KSH>(1DE[/5\+6C$DI[`R-]10.&0ISC-G\R,`8JO&Z)#GA2X-R(]8N4@]<1
M8<.(?9[';:=)5]PWNEM:BV;K:_[?C*UV'(M7;&J;E7$$9Y0YC96R:#(V6"Z>
M:G>$L+BWR01FQFA84JK0O>A#+T']B'AQ[RI^GH0U0#H?FJR;QDG)7:O&W1\U
MM^,V8TQN1QGK'J:>]();P@B>%%FN.['CZR>*BW%B7`(:ER@T7LEI``A%L-@L
M3P77O*7C=BQ?M!5%+)Y^@?#M;\3M1<*BRZO6QBX/CS&^U\XW@I=H8[V0A73R
MYG*5.#VEAKPUIC&9V(2*=N(2=EX%^.(^9.W.6K8NR/R5YY3D7+]R]4]1]-J%
M<?.MTF^&-7?\SD%@L\5(2N+837JE+'7QR3I5!^S`"-1@&,`?:^C6!U1=0_9V
MK6Z`M7I^QFZ_:Z8$'0TYZOL99$U;1*36=PF$[9=M/*#_`#`I.C$):YT<98$Y
M.5&$BW_&<DFDVA^@>RPLA!/$CT9`>F^I[03#Y8?HET9=74%DMUB.,]ZG;+A@
M<=Z&@SW#TT?*K)I=B^>Y`OCH'/T#4K6\X9I9HQZ'[8H@80VO@[Q:="\Q<UV]
MSA-$G++27-^.3.<FRSJLL/JR72*3S-%!3H,TR^:0^XGIS@L29%>EREP6)XPF
M2;`H,T206%.```!K]_\`AFMZXJFYMKI':]5)E%+^,F$<)R8Q]99,N99-+8W>
M/%EHN\J3(`(S1&PIV8^9'5#I,I]"G9KHGT,&R]';"&K1GP=6Y24ZM"?<_P!_
M0<!M?]9\\],<*PRU6&42"(UK":=K&\:Q<.7[.,:E*=YW5C7%>@GMFB+BUG*G
M1@;4;=O83?=MIQA;BD?&Y=[EQIW7S-UQT2Z3!;V^?;#<C316=W+;K#S7"+*J
MILK8J'5O-NBY9([`F")J<TJI^%I=IL1B6+C$Y24D@(?2%0>@?$EW7VE7CFQ]
M0W=RLURJN>2)#R;0PJ7BEK-<?D8;%LJA95:%O6\>_K/A2/.;O%:!;T+7&F(M
M8D:UJT]3\)&^J4``=NTFXMB49X\N3E7G(YO@R6Q8C.6MD4W@.8=41(A^F37I
M"L!.8]>4PE[I-H0Z`+TG7,YS@%,)(:;HD)8Q>G`ZJJ_\/W2#;PUY%N5GBT:@
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M-'X:]MGCIO3D"_YZR.EH3,Z6VW8QE#N\%M.$1*>2!9&VF(Q64U,L5.#.G`S`
M<$ZX*?U`AT'9`2UT;XM.^.R]3ZW.A+>Y*9.AV>F*7H^B6*J8_;A-,#;X%U[1
M_6%C3ZV'&2;-G(WBP7.C6UJ;V9K),21].,T6E:PTT1@0G6Q>6O*A-K]I+K%L
ME'`,?O"N*/Z1YV>6127T0]U@"&7;+*.E[#,F5/I&U25UEL<<:G/`J0*CTJ!2
M2H+"`T(MB&6%0H3X-[LY]MRJY14CGS3=,0K/FSCZC6MTO:<=2U;-FB0<SGSM
MPD<U:&.@9"AA[NBGCW.!*R&Q[&Y$-H$1*8&_9"4;.":*O\+,WJ*\H!TG%K8B
M;G9[;UUV[;L[C\W56!.JD,K3K6<VC)(E.*TK.5K'>#5SU%1[9-2$J5V:VE"A
M?$:IV0+SC"E85`0XG'7CL[EX/E=@V=72[F314AB%45:5S;2+A=\9YWLB3.%]
M0U=:_6<BJ^>2[XD<[SYFI?X;`WQ>OR-,7O:H>C!*BP)DV@L9VGP_V/:?64GZ
M#Y>L/FR*M%H\'/\`P].B;S8K)D#S%$$FLR1SA98\+986:@9Y*XMB)[`60W.:
MU(G/.+WHPP)>]^D*CTSX7[FYDZP;K1JPWF^T*G8M<5LD1?+=L/J.'7/#XQRK
MS[4%$.*DJ-5,\-].3)^?_P!&ZAY2`>TJM,$]6!,?Z4P?4"$LP'QL]Y5YSE/.
M!X[T;SLV\7M],]CUC6BX%:RQQORPR>C6&R4E6LMSN+FI/B,0;:7?;)&J7.T9
MT>X2H+:1HU.BT<I`8%<X[X/+LE/,3-RG;)'*,1@J>R>5)+,WNKYYU58;K9<6
MHY/*V*:HG9EO%X>V*&O#ZP28TUL`Q!2(P+3-A4:]B21Z@0\S_9Y^E8_4CDT.
M-[4E;5M2V?<4W):CY8)UO1MEMFT.=+.ZXGEGJI+)J_TUSUG0SIJZ`8VQL6MI
MQ#@E*8S=B]EZ2M;#<#O!+TXABU`"32WE67**GZ`[%N0RCI%+>L8O44.8>HHC
M4S"CA4$MN+2I1T7*CF"3P!TD2YP?W3UURY_,3Z+"E()`$)<MGP;V1=BVX;1D
MD_JR*6^]57P8P5!`V:2WO+^:`/W(B67)IK5O1%>RJ0IQ=!T':R!S;T`=R$EQ
MD*`LHU4`X)^Q@4A>KR1<H]G]<)J%@E423FU)0,>=`R_IBD+:<[8;&>_GUD,:
MU\%K]WDE<LFWE12K!(D@G-U9A:2ADXTZ9(O#[A[PF/"LT/\`'1V'S7>=@=#U
M=(:,M,-7N';TGY(KE<DF+`_2&5^1?I:I;SMYOO5U-=&J/-T;J7XEKF]A.9SQ
MFN"926J5`),3:2GA:?R+\J]B]4SF@&2IY1SNHY>@$E;[$NNC;F76FR`O>=Q9
M_1O5;MLR=:W:EJAXJV`.S<0]_%PPXE"_/))`70"A$GT08$+\K>*JQJ<Z*E<Y
MM:=U)85,06%]C0;G.,H8P_*9@Z(NT^PT/9<K?+R(D?O$4V]57,6-`T,6F@"@
MM:45MQ.VE4Z`0$([?/%AUXHY(\>/'3'=//:*%<HL',ZR7V(LB]ECLV!W+SK.
M8_(2KAHDQ(\$Q&:;E$,2.#`%AE[:0C;S587+1YY@/=,#T$X#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`\R'VLG]F!"O\:?-G]:E^!Z;?Y'\W][`^L"HGD#
M_P#`OMS_``B=)_W-33`H']G%_8G<#?V<3?\`OFLK`[M\!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@8A_9RI"PO;`>M=FTA\:')G.<6!T6,;ZWE.:,Y$8M97MN-(<
M&=V2@/V8F5$#`<G."$P`M"#K>!Y`Q'].TQ5G2$YJ?I+KBP[0@OG=HWBZJH_>
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ME=N0VM+6RF0,SHWM#LZ",)?`[VF'M'[403T1=O4U7(KJJ+H7HGIOFVG(UY(.
M=JPZFCJCH6SN@KCY)Y'?:)L)Z;+?8.V)/#XS80*#ZXNEHC1.Y*B3(]PAOVN1
M&*$"HQ5L@,19W5W6S33L\(\>G1_371<ZC7;]BPOQ>KWUS=;D4=6<X(^8(A(>
MNP6(LG3G'$=Z5!S5-'9\.@<Z>5+BL'*6]J;$J]:%49H87`D)UURU[\8\+X_[
MRZ%DG+WD]JZ)U+:=G6/+IX]7W"S^8(4[]`S:XJSE*]Q4*J<O3H:"Q>0P&;$[
M+(*9GDU*J2D%K4/H"$M>7&X[NKOH=Z@M>=*6SSE!#O%??LO436(,UDSV.0><
MM/77($1:[+DL=@"=VEJ(;7"9,\-;A*VXD][BC`Z.#L1]U*+>!S?'5T3.IWP!
MY$C4MO6^M=J7>+A:('T)#;6E?D8@;4I4<_1V5H9)R#9LFK^(7'T-&Z\?7$2O
MXMOY;T\II&%0TE+E!/L"20ZH*=[#OA-0UGPU+UA=LUJ!JNOQY%=8=HT5U):G
M45=UAS9:+E9+/>4XJ^Q[9K)BO_ERY'IRCK**PHVH6/J>`M+J!>W::S-'BV%A
MHWW0XTQ<M>O$9[2M.9>,.*^4NL(!7W4%P6Q)YJS3BO9%X^[_`)?>=6NUX241
MCO<]+0'H9L8/@MS=%+D20\G[1EKCPHBME!NG5_:UBS7IZ_76MNH[19?'O*9M
MXG2K8O>F9D_$LM,<TV>T]HZM:PJSFC(4J%5C-8EIP6'L$MES5[!6U-QOM1*4
MOJ:4%!*=2R=KOCHGB_GZD.U.[;7Y"LZ&>4E".U'^UK+A$UE@:IGG)*B!G0>\
MV=-%9G:T`KMR>7ENB,V6+'-P<D"MP("Y+"?7W@=:>K4NV"\:>&J?SSM+H=H^
MED[].2SI29]%>07IF@8@YNT(KQR10%H=KLAC/8DRK!D)=4)!S>SM[3[BZNH@
M@.T#VPSM!)_1?4?P%)KUW'/('T'%+,@?C(Y*L+QU0NCNLKENV(]$=7/#QTPF
M?&)A;),PA.[&3S&>Q6+,CBKDD>TM5-I^A'DI?6V82';CY(K@E$<L7QUQCJB]
M+/XXY`LN(7.[=4VS3MB22ETB/HR/02N5]-5!.+_AJI)(:L@;ZI=I@K3[)<VX
MI]<V5*C,4BUZI!X=.K/VEY&XJX57<$&LJ_[OHZE^3^_[*?8I+"GQOL[J#A^+
M]C#I2CNE`-RMMCJ4SH>`5#(6B;-CJI0)'.3L+$?KTA&ZB&<%Q.V.@;ICOBY\
M'DT=NAI?7[I<<DY61=&6E(NE[7YD(FK6_P##=HS&1&7!T+63'*;$BS=(;":T
M*U4K`WK#%3J$D!H->TV8`.N5+V+><E;N'F>VNQ)7$H`?$?)0TNEA6=Y!>C^3
MJAMI;6/65<,=)/T,ZDJJM)!8_14?8ZODBALB[U(8^WJY*A2KUJGV!J<!9H6U
MZ`ZC[S:V+R3&<_V9N2\]02V_$0T1&W0=)W`]6=7\8M"NN*%4A+YVWNMEZ*S8
M?:JF6*CY`].+Y'E3J6\N"Q208<8,L8;_`!?R'=7N/D3M2Y'5-T@V<$](RWI+
MB#G]_=FA(EYFC<TI"%:2T-==9/Z22*I'N?7E>E764S*SU+(A0FI%S!HM8=LL
M`0AK,A[VDO37B@\9%>\\=8/=E=F/UJ^-ZNNI6N"=%SBI[<4N-H-QL?L2+W';
M\#:Y%8U:$RR5ICDKN[E(%RI,I+$9HDT8=:V'9CV.;TARQXKX>@22RX*TD22V
MZ08NH[3B-WV3UI<='\W3WH)D2]$V-`[PL2%(;)E:^#58\JS4[N<P!51QN]H<
MG)"%O*."'3A:=W7O+9*Y4GP9U5TGT;Q[(?(-P56E.7"\=7W''54PF=CTEU(^
M]-\^,'<;$SS6UGFH6?</A;NL7$_&$+"^+C$)0O1OV"<.\?LBH;*@_ATN<I=9
M70]4W?SUS#=]W,DEJ_KZZIW8J*V(-6=DS!@:7CH1R10JR+GAR*0K2_\`T;R@
M((6$)4Q(TV@IRM:#J_F$[[FHJ7-\!YJLNQ+;:%O@HF/2D]-ZCZBO%6Z1NRI+
M-SUKM:\$DVX;:SH^VY'M&:2LC:HVTD(T6M%%*TY>M!P*W<H]0S^7=HPQGZ+[
M.>F-&E@/B<<XI#K?\C'2O.#_`"9?8G%G.DTL=1"^?H-`I77?0CE/++?%BEX3
MR!U:@.;TM.1J1Z+/,-T$O^='I&\*L[<LB+0;J9\HENC_`(RV6S:ACRKL.ZN9
MV=POO=PWJW`?*YK^LX/-HOTE;9K4QMI!<1D.F]O<BR4I!JD)9V]@#5.CNO+3
M5G]@3F8=8=B4=WQ#4O,SAXNN/D+E)8"CN^.S&BJ5ED5,>.8XZVJ('T));:O>
M22E@L<A<![+AX4)B4!C44C+.P+")O(-U+_NL"NAW(Z&;_'PY7(L\:JA45'23
M.2VN;)&I-'R[Z;7X,E&]&V:+N1,OK_X3^!=-8XELHSX1$/6B-!U<4UT-W]"N
M6EECV%?G45;/=J^&[MR]J[F<YZLN"_".KKGCT-]\85M:1V81>/-_(=W\V:;/
MC`H:&=Q7J79K="_=#3BDJL1(=]?BDN)5,NH;AA5`=-71U_QTW\B\]SF16)<%
MFRN\$%<=E2"66&WS>KH'<4U(&^N1#K6[:UNKTQ:6N"=A5^P$'W42T1&PZQ*H
MZMN-:BYOD;)U_P!03'R73VW>E6#R(\=R&<S-17]!T\PUQT*X3%V_0"I0ZAW.
MK%1\ACD1W`Y(U_!JB1FJ"0Z4NWP@9ZH=N/A"A/2I7',&OCHY^M!\D]W\UT!.
MF*2SWMR].HU,O'(ZY%+7R8+JTMB$1./\ZRAP7/1!JEH85;T1ZQVTPE7J(B1&
MAY\:I[%O;?#C#,^=>X.J[SNF0>);NBT.^FZ5778EH`YFNV"UI'W7GZ=QMXD.
MSW"A;:7V6J6M:-E:EQ'PBA]N=[IZ4(5.@M)&;>[1+[436/(;FZ)A%$B\OD,Y
MV=;X>NGK9D],0N#I*GI*6D<U33BX<06UVABO03Q)5<=:;&-=RR&>0O16U(4H
MRDHU`0CR=USTRMXOZ3L>!=4/MJ]PMO-W0[I'*^'WCT3T!T-'G%HN,+9()<;P
M-/JY3TY$)/6M0IUKHT;;7AX4@4(T8"TIVEYX`!?NRI)2$SX&\G4JX=\D'D1O
M<GFSG85_0NQP]$V^[1^%WI'*.MIV;6&&]#:1,TLL+;^>0A=)M7I[LXLC&X%(
M/0WMIJC9.!Q;KDT8I*V*>ISK_O;MCF7DDOQ\-=V4I;Y/2EOM,SN/KR8SN3++
M=:9/>?MW6765-JJAH8T=#ZX6GJ6]40['[*:UV@>R)#KHL&_O*),(Q,+?L2P^
MG*RE=7<8>+.37#8T9Z$MBIH_Q[*[W3V:18_2T[XHA$%?HOT6UEHHT@>)[&CO
M@XQA+`<':;:?WC:0.Q*M>H;!:?,@AB)_4UJ7^S6+UU9E<(*E@US65#I75%=?
MH1=G=B;[9X1L&NW:G9%R.Q&LQ3S'[JA#TUN3PH<4)YBE6!0H2##U?8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8'F0^UD_LP(5_C3YL_K4OP/3;_(_F_O8'U@5$
M\@?_`(%]N?X1.D_[FII@4#^SB_L3N!O[.)O_`'S65@=V^`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&!^?L2M^G7LB_1LS1N]>H'[INMZWHW?W/NF:WK7\;]W[F`
MT23H?M-%%Z'ZPA^OH`?7]<0=`$/UO1Z?6$#6M;W^[O6O1@?!"9,E`(M*G(3%
MC,,.$60462`1IPMC--$$L(0[,-'O>Q"_=%O?IW@??L2O9Z)]D7[+6M:T5Z@?
M9ZT'>MAUH'H]76@[U]S[GW,#Y,3D&^T]J029[8G:<WVA8!^U(WZWI(,]8._7
M)WZXOXN_2'[N_N?=P!:9.3HK1)!)6B"=)B-%E`!HE/KU/005H(=>S)U[,/H#
MKT!_BZ^Y]S6!_0D$`]70"2@:`(P8/5+`'U!F[%LT8?1K7JB,V/>Q;U]W?IWZ
M?W<#ZV6#8O7V`&QZ#L&A[#K8M`%O6Q!];T>GU=[U]W7[F!\)TZ=(26F2D$ID
MY6O5*(3E`))+#Z=[]4LHL(0`UZ=[WZ-:U]W`^2DB0@LTDA*G)*.&::<44266
M6:8?O>SS#0`#H)@SM[WL>]ZWL6_W<#YTA1!3E)`HTH4I`0A)3:3E:3DA#KT!
M"43H'LRPAU]S6M:UZ-8'WI*FT6,K2<C11A?L3"]$EZ+&5Z!!]D,&@^J(OT#W
MKU=_<]&]X'T`@DO102R2BPD%Z*)T`L`=$E:T$.BBM!UK19>@AUKU=>C7HUK`
M^!I$I@`%F)DYA9?I]F6,DL0`>G]WU`B#L(?3_P#A@`I$H!%C`F3@&4'U"AA)
M+"(L'H%KU2Q:#K8`^@6_N:]&ON[P/I0G3JR1IU1!*E.;K6C"%!0#B3-:%H6M
M#*,"(`]:$'6_NZ_=U@?IZ@/6]?U0^OZNP>OZNO6]3>];V'UO1Z?5WO7I]'[G
MIP/S,3)S2PDFD$F%`]'J%&%`&6'U=>J'U0"#L(?5#]S7HU]S6!\F(TAV@!-2
MIS0EA]0L)A!0]%A]&M>J#0@[T$/HU^YK[F!]^[D:#L&B2M`%ZGK!]F#U1>ST
M'1?I#ZOHW[/0-:#_`.S6M>C`>P)]F$GV)7L@>KL)7LP>S#Z@M"!ZH/1ZNO4%
MK6]?<^YO6!^8$2,K?I+2)B]^D(O2`@H&_6!O>P"](0:WZ0;WZ=;_`.F!R<#C
MDI$B<DI.G2IR""-^L00226423OTBWZ2BP!"`O?I%O?W-:_=W@?N((1A$$0="
M"+6PB"+6MA$'>O1L(M;].MZWK?W=8'Q[(KT^GV9?I]G[+T^H'T^R_P#[?I]'
M_P`/_P##]S`_+:)&(83!)$HC`^IZH]D%;&'V>M:+]46P>G7J:#KT?^ST?<P/
ML:=.88`TP@DPTOT>S,&4`1@/5WZP?4&(.Q!]`ONZ]&_W<`-,G,.(4&$$F*$W
MM=)CQE`&<GT>'0#M$&B#L97M@!UH7J[UZVM>C>!_?8$>S]C[$KV/I]/LO9@]
MGZ?7]IZ?4]'J^GVG\;]S]W[N!_!)DXP`+&02(LO>]E@$4`0`;V$0-[`'8=A#
MO8![U]S_`*;WK_K@?9919(-%DE@*+#Z?5++`$``^MO8A>@(=:#KTBWO>_P#\
M=X'YA2I@G'*`IR`J%`"RU!X22]''EE:%HHLXW0?7-`7H>_5T+>]:]._1^[@?
MJ$(0!T`(0A`'6@A"'6M!"'6O1H.@Z]&M:UK_`*8'Y`3)BP#*+3D`*,WO9A8"
MBP@,V+6@BV,`0Z"+>PZ]&_3_`-,#Z$00(`RQ$E"+,%ZQ@!%@V`P6O5]`AAWK
MU1"_BZ^[O_V:P/@M(D*,V:4E3EF[]/I,+)+`9OUONB](PAT+^-_U^[]W`^BT
MR<HH1!2<@L@>S!#)+*+`4(1PA#.V(L(=`%LT8][%Z=?QM[WO?[N!_#DR91HH
M)Z<@\)!Q2@C1Q19FB3R-^L2>5H81:+.)%]T(M>@0=_N;P/O910O:>DLO?M0Z
M`;Z0!W[4&M;UH)GIU_'#K0MZ]&_3KT;P/S`D2EG:4%IDX%`4X4@3P$EA.TE`
M+8P)M&Z#H>DX![].@>GU=;^[Z,#D8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'
MF0^UD_LP(5_C3YL_K4OP/3;_`"/YO[V!]8%1/('_`.!?;G^$3I/^YJ:8%`_L
MXO[$[@;^SB;_`-\UE8'=O@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@>9#[63^S`A7^-/FS^M2_`]-O\C^;^]@?6!4
M3R!_^!?;G^$3I/\`N:FF!0/[.+^Q.X&_LXF_]\UE8'=O@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>9#[63^S`A7^
M-/FS^M2_`]-O\C^;^]@?6!43R!_^!?;G^$3I/^YJ:8%`_LXO[$[@;^SB;_WS
M65@=V^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&!YD/M9/[,"%?XT^;/ZU+\#TV_R/YO[V!]8%1/('_P"!?;G^$3I/
M^YJ:8%`_LXO[$[@;^SB;_P!\UE8'=O@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>9#[63^S`A7^-/FS^M2_`]-O\`
M(_F_O8'U@5$\@?\`X%]N?X1.D_[FII@4#^SB_L3N!O[.)O\`WS65@=V^`P&`
MP&!QEIBHI&K-0)BEBXI*>8C1G*=HR5:H!0Q)TQJS1"G:4H\[6@B,]F9[/6_6
M]47H]&PZM&GR8+H^8!?>?/[O746'?5P\][>*[EK]?CT5*Z-@ED3Z>/IL*A-6
M(9(.(IFBMU`BE1)1INB3-G*"DX"]Z&%MZV[)YNMZS5U0UU9K;)INC:W5W3I$
MC<]$M+XECI<9-E1<9D:MM3L$C6Q(,S:M.A"-2<<B&N"`P.AEGA*#3I#Y`.68
MXV1-S-G,A>]SN,,,RAS1#ZOM&:2.1QR1M-M/[8XML<BT.=GH8/@&BI8M/",@
M`TJ9F-&=H&C"/:AH,C\FW+[!-V..E2%Y=H<Y1.9259:Z&*S#X@Z7Q==3K2WP
MZ)O(XW[A9$SD3U=K,@`VL9ZQ:E<#?=CB@GZ,`4&15^3CC9,G+4%6-(70(D4>
M./TR57:CR%`[RJ52^$L,+=%3=#E"%LL-?)Z\D"4+`>:6[Z&QK-[3Z"5K8@V$
MOO[GE*_K(X^R!W1N!,X:8:';'"++E29E#*I%$(9!W6QE39!`)ZN+F4UF:5I1
M!>1$$C6!.#H_?NROW<->WY.N+RXHGF:JSWMN95Y3&YLX'>K+79GJ01.10UWL
M)JL*/1QUA2-_>ZX/A$><7+;ZF3&-NB4)H/:^V]0H82'`>SJEM:\VRE:V^'Y:
M0OK^V9Y^DU-'Y`@K5=JHIM5T"D#1#I>YLZ2.V(:4_P!E;3J5#(L6$-ZEL.)/
MWH8P^@(M!Y.>6E:B#+6=VG;Q!)NVVB[$V<EK&?%0ML0U>SPMX,-&I5QTAP>O
MCKJ>MZ1A"V)UHW%S-T@"'2T04X@S$P\BW/,>ALSD;";/9D_PB$S>6R.$-M7V
M4A>H:X0S4L1%Q2V5"Z'A14N\262PM>V-PI-MO*5G$".)V8FUHT085G\F'.#M
M.X3&2G%]-AM@02+3&.6^U1N52"L3E$KM,RFVY(ME;-'5;*U1=7/S$S>ADZI2
M3'W10J#[JI-*`,T(?JY^2WFU([0TE$XRA9'Y0D7O*E^7PJ;QY:FBZJ++I'6\
MNBT/?(PCEEF1JY52`QMBRI@2K2W=PULA/LT[6R\#\8;Y..77XPIOELB>*SD"
MF;V%$`1Z8Q>6(G)G*AUO6'3,><YP6='D^Z[5V1+*S<R&9M>=)%RE22).``S/
M5]<)O?\`JROTG)4Q[%BS=*9-6<:IZ974T(W.,26`2&5Q&)1YTDI"E`Q3=D9W
M]`GDK8V>W;CE"(.E24\D\L(RS`;$&)8^W^<'U4H:M2]]8Y(C<6!F6PV6UY84
M2FJ-[D\XA=>,;(JB<AC#<^DNZZ263'-Z3[(]H!`_MZX6@HE11X@R$V[)H2OY
M7+(;(GZ6">(6Y,T:>SV*L++D[#N?21-$EL<JIKDT=B;G'GJV9"CGS(:AC:52
M<[J@.B?V9`MBWH(1DO\`)1R2A<D;("6S]U?E0"DYK!'Z+N^1/35(S]V.`B!2
M!N9:^7'QZQQGT]*BQ,*W1#H29'UFC20>H'UPX+[Y)^9R2300E_>9VX_&BNHP
MW>PBLOB\7?U4\D%/(UH8U8$JC;;"I"X0Z'W<RR-Q1)%ARH#88/?JZ$2IT0&I
MR/RJ\MIDC6H@;N_V)ITU*%`G!NB\L:XZQL+'4EBW`QSV1NRN.'KDE93EBK)S
M):7Y&B7I%1I!NP>L$@WU0E1)Y">6W%>[-#5+)H[O;?(38LU,+53MO+GV>/2.
M73:"/!%7,Y$($X6<FCDKK9^2N:EC+7)F\+4>>>,"?U#1AJ5\>1FFJ4KJIK20
M1^?V7#+KJR57'!7Z(1-^^#AP>*(8"['+7\"MJT]1U:\-%@I3$"12A"K4'E#3
M>R"HV`O8<Y9Y(N8&Q7Z'65/2!(>8U,J%L,@%H"L8<Y-D]UQJ1PEPJ[4#U*VM
MWBIM#/YIX!@$H."C,T`CT;3"5A/\WZ2J:OIO':[D+I(S97(F1ODVD,<@$\EY
M$=C+R\&1QBD4X<(K&WA#!F5_D91B!"H=C$@%*DDX(-["G4"*"!2?)9Q\84:,
MVP9.B/1&S?;XWKJBMU,ZQ1MKN(0B?2N0S)K'!_?HA'$,1LJ/JP+'$M,2>-X3
M)2]B6"$G"$U\Z]$L'1[39;W'(Q+HJCKBVY'4JA)-V)XBLB7.,:8XN\+7%5%I
M$V,\@CP1F27V`4ZQ.`W?L-FAV(HPL6PK#!_*KR9(ZCA]I2Z0RNM%4IC<+DFX
M+**[L7XUE-TSA,@GY+RQ(BH@`^:PANCD,?#S)$U%*&<8&=1ZAVQ[*`8&[N'D
MJXV:U1Q*RU50$),AD,>U(M0*POBBJU#5,?13>2-DL%%PQYX@D'7RUJ3O#^D4
MGL[>>Y)P'*`['OT!^%0^1?G:S6MM&^NKU5LC<'B7-((_/(U*FI$>3#W.UVY>
M_,\P61Y%$Y#%Q_H9?`_":)4:A`K(+2[-V>I2!4!+,U[`H6O$%1.TOD[XT,]W
MDQ%3!'@R!3PUI]UGCK&&")'2EQ(C9B.#B>GZ9M:,LIW&B4!.5?QRP@)4#)"*
MDODGY)7-;,Z()=/G`4GVC41%E14;=RF4S%A71FP9@FF<4BA5?"D+[`S([4\F
M4?#1"8;;O;(H+T=LW9(#0RB[R"\S"5)D,<GB=_$X/T69F-[&RS-M@LQ"\3NO
M(+)-U]8/Q36Q.>NL%6V8U[<D36I4#3'GZ)4#3^S5&)@T!1Y3>3@?%%R2N]AJ
M(;)&*62]UG2VI;)CS%#8+'*B+NQJGDB222+M+_\`$Z>P@X)K`X)4:A,XG!,*
M`+1A1@0AM]Y=ZUW3E1T5=R.)3*9P&ZKZ@U*G*_@Q?"W:!-LG62A-)K)D3!,6
MUM=SHS7J6(+5J\!1/KJ&\D2E*,TGU!C#5FGR7T24Z7F58#?+Z\C--=!/M#)I
MHICSY+(_+@1>+URZR&RC%</9W=-#(*ADT_VSEGNII(E(T!BDKUB!>D`#O)KS
MXIL(,'84L\6M)0%!JZSGZOY_$:R%\#VT;3<G0L$E>(EK<H<V>6(EA1(DA(FQ
M<8B.+*6^D&]Z#+3OR)5`V<I7IU-4S%-+B14>P-+RKK<$9DM7SB5GREBB\I@J
M-D;[-CT?6`2SV-3-M7-*X2<2142J#H(_7"8``8=)Y+Z15W"ZUD4QSE:QDU%2
M=CQ::1R./$T6V#*;M)?GUJJ>%UW#FQ]G#W+XW7[<AD#F,E,-.F;W'UA[`%,H
M&`/H/D";726`/B]=-:^E=VH12R>RY7;L,K*92B=@:&Q<_BKVG9\F9'N7L<+=
MGM,VNI0G!%(M+"E>D;.LTG+]X#8(SY'N9W>LZXG[[('Z/O%AH(F677:"%3J:
M31IETL1TP-#"Q-41BSFK='!0[]!P]"B4IRMI',U^2#3#&49L00W*!]Y<Q67-
M8=7\/FS\X2.=!:"63WJM+,:&5.^/\7E,R9H=(),\1%#'8Q.E\=@SV?IE<%29
MR+&T*23"0'!"6,/[,N\.:(!-9-7<KELI;9G&5#8A"PEU9:+BNE3B[6!`JJ2M
MM?DMD/6#GRS](EHQYI%IITK#I4[%>@6RP'C*#54WD+H61S.D(171DNGCC=$X
M9(3M>C@\W8V2O5SY![,G"9!/WI^C")IC,U)1U>N+-C*X]*^E>L$P:<(=E^T#
M26OR84XYVW=E2C0`:E?,;S:"_I*3/,I9T3#3E35RSI%B*RGPL)1[N\+9VZ.!
M1#8Q-R92M)2`,5K3$I9B`*\-^:_(YR,[N<<945A/ICO(7@EB4-_Z,K.V;"W)
M3-8Q720JS#2XB8DK4E;-9NR(2#7LQ"4=MW2G`$),;[;08G?DXXR+BY4O4V:^
M-[0M`PKF0IVJNUVAZD\:DD8E$T:IU%8\Z0I&^R2`&Q6#O:T3TC3FMX"VE0'9
MOM=%EF!IS%Y2>?7:SOB$N9K'8HZ:\39A06<K@TI=(2O4Q&T*ZJI#(`ND=97E
M$WUQ+WZT&H3=)%AZ9J$%0$(S`;]?8`WZV>V2JLZ9B?.ZNM@#+DI5>#1RN46`
MR5\MF9U@/[TPJ4E(,,H:R62Y'6NM-92N1M*5\0OQ*565IO;W(\99)@:[`O)U
MS/.*Y36)LBX&$LJ%P*:26/+Z.MAP=(<19$:%-(LROR]CB#E'0ORN'%B=A)R5
MINRVW05`MZ+-)V8&)9O*5SD\3EPBI;5:Q,;3)Y4M:;.#6LJ7P>6(V..<R2".
M&1`]K;5KM(EEEF]51Q!'D:5*8M<'#>B-%!,4HPGA+L?[XYADTSC5?-,SD@Y7
M(W1DCQR!75]GMR:&RR2RBPH/'X993NNB"=FK>9/,UJF0M"=K>E")8:O;1%:+
M_P"ZGV:$HW+TI4-"*6-)9;\ZMJA\:9')]%LD0ETPVQPB&GL2:9V'+MQ)D>@P
M^NX>HE#<!S>W+:9N1;6E>T-#K>]Z#2_IJ\ZZJI^NL<P=R*V9;)5U"DD"R"3M
MOW,K$22K4%W'JY;G".)7.PPJIJ$UK(6LY*QN/5IE'J'[+3G&`"KT]\LO/T2+
MTY1EFF%J1I:T;D33**]8Y$[-(&1("B#'0,F"9&R5T<DA0;V2Z3-(2EBQ0>@-
M2"T2N,+2X$V?[C/();FQ,RZT5#,[O0EB=8V/\(GC"OASLDF$QKP$=L1([QI&
M?`)(YSVO7MF0H74*50O<&XPI.$SUR=F!MSAVUSVUU56MRKGZ:$PNWFUUD%>D
MZJ2US9F_Q)B:54C?)OJN2H8.?-L*:(FDV[GN:MM(2!;CDYNA[]Z3!-",H[W_
M`!!\A=AV9NM+!,@$5ZSA')\.=6%G=Y`[6&YS6=5_7"6S6YD`Q("TU=ZDD\`:
MF6)53D%:W)_;`$$\T*4(:["?*CRA(*HBEFR]_E=:K9*PP]^^(DEKVQ!RGW&7
MQ.5S,AXC:4B(A,G<*0,<`D!QD@:"U+0,#*I]4[8O9`,#>-^2+D04B#'4L_DS
ME[1V.:29*TU+;;I`E.T$MAL%?7=+8*"$'PM5&(O++'CB)T=2UPFY`:_(MG'!
M";ZP0D:P.T>9ZMFB^NY]:#?')JW'RI,?'5;/)#EYIL+JYEN5^TCTD9U!*X)=
M?R!*J3"*$,*]2(:)-LY:4:G`%4!^6>C6V3-K'((3:2-GWL9D@G#!!)S,8LVH
M`5/+;@4O#*!@AY\DDS2Q1B&K/A@X#<GTUC+$(W6P:`(86XL'L+GRKI=$(7,Y
MLK0.<TC##-FUR0Q"9OD2:X5*)4V0:/2^739D8'"(PN-O$P>T;>2K=5J0K9RD
M(Q;T2$TTL(P6^2;CAG8GJ2R.TU\48V2$JK,$NEE<V;'`O5:E(]N+;8,43NT/
M2JY;#I2@)4',JYM+4DO`$2KW39VTI^@!S)!Y&N-8O(W6+O=SMR1Q8M2P+XI#
M'9@I96E5#C9^6XMRU]2L!S0%S<]59(1-9`3A&.P&P6TFCO;I/>`W64=FT+"X
M+7]ARAXFK+'[*C4BG$=3+*GM$$H1U]#D[>NF5BRV&:B`I9!H'$&YW1*7-U>$
M:)(C)7)MF#UM05H81U&.^JO/JB;W79#+(JR@#)T?/N<H*<L9I7(I)9;U!YDY
MP!.]LT8:XD4X%DRR21]QVW$)=N)8T:<`QJ`GC,3$!R;9\@O/]80@Z7I7-]F:
MLJ9MD+!$V2*3`F3*G'<FJ)EE):1I4QO;BH<HFTW0T.`T`2-K%NQ[2IP#5:$6
M`,%-/)?R[%(Y/75O=YW,9'7=3V#;4BK^-U?8)DQ:D%;E6*6_Q61H5\<1)X7,
MM.]32%OTB>34.RUK:,LP0-F)_;!FX%WW3\TN-12JEME\>D(UJ=I9WQ=%Y.**
M.DE<+!N2!(((H=U#`WB99^G-I!Y4N#>J+`2C]GLH*D\8![T&J1_R9<[21^=D
MJ$R6)XL@5MZ)AE2^&S4L^SE$C@//4[AA511='%ESY/5DF^D@PMA:$H)#F%Q-
M+`6F.`>`80DN+][<PS&=QFMF&:R`^72AP;&,")96=FM:&-RMY66$UM4'GCXY
MQ%(QP&=KGFIY(A"S.ZA&XA7,YY`B@FB)":&!.\A'/C/([+C,R-GL+6U=9TRK
MM^4.E=3)R;@M4`:JU72RV53A'65X1L%.,RZU6E$?(G(:1O)/.V(9@2@C&$+R
M8#`8#`8#`\R'VLG]F!"O\:?-G]:E^!Z;?Y'\W][`^L"HGD#_`/`OMS_")TG_
M`'-33`H']G%_8G<#?V<3?^^:RL#NWP&`P&`P&!6%3R!1ZL"@LYC>=A4V5<]L
MG:#)GH'K32_(?+H+9*W6PJM>JC<H[-W`M.FU_P!E&88`PD(1E@WH,+2W$E"\
M_P`_76)63._,SFL:%[44T'R%6LCJ`U\*C0),\IFXT.CE#W)CHFD/5'*CE(2U
M`E)B8"<2Q7[<-2@_CQYR@,C2RAJ3V(Y+VA(-EBR:163*7MKA<2!'+MBC9"(H
MW*UFT[7%6)DZ&E)2,C>C#0;6$[&:/:1-[(-44^+WE1606VGMMAFQUM83FJ*Q
M`ZQY&IB,(>5+E6#^LGL5CRH\]O23Q9*:>8'8U<>%2`3BG4&^RUI>X!5!MAWC
MUYZ,@4HK\D$\2-\T2PM-*W,J9K5#C(?B.Y3AV;MO*!Q3K8JYHW!98SOM6WGM
MIC6,)Y6BTI6DB/W<(/F/BZA0Y;7PZ@G#G4]:M+_5[S9463+;!?9%8".G;"@U
MAPM@62$^QTC4Y,A*J"E(M%/38[C2`7K3R1^NI.+,"7I9XV>6Y>W1%"K898VJ
MH)!J]K6*OK3,74I^9X36\*E%>,S(E<%WO^B].,1EZM.N4Z![X:<%.J`<4K2I
MCR@E6L^0JBJ.RU%FPLR<I%8&.Q(]'8<OG<A=*Z@[?;DNBD_L\4+AZU4:@95D
MXF\-1NBP_P!)IH5.SM$;)*.&7L(33^,+EHGX5.,262J<GMX>G=V?#;+DI#ZY
M#=8VUQY&6X.J`]&J<%L<41YJ=D3L?LQ^$^-"-<I7*3B?2(,T=XYN>U".2)#W
M*X-_I&:I"U72K36Y+VU;?07]9*'(*NX%+4L0BDZAA7S-Q$W%E:2)4R8_2+90
MV\LI(`-C:^`>8V5*^M37#7)%&WT45+^*">2O1<29&V'VTW7DV1Z+Q\"H+?'8
MP=:*$QT/;DH2T8Q+51(2P$';*T&HE^-/F'W5(2N1V0\K&-G9XQ"GQXM"7+G^
MNHC$$"])6D3@CL)>%2Q,U4*G,]?']^DQ6E<S-JCCE!WH%@?DB\9W,*-Y1R(U
M+83I(##)"HF#\\3]X<7NRUL@G5@67[Y/'<_6W)<-EFUHOBQ"4B-0)BRUFDAA
M1B$A.F*">%7-$*=*RL&DGMZF+K3D]IMCHO4#'(%J0F+P9KAKM!G'<:?T0R)&
MWO\`(F-S!I4NTJ]N$Y(2:5L!H1#$$))N!H$DN6CK0'(7B1%TY-;+MUP<)TN?
MIA9ECV]/()'ZN:GN7SA?("6I3$H?!8VWEI&CX'%ZC@PLJHDX@;=O2@-[GO$M
M-6)+9A,'=RM!J53.11^?KV6*V=*HW%D%OQ))#6^*72U1YL6E-Y-EQM!7K*6D
M4G!/0@V@";M((XPXPT.'$>#^>(6L3NK6S2I4^:E2">.K^\3:1.CS)9VE:KD:
MUTQDBQ0LW\*/L@W?DG4KQ["$H]4N`()8`IDX"PAVNO%Y1$06R$4F>)O.X]N>
M-4NK>%.<H?T\1K)''VBFV9I2-+0)V6`<GY0AI1M3N+F<+6UR0]65[$O:U:-2
M&<1^+_E9OB880A;9^BC:94>2V-Z&?/*`#1$#JVG52:K=#M#[MZ\)!!+&=4>P
M*-'N)XC"33EAIJ9.,L/JV/'Y#7MEC2ZE7Y15UGPEU<%\/G3FXSUZ.8DTAGD^
ML&5DM9L8GD(?6IP>WFS'@H2HI:+7P:K,0F%&)A^J$-N*X*J!SI;F^FYPZS24
MIN;JV:JT99&CDCI&7&7M":+1N.O>I:2WK#].*61+(DWN1I1AIAI2U&4,)V_0
M/V@<"P?'+S/9"6Q$CZUS5*7:SJX.D\`USAZ)2R#3O*K8F3LV+FE:->R'MBQ\
MNI^.+`-,(Q":8F/1C3*420\D)-L'D*H;'>&=W=#[%8/<*_;*J>V^#6?.(6EG
M5<L"Q:YQB(SE5'WI&]/;?&75T6*4AH59"O8ERHHXXY.I/),"'H%XRN4J_9I8
MQM\<E;LCG$)E=?R?X9F+KK:Z.3**59"G<M*G9/@5`RN((_2T<"G5H"4JDA4@
MVL"/WP]0>:$Z4SS8PT:[.;A%I[9[ZEDBV92*9HIY+E,O.F<\FBB%:4SE\<7$
MO2@#LRL\((;FY.DTE0(T2DXL!.M;!Z@0M*?&QRW*VB&M:E@E;:HKZ"UY6T.?
MFN8.@9`Q0VM8K.X2R-*->X?"(`F+XM8[HF7*=E[5G#$0I`:6K2)3R0S,C\>O
M-$D#$=&Q^2-9D,D=D/K6K:98ZDN!R"W9>Q3JQHBK<5@UJ_47DLFB[<H$%.80
MN2^Z!"F5$A,.T:$46!XO*7D\"?JX8'B3I(_-Y;"ARLR;R&63I='JICUS*KXD
MM8T^<.3,GZ.B9I.U)@3U8OA`!+<H$EV0<F(1ITX3_>W$]%=%SB#6#9#=)37V
MOT+2VLA;')ES,V"1,$ZC5E,9)R$C0PHS&Z8Q)$H$:A$C/6$%[2*QJ$0MI\"J
ML9\4D(8H_0J!3=UQJ914J9*SR2?M\L?VB6R2'-]46W7#97,,<2WM0.M8"@<+
MF>7,"(KX0.]8_17M_6(1G)`G$CQO\LI%K>))&I6FCL<<4CQ`8"1.Y*"!5D[A
MEL%G#VYU_'=+?8L*N722N6P]SWL9P3=>]`*"2%>NTH#)+?'USNH+CVF]/84<
M51B&QROVMSC%DRMD=0Q"*U`_4BT,QZ](NTH.)#"WX0C1^G1IZ]*G4#$(0!:&
M&;;N%>=4%/0VC#8PZ.-?0B;3:Q&UN5OBQ.-7+;&9K'8IBO7`:=-C>4A=D%KO
M>@-Z-.D;D8E`/=2"=$E:`$1/_BHY`D+0RL:F/3I,VLL>317126Q9*8<Y,::`
MU970BW%8XJ5ZSX96L5-L1BEX3F)WM2K+5#-6""X+@*`DAX\?_.;WN(A5-<R*
M20YJD+.C;D<ZD*9`ZHY#91MMBV_D`5;VYJ&><JU2I`9O8!)BU9Q/\8H00A#=
M?H=T9\1K`KO3&]ZC%FHZL0RU-J4/?O2I/3<;A\4@FDB[WKWIO&@9H*W`.$4(
M.U0RQC,]81@]["."/'5S2T[(60]KG$`D3:_2:3QJ80RP)(URF(/LLG,RG#NM
MC+FI5KP(2M?'US9$R4PLY&DC)I;424!(G3EEAR%_CWY[<'A,J.,M+46W*(+8
M$@K/=LS=77DVLVM2HWJ&V;,VAQ=5KD]SE`KAK0M6*]K2P/3BVDK',M8I]H:8
M&NUQX\JCA-@S":K@`7HU#5R;$JX96H4A:SXA$..530_UD-_>%TF>3I7,'B4L
MJ`3ZX%E-Y+LU,+,C4)S-H=G&A*4(XIH&O')F=HPP/J5:PV0UVNW#4RM]6@+F
M;/%I_#D*TPI2L,`<D`Q6:[EB3"ULD8S@#V'UBB]Z#22?';S43;[C=PFF8*)L
MOG:NQ@B/FCMML1R=QMBM[N<CRTI8BE+@C5614[*L+(7'*RT*5.)`CTG;Q[2X
M&3C'`U`0V?Q"P8R"PFA7#IF=9":,I;$DFH2]V*)!/F9+-Y3&A*A)']_;F"R7
M)O($=OV&DH$>AE#&@1C(#]YQP)S'8I4@*E<+<ENY7,KAF4D4)I2_MRQ['?L-
M2P:W(LXK$"Y.I4069,S6W&GM&Q>Z%.30W+B@EK$"0XD.)'N`.>&!N4HA()B]
M*W`ID+=GEXF#EMR==QRU8S<;,8>4U!:F=%[E,H<W;"6C2)2-I$_L=@V$PW9@
M8.7>-SEV8-<0;UC#*VY7`8/7]<0]_:I>Y@?V&'UQ&9]#69J0KG#X1+"8OC-E
MNJ9:I$4)4<(9"@!A:M(E/)#8P<"\Z%KILL^!Y<,B=&Z&O:C9S(S6IG*',:[L
M%6CCB<Q8(UJ2.$VK%M<CP^T,V-0-3KTZ+4#!@;99'(-4VI8A=A2ERLCU%+M7
M4@E5?-EB21!5<\?ZBD".55H^2Z!A5&-"ATB<@:T:D)J/2+;A[BE*7^]DIR2P
M!$YGC6YG,KY)6HDUA&,"":QR<H3U<]=G-S3N$1K1?3<:;/;NP5Z52R,=7N`F
MA(4>2::ET20L)-+<4Y"PL/R3>-'F9O(;$K6&T&E,QMS4@8"6ZT941MB-88;1
M,18GAJ4B5&+4SZS*N9H*^)U7M1&`?X\4KWZ?;JRU`;M'>#Z"BI*\]G12X4C=
MI5!K!>I>ZS)]=)%(+'KV;V-9$?GCZJ.5`*7/QLVM-W6J]``4F/",E/HH"9,0
M46&Q65R%6]Q,<!;+*?K#?76&UZ[52^REMF3E%WVTJZEJ6+%6/";+-C^T2=^C
M5E*X8WJ78DL"<W9I.])S2`&G!,#]Y)QU1DGI!JY^71]>17\<F(+!BFDSH:8\
MQ6:D3EQL5#(&5P<2UY6CF^3.IXBTZ@E0B&D,$E-),3"$5L(RUXXN90!8=$MD
M\3C8U;6K..*L23^VD7P4RUDT%I9,,U89\*(U2FG8XXG`_P"WZSBW!-#L(3#2
MQAR7CQU<Q/,[<;$-CLD12"0.DJ>)A\'2QS2IIHME$XL*QP_&$7I,7[31V8VF
M]JF\E(>D*"!6%.H"H3$$$EA(UC<AU%94&K2!N)DYC:&I8PK@\*?8/.7Z*RY#
M"'>($0.31%5)&]1I>O9)5%DI)"X)F]G;.3D*B3"5:<@\L/U!R+2R.KG&H&!K
M?8I#5MGQJX414:D;DVN4>G4.FT5L"+KXXX>T.&UH&610QOV4BUH23:<G9`RQ
M%C&'81/+/&WRW+FF&MBJ/2EL45]!X!7,*?FF7N8'Z.0^N8_8L396MO6N/PD4
M$Q=&[4>4JU2,H:H[9I!X#"U2-*>2&ZG\+<Z'MQK3N,OI;>:7/"?=BYA(_063
M9%H5G<$H*`:8X&'^A1-ZC9#BA"&(9)!!A(=^H>;H0?O:?#G-USVVAN^P84K=
M[$;ATR8E=2)&_-J/1E#6,YVC`1FLZ!>0UJ!?&1U,)=-C*%\,M02T"SVR0L!6
M@U-O\>'-38N5*TC3-0IUD$=Z_.:#)])#6C;6_P`,FE>O+H!(8K$($B<(9.E:
M`Q9H?K>S)3#UK1I(1[#^6%PA7-GVW$)S+)'*SZ^B-,Q"GA4^@=W-OC$R;H38
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MA2R-@@#O.Y58BA`P/YQ(]/TTF;_.9$C.2N1+HR.T76O,G6!TSN"-8V%IQE@`
M1K9!`BP@T_Q=\LB%[)"&W&5L1M[6FC+(S7'/$;7"G5K(J4G4NB@-NIJQ#,%P
MJ-C)JA><<H,&<A,&'01+5VU(<Q_\8_+DL$V[E*.Q9#[BQV.VJQ.MC2`]0]/E
MN(K(16-.W!>$TMR23*7:MI\,7F-YR)"K./3B.2F>X-^DH9M7X\*&/<$[ZC>K
M@9)6G<`R#<P8[1?VZ2*)@&PIE96ILH5@]9**4?#MER<C9P20DB;I$N3;*V`1
M'L`QC?XT.76A&UH6EOL1N)C3'"FN%&)[,EABN"O%?1>F(E%9U%5RI<H6))V@
M;.>X<,QP.&H]Z4,H3#BS/>%>E`2!"N&.?8&M1NS,SRA4^$3N'VBY/[U-)`[/
M$DL>&NECOR::214I5[TZ/;V_VR^K7+>PA)5GJPZ]F$LDDLL,--N`>?I]*YS+
M7O5B)U-FO3^OL)I9;%D;.P3&/S%HKQJG5=O+8C4@T97LX%5K.I<F\L96QJ2U
M/LC22ERTI0%V<!@,!@,!@>9#[63^S`A7^-/FS^M2_`]-O\C^;^]@?6!43R!_
M^!?;G^$3I/\`N:FF!0/[.+^Q.X&_LXF_]\UE8'=O@,!@,"B/:G;9?(1U=-R6
MIY#:KU/62UI?[DT.2IF2MD4IIFCSS+=Z<TT:DR?<F<02A(6UIEVFQJ,T%0<M
M<T*=.,W85P)\KS:\6J\U)%JB:79W<Y$1'*LD[E::R.P20J2K>?*@?CY]*G&L
M-M\03,;S'E'I-8-S(@UQ]5J]H!PWHK`VOE?OJ;VY;CO!+&@\&:85*YK<+?5E
MBQ&T&"4HRDU41*B7]VCKPG:6X;`\M0E=NFD-TD0/!X'0:/T[0)BS2##`VSH_
MR&%\[VM8$%754BD\:K.'5/))$^I[1:6>;.3C<Q5S%Q1MB59J8TK4/K4U+Z?,
MT\N)CFD"B1+1JB25(4*HL(1V9Y-I(SI#SYE1$+C"E`4:R.S:9T<Q&K6VP-\G
MJ^RTB%0)RKQC1$5D*J"BFY3+3SB24LG&8FVB&WDB=-A%2CS#)Q-L7ET<HZ5R
M(BV(/%)O7D"7OA+:Y1F/*".IY`\!M!?&XC,72!V?N-<_@)<HPK2'@CSP:<C6
MK$^F]R4E!:VDO((SVW/+;B3K5[Q!4M=5N^VM'BE#]\9IE.X;%CFQ+(UC>R,<
M>%"!K&M>\I4AZ-JE#XM;UYP4CF2WJ1`*&$(5]WW;M\WWR[641B,"KF/3=:FL
M*TUC;8;?:YSI5TNH!]MJLHPQO*.'-K6U392L0CU)D7HT8VD$)#4*U6E<0'Z#
M68YY'[S:K9LA+/ZJKE[J:`S7XC2`^`3Y9N8Q@+SWQ>_(4(>$3"XQ8\V:21S0
MPEF4N3/L]I+("2>I2J#S%9+>6$MU-Y-$=D<VW;T6Z4?(8>VU!!:^L].Q+Y2#
MV<GA%F1HN5,)YCJ\1>.*V!Y9VSVFW4(F]2TEZT`U$XKR#-FEAPG?R>)T\^G+
M'':8+E=?U5/&&&V+/6NTFH]R**E'2RSE]D5P:'-\5<_CD[_'1)M6K0&N3;[!
M*`PHLXY8$"<P*X`\P<X97J0+WFC6.4MLDA%;636T,KZR@RDYA@KI23]=DM43
MN=LL'7HVVP%K*)N3I&12WI6M*:6I4G/.FT'OV!8`_P`G;J@>H.>_4(FBU:6#
M<=D5BSS]WMHM:X-+/75YL?/8Y/,(A'*Z?C(>NDT]=S--Y2Y:!AUH@"92]IUZ
MM*D-"*63R\N&H-$7\-)(Y:)ZB[0WHP++CBL3L%^L8-7TO/G(3E708FM(CD!=
M#[C2IT;X4N4ECV1[42,HA4B$>&Z+?+26P3!7#))S?+AN$$<G5DN91#)0LEJ.
M..B*[;HHY'^C5<;`F)JL=(>^4FN7'`<E,6<`I%A!*5(M7:-2!#\6[R!7F^T1
MVI<;;$*41OM)HZ%>:OB8;-W-(6F9K8J^MI\L,GEC1YC:S??DJ6;FG&%`;2@)
MO9`]0U2D,*5F!92ENW5UT3J6P5FJMO(<@P2XIY6!:*SVMW<),FI>W%E)OC'9
M38&-(C*??)%-"R#&DLPQX`>WB4B.$0J0*D@0KXF\M4<?F4F8P^G#G&"I8E(9
M\\/DDLIIB+DMCM=*ZABEOQVOV%3&G`R<6O7%KV>LB9S![=`4I>8VL(]])./1
M$GACN?\`RB2^?S^L*DGM()CI1*)&DC<ZF->21V51"*N,TL*\8S``LI#_`!5&
ME>TS>SU!K<ATI=F]P2K%!P$2-?[FJ"4'QT=Y2GRN;*LNG:OKB#OTBB+@H:V*
M<2B?2!)#E#Q"[$YVC%H,DJTEKXEH:5K.R7J(17P8]O2E`K0!^$TJ0)X`8$@]
M!=D=$UUU@AHZMZ]J:7,/O5)J$3=(+`<XA(Y(BL"GNY)U+@.KK\4Y,GC+4T./
M-C6-$L2(7(TS83DXR=^]^U1!D^8_)<T=.7&QUPP4G,HU%9*P'*VF=/#J$1I$
MB;JJK*V'5L=&8;$B9QL>VFRRDB->V/+HI./3!-/1)4BQ*H&$&1SRB335GV^D
M4P`,R@T\F<:C_$R,UDE-5-5B)FCHZ"\F6$:=<,J8W&(S]N<I5/VJ=MJR/)EW
MLHFM,+$68:1ZX@V5;Y7G=J!(U[ES>$+)7VG".6(N07*WKEJ&S46NGT((S#6P
M5?I=RR+C?^85I`WA4:SJ0I'E(>!N,,*5)B@R]K>6N!5V[NK<RP1KFY48EC"U
M2?X(LCWEQ)BCI!>79>Y2QG31R#RMK]1B7=/(FTS3TN8FP:INT#X1`<M(("&I
M3[ORXJYJC@BX7U=7A,0LJS;./ZM<UC,I2H6FBZ\CUAF2J8Q<TMU,%'3*\+;$
M<C<3C/>@#:6E:#80^TT(`:/57E?LU$\FQ6VJ672Q^>[@E[@#XEIG".;KNA9-
M:\$A=/,QZ=0V2%LF-I,C'820Z0`6N,=3#-)T6G&-6L2(QAQ'_P`O<YDL-CTP
MA=)I8#&G9@D\Y6N\VDZK;\KKQ7S)T-=<$.BC8]0Z/(OTFE.]*>JY-AY:YA$0
M=HI$[+![4C1!/J+R<OJZ2MD2%0C`SN4_E\FC50NDEO9N9HF[H83<=O5%)WVT
MY#NN50:M+./J(Y8T)TI,C,<S71(A%M,J$,(0W:9>1I+'*&Y_NQMJQL6[NKG&
M>=2.4??[;C\7;8Q7-6PN$3.;,<>F`F!W:[!L-2GGJ0IB;R2D"%U+(4JC5R),
M1LS81V'J3I=WY7L6V29#6,:G<F[1FM/58TN*^+,IC55$;O-95J.)1A596X+"
MEU]O4;BB\UM2REP3-:J1*0)QG@`(E&$(]J?R3VTME3+7;HP5W8SB\-L2A#"^
M2][+Y[>`7&IM[KV'S-!;)+;^F6$QQFBL4YD$C$XQ=;(6YYE1H"VS6TCF2%`'
MXRGRZ.#K4)%QU[3IQ45(G]"Q@4?*ES+-.@Y@NF#QSQ)I[$ZUYZ;D;>X3TAVK
MRY#D,?>FQZ/VI<2BEPD06PTE48&4!Y49?%0V)84OJF'2RDS7V*,];2.N[:;'
M):FD,AXDAO5)497&K(JB9GR&[,-<RULO$L0`;`'E;VVFI4QZK09+?DQL(=X/
M-5D5Q77P\E`*MRF)3;21'6".V6,RWY=)9,+H(^(:+5P917-?$)D2<R,IUOQH
M$:VJ`$;*/4%!'%<>8Z1O%<QY<NYX=9K*"ZWJU.OD#?+"H3&Y;=DKK6AID\H$
M6W.+NK"QURN77:24WNB)U?%OH3@,-;RTBE,K&%SJQ[Y#*)5TE$;#JL4$>>=(
M5-YXK:8Y,%MA/,\C]:OTDC$S<X7K4%BD;?FTM]CFR$@D#HN6$J%):-W2L[D`
MU"`(BK7NJX+UZ6Y\J5@BM>U[&G`J7S*Y#V*QD%N`?(LKH^"V=5K!#Y0CAK0V
M!=##+#+%)"-`3GHMI$QB12J1+"CCP@>7^0/I"`2ZRSM26IY<%TE]C,E01Y2E
MB@Z5<6.#=*UU5:@Q';D"G,@M2%SB`0&5J-35HG42;R!2<(@-2K2=+[!8$K,?
MEC>9JYC9(-S"\+7%^F3FP5X?,;('`F=Y8V)+T,J>GF7+'"N'!QC3JE)YX7#`
MC:T4B2&>_`)VN`J2JTY0<*-=^6CT=,*XK1C7PSC'XV1*06*XV+*W".7%I>VC
MI7GF[:Y@,=,?"H-$D$X=H??2ARD"8XMQ"D0Q-?IO/4DF[<D@:W)_*U(@LD@C
M$)BC%,W6.QV*-&NBHXED"6II982VGZ]NUQD<2A,A0Z]I4LAB<ST2UJ`REP>0
M+!E[&A,;_P#\S$$S\M^1-UM"?U_4=G1-@8E\LB3XZIK1!(CF]DD\E9FDZ7+H
M\R1]+'G>.-2AGBN_74I'.2HG_8$XEQ;48VG$K!!)=\=;6;4W4#'2<-@<:LG<
M\B-,H(7'7B5_H\+1SFQ'SI$]XD$DFH6&9J28NWQFD2P!3)694J$I-WL&A>G8
M0A^?,OD`;.DWED4)8/%Z_@KXT,9:=QEUS19/8_QR=:AJ>X#VM)5IC0D.>(>2
MU6RF0DO2)T/-/5)MFB0%)%"908&M6SW3855]+652`*]K&1($:"IMU>JD%L#K
M`)RI_JOH"V;#7V/(W2*25MCS>0T4H)&PA3)5.UBP8]J!D)RU!Z4-=M'R(/D)
ME//4SC\)9W:F+<Y$5],2.,RF4H85:[.VK[`Y]8&@J(-(T#\"=3)"SW"86*.E
MB1%K%P"R@N!9QJ8H\/F!^1]UNJD.L;!A]2O-=.--\\2Z\*T=Y:H/=$,D;B4%
MMIHQJ2L;DS0]4TOJ5WK#9R]$D-<VK12GW<IV-4D*RTX:,N\K,GA;RS5U/.:7
M)3:#8#X2L9%";`/DD6;8H1#N:9@-WC,GU7;>A<)8J;^FFO6VEV"PM9"A`H+V
M\"`:A.5!]41Y#+8M>:<TP13'J\3D2V\E]36S+3I.F;)0^+C.<KPO9L3P"H34
M9SB5$R$<58BC)$)V,&8M3N"8+?[$L:L`;W*O)DO9YLAA$?HUMDCC.;<F--U.
M69<C>UN*^0UQTQ`^7YN[6\SE05V5U"PZE<[*=689.Y"J=FA,/8B$BLTA*8&8
MF'5\ZL^M>*9/`YQ'>9=])V7.8K-WN4(HO8I43W`:@NV4N,?9G"0*(XP.9:F<
M5D444O&02<I;]"WHA.89O105NA/F%<&IJ`AL*F76P=0B.RI5/K9JW:QHBLW+
M90WRX0JP:HC#VC=&=R@=FP^D`.Y6SI2%2GT]:"B+<TZ%4JT$SO?E!<(G9,6J
MR0T0VO4C.!!G.PG"IKE16G$HFP69/(_`X@8QRIO@#.U/,F2J7WWUX:GL46,2
M(@I]HC'$;BW@4!!-B>7&U6^C)E8B#GB+5^J,J-GFL+D+G=;9-$K<_61R78G6
M-6)Y''S(+$$.F_XLUHN02`[;H60V*CTQB8QP3B4F)0F9=Y6/@>T4E1N//SFZ
M2:/R]%&;2=H-/AS"#LJ1[L>(5VQNU;S0,":6:P!$J)B4H=D[H**B;3DYC>`:
MIP&G3G!O\[[`G;IQ94/22MYAW+[Q="F).L,BXO<>@)S,VZP(LZ/]75Q738K%
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M3_`SJ?("'4XA.)O*T%*$:\W^268=)W]6M8-570^$QAS/M1'/E;G-)2X/J@;+
M2]!W/6KC7R60UU7SBY)W9FN49;D2N;DH1%)-+$)ZE+L(S0XEA7ITU'$7;<W9
M;X8W"OJ#D\0J^LDB6D8NHE$MOZ2#9G(=7-JHR7Z;EK`-;:$.B*9>J(+4BD!K
MD,SU2TH`F!A2^H^D(S8BFN[1N^JF-1&7Z34?8KFS5:20=&G.M>)HWU3,NJ43
M,Z3!:X:ACE+E"QE(95(!H26E<WBVI]]"9L\)&-Z"Z6AG&%"6'8DOA#)9W0]K
M5M&U-FR"!E,\6H.M;ODJE7"G>>1,B2Z:%TZ88<H;6,[9C@F:#)HZ$^MH2(/L
MC0A8[RFFTN@=XA-=EWQ+X+;TBA4Y7G,OZ'9JPPQ"X4*F3/*^-PY);E?2)Q0"
MOQ#ZSK\*Q5@4Z+)2&"1NAAB0((3Y8+'4!8HD_<V!GUD";')1)`U=,7-/'!/[
M]/.@(O6,8BRJ00LQO<%*PBDM$O>UCBB6HUBT84*-R$E4E%AEF/S+0&?H7I36
M%4*7\9+^@1Q(Y_FC@W(IQ%9V%8]47,V!)"J\LB7.".Z(!#Y<_H$J1I5GH4$6
M4F*M@3[,4IPLIR_Y`V?IZ:0B",=6O,7>Y93<3Z&<2W*3MSB".TM8]:U9-:OF
M9IJ%M"F=/CY*+!<XXE3DF!UI=#GHSV@@)@A&'7OSEY0;]/<(INV4<<G`KHB*
M!16C0XCK"O&$FP'7I6*4>0$B:5M.[;>XA4[&VSUO4.A\WCK9(CU@TY+4E<#A
MJTR8)OGOEL1;I6S7V(P1JC-H,ATN@T:3O,Y8I,Q@G+%0G0%IG2]K*2)6LV>U
MHUR.A%Z-(M2[3`>V\P*T&TV@F$@#9FWRYQ!.IG+]-J:E,,IRO9"_I)-;#N]&
M(PL4.B-Q/M`R&:R&*NL7:32`!LU&W:(2M2YZ("UN!IRM6D5HQH30Q+_Y:W-C
MFFZ[USA[Y-EK4UM;5'MVT8@]PMXR0\Z1:1U;-I"MJ\N(LBF(/G1"4AQ4-3@_
M+$(FLW2M`G&H(!@37SYVS-[NZ9_1V\Q>`U_7>JHM]W1MZ>Q$<OG:R>U;T<UT
M"N#(FT;%%E<*1J7Q`YZ;4AA2LQR(/(&,2162I0E!V78#`8#`8'F0^UD_LP(5
M_C3YL_K4OP/3;_(_F_O8'U@5$\@?_@7VY_A$Z3_N:FF!0/[.+^Q.X&_LXF_]
M\UE8'=O@,!@,#4Y=`8+8"1N03V%Q.;H6AV2OS2BET<9Y(D:WQ"$T")Y;DSRC
M6DHG9&$\>BE!00G%Z&+U1:].\#5U5%4BMW+-K:<JM7N?#.,G6U5>Q%1N:&*7
M!([*#)9LUH'\8QJ'5O(5#VL]ML:@@LS?I&`.]!S7FGZKD#*9'7:O(<J9#1!$
M-N#'VU*G].CV10+0?=$Y`RPG&1MO]IH.]:-`B)`/0@E@UH,"9S[3:JU9'=CG
M7T;>[-D\5882OE+^UHWQ<EB\>3RY&E9V43H2JTQ)%Z.<N1*\*3V6G`E1ZBCV
M@0AUH-D7U+53J\CD;I6=?.4A,CA4/&_+X9'%CR.)$*2UA$6&Z*&TQ<*.$JR0
M&@0['[L$P&A:!ZVM;P/P>Z;J&2HG5ND=55O(&]]=$[X]H'N#1AU1/+TE6N3D
ME>'5*O:SR'!T3.+RL4%J#@C-`>J.'H6A&CV(,TRU_`XW(9#+8["8BPRN7>Y_
M&N3,L;9FN0R?X/*]BW_&%Z0HB')Z]Q)UZA/O)IOL@_<#Z-8'%C58UM"]`##J
M]@\3"6[NL@+#&HFPL6BWY^3EI'Q[!IK;TN@N[RD)`4K4Z_[R@L.@F"%K6M8'
M[(ZYKYO6/#B@@D-0N$A>$4A?UR.,,B98^2!M<B7EN?'A42A`>YO"!X3EJR5)
MPAGE*0!-"+0]:%H.,R5=64:9)%&HY74$8(Y,%+HLEK`R1&/M3)*%CXG]T>E4
MB:D+>0A>U+PE_P"TJ&I+-$H+_BF;%K[F!_&"K*PBC>F:(O7$#C;4BTUA1MC!
M$(\SMZ33(\:D3+I,B;FY,F(TT2`.ER7U0Z]W6:]L7ZIG\;`U[?/U#";5K,*D
MJBVSN,C(F+@T[K:&[;5\N3;5;32E:AVR^ZJI&GVO/]1<,`E0/;#]`]>N+TAL
MCC6%:O"Z/N;O7D&='*)O3G)(JX.,28%RZ,R)[7;<WE^CZM2WFGLST[N6_>%2
MI,(L]0?_`-P8A"^[@0BDXRY\2W69?8X9MPFP(^"--"%U<%+C#HPV!:6%B$3&
M(BJV8SLQ/P1&D1)2<L'N:/V9AB4D@U2J,.";5%7UHL?V&5JZ[@JJ4198]N,8
MDBB),![_`!QPDRDY;)%S"\&MXG%H62!8I,.7&IS"QJS3!"-V,0M[V'$:*?J6
M/QR10YAJZNF2(S#2[4MBK1"8TVQR4:=$PD;GJ1,:)L);'O3BD%LH_P!Y*-]L
M7O81^D/W,#+QZOX'$G60/L4A,1C+W+3D:B5/,>C;,RNLF/;B1IV\^0.#:B3*
MWDY"0:(!(E(S!%`%O0=ZUO>L#@KJLK%TU'=.=<P-QU$)"LET2TNB$?5ZB\K<
M'$]X7R>.^\-YGP)(5SLJ-5'+4WLE)JDP1@A[&+8MA^".HJG;Y`URQ!6%>(92
MQJ)`K99*CA4;32!H52U>O=94I:WDEL`XMZB3.CJJ4N`RC`"6J%)IAVQC,'O8
M<9RI6G'EUDCZ[U+6;J^3)":UR]Y<H'%ESK*VU0B(;3VZ2.*IJ-6/B$YN3%IQ
MDJAFEB(+"#>O5#K6@V-3!H4MD267K(?%E<L0MH&9%*%,?:3Y$C:"].6BVI*]
M&I!N2=M!IX6>@@!NBM>]'>@/_='ZP<%HK*MX_(A2]AKZ$,DL&PH8J.4-$486
MV1#B[64E(;(V)Z1("7(3"W$(2`$(]F^[D@)!H`-:`'T!RC(#!34L:0FPN)&H
MH88F.AZ,R.,XTL4-1:)"C-C2<2/93$8D"G+T4)+HK9>@!]7T>KKT!_2X%!B3
M#3287$RC3UX'0XPN.,X##G,L]U4EN)HPH]",7EJ7U<8$[>]F:&L/%K?I.,V(
M-)3\[\_I$#*UI:,IU,V1M<L<XZW)ZRA1*!@<G$A$E<'!E2%L@4[6N7)FU.6<
M:0$LPTM.6$6]Z`'6@W97`H,O;$S*NAD36LR-(\($C2KCK.I;$J&0HE;:_HDR
M`Y&-*0D?&Y>>G6%A!H"D@XP!FA!&+6PX#A5M9.[HR/CK74$<WJ-/BB41QW<(
MC'UKHP256!"6KD3(X*6\U6U/BHML3!,5D#+4#TG*UL>]%A]`8D%'4J6G<$A=
M/U:6D=I2=.'5,"OXF%.YS50D6H#Y@X$A:=%K92>A<E!(W`S0E8BE!@-F;",6
MMAK%N<VU-<T,/@\F8!,[6:L3+0K86<&*.Q1J=\.DHR!J6TD)#@VK7U2:L4(U
MA2E&>L,]Y&5M0$LT`9YJH>FFFO*ZJD%:0YSKZI4$7;JXC$D8T,K0Q$N%MI31
M%U;0*2E.JDEW9F\K0"EVQ[6:WL0MF[$(6]AM[Q`X/(8X\0Y_AD4?(C(CERB0
M15XCK0YQQ]4.CB-X<SWAC6HSVQS.<78P2H\1Y0Q'*1;,'O8][%@:HKHBCU[*
MGC:ZFJI61U)&T\-2L"NO(BH94T02NR9_2Q5.U',XT),;3/J,E:6A"7I*!64`
M[0-&!"+09D-5U>!_!*P5O`@2DML964N2AA\>"_@9XTO1.L=:0/.F[3B%L8'1
MM3J41&C/9)5"<LPH(1@#O0<A/6U=(T1C:D@,*2MQRM>X&H$\68B$1J]U9U4>
M=%IB4I`$@:MR8%QZ%09L.QG(SADCWLL8@[#!"HZE1Q<$''3]6CA1:-(WEP\5
M?Q,47`@;WH^2($((_MIVTA1HI$J,7DE:)]0M:8(\.M&BV+8<PFG:C3NNWY/5
ME<$/FV%IBNWDF$1DIUW%V`U`>Q1O;B!L"LVPLI[4E&D1^O[NF&F*V6`.RP>@
M,RQP&"QE[DLFC<+B4?DDS4$+)A(&..,[2]RQ6ET:%,JDKL@1IU[ZH3A.'HL:
MHPT0-#%Z-Z].\#B1>L:V@Y28B%5[!X@0C6.[BD)B\388^4E<)!I*%^7)BVE`
MD`0L>PH2-*S0ZT-3HD'M-B]0/H#$'TE3"ESF;VIJ*L%#S8[>-HL-W/@,4-<Y
MXU&>P]HV3->8TB52AO'[L7Z25PSR]^S#Z=?Q=>@,DW555[0YO#VTUO`FMYD3
MO\8)`[MT/CR)S?7[W%S;/AMX7IFXI6YN_P`&O2Q/[R>,9WL%9Q?K>J:/0@X<
MAIJH):Q#B\JJJMI-&C%30N,CLA@T8>F(Q;'VLMD85@VER:U*`2ID920(TAFR
M_73)0Z*+V$O6@X'+4U35RV0&RQ96T!5RDZ/DQ,Z2J8='3Y`;%DYQ2@B-&O)K
M<-Q,CY"@D`P(]F;3!&`(M`UO6MX&#>:$I&0;=QNU25TI4OT7%"7AP##V)*[.
M,-&J"N'%5+PC0IW0<=&L#HW:+VWN^S/XWJ>G`W]5&HXN=4SZMC[(L>T7NGN;
MRJ:D"AU2>X:<M(?=G`T@:LCW/3RL]EZH]>S][.]7T>U'ZP:I^AZI/A$3Q^BV
MN?A<;$R1<3K\2(S\(BC4:6('&.1T2[X,]YVQ,#@U)3T23UO=TIR8H90`B+!O
M0?M*ZFJN>&+SIS6E?S,YU1,[:Z&RN&QR1&.3?'7!:[1]`O&[MJP2Q$Q.KDI4
MHRC-B`E4*##"]!&,6]AS7ZN:]E3M&7^3P.&2-]A2H"Z&O3]%V1X=HDM+-3G@
M61EQ<$*A8PJ@'I"AZ,2C*'H90-^GTAUZ`_-IK.N&#4OTQ5_"&75@JU:^>Z:8
MHPMVINN<"U!2];+](T!/QE5K2E9H3C%OMAF!-'H6]Z%OTA^3S5E8R)0UK)!7
M,#?5;(_HI8RJGF(1]S4-$I;6]O:6Z2M9ZUO/-;W]`U-"1*0L*V!24G2E%A'H
M!8-!#Y(JFKDLE:)FFK:`IYA'VXQG8961#HZ3)61I-&XF&M;0^EMP71M;C3'A
M6(1!)H"A"5';V'TFC]8/V(K&MDT@>Y:FKV#IY5)EC&X223$1-A*D$@7QDPLZ
M-KGMY+;PN+LLCYI(!(33S#!I!!ULK8-ZU@<.45#4TWCK?$)I5]=RZ)M+AMV:
MHO*(5&G^.MCKO2P.W-O9'5L5MJ-PV%Q4:]L64$ST'F?=_CB](<PRL:V-?6"4
MFU[!S)-%&0R,Q>1&1-A&^QN-FISTAL?8'<2#;@SLAB14:4)(G,+(V68(.P>@
M6];#"-]&4FTE1(AJIZK&TB`.#D[00EOKZ)(RH4Z/)X%+PY1(M,T%@C;@ZJ2P
MF*3D>B3#QAT(>Q;UK>!G%-95NM;AM"ROH0K:3$B5`8UJ8HPGMPT*%A619$B&
MB-0#3"2(XPXJ&XHO8?4+0'F)PZT4,0-ABDU+4XB)AB9'4U9I$]<*UKA7B=-`
MXL03`U[FITM<EL,**:@`BZMP6:]L>8AT0,TW^,+>Q?=P.5*JCJF=1QHATWK&
MO9C$8^-*:P1650N-R&.,AB!`>U(3&AC=VU8V-HT;6I,3%;)*!LM.8(L/H`+>
MMAB7"AZ4<T[HF5U/7F@/<=8(@[FI(BQMRMQB<5/0*8U%U:]O1)5IT<8#6M-M
M&AV9[JGT0`(`:"'6L#*.U0U,_31LLA\J^NWJQ&32,+-/7:%1IQFC0%N$H&WZ
M;)2L;#GQ!I"-6;LGV1X/9;-'L/H];?I#GL%;5U%&,B,Q>`PJ-QM,]`DB:/,$
M68V=C3R$#B6\`?B&EN0)D!3T!V)`JTJ"7H_2D&C/6]?6A8'[LE?P.-+92Y1R
M$Q&/N$Y7;<YLO9(VS-2V8.0@G@$X2E4@1$'R!<(*HW6S58CC-Z,%]W^-OTA@
MXW3-/PW;1N(516L4VP.*AX8=QN"Q=CVR.RMI4L"IT:/@MK2_!KBI8EIR(P\G
MU#1I#1D[%LL0@[#;=Q>,B3*T>XZQ;2+WHF1KDNVAOVF6R%.O2.J=^5D;3^R4
MO1#H@(4@5#T(\)Y!9FA:&`.]!B5=<UZOD+I+ET#ABV5OD:,ACW)U<79%$A>(
M<</9IT3='HY"-R<(T:8+8A(#C1I1"WZ=@].!FW:.Q]_8ET7?6)G>HRYMYC0Y
M1UV;$3BQ.#2<3[N<V+FA80<WJV\U/_$$286(L0/XNP^C[F!'9?/]#E-498BJ
M3J,MDA1[DIAK.76\-`U1)2\FEGNZB,MX6;21A/=3B@#4C2@*$>(.MCV+>M8&
M935%4Z)_:I6CK"O$DI85<B7L<D30J-D/[,NEZ]<Z2Q:U/!3:%Q;E<H<W12I<
M3"3`#6GJ#3#MC&8/>P_)?3=0.C1N/N=55NXL.RHZ1MD7P:,+&C9$0]X^*1.V
MU0UF(]E1?WLWX.#ZGH1>U'['U/6WZ0Q\(I.O*]FDUG\79S44CG+-!XLO,&L4
M&MK'"JW1.B:%P6&LOK!:HC#&)7(71>6WH"22!.#LK4"T(9OW`^&^@:):44N;
M6JE*D;&ZP`>SGB!OKB'(D4V+VH.5[!+DJ9F+(D@/>U!AOH6A.U[08A?N[WO8
M<XVE*:/6M;D?4E9'.+'%RX.RN!L#BIBUGA1298B*A[6J&U;/;XN6C<%!06\H
M0$FBCS`Z+]48M;#G!J>K`+)@X@K6``<+#VEW/UP8;'0K)SM#O>T6Y@JTW:/D
MVT>Q;]E[Z(_V?I_B^C`_,=15.;)G*:&5A7ADQ>349[O+!PJ-CDSJ<W;0[;SG
M)^$V[=%QJ';8FV2(TT6RO=RO5]'LP>@.`KI"G%KTODIU70($D=Y%&Y:\R))%
M69`_O<EA[RVR*+O+V](4:9S>5K$^,R14F$J--]F<F+%K7I`'T!*6`P&`P&!Y
MD/M9/[,"%?XT^;/ZU+\#TV_R/YO[V!]8%1/('_X%]N?X1.D_[FII@4#^SB_L
M3N!O[.)O_?-96!W;X#`8#`Z[^TX9TK(;;Y4E7.+I+D+G5B^Z)\\LR)W/:ZPL
MA6@A;.A9:AN7UQ":P1VR4*]S0-:\\HTQA?=I'4D(A(ME&AUT4?9GE::(A6D3
M3P*;182&B6-\;8[:T#?IG(71;JD)38CP78LW,BCDR-%N`NQ$GAHD*J:$^R1"
M`84SJ]*BG4@-ED/2OE?75I+'HZF;`@LG&^F%05+&*B;'U:)+/X)9U_PI%)$N
MHO;#FD*K)F?X55KR<6Q&)G":-+MM0O:"3P.)(;&9+/)PKL:G;@=&2;'QE3)+
M>:+/@357R9F4512QDIYB3)'6!0S1:TNT[4>=;?%*/4B4J1I&),[B;"#EQ($J
M\+L]5/:JU*^H:51UIN&6<_;O92'HJ,U2T6"V68_5HU1&U8FV!!&8F)FL]\AS
M7>A,<6/*%F+-5N#*G&9HE4W[4%'!06R['[/9DL4JSFVH.LXW3+G#W]K1MEJQ
MYXELS.B$_<N@&TES^/REFF$^B3S"$**,J&5N?Y;&I#'&]2W)U+>Z&"5!0!CF
M%E[FC5G,%EO/T@HS%66.AK9[4,=>*;/<(+$9)<TX4RBT(=7+BDE:R>6B^M<4
MB:-:<:A>?<6)S4+D[?ZI'JA"3V67^5B919#('QXDE7OSN_*F0Z),=$UZY_`,
M<C'$7Z5&N7^UD&I*:6^V7TPL3L#@D.4*D;4,L]G2Z"I#[^$.`S79Y$&VP:H;
MBJCL6/-<BO"'.UE(2ZP<'2%.D`L6^&F.6.8-X4QV>.K&?759&*W8.CWV&D)2
MAD'IOAS_`-0@3!S>V;0\@KC9][5K0S#>#'7H*ZLQC89##*T3*U9"Q!S,JLB)
MSRKI:G@3B2MD3I<";483Z.E!BXU8(U&&.$"TC=E`7JO^(VQ(YSQU.:TEMKZ)
MC]@3`B7QI(+XN0AQ:9+S'>!3',+GBY3*WNBD+-9!3`2G1JQEMZ!Q6!$)%M4$
M@9(==%<L'6[9SQ=[3#`=3QB4O]&5ZVHV>:-DV<YK*NGT%$SH_IERCDMG)K@Z
M09(ZR$3.8QOC8K;X^[R]/L+4>8$\P9H8)'"NE03HDZ'1SJ=O@.[3BA_%!#P9
M<20NOH\GZ1@)]U#O1#(7,+PPQE\K`#L)G)GX-Z'%MJ4*`L!QQ24P+HSV\.L8
M[W,S1AH@EG+N8&=>J0SDU#5"R0L;C$RN<IM8NII#G^/01U<'1WU;[>UQH!.Y
M02X&+1FHP1HPHQ.\&A&3G+?)(791\A;'F4*(&;9TO7(J]W1T,);2X"Q=R1:H
MXC'#Y(>FW*PHY/RF_.4N6K!GA7[.;R%B<Q,F)5)%@6\Z+G;K:?,_4$5IQ%9J
M6UF^C7PYB:T,7E\.G*9_F<3?S8>3'!+T;2O#*1*&\6PDIS-*DAWL_::+V87Z
MP4;/N[R%CD+@A=VBV8]$#YBO2W+(HWS6BD;W0;<GLZ>M400<VMH&1\%T8QRZ
M$MK*8\.GN$I$SIU/O_H),/&WH`T9RMKR)V';[)#%D`O!MJLZ7T\I?5#C5)5>
MN#4*!]!<>NY\@2ND0;W-F;F.?05=.E+PWESN7EB;DRE*J2M(D^TZ@)$O9?W2
MQ=.W1NH16N\,#E+X".MG%UKS<KK>MHB_UG4,4D3O!#0@;&-[4[DP90K<VYP/
M6C2JDH%.RB`'@&>&H2VR_*;"$PD*<R831B=I2]-S_/!TBRIY574.B%W]!06-
MOT4CM>5?9:J5O=G0.+05S=M;BKZ6F)>5#@B2-Z(SU407D=KCZ`=./G5[C3`M
M%U/#HK3C7:K0QUT[*S(W+)6QUA*;:=Z]@\@4%@FCW"H!-5[FULP%*X)[PC`U
MFZ//":0(-,Y+EG9$XLV=.EU+YBVTW"H7M/5B&15#&X!*+P-=K<O-K;)Y/"EB
M)L=X;,FVN(;&#!,"5,PE:T[`6JTB7:L"-*%4.>[4\@ME7I2;G<;5?L,JEMMN
M.+WUO4U*&.A5-U@<X]!Z?X19Q*2M(L67#Z[M*.QPH*E-IW0M;JY$ZW)'<H:1
M8`-ED]S>1N0=&S6!0>.61$JJ=K&*B*.6O-*M+D57L8:>H*1@RB71)Q7P9'%'
M9'*J"?Y8_)52I_F9?LTI*U2F:#DYS,,)'YIOOL.3W_7M!VT%$(Q%6)UWVK(U
M$18(^\M$>9%LZI-JKA_8FQ4=N.RBUIFWLU@-RSV"<@YK+=4:702"0!+""HAT
MWW).5#XZ,;A:CK5IES7##K2GT:YD;W)YI*+P'J"T:U@VN=V<M@==]`FO\'BJ
M,F2J_<92)D#H3AHDHTP2`H-0?[8\G\S:W5@EC)=<+VOKFH)8M6U!39+.[P92
MPRSGU_F^P#7163IY3*9M&SY2`]I8Y,]K"!FJF@V/I-(`.J\.95'4W>-EQ>.2
MPEVN%;44H6FGV';<1Y1;W2;5JYI7SH5$TQNC:^+CCQ^F&#O.XE"D[F^?!S_M
M`!R,-TH(VJ.^!`V17<'EQ10QQG"N#G[EC^@>65?5B*K6@UAJQ*U1?FET7SZ*
MO32CE\KF$J)6R>P?<&\W3\C<3FTA&F0*STN_?PV2(S'R@3QVA1+G)I/7T84O
MM<Q5>]-=`QXUQ=(C*I9U2EE5EOA=D0R-N3/+XU$8/7QGLAL#&@3K'<2A2S:+
M7%(4@1^U7QY<7Y4O1N$$4PUZ<(-7`"6XJEG1Z:V(+_#Z"4/=@(%:J))HON;H
MYQ)Y80X1]3+G$Q(C0F%B9TND6G%4'W8,Y\E<*DMCN;6_7>\K6]@2PZ*B3402
M_1:7,=>=']>,?QS1D0FKK$:X9:]@UL37)YRL$;7-CHA6`'I"W)-B<V8+<7[;
MG9[4ZT<?6<)G34"0U5#I(HC*"K&:<%2B\72<0-%):BO"0MRQ^;*5AK'!')Q4
MF/2-<E3:4A4F%N9WN!2)P#%/L[[:BG%U529S4V/)>B['G3&.='QBHH\G=*BC
MS^B?G=0T'PUEKZSUR".Q\YI2-0EXHS*7/:EP`)0600,Q<WA0"?7KWPH;*AL6
M^D%EUTO8VF,*)A`]U<OA-'I03NG:4:6UXDMD-ZU(I76(^WE,9`T@BAKDI-0+
M4Q("T!/NQ2MQ"SC%TCY!(ZYM[S+:YMN4Q(*(!MJ-Z/FY4%\@5N/%<]+:%5-3
M-<>1B=;.IR.6-'H"!/+P:=B!@<-&*7<Q*J5:;`Q),T\K+M$W"5G/$ICC\&"W
MU,D<$34%`U10)/4U2U,[U+7NU"Y.K<E`+LLQ^D1"TS1^E)R=%I(VF(3"1*C`
MVL,T\GY<D>92F4/CFWDR@IV8:J74W"VJ-N#:M[;EU.HH2MF6R-2=!'TO+X6Z
M7*W+:G:X)X0..CRT&S6\P(GAUO\`EIEM>K7!>DD,9DK%75KS\XL//X-NSS:L
M/I6%RB.T<)+-H'`TQT-?+;7+6M&L:T"M2M2A4)$K^M-)+<PA)=9V)WG$[TK^
M)O9-WS2N7GHV^$,\12&H0$Z:X?(^A[3.ASJELQ5"%$575)#*>5QQ2W`"^QE:
ME3>DI$.1G:&T-P8&P$'?+1TUT3,*ZF-]*&*OC+QEE>1EUKEJDE931F<6'@5P
MKFJXH:O:B&QT9GQ<U3XL9S>:-_;CT[AHE4C,/4>]!SZ[M+RD3NPM1F4-RZNF
M99=1"25*T=0>^IH/%FLKI-U%%8G+9A`H[$GJ$RI/"H2A,?R3I@-&)WT>!Q`:
MN`B1!'D7Z$\IRNO!.4^BT\CCB-M7.B]9!^;7693%CNDNJ%SVUT@GBK_`(:D=
MJ/<K*`%`9*4:1T*1Z)`E%+#0*_A5*%[^)=6-"B;E9[QW8"V\+3N*]KH"S2).
MJ<6QM@[+)([#8[&8:_:+2QHB(-*0Y$F8"!GD'+4/I4:]<`330AUF'S3R4W82
M`^4PGH-F1-*B.O;#[&&O-:OR(R8QU(?,X8_D,<3K=`YDPI]9"RB0`+?"D9JD
M\!+\\D"+5["YO8DY[E.L*VZ\II%9;6PND'&Q5K\0ZM0O$><XP_4G9BZ<6DIN
M50E6"A]R0*T$;:BCS")0G]]$!'H*!=IR&K;PTF[JNZK8D_$=;5!.>@XVPHZ<
MJB)3-PC4=+E;6U3N.=2<1NTAF=I*E2!6!-(D-1H9NI]5T4@;%Z=.X)#"U!1Z
MA*H#GU7;_DJ.Z*JF$6'%UH:P(>`QQ_?W"JER-)8<.:Y->;)([(ECO'(0HBU>
MS3;7%8NL0I=2)B1'Z7`&F:%Y+B#2`,'<+[WY8/1TDJU@56U&JP1=#U&ZQ"R8
M55Q#(QUY7S'/X`6^A7*I+%R6FP=O\6=7@X:HI[F3,<6F&8Y-;$8E+;UP1A(N
MCO*\`AG1QVL["+EI%0R1F?2G.B$RF*K)\FYPGTHC-FMB9NBQR`2MPNUK96U0
MW'3)'O2D\]#J.@2C3.XPD"46KY08U85W0M.)X7L$-1.K1#)B.B764`?8TTJZ
M<(BMI-:Z"U(=&E,VG*=XD@G5`UF3`UIV$9I,2]#7I.YA,U@W+VH5S1SC*FN+
M6S#IO(XU81]NK6*DV6T;503J.P][,J-A<ZQ0M92)FB-JRQ$4)S<?@EK4("!I
MB%)<>,5G&-X:`U5WU2CY=Z'D,X370X658W8T;G=J1.*O#D58&^;T$]JQ-9U<
M4&X1U>TNVV!%5+4\(&7X(4$N[BBT:!$<)P/(,V&,6SCHBO!)FKDNK>H(;3RM
MWF3Q6;):==RVQ%MC6B1(:?:4,`D:.TU;K97-/-;^WK9&K)6O6V`\E64N7)U"
M1$6@1.08)=/O*TQQ=9,TZV52I]%"(M(TM<F4#"4K<3*IREZN;'R+>\(2$\C4
M(ZP_1]7C@0#:H"LU<^FZ6&GI%J9*C#/.\U\G4%='PHU[F]CQGXR.T27/J;GV
M#Z>XM`"6[EB2N]PPYAC:$@R:SQC+G]C(&1E&6J1N@8ZF3;0K'!,>8XAL]661
MY&7JR(F[RA-+@U0U636$03L[[24?C+M:%32ZR^DH[(;<L8(T:*1U],F:MHU!
M'E2UH2V<EK6+1^^(`!6^X(@A;IB(=.ZZ,OMZIMHZ:7S23H;4:H>\)FBU8X36
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M/1`$WK+`+#0)@TKCRRO(A:=L1AINO4[@E3L2Z=REX?)+2S9'WF>H2JXYF5Q.
MO7=TD5:UF9'DJ>>S>=@$:@CR5<;\!>[`7*R4_OZL,A;=P>0=B>;8C31#9PF8
M81:C9`8=8\(K1ID(Y_&['=I9:+)8:,A/"[5<VZ+U%7:1B@3NH21!\,62I>J.
M,3ITQ8G%$$&UM>/D=BC(N?9945N&RNZ$$!?PM!-2/LG;8I;ZZ#\'-$U;S$QI
M[DGJ^OF]"X6.=[-48G:@.+<OV488M`64>%B>?)UW!:-;=9M'2;#/(HNW4SJ3
M%$590U3%K%B%D/0+8:Y)%:/DDKBU;16;[CC2WL1T;7Z<7Y()P-+/-D*@"KV*
M$*X\LI+<;O'HLK0%87HR@)N^/N2M='X]T/&IA9W.K!;U&++^<8]#9Y(Y#9M/
MRF2P:025L+BR!U]Y?%#:ZKH_HW:G0M!9BBZ_OY'8/&LM<W7H-+7S:Y=GLCC`
M)B]/@6.-U$[368N_,CA;;*]!-E:NQ$];B8FQ(*1+5:YL*($0,DA<-:,T(%FW
M3_?[M873;?0R&26`VU[<MCUNH;#Z3*20ZL*[C;G0939,:[G;=&Y"XV];:5HE
MLJ4&L($S^<9M)K6V?UD91;L%KN2)7V[-'N</U]KW1IC$:I]D(KV/#J9+&@S^
M:.\\N0H4SD1LC98',!2AM@D5BNE#,!)%$FE#J><<B1^\D)D(4CADU\GLT"U6
M*X!MQDF53U9>)P@+*=0M,,O.1G/G&K[&80.`2:&P9]84*H[XZ(RC1LQ+\B+3
M+D[:^N:<D;FN"2(1<7DQL2[7*)?%^Q:XK%ULMA6%R*64HPE.$3C#6?U4ID,%
M3NCK!V6)IFM_U"*\1[="E<W+2DOFU"9Y4&*1$)`L-P?>W5,E3JFKLED=(_*I
MFNAC="6TRL9=&-LUA"KJ43>Y(4!S65]!VM=`88;'RR&9U]FZ)#SC!I@R!Y-&
M2,(5RM,[NB[Y4=5SR"Y&2#+.A8JHM!OCM9)85'(77$/[<K!GKUEK>U"D)"^U
MX7:W,XW>13<TE:XC;MM_LCC&LL\YH,#O*P&`P&`P&!YD/M9/[,"%?XT^;/ZU
M+\#TV_R/YO[V!]8%1/('_P"!?;G^$3I/^YJ:8%`_LXO[$[@;^SB;_P!\UE8'
M=O@,!@,"+;6NZGZ+94$CN2S(56+&Z.&VIL<YK(FV/I7!Q`D4.!R1"-P4$[5&
MI6U&<I/]30M$)23#C-A*`,6@W=BDT<E"8Q;&9`R2)&3M#HU6Q.J%W2E;<V9K
MD;;HQ0WGJ"@;<(\]HEY'IWKVJ)80>'TE&EB$&;P(>K7H2B[D=Y*P5/;U=6,]
MPX0-2=JADN9)"O9BC5:MO)6*TS8L4&Z;CW%O4)P*@Z$G&H3FE!'LPH80AMZ.
MQ("OF*^O$,SBZR=M)*U0YPU,^-QTF;T[:AB3FO.6,A:@3BF*1-T^8SS1#+UH
M!3NC%OT!4%;$&8D<DC\/87B4RM[:HW&H^WJG9]?WQ>F:V=G:T)0CUCBYN*PP
ME(B1)20;&8:8((`!UO>]ZU@9K`X#FZM;*DVO>')`TH0J$202US6)T"32IR6I
MVUN3;4JC"B=*%[BK*3D@];UC3C0`#K8A:UL.''9)'Y>RH))%7MJD<?=2AG-C
MVR+DSFUN!)9QB<9J-<D,-3*"P'DC!O8!;UH0=Z_=U@?D;+(J00[*CI+'R4S`
M[)F%]4&O+<60ROJT+8)&RNQPU.BVYV5A>T6RDQVP'&:5D^J'?M0>L'[1V21^
M7-"6019[:I$QK1JRT;NRKDSDVJC&]:H;5P"%B0PU.:-&X(S2#=!%O8#2Q!WZ
M!!WK`S6`P,/'I`Q2UA993%WALD,:D;4WOL??V5:G<F=Z975*4N;'5K<4AAJ5
M<WN"(\!I)Q8A%F%CT(.]ZWK>!^CD]M#.:TD.KDC;SGYT`R,Q2L\LD;H[F(EK
MB6VH@CWK:A8-"VJ#=%A](MEDCW^X'>!E,#C+5J1N1JW!P4D(D"!,>M6K%1H"
M$R1(E*&>I4J#C-A+)(()`(8Q"WK00ZWO?W,#C,SRTR)G:I`P.2%Z8GUM0O+*
M\-:HE<V.S2YI2EK<Y-RU,,Q.L0KD9X#232Q"`86/0@[WK>MX&2P-:/F423.$
MC:5$E8R'2'L+;*96W&NB,M;'(T\B?@-+^]IA':.;&=S%%G/1"@[0"C=H%'JB
MW[$?JA^#5/(2^+F5K9I;''5RD<3!/(^@;WA`K5O4)-.;TY<M:TY!XS5T=,4.
MR4&EA>A)]B4%Z];TC#Z0VS`8$9K[HJ%J1+G)RL^`H&UL;QNRYQ5RQC(0)VPI
M*[+CUXEIBT*821.B85IQI@1;"44D.$/>@ECWH-Z3,S.B<G-Y1M3:E=WH"$MY
M=4R%*0Y.Q;66<2V`<UQ1052\#<2H,`1HT0]$A&+0/1K>_2&OQF5U^ZMD6/B$
MAB2UIG#0JE\+$P.;28CEC&KVC=UTEC8$)WLWIL/$_D*3E:;1A>]K2S!B])P=
MB#<L#"G*([$FLG:@]EC+*2J0-R?9QB%F:REKRYIVQK0$^N),D+5.KRX%)TY0
M?0,]2>`L&A#'K6PY;JZMK$UN3V\KDS8T,R!8ZNKDM-`0C;VUO3F*URY6>9O0
M"4R1*2(PP8MZT$`=[W@:_%;`A$Y4RE)#94Q2=1")&HA\N`QN*=RU'94C1HUZ
MV.NHTHS"TKRA2N!.STXM^U($/U1Z"+6PZ#;\!@,#2GBR*_C\G9H4^S:+,\PD
M6DVV&+N;ZVHG]YTM-7$)-M;2H4EK5VE1S8H"7[,`O7$09K7W0"]`;&Z,S.^$
M)TSVTMKPF2N#>[)4[HA2N!"9U:%A+@U.:<I64<62X-B].6>G.#K1A)P`C!L(
MM:WH,E@,#@NCHV,;8X/3TXH&=G:$*IS=79T5IV]L;&U"0-4M<'!>K,)2HD*-
M,4(PTTP82RP!V(6]:UO>!J%E6G7%.1%?/[5FT:KV$M8TX'.5RUU2LK"W[5#]
MF1M<YK3"DJ4L8OY0Q!#K7W=[UK6!B:ON^GKL;SW6HK,A5D-Z5(WN"E5#I"W/
MI2=`[*G=$U+SO<#S1%HG17'UQ:8W>M%GB2':!L7LQ>@)3P&!A&V21YX<Y"R-
M+VU.3Q$ER)LE+6A7IE2^.N+DT(']O0O20DP9[:K7,;HF6%%G!`(Q,>68'6P#
M#O89%<M1MJ)8Y."DE&@0)5"U<L4#"4G2HTA0SU*D\T6]!+)()`(0A;^YH.M[
MP/X@7HG5`B=&U40N;G)(F7H%J8P)J98B6$@4)52<T&]A-(4$&!&`6ON"#O6\
M#EX&JF3F&E"?0#E+#HR+R1CATD+TYI!&,,KDR>-JX]''<L)HAMSR]))BTG)D
MYN@FG%.288=;"<#8@VK`Q[8[-3VDVO9G-O=T.E;@@VM;%J9>DTN:'!4TNR+:
MA*8:3[VV.J$Y,H+]/KDJ"1ECT$8!:T'\=GAI8&Y2[OKHW,K2B"`:QS=EJ9N;
MD@3#0$%B4K5AI*8@)AQH0!V(6M;$+6M?=WK`R.`P,,=(6%/(&^)GO+83)W9F
M>)"UQXQ<G`\N##'UK&VOKRB;1&:5J6QG<),W$*3P`V60:N("/>A&@T(,S@,#
M&E/#4>[KF`EP2FO38WMCJX-8#@"6HVUY4.B5I7*$^M^T+2N"ED6`)'O7H&),
M9K7W0[P,E@,#5DLXABZ2&PY#+(XMEA"9U6'QI(]-RE](2L1S"G>SSVLE0-:2
M6T'2EL"IV(&O8;<$WK^CVQ?K!EESRU-JMG0.#@D1K)`O.:V-*H.`6<ZN*=K<
M'L]$A+%O0E"DEH:5*D00^G>B2!B_<#O`Y0$2,I6H7EI$Q:Y60E3*UH""@*U2
M=$)2-$G4*0@T<<0D&M.V4`0MA+V:/8=:]87I#&.$FCK4\,$><WQI;WZ5F.14
M99EB],F<Y`:S(1.;N6SHC3`J'$;8W`V>?HH(ME%:]<7H#]W`_5YD#%'2"%3^
M\M;*G5*?<DAKHO2H`*UNTRE8%$DVI-+]Z6"2HS3-%%^L8(!0Q:UZ`[]`?E'Y
M-')6B$Y1E]:)`@`862:K9W!*XDD'G(DCB6F4#2FFZ3J1(%Y!WLQ^J9HHX`O1
MZ!!WL.6TO#2_-Z9W8G1N>FI8$8DCFTK4SBWJ@E&F$&B3+49IR8\)9Y0@"V$6
M_0,.];^[K>!_7)V:F8DA0[N;>U)U3@VM*4]R6ID)*EU>5Q#8T-A!JHPH!S@Z
MN2HI.F)#O9AYY@2P:$,6M;#(8'``0UM!*Y262@;$YAJEU<U`"TZ(DP\0-#6.
M2XT.B@"-V45K9AQF_3L(?XV_1K`^V]P;W=O0NS2N1N;6YHTS@VN3>I)6M[@W
MK20*4:Y"L3#-3JT:M.:$PHTL0@&`%H0=[UO6\#DF&%DEC--&`HHH`C###!!`
M666`.Q#&,8MZ"```ZWO>][]&M8&NQJ91&9DN"F(2=@E"9J5H4#DICSN@>$Z%
M8YQYCEK:F4GMYZ@HHUPBTF;G(C6]_P#=0KTYX?26:`0@V7`8#`8#`8#`8'F0
M^UD_LP(5_C3YL_K4OP/3;_(_F_O8'U@5$\@?_@7VY_A$Z3_N:FF!0/[.+^Q.
MX&_LXF_]\UE8'=O@,!@,"C_9M`6'=7Z*GFM&R+*I%7;K,%2=V/MZS^?;*C!L
MICQ;,G>JYM^M(_.P(TVA%"(>X\]QIX9G]"<#9FBCD1(3@ZX7CQ==2:/$-IM*
MO4BIT?F^42IXK^1+:8"_V2IYVYBJ0BZ01MLIJ<,<6E%3R>CY`?'6YF"AT)NE
M>]I5[.808G."4TGB]L33RZ2)7:19<G?9`PO+C+T5C6P-]3*5W4EQSZR'UM2J
MC!,I;^]\UV$W0U'H9&R"RT'P?_VFTHD6PRTNXSZ_GE$UI3"]3SE`6^CH73%>
M(55;/$B)D-^Q&M7EFU(8Q(Y/):E=6^FJSDC!'$2L,3"RS9&H>2PE+%0T1&A'
MA$QWBWZ(TSN`UUFQN3O2^%L["N/56;+$<H=U2-HX>1*4#Q.G6HY,TR=J+WS"
M[)C"GF-+V]Z0'H25R$&CU&T@7V.I"]IWQ/8/+$^^(B&>BHIJIQDL5O>Y$NA<
MT>%E6,K>]28UN="'>8L+.V2Q2K0A"K-6K%9"32KT%^VT06%677QU7,A=UTB:
MI7$YJBE$TFDSN.LI3:EN,<:OLE=TM9MHP*)R]_3LTE-8FF%5M.4*)-HEM5)@
M*64AK$F,:=Z&6%L;>YSL2W^/CJ`D+%5I\E8U%$*6!O536QGR$20NG975-A*4
M3])I2S/U@M7PF^P]P;"%2D4@6^[:3+E)QQYQZ8H*!KO%O?,:KI/`ZVE]9)F>
M4QZ(%6RP.$WL5.@?9VU/W2[LY3A@&]0^=19,M)W:T4+#[_'EH3$,?$202B4(
MVA6G"7HOX]+/;^4NB*0F.ZFFL\MZQ.>+</D[C*)N>V6-,ZK@?-*6::L9S6Q(
M]_:UDAG=(N0T[H26ZG'IG,E4>0`_1J;`B-S\6-Y,<71-5>6+&6ML=')LE-MU
MPAL"7,\;N*2DV9T?*S`/#M)ZYLQE9T;2U6_'CDQFXVL"H41<E&).2G)1*4X6
MIN/EGJ=\J:E857%E1YVET<Y4GG-UERFPK,L1I5'22;%T2J)N=`]1R(.SG.91
M'U-2N9!>EQ#0K4[?A'^]D?\`J"3@@\SQOW2R+T[P@E,/L)I>'=3)K@JF7VW<
MT?BMYR$=E]$/[`?*Y0@:9"Z,A,$CEM1Y0W>[H#RQJXFF;]DEHR4:A.$-Q3Q2
M=3M;,7$7V]VY2T[J&KZT4.3%:DZ8$942BU9T7!'JG4+*V5FCF7Q';':NGQU:
MW0<K`:)0XE';;$ZQ2X*!!NL^\>G43&]WT^U19Q%?P=W7S>30U!$)Q-Y9:8TQ
M<`N^.P=EBNMLU>EMA4=2S]K2H6-U>WP:4]&`+8\M:%(C0Z#3Z7X<O2W"I?9I
ML<WS:V-DW?7+GNL72PKS*(KQS2R7E!W23UE9).UL+\TIU950RU,02YL[><6-
MZ.T2B"WN*@P\.>F\8O59,;E+5*+*B]O)W9Q4AD4+GMU6`PPJZWM=$+SCH+EF
M2B#4ZTO<+FK2^64Q/'N`]RLU28QA)VZ`&@9U*8+'7MPWT]*:RY?C]%7I'ZRF
MM)TE&X9-UBEYGB>+S.PZ4:H9/N?%I*-E3B-4PI'?L!3`DY2DD"AUACFX(M@-
M$9H@016X^.;J!G6F_$FV8^I<V!2Q2!NM*26Q;I,VLUGCT0J\ANYYG+$G8W-D
MC%;ALN$N#_M_2*'-648L+$6U;.4N8U`8F;^.7J6=BLJ3RM_IZ6K[/=)FL?*D
M<K7N%HA"E-*9;VV^0M&[6&T00,H7I*1#TM'5+20!I`G4JF97LDIO-);#RPE^
MW.![DF#URPX15[KI,ZTOS/'J*66"IF=A1N45E-6J<4G)S;=K)E88XK;)RJ2-
M-:.25,W/"IJ":8N*+--TC.7E&!R>?.&^G*QK#K*'2'H!P33RZJG<8)";3;)N
MXR16FL]41:8!=#K6`-=0(V(39P-FC28H+"XR)?Z6DLG;F82D1>J$0Q'QE7X2
MWHU3[9+8TKXLC?'*K8R3;\[D#%5\[5S_`)RD2.3QU5&*SJ1E#[PU51(QBU\`
MA,3JI(H!O9^E[D<8&@KO$E;PXJP1E`911;?#BK`C$,:#I58GP+&&>:Q+HV,K
MYVSI-PE02V220*++CRIR:2B]DB]@J![^;M,F$I"0&;QR]/M4GF[_`">QV"X6
M1YM%1+Y%7TTN2;QB(]"LZB5W&\,QUA!AE1)':NWBOT4_8#VXOWJ8EJ5$:*0B
M,3MY2':<-_G_`(\K<>J<X=B$=>*S%/.8>97*A9>\JI98<=2.871FH0,F:HE)
MV9A5RWXI6,BIAPB3HI/TD=$[')C%X-'J4VT2@)9.Y-Z-0\IE02O+,C5:7U%K
MHE]KTR,N33:4UA44;ETJE*$FH1NZAK;)--XA%JDF[D@0@/;DJ0AT]V$F2ITJ
M-*`H*UROQE7(X.:YJ0O<!E,-CTP8Y.WK9_:5K.L@O2+PJ\Z#LZGZRMEI6QE\
M8X@32,1J5>SM+TA,>SE)ZHI3I,C]\=0'A*-`\,=+5E5W7<.EUU[D$TN^G'^O
MXC-SK!>W(AVLMR36P#5Y2)L;ZTASC`Y,[[FS2%9[!=)G(`&P)05YI"-`'0<"
MQ.-;%K[FI!4U?0N.V`YS+R"H[UF4499A,X7$Y'74UO=9/)(BL"3M[<M?DC5J
M)#)3O("T#BB4C+]D<G5)C#=#""5?C`[$6:?D:SI+:I2^4^[01IDZ2V9TS&P1
MK=:/?ZW)I5L(*K9?/I!7;#-'@I[1OPY6@7&G)BUI[5MS()4;"2I'XZ;S;[3L
MQTKAW@">D'YYA*\JI)+:=E"#8\,ALGK)<CJ%R?4$)V]UK`S8U$W1,J1JEDY0
MF*#DY:(AN;5;N@4!CV[QM=,LL=<9$VW!#U%V:-<&R+/#Y8M[.,4C%9N?-%L5
MD138%"56VR-=$H[9,Q8#REVO=W)Q0QQ,YJ!!<B2$X0TJ-^,.ZV8(7JTILQ+H
M0P/L_?AQ:`R&6R&P([73^RR8\<2K(^,UC7J!/*VMTD2Q6UIVAL;DX'$[UB0[
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M+-'!H9GCRZ:D[S,K*?[F883<#[-"I#`9+#[$MB0IZ699%>75L_GC1$BW)MC*
M%V4**\O&.LP1&(4A+EN/Z)-"E3)T/J!#&_%QT_I0J<([*J^JIK=9B:]CKJMK
MOL50VL4F+IKG&MF:^4\^G%*R60N-BQU[J"0+$;>G0MB@LF2;-`]E+!KAJ0DE
M[\:O03>ZU\]P&QHR1+DSM<[U8DVD=G6:XD+W2SK-ELAT[(HHJBSBX_#X*V=&
MUC2KFA^C(6SW`M*I3/+020A`$-Q;C+H^9W\16LI990"-1419]QWV^S6YH\BN
MB)-]U\?S9EK$DLH9,=?F5)6=9RV.,A[2M4G?!PQ`=260UR7$*PDE=XRNL03(
M"F-])G19C;HI-HI6K\QV-+D[E2$;5G]`I(K#HZPKJ_<GZ6L1[18\9]Z]$K8M
M)A,P@>HKVW-!P0LI6'%]L0^CKO@K,GK*EI!:?4M(7?'HY75CV;,XO$H=6R?E
MYOF#`=-9+%HW*EKI,DM)/0O=@(0(-A=BB#1;"-2/`K2Z^,/HQ@A4"CU<V7%?
MA.-LM$NZ_<@M6UCX\IO.%52ZPBS[?D32\Q66J9ON7R3X.6[TG4QR1&:2>\I7
MEJ6:'M0&YP?QP7#6;M))U$5E9IY=%+5B4RJ&/-UE6G'8D[1A/V9?G1EIMTB"
MGB[B@@KU;D`L]A95YB=KD.A*X^`H\TY&$H6!HC]XS>CYA5LG@MD+J4M:52>%
M1PH$\EUL7ILJ,FQQL)6*J.9XN".&MCM64FL)'I[,?G/2D].<M.,&R*%:1O4D
MA:2E^/;Z@39VVROTMC9;3T.Q2PBNPMEG6"YRIFEDH7VPJ.>E]CIH?#9#%6A*
MVS9I2-X@)G^2-&VX80NZM&E:TR<(1@/#':D+86"*H+*K9K97)PK!&Z*TEA3H
MAXJV+5?U:@OP*N.H(_6<;A-CS.9Q)2X,R[:9K@C.6("8K:0],(_U@UU+XOK?
M>F9N/?UM81:>02A+`@\%F<=N"_I$]//13^IYX5(NGY$O=TC45'I&_N=/+W!8
MD0)E)Z94K),4*74\PPX@)DZ3Y<Z`N[K6?R&!`1PN/I:;YP00N[7FQ+!8UT*?
M6&8]+.-I1BNX/&V]?&WX^QHV^,C+)5BI0W')6M:2;ZC@).F(*"-RO&]=T5"D
M8H0[U^I;$,-2M*>5R&Z+Z2OIS0HY874_)Z,<6Y"A6KCJ\DG0KF=:BB2DNY+Y
MMX.'L*0#@6F<B`TJ3^,SL)P@T:BRGHA#.3HXW1UHF*ERLB:1=;T+(&=7U::I
MNFPESY7=LMD%G3J[79&7]0V-;:XH$KFR&%-IZ$I`RC3A:_G/D#H:IKEN^722
MU$2Z/676*F,I9:JF$BL&QE5@^PC21AG7LGJ)11,QH6%,@<!FMCBX2G7O:@KX
M*/9T&U#<8$;<]>/>WH?:E-36UI%$BX15.VUW65M%+6N*8M4NN"/UZDBYW1+J
M.5M["4LF=AR8.W)P:EH5:5$-"F5B4KW$Y0>`-=F'C$FS_>MWVZR+ZXC"^1S:
MQ;(J63M4KL)JE#;.[!DW(TE!*)*@:&5*@;7>.AH)\0@&2J<P*"',G^(6`]62
M`(V#XQ>P#XO94?4='^ASF`I>G<)*9:\X(%/'21UET]#=6>YMT2K.'.$)FBIR
MN2/#/!MRD2H@IFWHIQ$%O:@:"Z'27'=AS*;<I.%`.L:@T4Y^4HV\#9(9E+RF
M5HCY$QKAU4#2PE#'WDV6.^HA$%R!"M3O\7=$BA4$D]:L:U;@B,"F,K\<O7TY
M3UF?.'*CIFHJFM(-4T?:W>\+U2!5+8705NTZ"^#9"W5N4XMLZ<99.VR1F-19
M1WHTWZUMT&O(2*P!DG+QF](N4T>WYZF]<SY(FM2!V>TND^G4Y6R>13".;G3*
M;/0.;?`4ZF"*V6/SPY8B9U9TN&4X)P(6]U:F@)*8L.;'?'3U57:.4-,`EE1I
MPV.:[HY](A67;#"X.*J3BY)?7NSE3>WP=QV^3A,NH^4,Q9!JM/M2C>DJP:TK
MVBU!H-=B/BYZ1A[W$TS)9<<C,,B4+D<0C;/!;;G$*1Q!`<;?1+@B9TK74QTI
M"1<JFR6=X?!H9`T[:'`D_P!4+H-L:3]A85AX6N<SCV+47+G.LW2:07J.KKRA
M!:E]>5[2Q1:`6Q#)WI`X2AN@$::G"=I4K6Z*$I[;$&-E-5G)R3$16]J5Q@9>
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MTQO&RIK$9:Z-;\(#407'*NFY+%H"79&TI9/N2</N1";80IC%/$U>40IT3'`K
M"@=-6XXQQ'"'Z0UU.[+$SK*^8./J2H5#!DJI5%T1*=IDUE5$:\*3MLXSFQ*Y
M:4DA4K"=DF!VL\<4Q-:%I)#7T\>MNKN5+IT_HD!4J%,FZ)Q^22AR>&"',S[J
M"UHF&TL#:J`64F2L;<A1;V).E*TG+*WL+38#`8#`8#`8'F0^UD_LP(5_C3YL
M_K4OP/3;_(_F_O8'U@5$\@?_`(%]N?X1.D_[FII@4#^SB_L3N!O[.)O_`'S6
M5@=V^`P&`P*QWUUG4_.4QI^&62L6MJNXE-@&MSV8-I;HK$8S5L//FLZF<UD+
MXZ-2!J8V9M"02`LD2E>K5*RP$)S-:,$6&@F>0;F;X[QN())CM>U2-C%(#+'+
M$UHJZC*!&Q]#/S^&9O;PZMJZ+K8DGYEDA+N0K2%G-ZG:8LT.MF&^Q"2X_P!?
M\P2<EK.9KSKH\3U(8M$6Y&JD"9J=#99-GZ0Q>)1<YG=O<G5%(Y`_Q1P2ID)Y
M):HPQ*+^)Z-AV(-5CG=7*DC=(VR%73`D3O-GPUG@Z$^4L*T<L(,D6XFS/K<<
MRN+HE0LTGDGJH&\:\Q&:H7FE)?9A4FEDB#:XSU]S#,8=9%@QJ\JZ=(/4#:2]
MV=*BI`F)8X2PJVY4\()"_."KV!"2..K,B,6HW#T[1+40?>"#3"=A'L-:9>[.
M0Y&E?E;%?D#=OBTG)4/*-"K6GNZ4PZ4DPC;:4Q@0[>5S\FEZHAM4-J<@UP2K
M52<HXD`U!.C`T9+Y)N.UT^2U\EM=(<K6')]IY7IM7@KH32IHE5T:&3#GYA((
MP3&2JO1C4FK!J`EE*=>P%Z!Z%ZH33#NK.=;`E,1@T-MN)2":SIMD[Q&8BB4J
M?C,K;86K4-\K5K6(Y*4Z,9;`X)A)U.EY2819^PE[UZXP!$&N+^V^3FP,AVNO
M>!)Q1=Z3,+N5MP/&H"O5AEIA)K:E+2C4/K1HF`/Q@W!`%2@**8W$8S@@0JA%
M!(4PZ%I*`2B+PR8V;$F"3S)J,?HXTK7('ME[&$0RB7DPTD)J9O:G!26(A&H4
MC))6J0[)3B--UL&!&K;W/R"\1=LFK7T+6JZ+/#P6R-SRG?`C2GJ#6%LE07$8
M?9>W31C45>D3H)Y-`!H`V+"%8E.DYQ9@@U2V/(3RO4C#8K\XV2TRK]%">;'S
MICA;@SNTD;10*%V+,7Q(U,ZQT;#I4M+,J]V:1%M6UGNCLG,)5[3`3+#4P;/!
M>U>?Y:V08Q\G,>KN33LI]&@A4NE,1/>&HV/2*315<FD#K%7^1Q)F4'OT.<TJ
M8M0XEF*E2!2G+#M2F4$E!IVO(=S0JJ^][H9),XR*L.>))!XU/)@SHD@FH\V=
ML=?R1M=6(Q<XH3%C(@9K);U"D\\*;>R?7-(">5LD9H3;&.GN?)F0C/C%O0=X
M]^<HHRITR=Y)`X?#<WD4JB,69#VP_1+BC>G>409Z;PI#B@*2UC2L*,``:8[0
M`@Q/Y&^417,X48Y3T^-R]MF$RKPY=*&E2PQLV=P>55M#7:,IG9?LK9YZE_M=
MF(2J]%_!YQBC1>U`31D@-">H[TG0LM:K'?(Y:\,=F:HD3BZV0Z)G<K2&*,;4
M!Z&MD:]2;HLHV+@^+3D$#H1LUO.,;E199PAIC@@#`ROKSF.#29LALNO"O6&4
MN[RD843$N?B`.&W)<EK]<G`J)!H?P>D]UM>,C&J4;*2E?#Z#1A@=JB=#"/`>
M07DT<RG\/U;#(+5;-4372.2D#TLC9SC,)19L4;XS'ST(E+I)7Y(MJ)]/5:0I
M#TI2)$:?H\0$ZK9`;2?V]R01(U,3UT#6RJ0(WMECRI`V/I;MI.ZR!G;I"V%&
MJVLM8A`FVP/2!<H4[-]V1HW%&<H,*+5IA&ABB^[^4$I2$$INVOH2YJXT]2X]
MJD<LCWK-C%'V:52=V5.3TSN;M%TYZ.(0ET>1I]+Q*`-"(U6(&B2QCT&QM797
M+;T7$#&V\8$H^/3\YQB-%[=!)U"E^9W]NBK@VN*5202ICQQ4G>4+<#;B!(`Y
M<O2D%[&:J("8'-IKJND^@9S9D%J&6$3=15#/`7B3R%GT4HBQY=BK9ZC84[&Z
MA.]=W$$->*SQJ"BO<C4RA,8F//"8+U`_"3=A\PPQYF$?E5V05A>((8E3R9"Y
M.0TXTBQ7)8W#"VU"8(CV#\[DS&9-#0>C;Q*E29T=4:0XL!ZDDL8:P/NCF)3,
MJ1@48LUEG4GZ`=6=O@#?"U*9YW[F_0^P)LV/CZ;[PG`SMRAGK-VUHD>]N'M2
M!?\`IO4+.&4'Z-_<_+:N12&)N-KLD6D,;N*444K;)<!3'3U4_AYT11/I;?MP
M*+`='$[M.VE`!W'LMN-<5Y"4)VSSB@#"5)=T)1T!-D1$VM:"Q,V).A++)P2"
M0M[5MB=%,"=K13HW/:PXK20P^O&%<\`V/T!$A1G&:WZ"A^J$,)^_N3%<C41Q
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M,V0XDG-R_P!9-[%*,[`Y)7</(YT\,K`KH&MASTJ7B@)D:T^`]]!+P2I?`SV,
M1FR_=-*4L];#6`\7M/9$/OJ-Q@@K32B!AC7#OCC9J:3'UTZ*K5N:RWDUC]Y7
M/!B41BLF/@EHUB=,>F`J51_XHBV[A=2P#:Q-)9JT*C:8HTT`9T7:/*FG"=M(
M;WKT]TK54-!,F](\>^+6UR+EX*_.:4:9(4<<_O*:=G%,QJ-NTK5%.B@A*,L)
MYY(!ALT/Z@YZL%V?V.$W#`Y.XQ2",]FR@#.^IE:6-P*0-Q+NRR=^<@;^#6AM
M<FH\*DK:@XL>T^A&>KZ@!;T&LL_:'++^?&DC3=T)4KI=(C8HQ-HE:M,ZG/I(
MHD#W5<U*T9#BR$'BL!@]@I7%)DJCX=;O9&#]^2^U".;,\BO*].V^[4M9$W61
M.21QV0,TI>7=E6(XA&U3K5[C;[<:XOY_J%'HSX2TJ5!IR4"@M'H@P2G9)19A
MH0FA/U+SLKF*V`)[C@9LO0/S-%S68+XGT8HD3\YH&-N96Q4+T('AR^'G9&WJ
M"DAIXT;@M3I5&BCU!)8PQ4V[!Y?K>,PF9SJ]*XB\3L=,\+X-(G:0I2&>3-,=
M4-Z>0OK:OUL2<R.1\3LF&O<A""A1D'@..-`4+0\#'D=J<JJ$T56$WC!Q)9H:
MZIV`[:U4`!BQE?W6)KD#ILQ('XNN7QL8UC40F<?=#U;HF,2$`,4!V7@;VIZ)
MHQ+$95/3;5A0H;"6V*.TID:=[2JVMH13QG9Y!"/;*$HCM'*YBSR)N/:TQ7M%
M"\+@ET0`8E!.AA!3-Y$.3'F$&3L-HMR%`)!;;PWLZPO8I(\L=.RNS(D\NK<S
MH1K3/5E"NHGT^/)3Q$.#RG0FZ)3[.)4%$AL"3O/D4^-"E:Z]81'VM/`HS9+G
MJ2N`F16S1F6((@XM6G5.M*!M.^EI[`8_>FP.QN",3NCT<2#WHCV@?"+OKCAS
MD!43;.A:W72E2[D1]*P`>@IEY[ZH>U,5+:=[7%I4R967,4NV,_VQA1:1\,*;
ME`BEAI1`P_>.=U\G2,E8$%XUZW.[/`T5B25A62AF4KHVQJV*'2(U.N7-"US8
M5[NA:[!8S3$K>L6&B+=T1A6C"E:89H2(Z],4*QU@UW,Z6C%DE:O;GIB9Y-M4
M<:!SD6ER]L41A"U$)S7Q3*6]P:5A*MK`FVO1F(E(3R2]IS_9AQ(;U3SC8EA;
MJJ!W37LOL#;,6_E1R.R)$[*%34;'HO+@'H5:,9K:X';B4V9W;V!!QA^FMS3*
M]@]W.`9L-6>^W>38X;)R'N]X$WJ8@^H8R])3G!0)8)^<ULH;$#8RI"DIBF4*
M%3M"7A&#X+"L#M:UJD_I]L086$)(B%_TE8"MC0P>TX/+5<E4N*6/D1Z0('8Q
MX.:8K&YPX[;](C3M*B4D/F+0Y"-#Z2O<W1(;H6PJ"MC"N]B>1[D2O654\[M-
M!-MI7B9,`FVOB!25>-TA56VI;:[>A`&E;P,KM'*:?D[<[#/"T+7)().!5Z2S
MQ$AOK!V_R?)62)2!KO."#035[-C;&$]T]W6:>T^HUM4C=41I05+$0FW-67UU
M:T)"+T/+?O1VPKDFS@RX^PN8@5RKMS]-4(,K5)/%57_'$A><I9U]B(SQI#H8
MR&ITYIDAD7OQ8TP$R`*DPU46,D&A&@$#0:\E[NX\7QD<R;^B*S<(J4[DLYK\
MWOFES:68?'$4P`[F*$A)P01+44<2'(;YOT,Q:$S1XE6B_2+0:;'O(YR3(I-+
M8H78JIH<H45+!O9S_&)"U(!GP^\Y/SNM;&92:WBW(7ITLR)J2&U$A"H5+TPR
MSBBQ:%O00D5?V=S,GC-MRMIMF-3)MHZI]7;9)4%4#ERQAKH^'?']K>-ELH%)
M*@]^B(RUR!*`S:A4G.+&`'J#"+8:17OD,Y.L44](06BW,#E72ET"_,LJ),:'
MP]L;%401:>F9IU[RM=DR]7/V,HE*4#;G[5W1%F)2S%:<)@;O".R^<;%=K*;H
MG9#8X(*EJZ*W).I6:2J0PUG@$K.GR<EW-D:XE.A"<PG5H[@=TX]@/:C4^RU`
M0&A,``,1'^\^.I5MW!'>AJY=S6)E<']T3HW4X:LAN;%\?;56BT>TH52MQ$IE
MS.(E$2`Q:I(>6\\DH9*Y(8<$AQ'IOGZ>`:!0^W(0_F/SNPQ]I2(7DG;BK?I,
MCDZYE8_@PW1;B0\*TT(>MB3&%`/(&SK@&A`-(H"6&F._;_)#"IG:)XZ`K=`K
MK1]%%YJF/>P^W:).5,DE=J(V44`H0W>0(I\XI650B1:4J4[HL3)30`.4D`,#
MC+^Z^/VU$ZKU?0M;!3L\E31!3HEZVK4J9"M2RU:C0,R)(0>MD0%2>`ONRSV\
MM2G&)D7AT9L2-1HL,F^=I\G1KXQB?.@:P;T\3CK;*WY>9)T1C6D87<$6,;UA
M#L0(UL<C%!,Y9#/8)33E("GE`8(L(%B<1@?K5W7M`VV@VKC4\;42P=@N-:IH
M_(#D[3)5DB)F5APQ@VF8S#S5VT<X/JUZ7,^QA`<H;T1IAA9(R5!1(?I(>Q>7
MXJ\36/OUW01`^UZO1M,K9_A,2IR1/*YP1-!;$@1(B%"B0/Z9V<DZ54@;@JU:
M)2>64H+*,&$.PU-[\@/%4<<-MCOTS4B=7\$M;[KV4H2KDHFAYC<?FB!>!>@T
MJ0&$"A$I;WTWU3=[3L:D+B=H"+0SPA+3!T-3$N>9_&H=8,=ELFK)&YKI?'F!
M<4L=$1+,J6MKMM&`0BDSL!K>VX]M5F)3#2D3F4)(H&4H"(O00Q`_(-R%8%61
M"WV^ZXBSQ:8IHZ:G3R%>2WOC,HD<,16`2FD#84-4-N3-D27:7+7'0C&A.D+,
M4;5[3@V;@<:O/(#S/8$C?XN*<(X8Z-MPSREH\1-E;4T'3>0UU)"8,_/;$F3N
M2\]MBCA/_;,;.K=PMHGIQ3[*1EFB&5H82!!>R>6[-<X6SP"\J_E;A8J82N#E
M-#QH\J3)Q&/@$)C6KV4!&=I]!&'(YKULS6W9,WJ3T6CR23!A"+Q>1KE%+;Z^
MEGF?'1F3MLRGU=JW.4-2EBC`)S73Y3\>>XZ!W7[*]H-2YW@QEIEFB_@T8AF!
M&H+%[$)P62KR\:BMAVEC%6]@QF8N\'6:12A`R+PJ3VP8G!V9P*M:V$`5S4:\
M,#@B`M3;.1F+$"H@)NS4YP`!*N`P&`P&`P&!YD/M9/[,"%?XT^;/ZU+\#TV_
MR/YO[V!]8%1/('_X%]N?X1.D_P"YJ:8%`_LXO[$[@;^SB;_WS65@=V^`P&`P
M*S]%\L0+I@J,`FSW,&0V'HY44P*XBXMJ!2B<Y*4R&)'_`/\`S-H=TY[I%GB.
M(G!O":68DVI(]522H($,D05@>/%;1<M429VG<[MV6R:>&OSG/I(<\1)E6R:3
MR%AO*.J)*!$Q0U`T,2MK07JKT@3HDY2,CX&;?:%';`KVL#&V3XGJ0N3;N]6A
M9MV2*Q),&R5THLIK?(=$I$[RN>,5<QF/39.AC<(0QQCD=-L=8H"8>8B1DEMA
MBA8><!4>K--V$G;\<U$%@L-,E52XAKL5?"%3G'P+F@AC;D-?WT+H-ACC20D9
M$RQ''A2?>FTXK1^SO@?7LBC2C]:4:").?O'Y.&:J>B*PZ+LOXRM%UU[4]*LJ
M&%.J5S/@]4T_#7"*L"%MD3C6\(TH5K-O*@>BES6XJ2``UM0XN)I@S`A*=B>.
MRL)^/2LNP[5B[@":VU./:LKI&C6Y>KN>XX+=<SC\@9'.,+6V1P]1(Z_1)@MJ
ML!A)B+TA/]L8$LP`1<'Q(41JO$=3F63<ZBO$\4;(:KCY[A7F]N32DH^7<_N`
MU*LBNR!D*WJ#OZ`XWW<)*<AR8TQI!111ZY.I"QG.'%-<<V2EXG,9?'Q[EDDC
MBV.R)<L98#&&MR"NEJN6C<"X]`(?$VA$M)-/+1@$`O>Q)$Q>C=F&ZV;L*P+/
M$-32]-.??;@NAS>)V7&D;C)GP-5/\C*1Q-VMMU9''X>>*S6/JB=H3+G==D28
M2K3VE.2H1ISR0D&E*`G;H#A**7>MKZ0BG\Y:)/54`,A<66[5,)SD];1EA/;Q
M2JPC8VJM+3<_KR"RI,E1.Y"21-XC"59!@MA,"%<VOQ"5B]PZO?TLVE/)S;4=
MK=@JR46`K9:F=4;M7Z&NH;7SE7[3%7^KE<10,@2(:4J1NFVSX>"K..,-5#+.
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M2+L468(&V1ZJF-_D9,7`A_[B44K5EZ))T1[=6&ROOCZJN23"W9:[32R5'Z7%
M3VI5L@5T6*;8L&3S&G9])$L=/#%?A8Q*[2FEFX_85ZE9LDM6J*+V$O9.B0X=
M-^.2BJ7A%V5TP+9(NB=V5F=2[FF.109F=HY5>R9V0CC+9)HQ#662/BYO*L5P
M`6Y/:IT6;``C>Q;-">:H##-GC;K?UI^Y3&V+AL"66;&'F*2V6/I]=M2T]L>$
M/.;5L+:UQ*OH\PM>D35S#'2"P%I=@'[5:,W1@S@")#27[Q04](3&M0Y6E:S@
MI@Z.),--EO2"II`T5'#(:1=;:TQ%G8WFLUC;+T>H_?;X@$KD@'=PT40@,">%
M0E&<>&U.OC#I13"(U`6&8V)$66,6&=8;:K8"J\32!M<%$)@D!V7$Y#J!:=Z[
M<$+'7J+W%QCIK6N2".4`"8).8$@`0(_^*UY=ID373=9BQCY%7*I%*YC&B'Y$
MNL.73F2<Z6#SJJ=#T2^KCDC2Y)X[-DQA:]-(`M8B&=.48PC5#.<!A8"P_&%0
M5DV^YW,^NLM'(9+,?C/,VU6AK^0L\D;BGN#R5#%"BY5"'U;&FQ$]0,@05;6<
MD=-IURLK:GUO=#$82=1?'QG/<D1/$-NJPY`TA8*MK9;'IRUP!Q3$4C2$3MAA
MJJL&);'XA&7)&)B=[.`X*WM6<N=W(3644<=L!Q_KA'*GQK5.Y7RHZ`>[&ME]
ME&I\9/FMM=7"'*T3:H-NVI+]+CPG<V&CECA%F:9TRU(VE"<X"):6,1J1/H(M
MA/"&5@_COK>O+!A\UC%F6PE:(O:1UVN$`/5PA7&9A:FX[9,.12B0+CX2*6$%
MHHI9AZ/W)O<4*0X38@.,`(TM2)4'$F?CDK::3&RI2IM"W&MON%]?3[*B+8K@
MWP')81*'.#R605K[VNA"V1-4><9;"=K-+$BTEX()=W!*4K`2-+I(&_WCPK3%
M_P!CO5H31?.$,A>J:64Z:GC;VWMS.CW\8/C!&K.1MJME<2MVK!1*EZ)I<C]G
MIRVUU6)3TQY)WJZ"%)3XN*JFQ[H]RRU+5D,SD3V1.)9)W5+6*Q/)K-9IRQ36
M(39PB9M>;B9`(HF9S&,EJ3I"6Q4RJAZ5%'+BR5Q82F\<`4T]5U0]:*'>8I&+
MGY&<GBIK3\3V4YX/5R6(RYP7/[>T1!#'0'+WR'$FC+;D2!.'W@[0"PZV#U`R
MMF\0UW9=,O%*J)1*6=D>+HL:\S'<#;`Y"Z)I;9\XGD]?B$94MASXW-Z5K>+#
M6":5:4E.[MIB=*:4L]J4,1H1$#QC5P2[MSN1==[C%#W5UEE5IW1W@3Z.O+$?
MK`IBUG^P=NSQ`%<@GT@>K!HYK7*`218ZI!`7.!(20@4`]B$YP+CN'PF3L$W7
M6!9LYF3/<RJ^'"1S!SCARR36`X<WCYC7*'HAEC#*@`UF08T2DI*D*3`3+O5T
M3L"4(4V@U93P)42DU8=J26(E-6/:Q_V<B>69*>E<%W8IO;1QJ(\N/Z-2F!M8
MWW0`P[]H%H"$OUMJ=>]8$,0+Q.4A""Y8-19-Q2MSF5?2BN'M[?W"#!=533*J
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M@V2QB,0.@K&YOC+9%UK:E+;ZYLI!6K6ZDA$XM+D(3DV-U6-Q*,?_`,((!G:-
M+-]8/J!#LH\:U62&SFNTA6':FU;-;R&]4D,6.D06P_5A,]Z.?0"$QM`YPAU<
MHHW.TK=-M[P8V&$KW-E2I$YI_I3:$,,C2'![1`.4OT"2*2+F:5NMII;R4RZ#
M.@GH4$L*+V:PV'3K5"ETY8E);]$:(:8-%HLR%.[7LE;'XVF*5)0A,&5H-"0^
M)RARY<";O<WLF62)W-?7*PW61(JJ5.L^D;O+[>FR61C=2*U3+H*N:'NZW;90
M(T-H)&4E0:&'8B#AJ0_L7\3U$QV1DR=3-;"?W(#C").H5N;54Y3LMGD2=:B=
MG"7GR-MK5%)"=RP^F&[2ML(5DM16EZ_2=.4$U,%($QO?`5/OPW4:N03\O;P\
M/[VITG=&(`0+)'V']-=RT3H<=,]4L=I_^BUZ?2+;+KV0MB4?^JP(L<_%+SL[
MULTU@ND%DJ&5A6G/#0K4N,55+$\@+B%*1)E>E2=3$C6EU-8=T(Q+2DZI,<C4
M*-J2U)1R8W1``F9MXHB4;JBKJ[A%@3&"R2G[/EER0FS8PPU>@>T5@3Y)8[7-
MEQ\/#`-UDJ:7YAME]0;1C9=^R)4%FZ,VK*TIV'#I'@6EN?U]>+("YSK1-9R=
M^E<>1/3RVN1)[G(J-@5!N&W<X+(F5K@BBE?)58=Z,+'IQ4'B]/L!%D%A'];^
M,ZIJ\NE+>HK)MV831NEX):A,EKE#UWM#4SK;3NW)'QX30U)*)-M`9<[JF+4+
MEYQX$*="07L`4X]G!L'-7#[-S]=LHLE&M`?'6FA*4YTJEI^&ESJX"C];1AI8
MYE9TT3#9&)D;K+LE!$HFR.'P:6:G-:8.V&B,T::800&@*_%E5"]C0,2VW;I4
MIXY!V^G80<-77>CH=0S97%XU4EJ)'H-?:)>&T$/Z#?B=O#D!6_[,)0&>^>LF
M'L\-@LOQBT-9UEF6L\O4P*E#@YIA/P5"&O9,UN\6*BU%18^(%MTR@TB3LR94
M3SVRG>_HM$N90E2\`#PEG$!2A/S/R?73)7%$5BE<Y2-@Y[L-FLN&J#UC6-R<
M'YC^-.TA$@-"T!3JF\0I<H$,)!2<W8@%[T9K>A>L%3K!\2U&V!#4$#469=+-
M&2*>A]&NC8@=H0N;WJ%0FJ"*B8W%6T/T%=F0$X;V%/M0D=])MFMZM2J&E`3H
M\6@AGIKXOJHG*U4N=;-M`P1<MD,ZCR!8EK-Z9H])GFZ)7>K<H"U/-?+D[X@8
M)A94K3%)G#WD)[7(!DG[&<B;U"8)MK/B.I*KI.WJ%CKA*A0NZHV&,RTX9D8:
MG1,D'241HE8K8"XU&&)@9EJV,0XA8+12#2<MR.-&44`CU"`!%;SXV:V>XPW,
MZFV+D(D*%UGL@431O<H<VN;Z^63):<E4NW(6IOAR5@<H^]KJ4;TRMI"F*1*F
MU<N2F!$6<#V09JK?'=5E35_;%8,$[LI=#;FI1\I*8-SF."E#*;'Z9WC,SY.Q
M"9(0S)V9_3'7\\HR22BO@H*0A'KW39I1AAP?G/\`QU57.S'5:"P+9BSNY2AV
MEP7&.OC"G]FX/$1H*%+&I8E41M02[1-:P<[,Z98VJ/6)6I%S@G.V(D\`"0U:
MB_'=&J-OJL)^QO)Z^!TK55FQJ()W)S*%)998EO6W.K'72V7QZ/16)P5H3U*T
M65*F6)[;RS#?@Z;.I)P"M$DC/#[A?CM:]S,4]MFTI?+W"+]'V_>E0QAH#&&R
M*5RFLKJ%LZ0-:"S`Q!-))`H>U\.827/;DM6A2"(5`;AD`/\`7T&J+_&7I@EE
M(2FI^@K/ASG3,B2LL1?'%/7;V[5O1377%_QQLJZ`HG"N%S&_*-R>YR=GN<G)
M=7`32W%%A4Z4%;,4!^T1\17,<$?2'&*.,V;&5N70I[98^,J`N"AJDD/<ZC<1
MO)<V<8,JL)2!_P#T,MH%2(QUVB#[\OV44#1J8*0)1BW#[/&.KX;>Z9?K<5KZ
M-WPYM2$]\7JY!++9Z#N>>6BN?I4TE,C;'B&>F6RT)>U1(X!ZI=M+.',M1ZGL
M"S5(9!YX6:5KX-[8KVN:)`8;?F5]54QM.ZW5L-5VO9;Y)GZR9*V(WJOW)1,4
M\M/F[Z1[G(3G1.VI'M8!#I.+9!B<-39?&-04>@2VNFB16<0Q+VZS4*A2>_,*
MIV-46SS7$.89<\'*S(QHDQV/B$/+<RA^RT24\JCQ!+]TV4C*#<:(\?U,\]S*
MQI;!US\87/F6?1Y,T.+9!0CBS1:,[765.4J*5-</;IR_Z<Y@NV:3\+N:\"1,
M222`.]E^T$%?G#Q`4<^QZ)MLJM"V)A)(7!F2H&*<2MMIM\=B*28($"N6^M#8
MZMJDROU`"6;UUGPR-G$];=31&B4"3[VDV$N.OC?J5P7O.DL\M%GBTVD"-ZL^
M%-ZZ(B9;#21R^IATA`H^O6+8BJ?8TT0>R9TY:3_`JIN4+&H_W168?H(#`A\1
M;QIT3#K4J2U69UE(W.IX=2\4(;'5OKYZ(DI_/\(=*_K.0N#PZ0A5)HZZ(6)V
M$):!A6M258I3)C/9EZ">%0&QR+@"KY3+;@E3M-;(,_2^5.25;,4MBQ3=%"K(
M=:(?IB5&S_BJ)U&4Y/G/S0H`%>H6Z(][5E@]!0B`$!G^6^'*FY*?9H]5PM>%
MFI2V((VVHGAI@R847B#5))5*V^.IWV.Q%CE,F"F=9@I!I4^+W)5M,2G#L?M0
MGG*`N=@,!@,!@,!@>9#[63^S`A7^-/FS^M2_`]-O\C^;^]@?6!43R!_^!?;G
M^$3I/^YJ:8%`_LXO[$[@;^SB;_WS65@=V^`P&`P*?=7=B1SE$F/FO59V190W
M:%6Q9;D17FH4$Z.U]23=&7BPG]=N:3"(DK5:9NE*?3>@2#/5."K_`+(0@]/K
MZ"NX_*U3S;--P"3U;<<>D\9>SV.X$0&:/R@%0F'6;)ZI8G%Z4PZ0/R>3-#L_
M1)8L-/9A+=-S07M2IT6((BM!&:GRX-DJ;(D^5K2,]21A_CLUESU*)\B:TGP!
M$4%8M%E5_)VF/I9,@*FY<H3.ON;B@1NA*ME5%;"=O8!DF&A,+%Y,XG*'Q#$8
M_P`_W:MF\O6CW4T6/55.W*+0CK>MO-+(I2VNBVR2F2+(65/SK)%.D[TH0+59
M`D'L"AF*AEIPOI4UBM%P576EMQ]$Z-K#:5?PVQ61N?"DI#TWM$WCC;)FU$\$
MH5;@A)=$J)S`6H"2>>4$T(M`,&'T"V$@8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`\R'VLG]F!"O\`&GS9_6I?@>FW^1_-_>P/K`J)
MY`__``+[<_PB=)_W-33`H']G%_8G<#?V<3?^^:RL#NWP&`P&!H4UJRN+(]'Q
M^A$9F'JQN60X/QA:$;IZ(K.R&Q-,X_KWHLST-,G3LR0"TC_W%`4Y>AZWZNL#
M1G'F'GIVEK7.W&G(`JES1('.5(WTR/(M+1R-W>-2):\.'J`"4[KM2/7PB2-6
M$_W5Q]*HGV9^]F8&LI.+^44+6C94M`5B4U-\@52=`A^+*,9"-W61<^$FB2Z,
MT,1#:7#U`FLE"'>D*=!H)!1("P`"$-5N[AJB+J@Q$'VP(ZZ)3&M@"7J#Q2NU
M#GII:W"9NQ+`)-.89,F/;3IXL)W7`UI($XE<L&<`P.QF!,">:DJ"`T?"&*OZ
MX90LL>8&&(1U,`9YRM:K10:$1JNHX<Y+#Q",6+4</B#<CV;O6MC`F#O>O3Z=
M["3<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>9#[63
M^S`A7^-/FS^M2_`]-O\`(_F_O8'U@5$\@?\`X%]N?X1.D_[FII@4#^SB_L3N
M!O[.)O\`WS65@=V^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&!YD/M9/[,"%?XT^;/ZU+\#TV_R/YO[V!]8%1/('_X
M%]N?X1.D_P"YJ:8%`_LXO[$[@;^SB;_WS65@=V^`P&`P(;M+H6CZ1.TGMZTX
M57)VZ\LZV0@ESVD9O6K:ET#*ZVO,P"5C``;%`&V1H3W0[6]Z2E*BQ"UZ-^G`
MTV-]D\K3&:,E=Q6_:QD,XDL903-@C#1*$"YU>(JZ5\V6NWOK>G3C'[RW+*U>
MD;X6,.]^LV*B3_\`X9@-["/67R/<+22;Q>MX[U#4[]-YG'X;*XS'F5^$Z*W6
M-V'$DD\@SV6:A3'I$[=*H8N)<T1AQA83T1H30_Q=ZW@3-6G3//MR"C`*IN*O
MK"%-*L0W=%/BE)&]Z"_U*Y/)\=1V`VC1&FA41LU_2FHMGZWZ`*RAE"T$81!T
M%<6?RJ^.600F3V,Q]E40ZPJ'+H:W21]0S1&H);5-BN2YF@7I3`#M>J33)X;%
M"1L/(*-(6J2#"BAB&$0=!GY%Y+>`XE`:]M*1=<4:UU_:JN4(X%*3IPV&-K^.
M#.(6>=GAVG&<>VMT"=C`)7Y6L`G2LB@8"UIA`QAUL,\O\@O$C7;#W1CCU#3:
M&VXXV*7=Y@JJ9-I#RD0I*]+MI0,.C!A2JSP5>9J0:()-,/$S^E6$&R-;'H-`
M(\JGCM4P@-DD=<5"9!390P0I))PO*SX,<I7*H_(I7'6)G,VWZ&\KWB,Q)S7D
M!2!.T-(B--]/J!].!8RONGN>+80&.=7W-7EAH2ZPCUT#/A4F;I-_]JI8OEK3
M&YT$MG.6&C8'EV@3VC(-"'>QJVI41Z/:D&`"'XPCJ;G.RC6TFOKHKV:#=Z68
M>C&_XM2-"\%GT7*5CBWQJTMG(3#B28?(%S,M)1JC!`"I,0J0E^MM.=Z@1#7/
MDAX4MM(@<:ZZBJ>4M3K+8)`VQY1/PB61QF%H:>OT<1]$]+DR1J5.,Y''5A;4
M$!PM+3BO9E;$8,L(@_!#Y*>#G655]"6CJ6IWF56NBC3G7#,S/AKNIF33,Y2[
MPJ(/+&-M2*DZMEE,H8%J1N6>OI*M&F&(DP8->M@9%+Y%N%5LBLF)I.K:2/D5
M0JTB&Q6HN<-6SXVH63YGJK6C!>U]BY$HK.D*&/+#48E!2![5DHE(BE)@2]AQ
MK9\D'"E%/:^-V[U'4T"?6J:N%;N36^2#9:I#8#6T1)_70M4!.G4:)DY3-.V9
M2%$+>E!A3D1L`1>OK`X9'DOX)4N]@,1/5-2C<ZI89?)K**^'3`IX.QP!K^&9
MJODJ\20+>U!B[9KVRTLTT)I`?N"#K?W,"=J'Z4H/J"+.,UY\MN#VY&&9[.C;
MVYPI[3.OP#(2$:-Q&R/R,&P+V1UVVN"=4`A642:8E4%'!ULLP`A!`AWDVX"2
MS2?UTKZNJ%'-ZJ,<2[(C:V0#1N,($UOGQ:6;D@5*4HIK+T_>E(4,T00*#M;"
M5L?HWZ`E:7=C<KP%^F,7F]_5;$W^O?CCN<M<AEK8TJ8GJO:ZAENS;;][Z<26
MVAC%96(Q/BS9@@Z*;G9,;O[AH?2&-9.W.2I%0\QZ=:+_`*V4T)7:QS;+!LTQ
M]+1Q^".S*I;TCJS3,*XM,XQ9[0'.R3VB)<00J"!60/V?J'%B$$3NOE2\=#'%
M(G-W7L>BD<6FZV;ML:=S)DD$4L7UH8P%V$D5IR@#6,Q\*^-38-T"M+3[1%."
M<PWU2SBQ""3W#NOC=JMZ%4(NZ8ILNWK%0Q5QA,(+G#*I<9"1/4(G2`%(E250
M<U!<+`;`^\L"0Q0!4]D;"8B+/`(.]AP$'?O%;H;%R6[IJH5QDR`P#8`II<@.
M]MJ56LHHJ-`<=@%L+"<^W0C/BJ4"_:49T@3G(`ZVI*,+"$C(NH.>7$MK/0W#
M`U29[O%^YH9E9+ZF$B=K]BVY""1U*VK?3[JMFS*HB3H0I1EC$,I4WJ"!>@XH
M8-!'$;[_`.*)BDK-?%.H*9D2"Y4FU]6+6::M3@DGB+4U=ZYTJCBE,:82O)%/
M(^O:0B"+T"7(SRM>D10]!"8VN_*5>FBEW]IM&$.+)T9M)JAW1)(&\Y#;FU\'
M=[+1:@*@!VRY)M57\?6O(/=MC]9N2FG:_B`WO`T?H/L3E_E(V)$=&7?`Z?/G
M9$E5Q`F9NNV\Y^0PTMH.ESBB*`2</;9&27]$->I%H)"0"HL1HPZ%K>!KJ3O'
MCERN9MYZ:>BJR>KG=]143;`6)]"^.RLN<Q%NG\-.+.:2EC;HB40EX2.J$S9^
M@*4"DHXO8@##O8;T?U+SHE-6D*;FK].H;KQ)YH7ISI`D*4([]/9D\D*J90G&
M()Q4U'&U9;E[F(.AZ;AZ5;_['_<P("2>4OQW+X;.K"0=@T>NA-:+&9).9*CE
MZ=4UQXF1FNI$>?%1Q!9FSHB^G,2T*-[)T:T*A)#M%*1>S'Z`_=D\H'C^DK]`
M(O'^K:G>9'::9D6U^R-KLL5N4H0R66.\%CS@@2$H!FA;GR7,"U`D4&Z+)4'I
M3=`$+0-[T$GT3VUR1TY*)3":`Z&JNV)A"TRA=)HQ#I4@<GUM;4;R?'%KO\%^
MN6L6LJ&0IQ(#UJ<!J4E9Z"1F!,$$.PV1RZLYJ9G&_6AWO2KFQSY7:(Z_]'H5
M\Q94JBDV:71P^7Q9RL@L]4#<72R&,IC%J,2GU/>"0[V#T[^Y@:PS]N<E/U"R
MWJ!KZ`K9104`7.+5/;/,?2TD>@[PT+F]M<V.8Z6%IW"+OJ%:[)`&(5Q!"L/O
M1(ME^J:7L01VY^3?Q_M$"B-G+NM*8#!YY)Y3"HD^)I42OT\3&#HT3E,8J6W(
M"E+LFD48;'-,J7(CR"E"9*I).&#19H!"#9]^0/BD$XW6IO3-2D3H,&/L<4;4
MR=.E7@B22N]6\L6#]X"40!R151OXS'-NQZ<R6#_\P&G"E_[N!R"^^N+3;7@M
M&E]-T\.V;+;(H[0:$!F+;MVD)$]CVI;!$:86C/<B'R;Q807%F;3S2G%T0B">
ME(-+$$6PV^$=><O64Q1Z40&^JMET;EE736ZXX_,4N:5[0[U-6\A0Q.P+`2.!
M*@2448A<G<B&]T4[%H*)69HHWU1ZWK019//)1P;6,1J6>SOJBH8["KX8")/3
M<I52/2ABLEC4C)*3+(DXH2%29V$H./"`!(!>W&/TAT#8@BUH/P*\F/`YSE9#
M47U54>UE/L\O?K1WM^&!'!&F`F%DS55)7(:4+:V[BYYH2UI8S=&D&;]00="U
MO6!)<-[/Y2L*EIYT5"K_`*PDE(U8GD:FS+(;9.B-CM?%Q%J+?I*&:FB$!3&%
M#,QGEK3R5I9)H49I9WJ[+,`(08.MN].-;?41M'6W2-4RQ;+I>\P"/($$F3$N
M#A-V""JK/=(I[@OTD6)'\NN$*A]*2G@*-4M*<Y43HPDHP80Q<_\`(9Q+5M95
M7=%A=*U?%*GN]*<NJ*PG1Z,!%;#1%&-I0%D7=RDQJ5S2K1O"3W0P&_46>]%;
M(V9HP'I#<V?LKE=^CJ26-%\5NMCBVPTU2IG8$@3EIAV:KK0FY$\#'[?11A,I
M'5AX'[W,80G!;1:-WK6L#$4[W/R)T#$9_/J8OZO;#A%6QQ/,+`ED?<SC8_&(
MJJ;'=Y3R)>ZJ$J=&)F.:6%8I"H*&85L@@0_3ZOHWL,DX=I<G-*R*('3H2JFY
M7.4%'ND0)72UM2;D+=TLZ2!DH!:V"/-+`H3V\[Q5Q3,(M;]#@>C-`7Z1!]&!
MI<W\B_"M:29EA]@]5TK#)'('V71ML;I'-6UI]=Z@-BN5135&M5JQE(6D,6L]
MH5,2XU6:02G<R!$#'H>O1@?#CY&>&FF8VC`'+IZJD<NI-%/G"VV@Y]&']':2
MK6M0]6(9*UWNVVUH%#6I(8>O`8=H9``[].OW,#%$>37@%76[G;B3K*FU<`9I
MB@KYS>4DG+5*T<U=8^LES;&C(\029)MNJZ(MRIV*+"CWZ[4D4+-?^F(.-`&V
M2COWBJ&PUXL&0].TXDAK&969*M_33)L=DBI3<T1+G]3I&(#.8O4R=;8D&-T\
M-!#:!6:N;`B5%!$2`8PARD'>'&+HRG2)KZ=I5S8R*/1]+&N;=/F%<D#02V3.
M,**MOVB56;ZT(*F#0I:CUNO26F<21)SO4.UZF!J:CR4<')'FVF%3U-4I#E0Y
M$W4W&`U_$!)715:OQ<7GVI0Z"3::V\Z)2,T*%<7L[9A*K?L]A];6]:">J,Z(
MHWIB''V!0-J0JVH>C>U\:<7N%/:5W(:)(V%ICG"//:<H6EK&^)$RT@X:1642
MHT0>4;ZGLS2Q""%Y-Y$.(8=+F"!2/IFJV^:2B0RR*,,8T_;6O+C(8)8SE4,R
M:RD+>G5'%GQFSV94Q+-F:``AR3C)$+0@[U@2I+NHN=8%(YW$)I<]>1B55BQU
MW);`CKS)6]$]1*/6U*3816KV\MQINE29KF<O)VVH3_5V6:LV$KTZ$(.MAK4+
M[3Y-L6[Y-S9!N@ZME-ZP\Y_2O]9,\J0*I,E71(Q.3,&M*0$>D[N\PLY46!Z1
MHS%"IG&/05A9`ON8&'E'>?&<)MF2T5+>EZ@CUNPV.OTIE,#=)BVI7QC:8M#E
M%B2,#@`9GNY+RQUZD-?E39[3;D2R%B7"(TEU[7`RTO[5Y-@$;?I?,^@JOC<;
MC,!JNT'IU=).B()2P*\G)]9J:D91?K"4+DUI/$8<$C`6G`:H=520PI.688'U
M<#%MG>/&3Q"4]D-_3=,G0-36LXN`,K'.&9,RD5M6<J8X+8<J7*U2@@#:CA,W
MDJ!F="E'LE*)U5E)#2PJ!:+P(Z7>4KQY-L1A,Y6=<TT"-6(XS=GAZPN1B4K'
M9XK4YB3V"S#9$R4Y];'B&&2EL^$DJM,G4)`N"81@`A/*V()ZLCJGG&GT@%MH
MW/`($G-K1SN(@4H?TK28IK-G?H;%7"7I4ZK8%"MM+E%AL3:#181''.#ND3E@
M&<>6`08A%V1RRXT&KZB17O7"CG]`I4MZZT02!/J.(GM')=0M3&%FQ:"O2S$F
M9B"S[9ADA=?A804?N_O(M%;"*5WD[\?#6362ETZ_HIM2W&A4N5<*W&<-J%)(
MD*"9J*X<U&U2H12=F"SV"C.8UVEXDHD+L4-(?HL\`B]!L;1Y"^(WZ66?"&OI
MNICY'2J2PU]M)C)*2C05VCJ5Q.:;-4RU^6EIV!F*@KFG,(<]G*@^Z&EB"/T;
M#OT!C&GR2\&/D"'9[;U=3!T%)#8NUC^;+DB,IL%4D;:IE9)#RB6A3N;*KAT0
M?4+JM)5DDF@;5R=3H.R#RAB#\`^2S@O<)66,;U14B2%-[.YR!6_N#\-M3%,C
M/-(!7+DZ:)<$J98:C33RU(XT;&`L6A.#TE)#Z1FAU@8]?Y0_'LT(X&X/?75+
M1]!9P'<Z#+9'*2X\E?4<?D*:)/;F%0]$H"F]F:I*M)1'K56R$A:@T(!&:V+6
M!9FZ;WI_G6NW.VKOL&/5K6S,<@)=9G)5(TS$WC=#P)D&U:LDH_1)2@X>M>TW
MKU`Z^Z+>@ZWO`A*(>0CB:?0R2V)#^FJF?81#JZ_2[*),EDI(&MCJX4@>(J7/
MW`]2`C9,2/D4?6I"UWH]@:<E,T`6]!].!L4`[9Y0M2XY+S]7-[0*9W+#G66L
M4I@$?<#W!Y87N!K!MTS:'(1*7:%.YQE>6(E81L[VI)H=A$'TZWK`CT[R:>/]
M.YVTRJ>NJ/2NU%)Y4KMIN535O3*X0E@TM10*:GNA)^RQFE1&:N29J<MI]':0
MKE!1)WJ#,!K8<D_R3\&)JHU=YG5E.;K`4\,JX,E)E)"D8[))9P2,^!EL*<LV
M2&2U/&3`NAC>%'M26U;]]$#27_NX&YB[FX\T4WG`Z3I]2!Y9*;DD?]QFK0X#
ME+!T-)ET,I!WB):$]09+4%GRUL4MK08VZ5!5+4YA0?XX!:T&WUQU-SG<#I"F
M2K;GKVP'BQ:]?+8A;9$Y$B>ES[6\:E*:#/\`,B$R(9IJ=C:9HJTT'FGZ*]1S
M`:EWKVQ)H`!/F`P&`P&`P/,A]K)_9@0K_&GS9_6I?@>FW^1_-_>P/K`J)Y`_
M_`OMS_")TG_<U-,"@?V<7]B=P-_9Q-_[YK*P.[?`8#`8'6%Y*_'LL[W+Y93M
MLV:82EIWH%HD-N)W9N5N!=J\NREK4LG05"%:2;UI+NV6A*VIQFG>LG"6EWZX
M=^G6!UYU+X&'V'N-4IIQ?;B]QVO+:ZZE*APKZ96Q4%B'5E8M,51SSRE7+7/:
MTD$3DB9LIBI:>:T#NE$KTB<-;&#03@;WL8<SECQ$=6<OS]N<6^SJ=E\2=*)Y
M8J"5+";9ZRKM4UK*(Y1B_-\H>4M00:2(*0M<I^6,A[DV_'%O7')2C"RM[#L`
M=A"=_&]XCI-X_P"TRY&W6VRR6KA<4UE1""L4;:Z)T$`NM.ZHY/?4IKXU;ZXD
M55VQ8211*BFLX>ST+X]..RP`*-T'`AN%>!AHBO+O,58*+DF+E?M:R#BUOMRZ
MS;5N#2HBH.6K&46,X5ES.I(?$CO0[8K?'-6K9/@GW(:-:(HPTT6B2_5#^P'Q
M*]<\]Z<GBD+BYRG,WE%/]+\PSV5=$1BR92XV!6UV7D_7?'^B)PX-2PURE73"
MESE:Q/8")0:%AG!R=&I"J:]$A3A#9:B\%,0KN+7.QRBW)A8ZOX)BR/EY(^S2
M<IJX@4KA_CWKKAUGN*QJE1.)4+D]M`(CKRJ`X;*5Z2-;D203Z#DX3-!J%>^'
MOI!TJ7E"DK?NI#`XYS+:$+F8;!Y^Z>[.=+<=6^,\FWISJ:OKJ3V_*WO]!#P!
M^L9H=4[5&-I8X-$F5(E"4PGV)0@F#D#Q^=H\9V/63W!9#Q[)8@GYMHGF6XO>
MF^Y8L_O;=3-[]%6,]7!#F])\84'Z1K<8;W,='U,Z+#DVI=I4:!0)*>'U0M-R
M=X]([RQ'N[6B+$P=L5=;WU;%E1M1'6UT()AE?32*HF^&5PL)7FG:2,<)E;E(
M7),V-FB6A&-]4[2DEC/.]8.N.!>'SJA9P2+QTVO9=,MU1RM@YRJ^T+)CEH]3
M7;.%M44T6)1*SZCK_H]YE=5418,I6L346TF1Q(E:&`)YR@I(:<WM8"@W^HO&
M7VC5G1=3W>NGW/,L#%*"Y,Y[F":(V5UGSHU*6;E266F2VRYKJFD9$R5?+13&
MOYPB&.,RA.Z1]J=4RE,E!IN4#",/E/XINM3.37CB9==7,A%.U)7AD7YAFB6H
M98KMV3R1@Z.KCH.O'R^GP]]1IXTTI-5DG9Y,ABPS]RE4O->##4QJ9.BV$V1C
MQS7RZQ)R>[/L6HT=O6)Y3J2\B=D-]?M\T45LQL%1$4_&M5?"G"1:3R9Z=W.)
M4ZE.VYKDR(C;DN-#[N`@H&Q!6Z5^)#JEX:O)#7+79-/%0'N-Y[+?HW)'"V^L
M1*H0=TL-<Y1AO>^>"I$;S6J51MU]V`X/B1J"]&D:,,*.]KO^,%XN8N;^MJ:Z
M#L:_;/4T7*Y3UC,ZV9[Y:ZNW,6B%5-4O/E"S.*5>Y0=5,EGQGGMDS"QG%*6]
MJ5J8@@IF.+)*!KW`!QX:1V!XU["Z6!Y&D[-9<2C:;MBG^+JRB>UZ22`60A1S
M/8%E2V7.3RM:#"E/HD[?.BBFLQO&!0D4D",$+6_4WH*P3+PD3$RP;O>8):D&
M?8)8[_TV],$7Z4,M_HU:M2WSR'RGSZDCUJ2"<3@R;35G3RV@714H&%^)6(&A
MS1A;CR5"(O00E%%XO^C'[QS=?<<SJ\HV&6]'V`7)*W$*77!;4=H:'$"J@)<)
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M(4WKFR%>Y3YQ`_G*E2@9BY4J>S5"H9AIANQ!52">"URJ*R)6Y5A:4-:ZE;>D
M>5K!HB`N+&[B/J2C*3:K;E5E5@WJ$F@)OA*Q;WNAXD)0P>LF`7[/1N_7]`0A
MO4$X0\D$+ICQ^0/4IX>6RKQS/\%_1@KV??I<<LZ,,/*UN\S/QT\U\$[=(](C
MB9\A=T@6_2A+[4@\HST`V7Z0D/R)>//I?M9QY4G3/+:ACLVJND^C:PN*-EVE
MTW4\6?77HV-5*TO*J%3BBGJ)62XQ%@70!9ZS,\'`1O"522%87L1?W`TKE'QC
M=2\M]1E6J.T:KL^!/+-RXS2QT*L/I>DWH7Z"N2JLYHE+@GYTJ>2H>796;(U=
M?'N;84_-JP+80I)(`,/NI(@!(E\>)4^]NT;;NUPN$V+\\W'1DV)D51L3:<&3
MMO9$MH66\?$=+-#N9O306-FY5F:AF)3"![?3JF(5>MZ`_<#18GXR.HY/%;&2
MWK:7.R.3M/B\LOQCT3^A.%39BCCE';`;68@^X+<(D*PQ:VJDJR$LON$69_>T
M#,4:Y;)6J!*B]%!FG#QQ]+1OL6J>D:_FE7O4<C/,?']`2UC>;FZNI]P"Y<U2
MZS)`^25/'J-D;'"+89I*EL/U4K/-2'%N+&F&683[%4I"8'+X'\:O0?.MB<\R
M"]+,I9]B?'U2=/U'2**H&":HI5.T74=O0ZS)&_V^\RU06@1$Q%%`D:-N9VE,
M:G-5J3E9BC7LB2<"N#9X5NE6Z17G:#KTO2UE3[L&N.FXEU-7UIT<0]4@^N5O
M3Q/:E6%,H(L;#K0ES'5#VUE1E"<_O8W-FC*Y0-G.1'DD$B"=DGC)Z8<O''UA
MR-*;MA:NP[WM!%/JJ`^RBX+=@]*1UE=:C=6JN7&V[05+[\MAM-<JV6+-N;X<
M8X(@NX4!'_I$)&]A#%G^);L"Q;A:>JE]G4#^G60]"6+=%E0*%SOJB@JQ;VI^
MY9J3EF',$"M.E)2P7EMZ3,=5`>']<<H0IWI2M]T$E"F3@]<-EL7Q1=4V!=LN
ML=NM:CZO:;+ADH(M!5!'KH=<NLERE'&SOS=J!697,QEC]5-A*&":+TSJEMPY
M&ALL^/-Q#2HT9OVB@8?O7OBEZ_J:1UW$:YZ7KJ,TJ3T50'45H/;>DL-+:3I*
M*VJ6CJRL^H=1PM4*O;%K6>ET<GVP.;R-$ZQ!(ZG%DDJQIDQF@KO"_`)>M8PI
M35U8=3Q6#5U9O%K'RW<#*@CS\X"B$MLBV*.?^S+.HLEQ"<B;TG0U:4[LK;,Y
MA]S32IS6.0]"`L4%;"[U8>+FY:QJJK*(W?<3FU<T5Y*87VG5;FZ0A)#GQOJ?
MX1<+%L.G#8I`6QE@+`K)M^8R$^.A:$J5H1LBI,FVG)V1ZNPKS)?$3U<[0WR'
M5,@LRFR87V9)^OI9$I4XVWUHN-B"KHFSEEG15N?>=SY(?S>G41Y:,A(Y/;4U
M%/9Y8332CO:'&^T"SKUXZ+]M.@?*8VVY9%/-?0WDIKG5?&E5JSS0-*U8CB]`
M!HN"JA'R0TR;RYW5E[,<'EP&0E&(O:=(01H"0!AH5A(\*-KSKF'LVH+EL6L5
MLQZ6FG,LR@9J:7]"6SNK9#0*)FC+Y,S+ZN:4O'0CJ]6#`DA[*4VE+R&AA;=F
M)48-$.+@$P.W;K3EQ1>?/,1HFL%T6K1!#;@Y.G3&F$U')XTT0[F_H.IK<.B3
M0TL8"0MX5<9K@;:V@+"%.E.,)V+6B@;U@=;4[\-TEEMU67>J:XC$<MG'?\HZ
MG0,I\TMTRLT-4/\`R`?SN3%%U.ER/55JK<3R\_;B*3?!&UNVC6DFE/HUH&!+
MG"GC[O>BN0;#X_OB6P-=')%SA%N?F6;U_<W4MMKS0MU9/E8O<F+A/1DI?(C5
M2,U`M(5I&2'A;VH(_20(K1*=+Z@4_*\)=SW+&XK&.MK!H:0,,;BG`U".$=J=
M!9K6CE%#<2-/0I!DL->7Y46\QFYYX]WF4M0%HMB01PUE),+5JC1^T`&LM/A>
M[<CL(E4#WTU0%E++SY@["Y.Z'MFTH-.E4R<XYU?U+8UX.]R16)1Q0UQITM!)
M%YUZAZ%>J3-@G\(CM&C3Z]48;HI\/73Z&+>0"G8_9]5'5CV(V=5MT7EK_</6
M)S_#B+W@.HO$@R>@DDBUS4^/C&YMZ0QT?R6D+V>6(TTD[1V@>D-@F/AKMIK*
MM=+`;!KRV`R>_*UO"#3?HFR^HD/3C$GCM!RFFU4&3]>UA.T5Q0U-4SJ^&+8.
MXMVU6SHX\NT=>$IY!^EP@_.*^(CK&NG^%70T=(U=9?0]9*:55M#U.H],85%[
M"-C_``T\<:6\OD*Z`#$^5S,EA;Z)[B;^SD+U#:)-LI4G.VM4#"$,67X$NB;6
MK5:MEO7$=7=.)>>(_2\:N0UDE1Z?X&D71W2MGWE4TW(4*CG*<4],:BO1KCB9
M0J%IX,?HHA?C@@4EZ+V$DO\`XA.L'*N>^J90673!$1ZTF?5,WA4L<;<ZW=0Q
M=7>_0QU\15J?^=ELD4<YM!K$,1;>XO3$UIWH_03#2SMB4J-&AV/\I<S]/5%<
M]W7S:\IH1WE?6=H,4SO:,UNVV"@B\(CE64/%:>J9KJ=3(E!B^1REU7Q4*Z3N
MCT4D`:F/`F2)P:2%C,"M-#^):35_U\;TC/;H>QL#<NZF?(]&J<L*WJD<U[Q>
M_>]@==1EOL,</D<?;;$A#+%)>0T.K$[Z6M2UP),,]W&2+6!K?;7A^F?473=C
M]20JXX_6T\?S..8Y'AB;'E26_P!.4I8CY-[TIVS`$;&F<HQ8;D"./;$:F+VI
M:Y%&$QNQEEFG;$&UT/XT[]K>T^8X[,;2IISY@XKZ)Z:Z2I-PB\5EZ3HZPI%T
M.EO)`BA]MO#BX"AC0SPY)T.^"='!JVI42Y2WMYIZ=#OWD)@?G)/'7U82;UO4
M4"M7FXKFOINS>K[]$\3JLI/([_9['Z=I26U\9!"W+3AJ'M$4B4YE&G$B4)=&
M/WQ93!8`HPEB&L$$",GA(LJJ9!!K)IJ[65SL*H8YX^)+!&>^)7==PPJ1W!R`
MT]/Q2P6R2KYG)Y'*(94TWB_1>QQ=*Q#T&)O+<%84@'K8B3`X3[X5+XFSS-+7
ME%Z4\UW+83_:=[O34PPB6+Z<9^A'OK;C3IFMHHDCC@Z(7B14<E;^0DK/*3E)
MR5Z>E[PI=2RB#!:(`$B7=XY^\+KL^C.B)-/^6M6M`1=2(Y3":RF'67,$/3,%
MYBY[3Q!$VV]SW+(K<UBO<:1T><8[KGL2%.[&.A)7N0"FY-O`L/V[X][1ZOE4
M9G"-]HP2QGY$F=%/4%M)AL24PN1S>37[RW=I2LM]C,CBE@1AI2@H-:F;Y(VN
M!$IC[LK0.Z/VBA&(H8:LR>.SH(SQWSCE2Q;)JFV['DUW*;<8D5JJKEG<!C$4
M3V^Q65&ZD_36*4QWIMWD472,?H:;/.<=3-I>QD.)83=HB2!!`-5>$>4R>811
MS[1O1[MZO4E&VK54NK&%V=<;9\:6N>=4K[[C-5V-8[B[()[?U31")J"V9:KE
MBD3W(U81J%WI"/U-!AD_A[Z27P[LFFGBTJL;:[Z-M#H.VX7,$5G=3R@R,OUA
M]0E=25JPR;EJ1RY/S!\`-DC;$+1)%#,B0.[HU>]A+5!,6J!&!M_6OC![/[@A
M#R?<UL\KPJR7Z)]9P\""IH'/440C[3?'/E<TK#=+I6ZF@F5C/K,ZPI4ZN#JO
M3(3DZ)8G;41/LD(#C0SW;?A_G=ZHFANI2Z%Y".-48&N6I1T3:]^6=.W"4E=P
M<C]9:5.-SJY4]VLV1[;'SDO9DIJ)R`X-"ER3'(=DA(WZ`TBR/&%W'8'O0V^P
MN8HT*Q^)>C>#[4!-YIU;T@KC]==!60T3-98T,EUTR5SL*>3!A;DZHE.TR)W*
M:RC1$EE&%I2_8X':BT5#;,CY8N_FV5%1R-!W";"Y^I"4;=%S^L>JLW5Z.!P&
M?V/[,8S"9<N7GJ3G).EWH(BB@#"`L9@BP!U77[X29C>T/VT.5V%LK^Q^+/GS
MA2'GQN97%"8T;:M/2>:/KU.[$C<)D;(U695KR3(TX$K$^$.("C"SA#)ULS>]
MA9OBSA+HOESIZ]Y^_2FMI13]PWSTW<B8QJN?JDJ2M*&];#<["8V`5`.DE,Y<
M2O#"J4D)ECVD:BW10`!A@3O:&F>N%;)CX,$<QY^Z/C;M:[F\]"VS9O4;Y5DP
M?YS9RZI*-KSIKK]!T3+F6NJV*<R&Z$S*1Q-A;6YZ=VTC2Q0Z)A'E'`+,'H09
M^,^*?I&@[C0WW0EQ5=9EC5ST/?=F5^\=4K;:FDML^L^E:=K2MI!&+]M,I?))
MFOLRBOT7-C1"9,CTK]YA"?32N2EGFGKS`T*%>%V]X)87$-M(+QI%TF7`!CV_
MU0UJZEVFBUC2WINXYU8O:Y,V$:2[/\-AR",SD373R%I4JAQ%<CTX*S%(E!A(
M`[.^1^&HGRS>_<=RL;=#4PNK[N9+&CA$=0.2=PB$-30*/#?H8M$O.-1)"'N^
MG:<3,PAM"2C,<)8I/&#:@PS>!?O`8#`8#`8'F0^UD_LP(5_C3YL_K4OP/3;_
M`"/YO[V!]8%1/('_`.!?;G^$3I/^YJ:8%`_LXO[$[@;^SB;_`-\UE8'=O@,!
M@,"B':?D$J3A8,>.MJ,6`\I9;5M_6'%SX4V,[F)_?J&C<:DXJD;$[@]M2A59
MEHHY"(J+HPAVG6J4)Y9QQ'H!L84Y5>=WE4EB<)8CKN\'>)-U3J;4-?VUEA)B
M<S;3S[3G1\F@I1"B<IS_`([Q.&7HP(W%./0"$SN::GV;Z"MCV'9ZNZ#AZ#IR
M,\J&MDB%/I51$YZ"0/):5!N)DQ"`V!7M<NS8K6B<0N@)"I>K)1&IR@I!D"3%
M'"$<`80`&%&.N/+M1?'72C9S38$`G\@D2F%TO.U[U&I+2R`SX)O:V9/3<.00
MNOYM:<2M6X)*CE45.-<6N(,CXO2(3B3?9#V8$&PW7E[R85YU;T/;G/\`!JVD
M#*JIV=7A7LAE$@MCFLY>I?*&LE75DH6$TS';I?>A&N-NTC1#$W.;E%$2$Y,,
MDP9A?MR=#"+GGS.<X,$-CTH<:\NTQZ7QR^W*65PV1V,.=@UY+:(Z7A_'6JME
M#,GEWN8+!MCI2=-\9B1!*DQ&X#$8K4*4J,DP_0<"=>7<FNHY/#9-Q+U"GLJF
M[.IVK;PJ`E_YI')JV<ND'>(1[G23`D)M\DP6=0JX)%,0-J1<PN:\;6N;EY;H
M4B"F]H,.`7YG:P)LKH.LGZA+*C#WRY&K#?+G1O5N<D%2YD7UASBAZ3EK''*G
M3=#*+>GX44<<BFH+JQL2]C&Z:.WI9[HF4*B@GFB_)/!+ABMTNDFI6Z:0F=(T
M!"NHWBL[()KARD4MH:RHW.)'7]@05YK:P9W#GE)(15P\MYB0YQ2N#>Y(ME*R
M"0C*&,(&J[S*P>Z*^J&35;S/;T^GW1$@-9J'IV%6KR/,Y9,T+-62>W9U(9;(
M8GT0]P"F$==0MQ0;=T$O=6=]+7NJ)(4@--/WZ@1U*OM`'+L:=(ZD+J&]'1&I
MK^*SJ>$C649&YS6ZQ_O:SN<'ZNS:FEURL-F6C9U>6K43TB>V>"MDH-+***.3
M"4EJ"-F!;'I;R9UUS=U7`^1%U;2*86-.ZWB-H)'7=K<V5/&$\?F=D2&L&IN;
ME%]735KI-94%^C9QAC4P)71=[N85L)8AF!!L,5)O+ARK"["[:@,I+L=K^@U!
M$T[FLH!$RU\=M@E*!H03:,T2H2.9BJ>2^LYO*F.,/J,92/2.0OJ)+ZXO:"&`
M/T4>42OJY>ZECG6=+6MQ,XVW:\KJEL>.DI!24=KMK51VD7>]$4I46K';7DE>
M.<;?V9H$QE^Y.!ZU+*1?!RA.7O6C1!D0>3>M7_G#DV^:RJ2W;5DO;[L!AYOH
MB+!K]#8\P<BHI,9\]J7=ZD\X8ZSBL;BT#@;F[N+HL?`I"TQ18"MG'G%%#"$&
M+S54S+;;J:C8Q2-K?I/L4F1HY1$IW/>9JA=:JFD'OV0\WSVM'XFT[WB8)[8$
M7L6,*=Z;88.2&N;:-.J0^\EJ"O6"QM[=\.M%],0WF]9R?>\V^/D$GMG1NUHG
M(Z"*@2N!5&E@:BWI`:WR6XF"?)=UZ=9#62<D,9@K'(PP>V\I6``A8%1G?S\<
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M-PM$BA%.W3<C6D7,T2)2V`WT-T7<?.4ZA<,<AS#2)580G2DGB1(6Q2-,-9&2
MQJ@BT8E5DD!^;MYPJ+:$_83R=3UAJ(OQ>9?:6Q5R.T>6E$R?%?/=E`JJ4C8J
M7+OO=V-3$\R@8=M[P]QYJ:!)3"CCE)(#BO7#^S3S<T[`8%5,S?J0G:M7<$TL
M^*1)EBEY<73-F7!J-C@[W)$J"V8STPXTFZV4_!G9">.00B1BF3^<C5[3M_LB
MM&#"R/6/DC@G*ML\^TJXU;,)S/.C(;-YQ#TFK$Y[IUK;FN!O=;Q]T:G5\Z)N
M&HVE7,%SE:#>!$S-QRYR4Z*4;`3O1(L")Y!YAJBBYS[*'NA^@TG/WQRZ)JFM
M.E?@NN3*VN*Y.8(S;$CLFNHBQ@L05F-`G(ZCY4V1YX>F-M97QU9S225(0FI3
M%`;7R;Y7J<ZRAEZRYAK6QH7N@Z<AU[R5"X2.D[&0/-?SV.S>1QPIFF%'VO9\
M-0SH":OG`#C&G9<V/C4(:82E,`M0`>!']>>9JH)<AK4,RH#H6GY/<"/EB75I
M$YPGJ9T6S*H.P'A_C]46^T.T`M*8L((XC>XV>F?&Y4I3/[28<G]="()X!8$"
M1;[1#S-)ZG<[6U1UT-R$$+H"P8XVF3KEIU2N\7Z-MR/TM"/C9-(]T$[P&D9&
MURR2ICW9HGSG&7%"V!/5;*$6F4>R"TJ7RLLC^G@:"N.5;]NV>2.KWN^)K7]$
M2OFJWUU:4>TV8]U0@G*F80F^'2MK&>)A*HTYA9HY$'E^?E86E<`Q,0>FV2(.
M--_+(P5;/^F8C:')G2L.8.68W`)/-IS[U1$B0R5->$ID<&YN9X+%(U<SG.WB
M4=`3.-F-;,@4-J0QM6*"0O.VT`]C"&D6)YHZ[J->CK^T>:+KKKH/]+<9JA\H
MV>3_`);A9S!J<4[8%X0:P%-R2F_6>@%,`E<1K%[1)E()/[YI_;SFT:8*C1?M
M0M=`O(93MAU#Q-<[-%;.0QSNNR&VK:N:WV/M39((Q)'"`6I86SYVD$_FHD[&
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MA%96Y8*_K^7,%><[4>PH8:@M.=SN0M\P?2V1:HD$Q::^BC>QQ.`/+TZN;B]D
MH$#8W&CV8,W99)@51L/ST\PU1#;&?[!I_HJ.R^J657\=*D%&H,Z6&GL*+7ZV
MT':%5,B5FG[@PR>3UD>_M<K6JV]>H:%<,=$[BD5';V,@`782>0JDE?-?2G5Q
M;=+QU%S?-;@@IKDE1M"]=;CM3JXJ-KAU"E0O*@J1E32?[,CK``\Q(<X.Q>B_
M4``PL8@K*]^;;DJ-M=!.<@8[691=%\O7OTC"4#K'F1`M:'KG5M7*['YUF@5,
MC+(C-]I72/O;0G;3C-MY[VQJD.EGM]D`.#;J]\L]63NWFJO5-'7M$Z_D%^Q?
ME=CZ!>R*O55>HZ(F=(16_8S6KBU,EE.EHLHGN'2]*E3.Q\>TS&/`@I-J@B&`
M6PYD_P#+IS15W2K;S+/6:PXY(7:_)SS>DG2YNCH*[)LB'T51=YMA+H\_&3WY
MH:)XGZ"88XS*5"4`3I,9[J=HDLT@\T,?<?ENIVHZ;XEN(=9SE^1=W1$,SJMB
M=IW0%1:C#8&K&VVST]BSB\[?K2L(ZYEQUR"060![/&J7!V21[46P>L&YR/R?
M5''K_L#F(%:6\^W#7_+SKT8<SL#7%'-AE$I8X>@L1VY@A\N(EFX\_=%I*]?&
MM^TUE'_!IK.YIU0%PBMB$$([5>8BB7YSA4;I"KKEZ"F%JQ?FMVJ.-UZC@C=N
M?RGIZJ;(OV+P(I^F\WB\:B[S`J$K)5+Y6J=E:-O:6I<@``Y0K5E)MA"%C>?G
MG&M?<B'JC;WT]-$&MN96Y#W!\YUB$VJ1PHBW'RE[7KHR.SJ]8P9;%G,,MCYQ
MJ%E@QLD5/K<<G4M^E`%!?I"]'1'>;/2LZA=40&@[QZ6MB54])NB76O*@1P!H
M?(3140<F5E=IQ)#[;G=;-8G9R?GXIO9X^D/4O;JM)4`+3A"08/00O0'ESH[J
M+I!JH"CX/*I8W.T1JN=)K0<K`H"&(%46N"A&#H>+/#'4DQMYDZ&EJ-'#9*F3
M.9C1$5Q;:XA/+/$`M.<8`(FL+SI\Y5A:-^UK+*BNHL%$KNIF$V3M*VEWLJ;2
MOD.GE]Y6BRLT&;[:-M:.MBV#-AOP0^OS"UQY:X>HDVM+.,+"(,E7_FOJ>T4P
MHU`N=KSE]Z.]FP6JJ]I*'2CG"=&62_3RJIO=A+@P7-!;SDM`MK1#*SKAX<I.
M%RDR->P:)(*4)?;+40#PT^;^?/FR!*V-*^4E?R<Y)'W]WN-K6G4>QRJC7F&=
M$O7+TX@C]$)#<C2_67.HO:;$:';;!2I0>X-9A*U#I24<7ZP3GORY50G?QKW&
MA.D$U#OEA7W3E3](((O"Y#!;IN/FYBM)\L2O('"H_.W*X@KG<=*2EOC"QQCJ
M%!)71G,3I#?2<D$H#3(QYJZ)D7&MB=G!IVYE<5ADP@<&BU?0-QIBXYS<THLD
MI@51J,U.?4=KS.)/4S;DKZ+3\Q+7)O>(^>W+2UB<'L0C,"^-+=>U+?\`9LKK
M:M#'AZU&J)YTZ)2372=!J&2RN.GR[*4UJMC"TIQ.<E2L2&L%BA6$Y*0664J3
M;+&;L1FBPU-9VI'6GL2+\>R"G[ECKO/VZ;'UQ;3PU0\FL[`<JVA$3L">)HTD
M(F:BR!QV-LDU0I#9$I8$\>,?O:-1:P2P)99H?O>_9\6Y^OKG:C)95]INQ?2$
MN;:_BEG1Y+"SX.U3E](DRMHC"QO<9HVV#(%I+9$%S@[FLC(Z)8\U:*6N1J=.
M;H>@REE=W\A4[/9E65I7Q"H'-:_@3_9LO:9*)U;4[-"HK'T$MD[J-[.;-,*Q
M1'8HZIG5<B3JCEZ1M/`J-("0+1F!7ZY?+[P=3].*[B_30U3Y-LV>(6*#0A,L
M46#(GJLY!&XK-V4N./:=E-C:EAD$P:DAISV)L1B4.:,L!PAJTVC0L!=O:%0T
M7?O,/-4C!)'RU>JI@^QB%M$6;"7))$FR/PN73%5-;&7&K$I,7BSAN'GMK<(7
MM%3FX[&!*2:6D7&I@C_N#R$U7P>@:5]E0NR)EMZJ6_[@0HZZ;6!R7&LG.[3!
MW:4LQ:=[D+%LZ0OY4\2%-1(-B+..+,":85_$V,/UI[OVN^DXE=<KYG@DZO+5
M2,U//;,UQM9`HZHMA-=54Q*WHTGA+E.YE&&%K7-4>EH$KH2_JF<Q$YHU*8>O
M:%_="H,1\YG-RF"5I8UR5S8G,L5NJD.@+[IYQO&9\_L9%BQ'GL==I7IE8U#)
M<;ZE*G4T=+"TE8652,A>L&V*QC+**T28:&(F'G=YZC3C"V-!4-G.+U.'14V-
MA4JG_--+L*3:+G#FGII48Y3B]+RK>$)CPPSJ-C1%I-.`EJAS0KPE$C))+.-"
M3H]YB:8>NL$O)JJHK3;)*IO1BYO'*B9304C3HK6?Z8:+P3A5UK&+D=[P'6R2
M,NX4JB:)XPHBI3@`0-KO9:V=H-XD_E+K>&]%3ZCI)2-X(877'0=:<JR;HTDJ
MLEM1MU]7#5\)M.MX:N:B+'W;")ME"&PFEJ+>11L342]+2DYQY8!;."$259YN
M><;6L^LJ\;:VMF.(+`HZM[\<Y9+U]1L`H1!+-I-;?3=)'"O%EG!M>9P"+0YO
M,12"51=C?(\S/W_H#U7K@.&4'.??,1&8G1*/HB:<?=2P.MINNYX,HY_G9U`Q
M*/7+&>GI:&(UE(4LT=[N(A%7*DPSDSD^-<U<8\X,C.N3*E)>@B-"2&A:\[M"
MK3ZE:6:E[',D=J$WCLMNEEO<@5C'695S];C#2\X3-5HV1T=%ZEM0IQEDB3FL
MA\,?)`2[MVC5!`MZ(/"6$N/WE@10JP.A(/87'O1\)1<T2&B8W8TR7R#G-XC_
M`+[TQ9<;K:DCF5)&;P>I&X)9B;(].8]^X@$VH4QH5@2%.RR!AJ<C\UM)Q*'O
MMKR&@NC6ZBW6'])ROGRYA--9J8ST\IY7C4QEUB1JN&)%92F;Q9YE$;@#PX0_
M<L;&%-)4#>:<2:7O90#`N/R1WC2/:JV7AI+XQKV2)5[15CBD;PB;T"%R:[ZC
MDDD#*REHB7-6[M4KAA\46MDA;EZ=*H;'8@Q,+0AEF>J%U,!@,!@,!@>9#[63
M^S`A7^-/FS^M2_`]-O\`(_F_O8'U@5$\@?\`X%]N?X1.D_[FII@4#^SB_L3N
M!O[.)O\`WS65@=V^`P&`P*G=5<7TEV.+GT=SH7Y7OFGHVN>GZY^`'4EIT=8=
M9?"GP(UR?1R!?I[@[G\+"^$FS_M!6Z**T(P.@?="E:SP?<5'5O(JM;#[AC<9
MDK]UY(U@X_-V9*Y)''L\,.3V7\'*%,06IR$T3:H"TH8N6(DP+6C1@+.][^Z+
M`E5;XU25T]@5MG=N]QZM^`1"=5TDM`N8<_!E#_6]@RF`S1Y@4E2[YO%%E3`D
MD=<H%"0Q,VI'`KUS@C4F`&$(`_'JSQ44#V!<$BN"R)_>4>4SJJ*\I*RH1`))
M!&>&6)6]93J96%&V1X4/=;22>1Q4)]GKD%2NC;XQKS4Q@`!.`(L`]!(G.?`4
M)Y@M.>6-7%UWVJC]A6#<MGO%-RARJ1SK%)+[SG3M8\S6-BM%3[5:VDB>5O:@
M]`F4RA22G"+0!!,"`/H#0W[Q-<@2*1]L2I>RSLEY[O75D]6JJ:YJJ:#8-)ZC
M<TDLADLI)2VI$JVMY&1:#>GF2I06:ITLE*<M8:$00Z)P,BT^,6D00FUXW.+%
MO>W)G>5M\^W':]V6/,XPKM>7OO+TQ@\UI6-C41>#16",,$B2^!IR`M;4PH2S
MB5JXP8MJU9JG8860>+*I'ZP>G)F7=G1K'&^OE5B+[SJ-F?*@_1W(E]GTBW4%
M)U;:M=J7=;0C^]PAE1&IRDDD+3E."0!VRQ`&<4:&VT?XVZ;I.(7)'#+$O6W'
MZ\*5BO.<JLNX)I'GV?L]'0*-2^,P.M88=%X7#HI&8_$BI^]+$^RFD2I2XN)J
MA8<J'H'J!^3]XSJ`/K'FB`5P^V90DEY'0(F^D[LI-UAL8MQG)U6B2HY-N2+'
MB"22!SC](,);TY+Z!W8%A2M0F(4E@)4)R#"@APGPH\5(F<21L)M1ME22&5$P
MQ:UR9LA67!`I[3=XVGT:S7_";%=XVY/[->DLMZY'YRDCKL9J%[)5>Y'H=HMF
M)S`GZZ.`87<71\=ZH2W;?=36NQU5&*97'U@OJ'<?E$&B4]D-CM21]9[*IVR-
MI7#XR2A9LQ4UG-IPB!A!H0?4"+05N_V,^"#!O#BKCUGKY7.&SHMGN*<JK->=
M2V\V_J!P<9%91=F+DQ*=$8I2SLYNDC,I94[,I:GU@:U!1FPI=EF!-T1\:-1-
M<QK*Q+,MGHGI*=U9:DIMIFD?0\^CL[*<WN3T8Y\]`8W*)-T&C<";(HPP-V-/
M2I65I:3#WS>W)<:L5C,,&'[J/&A1B?GGF?GV'36Z:UWQZ]D23G2YX),6)ONJ
MNWKX!E<1=5!#XZQ!YAC\@DT+G#JSNC<YL*QL6H%>PC3^T+)-+#ZH#QB<P<[V
M2RV['$DSG5BM<`DL,7RJVWMIG[O)Y#-[PD_1$YN&0KW"/$+#+?E]H2]:K5N:
M0Q(E*3>R3)4B<@@D``L':/,%<6Y:\#N24JI23+:ZJ6^*88"F=V2HF8R(]$AK
MH,].<41K:J/4O2?58-OP:>$XL"7UC_7+-]H'U`HW(/"[R0[0FO(6Q/5O5\*K
MJ8Y8I2(RF"OD`028IJX]LY';=03-XT\5J^1R26"*8("AO"UP;E*5S3A]F-*'
MUA;V%HUW$D!E%44_4MGV':MO-E,W-'+O8Y'.U-<$2&22**NKVY-4=F:*#UM#
M(2ZPC9+^>C4($[.D&I1ZT$TT0]C,&%08QX1^5ZR@T;@M%6;T_P`^IH]&KMK@
MZ0U):C(VRN1TO?-C+K1E=*R)VDT$E0%$*CDG<3MQM<G)2RE@),'I*[A&:<88
M'#E?@AX#E,L02T$>L:,GL30NCT69XO,T:%BBC`?4G/\`2C6SLB5='7)5M+%X
M-SFT`;1*CU1Q"IS=CA#,$L#[$,U/O"-Q-9D*LR#3$JU7-OLYR8WQ0[?')H*D
M4,D,?Z4Z`ZC12"`.X(I[2/.JB;=,RMI5"$%04JBZL#<:`6M&FFAE'SP]T<_Q
MCIRO%MZ=/%U-U>\WC);'JI)(Z:(C#7)+_GZJSIJ]0]\_0<.QV\]#,UIBIL3K
M7UP1)M;T680<6$(=!E++\4$!N&KCZGLGJSL64,#FALB-28X^74>VD3&O+69H
MPS2VO)/"F.@&NJE[<7\5BU34^`CQ4R8E:I6)N>DQ:@PO86A5<44$NMBA;>7Q
MM0Z//-M(2^@:KCSX:@DD3:H1,76J'94O6(9&VNSJLF#093C24A=-+0'E$C5:
M'[41_K!"K#[X?>:Y&Y21([V'T8IJ=SDW05A0[G?=F-7Z$*AM;IR+6-%+6M.L
M8^*'"DR"5*4]P2I:TIG1W=F)B<W]8I0-Y`Q%^S"9:>\<G/%"-USQZJMS:)0N
M_P"GX14]GP%L>VE+"GEP@U>J*J)N-"PI8^0F8[IE=?>YML@=TGL4ST!I0&J$
M@E"?VH@@JNO#;S5!&^"D.]E](6H]5@#FEEKR76?8,4=)%#JWY,<WY[INH6(,
M:KR*1]'7K<\R54J<@^X;=W<[90E2\SV!&BPUL7@\X\;*^8ZXK^1794K.U5SR
MY`W597$D@#8LG#YQM.F.?4!<D\;WFL7Z+2:[8HN9/@]6^FMVOAAF4F(UY"@H
MM)[L$G2GQ85U+MQIU<.F>PVB?-U<R"EIO:L&LR`UI85P4>_S95/P5)8#C7-3
MQ5E;H_')"Y+ML[I%T$<E+82Y+0D.H=JCA""8;5\?//5S']-FSPB<+@=6US1%
M;V"4@F*QI-CR7FMYF<FIZ6UVZMY!#]%YY$Y7-#'4MS$K5"VX($9N@:]D,)H0
M<E\07+3U)DDYNY[M;J2>GV$IG\VEO1;Q`YN=:)6J`L7FMA@,ZC#3748@(ZWB
M%<6J^&-C8U-#5LMZ6F.)QIZH9@QA(<C\<5=/W/G,G/B&\NF(LEY"G3//:,ME
MDGD/<;GCRV-PZP*ZC3.[2F9UU+&.4,C#7MCK64GW]J/6&HR$PCU!R@!AYH1M
M.O$G4%@-5@$._0G62:36X]$O-NS9%8%='.-JA'0<`YT>&R?PIXJ1UIZ1(GN#
MUJUK-&FQGWUI?`FK6D]OV<87L)"E7B^YCE,(F-=#W8[+$9GP/'?'`I;&>8@&
M8T<YQ34F`Q[9W![:7EQ^/Z0B5J"Q.RPU9HT)96S"!#T(0PCYU\4D/>$M3*%7
M7_:*6:4;)9Q(:MLUBE7/T8G,32V/7:6L)C&4AL:YQ:(RH9':,)`_]X]L-=2%
M._:E+0;"#0`W>Q/%]S[,JDY)IR'2:UZ/CO$J@9]".M6O4*7O[/[Q64BJ5Q+D
M@K=@%K,4N$[1*5+MJ3UR`U4:O/VJ]KH[^-@:!47B&HSG^<P.<T==72]9&0NO
MZ9K1RCC7**HDK!84:I"23B51H,S/L&FIC*$RYZ=;)>].9C"Y,83"%WLDP4H"
M4VB0_"+>(>IHE5$,IUNZ6[!/BU.3"*6#S4M5V!5I<BY@FT0'+4J%_I]X;*7;
M3%&W2,SIV8G)%*@R9M<61>:F.3B];8\#+M'A[X_22:@9Q(B;+L.<4)-^H++U
M,+`F"%^>[BL/KZ-?%:YY==FRH\@;Y4O6(24PVI,@3M+<RF(DP$B8L@@!.@V9
MM\5'*[?Q+3OCX.#9+IS-4$NB4O%%W":!"\V@=$+#76PE9+7D#:T-RN0Q]WL5
M46ZN!*/3::H4)"0Z-`6$8!A#3SX+N$'N!6I5*IJM(-76;#;7A3=`-3X"ICJ1
M'<%F5[=,@=ZA5.3&OD$:?V>WJY3R1K/5K7("5R<7#URS2%0B`A*4'\4?/T'N
M9OMLNPK]DC,SW6Q=),U'2:<1D^D6R_XQ34>HF/6P"/,\$998XR)E@482^ZIE
MSVJ:2'$/O@$85`"AEAS+3\3_`";=$TNN:60CGLD.OW5S[G[`HDZ$N.^VO&HN
M>J:DJV/IR6$#FQ.D=8>9(NXL"PE7[TTOI1RTLS8Q$A("1FSQX<ZHV;B*/.B*
M2R]EX&@[E`:7;)JM8I(@?6ATJ1'3!RRS4*Z."1RMY)BJ$!Y2@DM!HMQ])WJ^
MKOV>!&C?XF.26OH-!UBA364GZ50](/O2F[D#/5>Y0M>)%&7"`.%7+$(D6XMN
MFM5>M+BQ326WEJRV-$E+]\V>3I1L-:B/AWY2K2K"*TJ)\NFHW)AZADW75=VQ
M!)VUI[4JJU9-%EU='-L&=GR*/L9W6S74CB=#TD;=FEU:PQL6DYI9IH0GA#75
M?A)XK=FAV22(5OR>3O-=2V)*K0?YZC66JFL69WVIZ;=>F66<%QM.Z1WI!+=)
MX79"^M_NR%"6G)1DH`HB@I]!8WH7@6"="2>%6*=<W0].V[$JFDU%.=OT9-XQ
M"YW8-0S10RN4H@\Y$ZP63QE2D7R!B(=$JUN;6UU9W$1IK8J1^V,"(,]S1P'S
M+R3)9E**6@X&99+6NHF!"0Z_![V&"1NDZ2AU`0N.0)T6-NY*S-`X!"$GOX3U
MZLQ:N-4'C'Z3A!P--5^,_EI9`NSH,9''0M5W8X7<KNVQ2-QDJU4Z&_8TAB\V
MC<*G>HOMU9(LC0MY9K:@4^_$I5.]C%HWTZ#H(\=?$GS44[N\BK*57/0,@.M6
M%7Q"W*D)5%(@GJ2[HS5CS2,ML^LHXN@C[$&AYO*JGH31/4"UN<&*2Z(*5FH"
MW#1BLP-HHSQ8<FT/9D8N)L8I)9%DQB%22-`EUSKV&R7MVELVNV4]!SB['-S=
MXT!>1=$OLV8K5*MW0&HB"DNRDJ5*G(()``-5*\2?.H)>8ZFV-TJ;6[9/+MMN
MN.?4UPGL5.TK</0C1/6BR;6J0N,L3)9<7F(MVK)UK+LV2JT,9<GY6K:$R(_V
M(R0CQL\(''BQX$^VU(KUZ#<G&R8S:TP,MB=1U(18<PK^II)3-8.,Z251!JO2
M/2VN(E,W@Y"O"`EU7.KD:L=%;@:!/[$)#H[Q357S5.8=,*)Z&ZOKEHB$-K>L
MC*V;IW6SU`)55-/V#:4^K"L)01+*AD$K-B,()M]W84.D+LA7@CVDZ82D9I`5
M&PVF;^.\EVZ#OGJVONH>C:\O*\:K;ZB+5Z<ZTE,$K*+,C;I)'4M;QY[K0R51
MEN8WPU1(-MR5_);W.0J!JW`I3O182PEZ]N,8)T/;-16C/+&NM.VT_*J]G3=4
M$=G"-OIR4S>IIDHG];RZ3QA9'W)X22",RD_1QBEC<F4;PE))1.WOZ$DM,$*Q
MW_X>^9NE;GM*[;/G%]K7ZUHG.8:ZQY'-XON,QIDL:FFNCI8BA0W>!N\JC[4M
MB;.2L):M.AK,D?!J%Y*,!RQ7LX.!;WAJY?N"2VI*W"=]!0YVO%\M9?;HH+/8
MPVD3R-W`^5#*I+7;H6\P)_&AA;?*J19%[?I")(Z$#VK(,6FHU9J;83S?'C;Y
M3Z(Z`J[J:<124-=_5'(XA(XO8\+GDJC+@K,KUELAK@;5(6A.XG1EY9XBX6DZ
M.B,L:+1NEXM:,,,2&JTJD/GH7QY4YU%&:MC]R32X9$NJJH+%II!,4\K86Z72
MIHM5FKQGFLJF2U+$0MCA-G3=:H56E21(A2EJSU(@IM`,`66&_P#-'%-%<D3#
MI284DTO$=,ZGN$Z\K&CI[D2JBS7/%S*B:GHZ$-9:%,;'6=^6IC7-2CV<H*"X
MK#Q$^Q)$`D`0,U>*'E-LAU.04\B=OS#1G,U^<J04N2O,>>SBJ[Z,=H6\SI[<
M1+(F(@Z?-JR"(M-#F26G"B+&<$1)OM/XH1@H\+_.:*0PZ90*W^E:MFL&4KCF
M.5Q"4U0[.'N[IS_SMS:Y-RQNLBF9]&U*197W,$9-$+W$*@#GM8>`T`%&B2PE
MZ.^+KG&+6ZT=!M#K9A%^-709W1!]S`?(LFG[\\/5,P6BY[6<B=&Z%H4SK2=F
MQ"O&]4]1L1`4WPV#X01#1GE)MD!QY#XNZ*EG1$RZ!D=AWRZI)[=\#Z4DM$&S
M:-D4*OO:KZRB=5UY9"B-HH.FFBQRB+)!FE:E0J7\]HV[H259B0P98-!"-&7P
MP\LM:RA$+E.>A9G6?.S?5Q4&I*=V(PRFL#GVHZH,IF,RA64X0?<V8%#I"QZ^
M'&>.O;'%GY>':M<U''F'B-#-QKQ#\^-,3C,`E=L=/6[7\`D?-[C64!MVUFR9
M0FN8=RM.Q6!555,$5'#$+&[0KX2]FB>%KX0[2IX9TY")2\#))+UH,(D\.%"1
M5\@KY45V=,T<.KF.XX36;57DBIQS8H#5=U6;'K>?:@BK3:5(62E:JYB<WC2<
MR-I0:]Z8T/I0$*/<@%$%A8NQO'U1UHN/0KK*7>R!N'3+ORH^V2I021J2B`Y<
M>RQFF=5'1T`HX<4UA<'IC)V]!&$\*XH0PEZ3^G6]!7%R\+W++VUOT.?)]T8\
M5+J,=#1BI*47V2R#K+FX/4#9(F.UWJCV\N$%2!"]&,,O=F]D%(G*1IHV@<U*
M9L)2DF>IH)VJOQ[5ES]?MC7MS[*I=5AE]74U75T-`&\;0O@UD.;-4U@U\4P-
MC48V)SH:U/DSG>IH[;3'&C5R-%HP&B2CSB]A?[`8#`8#`8'F0^UD_LP(5_C3
MYL_K4OP/3;_(_F_O8'U@5$\@?_@7VY_A$Z3_`+FII@4#^SB_L3N!O[.)O_?-
M96!W;X#`8#`ZX?)1=W47/5:5;8/-LGHEFV_WY0](2]MNRKIW8@%>^B+QK&E8
M](8ZJA-O5:)GW"#9JI<5:90!=\*A++(+,1[T(P8=<3]Y@^E8;.)S4;W2C.\O
MU>]SW#R\XWB@KI_9.>GV+U9Q!-.ABT*-R46Z]2AIN-VL6+`$-O&0I;B8T,9>
MC1*PZ4;"P7(G=O6UF>/N]>Q+MCD,02B,<I)NAZPC8*+=J?B![B924DM(:3X6
M.ZDOAVL>$FN*9$04X[)B"KW4(AB3>N?ZJ4*""\OODL:ZFI&:RVCXLR-5YV=!
M6J%V8W\7=`.TBE,(6<:7/TY;I=>\EG](-UG3\-6OE;-Z(B4)Y&F;GUH7J5"1
MN$8CWHT-Y)\PG8\FHB<WF@2\85L+F7Q\TGW;;4)F"R6RD'3:2Y#[B=FJ(T#+
MHY:"1MK=E51"J"$B=Q/!.3")J_DLYI9ND1AJL,E;GF;Z2A%M]X56PLG-(M<;
M458W0;&Z/*2?G/\`:"9S9:;>('2AL732U`W,=E\WZLTPNW#DSJOV'WV/[3(F
MS;DI`E#;X]Y.>ZY&P=X6&VQ&C$\7YXGO6=84LCG5>:JVKY3+*6OPZE:Y0RGI
MN7=>%-JV3O\`L&AGLYT+C"%Q==Z1%O"``@J=A9RH/)TZLOCZZ\ZNZ,VQCL'C
MF46M"I[!D%83"E921-XM&8I(*\J^9UO))I::5@LZ:*9XR(@`8)7*&-;MU2'(
MU^Q'&)DX=:L@\\O1*OGCG28QAJIO]*.GKM^(=A+ZXH2Y>CXG$7OD*(PF?MTK
MJRNFBXZAG?Z+IY7T[;)`>[.3@I&VM2\)NRAA*,%L+@\N>1GN'H;K=LJ!^@]3
M1*OHS`^-I+:(ZUK)3=K$C?>A.;XM=4W:B.A4O54+C[*SI'QY.21YQ;8;+DJM
M#LDT1A_K>N,).N3RZ-E7^5VL.#P!K@55.J2%5A:,M=#),"P8YTK>$5FT^I=@
M9C4HMP_4'*8H<TMCW[WZJ_3S8+`$G82_;:&&%D'D?Z5E?C>X?Z9IR,TZZ]"=
M1CJ4V<0%I*;)@[LC9+JXF4\F6J*I.5WG3CM=$Z9AQ<`B8O\`'%$Y[9@N"XOW
MLQ![J<%6U?F>Z*E=/6ST363MR/J`\D\H<U]"VO$91&K>;)'U5(+G*EI\OC-`
MJ)',(?(:;:FI=#E,9CPGMBEBQ?.-&MIX/9)]&J`M[Y0O+FA\?]J\JP5$A@JM
MNG!P;<Z7+G`)-\98)RXBFL)K1Y>8.BCHPI063\-SQ0]I`.@MMQC)"GX.]>U`
M4((85G\C_1=CV7":7@9=!QZ9V-Y&N].,VEY?(U+9@GC-?\V4?;%GU98;K#VF
MS8PZ/+HZKHBS&/.P+D2-8W.'_IM)-GD':"`*V\LG:,=C_(\JN"MJ_ODCJ%P\
M@:,4+Y/I"9H9[$T_&LH_1\Q.:=!/NB'EO>FE_?T*AS>3]G)QHT1Q24DH9H1*
M!AK42\R/5LSIATZ63MG,$>AM!UOXZW^Y*+=V2>&V]T').U:SINQ90KHE^U8Z
M9%7+"WBMW3+!$RUEEITD?V9:E4*"-:T(L(L0><7M,I-T<\JZ\I1>AK*G>X+8
MC;6^4]9=8)$;7S-T^/GBMG2(3EXOB4)^H&>7+T2E/+@1]FC@X<Y>P]Y.T6H3
M`5!-5V^43NR$E=D6543WR;<?.M&7)27-]7SMKI.R$DFFU^6QU;6-.3J%Q)B-
MZA`W7`P\^0:;C;W=]*511N>Y^/X.1C)(;W`00SMS^2_N^IDIY:A3S''7>K^!
M>B^[+/;+SI"<56\SM/2-PEPIKI^.,L:ZRLYOJEUEL7'ZZ=X/=Y?[16:0=\'E
M@,$E`%X.N>E.P(PMX'>^=7VA8!%NQK4@=,OL8ONF+%L"9P20SBE[>O#4A+7P
MZ\JJ0F`9VJL0,YS0<B]KM8I&H]\"`OW?85\H;R7=&6';/-,DE1?.RFD>MNPN
MH^0HQ0L4;)@GZ@I)5SDGOX:>RY_)%TZ<X[*P+3*".'*&4$99?BV1)&S9:U7L
ML>U8:1T'Y>^@*%L[J6D3*BKV8VIR*?U5TA83&V)I:B3OO`=7\WL]M4-.FU1M
MX7_!,YL>WK)8H*Y..]+&\@Z/2%22WZV6244&JW1Y(.^:9@'6#<1/.&[3LCG+
MB&OO(.CL>OJKM9SJ%V@,K%:[0Y4*],!'0ZAW:)*YN\'1ND7F&GLPAU8=JA&L
MA9@`G["<(%VGWDY>0)^Y`DNZAD<-I]OYB66I8E9<P2Y2UOP[O9Y1*'[WA\E'
M9K4IIE(E:V0I*V#TQSDP9NS5!P-ZT!/L-SNGR16U6U^]&4^U,%5G$U5VEXNN
M=H0F=B'WXS/\"[<=ZV;K.?EJ0F5)-N,@8`25V^`3TB<I(2)!OWDE5H@[TA0"
MF?,9Y#9M22&XY72=---?VV[T'6=:7M*:CMZG:2JBY+YZP1<^HTLH=I5;<F4]
M#UI%8*L')%3]'38PB^$BB&DPXH2\"A.$@3?S,]*<]W.JJFVH;25PP>@[BZ!@
MW5]\4C'9JW,Z6IJ]H?F"UV:ZX9"%U@2]4PJJ5?.E4J2TF$3C(#4;6UJEJ,XC
M8!$%A.]\^2#K1@X@\?/0-01.G%UC]1T<U79;[63'C[+>8TS)^?FJV)"[5!0)
MMZ5!.K-@C-)WA.5(532_/+U&X\;I86VN9@O26&OQWS`61*TI#S&&JEI:RN_=
M/!U`1/<413E0OFE&]3\<4UTM*9M%6J0O$<DZV1&NDZ=@1L]6UH2PMB4L*U`)
M02I%@:(B\L'5L?Y8K;JZ1/?&-H!Z!CG%-KU_S)2B6=+^D*X@W2_5M2TM+(:Y
MQ]ULXQMM=T88A9`VE'(@BB*<JQ$HD)S:8D%O1(3QORIVX=Q5V/TT.I(_!9A3
M?;Z?DFM(E<2!VA:"!-4NL:B*NC,\Z8(:97)!MB2!.%PG/4DVU.*8@YJ0A`28
ME$8(\`1%9WD#\@$)2=`0)@F_&<DL#EKJKC2@)C:1-(VPY5M9[-W%)*7B\2$U
MQ)LZ03.%:631ZFQ5BR0-AKZ_D/+>:UC*$V#4C#H/A[\O/2T+L694O(*89WU_
M@/>DLY5=;U:JY?V+GEYBL/XH<.@521*O5V\^2AGN5SL-NV,#>,E6W$1LS1>S
M3%6O>-A#C3Y9?(4/DGEZ^'B%0K4NZFM7GR+,;(S<56+(%33#K.YLNZ^I@[57
M741[AELQZ$-;S:[;TZ`W:F'*-(1G'B0'FG!(3!/]H^6'I6O_`!8\:]VH:[I.
M16!>UQQ%NG<=:#WMWABZA3#;;F,DE\,2,DY<W")6(ZTK68';3(O=GD<:>5![
M4M]Z/2&;V%2Y)]H2N)LY8L.\6B`T4JF\H[AL.!<LPYV)L-&CF?%<"H2%]5-T
M^F!+:[NCR;:UB5'+FAH:3DP431J4S%E+,3:)T=H8=DR;J_L.[NO:SK7FFY.2
MBN=.@.+7'M2H)9,N>;4F,V20\#]5$,8F%\<&+IR&,3Z-Z<;/`["5D(&_:=*G
M]RV2(T6U>@HZC\H/DC,A?'RK2?G*6RWJZU>Y8B6EJCEVQI>Y1&.\93E\K@9Z
M*$RGM6O")*KFKNP&.*E4.1(`M*0X)`$JPP.SA!NS;Y9>PD_=YG.#K%*94UT@
MZ334"H<Y#4L[JR..3/&N+H'T]:\N^DT[WU*ZX8;1B:Z6C/*KL$9=W)5'BAG$
M+E&DZE84%JO&1Y#+EZ,_32S=>"JBO9K7%04[T`-BB<0=HLRLM86BBGYZF;QZ
MR4MMWC4UY4.I4P4_<8F[*_MZMT2IU(W%D;-Z(]L%%*7\ZMX]+T'?[Y4,+HD5
M[L5\T4?1T*]\4B=Y%R+TS(W1)7*YM@5F6=322WNMHRRPY\)71!OE+"WN3L6F
M*2GZ$8%.<%BKH\L=V5[XS>;.SJ^8*EL^QYOT4DJ&X&(4*M&&1](QU_*;?;[[
M0L,(DK^CFL,LV*,U..1&T*U<\H$+V0>44>Z)`DJCPIM)OM#%P-?,UE74SP*B
MUDND7;L^A/+$1=D]B(B9OQ+`:#AO4J2P9>G;GAU>!VS9%5RMI:&4U,!$T:D\
MR92S4_L='>N'9\U=W=*6-V'0M%TU$J>F%!=45K".R:@Z)."\A*9N-V".QY+>
M46D\5+F1"YWO558\YAR:++T82V0+-,!J%B8P]C4%+@KY;WDM[GC/:/5U2U13
M4&L"C>8)J1'9>XGTU:2<B'P,SB)NZ4<K6G'20+235@A>&*Q'E`TE0HN-[=W=
MK6`,)4$CW[?05EH7S3]I6=!TZ"1Q2@H]-[%E?CTK*+V#.:DL>E8S2=@]N-DT
ME[HYS^HWZ^YY+[6J!G@D<0"A4O1O<3:II(G@MJ+V48G5[(#*V/Y>/(2V6"MY
MXIVMJ7NN\:V?.WX8[.]5<_71;4/Z*FO,*?E%SKMLA+#%[P9%-`LLJ-Z4%'9H
M]/;S)6N(21J'K9AI0O9:#?EWE6[J3,/DFLU77U6,4+XF:^OD<;8#Z5D#W%%\
MTYZJ@F6L4>EW0"7JEK5N+MJ6+-)W%&WUVG(6)4^])UR?9OMB@W3EGRM]1V#8
M\%@-QQ"J&UI>NY89R?))&[UG->>+!9RGGB>Z^GI>B>Z)F=T6I((.Z,,C@\=)
M89`X.IC7+V%X/4(40?8@4C"YBKK#KG?D6:^)6R`5&NKV0LR?JAIOXL3J:B(X
MY:&I-!9?79\7+F@5RSI'?13BVI$#L3_^K0H:Y[6C2;7)!IS@C%7W_?*F_NBE
MB21\L0^B.:>F7'EQ=0=@AF"'JR\WUJYQ8;UW(:ADB68%QK<WFBV0@3Q&(F1=
M8![94"M:)U(,$`LD*!6)YBN[Z]Y_KZQV-OXPNFR>L.-(AUKSS#:]9K)`UTH]
MR:_^6ZE1U'=9^[5<UMBL\C0]+`;VJ3(MQ,P<I85Q`FX1.]`(#36WSV]37@^N
MZOG>M:M!7,]Z9YBJ?GYR4U=+[0L-\KBSJ#Z\E-I2)QA)E]4DSR:2M=W<I.36
MU@`\L29.SEJ!G:5'A+WL.R[LCN+K'GVF?'Z?"(Y'GZY>JK4.KFQ"#.>G>4OC
M-[ASW;MQK?BA0J'JJ)DHI`0[UXG2+4:JQW`E`C$J,"H5&%EA$%5N7/*_V7U=
M>'/L)C,3JIDA<EYUY3MN[E<)HV5VJ5&YK;5P7M6%N19QF#_U'3HJH9XBII,]
M,G."PSDY$O\`?="^$2DA(UH:_1/EA[HM;GRH+0D<<IVOWKJOI6J^;*AE\[YS
MLN"496A\^>+D/<;#'.%?3$D5]&H"V"I@-+6@2IX%I1*7MO)&HV4=ZF!$-\^<
M'L^ICI5$FJ.41('NB$7;K=:EJ1"A;6M2J;(?N6K%Y\A4+E"$AJZ'@PN>JFD2
MJ^26B;2%Y=Y.W0E_;56CC3$A1AI8=B?*/='970/;5OT_+8A`8A2]-VJDJ^1?
M%&GG&;(0NH^6JJNAR;EG21_3K`C3/*:<60-$D]SK!Q1KFTA*()Y8E@S4H1AV
M+WWWGRW8/D+/0OO*<OK?D'E^L.G(3&#*1M9#/),AO2Q;K@D+@LBE`.B#&,YP
MA0:D`>N7IFE,!\,7>S)3M_J>M@1;:WF$Z]=;O65%35#'UJJ6]8*Z+9XI;U!N
M$^OEIB#-PE"NI5[J\58S=35)%7!V=)>^*@)U`)4D))C0B#=ICE01!,"SGD$\
MG]G\`(^`9A,XW"7^M+7;9C).QWY;%)`P26$PB&Q"N2W655U&FR?RI)&%;;/K
M'2;6-ZY?)0$(`C)`J-&#WH84EY>\N'D8Z(G?/-;OE9TY!Y9*JJE$^O-%`J$F
M%ME0]\CW:UU<U*V0XV0];TV."QUGB]9IS%;F(,F4?"WO0PHM$!+(T%B*![T\
MA'1D.ZPGK%ND*[9*@=^MDM:+Y5RQ-7VN7=-S1T!+JW2(3[,:^V6V139_D$0A
M"G:LHN'QPA(XFF&@,,)2!(6!"DD\N7?E?UQS\Y@K+G>^+4O'FC@OI=E@$`B,
M\K@;_P#2^NUZB;M3T8.DUP3$H$J;H*S;1LKJI/\`=E+^<6<<D]WW[K@?HU^:
MV\KY9W]^Y^749!H8RPOL?H./6%8E(W;:*RQZ;H#H!DIJO8'':>@]A0Z>`FR1
MN>`NUCNQ)JPR,I!%"(9A^T%LH+7^0KRY+.6>*^3N@J:0U;.[1ZS9(E8U>QR7
M;GQ,+?:N:J>'?MGNK*0B;F:<%K7N*IT<;C&UR1*($GE+.%>0``CBL""I?YPY
M>AZ./@,2@T$=^?KBMWQQUWR/=YC?(E2*9.75C;0MB6U75@^YR8"=JL`ZB[A6
M2:#'EEI41_Q><DZDM4:F]0P)I\;'D=Z5Z4L+GB*7T7SO(&SJKD2T.JXB71,=
MF\6D]([JNV:\K97![412JR+(2R1MFB:R23FAZ3Z8Q>_,ZY.)&:'83"0[V,!@
M,!@,!@,!@,!@>9#[63^S`A7^-/FS^M2_`]-O\C^;^]@?6!43R!_^!?;G^$3I
M/^YJ:8%`_LXO[$[@;^SB;_WS65@=V^`P&`P-:E4,B,Z;DK/-8O'I<TH7V.RA
M$V25F;WQ`DDL0>T,EBD@3)').I((>HU(FM,O0*@AT<D6)RSBA!,`$6@TQ70U
M(+]+@KJ?K%8%TGCM:;EI5!8RHTX68_117`WRPENC6P6E,V>(0O/9U3H/UEI[
M8<-*,P1(A`V&EUGQ_P`GTNQSJ,U#S10U71RT&<N/62P5_4L$B#-/V`I&ZMY3
M),FQA8D"*2M):!]6D!3K`'$Z*5G`]7U3!ZV$ICK"MS-5V$R`0P>JB/`IJG0H
MRS"U6JDN+N,(+/@>MH__`-4C@0UW5M.A(/8;TVJ34W_P3!`V$.N/%7'CN=72
MAUY6YV<CJA<G-XJH:ZF:\5[K=S>9(IF3JL@VCX\/45.7S!8:[&^Y:)T)S'M5
MZ/;^@S`S[MRIS$_H0MC[SQ23RW@?;$D^D;I5T*<$^Y';VSQ6N_#+5,IH3'>S
M1*C-R!0+TFO&Q>E6(WT:]`:N#AWC`$LF\\#R9S=J:V8DEJ"QI9NDZX%(9\AG
MVSMSI%,W84<VMDZ29;4&;="UHSP+]C%[?0_3O`W**<Q\XP6NFVH870U/12JF
M>4M,Y:ZXC]<1%I@Z*;,4A;Y<RS`B+HFDEF#*&F5-"1R3N'L=JR5Z4E0$S1I8
M!A#/BHVEAS]9:PZDK4=GN.U(G"PQP>-"FRX:V,-T*6C62@3;MZ4C60UG1M)H
MAG;V8V)"4HO2246`(10U\*\5,DOAM@,W)'-C3.ZZ)C":`3)MI.N4,HA*:$DD
MIH:FB;\FCI;G'TT22IRRFPM(:4!`46$!&@!#K6@EE=2%-.C;*F=RJBN7!JG,
M\9[2FC<MA<=5(I99D>41A6P6%(TQS<,IZFS$IA+,8C=%&C%R4;2CV4:':4GU
M`@Y-X].#$4:EL-1<7\LHHG/%C&XS6-HJ%K!(R2IQC"IP6QMP?FQ/&"TCFNCZ
MQV5&HCC0",2F*31%"#LP?I#=WCC_`).D#O5C^^\R4`[O5&MS8STNZ.-/U^L6
MU.T,AY:MC::Z4'Q\8X:V,:PH!Z).W[3DHSP!-)"`P.A:"2WFIZND3A-7:05Q
M!7UTLF$)JRL-P>(HQ.:V=5PC^,7NL`ERE:A/.D4+3_&YU]1K5[.1!^$U7H+_
M`/4&^L&C1;ECF>$6>==D-Y\I:*7$ICR2)J+4CU90UGL,^,H6QN9$C$;,4#,1
M(#&PAE9T:,)6U&P>Z)"2?1[,HL(0V5MHNE6;<5VT5'6C7N"ESTJ$[;X/&D>X
MB5:BT;C9I<9VG;2_@,%AN!@CWO2;V6G0X6QJ?:"WZ<#23^0>45,JJV<J.:*%
M/FE(,;%&:;EAM20,R157'(L'U8LPU\\"8=KXBSQ?6]_!J9"802W[%O:<)>][
MWL,LZ\O\V/K.R1YZH"F'9AC0[`,CK,Y5E#%K6Q"MA>H=;1^"$*AF,3-P+(=5
M9BI^"4$`7=2/9JK1H_XV!%0?'5P$`<G,!Q+R@$<V3'HIB(//U5:^-*12_M\K
M4)I#K46]#P0?*&E*XC"H]IH2Y.6?O_N@"+09`O@'A8I/"4@.-N7/=*U5KE]>
M)14+5XTT&7.;L4_.*N)IQQ@1,?4KGT@M::-+HH1BL`3M[V8'0M!920PR(RU5
M%ULIB\>DBR$20F90Q4^LS>[*(G+D[2[L)$HC9RY.>8R2`ECD"]&!8FV6H"E6
MGE:'ZAHPB"-H_P`T<Z1.VY'?L7H>G8[>4O3'I)5<+'6T/:[-D296%.%84\SE
M$SD21Q"N`C(TH]JI%L_1!6C/6T6#U0W4=85L9-'JQS*^A)EA22'(Z\D,Z,BS
M&.7OL!;E[BZH(0\202';PY1)&YNZI04W''#1@/4FCT7H0Q;V$7PCD/E*M(+/
M:PKOFFAH)6]IZ5!LR`Q"I(''8;8):U(:@4D3.--+$D9Y*F-;SAI_9+"3BPIQ
M;+T'0/XN!]2GD;E:<VFSWC,^;J+EET1Y5'%K#;,CJF#O-D,RR'G%*(FJ:YJX
M,BB1H5$9/)`-`,M0$2,0=;*V'>M8&<D?-G/$PMF+7U+*+J&37?!TI2*'6^_5
MS$7:RXND3[6[2IV&;KFD^1M92/;DIV1HE2#1&U)WL_5]J9ZP9H5'TP.JSZ+,
MJ6M3*45,RF.J:B,@\:,K-0P+5!JM6R'P8;:*,FM2E6<,TQ.)-LH1@MBV'UM^
MG`UB(\L\SP&-L$.A'/=*1&)Q5GG$?C<:CE7PIG8F1CLT"(NR6EM:D+*0B2-]
MA`;4^GPH`-`=M$`]ZT;ZNO0'Y3OE3F*T:YAM/V3SQ2<^JFN2F9/7U;3"KX7(
MX-!D\>:O@%C3Q"+.S*K98VG:6+TH2`(R20%HM[(UKV6]@V'ZZY:YGU:<:O$/
M/=*!N:&L*.+Q&U05?"@6%%XXW-A[*VLD?EX673\SMC:RJ342<E.>6`A&:,@O
M02AB!L,:P<@\H157,U\8YGH..K;%ET;G\^5LE10%J4S2;PV3$S6(RV4'H6$@
MQ]D47F:<+PWJU.S#T;KK:LH0%&]F;"1AU#5!D>GT2-K*OSHI:SF_O-H1@^'1
MX^/6,[RM$G;I0YSME-;AMLM72-O1E$+C5Y2@:LDH(#=B"'6M!I\,Y?YMKJNT
MM10&@J:AE6(I4USI+7,8K6'LD))F[&^M4H99B&,MS.G9]RIIDC$A7IG#9.U9
M"Q&0<`S0RBQ!#/JZ+I1?M>)=459K!.D_5VNY[50:-*-N%H.$5,@RZQ5NS6P?
MO4X60HT30:ZC]9<8V"VF$;LG>P8$:UOQ)QO3JY,YU+RGSK63BB?V>5HUT"IF
MO(DK1R>/-DB96"1)5#%'D)J9[9&>7.J5(J!L)R=,Y*BRQ!`>;H02`#GRARXL
MB@P*7JL,*;99()XVQ#4`BOQ7;YM+#9$?*9:A8/@KX*1R.1GR]V&N6%E!4*AN
M:O9HA;4&[&'S"^>:$K=^0RBO:4JB"R1K8C(NV/T0KZ*1MX;HV:S0B.&L"!Q9
MVI&K1LQL?K..(1)BQ!)$C8&XG8?9HDX2PR<-I2G:[/C:F`557<)40V&K:[B!
M\3AD>CQL6K]Q>$4A7P>.F-3>D$RQ%8_-R=88VIMEHQJB"S-E^N`.]!'<YXWY
M(L^+QF$V/S#0$]AT+=Y5((?%9A4,!D<=BS[.792_35YCK,[,*MO9G27/:PU8
MYGIRRS5RHT9IPAC%L6PV=#S9SPUM:%D;:*J!`SM<UB-E-C6CKB()D#?8D`8&
M6*0:=H4I+0`E),(?%HVWMC8Y%Z"L1-Z(E,28`DL(-!AX)R7RU5L:L:&5ISC1
MM?1&X"%R2UHQ"JKA$78+(1.:%>UKT$W:&5D1().WJ6QT5)Q)UA9Q/L%)I>@^
MJ8/0@R$\YAYNM)O&TV50-,SYK'"4-:[;YA64,D2/5>M;TVR1IA`$[JS*BBHJ
MSR)F2."-`'6DR1<F*/)``TL(]!ETU`44B@4/JM'3-6):RKTXE1`Z\3P"*DPB
M&*"$3JVDJ(O%BVH+(Q'EM[XM)T-,04+V2P\/I]!IFA!^$)YWH*M'Y#*:ZI*I
MX')6R/?%)M?X=7L3C3PW1;X&A,=^+B%Q9FE&K1L>V"M8ZAVE+&$C:1A;R=A]
MFC3A+#+1&E:>@!D0-@U5UW#C:^B+M`(&9%X;'F$<*@C\Y-#R]0N*";&],*/1
M1V=F!`I4-R3V20X]$0,1>Q$E["&5+K*N"AV$:5`H:69;9H3[3,!&F8([(.#&
M4,+";.Q!1ZW+#`P]L3-6A+_;[^#DY:?_`."`(-!H#]RYS3*6E:P27GZEG]C<
MJRC]*N#.\UC#')K74_$G'3Q$ZN6(%;,<E4P"*N^O>FQH&':%O4[V:G*+'O8M
MAEX#SW0U4DPM/6-+557A-;QZ31.ORX3`(K%PPF,35U:'Z9L$5TRM:+X!:9>^
M,"%:Z$)O9EN"Q&2<HT886`6@CMSX>XQ>IO+;,=^3N<'2Q9\FE".<SIPI6NED
MNF22<,ZR/3--*9"HCICJ_D2QA<#T3D%4::%:E.&4=ZX!"#L,Q8W'_)]OFNA]
MK\ST+91SV9$37DV=U)!)68['0!M?66"GN8WMB6B7*(:S2=R1M9ANQ#0)5Z@D
MC8"SC`B"1(G3M2P-3&5L(K&`Q!9"X"154/5QJ(L+(JBU8I5:%P35Y'E#:@3&
ML\)(7M:8X#6GV6B":G+'HOU@!WH,$LYUH!QN)OZ&<*0J5=?30U;8FJZ5=>1)
M3:C<S^Z'H--R&?'-(Y0E2!;U1R<(`*@Z"G.,*UZ"S!AV&K1/CSDN!'351".8
MZ`B!]D/[#*;`.C-00!C,FLCBLF3S6,/<H&VL"83XY1V9)"W=":I]H)(Z!][*
MV$_TF8&,D'$7&DKC.H7)^3^<)!$`J61:&+/%*5RX1X"R-'3)3'58&95'#6\"
MEB46+(#$8]%Z$F&^+]E[#M6H]H&6E/('*$YK.&TO-.::'EM05TJ+75_5TDJ:
M"O=?PA:4F<$9:N)1!R8U+#'E0$CLJ*T8D(*%HM2:'T^J8+6PPKGPYQ>]/\$E
M3MR7S:X26KFB,1^M'Y525;FN]>L,)<#W:&LD)<!1O:F+M$4=%)BEM3(A$$HC
MS!#)"`0M[V$CNO/M$/M3'4*]4Q5;M1ZA'[@=3[C`(LMK(:/X3V]A3_$=0UF1
MK11;UOWP&M)M>HK_`.\'T&:T+`QL>YEYQB3"T1:+T'3,>C+!7\KJ=ECS-64,
M;F1KJ^>+T;K.J[0M21F*0IX3-71O(4N[6$&D3DH*`8I+,&'0L#4HYQ1QW$+%
M9;?BG+'/4;M>.$MZ=@LMCIV`-<]92&F-$PQK*;)<B8"7Y$6VQ!,6UD:+/#[)
MO+"G#Z"@Z!H)1E5+4_.C)F;-:KKN7&6-&6*%6`9)89'7P<XA\7<'=WC45EHG
M)N4BD4=C[J_KE*)$K]LG2GK3S"P!$:/8@T.SN1>5;L,<C;BYLHFU#7F2(YD[
MFV'5$&F)KI+FZ+-\'02=P,D#&O&LD"*%M*5I*6&;$H+;4Q28(]$EA!H,\]<W
M<\R2)1>`R*BZA?H-"8DN@,.AKU7$0=8O%8.YHFIM<8='6%<T'M;-&%[>PH2#
MD"<HM,:4C)`(&PE`T$-%F'#W&-@O#/(9WR=SA,7Z/+'AP87J34K73VZLJZ0R
MUVGS\L:U[C'5"I`I>9R_+GE4,H01'NBPY4/8CC1C$&3BG''),$F\LLN$\QT#
M$+$GJ64H9O.HS44"8Y=,$<X5[7S1+)I"VL*9U?$\M7;]LY`4FFA7&_QSM#%]
MW`W(//E#@4Q-8"EZK"K@;)!(U!U08!%0J(?':N<S'NM&&,'::M&,3/7SP:-6
MRIDNRB6M2+9B8)8][W@:/-.,.0+'CR")6!RUSS-HLUS236,VQR54W7K\QH)]
M-G(QXFDR2-3G'E*%/)9BZG#4.RT(-'N1P]B4B,WO>\"9"*XKY-((Q+$T&B*>
M40F*N<%ALA(CC02]1*%/9S"H>8C&7(M&%6Q1IV/BK6-2A2C*3'B;DVQ@W[`K
MU0CIHY9YF8&=%'F/GJDV=A;)1")NVLK95L)1-3=,ZS"F!7,L0($[(6E12.`E
MHR0,RTH(5+8`H(4PRPAUK0?K4',/-W/BR1N%#T!2]+N$Q&0.6N%5UC"X"OD^
MTIRA0ET_K8LRM:EW`E4+#C"@J!&!+,.,$'6A#%O83G@,!@,!@,!@,!@,#S(?
M:R?V8$*_QI\V?UJ7X'IM_D?S?WL#ZP*B>0/_`,"^W/\`")TG_<U-,"@?V<7]
MB=P-_9Q-_P"^:RL#NWP&`P&!T]^89\[3D5653SIP>Q7<3<=U3)]?I#:=+.47
MA[C5E=4]'#IA[539%@NL>K^-JIU:BF*,IK>M<"E;U'%+T4D+.&4,.@ZJ'2^^
MZ;EN]79S(Q^0>K>AY6R^,%\H*@&V(]!M'+#$^+Y*!K\AL.N5L<([]'TB,1EH
M0NY:UPD*Q*X[*`D5LYVSS2!#"4+5OOJ:]+GLRTR&OR+U1X_'OH'D2%W*RQ6M
M;SK;H"MH3&>>>D5-PM=>0N+,I]N-<7!TDOKM%/Y!7H%PU;?HSW%>>C*6'EA!
MSY<'D9K^J;BV>J\@;I'[EXS[OJ'Q_KU%>77++E66=OIUP(XTD%T$QV+*WZK+
MQ=:;>T@VV334IE6&,"0)SHI`O+5ZV')DI/E(C'0MZV&M?NODM8K;S[\KZ".D
M9FO04[*<-Q/DB0&4#6IM`J4H*TKBJ)M9:X3K$;5CY2]9J3L)#2<)-\*$';"-
MI9*?-F.$*:T5.'50+0I6*^.8J&VS$VJ=H8ST@TMC?U]=<ND<B0IR#2T$XE#*
MGA]>6RB5BWLU]:B35'I(6I-##1$U@>4&0JJ^F=[23N"NHC;_`%!U'<LEC!J3
MO)`S517MO<S\CVW1E'J@\;QMQN5JBM126;2".MR0HD+20_MSN2IV%06:`(76
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MNK=O,B6L]\#MR(_IM=5"0E/`B(VAN<E-!SXX:Z&%[&F#LTL+@</(.U8I=W6W
M4G:#K<!]?5];,OBK1#&ZP^LI89LXRM:03J":AY1C;8[T_-Z<2S)_?Q-+XV(U
MKIH\LP1>]EIQ#`'H*P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/,A]K)
M_9@0K_&GS9_6I?@>FW^1_-_>P/K`J)Y`_P#P+[<_PB=)_P!S4TP*!_9Q?V)W
M`W]G$W_OFLK`[M\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,#S(?:R?V8$*_QI\V?UJ7X'IM_D?S?WL#ZP*B>0/_P+
M[<_PB=)_W-33`H']G%_8G<#?V<3?^^:RL#NWP&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/,A]K)_9@0K_`!I\V?UJ
M7X'IM_D?S?WL#ZP*B>0/_P`"^W/\(G2?]S4TP*!_9Q?V)W`W]G$W_OFLK`[M
M\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,#S(?:R?V8$*_QI\V?UJ7X'IM_D?S?WL#ZP*B>0/_`,"^W/\`")TG_<U-
M,"@?V<7]B=P-_9Q-_P"^:RL#NWP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/,A]K)_9@0K_&GS9_6I?@>FW^1_-_>
MP/K`J)Y`_P#P+[<_PB=)_P!S4TP*!_9Q?V)W`W]G$W_OFLK`[M\!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#S(?:R
M?V8$*_QI\V?UJ7X'IM_D?S?WL#\E2I,A3*5JU20C1HR#E2M6J.+3IDJ9.6(T
M]2I/-$`H@@@H&Q#&+>@A#K>][UK6!0OLJV:KM#@KN[=:677]B:9N1NB@/&X-
M,HY+=-(UE,3@20+E\`.3A[B)4$D>R]&^IL>@"]7T^C>!4/[.+^Q.X&_LXF_]
M\UE8'=O@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@>9#[63^S`A7^-/FS^M2_`]-O\C^;^]@0CTJTH7V@[9:'2+2":
MM;A"GA.YQB**#$\F=&X9/I7!8O9-;X8J=4J70SR4ND*WWP96B/=S_:>R&'2K
M*K!*M:B?(I*#9:JM<N.<(=HP.(39.GC32="XG'VQ[:!1^RV&&TE5K$V2VTC6
M)+(&,G;B\"(:42C19*'0S#%X3']G%_8G<#?V<3?^^:RL#NWP&`P&`P&!QU:M
M*@2J5RY02D1(DYRM8K4F`)3I4J8L1RA0><9L)91))0-B$(6]:"'6][P(HH6_
M:<Z@J:(WI0%@L%I5'/"711$9U&35!K,]ELKVY1MV]VVK3I%99C<_,ZI(<`PH
M`P'$"#O7W,#32^O>:S>;''L$NW8R/FAICC_+G*WM`=/BPDC<7=W!AD#N:'X.
M^%?=6MW:U!!GH3;%ZY0O1K>O1O86.*,`<66<4+0RC0`,+'K]P8!AT(`M>GT;
M]`@[].!]X#`8'`=71O8VMR>G946A:F=`L='-:=ZWLD;>WIS%:Q4;Z@1#]FG3
M$B&+T:WOT:^YK`U:L[)@]R5U!+:K*1HI?7-FQ".SV!RMM"I`W26'RQI2/L<?
MD`%A"56%&[-"XH\KVA98_4'KTAUO[F!O&`P&!HS!9<$E,TG]>1Z2H'::58.+
ME6$P)=*!*HJ?-&84ABZ=S-$0%*%4[L8=*P%`,&8`@98QZ#HPO8@WG`8#`8&J
M2^=0R`(6IRG$J8(D@?93%H.R*Y"ZHFDEXF4X?4,7AL4:A+3B?A"0RB1.:=$@
M1D^NH5*3@EEA$+?HP-KP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/,A]K)_9@0K_&
MGS9_6I?@>FW^1_-_>P(NO%S;&:F;4=WJ?O\`5+0UU]+5[G9T5;RW:25ZA2,:
MT]3,V1L.8Y*2X.4:*!M842-O6@,&3H(B3-;V'8=9UTO,(=.).]?BM=?2MJJ?
MH1=$'J2;LADUC,<(3F5)+/5=H\IDM1UX@4N"HST:]F0J5"T0/>_4]7^/H-,^
MSB_L3N!O[.)O_?-96!W;X#`8#`8#`HMY+8=T)9G#W050<LM.G&[;NB!%'QET
M->&YB1P5FN!Z;*[GUH+G)P7H!%IJPKV1.C]HM*(QP4&H`%)2C#QEAV'03`/'
MCW/0">-4//\`GK5R\957VY(K[,I?C"U1TW%)W`+SYI>V*/QV$LUAW?"YHEC?
M-W5K3\8G5K>)$G`I-DQ;JBTL"W;3%!529>+/R`'\1LG/\PY4MRU)F?X\45-T
M,PQ'J"$1^$\Q]&$=-7Q/+J<K4"KM^+,4\,MJJY;$M)WDE%(=O1;.:T*RT8#Q
MF;#T"5OPI)Y+W;VET5<;?8@4B&?\^2KB!Z67E86X+$7!EYB@L4M)Y8JJBEB)
M(ZA0NEGM!I#VWNS9[J]`2!WL@T@7KC#J/YIX&\DS)076\1M9'UBU6/..36JN
M+!.@]T5=$5W073I=NII+)+DJV>2KH>Y`ODA6PLMQ(->'=NK-#(&)Y`PGHF\:
M8I2@#:EG%/<SUQ)&*X?:<MYD10WL^76!%8;7QT14K)73[W2^F-O?+VY$GW;K
MQ#MQ8JT7186DB,*N)E`RJTR62I$11^STVP]$?#S#<\5Y"YTC'0\5:8/=4<J>
M)L5AQ)EG<HLU`POC0W@;]-^I[,Y--91)EA:).3M4H6/3P9[ULP&EZP`0J30Z
MBD'+W3)/:%[R>P^;+NM.=S&_KJE]9=A-O622%4)$./951:^+UI1BZF"9^J=9
M>ZQ:4FZ:E$)5PQ*SK7<SXT#?`&!].PJ)5/CJ[?Y@YS01JG*0G#P[2_PRT;4E
MV56NZ@E;6SR7M",V9!V^<(&M<PW?&'%GE\4I5;(2&LR//4=8W)*E3,@71(E&
M4,D-LYB\<G6;](Z4K3H*O+E;.3VGNWKJPY!`'FZ"(2G0<O63PY`&6HHV[1.J
MN@)TO:(>+II.[&@B*60/&FM>,1ZC8B3##!AU;]@INC*%HF-4]U!(+%D?7#;X
MY^3X-0#4A[.20VT^?+.0]+67#[-==0I%:C1(.BI+?D771EI3KHJFF3HN+9!-
M3F!`E%[T8'=U4?)7>S+Y9Y5=4^':XX"HZ9N*>IK?9I'%U-42'D*0U";'*FH)
M^3N?0IS^:3%988E#J-)*L1";G]LV_@?#P*CM'A/]N<V=;S+BCNE;7K1)V'HK
MIKKMXM1;!FF>H*WG\QYPKNW*TJQ)4D<M!L>B$L`DMQ\:4B!&W+?A%+IN62/8
M33T8]FG$A4"9\GW.\0FD#6S@7K-!Q5%[^Z*D4]X#3]LM;I>$F23*J8(R4/:N
MCU-_1^'0"O(9937(3=URW6,X)VE4\$R(L(E`!HDH=?EU^+7R]SE`RN<F.NF>
M6=&N0JU@Y$HC/6J]A0*+5C')?2FDK:LVGM**I)9(H[T(*LTSG(%R+07]W:2G
M(T9J72D>!-5.>.+RAQ?LABO50GN%A4*>F9A,ELND/2RF4PUHBLOLKR0HA2)Q
MK(RTG1A7,*.MYU4WI:R6D8RT>RR22`GDK=`#]*/\>WDM3\W6C`)2U=&Q::RD
M/CNCEJ(#KBCT5+M"T*X[!@TVZTOJ!6&Q=4VQ-ESRZTRF>`.DJV;!CI:VJ$R4
ME@*5H0%Z"?+L\6UKOG/=K0)30]@6M#*-\P<`Z0YHILB_7`4G<^(RUO-[_;L8
MJIZDEO,2)K6NSDTS$UG:7YZ;%*%5[;:$Q&,].,8;UV?S%V3.>J><;PYSH.ZC
MD$?K3E=MBE;VK9\6,J2KE$&LM8_6"RO\OKCJ2O+6Y\LB/0MST"0O+.3:['82
M=$F:S4YH"1@/#O@88^E3]*V1)PU9.&M8YU#5C.=<JV=EKZ[F*=IE%FJB*_CU
M;ZFRTR.2N#C=!KG-WW'F_3HF>D9.ERSW/9*0)ZP&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P/,A]K)_9@0K_&GS9_6I?@>FW^1_-_>P(]MM-8JNM9HGJ10T);*&QJMPPQ
M_.+3,HWPOU34J5S5&L\A+2)%OJ;)&<)"KT5HSU_9#]7U=AUI=.LE\,O)W;;G
M:\]"I#/.(.WI&]5/IQ:Y#'J[5M["\IZO;:T?VJMH4>>T,U;.PD+^-P/,/7.8
M4Z@DG7I4&"".?LXO[$[@;^SB;_WS65@=V^`P&`P&`P*@SBVK6L>R))2/-`8P
MT*8`)$DNJ^ITS+Y+#JU?'EI1/;36\(AS>ZL!MD6\?'G5*Z+2SG!$S1QO6(SE
M@UAZHMN$'/*YXMPPL!CCV]TH:N$`/O(VN+<HM;=LW0=:%[FWF<TN!J4CTZ_B
MA&></6O_`'ABWZ=[#]/HZV?]=KJ/\"\G?Z7L!]'6S_KM=1_@7D[_`$O8#Z.M
MG_7:ZC_`O)W^E[`?1UL_Z[74?X%Y._TO8#Z.MG_7:ZC_``+R=_I>P'T=;/\`
MKM=1_@7D[_2]@/HZV?\`7:ZC_`O)W^E[`?1UL_Z[74?X%Y._TO8&+7<L3)S6
M-CBZ=>=#.CDR'&J&1R<X9QVX.+(H/!HL]0S+UG*AZMI4'%AT$8TXRQ"UK6M[
MWZ,#*?1UL_Z[74?X%Y._TO8#Z.MG_7:ZC_`O)W^E[`?1UL_Z[74?X%Y._P!+
MV`^CK9_UVNH_P+R=_I>P'T=;/^NUU'^!>3O]+V`^CK9_UVNH_P`"\G?Z7L!]
M'6S_`*[74?X%Y._TO8#Z.MG_`%VNH_P+R=_I>P'T=;/^NUU'^!>3O]+V`^CK
M9_UVNH_P+R=_I>P'T=;/^NUU'^!>3O\`2]@/HZV?]=KJ/\"\G?Z7L!]'6S_K
MM=1_@7D[_2]@/HZV?]=KJ/\``O)W^E[`?1UL_P"NUU'^!>3O]+V`^CK9_P!=
MKJ/\"\G?Z7L!]'6S_KM=1_@7D[_2]@/HZV?]=KJ/\"\G?Z7L!]'6S_KM=1_@
M7D[_`$O8#Z.MG_7:ZC_`O)W^E[`?1UL_Z[74?X%Y._TO8#Z.MG_7:ZC_``+R
M=_I>P'T=;/\`KM=1_@7D[_2]@/HZV?\`7:ZC_`O)W^E[`?1UL_Z[74?X%Y._
MTO8#Z.MG_7:ZC_`O)W^E[`?1UL_Z[74?X%Y._P!+V`^CK9_UVNH_P+R=_I>P
M'T=;/^NUU'^!>3O]+V`^CK9_UVNH_P`"\G?Z7L!]'6S_`*[74?X%Y._TO8#Z
M.MG_`%VNH_P+R=_I>P'T=;/^NUU'^!>3O]+V`^CK9_UVNH_P+R=_I>P'T=;/
M^NUU'^!>3O\`2]@/HZV?]=KJ/\"\G?Z7L!]'6S_KM=1_@7D[_2]@/HZV?]=K
MJ/\``O)W^E[`?1UL_P"NUU'^!>3O]+V`^CK9_P!=KJ/\"\G?Z7L!]'6S_KM=
M1_@7D[_2]@/HZV?]=KJ/\"\G?Z7L!]'6S_KM=1_@7D[_`$O8#Z.MG_7:ZC_`
MO)W^E[`?1UL_Z[74?X%Y._TO8#Z.MG_7:ZC_``+R=_I>P'T=;/\`KM=1_@7D
M[_2]@/HZV?\`7:ZC_`O)W^E[`?1UL_Z[74?X%Y._TO8#Z.MG_7:ZC_`O)W^E
M[`?1UL_Z[74?X%Y._P!+V`^CK9_UVNH_P+R=_I>P'T=;/^NUU'^!>3O]+V`^
MCK9_UVNH_P`"\G?Z7L!]'6S_`*[74?X%Y._TO8#Z.MG_`%VNH_P+R=_I>P'T
M=;/^NUU'^!>3O]+V`^CK9_UVNH_P+R=_I>P.,KY]NY(G,/C/;M\!>0:T)'J;
MP+F25Q<PP.]""6\,C#14$?%B,8M:T8%&\-RC8?3H)P-[].@R-0W-.QSUQH3H
M%ACT;N5O8%<RB4EA.G0-87C7K>O0-;M,("0]J%KU&)!$71W1)I)&%ZI<I9C%
MZ,XE:X(U92K`M'@,!@,!@,#S(?:R?V8$*_QI\V?UJ7X'IM_D?S?WL"/;;B:^
M=5C/(>V3%?7R^1Q=W:DLU;1G%JXT8J2&`^%0&)7%F6@*3A]/M=IUJ)3HK8O8
MJ4YOJ'`#ISLB#-3)RCWR_1&9TDY1P/!?3D>=X[S2]2%^KY1(`5HYJD4CL50_
M6/*BD4[*1IU)+06G;B5!B)0X[5KEFP)@)PS/V<7]B=P-_9Q-_P"^:RL#NWP&
M`P&`P&!3W@X(57,L/E!P0">K"E%KV1*EOJ`T>YRF=VO-9&]+5!@0A$;ZJE?[
M`CUO3LI*244'T`+#K07"P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P*C=3)/=)'RA,T.BB'Z+=20MM1+MEZ]OMEL2(SJNI6T[-UKU]HG%GDNS!%
M;W[,2E*G,WKUR2]A"W.`P&`P&`P/,A]K)_9@0K_&GS9_6I?@>FW^1_-_>P(X
MN*(0^?U9/X78#J)BA,EBSNU2=Z`Y(&CX*9E*4>EC@)P=B5+004D+UZX]+23T
M0P!V!04:2(98@ZJNA(1#$O-/<TP:;RAMX/Z'Q[]20\"V*#IB."C$>45ZM<"V
M]PBE41I`L?MN*MH`,#@XK1)6OV`B$*0C:Y6,P,-]G%_8G<#?V<3?^^:RL#NW
MP&`P&`P&!27B61QZ)\75(_RI^9HRQ(&I^VN>I`Z(69I1^\3V1)2/>W)Q/3(T
M_MU)P"P>N/7K#'H.O3O>M8$Z_2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?
M2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[T
MU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>
M8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^
M7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$
M?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G
M/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOU
MGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?
M2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[T
MU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>
M8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^
M7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$
M?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G
M/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOU
MGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?
M2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[T
MU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>
M8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^
M7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$
M?CS`?2,Y[^7>FOUGPC\>8#Z1G/?R[TU^L^$?CS`?2,Y[^7>FOUGPC\>8#Z1G
M/?R[TU^L^$?CS`R#5>U'OKFA96.Y*J>7AT5%(FQI:K#B+BYN*T\7J$)$*!(\
M'*E:HX>_0`LL`ABW]S6L"*.J_P#Y?GC_`!64I_\`4G3`M9@,!@,!@,#S(?:R
M?V8$*_QI\V?UJ7X'IM_D?S?WL"&NBPN1E#V\0T5RVV\XJJ]E")-6+RU%OS1.
M=K6I2D-CCHP&J487]O<23A`.0Z.)$L+])(3"Q#T/0=4LZ?;%?>+O(7\=Z19Z
M41LW&O4K"QHF?G9WJS4L:FFOYH@99HME[K,G_11DI:$I:XJ)EDJ3&4!V]'NB
MXT/_`&PY7V<7]B=P-_9Q-_[YK*P.[?`8#`8#`8%)^(X^PRCC"HV.3,C1(F1<
MU/VEK.^MJ-W:U?L)[(E)'O3>X$J$BCV*@D!@/7!OU1AT+7W=:W@3Y]'^A_D3
MJ/\`5O#?Q-@/H_T/\B=1_JWAOXFP'T?Z'^1.H_U;PW\38#Z/]#_(G4?ZMX;^
M)L!]'^A_D3J/]6\-_$V`^C_0_P`B=1_JWAOXFP'T?Z'^1.H_U;PW\38#Z/\`
M0_R)U'^K>&_B;`?1_H?Y$ZC_`%;PW\38#Z/]#_(G4?ZMX;^)L!]'^A_D3J/]
M6\-_$V`^C_0_R)U'^K>&_B;`?1_H?Y$ZC_5O#?Q-@/H_T/\`(G4?ZMX;^)L!
M]'^A_D3J/]6\-_$V`^C_`$/\B=1_JWAOXFP'T?Z'^1.H_P!6\-_$V`^C_0_R
M)U'^K>&_B;`?1_H?Y$ZC_5O#?Q-@/H_T/\B=1_JWAOXFP'T?Z'^1.H_U;PW\
M38#Z/]#_`")U'^K>&_B;`?1_H?Y$ZC_5O#?Q-@/H_P!#_(G4?ZMX;^)L!]'^
MA_D3J/\`5O#?Q-@/H_T/\B=1_JWAOXFP'T?Z'^1.H_U;PW\38#Z/]#_(G4?Z
MMX;^)L!]'^A_D3J/]6\-_$V`^C_0_P`B=1_JWAOXFP'T?Z'^1.H_U;PW\38#
MZ/\`0_R)U'^K>&_B;`?1_H?Y$ZC_`%;PW\38#Z/]#_(G4?ZMX;^)L!]'^A_D
M3J/]6\-_$V`^C_0_R)U'^K>&_B;`?1_H?Y$ZC_5O#?Q-@/H_T/\`(G4?ZMX;
M^)L!]'^A_D3J/]6\-_$V`^C_`$/\B=1_JWAOXFP'T?Z'^1.H_P!6\-_$V`^C
M_0_R)U'^K>&_B;`?1_H?Y$ZC_5O#?Q-@/H_T/\B=1_JWAOXFP'T?Z'^1.H_U
M;PW\38#Z/]#_`")U'^K>&_B;`?1_H?Y$ZC_5O#?Q-@/H_P!#_(G4?ZMX;^)L
M!]'^A_D3J/\`5O#?Q-@/H_T/\B=1_JWAOXFP'T?Z'^1.H_U;PW\38#Z/]#_(
MG4?ZMX;^)L!]'^A_D3J/]6\-_$V`^C_0_P`B=1_JWAOXFP'T?Z'^1.H_U;PW
M\38#Z/\`0_R)U'^K>&_B;`?1_H?Y$ZC_`%;PW\38#Z/]#_(G4?ZMX;^)L!]'
M^A_D3J/]6\-_$V`^C_0_R)U'^K>&_B;`?1_H?Y$ZC_5O#?Q-@/H_T/\`(G4?
MZMX;^)L!]'^A_D3J/]6\-_$V`^C_`$/\B=1_JWAOXFP'T?Z'^1.H_P!6\-_$
MV`^C_0_R)U'^K>&_B;`?1_H?Y$ZC_5O#?Q-@/H_T/\B=1_JWAOXFP.<V4G33
M(XHG=FJ2L6AV;5)2QN=&R!15`XH%9(O7)5(EJ1J*4I5)0M>D(RQ!$'?[F\"(
M>J__`)?GC_%92G_U)TP+68#`8#`8#`\R'VLG]F!"O\:?-G]:E^!Z;?Y'\W][
M`^L"HGD#_P#`OMS_``B=)_W-33`H']G%_8G<#?V<3?\`OFLK`[M\!@,!@,!@
M4^X%_P#$6F?_`-%2/_\`;:38%P<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,"J?5?\`\OSQ_BLI3_ZDZ8%K,!@,!@,!@>9#[63^S`A7^-/FS^M2
M_`]-O\C^;^]@:%:C_,8O7$TD->Q<N:3AIC[@KBL7//.3IGA[`3L*!.K,2EFK
M-HP'"T8<`@(E!A0!`*ULP0<#K9[$MB[@<S=C5#<E:LK!HSA'KUZ+M>(J7!36
M,^?D56JOBLPPPUX4!>625J(Z.0K76/+RU"I(2TA4)%BU)LTXL(M^SB_L3N!O
M[.)O_?-96!W;X#`8#`8#`H3R-8\$JGAZI)I9$K987$T"%W3+9!(%A:!L3*'"
M?R)&A).4F_Q`#5*C0E@U_P!1"UK`WWZ>_&/UE:D_.M%_#@/I[\8_65J3\ZT7
M\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]9
M6I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#
MZ>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_
M.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\
M8_65J3\ZT7\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7
M\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]9
M6I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#
MZ>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_
M.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\
M8_65J3\ZT7\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7
M\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]9
M6I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#
MZ>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_
M.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\
M8_65J3\ZT7\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7
M\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]9
M6I/SK1?PX#Z>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#
MZ>_&/UE:D_.M%_#@/I[\8_65J3\ZT7\.`^GOQC]96I/SK1?PX#Z>_&/UE:D_
M.M%_#@/I[\8_65J3\ZT7\.!LD0['Y9GTE9X;"[YK632F0*_<61A:)&D5N3HL
MV68=[LC3`WZYQOLBA"]&O^@=X&(ZK_\`E^>/\5E*?_4G3`M9@,!@,!@,#S(?
M:R?V8$*_QI\V?UJ7X'IM_D?S?WL#0[2E[Q`J[E\QC\37SI]C[(J7L\1;3%!*
MI_<PZ"6B;_>$C>[*TJ8Q08'9YQ214:21H8P$FB#HL0=6?9$LMVRN8.HFJZJ@
M1U>H@_*?;L]AJ^*S9PFK>]+(-3-ET:^?&;X3@$6*9F*<HK,#((ELE2:N7-9(
MA+"4AI1I`@U+[.+^Q.X&_LXF_P#?-96!W;X#`8#`8#`I]P+_`.(M,_\`Z*D?
M_P"VTFP+@X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%4^J_P#Y
M?GC_`!64I_\`4G3`M9@,!@,!@,#S(?:R?V8$*_QI\V?UJ7X'IM_D?S?WL")+
M]7Q5LI6SU<Y/F".&!A;X1*7"`/KK%IDU,"Q&8C=7F/2AC=F%WC2]G1J!JM.*
M=:F-0A)V>$P/J>G`Z-U2"%QB@O*FWL\AF<R'+N-.F2:_F\@L%PEH9?!:,@,S
MJ^5O,@93+FL9,T20<Z<]!3.`V>-E/3=Z#T:4O05A)03=]G%_8G<#?V<3?^^:
MRL#NWP&`P&`P&!3[@7_Q%IG_`/14C_\`VVDV!<'`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`JGU7_\OSQ_BLI3_P"I.F!:S`8#`8#`8'F0^UD_
MLP(5_C3YL_K4OP/3;_(_F_O8$17\ZK&*EK,>V^9H*^7L\1=G1'+W1$>Y-K0J
M;R?>R/?V]&WNS@N1KS2M)3"DB14L,"=L*<DT_98!!T2)742KFSR:&(&F(5^B
MDO'W:SV^1*)$O.XW+WEK9Y0C95,0+74)3;=&EE$L#M\5)<UEGK74I]6E!=TR
M1>2,:D+!_9Q?V)W`W]G$W_OFLK`[M\!@,!@,!@=?W,EBMM.4%*:X>8_-9-,N
M:[/F=6S&&0*)NLOFQC>ZS9TDE9RY%&&LLQS6L,XK"3M#V6J+#L@L"@\O8O:)
M3P`"0_IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5^Z^_RU6)]XX#
MZ8C']7[K[_+58GWC@/IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5
M^Z^_RU6)]XX#Z8C']7[K[_+58GWC@/IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M
M5B?>.`^F(Q_5^Z^_RU6)]XX#Z8C']7[K[_+58GWC@/IB,?U?NOO\M5B?>.`^
MF(Q_5^Z^_P`M5B?>.`^F(Q_5^Z^_RU6)]XX#Z8C']7[K[_+58GWC@/IB,?U?
MNOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5^Z^_RU6)]XX#Z8C']7[K[_+5
M8GWC@/IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5^Z^_RU6)]XX#
MZ8C']7[K[_+58GWC@/IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5
M^Z^_RU6)]XX#Z8C']7[K[_+58GWC@/IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M
M5B?>.`^F(Q_5^Z^_RU6)]XX#Z8C']7[K[_+58GWC@/IB,?U?NOO\M5B?>.`^
MF(Q_5^Z^_P`M5B?>.`^F(Q_5^Z^_RU6)]XX#Z8C']7[K[_+58GWC@/IB,?U?
MNOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5^Z^_RU6)]XX#Z8C']7[K[_+5
M8GWC@/IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5^Z^_RU6)]XX#
MZ8C']7[K[_+58GWC@/IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5
M^Z^_RU6)]XX#Z8C']7[K[_+58GWC@/IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M
M5B?>.`^F(Q_5^Z^_RU6)]XX#Z8C']7[K[_+58GWC@/IB,?U?NOO\M5B?>.`^
MF(Q_5^Z^_P`M5B?>.`^F(Q_5^Z^_RU6)]XX#Z8C']7[K[_+58GWC@/IB,?U?
MNOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5^Z^_RU6)]XX#Z8C']7[K[_+5
M8GWC@/IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5^Z^_RU6)]XX#
MZ8C']7[K[_+58GWC@/IB,?U?NOO\M5B?>.`^F(Q_5^Z^_P`M5B?>.`^F(Q_5
M^Z^_RU6)]XX#Z8C']7[K[_+58GWC@;)#^GVB8R9FBY%+=-1\YZ6>YEO4PH:;
MQJ,MPO9&F^\/+\XI`(6M'Z"O5]J;O0?7$'7[N]8&J=%.)4ON'E>E&-1[Q)Q6
ML7?,M3)O4.,CE44^POHSY$ZZUL6T:9^LU]CS&CT/01*AK5`RO6"D4;+"XN`P
M&`P&`P/,A]K)_9@0K_&GS9_6I?@>FW^1_-_>P(NO!L&\TY:+87$XW.SE<"E(
M$\-E\G.A$9DJD#.K-3,[W-$R%R4P]`M/+"`;J6088W>GW@.O6+UO0=0,NC$!
M*XQ\@\CAK?SEL:;B7I5"L44GU18?1*]E<976<MD4C`[,TK:4K#$7">/+=IS?
M'1&;M?)G=-I6O&K/#[QH,U]G%_8G<#?V<3?^^:RL#NWP&`P&`P&!7*V^>2)U
M+&JUZ]G#[2]YL#/\7$5DQ=`V/*.31(*E2O*@EJ0AZ+&PV/"4KDM.4I"C]I71
MH4GGFM3@WF*50C@U`;1WJG%LDF?\C.A97\0+@HJ.XV4Y7K7W/;&-1-U/A2$8
M]?N@"K/UK?[@O1]S`^/@[OK\L.0/U;W/\ZN`^#N^ORPY`_5O<_SJX#X.[Z_+
M#D#]6]S_`#JX'#7Z[K:DAS@YSWC1M0)@A$H6KX!<*-(0$8PEA$<I46P624$1
M@]!UL0M>D6]:_=W@:VGF/7:I=*&Q+='""ERA!`E4T;T\=LXY=$$P"CCAJ90D
M+N(1[`0$E.8/8U82@Z"`6_3Z-;]`9E@7]MRIF;9'%[+XIDD>>$I:YH?6"$VV
M\,SJB-].REC:Z-UMJ$*Y*;K7\4PH8@"_Z;P,O\'=]?EAR!^K>Y_G5P'P=WU^
M6'('ZM[G^=7`?!W?7Y8<@?JWN?YU<#X`B[V-#L1<SX],#H9A>Q`KJYAAT828
M(HT&]AM7>M#*-!L(M?NA%K>M_=U@?@('=H%A#<.=\;`<%*94M3(!5_<05BA&
MB-2$+59"7=KZ/-3)#EY`#3`AV$L1Q>A;UL8?2'*^#N^ORPY`_5O<_P`ZN`^#
MN^ORPY`_5O<_SJX'`V9W,%S+9!6#QB%Y-0'.A31N!V_IS,;$Z@A(>XEH-VS[
MT-`0J4EE#.T#983#`AWO6Q:UL/Q-6=O$$KU!UD\5DIVI84W.AYL(MPLEM<#P
MHQ$H5YH[:T!&L."X)]A*,V$8M'E^C7\</I#*_!W?7Y8<@?JWN?YU<!\'=]?E
MAR!^K>Y_G5P,<\']QQYJ<7U_L7BYC8V=$I<G=Y>(+;S8U-;<C*$>L7N+BMMD
MA(A1)2`"&8::,)8`:WL6]:U@<)@>>TI8B3N46M/B*2MRMO;W9(O8(?:[RB5-
M3N68<U.:=4W6ZI(.;W,DD8TYP1;+."'>P;%K6\#/?!W?7Y8<@?JWN?YU<!\'
M=]?EAR!^K>Y_G5P'P=WU^6'('ZM[G^=7`?!W?7Y8<@?JWN?YU<#B*P]UH-$"
M73WC5$%4K3H$HE<`N)-I2N5F:*2(B-G6P#1RM4;OU2RP^D8Q?<UK>\#Z3E=W
M*Q*0)9UQNI&B4B1K`IZ^N,X216$HH\252$NUQ;(4A)/+'L`_0+01AWZ/1O6!
MR?@[OK\L.0/U;W/\ZN!K+-(^R9$[R./Q^W.&GU^AZI,AEK(S16TW1WBRU:4,
M]&CD;:BM\]:R*E9)8AE%J0%#,"'>PZWK6\#9O@[OK\L.0/U;W/\`.K@/@[OK
M\L.0/U;W/\ZN!\#1]ZE[!HR:<>E[-'HHO0ZZN8.S#-Z$+18/6M;7KCV$.]^C
M7W?1K>!]_!W?7Y8<@?JWN?YU<#B*P]UH-)]KI[QJBTL5D($FU<`N%-I4N5"V
M%,B3[.M@'MU:@6MZ++#Z1CWK[FMX'+^#N^ORPY`_5O<_SJX#X.[Z_+#D#]6]
MS_.K@/@[OK\L.0/U;W/\ZN!@WEU[5CAC25(;0XD8C7]T3,;$6\PVV&LQZ>UG
MI]T9VD"ZW"!.+HJ]7?LTY/KG#]'\4.\#.?!W?7Y8<@?JWN?YU<!\'=]?EAR!
M^K>Y_G5P'P=WU^6'('ZM[G^=7`?!W?7Y8<@?JWN?YU<#BG@[L2GHDJF><;)U
M+D<8F;DY]?W$4>O4$I3UQQ"(HRUPF*CBD24TX0`:$()18A[UZH=[T'*^#N^O
MRPY`_5O<_P`ZN`^#N^ORPY`_5O<_SJX#X.[Z_+#D#]6]S_.K@/@[OK\L.0/U
M;W/\ZN`^#N^ORPY`_5O<_P`ZN`^#N^ORPY`_5O<_SJX&(+7]MG*$B0JR^*35
M;@I=D2!,7"K;&H6K&$TPA\2)"0VWLQ2I9CR1@5E@T(:<8-Z,T'>MX&7^#N^O
MRPY`_5O<_P`ZN!Q1@[M+6)V\R=\;%KU:=4K2H1U_<05BE*A&E*6J4Z85KZ..
M3HS%Q`31A#L)8C@:%O6QA](<KX.[Z_+#D#]6]S_.K@/@[OK\L.0/U;W/\ZN`
M^#N^ORPY`_5O<_SJX'!6C[G;25"EQL#C)`G2`),5*%L"N!*2F+4F[(3C4&GV
MP6`D!YVM@!L6]:$+[FO3O`YWP=WU^6'('ZM[G^=7`?!W?7Y8<@?JWN?YU<!\
M'=]?EAR!^K>Y_G5P'P=WU^6'('ZM[G^=7`?!W?7Y8<@?JWN?YU<!\'=]?EAR
M!^K>Y_G5P.&I^G4C/;TJR?<:)53LI,1-:93`;A(/<EA*-4XFI&\DVV`F+%)3
M>A//$67H0PDDC'O7J@%O0?TH/=ARM4WDSSC4U>A+2G+4)4`N(Q6C)6^W]R-5
M)@VQLY.6K]V,]D(8=:,]F+U?3ZN_0!=KNMK3"6.<]XT;D8#4Y(E2Z`7"D3!.
M6*2D:0H1ZBV"RM&JE9X"BP[WZ1F#"$/I%O6L#E_!W?7Y8<@?JWN?YU<!\'=]
M?EAR!^K>Y_G5P'P=WU^6'('ZM[G^=7`?!W?7Y8<@?JWN?YU<#^_%[O!T`:A6
M6IRO$R%!8RQ/K#2UI2=X0^L'>MF-[6^78SM`E8?3Z2S%`CR0"UZ1D&Z](=A)
ME,4-'*=^-#X)]DMB6?82I"X69;T]4MZV;S=2U!5ELC>;IH;F>/1B'Q@E>>6S
ML#,A;V9L"><,I/[PI5'GA.6`P&`P&`P/,A]K)_9@0K_&GS9_6I?@>FW^1_-_
M>P()Z@1-CCSO<R)YBTCFS8HKV2`5Q6)'&)Y$\@T@,$%,UG%-KV8`X!@0F"]"
M!Q])8!:VC5Z_].:'3G/'B02CG_O-XF\]C%W2-L\</3[6S6+6#DQJX/!(\N@J
MA6LKV5EQRC*A1[F4E7(B%J`9ZIP,TE:%OLT+2$0]+PDW[.+^Q.X&_LXF_P#?
M-96!W;X#`8#`8#`8#`8#`8%3NOF*2/4/J=2T(E[O&HSTI0<LLYC;$BIP5NE?
MLD_;CE*@3<B(4J5[=%9.-K?5Q00"_P#0-1PMZ%H.P["EMR<C6A<:;RD1/50(
M8@DZ9C]?HJIF[7935&%ED+8K6B*(*TTJ5056WRYC:S7A`(PU.YF'IEJ-0(!I
M>PB-*V%H>P2)K3?*FU?.0)/NR*G=JY<*:@[>IG,A#:,C8Y,THVJFILM:B)'(
MEL7M9&><QN3JX;,(:]KM.JL\O239P`I/.N9/(H@T_L$!MV?/TM21;>F2[7:^
MW1HB3]'0<M'15VK8ZJ_6.(8;,D/60C92DE06XP38R'DDA<@E)=-(PM7J#]?S
M#E7K)F7+GRN+TM63W*X40E!:"%P?ZOC$F;T"&N6U-.&0I8SQAU9!$&J`EHA+
M$S<H,]!9I^M>T$%=W'F[NIAL96WQ:>V(\5ZAM)L54@_.?2$H6!JB'D77'IE.
MW&Y&F0N"R0WLUS*JCE["RMKH<^',^TXTH`HBE9;@E".I1R-VG$*>!5-$+K*A
M:!@Z6Z?FS\M;.BGQWD5G16V7ZU)92<IBLID]FM+[$&VOG*5M8G]G6JDP%+N4
M:X"0O?LMEK@LAS7SUTK%^KDEJWH:_P`M/CM5]'0=XMASM[<BBDX.M"X:1F56
MI*YI@!25#5*:*5W7AK6^"2HFDE:Y)`&^R6>UTJ"$/2;G?R"3/I&7.ADNF,,H
MV4V3LN1$1CH>8-8E]:-?35(RA@-AWL)JY.465NO/D=E3<YDLS5#3D9[H:WEB
M<O7+=\#;.=H7U\S=)5Q5$^LFP'RM:[K0FT;B='>1S5_]:P&-VLFL:>K!-/75
M`D:YJQ6/6,C:I5(22%JU8FD$'+/<M>T>A#/#%],\D=GSOI2?]1TA,H%#YFEA
M[IS5521;I4@DJ*BY74+VK?)G\?4[HN;F5<DZ4DJ)]TSF,"Y085$$!X5/I'I)
M@5_<N'^M'@R;(D\'G[=6]F7NPV0S5U(>M%C\[0=Q99IRZO<9S=S^<ZO.[K;W
M.#5.\-S<R*EDAVV:+`0'>M+_`'Y`$\V1RIVJEHV$A@EMV^[6H[VU8,CO=M+O
M^8*G5]AJ@NZ2:B;ZU=7>PH+'H&CASA*8P<M2M2UG"L1M)0E@'4Y+M,M#$K^>
MO(A\-7JE4V'8CVVRVJ8DWM,M178G;'P$Z9%=$&.!55LR)YC$(:FJ0(X[+]N:
M95'X6Y%FKAIDLF$!STN:`L7+*/Z&G?"]5U_.F)BF%SPB<4;84XKQVFS@]M-H
ML5/WK%[&<:]>IE-W27[4O4QA$8`09IV<G=N"\BTG4.*I'H2\85O/Y'ZI;K"G
ME]TY!V.@)9+/B!IGIB$WHX1FM]1]%$NG/C:T3UHA[&7!5TQ>YE8T<7KG0EK=
M!M[KHT]K5&^Z[4*PU&#\J^1M0CDQ\FLZRF`N.$3"14TRZZ-F)1Q4S<#>1ED>
M+GI&K#LI3)65`X0FR?0UO4DDC3M,]BT8#>E@"$81#%8QWM;KO8K)!9)T(G10
MQ;3Y-RK'RS;,807#+T4GZQ26**E4TZ?*<-IHS2ET@#JOCS6],:(MB0ID>MB`
M$L#H%^>9:>[:@G2:.0W%,9%.JS4TI&V&6O,LM,UZ;]SYIKFGF<:F#0Z-K6",
M:/=)JP2)8Y^_Q!&I(/5G*TSVJ)</@Q&$/W+0/D0GG2UB/,-ETJ@E-21ZVP@4
MQ?H"3,Q:BO-R#GYP;G.,M@Y2N)B,M(98M,4RD+;'6`]$8Y"T6XNNEQAI`<-3
MR-U^KN"K`2USF5BUE7G24,G==.;QT2^*FJM:CKOHB\Y2%NL2*ORE8YW--Y!5
M+_#2VMP<-.CBD&V:).7)340C',-TM/G;L0VO8D*M3'MIG$Q;^GIE,4$%NDZL
M`P'IFYYI'932-G35U;%):>UJSHMB(<&1>Q;^$DZY/I-O36Y!T'W<+K\TTU/*
M^,L67VO.9_+K`F5HW.L))>[0ELJA#96CE<$P?*C;(I!E[F.(0O3-7:MN3Z+1
M(RU90=B(4*%'LPBT'7?$N6>E('"8;"T-#LI*JM+`D6K=MBJKP:ZOO3KZO9;+
M[7E.T4?GS&FC<MAR04RDD?E\C)>Y"TJESBE6MR<9R<P:I8$#KN+/+2M6)7)U
MZ2L!<[.0ZR996)@Z;F$>C9D830T#-81K"Q($K0C9Y"-:E(]5R1I4*Q4LV>N!
M[$T[?JAML`Y2\J4:>*]32.]9\]-3(5#C6]Q-NM5(U$?>B'9LD%NK+)7OLA;M
MSEDG:=4I:V9.:S2;;62G&2D+90F$KP!(A'&'5#>RTNOG#Q:UU&T]:W-5MFQQ
M9U9.B)D]2,CFN5U=T6I:)BZRAD2Z)-M1_2/A+8J6)6DU*4X:;RDOOIB8\+A<
MUUOU##>E^CW^T75^>:8F#B].M?*)992^4JT"U7/GUQ86B&QE#(%,6:H:W09:
M01ZPH_%W5"(DA`<)^T3MW$%!+5Y7[ZL2W9+(I.R262U,ENUCL(F`1WIE^CKB
MZ-\&Z32R:).-8/[O.E0X0[GT8>H3G:;R8$$!PQ-0@&!`4\#"0H3S!Y$7%0RQ
MN?W%8+`^K6M<0NNYEOIS>8]$ZW4\W.\0C-6CK'7P<3+;GA_19K;)%TV&V`-?
M$*,X1CCH)XFH8<HRA?)H_3:@)U*K.<&16\*VF<6Y#:ZM!0;!:EGCC>2&43")
ME%O;I'TL\JQOH5*CBC:48R2`1RM(X*-(V]0["<R0[;HS)Y)(VR;&O4*=H2H8
M95+HVQ`7K$CB;*&1D-V2S39L"@]4Q.WR,&_:$)S=:/+]7>M^G6PBV'3]SI0/
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M[>D)LI%+;"=VH[4N1.SFC/,D+RJ1Z6@V`Y.#12!$%+&;EWRG18<"9BK$FLH2
M1ZQH;-"98]].S*0.R=$G?>?5$_BTH*<Y:Q)':+.,?C,O*0%K6^6@-,<#4ON;
M<6K$O$$T3WA[KE^K"D5<,NV6-70D?N"VK`L2<3^V9A/FY''G.N^BHC$8E`?A
M-<K(JX$K9+"9HPJ>8NB3NS(VCVXE@5.2(LX06ZZ6A=^SJNJ*,@4=G!*5G<3'
M*YJ=@M]JJNL-T3KJHE+/&V9LO1O<VU4K+@5H.38N7F!<$_PH2BVHWI7[/W!8
M%09!SIY"7UWG2%)8,^C"IZ^-"9XG;7TFYK&21Q5\M"DWBLH_6$<VUM.JUE=2
M5BQ29K>7PME9S']8:<>+2W;MOX."S<HY:N$N8VTOK6X;88&UAYICD4Y:W*+[
MM*3QR.7^>LZ+-DDRLJ.N[X\J;%1)"I?#BPCD>WLK:1L"`D@)B?UQ!32,<Z>2
M!H:*B6"FEG.+A'[A+?G&)S._%)K*FC9C=1*1YW/7-BLE?-'Q@5.L8EJY"+XR
M2THGX4.*/C!A#F6F90U2HZF[\E\9C<X>"^AEE=K7=P.M.J9#U'((5;]P.9,B
MZ&2L,RKR4JG=D<J)C#"3(H6:JCQ:YB"Y(VC18B#M(M;>0WUOY5\D#8QI'N07
MA-)E/7$\]NM9(S7[)(\P3*O&F*<SB/BU8-HB6V/5;-)D\PF>)D4D0HVQS0*Y
M`-28J3D'A"D"2ZOY*Z#A<,KIR8BGR%3)I.\@ZM8S/=V.\W6L)70-B6?8-%FN
M;RI5.#-(I^VKI6AVZ/X0G.1(PC*,7+"2_7,"H'0M==LT!!CXX"<=+65J65\[
MM=/M,(O>Y'2PD72[C2O/+*&;O-C-3:]F.<?26FTS(]-$'564S+3'<Y8D0^[$
MF[;@[#.[:&OFT+)I><T6W203W#:DZ3@39*HK<Y]0J:[LBU'6@UU8SZ4I4QA)
MUCUU%UM<+U;PQ;TM*5Z*)`-O7:'HL`5M<>=/)JO8K&:8G:T@@UE/)*="AMN0
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MD`C5"Z0UZT,-F2R.1,GH,N:N[D@E,W@,:7MR6<,Z..C3)SDSGM6VK$IAI!R4
MP6BAEAU_UAS3Y-6>L6UO=+HEZ2;/,NBU>SS<PMP]["V5O/*^:(E?]UUXM(=I
MPJ*G47E[<1(X2F4+T0`JBUFBVYE+<34V!M#?S'W\[6):Y$GN2R$4*DMP,"L+
MC'KB<(\A=JC%U_#INF15_I#*'F109VBW)Z!SBSG[DBBAB]2J&#_\T4[(>"`R
M]W<X]VI[5LM/S58\W:X(X\_OT$KF163>,GD2"(R,JL%#3'E[*G62I2\+ITMG
MI9>U*V2L3ZK)"<)V)DI1@-,N!/U4U/U`U<9W17\HE]B$W'*"[<U4RIPLAJ'8
M\$:GYL$EA+2CLA<LME,V.S:Z!.5MYZ]UDPFX*@HH:S99(2TX:I3=!]/%1GEM
MZLAT5M]B539]\CD2ASLR9RPD56R^N[J8ZW<)1&9!8-EL[Q-$<HD$<&8G`^/8
MFE(`U.C<O=/:I]A0=3QEY&4I3[(HP]6+%I-)66H8_:;@FZ6/DM@VG/*^I^V(
MZILZ-RY7+(F*%5HGMZ7D/:6.F+RTX2U.E/P%O2;;,8';-?R.P'?E3H:OYC#%
M\M=?H_*XE'7ME5(WIWMBQI+7ZYG'\$1MC:D2J,N1$_/2@3'B*)*":<%27I.6
M3O8`M/"4<B;H9$6^7N!+M+$$88$<H=4^O5(<Y$E:DA#VX$A]4'JDK7(!I@=>
MC7HT+7W,#9\!@,!@,!@,!@,!@,#S(?:R?V8$*_QI\V?UJ7X'IM_D?S?WL"#.
MG5S>V<]7&O=)?(($@35_(AJ)?%4RE7(6/6T)@0*FI,C<V16:I,-$$OT%+VXS
MU1[V%8DWZ%!0=/%@,<JB'/G>3%.X$U44^.?CEZA>&6L(*2G'#9^RH8*H1.%E
MR-6TWA;;27,(NM6$($I0TK>J$F>56]KG8`=>X!(OV<7]B=P-_9Q-_P"^:RL#
MNWP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P/,A]K)_9@0K_&GS9_6I?@>FW^1_-_>P/P6HD;DC5MSBD3+V]>F/1+D
M*T@I4C6HU10R%*16F/`80I3*2#!`,+&'8!@WO6];UO`H-V-3M1U5P=W@96%7
M5W7)CYR)T5\-&02%1N)#=M(J:G/N07(;`VH!+@(_;F>R"9ZVBO7%ZOH]._2%
M2OLXO[$[@;^SB;_WS65@=V^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP.J7IKR]4'S9;5FT\DIKJ[HMZY_C$<FG44BYCI?=GPWF*+RQI/D;$NN![/DD
M=,3.*R)IQO6VQG(>',IF`-6,@(`^C87[;.@*2=&^J7`%J09N_3DQ,LCJ%LD4
MB;8K(K$:9`VHW=I.BT6DI[3)'12H;W`D8DP$NU).S-!,+`/TAT&74W)4*.5H
M8&KM6MTLX='A7'FR&*9S&")6XR!`@1NJYC0QTUT"[JWA&UN*=2:F+)$>6G/+
M,$'0!AWL*G07R2\S6V^(66EG22W(`76$LXXDKU7[:T+&:!VG"H_('U_>I8:]
M/[&NU6X#HRK0)'IN3N)3DL!H2,!Z7UE(0M.RWE2<D5NC?';AJU_7L<8U-GI$
MRV#$G16T0S?K^B7.B9"[GG-\8W[,7_KS0@2?Q=_]S[F\#84]B5^K&G+23J'*
MC%D/U820">3LAPU4`V(L&IPG"6N$(^'[&<#6G,/I1>D6M>T^[K`UU/>=)JZ\
M46ZDN&K%53HQ&!5V>GL&)'5XE$2M`VFA434MW%&R!%.)@4XM"4Z]4X6@;_C;
M]&!&?+W6]3]=MEU/-2:D8VNB>BK4YDEB]_0-R)([SVHE#4GDCQ$5+8\/*=[A
M#CIY(,;7`0B!JBM[%LDO7H](2.QWU1DG:I&^QJYZGD+)#GA)'I<\,=BP]V:H
ML_KUP&Q"QR-P0/"A(QO"UR-"G*3*AE'&'BT6$.Q;UK`Y*:[J760R06.CMVL%
M5>1)<N;)5/$T^BA\,C+DV*"4CDWR"4%.PF-F7-ZI266>4I/+,*,,"$6M;%K6
MPACGOM>C.E6[I-\@+JY-T9Y6N^<419TMEH&5IBI\AK^(1*=/\LB[\C?'1O=:
M[W')FD/(=3AI=#"`T0BP@!H8@_E+]U\GWSSW`^IH1=L%04=92TUMB$UG4@:J
M_2KW0+DL;4S,J32Y8TJFE_<!(]FDMJL!+AL@P`A$!V+U=!L'7/5M8<6\Z3OI
M^VD\I=*VKP<*"]DP)K0R"2*=3V>16NV(QI;EKLRHEA6GV8)!G"$J+T!+HPP/
MK[#H`@DI)=5-KX9(+&0VU62VO8DK<6^53Q)/(JIAD97LYI9#NBD$H)=1L;,K
M:SS@`4EJ3RQD#'K0]!WO6!N;))8[)6!OE4<?V5_B[LWE.[5)&1U0NK`YM1Y7
MMR7-O>$)Y[<M;SB/XX3BS!%B!]W0O1@5TGW8=*Q*J72X88]EW_&&6=PFNW5+
MSX_06QW5!(9O-&&$D!6;+F#4RI"8^LD!:QS`:M`J3H"31EDG&!"4,)?4W#4:
M.7J:^5VG7*6>HU+$C5PA3-XR1+TJR4>MJ,I%,:-<PO)"F1;!OW`L1.A*_1OV
M6A^C`^(Y<M03&0_%&(VK6TJEFF<R0_%B.3F,/DA^`"G`YI-?/@5L=%3E\#E.
MJ<Q,)3[+V(5`!%[%ZX=ZT'TQ7%44I9I9(XS:=<2./0)4YH9R^L4XC+NS0M<R
MDC4/*.6.C>Z*$,<5-*<L1BDM8,D9``[$/0=:WO`A2A>TZ-Z5N/H^EJB=UTH>
M.8A4Q\=I@@VQ.=<2=/>U?#LJ$KJXES$_.Y$J0%,!8BUQNRDP2%8=E@]KK6QX
M$[(;4K!SF$@KUML>!N$_B3>6[RJ#H9?'E<PC+2=HL13G((R0XF/3,WFA.!L)
MRD@LL6A:]`ONZP./$K>J:?.ZZ/P2T*[FK\V-+8_N3)$IK&I&[M[$]%@.9GI<
MVL[FL6I&EV*,"),I,`$D\(M;`(6MZP/W5VK5[?+28"OLB!(IVI$H`GA2N81Y
M-+5`TK&.3J@$QPYQ`\&B31HL3B9H).]@0AV?OT%:V/`X$;NFG)DVLCS$+9K.
M5,\ED"R)1QUC<[BSXVR"5-Y!RE?&61<V.JI*ZR!"F3&&'(B!&*2@%B$(&M!W
MO0?#]=M,15`I=91;M81MK1S']'BQR?I]%&=`EG^@%F;@RE8X.R=.1,=`.`+X
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MP*B>0/\`\"^W/\(G2?\`<U-,"@?V<7]B=P-_9Q-_[YK*P.[?`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8'GUG-(>3WCWJ7O^?\`#-!4GTC%O(&^0"SH
M5/[(NU!51O+-U1RK6FIGE7:D,<V!R<K>JX(&-&]H2(ZI)<O2`U"86'1@5(0I
MYW?XKNW;QN#K!X<N>.;>MYIVKSCR95,!ZODT[;*S'X\K/IJ/GLUK3*LX5+6V
M76.V0N13I:;.64N'.!CL)T"%&X;,!Z%&@V:Q_#E>4DG?5%L?HIK"7W5+?*'P
M)T93=X/;I"R+.,HR@$%$H;<DB:4&A$\PEV=C8G(E!K04>2<X#5"UZIGKE[V'
MW1WBMZ4K'H&/&M/-545W7E>>=&Y>Z4=D0^7UJ@*G/*]EUST`S5\W$11C2M\D
M9UU.GSEN:R&-6#>B-.!VT`=)RS1["%N>?!ET16M'^/F%)*>I.K+.B'$?E8YY
M[#G<>>XF!P>)IU7%U#)S]\;WN-H?AFW6-N6K!&B&(2L+&4'8"P@UZH<#1Y'X
MEO)GT+3JJOI!4$!YG=8-X/JP\;<2<1WY$ILHLBS*8Z-I6RW]`Z'PMF/+B%:7
MO!*\<&P@)OP@%$F6;`Y`]!@R-ANK1XC>N$-8$6.'EIED.FOR+T)U9,?'_:=R
M\L)H;==?5/0\@IIX5)F2@J,J?DRO)>8\2!$[$-9B=<WONH\0K<CB'`>RQAV@
M^-SB_I?F'A[O:KWFF:0J:T[UZ6[0NF@J4+DZ:<T5%H_=<;:AU'`Y&NBK>R#W
M!&9U(TU."5,D1F!;DXO8DE`&4`(=&*;PI>0J6T9U]$W'G&O:]=NB./N%JA%7
MJ>=\M1*$K[6YW[%@5H6B%JB_/$$KZ$1B`;KA$Y&1@QST_2(Y&0$IR=1K5.DY
M`7DZ-\05^DV]UE+J&YOI%]YU.\A?CHZ^KKD)#(X)7%9])5GSWSF[5O?%9.$2
M$V`KB#N;G9#V0]DDOJ,+2\JV@LU3H?K`W@=@WBDX>L^@J2\@$!OV@ZFIJ/\`
M5O9W05T0BA(B_P`8L:M8W3%RUS73"WP1P)9F1MC8D"$YK<&Y<V@;BD.P%C"0
M3[H,G6PZ;J/\2G8=-4GPF"Q_&[SGU,FYEH;J3FJQ^1)Q<E-((7([-MF31)[C
MG<D<?'>-NL%>'F7QYE-C3R6Z`)ES<S@+-(T>=ZI)8=E-P>-#JAP^STM7C12/
ML6NGJ!LJ&D(.J5O\L5M,&<UD3O>`6"\Q8,O?"`N.X="H4T'LR%082!4J0-Q7
MJ$@-,"7H.O2W_#YVM;IO1MQ5_P`V51R=#Y3UEP5;+'X^*QL:CGV,6;#^2(99
M$4LJ4^\OM<NO+J>5V"\3QK=&1MDL>-:7`,5(V_)0*!%>S#MQXXX*LJK?%-?O
M*,\KTY'+KW2]9.::BI1>L;):8LCO\Z4C25H1:5`T[!X74S.ZC>#%1I$.C:UJ
MC"MS/"W>]DDEAV'4%4?B/\@C=RWTM3*BE(+#6*93[QL/%:QF?OO*9]YN@^8.
MA(?-K2+FET\W0.NHI8=6Q*NV0TF+&R=**6K#AF^T)3;,V4:%17%CC`?)54_/
M+%!N<;4OE@^T3N'2,FOI@D+H+LI15;HZS.?/,*G5.2*M&:QF&IZ=CP$R=9*#
M78Z#*BV]KVR;4[,&<0%X*>\&W3L,JCA-KC4$JJB+]B"7S#1OI.^89((T3-&A
M%U]!+SBO,3XXR:+E$R2R4;`ME<=,]V).--8"TVA%!+,)P(>K/P>]N`Y0Z&@A
MM.,=;6`HYVXKIO\`1:_73SJBJ#K=3RW>;#;<U8'9DYOH.`$M$:G+"QKF=MED
M]<GB9.!+Z-*^`$G+$IT'==XGN0KIY]Z+\CEX6+RY67'=>]8RWF265%1%7S>#
M3%JAA%;U"ZPJ=I'0%>-;/%6=[<)./3DK+0$;0F*G`WV!JC0!'F!UM<Y>)#L*
M`71SZR2+G6D8?(>;^D>P[XM7R5L-H1ITN3N2$WNW7&FBU32:))X\19*57*`V
M4TI),5)UPV=K31LH3:8HV,)>@GSQH>)>V^.[/\65A*Z8JJMWBCN%.D:2[%D\
M%<X@5(97:U@3.LI+`BI"Y,0"W*T""S&%S.`M,,5$H!B]4(@:V7K`S'5/B#M7
MHVY/-W:K5$JKC%H==4-S?67$M\/JAG7S&,GQ"@WJ`W;'"W=(W.$MJ5DL-485
M''=4EUHUR9E8O6`>05[+85DJ#P\]3).;NIIHU5&EH+J=HM3C/H_C6"2FR^:G
MN)(NAN)V56%ODHXGRW2=+4O6K;;3&[KX.O6:/7N;_'SRE#U[J<1ZHPT._/"1
MU\74?&+DVP=@Z5G**H^PUO95;(91S>P*W3KSMU\:K%L6YVAYZ;J6VJQ>FA&\
M&*HBK>$B!/+VZ.MZ`UG-&+1I.PM9`_#',`27J]SN6CJUNER>?%CR5R!SO+;#
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M;Q6>)3K#E7LNN;!O&++`IJ))[%*>ND66T^?R&CIH/15@'R%B&\0Z#T8AZ4L$
M]62<F>'+])TQ/U'7MM!IG$<F,]B$/5G@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,#S(?:R?V8$*_P`:?-G]:E^!Z;?Y'\W][`^L"HGD#_\``OMS_")T
MG_<U-,"@?V<7]B=P-_9Q-_[YK*P.[?`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'#"WMX%QCF%"C"Y&IPI#7`*8G2XQ
M*`>C`IC%>@:4#3A,UH6@;%L.M_=]&!S,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>9#[63^S`A7^-/FS^M2_`]-O\C^;^
M]@?6!5SN*/O4LXJ[`BL;;5;U(I+RYT!'V!G0$B4+G9Z>:GEK<U-J(@&MC.5K
MURDLHL&M;V(8]:U^[@=2GV:2]:;E7AIY`C3%9L)6R2L6.>PBPH]N1M2=]ALJ
M)M:=/`6>0M*A44N;%*IF=DBU/[4`0J$BDHTO8@#UO`[X_CY!_P`LXI^<31]^
M8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`
M+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T?
M?F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_
M`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-
M'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!
M_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<
M31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^
M0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?
MG$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^
M/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SB
MGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@
M/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`L
MXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^
M8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`
M+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T?
M?F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_
M`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-
M'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!
M_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<
M31]^8#X^0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^
M0?\`+.*?G$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?
MG$T??F`^/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^
M/D'_`"SBGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F`^/D'_`"SB
MGYQ-'WY@/CY!_P`LXI^<31]^8#X^0?\`+.*?G$T??F!Y@/M6%GUW(^&*%HB-
MS6,R.YK;[9Y\)K>L(^\M[S-I?\%+9"2X*&B/-RA0XGH4BMT2)AJ/9Z)TJ6)R
M?6]H<6$0>JGT?Q?1_P!?5]'_`/3`_N`P/#%V[%/L;S[T[;*F\;,;H7=9<L>"
MK6;N>$'82JO#YSIP4"D2HH='U]+*ET\[=-FA7:9#P$^]Z,]J#V_M-["J'Z./
ML1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B
M.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1W
MR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7
MVY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W
M)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/
MP-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!
MO(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y
M%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M
M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF
M5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN
M`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'
MZ./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1
MQ]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./
ML1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B
M.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1W
MR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7
MVY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W
M)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/
MP-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!
MO(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y
M%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M
M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF
M5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN
M`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'
MZ./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1
MQ]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./
ML1WR^W)^!O(M\RN`_1Q]B.^7VY/P-Y%OF5P'Z./L1WR^W)^!O(M\RN!V5>**
M-_906#L"`_03G[)-^M%!YWZ'OTY(^I$BE`_`2J/1^C;Z0\*B-?CGQQ&Q^X^[
0^V>]#UOW+U1^GTA[(L#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
